{"doc_id": "10099659_2", "wnd_id": "10099659_2_1", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck , breast , ovarian , and colon cancer .", "tokens": ["5", "-", "Fluorouracil", "(", "5", "-", "FU", ")", "is", "an", "analogue", "of", "pyrimidine", "nucleosides", "that", "is", "widely", "used", "in", "the", "treatment", "of", "head", "and", "neck", ",", "breast", ",", "ovarian", ",", "and", "colon", "cancer", "."], "event_mentions": [{"id": "10099659_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 17, "end": 18}, "arguments": [{"entity_id": "10099659_2_Ent1", "role": "Treatment_Drug", "text": "5 - Fluorouracil ( 5 - FU )", "start": 0, "end": 8}, {"entity_id": "10099659_2_Ent0", "role": "Treatment", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides", "start": 0, "end": 14}, {"entity_id": "10099659_2_Ent2", "role": "Treatment_Disorder", "text": "head and neck , breast , ovarian , and colon cancer", "start": 22, "end": 33}]}], "entity_mentions": [{"id": "10099659_2_Ent1", "text": "5 - Fluorouracil ( 5 - FU )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10099659_2_Ent0", "text": "5 - Fluorouracil ( 5 - FU ) is an analogue of pyrimidine nucleosides", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "10099659_2_Ent2", "text": "head and neck , breast , ovarian , and colon cancer", "entity_type": "Entity", "start": 22, "end": 33}], "lang": "en"}
{"doc_id": "10212021_4", "wnd_id": "10212021_4_1", "text": "Methadone has two roles in human immunodeficiency viral infection : pain management and treatment of opioid abuse .", "tokens": ["Methadone", "has", "two", "roles", "in", "human", "immunodeficiency", "viral", "infection", ":", "pain", "management", "and", "treatment", "of", "opioid", "abuse", "."], "event_mentions": [{"id": "10212021_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has two roles", "start": 1, "end": 4}, "arguments": [{"entity_id": "10212021_4_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent2", "role": "Treatment_Disorder", "text": "human immunodeficiency viral infection", "start": 5, "end": 9}, {"entity_id": "10212021_4_Ent0", "role": "Effect", "text": "pain management and treatment of opioid abuse", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "10212021_4_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent2", "text": "human immunodeficiency viral infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10212021_4_Ent0", "text": "pain management and treatment of opioid abuse", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "10225085_3", "wnd_id": "10225085_3_1", "text": "We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["We", "report", "a", "patient", "with", "chronic", "renal", "failure", "and", "ischemic", "heart", "disease", "who", "developed", "clinically", "significant", "methemoglobinemia", "after", "an", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "10225085_3_Ent0", "role": "Subject", "text": "a patient with chronic renal failure and ischemic heart disease", "start": 2, "end": 12}, {"entity_id": "10225085_3_Ent3", "role": "Treatment_Disorder", "text": "chronic renal failure and ischemic heart disease", "start": 5, "end": 12}, {"entity_id": "10225085_3_Ent1", "role": "Effect", "text": "clinically significant methemoglobinemia", "start": 14, "end": 17}, {"entity_id": "10225085_3_Ent2", "role": "Treatment", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 18, "end": 32}, {"entity_id": "10225085_3_Ent4", "role": "Treatment_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent7", "role": "Combination_Drug", "text": "bupivacaine", "start": 22, "end": 23}, {"entity_id": "10225085_3_Ent6", "role": "Treatment_Route", "text": "injection", "start": 25, "end": 26}, {"entity_id": "10225085_3_Ent5", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "10225085_3_Ent8", "role": "Combination_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "10225085_3_Ent0", "text": "a patient with chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "10225085_3_Ent3", "text": "chronic renal failure and ischemic heart disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "10225085_3_Ent1", "text": "clinically significant methemoglobinemia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10225085_3_Ent2", "text": "an axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 18, "end": 32}, {"id": "10225085_3_Ent4", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent7", "text": "bupivacaine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10225085_3_Ent6", "text": "injection", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10225085_3_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "10225085_3_Ent8", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "10332990_1", "wnd_id": "10332990_1_1", "text": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma .", "tokens": ["Pulmonary", "edema", "during", "acute", "infusion", "of", "epoprostenol", "in", "a", "patient", "with", "pulmonary", "hypertension", "and", "limited", "scleroderma", "."], "event_mentions": [{"id": "10332990_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "10332990_1_Ent3", "role": "Treatment_Route", "text": "acute infusion", "start": 3, "end": 5}, {"entity_id": "10332990_1_Ent1", "role": "Treatment", "text": "acute infusion of epoprostenol", "start": 3, "end": 7}, {"entity_id": "10332990_1_Ent2", "role": "Treatment_Drug", "text": "epoprostenol", "start": 6, "end": 7}, {"entity_id": "10332990_1_Ent0", "role": "Subject", "text": "a patient with pulmonary hypertension and limited scleroderma", "start": 8, "end": 16}, {"entity_id": "10332990_1_Ent4", "role": "Treatment_Disorder", "text": "pulmonary hypertension and limited scleroderma", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10332990_1_Ent3", "text": "acute infusion", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10332990_1_Ent1", "text": "acute infusion of epoprostenol", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10332990_1_Ent2", "text": "epoprostenol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10332990_1_Ent0", "text": "a patient with pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "10332990_1_Ent4", "text": "pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10348150_1", "wnd_id": "10348150_1_1", "text": "Hydroxyurea - induced acute interstitial pneumonitis in a patient with essential thrombocythemia .", "tokens": ["Hydroxyurea", "-", "induced", "acute", "interstitial", "pneumonitis", "in", "a", "patient", "with", "essential", "thrombocythemia", "."], "event_mentions": [{"id": "10348150_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10348150_1_Ent2", "role": "Treatment", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent3", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 0, "end": 1}, {"entity_id": "10348150_1_Ent1", "role": "Effect", "text": "interstitial pneumonitis", "start": 4, "end": 6}, {"entity_id": "10348150_1_Ent0", "role": "Subject", "text": "a patient with essential thrombocythemia", "start": 7, "end": 12}, {"entity_id": "10348150_1_Ent4", "role": "Treatment_Disorder", "text": "essential thrombocythemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10348150_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent3", "text": "Hydroxyurea", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10348150_1_Ent1", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10348150_1_Ent0", "text": "a patient with essential thrombocythemia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10348150_1_Ent4", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10357715_1", "wnd_id": "10357715_1_1", "text": "Allergic and irritant contact dermatitis to calcipotriol .", "tokens": ["Allergic", "and", "irritant", "contact", "dermatitis", "to", "calcipotriol", "."], "event_mentions": [{"id": "10357715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "10357715_1_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 3, "end": 5}, {"entity_id": "10357715_1_Ent1", "role": "Treatment", "text": "calcipotriol", "start": 6, "end": 7}, {"entity_id": "10357715_1_Ent2", "role": "Treatment_Drug", "text": "calcipotriol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10357715_1_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10357715_1_Ent1", "text": "calcipotriol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10357715_1_Ent2", "text": "calcipotriol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10367184_1", "wnd_id": "10367184_1_1", "text": "Myotonia associated with sarcoidosis : marked exacerbation with pravastatin .", "tokens": ["Myotonia", "associated", "with", "sarcoidosis", ":", "marked", "exacerbation", "with", "pravastatin", "."], "event_mentions": [{"id": "10367184_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "10367184_1_Ent3", "role": "Effect", "text": "Myotonia", "start": 0, "end": 1}, {"entity_id": "10367184_1_Ent0", "role": "Subject", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "10367184_1_Ent1", "role": "Subject_Disorder", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "10367184_1_Ent2", "role": "Effect", "text": "exacerbation", "start": 6, "end": 7}, {"entity_id": "10367184_1_Ent4", "role": "Treatment", "text": "pravastatin", "start": 8, "end": 9}, {"entity_id": "10367184_1_Ent5", "role": "Treatment_Drug", "text": "pravastatin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10367184_1_Ent3", "text": "Myotonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10367184_1_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10367184_1_Ent1", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10367184_1_Ent2", "text": "exacerbation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_1_Ent4", "text": "pravastatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10367184_1_Ent5", "text": "pravastatin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10367184_3", "wnd_id": "10367184_3_1", "text": "This case suggests that sarcoidosis and pravastatin , two entities not frequently associated with myotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans .", "tokens": ["This", "case", "suggests", "that", "sarcoidosis", "and", "pravastatin", ",", "two", "entities", "not", "frequently", "associated", "with", "myotonia", ",", "may", "interact", "in", "a", "synergistic", "manner", "to", "produce", "severe", "clinical", "myotonia", "in", "humans", "."], "event_mentions": [{"id": "10367184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 17, "end": 18}, "arguments": [{"entity_id": "10367184_3_Ent2", "role": "Treatment", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent1", "role": "Effect", "text": "severe clinical myotonia", "start": 24, "end": 27}, {"entity_id": "10367184_3_Ent0", "role": "Subject", "text": "humans .", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10367184_3_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent1", "text": "severe clinical myotonia", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "10367184_3_Ent0", "text": "humans .", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10410183_10", "wnd_id": "10410183_10_1", "text": "CONCLUSIONS : Marked elevation of serum CK may be a possible complication of olanzapine therapy .", "tokens": ["CONCLUSIONS", ":", "Marked", "elevation", "of", "serum", "CK", "may", "be", "a", "possible", "complication", "of", "olanzapine", "therapy", "."], "event_mentions": [{"id": "10410183_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "10410183_10_Ent0", "role": "Effect", "text": "Marked elevation of serum CK", "start": 2, "end": 7}, {"entity_id": "10410183_10_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 13, "end": 14}, {"entity_id": "10410183_10_Ent1", "role": "Treatment", "text": "olanzapine therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "10410183_10_Ent0", "text": "Marked elevation of serum CK", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "10410183_10_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10410183_10_Ent1", "text": "olanzapine therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "10431414_3", "wnd_id": "10431414_3_1", "text": "The association between heparin and priapism is often recognized ; abnormal platelet aggregation could play a role in the pathogenesis of this side effect .", "tokens": ["The", "association", "between", "heparin", "and", "priapism", "is", "often", "recognized", ";", "abnormal", "platelet", "aggregation", "could", "play", "a", "role", "in", "the", "pathogenesis", "of", "this", "side", "effect", "."], "event_mentions": [{"id": "10431414_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10431414_3_Ent1", "role": "Treatment", "text": "heparin", "start": 3, "end": 4}, {"entity_id": "10431414_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 3, "end": 4}, {"entity_id": "10431414_3_Ent0", "role": "Effect", "text": "priapism", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "10431414_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10431414_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10431414_3_Ent0", "text": "priapism", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "10442258_2", "wnd_id": "10442258_2_1", "text": "Alopecia and hair loss are rare side effects of psychotropic drugs .", "tokens": ["Alopecia", "and", "hair", "loss", "are", "rare", "side", "effects", "of", "psychotropic", "drugs", "."], "event_mentions": [{"id": "10442258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 6, "end": 8}, "arguments": [{"entity_id": "10442258_2_Ent0", "role": "Effect", "text": "Alopecia and hair loss", "start": 0, "end": 4}, {"entity_id": "10442258_2_Ent2", "role": "Treatment_Drug", "text": "psychotropic", "start": 9, "end": 10}, {"entity_id": "10442258_2_Ent1", "role": "Treatment", "text": "psychotropic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10442258_2_Ent0", "text": "Alopecia and hair loss", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10442258_2_Ent2", "text": "psychotropic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10442258_2_Ent1", "text": "psychotropic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10456487_15", "wnd_id": "10456487_15_1", "text": "Whether concomitant fluvoxamine treatment reduces tacrine - induced hepatotoxicity needs further study .", "tokens": ["Whether", "concomitant", "fluvoxamine", "treatment", "reduces", "tacrine", "-", "induced", "hepatotoxicity", "needs", "further", "study", "."], "event_mentions": [{"id": "10456487_15_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduces", "start": 4, "end": 5}, "arguments": [{"entity_id": "10456487_15_Ent3", "role": "Treatment", "text": "concomitant fluvoxamine", "start": 1, "end": 3}, {"entity_id": "10456487_15_Ent5", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 2, "end": 3}, {"entity_id": "10456487_15_Ent4", "role": "Treatment_Disorder", "text": "tacrine - induced hepatotoxicity", "start": 5, "end": 9}]}, {"id": "10456487_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "10456487_15_Ent1", "role": "Treatment", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent2", "role": "Treatment_Drug", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10456487_15_Ent3", "text": "concomitant fluvoxamine", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10456487_15_Ent5", "text": "fluvoxamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10456487_15_Ent1", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent2", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent4", "text": "tacrine - induced hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10456487_15_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10461415_2", "wnd_id": "10461415_2_1", "text": "Hepato - biliary abnormalities secondary to ceftriaxone use : a case report .", "tokens": ["Hepato", "-", "biliary", "abnormalities", "secondary", "to", "ceftriaxone", "use", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10461415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 4, "end": 6}, "arguments": [{"entity_id": "10461415_2_Ent0", "role": "Effect", "text": "Hepato - biliary abnormalities", "start": 0, "end": 4}, {"entity_id": "10461415_2_Ent2", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 6, "end": 7}, {"entity_id": "10461415_2_Ent1", "role": "Treatment", "text": "ceftriaxone use", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10461415_2_Ent0", "text": "Hepato - biliary abnormalities", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10461415_2_Ent2", "text": "ceftriaxone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10461415_2_Ent1", "text": "ceftriaxone use", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10465148_4", "wnd_id": "10465148_4_1", "text": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery .", "tokens": ["Reported", "are", "three", "children", "who", "developed", "progressive", "paraparesis", "after", "intrathecal", "methotrexate", "administration", "followed", "by", "complete", "or", "partial", "recovery", "."], "event_mentions": [{"id": "10465148_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10465148_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "10465148_4_Ent0", "role": "Subject", "text": "three children", "start": 2, "end": 4}, {"entity_id": "10465148_4_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "10465148_4_Ent3", "role": "Effect", "text": "paraparesis", "start": 7, "end": 8}, {"entity_id": "10465148_4_Ent6", "role": "Treatment_Route", "text": "intrathecal", "start": 9, "end": 10}, {"entity_id": "10465148_4_Ent4", "role": "Treatment", "text": "intrathecal methotrexate", "start": 9, "end": 11}, {"entity_id": "10465148_4_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10465148_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10465148_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10465148_4_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10465148_4_Ent3", "text": "paraparesis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10465148_4_Ent6", "text": "intrathecal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10465148_4_Ent4", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10465148_4_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10466445_2", "wnd_id": "10466445_2_1", "text": "Arsenic trioxide has recently been introduced as a promising new agent to treat refractory acute promyelocytic leukemia ( APL ) .", "tokens": ["Arsenic", "trioxide", "has", "recently", "been", "introduced", "as", "a", "promising", "new", "agent", "to", "treat", "refractory", "acute", "promyelocytic", "leukemia", "(", "APL", ")", "."], "event_mentions": [{"id": "10466445_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 12, "end": 13}, "arguments": [{"entity_id": "10466445_2_Ent0", "role": "Treatment", "text": "Arsenic trioxide", "start": 0, "end": 2}, {"entity_id": "10466445_2_Ent1", "role": "Treatment_Drug", "text": "Arsenic trioxide", "start": 0, "end": 2}, {"entity_id": "10466445_2_Ent2", "role": "Treatment_Disorder", "text": "refractory acute promyelocytic leukemia", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "10466445_2_Ent0", "text": "Arsenic trioxide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10466445_2_Ent1", "text": "Arsenic trioxide", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10466445_2_Ent2", "text": "refractory acute promyelocytic leukemia", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "10466445_3", "wnd_id": "10466445_3_1", "text": "In the present study , arsenic trioxide was given intravenously for 42 days to a 56 - year - old female patient suffering from chemotherapy / ATRA - resistant APL , with 43 % APL blasts in the bone marrow and elevated D - dimers .", "tokens": ["In", "the", "present", "study", ",", "arsenic", "trioxide", "was", "given", "intravenously", "for", "42", "days", "to", "a", "56", "-", "year", "-", "old", "female", "patient", "suffering", "from", "chemotherapy", "/", "ATRA", "-", "resistant", "APL", ",", "with", "43", "%", "APL", "blasts", "in", "the", "bone", "marrow", "and", "elevated", "D", "-", "dimers", "."], "event_mentions": [{"id": "10466445_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 8, "end": 9}, "arguments": [{"entity_id": "10466445_3_Ent3", "role": "Treatment", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent4", "role": "Treatment_Drug", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent6", "role": "Treatment_Duration", "text": "42 days", "start": 11, "end": 13}, {"entity_id": "10466445_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 15, "end": 20}, {"entity_id": "10466445_3_Ent0", "role": "Subject", "text": "56 - year - old female patient", "start": 15, "end": 22}, {"entity_id": "10466445_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 20, "end": 21}, {"entity_id": "10466445_3_Ent5", "role": "Treatment_Disorder", "text": "chemotherapy / ATRA - resistant APL", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "10466445_3_Ent3", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent4", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent6", "text": "42 days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10466445_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "10466445_3_Ent0", "text": "56 - year - old female patient", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10466445_3_Ent2", "text": "female", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10466445_3_Ent5", "text": "chemotherapy / ATRA - resistant APL", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "10467499_1", "wnd_id": "10467499_1_1", "text": "A 22 - year - old black man developed fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption 3 weeks after starting minocycline therapy for acne .", "tokens": ["A", "22", "-", "year", "-", "old", "black", "man", "developed", "fever", ",", "chills", ",", "fatigue", ",", "night", "sweats", ",", "tender", "lymphadenopathy", ",", "and", "a", "generalized", ",", "pruritic", ",", "macular", "eruption", "3", "weeks", "after", "starting", "minocycline", "therapy", "for", "acne", "."], "event_mentions": [{"id": "10467499_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "10467499_1_Ent0", "role": "Subject", "text": "A 22 - year - old black man", "start": 0, "end": 8}, {"entity_id": "10467499_1_Ent1", "role": "Subject_Age", "text": "22 - year - old", "start": 1, "end": 6}, {"entity_id": "10467499_1_Ent2", "role": "Subject_Race", "text": "black", "start": 6, "end": 7}, {"entity_id": "10467499_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "10467499_1_Ent4", "role": "Effect", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "start": 9, "end": 29}, {"entity_id": "10467499_1_Ent8", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 29, "end": 31}, {"entity_id": "10467499_1_Ent7", "role": "Treatment_Drug", "text": "minocycline", "start": 33, "end": 34}, {"entity_id": "10467499_1_Ent5", "role": "Treatment", "text": "minocycline therapy", "start": 33, "end": 35}, {"entity_id": "10467499_1_Ent6", "role": "Treatment_Disorder", "text": "acne", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "10467499_1_Ent0", "text": "A 22 - year - old black man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "10467499_1_Ent1", "text": "22 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10467499_1_Ent2", "text": "black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10467499_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10467499_1_Ent4", "text": "fever , chills , fatigue , night sweats , tender lymphadenopathy , and a generalized , pruritic , macular eruption", "entity_type": "Entity", "start": 9, "end": 29}, {"id": "10467499_1_Ent8", "text": "3 weeks", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "10467499_1_Ent7", "text": "minocycline", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10467499_1_Ent5", "text": "minocycline therapy", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "10467499_1_Ent6", "text": "acne", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "10475726_1", "wnd_id": "10475726_1_1", "text": "An acute ischaemic event associated with the use of venlafaxine : a case report and proposed pathophysiological mechanisms .", "tokens": ["An", "acute", "ischaemic", "event", "associated", "with", "the", "use", "of", "venlafaxine", ":", "a", "case", "report", "and", "proposed", "pathophysiological", "mechanisms", "."], "event_mentions": [{"id": "10475726_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10475726_1_Ent1", "role": "Effect", "text": "An acute ischaemic event", "start": 0, "end": 4}, {"entity_id": "10475726_1_Ent2", "role": "Treatment", "text": "venlafaxine", "start": 9, "end": 10}, {"entity_id": "10475726_1_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 9, "end": 10}, {"entity_id": "10475726_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10475726_1_Ent1", "text": "An acute ischaemic event", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10475726_1_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10475726_1_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10475726_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10485779_10", "wnd_id": "10485779_10_1", "text": "Ritonavir can inhibit the metabolism of fentanyl significantly , so caution should be exercised if fentanyl is given to patients receiving ritonavir medication .", "tokens": ["Ritonavir", "can", "inhibit", "the", "metabolism", "of", "fentanyl", "significantly", ",", "so", "caution", "should", "be", "exercised", "if", "fentanyl", "is", "given", "to", "patients", "receiving", "ritonavir", "medication", "."], "event_mentions": [{"id": "10485779_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 10, "end": 11}, "arguments": [{"entity_id": "10485779_10_Ent4", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent6", "role": "Combination_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent1", "role": "Effect", "text": "metabolism of fentanyl significantly", "start": 4, "end": 8}, {"entity_id": "10485779_10_Ent2", "role": "Treatment", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent0", "role": "Subject", "text": "patients receiving ritonavir medication", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "10485779_10_Ent4", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent6", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent1", "text": "metabolism of fentanyl significantly", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10485779_10_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent0", "text": "patients receiving ritonavir medication", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "10492493_1", "wnd_id": "10492493_1_1", "text": "CONCLUSIONS : This case suggests that losartan can induce late - onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms .", "tokens": ["CONCLUSIONS", ":", "This", "case", "suggests", "that", "losartan", "can", "induce", "late", "-", "onset", "angioedema", "in", "patients", "with", "normal", "renal", "function", "and", "that", "the", "reaction", "can", "recur", "after", "initial", "resolution", "of", "the", "symptoms", "."], "event_mentions": [{"id": "10492493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_1_Ent2", "role": "Treatment", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_1_Ent1", "role": "Effect", "text": "late - onset angioedema", "start": 9, "end": 13}, {"entity_id": "10492493_1_Ent0", "role": "Subject", "text": "patients with normal renal function", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "10492493_1_Ent2", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_1_Ent1", "text": "late - onset angioedema", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10492493_1_Ent0", "text": "patients with normal renal function", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "10492493_3", "wnd_id": "10492493_3_1", "text": "OBJECTIVE : To report a case of angioedema associated with losartan administration .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "angioedema", "associated", "with", "losartan", "administration", "."], "event_mentions": [{"id": "10492493_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "10492493_3_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "10492493_3_Ent1", "role": "Effect", "text": "angioedema", "start": 7, "end": 8}, {"entity_id": "10492493_3_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "10492493_3_Ent2", "role": "Treatment", "text": "losartan administration", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10492493_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10492493_3_Ent1", "text": "angioedema", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10492493_3_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10492493_3_Ent2", "text": "losartan administration", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10492493_4", "wnd_id": "10492493_4_1", "text": "The incidence of angioedema secondary to losartan , an angiotensin II receptor antagonist , is unknown .", "tokens": ["The", "incidence", "of", "angioedema", "secondary", "to", "losartan", ",", "an", "angiotensin", "II", "receptor", "antagonist", ",", "is", "unknown", "."], "event_mentions": [{"id": "10492493_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "10492493_4_Ent0", "role": "Effect", "text": "angioedema", "start": 3, "end": 4}, {"entity_id": "10492493_4_Ent2", "role": "Treatment_Drug", "text": "losartan", "start": 6, "end": 7}, {"entity_id": "10492493_4_Ent1", "role": "Treatment", "text": "losartan , an angiotensin II receptor antagonist", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "10492493_4_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10492493_4_Ent2", "text": "losartan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10492493_4_Ent1", "text": "losartan , an angiotensin II receptor antagonist", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "10513720_2", "wnd_id": "10513720_2_1", "text": "We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer .", "tokens": ["We", "report", "a", "case", "of", "glaucoma", "induced", "by", "doxetaxel", "therapy", "for", "metastatic", "breast", "cancer", "."], "event_mentions": [{"id": "10513720_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "10513720_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "10513720_2_Ent1", "role": "Effect", "text": "glaucoma", "start": 5, "end": 6}, {"entity_id": "10513720_2_Ent3", "role": "Treatment_Drug", "text": "doxetaxel", "start": 8, "end": 9}, {"entity_id": "10513720_2_Ent2", "role": "Treatment", "text": "doxetaxel therapy for metastatic breast cancer", "start": 8, "end": 14}, {"entity_id": "10513720_2_Ent4", "role": "Treatment_Disorder", "text": "metastatic breast cancer", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10513720_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10513720_2_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10513720_2_Ent3", "text": "doxetaxel", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10513720_2_Ent2", "text": "doxetaxel therapy for metastatic breast cancer", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10513720_2_Ent4", "text": "metastatic breast cancer", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10530201_9", "wnd_id": "10530201_9_1", "text": "Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned .", "tokens": ["Emphasis", "is", "given", "to", "the", "differentiation", "of", "diphenylhydantoin", "induced", "gingival", "hyperplasia", "from", "the", "angiomatous", "enlargement", "of", "the", "gingiva", "before", "any", "treatment", "is", "planned", "."], "event_mentions": [{"id": "10530201_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10530201_9_Ent2", "role": "Treatment", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent3", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 9, "end": 11}, {"entity_id": "10530201_9_Ent1", "role": "Effect", "text": "the angiomatous enlargement of the gingiva", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "10530201_9_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent3", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10530201_9_Ent1", "text": "the angiomatous enlargement of the gingiva", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "10555917_4", "wnd_id": "10555917_4_1", "text": "These findings suggest that bicytopenia in this patient was caused by D - Pen and may be due to different sensitivities in the hematopoietic lineage .", "tokens": ["These", "findings", "suggest", "that", "bicytopenia", "in", "this", "patient", "was", "caused", "by", "D", "-", "Pen", "and", "may", "be", "due", "to", "different", "sensitivities", "in", "the", "hematopoietic", "lineage", "."], "event_mentions": [{"id": "10555917_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "10555917_4_Ent1", "role": "Effect", "text": "bicytopenia", "start": 4, "end": 5}, {"entity_id": "10555917_4_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "10555917_4_Ent2", "role": "Treatment", "text": "D - Pen", "start": 11, "end": 14}, {"entity_id": "10555917_4_Ent3", "role": "Treatment_Drug", "text": "D - Pen", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10555917_4_Ent1", "text": "bicytopenia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10555917_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10555917_4_Ent2", "text": "D - Pen", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10555917_4_Ent3", "text": "D - Pen", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10566542_1", "wnd_id": "10566542_1_1", "text": "Postoperative hypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking alendronate sodium : report of a case .", "tokens": ["Postoperative", "hypocalcemic", "tetany", "caused", "by", "fleet", "phospho", "-", "soda", "preparation", "in", "a", "patient", "taking", "alendronate", "sodium", ":", "report", "of", "a", "case", "."], "event_mentions": [{"id": "10566542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "10566542_1_Ent1", "role": "Effect", "text": "hypocalcemic tetany", "start": 1, "end": 3}, {"entity_id": "10566542_1_Ent2", "role": "Treatment", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent4", "role": "Treatment_Drug", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "10566542_1_Ent3", "role": "Treatment", "text": "alendronate sodium", "start": 14, "end": 16}, {"entity_id": "10566542_1_Ent5", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "10566542_1_Ent1", "text": "hypocalcemic tetany", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10566542_1_Ent2", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent4", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10566542_1_Ent3", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10566542_1_Ent5", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "10573314_2", "wnd_id": "10573314_2_1", "text": "To report two cases of warfarin therapy in which the addition of tolterodine resulted in prolonged international normalized ratios ( INRs ) .", "tokens": ["To", "report", "two", "cases", "of", "warfarin", "therapy", "in", "which", "the", "addition", "of", "tolterodine", "resulted", "in", "prolonged", "international", "normalized", "ratios", "(", "INRs", ")", "."], "event_mentions": [{"id": "10573314_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 13, "end": 14}, "arguments": [{"entity_id": "10573314_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "10573314_2_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "10573314_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_2_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_2_Ent3", "role": "Treatment", "text": "warfarin therapy in which the addition of tolterodine", "start": 5, "end": 13}, {"entity_id": "10573314_2_Ent5", "role": "Treatment_Drug", "text": "tolterodine", "start": 12, "end": 13}, {"entity_id": "10573314_2_Ent7", "role": "Combination_Drug", "text": "tolterodine", "start": 12, "end": 13}, {"entity_id": "10573314_2_Ent2", "role": "Effect", "text": "prolonged international normalized ratios ( INRs )", "start": 15, "end": 22}]}], "entity_mentions": [{"id": "10573314_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10573314_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10573314_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_2_Ent3", "text": "warfarin therapy in which the addition of tolterodine", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10573314_2_Ent5", "text": "tolterodine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10573314_2_Ent7", "text": "tolterodine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10573314_2_Ent2", "text": "prolonged international normalized ratios ( INRs )", "entity_type": "Entity", "start": 15, "end": 22}], "lang": "en"}
{"doc_id": "10573314_3", "wnd_id": "10573314_3_1", "text": "Two patients , each receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation , developed adverse effects after the initiation of tolterodine for urinary disorders .", "tokens": ["Two", "patients", ",", "each", "receiving", "warfarin", "for", "stroke", "prophylaxis", "in", "association", "with", "chronic", "atrial", "fibrillation", ",", "developed", "adverse", "effects", "after", "the", "initiation", "of", "tolterodine", "for", "urinary", "disorders", "."], "event_mentions": [{"id": "10573314_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10573314_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "10573314_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "10573314_3_Ent4", "role": "Treatment", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "start": 4, "end": 15}, {"entity_id": "10573314_3_Ent9", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent11", "role": "Combination_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "10573314_3_Ent6", "role": "Treatment_Disorder", "text": "stroke", "start": 7, "end": 8}, {"entity_id": "10573314_3_Ent2", "role": "Subject_Disorder", "text": "chronic atrial fibrillation", "start": 12, "end": 15}, {"entity_id": "10573314_3_Ent3", "role": "Effect", "text": "adverse effects", "start": 17, "end": 19}, {"entity_id": "10573314_3_Ent5", "role": "Treatment", "text": "after the initiation of tolterodine for urinary disorders", "start": 19, "end": 27}, {"entity_id": "10573314_3_Ent8", "role": "Treatment_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent10", "role": "Combination_Drug", "text": "tolterodine", "start": 23, "end": 24}, {"entity_id": "10573314_3_Ent7", "role": "Treatment_Disorder", "text": "urinary disorders", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "10573314_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10573314_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10573314_3_Ent4", "text": "receiving warfarin for stroke prophylaxis in association with chronic atrial fibrillation", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "10573314_3_Ent9", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent11", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10573314_3_Ent6", "text": "stroke", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10573314_3_Ent2", "text": "chronic atrial fibrillation", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10573314_3_Ent3", "text": "adverse effects", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10573314_3_Ent5", "text": "after the initiation of tolterodine for urinary disorders", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "10573314_3_Ent8", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent10", "text": "tolterodine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "10573314_3_Ent7", "text": "urinary disorders", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "10579985_3", "wnd_id": "10579985_3_1", "text": "The second is a 29 - year - old man with CD in whom nodular sclerosing Hodgkin 's lymphoma was diagnosed 3 weeks after infusion with infliximab .", "tokens": ["The", "second", "is", "a", "29", "-", "year", "-", "old", "man", "with", "CD", "in", "whom", "nodular", "sclerosing", "Hodgkin", "'s", "lymphoma", "was", "diagnosed", "3", "weeks", "after", "infusion", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 20, "end": 21}, "arguments": [{"entity_id": "10579985_3_Ent0", "role": "Subject", "text": "a 29 - year - old man with CD", "start": 3, "end": 12}, {"entity_id": "10579985_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "10579985_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "10579985_3_Ent5", "role": "Treatment_Disorder", "text": "CD", "start": 11, "end": 12}, {"entity_id": "10579985_3_Ent3", "role": "Effect", "text": "nodular sclerosing Hodgkin 's lymphoma", "start": 14, "end": 19}, {"entity_id": "10579985_3_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "10579985_3_Ent4", "role": "Treatment", "text": "3 weeks after infusion with infliximab", "start": 21, "end": 27}, {"entity_id": "10579985_3_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}, {"entity_id": "10579985_3_Ent8", "role": "Treatment_Drug", "text": "infliximab", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10579985_3_Ent0", "text": "a 29 - year - old man with CD", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "10579985_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10579985_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10579985_3_Ent5", "text": "CD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10579985_3_Ent3", "text": "nodular sclerosing Hodgkin 's lymphoma", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10579985_3_Ent6", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10579985_3_Ent4", "text": "3 weeks after infusion with infliximab", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "10579985_3_Ent7", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10579985_3_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10579985_4", "wnd_id": "10579985_4_1", "text": "We describe the clinical course of 2 patients with Crohn 's disease ( CD ) in whom lymphoma was diagnosed after treatment with infliximab .", "tokens": ["We", "describe", "the", "clinical", "course", "of", "2", "patients", "with", "Crohn", "'s", "disease", "(", "CD", ")", "in", "whom", "lymphoma", "was", "diagnosed", "after", "treatment", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 19, "end": 20}, "arguments": [{"entity_id": "10579985_4_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "10579985_4_Ent0", "role": "Subject", "text": "2 patients with Crohn 's disease ( CD )", "start": 6, "end": 15}, {"entity_id": "10579985_4_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 9, "end": 12}, {"entity_id": "10579985_4_Ent2", "role": "Effect", "text": "lymphoma", "start": 17, "end": 18}, {"entity_id": "10579985_4_Ent3", "role": "Treatment", "text": "treatment with infliximab", "start": 21, "end": 24}, {"entity_id": "10579985_4_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10579985_4_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10579985_4_Ent0", "text": "2 patients with Crohn 's disease ( CD )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "10579985_4_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "10579985_4_Ent2", "text": "lymphoma", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10579985_4_Ent3", "text": "treatment with infliximab", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "10579985_4_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10586009_2", "wnd_id": "10586009_2_1", "text": "We report a case of codeine intoxication in the neonate , in which the drug was prescribed for cough control during an emergency department visit .", "tokens": ["We", "report", "a", "case", "of", "codeine", "intoxication", "in", "the", "neonate", ",", "in", "which", "the", "drug", "was", "prescribed", "for", "cough", "control", "during", "an", "emergency", "department", "visit", "."], "event_mentions": [{"id": "10586009_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "prescribed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10586009_2_Ent4", "role": "Treatment", "text": "codeine", "start": 5, "end": 6}, {"entity_id": "10586009_2_Ent5", "role": "Treatment_Drug", "text": "codeine", "start": 5, "end": 6}, {"entity_id": "10586009_2_Ent3", "role": "Effect", "text": "intoxication", "start": 6, "end": 7}, {"entity_id": "10586009_2_Ent0", "role": "Subject", "text": "in the neonate", "start": 7, "end": 10}, {"entity_id": "10586009_2_Ent2", "role": "Subject_Age", "text": "neonate", "start": 9, "end": 10}, {"entity_id": "10586009_2_Ent1", "role": "Subject", "text": "for cough control during an emergency department visit", "start": 17, "end": 25}, {"entity_id": "10586009_2_Ent6", "role": "Treatment_Disorder", "text": "cough", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10586009_2_Ent4", "text": "codeine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10586009_2_Ent5", "text": "codeine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10586009_2_Ent3", "text": "intoxication", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10586009_2_Ent0", "text": "in the neonate", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10586009_2_Ent2", "text": "neonate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10586009_2_Ent1", "text": "for cough control during an emergency department visit", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "10586009_2_Ent6", "text": "cough", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10589077_6", "wnd_id": "10589077_6_1", "text": "We describe the clinical response , as determined by increases in total Hb and decreased transfusion needs , in five patients with thalassemia intermedia treated with HU alone or in combination with SPB .", "tokens": ["We", "describe", "the", "clinical", "response", ",", "as", "determined", "by", "increases", "in", "total", "Hb", "and", "decreased", "transfusion", "needs", ",", "in", "five", "patients", "with", "thalassemia", "intermedia", "treated", "with", "HU", "alone", "or", "in", "combination", "with", "SPB", "."], "event_mentions": [{"id": "10589077_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 24, "end": 25}, "arguments": [{"entity_id": "10589077_6_Ent2", "role": "Effect", "text": "increases in total Hb and decreased transfusion needs", "start": 9, "end": 17}, {"entity_id": "10589077_6_Ent0", "role": "Subject", "text": "in five patients with thalassemia intermedia", "start": 18, "end": 24}, {"entity_id": "10589077_6_Ent1", "role": "Subject_Population", "text": "five", "start": 19, "end": 20}, {"entity_id": "10589077_6_Ent6", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 22, "end": 24}, {"entity_id": "10589077_6_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 26, "end": 27}, {"entity_id": "10589077_6_Ent7", "role": "Combination_Drug", "text": "HU", "start": 26, "end": 27}, {"entity_id": "10589077_6_Ent3", "role": "Treatment", "text": "HU alone or in combination with SPB", "start": 26, "end": 33}, {"entity_id": "10589077_6_Ent5", "role": "Treatment_Drug", "text": "SPB", "start": 32, "end": 33}, {"entity_id": "10589077_6_Ent8", "role": "Combination_Drug", "text": "SPB", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "10589077_6_Ent2", "text": "increases in total Hb and decreased transfusion needs", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "10589077_6_Ent0", "text": "in five patients with thalassemia intermedia", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "10589077_6_Ent1", "text": "five", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10589077_6_Ent6", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10589077_6_Ent4", "text": "HU", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "10589077_6_Ent7", "text": "HU", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "10589077_6_Ent3", "text": "HU alone or in combination with SPB", "entity_type": "Entity", "start": 26, "end": 33}, {"id": "10589077_6_Ent5", "text": "SPB", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "10589077_6_Ent8", "text": "SPB", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "10592946_3", "wnd_id": "10592946_3_1", "text": "Severe rhabdomyolysis following massive ingestion of oolong tea : caffeine intoxication with coexisting hyponatremia .", "tokens": ["Severe", "rhabdomyolysis", "following", "massive", "ingestion", "of", "oolong", "tea", ":", "caffeine", "intoxication", "with", "coexisting", "hyponatremia", "."], "event_mentions": [{"id": "10592946_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "10592946_3_Ent4", "role": "Treatment_Dosage", "text": "massive", "start": 3, "end": 4}, {"entity_id": "10592946_3_Ent1", "role": "Treatment", "text": "massive ingestion of oolong tea", "start": 3, "end": 8}, {"entity_id": "10592946_3_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 4, "end": 5}, {"entity_id": "10592946_3_Ent2", "role": "Treatment_Drug", "text": "oolong tea", "start": 6, "end": 8}, {"entity_id": "10592946_3_Ent3", "role": "Treatment_Drug", "text": "caffeine", "start": 9, "end": 10}, {"entity_id": "10592946_3_Ent0", "role": "Effect", "text": "caffeine intoxication with coexisting hyponatremia", "start": 9, "end": 14}]}], "entity_mentions": [{"id": "10592946_3_Ent4", "text": "massive", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_3_Ent1", "text": "massive ingestion of oolong tea", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10592946_3_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10592946_3_Ent2", "text": "oolong tea", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10592946_3_Ent3", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10592946_3_Ent0", "text": "caffeine intoxication with coexisting hyponatremia", "entity_type": "Entity", "start": 9, "end": 14}], "lang": "en"}
{"doc_id": "10592946_6", "wnd_id": "10592946_6_1", "text": "We hypothesize that caffeine toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis .", "tokens": ["We", "hypothesize", "that", "caffeine", "toxicity", "injured", "the", "muscle", "cells", ",", "which", "were", "fragile", "due", "to", "the", "potassium", "depletion", "induced", "by", "the", "coexisting", "hyponatremia", ",", "to", "result", "in", "unusually", "severe", "rhabdomyolysis", "."], "event_mentions": [{"id": "10592946_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "injured", "start": 5, "end": 6}, "arguments": [{"entity_id": "10592946_6_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 3, "end": 4}, {"entity_id": "10592946_6_Ent1", "role": "Treatment", "text": "caffeine toxicity", "start": 3, "end": 5}, {"entity_id": "10592946_6_Ent0", "role": "Effect", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "start": 7, "end": 30}]}], "entity_mentions": [{"id": "10592946_6_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_6_Ent1", "text": "caffeine toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_6_Ent0", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 30}], "lang": "en"}
{"doc_id": "10599932_2", "wnd_id": "10599932_2_1", "text": "A pharmacokinetic interaction between the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine , was noted in a patient treated for major depression and obsessive - compulsive disorder .", "tokens": ["A", "pharmacokinetic", "interaction", "between", "the", "selective", "serotonin", "reuptake", "inhibitor", "citalopram", "and", "a", "tricyclic", "antidepressant", ",", "clomipramine", ",", "was", "noted", "in", "a", "patient", "treated", "for", "major", "depression", "and", "obsessive", "-", "compulsive", "disorder", "."], "event_mentions": [{"id": "10599932_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 2, "end": 3}, "arguments": [{"entity_id": "10599932_2_Ent1", "role": "Effect", "text": "A pharmacokinetic interaction", "start": 0, "end": 3}, {"entity_id": "10599932_2_Ent2", "role": "Treatment", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "start": 4, "end": 16}, {"entity_id": "10599932_2_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 9, "end": 10}, {"entity_id": "10599932_2_Ent4", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent8", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "10599932_2_Ent0", "role": "Subject", "text": "a patient treated for major depression and obsessive - compulsive disorder", "start": 20, "end": 31}, {"entity_id": "10599932_2_Ent5", "role": "Treatment_Disorder", "text": "depression", "start": 25, "end": 26}, {"entity_id": "10599932_2_Ent6", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "10599932_2_Ent1", "text": "A pharmacokinetic interaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10599932_2_Ent2", "text": "the selective serotonin reuptake inhibitor citalopram and a tricyclic antidepressant , clomipramine", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "10599932_2_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10599932_2_Ent4", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent8", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10599932_2_Ent0", "text": "a patient treated for major depression and obsessive - compulsive disorder", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "10599932_2_Ent5", "text": "depression", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10599932_2_Ent6", "text": "obsessive - compulsive disorder", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "10599932_5", "wnd_id": "10599932_5_1", "text": "After the addition of citalopram , a desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed .", "tokens": ["After", "the", "addition", "of", "citalopram", ",", "a", "desmethylclomipramine", "plasma", "level", "increase", "and", "an", "8", "-", "hydroacy", "-", "desmethylclomipramine", "plasma", "level", "decrease", "were", "observed", "."], "event_mentions": [{"id": "10599932_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10599932_5_Ent1", "role": "Treatment", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent0", "role": "Effect", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "start": 7, "end": 21}]}], "entity_mentions": [{"id": "10599932_5_Ent1", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent0", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "entity_type": "Entity", "start": 7, "end": 21}], "lang": "en"}
{"doc_id": "10614572_1", "wnd_id": "10614572_1_1", "text": "Intravenous valproate associated with significant hypotension in the treatment of status epilepticus .", "tokens": ["Intravenous", "valproate", "associated", "with", "significant", "hypotension", "in", "the", "treatment", "of", "status", "epilepticus", "."], "event_mentions": [{"id": "10614572_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10614572_1_Ent3", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10614572_1_Ent1", "role": "Treatment", "text": "Intravenous valproate", "start": 0, "end": 2}, {"entity_id": "10614572_1_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 1, "end": 2}, {"entity_id": "10614572_1_Ent0", "role": "Effect", "text": "significant hypotension", "start": 4, "end": 6}, {"entity_id": "10614572_1_Ent2", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10614572_1_Ent3", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10614572_1_Ent1", "text": "Intravenous valproate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10614572_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10614572_1_Ent0", "text": "significant hypotension", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10614572_1_Ent2", "text": "status epilepticus", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10614572_2", "wnd_id": "10614572_2_1", "text": "To our knowledge , this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "significant", "hypotension", "associated", "with", "intravenous", "valproate", "in", "the", "treatment", "of", "status", "epilepticus", "in", "the", "pediatric", "population", "."], "event_mentions": [{"id": "10614572_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "10614572_2_Ent2", "role": "Effect", "text": "hypotension", "start": 11, "end": 12}, {"entity_id": "10614572_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "10614572_2_Ent3", "role": "Treatment", "text": "intravenous valproate", "start": 14, "end": 16}, {"entity_id": "10614572_2_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 15, "end": 16}, {"entity_id": "10614572_2_Ent6", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 20, "end": 22}, {"entity_id": "10614572_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 24, "end": 25}, {"entity_id": "10614572_2_Ent0", "role": "Subject", "text": "pediatric population", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "10614572_2_Ent2", "text": "hypotension", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10614572_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10614572_2_Ent3", "text": "intravenous valproate", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10614572_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10614572_2_Ent6", "text": "status epilepticus", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10614572_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10614572_2_Ent0", "text": "pediatric population", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "10619721_1", "wnd_id": "10619721_1_1", "text": "In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine .", "tokens": ["In", "both", "patients", "the", "rippling", "phenomena", "worsened", "with", "pyridostigmine", "treatment", "but", "markedly", "improved", "after", "immunosuppression", "with", "azathioprine", "."], "event_mentions": [{"id": "10619721_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "worsened", "start": 6, "end": 7}, "arguments": [{"entity_id": "10619721_1_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "10619721_1_Ent0", "role": "Subject", "text": "both patients", "start": 1, "end": 3}, {"entity_id": "10619721_1_Ent2", "role": "Effect", "text": "rippling phenomena", "start": 4, "end": 6}, {"entity_id": "10619721_1_Ent3", "role": "Treatment", "text": "pyridostigmine", "start": 8, "end": 9}, {"entity_id": "10619721_1_Ent4", "role": "Treatment_Drug", "text": "pyridostigmine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10619721_1_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10619721_1_Ent0", "text": "both patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10619721_1_Ent2", "text": "rippling phenomena", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10619721_1_Ent3", "text": "pyridostigmine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10619721_1_Ent4", "text": "pyridostigmine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10633877_2", "wnd_id": "10633877_2_1", "text": "Salicylate intoxication was excluded , and theophylline was finally incriminated .", "tokens": ["Salicylate", "intoxication", "was", "excluded", ",", "and", "theophylline", "was", "finally", "incriminated", "."], "event_mentions": [{"id": "10633877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incriminated", "start": 9, "end": 10}, "arguments": [{"entity_id": "10633877_2_Ent0", "role": "Treatment", "text": "theophylline", "start": 6, "end": 7}, {"entity_id": "10633877_2_Ent1", "role": "Treatment_Drug", "text": "theophylline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10633877_2_Ent0", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10633877_2_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10646879_2", "wnd_id": "10646879_2_1", "text": "Ten to 15 % of patients treated with ifosfamide develop an encephalopathy .", "tokens": ["Ten", "to", "15", "%", "of", "patients", "treated", "with", "ifosfamide", "develop", "an", "encephalopathy", "."], "event_mentions": [{"id": "10646879_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10646879_2_Ent1", "role": "Subject_Population", "text": "Ten to 15 %", "start": 0, "end": 4}, {"entity_id": "10646879_2_Ent0", "role": "Subject", "text": "Ten to 15 % of patients", "start": 0, "end": 6}, {"entity_id": "10646879_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 8, "end": 9}, {"entity_id": "10646879_2_Ent2", "role": "Effect", "text": "encephalopathy .", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10646879_2_Ent1", "text": "Ten to 15 %", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10646879_2_Ent0", "text": "Ten to 15 % of patients", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "10646879_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10646879_2_Ent2", "text": "encephalopathy .", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10656221_2", "wnd_id": "10656221_2_1", "text": "There are few reports in the literature related to sulfonylurea - induced hepatotoxicity .", "tokens": ["There", "are", "few", "reports", "in", "the", "literature", "related", "to", "sulfonylurea", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "10656221_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "10656221_2_Ent1", "role": "Treatment", "text": "sulfonylurea", "start": 9, "end": 10}, {"entity_id": "10656221_2_Ent2", "role": "Treatment_Drug", "text": "sulfonylurea", "start": 9, "end": 10}, {"entity_id": "10656221_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10656221_2_Ent1", "text": "sulfonylurea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10656221_2_Ent2", "text": "sulfonylurea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10656221_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10660641_7", "wnd_id": "10660641_7_1", "text": "The infection tended to subside with the AMPH administration .", "tokens": ["The", "infection", "tended", "to", "subside", "with", "the", "AMPH", "administration", "."], "event_mentions": [{"id": "10660641_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subside", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_7_Ent0", "role": "Effect", "text": "infection tended", "start": 1, "end": 3}, {"entity_id": "10660641_7_Ent2", "role": "Treatment_Drug", "text": "AMPH", "start": 7, "end": 8}, {"entity_id": "10660641_7_Ent1", "role": "Treatment", "text": "AMPH administration", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10660641_7_Ent0", "text": "infection tended", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_7_Ent2", "text": "AMPH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10660641_7_Ent1", "text": "AMPH administration", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10660641_9", "wnd_id": "10660641_9_1", "text": "The symptoms did not recur during the 36 months of itraconazole treatment after discharge , and it was concluded that ITCZ was effective for A. flavus hypertrophic pachymeningitis .", "tokens": ["The", "symptoms", "did", "not", "recur", "during", "the", "36", "months", "of", "itraconazole", "treatment", "after", "discharge", ",", "and", "it", "was", "concluded", "that", "ITCZ", "was", "effective", "for", "A.", "flavus", "hypertrophic", "pachymeningitis", "."], "event_mentions": [{"id": "10660641_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 22, "end": 23}, "arguments": [{"entity_id": "10660641_9_Ent0", "role": "Effect", "text": "The symptoms did not recur", "start": 0, "end": 5}, {"entity_id": "10660641_9_Ent1", "role": "Treatment", "text": "the 36 months of itraconazole treatment after discharge", "start": 6, "end": 14}, {"entity_id": "10660641_9_Ent3", "role": "Treatment_Duration", "text": "36 months", "start": 7, "end": 9}, {"entity_id": "10660641_9_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 10, "end": 11}, {"entity_id": "10660641_9_Ent2", "role": "Treatment_Disorder", "text": "A. flavus hypertrophic pachymeningitis", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "10660641_9_Ent0", "text": "The symptoms did not recur", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10660641_9_Ent1", "text": "the 36 months of itraconazole treatment after discharge", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "10660641_9_Ent3", "text": "36 months", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10660641_9_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10660641_9_Ent2", "text": "A. flavus hypertrophic pachymeningitis", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10667036_1", "wnd_id": "10667036_1_1", "text": "Caution is , therefore , needed to prevent undesired accumulation of TCA that may lead to protracted Cushing 's syndrome .", "tokens": ["Caution", "is", ",", "therefore", ",", "needed", "to", "prevent", "undesired", "accumulation", "of", "TCA", "that", "may", "lead", "to", "protracted", "Cushing", "'s", "syndrome", "."], "event_mentions": [{"id": "10667036_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead to", "start": 14, "end": 16}, "arguments": [{"entity_id": "10667036_1_Ent1", "role": "Treatment", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent2", "role": "Treatment_Drug", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent0", "role": "Effect", "text": "protracted Cushing 's syndrome", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "10667036_1_Ent1", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent2", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent0", "text": "protracted Cushing 's syndrome", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "10682234_7", "wnd_id": "10682234_7_1", "text": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically .", "tokens": ["Intravenous", "levodopa", "25", "mg", "ameliorated", "his", "akathisia", "symptoms", "drastically", "."], "event_mentions": [{"id": "10682234_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_7_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_7_Ent0", "role": "Treatment", "text": "Intravenous levodopa 25 mg", "start": 0, "end": 4}, {"entity_id": "10682234_7_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 1, "end": 2}, {"entity_id": "10682234_7_Ent1", "role": "Treatment_Disorder", "text": "akathisia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10682234_7_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_7_Ent0", "text": "Intravenous levodopa 25 mg", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_7_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10682234_7_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1068531_2", "wnd_id": "1068531_2_1", "text": "The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy .", "tokens": ["The", "development", "of", "erythroid", "leukemia", "plus", "carcinoma", "in", "these", "two", "men", "suggests", "mutagenic", "change", "secondary", "to", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "1068531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggests", "start": 11, "end": 12}, "arguments": [{"entity_id": "1068531_2_Ent3", "role": "Effect", "text": "development of erythroid leukemia plus carcinoma", "start": 1, "end": 7}, {"entity_id": "1068531_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "1068531_2_Ent0", "role": "Subject", "text": "two men", "start": 9, "end": 11}, {"entity_id": "1068531_2_Ent2", "role": "Subject_Gender", "text": "men", "start": 10, "end": 11}, {"entity_id": "1068531_2_Ent4", "role": "Effect", "text": "mutagenic change", "start": 12, "end": 14}, {"entity_id": "1068531_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 16, "end": 17}, {"entity_id": "1068531_2_Ent5", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1068531_2_Ent3", "text": "development of erythroid leukemia plus carcinoma", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "1068531_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1068531_2_Ent0", "text": "two men", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1068531_2_Ent2", "text": "men", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1068531_2_Ent4", "text": "mutagenic change", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1068531_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1068531_2_Ent5", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "10698143_1", "wnd_id": "10698143_1_1", "text": "Central nervous system manifestations of an ibuprofen overdose reversed by naloxone .", "tokens": ["Central", "nervous", "system", "manifestations", "of", "an", "ibuprofen", "overdose", "reversed", "by", "naloxone", "."], "event_mentions": [{"id": "10698143_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "by", "start": 9, "end": 10}, "arguments": [{"entity_id": "10698143_1_Ent1", "role": "Treatment_Disorder", "text": "Central nervous system manifestations", "start": 0, "end": 4}, {"entity_id": "10698143_1_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 6, "end": 7}, {"entity_id": "10698143_1_Ent0", "role": "Treatment", "text": "naloxone", "start": 10, "end": 11}, {"entity_id": "10698143_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10698143_1_Ent1", "text": "Central nervous system manifestations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10698143_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10698143_1_Ent0", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10698143_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10698143_4", "wnd_id": "10698143_4_1", "text": "We report the case of an 11 - month - old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone .", "tokens": ["We", "report", "the", "case", "of", "an", "11", "-", "month", "-", "old", "female", "infant", "with", "a", "depressed", "level", "of", "consciousness", "after", "ingestion", "of", "ibuprofen", "whose", "mental", "status", "markedly", "improved", "with", "administration", "of", "naloxone", "."], "event_mentions": [{"id": "10698143_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10698143_4_Ent0", "role": "Subject", "text": "an 11 - month - old female infant", "start": 5, "end": 13}, {"entity_id": "10698143_4_Ent1", "role": "Subject_Age", "text": "11 - month - old", "start": 6, "end": 11}, {"entity_id": "10698143_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "10698143_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "10698143_4_Ent4", "role": "Effect", "text": "a depressed level of consciousness", "start": 14, "end": 19}, {"entity_id": "10698143_4_Ent7", "role": "Treatment_Route", "text": "ingestion", "start": 20, "end": 21}, {"entity_id": "10698143_4_Ent5", "role": "Treatment", "text": "ingestion of ibuprofen", "start": 20, "end": 23}, {"entity_id": "10698143_4_Ent6", "role": "Treatment_Drug", "text": "ibuprofen", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "10698143_4_Ent0", "text": "an 11 - month - old female infant", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10698143_4_Ent1", "text": "11 - month - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10698143_4_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10698143_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10698143_4_Ent4", "text": "a depressed level of consciousness", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10698143_4_Ent7", "text": "ingestion", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10698143_4_Ent5", "text": "ingestion of ibuprofen", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10698143_4_Ent6", "text": "ibuprofen", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "10707759_3", "wnd_id": "10707759_3_1", "text": "We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome , a rare congenital disorder .", "tokens": ["We", "describe", "a", "case", "of", "interstitial", "hypoxaemiant", "pneumonitis", "probably", "related", "to", "flecainide", "in", "a", "patient", "with", "the", "LEOPARD", "syndrome", ",", "a", "rare", "congenital", "disorder", "."], "event_mentions": [{"id": "10707759_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10707759_3_Ent1", "role": "Effect", "text": "interstitial hypoxaemiant pneumonitis", "start": 5, "end": 8}, {"entity_id": "10707759_3_Ent2", "role": "Treatment", "text": "flecainide", "start": 11, "end": 12}, {"entity_id": "10707759_3_Ent3", "role": "Treatment_Drug", "text": "flecainide", "start": 11, "end": 12}, {"entity_id": "10707759_3_Ent0", "role": "Subject", "text": "a patient with the LEOPARD syndrome", "start": 13, "end": 19}, {"entity_id": "10707759_3_Ent4", "role": "Treatment_Disorder", "text": "LEOPARD syndrome", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10707759_3_Ent1", "text": "interstitial hypoxaemiant pneumonitis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10707759_3_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10707759_3_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10707759_3_Ent0", "text": "a patient with the LEOPARD syndrome", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "10707759_3_Ent4", "text": "LEOPARD syndrome", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10723699_1", "wnd_id": "10723699_1_1", "text": "Tetracycline - induced benign intracranial hypertension .", "tokens": ["Tetracycline", "-", "induced", "benign", "intracranial", "hypertension", "."], "event_mentions": [{"id": "10723699_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10723699_1_Ent1", "role": "Treatment", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent2", "role": "Treatment_Drug", "text": "Tetracycline", "start": 0, "end": 1}, {"entity_id": "10723699_1_Ent0", "role": "Effect", "text": "benign intracranial hypertension", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "10723699_1_Ent1", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent2", "text": "Tetracycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10723699_1_Ent0", "text": "benign intracranial hypertension", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "10745478_1", "wnd_id": "10745478_1_1", "text": "This case report illustrates the use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine - induced refractory coronary vasospasm .", "tokens": ["This", "case", "report", "illustrates", "the", "use", "of", "continuous", "high", "-", "dose", "intracoronary", "nitroglycerin", "infusion", "through", "a", "6", "French", "coronary", "guiding", "catheter", "in", "the", "treatment", "of", "a", "patient", "with", "cocaine", "-", "induced", "refractory", "coronary", "vasospasm", "."], "event_mentions": [{"id": "10745478_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 23, "end": 24}, "arguments": [{"entity_id": "10745478_1_Ent3", "role": "Treatment", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "start": 5, "end": 21}, {"entity_id": "10745478_1_Ent7", "role": "Treatment_Dosage", "text": "high - dose", "start": 8, "end": 11}, {"entity_id": "10745478_1_Ent5", "role": "Treatment_Drug", "text": "intracoronary nitroglycerin", "start": 11, "end": 13}, {"entity_id": "10745478_1_Ent6", "role": "Treatment_Route", "text": "infusion through a 6 French coronary guiding catheter", "start": 13, "end": 21}, {"entity_id": "10745478_1_Ent4", "role": "Treatment_Disorder", "text": "cocaine - induced refractory coronary vasospasm", "start": 28, "end": 34}]}, {"id": "10745478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "10745478_1_Ent1", "role": "Treatment", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent2", "role": "Treatment_Drug", "text": "cocaine", "start": 28, "end": 29}, {"entity_id": "10745478_1_Ent0", "role": "Effect", "text": "refractory coronary vasospasm", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "10745478_1_Ent3", "text": "use of continuous high - dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "10745478_1_Ent7", "text": "high - dose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10745478_1_Ent5", "text": "intracoronary nitroglycerin", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10745478_1_Ent6", "text": "infusion through a 6 French coronary guiding catheter", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "10745478_1_Ent1", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent2", "text": "cocaine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "10745478_1_Ent4", "text": "cocaine - induced refractory coronary vasospasm", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "10745478_1_Ent0", "text": "refractory coronary vasospasm", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "10749332_1", "wnd_id": "10749332_1_1", "text": "However , as illustrated by these and other cases reported to date , the onset of troglitazone - induced liver injury is insidious and temporally variable .", "tokens": ["However", ",", "as", "illustrated", "by", "these", "and", "other", "cases", "reported", "to", "date", ",", "the", "onset", "of", "troglitazone", "-", "induced", "liver", "injury", "is", "insidious", "and", "temporally", "variable", "."], "event_mentions": [{"id": "10749332_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "10749332_1_Ent1", "role": "Treatment", "text": "troglitazone", "start": 16, "end": 17}, {"entity_id": "10749332_1_Ent2", "role": "Treatment_Drug", "text": "troglitazone", "start": 16, "end": 17}, {"entity_id": "10749332_1_Ent0", "role": "Effect", "text": "liver injury is insidious and temporally variable", "start": 19, "end": 26}]}], "entity_mentions": [{"id": "10749332_1_Ent1", "text": "troglitazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10749332_1_Ent2", "text": "troglitazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10749332_1_Ent0", "text": "liver injury is insidious and temporally variable", "entity_type": "Entity", "start": 19, "end": 26}], "lang": "en"}
{"doc_id": "10749332_3", "wnd_id": "10749332_3_1", "text": "Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity .", "tokens": ["Other", "thiazolidinediones", "currently", "in", "clinical", "trials", "may", "be", "able", "to", "provide", "the", "therapeutic", "benefits", "of", "troglitazone", "without", "significant", "hepatotoxicity", "."], "event_mentions": [{"id": "10749332_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "provide", "start": 10, "end": 11}, "arguments": [{"entity_id": "10749332_3_Ent0", "role": "Treatment", "text": "thiazolidinediones", "start": 1, "end": 2}, {"entity_id": "10749332_3_Ent1", "role": "Treatment_Drug", "text": "thiazolidinediones", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "10749332_3_Ent0", "text": "thiazolidinediones", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_3_Ent1", "text": "thiazolidinediones", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "10749332_4", "wnd_id": "10749332_4_1", "text": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury .", "tokens": ["The", "three", "reported", "cases", "demonstrate", "that", "troglitazone", "is", "an", "idiosyncratic", "hepatotoxin", "that", "can", "lead", "to", "irreversible", "liver", "injury", "."], "event_mentions": [{"id": "10749332_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 13, "end": 14}, "arguments": [{"entity_id": "10749332_4_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "10749332_4_Ent0", "role": "Subject", "text": "three reported cases", "start": 1, "end": 4}, {"entity_id": "10749332_4_Ent3", "role": "Treatment", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent4", "role": "Treatment_Drug", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent2", "role": "Effect", "text": "irreversible liver injury", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10749332_4_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_4_Ent0", "text": "three reported cases", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "10749332_4_Ent3", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent4", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent2", "text": "irreversible liver injury", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10752888_2", "wnd_id": "10752888_2_1", "text": "We present two cases of nitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis .", "tokens": ["We", "present", "two", "cases", "of", "nitrofurantoin", "-", "induced", "pulmonary", "toxicity", "in", "which", "the", "initial", "HRCT", "showed", "a", "widespread", "reticular", "pattern", "and", "associated", "distortion", "of", "the", "lung", "parenchyma", ",", "thought", "to", "represent", "established", "fibrosis", "."], "event_mentions": [{"id": "10752888_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "10752888_2_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 5, "end": 6}, {"entity_id": "10752888_2_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 5, "end": 6}, {"entity_id": "10752888_2_Ent0", "role": "Effect", "text": "pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis", "start": 8, "end": 33}]}], "entity_mentions": [{"id": "10752888_2_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10752888_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10752888_2_Ent0", "text": "pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis", "entity_type": "Entity", "start": 8, "end": 33}], "lang": "en"}
{"doc_id": "10759907_3", "wnd_id": "10759907_3_1", "text": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan .", "tokens": ["The", "temporal", "relationship", "suggests", "that", "the", "spinal", "cord", "infarction", "may", "be", "related", "to", "the", "use", "of", "zolmitriptan", "."], "event_mentions": [{"id": "10759907_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "10759907_3_Ent0", "role": "Effect", "text": "spinal cord infarction", "start": 6, "end": 9}, {"entity_id": "10759907_3_Ent1", "role": "Treatment", "text": "zolmitriptan", "start": 16, "end": 17}, {"entity_id": "10759907_3_Ent2", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10759907_3_Ent0", "text": "spinal cord infarction", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10759907_3_Ent1", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10759907_3_Ent2", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10774758_1", "wnd_id": "10774758_1_1", "text": "Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use .", "tokens": ["Perinatal", "vasoconstrictive", "renal", "insufficiency", "associated", "with", "maternal", "nimesulide", "use", "."], "event_mentions": [{"id": "10774758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10774758_1_Ent0", "role": "Effect", "text": "Perinatal vasoconstrictive renal insufficiency", "start": 0, "end": 4}, {"entity_id": "10774758_1_Ent1", "role": "Treatment", "text": "maternal nimesulide use", "start": 6, "end": 9}, {"entity_id": "10774758_1_Ent2", "role": "Treatment_Drug", "text": "nimesulide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10774758_1_Ent0", "text": "Perinatal vasoconstrictive renal insufficiency", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10774758_1_Ent1", "text": "maternal nimesulide use", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10774758_1_Ent2", "text": "nimesulide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10779995_2", "wnd_id": "10779995_2_1", "text": "Secondary leukemia in a child with neuroblastoma while on oral etoposide : what is the cause ?", "tokens": ["Secondary", "leukemia", "in", "a", "child", "with", "neuroblastoma", "while", "on", "oral", "etoposide", ":", "what", "is", "the", "cause", "?"], "event_mentions": [{"id": "10779995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "10779995_2_Ent2", "role": "Effect", "text": "Secondary leukemia", "start": 0, "end": 2}, {"entity_id": "10779995_2_Ent0", "role": "Subject", "text": "a child with neuroblastoma", "start": 3, "end": 7}, {"entity_id": "10779995_2_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "10779995_2_Ent4", "role": "Treatment_Disorder", "text": "neuroblastoma", "start": 6, "end": 7}, {"entity_id": "10779995_2_Ent5", "role": "Treatment_Route", "text": "oral", "start": 9, "end": 10}, {"entity_id": "10779995_2_Ent3", "role": "Treatment", "text": "oral etoposide", "start": 9, "end": 11}, {"entity_id": "10779995_2_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10779995_2_Ent2", "text": "Secondary leukemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10779995_2_Ent0", "text": "a child with neuroblastoma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10779995_2_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10779995_2_Ent4", "text": "neuroblastoma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10779995_2_Ent5", "text": "oral", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10779995_2_Ent3", "text": "oral etoposide", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10779995_2_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10803790_3", "wnd_id": "10803790_3_1", "text": "Case 3 : A 29 - year - old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment .", "tokens": ["Case", "3", ":", "A", "29", "-", "year", "-", "old", "female", "alcoholic", "complained", "of", "general", "fatigue", "and", "a", "slight", "fever", "after", "1.5", "years", "of", "abstinence", "with", "cyanamide", "treatment", "."], "event_mentions": [{"id": "10803790_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 11, "end": 12}, "arguments": [{"entity_id": "10803790_3_Ent0", "role": "Subject", "text": "A 29 - year - old female alcoholic", "start": 3, "end": 11}, {"entity_id": "10803790_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "10803790_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "10803790_3_Ent5", "role": "Treatment_Disorder", "text": "alcoholic", "start": 10, "end": 11}, {"entity_id": "10803790_3_Ent3", "role": "Effect", "text": "general fatigue and a slight fever", "start": 13, "end": 19}, {"entity_id": "10803790_3_Ent4", "role": "Treatment", "text": "after 1.5 years of abstinence with cyanamide", "start": 19, "end": 26}, {"entity_id": "10803790_3_Ent6", "role": "Treatment_Duration", "text": "1.5 years", "start": 20, "end": 22}, {"entity_id": "10803790_3_Ent7", "role": "Treatment_Drug", "text": "cyanamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10803790_3_Ent0", "text": "A 29 - year - old female alcoholic", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "10803790_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10803790_3_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10803790_3_Ent5", "text": "alcoholic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10803790_3_Ent3", "text": "general fatigue and a slight fever", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "10803790_3_Ent4", "text": "after 1.5 years of abstinence with cyanamide", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "10803790_3_Ent6", "text": "1.5 years", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10803790_3_Ent7", "text": "cyanamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10812579_1", "wnd_id": "10812579_1_1", "text": "A 77 - year - old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma .", "tokens": ["A", "77", "-", "year", "-", "old", "woman", "with", "no", "history", "of", "epilepsy", "presented", "a", "probable", "nonconvulsive", "status", "epilepticus", "while", "receiving", "continuous", "intravenous", "morphine", "for", "back", "pain", "relating", "to", "vertebral", "metastasis", "of", "a", "malignant", "lymphoma", "."], "event_mentions": [{"id": "10812579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 19, "end": 20}, "arguments": [{"entity_id": "10812579_1_Ent0", "role": "Subject", "text": "A 77 - year - old woman with no history of epilepsy", "start": 0, "end": 12}, {"entity_id": "10812579_1_Ent1", "role": "Subject_Age", "text": "77 - year - old", "start": 1, "end": 6}, {"entity_id": "10812579_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10812579_1_Ent3", "role": "Subject_Disorder", "text": "no history of epilepsy", "start": 8, "end": 12}, {"entity_id": "10812579_1_Ent4", "role": "Effect", "text": "a probable nonconvulsive status epilepticus", "start": 13, "end": 18}, {"entity_id": "10812579_1_Ent8", "role": "Treatment_Freq", "text": "continuous", "start": 20, "end": 21}, {"entity_id": "10812579_1_Ent5", "role": "Treatment", "text": "continuous intravenous morphine", "start": 20, "end": 23}, {"entity_id": "10812579_1_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "10812579_1_Ent6", "role": "Treatment_Drug", "text": "morphine", "start": 22, "end": 23}, {"entity_id": "10812579_1_Ent9", "role": "Treatment_Disorder", "text": "back pain relating to vertebral metastasis of a malignant lymphoma", "start": 24, "end": 34}]}], "entity_mentions": [{"id": "10812579_1_Ent0", "text": "A 77 - year - old woman with no history of epilepsy", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "10812579_1_Ent1", "text": "77 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10812579_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10812579_1_Ent3", "text": "no history of epilepsy", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10812579_1_Ent4", "text": "a probable nonconvulsive status epilepticus", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "10812579_1_Ent8", "text": "continuous", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10812579_1_Ent5", "text": "continuous intravenous morphine", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10812579_1_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10812579_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10812579_1_Ent9", "text": "back pain relating to vertebral metastasis of a malignant lymphoma", "entity_type": "Entity", "start": 24, "end": 34}], "lang": "en"}
{"doc_id": "10812579_3", "wnd_id": "10812579_3_1", "text": "Nonconvulsive status epilepticus : the role of morphine and its antagonist .", "tokens": ["Nonconvulsive", "status", "epilepticus", ":", "the", "role", "of", "morphine", "and", "its", "antagonist", "."], "event_mentions": [{"id": "10812579_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "the role", "start": 4, "end": 6}, "arguments": [{"entity_id": "10812579_3_Ent0", "role": "Effect", "text": "Nonconvulsive status epilepticus", "start": 0, "end": 3}, {"entity_id": "10812579_3_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 7, "end": 8}, {"entity_id": "10812579_3_Ent1", "role": "Treatment", "text": "morphine and its antagonist", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "10812579_3_Ent0", "text": "Nonconvulsive status epilepticus", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10812579_3_Ent2", "text": "morphine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10812579_3_Ent1", "text": "morphine and its antagonist", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "1087773_1", "wnd_id": "1087773_1_1", "text": "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor .", "tokens": ["After", "seven", "months", "'", "continuous", "treatment", "for", "suspected", "tuberculosis", "with", "rifampicin", "and", "ethambutol", "a", "nine", "-", "year", "-", "old", "boy", "developed", "polyarthritis", ",", "rash", "and", "hepatitis", "in", "association", "with", "anti", "-", "native", "DNA", "antibodies", "and", "positive", "antinuclear", "factor", "."], "event_mentions": [{"id": "1087773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "1087773_1_Ent9", "role": "Treatment_Time_elapsed", "text": "seven months", "start": 1, "end": 3}, {"entity_id": "1087773_1_Ent4", "role": "Treatment", "text": "seven months ' continuous treatment", "start": 1, "end": 6}, {"entity_id": "1087773_1_Ent8", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "1087773_1_Ent5", "role": "Treatment", "text": "with rifampicin and ethambutol", "start": 9, "end": 13}, {"entity_id": "1087773_1_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent11", "role": "Combination_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent7", "role": "Treatment_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent10", "role": "Combination_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent0", "role": "Subject", "text": "a nine - year - old boy", "start": 13, "end": 20}, {"entity_id": "1087773_1_Ent1", "role": "Subject_Age", "text": "nine - year - old", "start": 14, "end": 19}, {"entity_id": "1087773_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 19, "end": 20}, {"entity_id": "1087773_1_Ent3", "role": "Effect", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "start": 21, "end": 38}]}], "entity_mentions": [{"id": "1087773_1_Ent9", "text": "seven months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1087773_1_Ent4", "text": "seven months ' continuous treatment", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1087773_1_Ent8", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1087773_1_Ent5", "text": "with rifampicin and ethambutol", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1087773_1_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent11", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent10", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent0", "text": "a nine - year - old boy", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "1087773_1_Ent1", "text": "nine - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1087773_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1087773_1_Ent3", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "entity_type": "Entity", "start": 21, "end": 38}], "lang": "en"}
{"doc_id": "10891991_4", "wnd_id": "10891991_4_1", "text": "OBJECTIVE : To describe the development of valproate - related reproductive endocrine disorders in women with epilepsy .", "tokens": ["OBJECTIVE", ":", "To", "describe", "the", "development", "of", "valproate", "-", "related", "reproductive", "endocrine", "disorders", "in", "women", "with", "epilepsy", "."], "event_mentions": [{"id": "10891991_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10891991_4_Ent3", "role": "Treatment", "text": "valproate", "start": 7, "end": 8}, {"entity_id": "10891991_4_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 7, "end": 8}, {"entity_id": "10891991_4_Ent2", "role": "Effect", "text": "reproductive endocrine disorders", "start": 10, "end": 13}, {"entity_id": "10891991_4_Ent1", "role": "Subject_Gender", "text": "women", "start": 14, "end": 15}, {"entity_id": "10891991_4_Ent0", "role": "Subject", "text": "women with epilepsy", "start": 14, "end": 17}, {"entity_id": "10891991_4_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10891991_4_Ent3", "text": "valproate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10891991_4_Ent4", "text": "valproate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10891991_4_Ent2", "text": "reproductive endocrine disorders", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "10891991_4_Ent1", "text": "women", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10891991_4_Ent0", "text": "women with epilepsy", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10891991_4_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10891991_6", "wnd_id": "10891991_6_1", "text": "RESULTS : Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women .", "tokens": ["RESULTS", ":", "Replacing", "valproate", "with", "lamotrigine", "resulted", "in", "a", "decrease", "in", "serum", "testosterone", "concentrations", "in", "all", "3", "women", "."], "event_mentions": [{"id": "10891991_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "10891991_6_Ent4", "role": "Treatment", "text": "Replacing valproate with lamotrigine", "start": 2, "end": 6}, {"entity_id": "10891991_6_Ent5", "role": "Treatment_Drug", "text": "lamotrigine", "start": 5, "end": 6}, {"entity_id": "10891991_6_Ent3", "role": "Effect", "text": "a decrease in serum testosterone concentrations", "start": 8, "end": 14}, {"entity_id": "10891991_6_Ent0", "role": "Subject", "text": "all 3 women", "start": 15, "end": 18}, {"entity_id": "10891991_6_Ent1", "role": "Subject_Population", "text": "3", "start": 16, "end": 17}, {"entity_id": "10891991_6_Ent2", "role": "Subject_Gender", "text": "women", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10891991_6_Ent4", "text": "Replacing valproate with lamotrigine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "10891991_6_Ent5", "text": "lamotrigine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10891991_6_Ent3", "text": "a decrease in serum testosterone concentrations", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10891991_6_Ent0", "text": "all 3 women", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "10891991_6_Ent1", "text": "3", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10891991_6_Ent2", "text": "women", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10907391_2", "wnd_id": "10907391_2_1", "text": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity .", "tokens": ["Phantom", "limb", "pain", "as", "a", "manifestation", "of", "paclitaxel", "neurotoxicity", "."], "event_mentions": [{"id": "10907391_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestation", "start": 5, "end": 6}, "arguments": [{"entity_id": "10907391_2_Ent0", "role": "Effect", "text": "Phantom limb pain", "start": 0, "end": 3}, {"entity_id": "10907391_2_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "10907391_2_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10907391_2_Ent0", "text": "Phantom limb pain", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10907391_2_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10907391_2_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10907391_3", "wnd_id": "10907391_3_1", "text": "Physicians should be aware that PLP can occur after initiation of paclitaxel .", "tokens": ["Physicians", "should", "be", "aware", "that", "PLP", "can", "occur", "after", "initiation", "of", "paclitaxel", "."], "event_mentions": [{"id": "10907391_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 7, "end": 8}, "arguments": [{"entity_id": "10907391_3_Ent0", "role": "Effect", "text": "PLP", "start": 5, "end": 6}, {"entity_id": "10907391_3_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 11, "end": 12}, {"entity_id": "10907391_3_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10907391_3_Ent0", "text": "PLP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10907391_3_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10907391_3_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10981493_1", "wnd_id": "10981493_1_1", "text": "Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies , but has not been well described or emphasized in the medical literature .", "tokens": ["Ataxia", "caused", "by", "propafenone", "has", "been", "reported", "to", "the", "pharmaceutical", "companies", "and", "drug", "monitoring", "agencies", ",", "but", "has", "not", "been", "well", "described", "or", "emphasized", "in", "the", "medical", "literature", "."], "event_mentions": [{"id": "10981493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "10981493_1_Ent0", "role": "Effect", "text": "Ataxia", "start": 0, "end": 1}, {"entity_id": "10981493_1_Ent1", "role": "Treatment", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "10981493_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10981493_1_Ent0", "text": "Ataxia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_1_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10981493_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11008259_3", "wnd_id": "11008259_3_1", "text": "This is the first report of non - convulsive status epilepticus provoked by tiagabine in adolescent patients .", "tokens": ["This", "is", "the", "first", "report", "of", "non", "-", "convulsive", "status", "epilepticus", "provoked", "by", "tiagabine", "in", "adolescent", "patients", "."], "event_mentions": [{"id": "11008259_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 11, "end": 12}, "arguments": [{"entity_id": "11008259_3_Ent2", "role": "Effect", "text": "non - convulsive status epilepticus", "start": 6, "end": 11}, {"entity_id": "11008259_3_Ent3", "role": "Treatment", "text": "tiagabine", "start": 13, "end": 14}, {"entity_id": "11008259_3_Ent4", "role": "Treatment_Drug", "text": "tiagabine", "start": 13, "end": 14}, {"entity_id": "11008259_3_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 15, "end": 16}, {"entity_id": "11008259_3_Ent0", "role": "Subject", "text": "adolescent patients", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11008259_3_Ent2", "text": "non - convulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11008259_3_Ent3", "text": "tiagabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11008259_3_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11008259_3_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11008259_3_Ent0", "text": "adolescent patients", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "110153_1", "wnd_id": "110153_1_1", "text": "There have been many reports of probable lithium - induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range .", "tokens": ["There", "have", "been", "many", "reports", "of", "probable", "lithium", "-", "induced", "organic", "brain", "syndromes", "occurring", "when", "serum", "lithium", "levels", "are", "within", "or", "close", "to", "the", "therapeutic", "range", "."], "event_mentions": [{"id": "110153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "110153_1_Ent1", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent0", "role": "Effect", "text": "organic brain syndromes", "start": 10, "end": 13}, {"entity_id": "110153_1_Ent2", "role": "Treatment", "text": "when serum lithium levels are within or close to the therapeutic range", "start": 14, "end": 26}]}], "entity_mentions": [{"id": "110153_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent0", "text": "organic brain syndromes", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "110153_1_Ent2", "text": "when serum lithium levels are within or close to the therapeutic range", "entity_type": "Entity", "start": 14, "end": 26}], "lang": "en"}
{"doc_id": "11020127_2", "wnd_id": "11020127_2_1", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity .", "tokens": ["Protease", "inhibitors", "(", "ritonavir", "and", "saquinavir", ")", "were", "added", "to", "the", "treatment", "and", "the", "patient", "developed", "progressive", "ataxia", "related", "to", "carbamazepine", "toxicity", "."], "event_mentions": [{"id": "11020127_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "11020127_2_Ent5", "role": "Treatment_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent6", "role": "Combination_Drug", "text": "Protease inhibitors", "start": 0, "end": 2}, {"entity_id": "11020127_2_Ent2", "role": "Treatment", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "start": 0, "end": 12}, {"entity_id": "11020127_2_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "11020127_2_Ent1", "role": "Effect", "text": "progressive ataxia related to carbamazepine toxicity", "start": 16, "end": 22}, {"entity_id": "11020127_2_Ent3", "role": "Treatment", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "11020127_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11020127_2_Ent5", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent6", "text": "Protease inhibitors", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11020127_2_Ent2", "text": "Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11020127_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11020127_2_Ent1", "text": "progressive ataxia related to carbamazepine toxicity", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "11020127_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11020127_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11020127_4", "wnd_id": "11020127_4_1", "text": "The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir .", "tokens": ["The", "patient", "was", "diagnosed", "with", "carbamazepine", "toxicity", "related", "to", "the", "introduction", "of", "ritonavir", "."], "event_mentions": [{"id": "11020127_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "11020127_4_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "11020127_4_Ent1", "role": "Effect", "text": "carbamazepine toxicity", "start": 5, "end": 7}, {"entity_id": "11020127_4_Ent2", "role": "Treatment", "text": "ritonavir", "start": 12, "end": 13}, {"entity_id": "11020127_4_Ent3", "role": "Treatment_Drug", "text": "ritonavir", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11020127_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11020127_4_Ent1", "text": "carbamazepine toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11020127_4_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11020127_4_Ent3", "text": "ritonavir", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11026106_2", "wnd_id": "11026106_2_1", "text": "Minocycline - induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis .", "tokens": ["Minocycline", "-", "induced", "autoimmune", "hepatitis", "is", "usually", "identical", "to", "sporadic", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11026106_2_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent3", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_2_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 3, "end": 5}, {"entity_id": "11026106_2_Ent2", "role": "Treatment_Disorder", "text": "sporadic autoimmune hepatitis", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "11026106_2_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent3", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_2_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11026106_2_Ent2", "text": "sporadic autoimmune hepatitis", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "11033734_4", "wnd_id": "11033734_4_1", "text": "Three of these patients had convulsions attributed to imipenem / cilastatin ; 3.6 % of the patients had seizure , or 2 % of imipenem / cilastatin administrations was followed by a seizure attack .", "tokens": ["Three", "of", "these", "patients", "had", "convulsions", "attributed", "to", "imipenem", "/", "cilastatin", ";", "3.6", "%", "of", "the", "patients", "had", "seizure", ",", "or", "2", "%", "of", "imipenem", "/", "cilastatin", "administrations", "was", "followed", "by", "a", "seizure", "attack", "."], "event_mentions": [{"id": "11033734_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 6, "end": 7}, "arguments": [{"entity_id": "11033734_4_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "11033734_4_Ent0", "role": "Subject", "text": "Three of these patients", "start": 0, "end": 4}, {"entity_id": "11033734_4_Ent2", "role": "Effect", "text": "convulsions", "start": 5, "end": 6}, {"entity_id": "11033734_4_Ent4", "role": "Treatment_Drug", "text": "imipenem", "start": 8, "end": 9}, {"entity_id": "11033734_4_Ent6", "role": "Combination_Drug", "text": "imipenem", "start": 8, "end": 9}, {"entity_id": "11033734_4_Ent3", "role": "Treatment", "text": "imipenem / cilastatin", "start": 8, "end": 11}, {"entity_id": "11033734_4_Ent5", "role": "Treatment_Drug", "text": "cilastatin", "start": 10, "end": 11}, {"entity_id": "11033734_4_Ent7", "role": "Combination_Drug", "text": "cilastatin", "start": 10, "end": 11}]}, {"id": "11033734_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11033734_4_Ent8", "role": "Subject", "text": "2 %", "start": 21, "end": 23}, {"entity_id": "11033734_4_Ent9", "role": "Subject_Population", "text": "2 %", "start": 21, "end": 23}, {"entity_id": "11033734_4_Ent12", "role": "Treatment_Drug", "text": "imipenem", "start": 24, "end": 25}, {"entity_id": "11033734_4_Ent14", "role": "Combination_Drug", "text": "imipenem", "start": 24, "end": 25}, {"entity_id": "11033734_4_Ent11", "role": "Treatment", "text": "imipenem / cilastatin", "start": 24, "end": 27}, {"entity_id": "11033734_4_Ent13", "role": "Treatment_Drug", "text": "cilastatin", "start": 26, "end": 27}, {"entity_id": "11033734_4_Ent15", "role": "Combination_Drug", "text": "cilastatin", "start": 26, "end": 27}, {"entity_id": "11033734_4_Ent10", "role": "Effect", "text": "seizure", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11033734_4_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11033734_4_Ent0", "text": "Three of these patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11033734_4_Ent2", "text": "convulsions", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11033734_4_Ent4", "text": "imipenem", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11033734_4_Ent6", "text": "imipenem", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11033734_4_Ent3", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11033734_4_Ent5", "text": "cilastatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11033734_4_Ent7", "text": "cilastatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11033734_4_Ent8", "text": "2 %", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11033734_4_Ent9", "text": "2 %", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11033734_4_Ent12", "text": "imipenem", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11033734_4_Ent14", "text": "imipenem", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11033734_4_Ent11", "text": "imipenem / cilastatin", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11033734_4_Ent13", "text": "cilastatin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "11033734_4_Ent15", "text": "cilastatin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "11033734_4_Ent10", "text": "seizure", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11033836_2", "wnd_id": "11033836_2_1", "text": "Placebo - controlled clinical trials of recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] ) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL , and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions .", "tokens": ["Placebo", "-", "controlled", "clinical", "trials", "of", "recombinant", "human", "interleukin", "-", "11", "(", "rhIL", "-", "11", ",", "also", "known", "as", "oprelvekin", "[", "Neumega", "]", ")", "in", "patients", "with", "nonmyeloid", "malignancies", "have", "demonstrated", "significant", "efficacy", "in", "preventing", "postchemotherapy", "platelet", "nadirs", "of", "<", "or", "=", "20,000/microL", ",", "and", "reducing", "the", "need", "for", "platelet", "transfusions", "while", "continuing", "chemotherapy", "without", "dose", "reductions", "."], "event_mentions": [{"id": "11033836_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "preventing", "start": 34, "end": 35}, "arguments": [{"entity_id": "11033836_2_Ent4", "role": "Treatment_Drug", "text": "recombinant human interleukin - 11", "start": 6, "end": 11}, {"entity_id": "11033836_2_Ent2", "role": "Treatment", "text": "recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] )", "start": 6, "end": 24}, {"entity_id": "11033836_2_Ent0", "role": "Subject", "text": "patients with nonmyeloid malignancies", "start": 25, "end": 29}, {"entity_id": "11033836_2_Ent1", "role": "Subject_Disorder", "text": "nonmyeloid malignancies", "start": 27, "end": 29}, {"entity_id": "11033836_2_Ent3", "role": "Treatment_Disorder", "text": "postchemotherapy platelet nadirs of < or = 20,000/microL", "start": 35, "end": 43}]}], "entity_mentions": [{"id": "11033836_2_Ent4", "text": "recombinant human interleukin - 11", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11033836_2_Ent2", "text": "recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] )", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "11033836_2_Ent0", "text": "patients with nonmyeloid malignancies", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "11033836_2_Ent1", "text": "nonmyeloid malignancies", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "11033836_2_Ent3", "text": "postchemotherapy platelet nadirs of < or = 20,000/microL", "entity_type": "Entity", "start": 35, "end": 43}], "lang": "en"}
{"doc_id": "11059196_1", "wnd_id": "11059196_1_1", "text": "Acute pancreatitis in a child with idiopathic ulcerative colitis on long - term 5 - aminosalicylic acid therapy .", "tokens": ["Acute", "pancreatitis", "in", "a", "child", "with", "idiopathic", "ulcerative", "colitis", "on", "long", "-", "term", "5", "-", "aminosalicylic", "acid", "therapy", "."], "event_mentions": [{"id": "11059196_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "11059196_1_Ent2", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "11059196_1_Ent0", "role": "Subject", "text": "a child with idiopathic ulcerative colitis", "start": 3, "end": 9}, {"entity_id": "11059196_1_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "11059196_1_Ent5", "role": "Treatment_Disorder", "text": "idiopathic ulcerative colitis", "start": 6, "end": 9}, {"entity_id": "11059196_1_Ent6", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "11059196_1_Ent3", "role": "Treatment", "text": "long - term 5 - aminosalicylic acid therapy", "start": 10, "end": 18}, {"entity_id": "11059196_1_Ent4", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11059196_1_Ent2", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11059196_1_Ent0", "text": "a child with idiopathic ulcerative colitis", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11059196_1_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11059196_1_Ent5", "text": "idiopathic ulcerative colitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "11059196_1_Ent6", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11059196_1_Ent3", "text": "long - term 5 - aminosalicylic acid therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "11059196_1_Ent4", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11059196_2", "wnd_id": "11059196_2_1", "text": "We describe a 10 - year - old boy with ulcerative colitis who developed acute pancreatitis while on long - term treatment with 5 - aminosalicylic acid .", "tokens": ["We", "describe", "a", "10", "-", "year", "-", "old", "boy", "with", "ulcerative", "colitis", "who", "developed", "acute", "pancreatitis", "while", "on", "long", "-", "term", "treatment", "with", "5", "-", "aminosalicylic", "acid", "."], "event_mentions": [{"id": "11059196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11059196_2_Ent0", "role": "Subject", "text": "a 10 - year - old boy with ulcerative colitis", "start": 2, "end": 12}, {"entity_id": "11059196_2_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 3, "end": 8}, {"entity_id": "11059196_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "11059196_2_Ent7", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 10, "end": 12}, {"entity_id": "11059196_2_Ent3", "role": "Effect", "text": "acute pancreatitis", "start": 14, "end": 16}, {"entity_id": "11059196_2_Ent5", "role": "Treatment_Freq", "text": "long - term treatment", "start": 18, "end": 22}, {"entity_id": "11059196_2_Ent4", "role": "Treatment", "text": "long - term treatment with 5 - aminosalicylic acid", "start": 18, "end": 27}, {"entity_id": "11059196_2_Ent6", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "11059196_2_Ent0", "text": "a 10 - year - old boy with ulcerative colitis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11059196_2_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11059196_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11059196_2_Ent7", "text": "ulcerative colitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11059196_2_Ent3", "text": "acute pancreatitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11059196_2_Ent5", "text": "long - term treatment", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "11059196_2_Ent4", "text": "long - term treatment with 5 - aminosalicylic acid", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "11059196_2_Ent6", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "11077455_1", "wnd_id": "11077455_1_1", "text": "CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .", "tokens": ["CONCLUSION", ":", "Marked", "visual", "field", "constriction", "appears", "to", "be", "associated", "with", "vigabatrin", "therapy", "."], "event_mentions": [{"id": "11077455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "11077455_1_Ent0", "role": "Effect", "text": "Marked visual field constriction", "start": 2, "end": 6}, {"entity_id": "11077455_1_Ent2", "role": "Treatment_Drug", "text": "vigabatrin", "start": 11, "end": 12}, {"entity_id": "11077455_1_Ent1", "role": "Treatment", "text": "vigabatrin therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11077455_1_Ent0", "text": "Marked visual field constriction", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11077455_1_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11077455_1_Ent1", "text": "vigabatrin therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "11077455_5", "wnd_id": "11077455_5_1", "text": "The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .", "tokens": ["The", "field", "defects", "and", "some", "electrophysiological", "abnormalities", "persist", "when", "vigabatrin", "therapy", "is", "withdrawn", "."], "event_mentions": [{"id": "11077455_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "persist", "start": 7, "end": 8}, "arguments": [{"entity_id": "11077455_5_Ent0", "role": "Effect", "text": "field defects and some electrophysiological abnormalities persist", "start": 1, "end": 8}, {"entity_id": "11077455_5_Ent2", "role": "Treatment_Drug", "text": "vigabatrin", "start": 9, "end": 10}, {"entity_id": "11077455_5_Ent1", "role": "Treatment", "text": "vigabatrin therapy is withdrawn", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "11077455_5_Ent0", "text": "field defects and some electrophysiological abnormalities persist", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "11077455_5_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11077455_5_Ent1", "text": "vigabatrin therapy is withdrawn", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "11096051_2", "wnd_id": "11096051_2_1", "text": "Management of hypophosphatemia induced by high - flux hemodiafiltration for the treatment of vancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate .", "tokens": ["Management", "of", "hypophosphatemia", "induced", "by", "high", "-", "flux", "hemodiafiltration", "for", "the", "treatment", "of", "vancomycin", "toxicity", ":", "intravenous", "phosphorus", "therapy", "versus", "use", "of", "a", "phosphorus", "-", "enriched", "dialysate", "."], "event_mentions": [{"id": "11096051_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Management", "start": 0, "end": 1}, "arguments": [{"entity_id": "11096051_2_Ent2", "role": "Treatment_Disorder", "text": "hypophosphatemia", "start": 2, "end": 3}, {"entity_id": "11096051_2_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 16, "end": 17}, {"entity_id": "11096051_2_Ent0", "role": "Treatment", "text": "intravenous phosphorus", "start": 16, "end": 18}, {"entity_id": "11096051_2_Ent5", "role": "Treatment_Drug", "text": "phosphorus", "start": 17, "end": 18}, {"entity_id": "11096051_2_Ent6", "role": "Treatment_Drug", "text": "phosphorus", "start": 23, "end": 24}, {"entity_id": "11096051_2_Ent1", "role": "Treatment", "text": "phosphorus - enriched dialysate", "start": 23, "end": 27}, {"entity_id": "11096051_2_Ent4", "role": "Treatment_Route", "text": "dialysate", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11096051_2_Ent2", "text": "hypophosphatemia", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11096051_2_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11096051_2_Ent0", "text": "intravenous phosphorus", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "11096051_2_Ent5", "text": "phosphorus", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11096051_2_Ent6", "text": "phosphorus", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11096051_2_Ent1", "text": "phosphorus - enriched dialysate", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "11096051_2_Ent4", "text": "dialysate", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "11105373_2", "wnd_id": "11105373_2_1", "text": "Nail staining from hydroquinone cream .", "tokens": ["Nail", "staining", "from", "hydroquinone", "cream", "."], "event_mentions": [{"id": "11105373_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "11105373_2_Ent0", "role": "Effect", "text": "Nail staining", "start": 0, "end": 2}, {"entity_id": "11105373_2_Ent2", "role": "Treatment_Drug", "text": "hydroquinone", "start": 3, "end": 4}, {"entity_id": "11105373_2_Ent1", "role": "Treatment", "text": "hydroquinone cream", "start": 3, "end": 5}, {"entity_id": "11105373_2_Ent3", "role": "Treatment_Route", "text": "cream", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11105373_2_Ent0", "text": "Nail staining", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11105373_2_Ent2", "text": "hydroquinone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11105373_2_Ent1", "text": "hydroquinone cream", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11105373_2_Ent3", "text": "cream", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11111942_1", "wnd_id": "11111942_1_1", "text": "Diarrhea - associated over - anticoagulation in a patient taking warfarin : therapeutic role of cholestyramine .", "tokens": ["Diarrhea", "-", "associated", "over", "-", "anticoagulation", "in", "a", "patient", "taking", "warfarin", ":", "therapeutic", "role", "of", "cholestyramine", "."], "event_mentions": [{"id": "11111942_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - anticoagulation", "start": 3, "end": 6}, "arguments": [{"entity_id": "11111942_1_Ent1", "role": "Effect", "text": "Diarrhea - associated over - anticoagulation", "start": 0, "end": 6}, {"entity_id": "11111942_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "11111942_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 10, "end": 11}, {"entity_id": "11111942_1_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11111942_1_Ent1", "text": "Diarrhea - associated over - anticoagulation", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11111942_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11111942_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11111942_1_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11122162_1", "wnd_id": "11122162_1_1", "text": "MI related to the use of activated and non - activated PCCs predominantly affects young patients who often have no preceding history of , or risk factors for , MI and tends to be associated with large cumulative doses of concentrate .", "tokens": ["MI", "related", "to", "the", "use", "of", "activated", "and", "non", "-", "activated", "PCCs", "predominantly", "affects", "young", "patients", "who", "often", "have", "no", "preceding", "history", "of", ",", "or", "risk", "factors", "for", ",", "MI", "and", "tends", "to", "be", "associated", "with", "large", "cumulative", "doses", "of", "concentrate", "."], "event_mentions": [{"id": "11122162_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "11122162_1_Ent2", "role": "Effect", "text": "MI", "start": 0, "end": 1}, {"entity_id": "11122162_1_Ent6", "role": "Treatment_Drug", "text": "activated", "start": 6, "end": 7}, {"entity_id": "11122162_1_Ent3", "role": "Treatment", "text": "activated and non - activated PCCs", "start": 6, "end": 12}, {"entity_id": "11122162_1_Ent5", "role": "Treatment_Drug", "text": "non - activated PCCs", "start": 8, "end": 12}, {"entity_id": "11122162_1_Ent7", "role": "Treatment_Drug", "text": "PCCs", "start": 11, "end": 12}, {"entity_id": "11122162_1_Ent1", "role": "Subject_Age", "text": "young", "start": 14, "end": 15}, {"entity_id": "11122162_1_Ent0", "role": "Subject", "text": "young patients who often have no preceding history of , or risk factors for , MI", "start": 14, "end": 30}, {"entity_id": "11122162_1_Ent8", "role": "Treatment_Dosage", "text": "large cumulative doses", "start": 36, "end": 39}, {"entity_id": "11122162_1_Ent4", "role": "Treatment", "text": "large cumulative doses of concentrate", "start": 36, "end": 41}]}], "entity_mentions": [{"id": "11122162_1_Ent2", "text": "MI", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11122162_1_Ent6", "text": "activated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11122162_1_Ent3", "text": "activated and non - activated PCCs", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11122162_1_Ent5", "text": "non - activated PCCs", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "11122162_1_Ent7", "text": "PCCs", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11122162_1_Ent1", "text": "young", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11122162_1_Ent0", "text": "young patients who often have no preceding history of , or risk factors for , MI", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "11122162_1_Ent8", "text": "large cumulative doses", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "11122162_1_Ent4", "text": "large cumulative doses of concentrate", "entity_type": "Entity", "start": 36, "end": 41}], "lang": "en"}
{"doc_id": "11131346_3", "wnd_id": "11131346_3_1", "text": "An 8 - year - old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug .", "tokens": ["An", "8", "-", "year", "-", "old", "child", "with", "familial", "Mediterranean", "fever", "exhibited", "signs", "of", "colchicine", "intoxication", "while", "receiving", "prophylactic", "doses", "of", "the", "drug", "."], "event_mentions": [{"id": "11131346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 11, "end": 12}, "arguments": [{"entity_id": "11131346_3_Ent0", "role": "Subject", "text": "An 8 - year - old child", "start": 0, "end": 7}, {"entity_id": "11131346_3_Ent1", "role": "Subject_Age", "text": "8 - year - old", "start": 1, "end": 6}, {"entity_id": "11131346_3_Ent2", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "11131346_3_Ent6", "role": "Treatment_Disorder", "text": "familial Mediterranean fever", "start": 8, "end": 11}, {"entity_id": "11131346_3_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_3_Ent3", "role": "Effect", "text": "colchicine intoxication", "start": 14, "end": 16}, {"entity_id": "11131346_3_Ent5", "role": "Treatment_Dosage", "text": "prophylactic doses", "start": 18, "end": 20}, {"entity_id": "11131346_3_Ent4", "role": "Treatment", "text": "prophylactic doses of the drug", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "11131346_3_Ent0", "text": "An 8 - year - old child", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11131346_3_Ent1", "text": "8 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11131346_3_Ent2", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11131346_3_Ent6", "text": "familial Mediterranean fever", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11131346_3_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_3_Ent3", "text": "colchicine intoxication", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11131346_3_Ent5", "text": "prophylactic doses", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11131346_3_Ent4", "text": "prophylactic doses of the drug", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "11144696_2", "wnd_id": "11144696_2_1", "text": "To report a patient having a first - time seizure after receiving venlafaxine and trimipramine for depression .", "tokens": ["To", "report", "a", "patient", "having", "a", "first", "-", "time", "seizure", "after", "receiving", "venlafaxine", "and", "trimipramine", "for", "depression", "."], "event_mentions": [{"id": "11144696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 11, "end": 12}, "arguments": [{"entity_id": "11144696_2_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "11144696_2_Ent1", "role": "Effect", "text": "seizure", "start": 9, "end": 10}, {"entity_id": "11144696_2_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 12, "end": 13}, {"entity_id": "11144696_2_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 12, "end": 13}, {"entity_id": "11144696_2_Ent2", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 12, "end": 15}, {"entity_id": "11144696_2_Ent4", "role": "Treatment_Drug", "text": "trimipramine", "start": 14, "end": 15}, {"entity_id": "11144696_2_Ent7", "role": "Combination_Drug", "text": "trimipramine", "start": 14, "end": 15}, {"entity_id": "11144696_2_Ent5", "role": "Treatment_Disorder", "text": "depression", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11144696_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11144696_2_Ent1", "text": "seizure", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11144696_2_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_2_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_2_Ent2", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11144696_2_Ent4", "text": "trimipramine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_2_Ent7", "text": "trimipramine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_2_Ent5", "text": "depression", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11144696_4", "wnd_id": "11144696_4_1", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d , she was hospitalized because of seizures suggesting a secondary generalized grand - mal episode .", "tokens": ["Eleven", "days", "after", "increase", "of", "the", "trimipramine", "dosage", "to", "100", "mg", "/", "d", ",", "she", "was", "hospitalized", "because", "of", "seizures", "suggesting", "a", "secondary", "generalized", "grand", "-", "mal", "episode", "."], "event_mentions": [{"id": "11144696_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hospitalized", "start": 16, "end": 17}, "arguments": [{"entity_id": "11144696_4_Ent4", "role": "Treatment_Time_elapsed", "text": "Eleven days", "start": 0, "end": 2}, {"entity_id": "11144696_4_Ent3", "role": "Treatment", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d", "start": 0, "end": 13}, {"entity_id": "11144696_4_Ent6", "role": "Treatment_Drug", "text": "trimipramine", "start": 6, "end": 7}, {"entity_id": "11144696_4_Ent5", "role": "Treatment_Dosage", "text": "100 mg / d", "start": 9, "end": 13}, {"entity_id": "11144696_4_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "11144696_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "11144696_4_Ent2", "role": "Effect", "text": "seizures suggesting a secondary generalized grand - mal episode", "start": 19, "end": 28}]}], "entity_mentions": [{"id": "11144696_4_Ent4", "text": "Eleven days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11144696_4_Ent3", "text": "Eleven days after increase of the trimipramine dosage to 100 mg / d", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "11144696_4_Ent6", "text": "trimipramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11144696_4_Ent5", "text": "100 mg / d", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "11144696_4_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_4_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11144696_4_Ent2", "text": "seizures suggesting a secondary generalized grand - mal episode", "entity_type": "Entity", "start": 19, "end": 28}], "lang": "en"}
{"doc_id": "11147747_1", "wnd_id": "11147747_1_1", "text": "In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .", "tokens": ["In", "2", "of", "the", "3", "cases", "the", "patients", "were", "also", "taking", "lithium", "carbonate", "and", "beta", "-", "blockers", ",", "both", "of", "which", "could", "have", "contributed", "to", "the", "incontinence", "."], "event_mentions": [{"id": "11147747_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 23, "end": 24}, "arguments": [{"entity_id": "11147747_1_Ent0", "role": "Subject", "text": "the patients", "start": 6, "end": 8}, {"entity_id": "11147747_1_Ent3", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 11, "end": 13}, {"entity_id": "11147747_1_Ent6", "role": "Combination_Drug", "text": "lithium carbonate", "start": 11, "end": 13}, {"entity_id": "11147747_1_Ent2", "role": "Treatment", "text": "lithium carbonate and beta - blockers", "start": 11, "end": 17}, {"entity_id": "11147747_1_Ent4", "role": "Treatment_Drug", "text": "beta - blockers", "start": 14, "end": 17}, {"entity_id": "11147747_1_Ent5", "role": "Combination_Drug", "text": "beta - blockers", "start": 14, "end": 17}, {"entity_id": "11147747_1_Ent1", "role": "Effect", "text": "incontinence", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11147747_1_Ent0", "text": "the patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11147747_1_Ent3", "text": "lithium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11147747_1_Ent6", "text": "lithium carbonate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11147747_1_Ent2", "text": "lithium carbonate and beta - blockers", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "11147747_1_Ent4", "text": "beta - blockers", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11147747_1_Ent5", "text": "beta - blockers", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11147747_1_Ent1", "text": "incontinence", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "1115340_6", "wnd_id": "1115340_6_1", "text": "There is the risk of convulsions occurring in susceptible patients following the use of the new anaesthetic agents which are capable of inducing CNS excitability .", "tokens": ["There", "is", "the", "risk", "of", "convulsions", "occurring", "in", "susceptible", "patients", "following", "the", "use", "of", "the", "new", "anaesthetic", "agents", "which", "are", "capable", "of", "inducing", "CNS", "excitability", "."], "event_mentions": [{"id": "1115340_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "1115340_6_Ent1", "role": "Effect", "text": "convulsions", "start": 5, "end": 6}, {"entity_id": "1115340_6_Ent0", "role": "Subject", "text": "susceptible patients", "start": 8, "end": 10}, {"entity_id": "1115340_6_Ent2", "role": "Treatment", "text": "the use of the new anaesthetic agents which are capable of inducing CNS excitability", "start": 11, "end": 25}, {"entity_id": "1115340_6_Ent3", "role": "Treatment_Drug", "text": "anaesthetic", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1115340_6_Ent1", "text": "convulsions", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1115340_6_Ent0", "text": "susceptible patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1115340_6_Ent2", "text": "the use of the new anaesthetic agents which are capable of inducing CNS excitability", "entity_type": "Entity", "start": 11, "end": 25}, {"id": "1115340_6_Ent3", "text": "anaesthetic", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11155197_3", "wnd_id": "11155197_3_1", "text": "Type II heparin - induced thrombocytopenia ( HIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications .", "tokens": ["Type", "II", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "is", "an", "immunological", "disorder", "characterized", "by", "antibodies", "to", "heparin", "-", "platelet", "factor", "4", "complexes", "and", "a", "high", "risk", "of", "thrombotic", "complications", "."], "event_mentions": [{"id": "11155197_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "11155197_3_Ent1", "role": "Treatment", "text": "Type II heparin", "start": 0, "end": 3}, {"entity_id": "11155197_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 2, "end": 3}, {"entity_id": "11155197_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11155197_3_Ent1", "text": "Type II heparin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11155197_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11155197_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11160777_1", "wnd_id": "11160777_1_1", "text": "New oral therapies for type 2 diabetes mellitus :", "tokens": ["New", "oral", "therapies", "for", "type", "2", "diabetes", "mellitus", ":"], "event_mentions": [{"id": "11160777_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "11160777_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 1, "end": 2}, {"entity_id": "11160777_1_Ent0", "role": "Treatment", "text": "oral therapies", "start": 1, "end": 3}, {"entity_id": "11160777_1_Ent1", "role": "Treatment_Disorder", "text": "type 2 diabetes mellitus", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "11160777_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11160777_1_Ent0", "text": "oral therapies", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11160777_1_Ent1", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "11171531_3", "wnd_id": "11171531_3_1", "text": "Poorly controlled hypertension in a painter with chronic lead toxicity .", "tokens": ["Poorly", "controlled", "hypertension", "in", "a", "painter", "with", "chronic", "lead", "toxicity", "."], "event_mentions": [{"id": "11171531_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "11171531_3_Ent1", "role": "Effect", "text": "Poorly controlled hypertension", "start": 0, "end": 3}, {"entity_id": "11171531_3_Ent0", "role": "Subject", "text": "a painter", "start": 4, "end": 6}, {"entity_id": "11171531_3_Ent2", "role": "Treatment", "text": "lead", "start": 8, "end": 9}, {"entity_id": "11171531_3_Ent3", "role": "Treatment_Drug", "text": "lead", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11171531_3_Ent1", "text": "Poorly controlled hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11171531_3_Ent0", "text": "a painter", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11171531_3_Ent2", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11171531_3_Ent3", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11174414_2", "wnd_id": "11174414_2_1", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection .", "tokens": ["Nevirapine", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "widely", "used", "in", "combination", "with", "other", "antiretroviral", "agents", "for", "the", "treatment", "of", "HIV", "infection", "."], "event_mentions": [{"id": "11174414_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 19, "end": 20}, "arguments": [{"entity_id": "11174414_2_Ent1", "role": "Treatment_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "11174414_2_Ent4", "role": "Combination_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "11174414_2_Ent0", "role": "Treatment", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents", "start": 0, "end": 17}, {"entity_id": "11174414_2_Ent2", "role": "Treatment_Drug", "text": "other antiretroviral agents", "start": 14, "end": 17}, {"entity_id": "11174414_2_Ent5", "role": "Combination_Drug", "text": "other antiretroviral agents", "start": 14, "end": 17}, {"entity_id": "11174414_2_Ent3", "role": "Treatment_Disorder", "text": "HIV infection", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11174414_2_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11174414_2_Ent4", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11174414_2_Ent0", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents", "entity_type": "Entity", "start": 0, "end": 17}, {"id": "11174414_2_Ent2", "text": "other antiretroviral agents", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11174414_2_Ent5", "text": "other antiretroviral agents", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "11174414_2_Ent3", "text": "HIV infection", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "11191005_1", "wnd_id": "11191005_1_1", "text": "There is evidence that the angiotensin II receptor antagonist , losartan , increases urate excretion by reducing reabsorption of urate in the renal proximal tubule .", "tokens": ["There", "is", "evidence", "that", "the", "angiotensin", "II", "receptor", "antagonist", ",", "losartan", ",", "increases", "urate", "excretion", "by", "reducing", "reabsorption", "of", "urate", "in", "the", "renal", "proximal", "tubule", "."], "event_mentions": [{"id": "11191005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increases", "start": 12, "end": 13}, "arguments": [{"entity_id": "11191005_1_Ent2", "role": "Treatment", "text": "angiotensin II receptor antagonist , losartan", "start": 5, "end": 11}, {"entity_id": "11191005_1_Ent3", "role": "Treatment_Drug", "text": "losartan", "start": 10, "end": 11}, {"entity_id": "11191005_1_Ent0", "role": "Effect", "text": "increases urate excretion", "start": 12, "end": 15}, {"entity_id": "11191005_1_Ent1", "role": "Effect", "text": "reducing reabsorption of urate in the renal proximal tubule .", "start": 16, "end": 26}]}], "entity_mentions": [{"id": "11191005_1_Ent2", "text": "angiotensin II receptor antagonist , losartan", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11191005_1_Ent3", "text": "losartan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11191005_1_Ent0", "text": "increases urate excretion", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11191005_1_Ent1", "text": "reducing reabsorption of urate in the renal proximal tubule .", "entity_type": "Entity", "start": 16, "end": 26}], "lang": "en"}
{"doc_id": "11197767_1", "wnd_id": "11197767_1_1", "text": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus ( Digenea : Philophthalmidae ) .", "tokens": ["Toxicity", "of", "cadmium", "and", "zinc", "to", "encystment", "and", "in", "vitro", "excystment", "of", "Parorchis", "acanthus", "(", "Digenea", ":", "Philophthalmidae", ")", "."], "event_mentions": [{"id": "11197767_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Toxicity", "start": 0, "end": 1}, "arguments": [{"entity_id": "11197767_1_Ent0", "role": "Effect", "text": "Toxicity", "start": 0, "end": 1}, {"entity_id": "11197767_1_Ent2", "role": "Treatment_Drug", "text": "cadmium", "start": 2, "end": 3}, {"entity_id": "11197767_1_Ent1", "role": "Treatment", "text": "cadmium and zinc", "start": 2, "end": 5}, {"entity_id": "11197767_1_Ent3", "role": "Treatment_Drug", "text": "zinc", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11197767_1_Ent0", "text": "Toxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11197767_1_Ent2", "text": "cadmium", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11197767_1_Ent1", "text": "cadmium and zinc", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11197767_1_Ent3", "text": "zinc", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11213850_6", "wnd_id": "11213850_6_1", "text": "Each subject was treated according to the following sequence : baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 ) .", "tokens": ["Each", "subject", "was", "treated", "according", "to", "the", "following", "sequence", ":", "baseline", ";", "phase", "1", "(", "days", "1", "-", "6", ")", ":", "cisapride", "10", "mg", "4", "times", "/", "day", ";", "washout", "(", "days", "7", "-", "13", ")", ";", "phase", "2", "(", "days", "14", "-", "44", ")", ":", "fluoxetine", "20", "mg", "/", "day", ";", "and", "phase", "3", "(", "days", "45", "-", "52", ")", ":", "cisapride", "10", "mg", "4", "times", "/", "day", "(", "days", "45", "-", "51", ")", "plus", "fluoxetine", "20", "mg", "/", "day", "(", "days", "45", "-", "52", ")", "."], "event_mentions": [{"id": "11213850_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11213850_6_Ent0", "role": "Subject", "text": "Each subject", "start": 0, "end": 2}, {"entity_id": "11213850_6_Ent1", "role": "Treatment", "text": "baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 )", "start": 10, "end": 87}, {"entity_id": "11213850_6_Ent2", "role": "Treatment_Drug", "text": "cisapride", "start": 21, "end": 22}, {"entity_id": "11213850_6_Ent6", "role": "Treatment_Dosage", "text": "10 mg", "start": 22, "end": 24}, {"entity_id": "11213850_6_Ent10", "role": "Treatment_Freq", "text": "4 times / day", "start": 24, "end": 28}, {"entity_id": "11213850_6_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 46, "end": 47}, {"entity_id": "11213850_6_Ent7", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 47, "end": 51}, {"entity_id": "11213850_6_Ent4", "role": "Treatment_Drug", "text": "cisapride", "start": 62, "end": 63}, {"entity_id": "11213850_6_Ent12", "role": "Combination_Drug", "text": "cisapride", "start": 62, "end": 63}, {"entity_id": "11213850_6_Ent8", "role": "Treatment_Dosage", "text": "10 mg", "start": 63, "end": 65}, {"entity_id": "11213850_6_Ent11", "role": "Treatment_Freq", "text": "4 times / day", "start": 65, "end": 69}, {"entity_id": "11213850_6_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 76, "end": 77}, {"entity_id": "11213850_6_Ent13", "role": "Combination_Drug", "text": "fluoxetine", "start": 76, "end": 77}, {"entity_id": "11213850_6_Ent9", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 77, "end": 81}]}], "entity_mentions": [{"id": "11213850_6_Ent0", "text": "Each subject", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11213850_6_Ent1", "text": "baseline ; phase 1 ( days 1 - 6 ) : cisapride 10 mg 4 times / day ; washout ( days 7 - 13 ) ; phase 2 ( days 14 - 44 ) : fluoxetine 20 mg / day ; and phase 3 ( days 45 - 52 ) : cisapride 10 mg 4 times / day ( days 45 - 51 ) plus fluoxetine 20 mg / day ( days 45 - 52 )", "entity_type": "Entity", "start": 10, "end": 87}, {"id": "11213850_6_Ent2", "text": "cisapride", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11213850_6_Ent6", "text": "10 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11213850_6_Ent10", "text": "4 times / day", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "11213850_6_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "11213850_6_Ent7", "text": "20 mg / day", "entity_type": "Entity", "start": 47, "end": 51}, {"id": "11213850_6_Ent4", "text": "cisapride", "entity_type": "Entity", "start": 62, "end": 63}, {"id": "11213850_6_Ent12", "text": "cisapride", "entity_type": "Entity", "start": 62, "end": 63}, {"id": "11213850_6_Ent8", "text": "10 mg", "entity_type": "Entity", "start": 63, "end": 65}, {"id": "11213850_6_Ent11", "text": "4 times / day", "entity_type": "Entity", "start": 65, "end": 69}, {"id": "11213850_6_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 76, "end": 77}, {"id": "11213850_6_Ent13", "text": "fluoxetine", "entity_type": "Entity", "start": 76, "end": 77}, {"id": "11213850_6_Ent9", "text": "20 mg / day", "entity_type": "Entity", "start": 77, "end": 81}], "lang": "en"}
{"doc_id": "11215836_2", "wnd_id": "11215836_2_1", "text": "OBJECTIVE : To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen .", "tokens": ["OBJECTIVE", ":", "To", "report", "on", "the", "possible", "development", "of", "serotonin", "syndrome", "in", "a", "patient", "receiving", "clomipramine", "after", "clozapine", "was", "withdrawn", "from", "the", "treatment", "regimen", "."], "event_mentions": [{"id": "11215836_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "11215836_2_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 9, "end": 11}, {"entity_id": "11215836_2_Ent0", "role": "Subject", "text": "patient", "start": 13, "end": 14}, {"entity_id": "11215836_2_Ent2", "role": "Treatment", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent3", "role": "Treatment_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent5", "role": "Combination_Drug", "text": "clomipramine", "start": 15, "end": 16}, {"entity_id": "11215836_2_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 17, "end": 18}, {"entity_id": "11215836_2_Ent6", "role": "Combination_Drug", "text": "clozapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11215836_2_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11215836_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11215836_2_Ent2", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent3", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent5", "text": "clomipramine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11215836_2_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11215836_2_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "1124417_2", "wnd_id": "1124417_2_1", "text": "Renal failure associated with acetazolamide therapy for glaucoma .", "tokens": ["Renal", "failure", "associated", "with", "acetazolamide", "therapy", "for", "glaucoma", "."], "event_mentions": [{"id": "1124417_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1124417_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "1124417_2_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1124417_2_Ent1", "role": "Treatment", "text": "acetazolamide therapy", "start": 4, "end": 6}, {"entity_id": "1124417_2_Ent3", "role": "Treatment_Disorder", "text": "glaucoma", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1124417_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1124417_2_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1124417_2_Ent1", "text": "acetazolamide therapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1124417_2_Ent3", "text": "glaucoma", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1124417_3", "wnd_id": "1124417_3_1", "text": "This sulfonamide like nephropathy should be differentiated from acetazolamide - related calcium phosphate nephrolithiasis .", "tokens": ["This", "sulfonamide", "like", "nephropathy", "should", "be", "differentiated", "from", "acetazolamide", "-", "related", "calcium", "phosphate", "nephrolithiasis", "."], "event_mentions": [{"id": "1124417_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "1124417_3_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent0", "role": "Effect", "text": "calcium phosphate nephrolithiasis .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "1124417_3_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent0", "text": "calcium phosphate nephrolithiasis .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "11247558_1", "wnd_id": "11247558_1_1", "text": "Ischaemic colitis in a patient taking meloxicam .", "tokens": ["Ischaemic", "colitis", "in", "a", "patient", "taking", "meloxicam", "."], "event_mentions": [{"id": "11247558_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 5, "end": 6}, "arguments": [{"entity_id": "11247558_1_Ent1", "role": "Effect", "text": "Ischaemic colitis", "start": 0, "end": 2}, {"entity_id": "11247558_1_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "11247558_1_Ent2", "role": "Treatment", "text": "meloxicam", "start": 6, "end": 7}, {"entity_id": "11247558_1_Ent3", "role": "Treatment_Drug", "text": "meloxicam", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "11247558_1_Ent1", "text": "Ischaemic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11247558_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11247558_1_Ent2", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11247558_1_Ent3", "text": "meloxicam", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "11250985_2", "wnd_id": "11250985_2_1", "text": "In patients with chronic heart failure , spironolactone added to conventional treatment may lead to serious and , occasionally , fatal hyperkalaemia .", "tokens": ["In", "patients", "with", "chronic", "heart", "failure", ",", "spironolactone", "added", "to", "conventional", "treatment", "may", "lead", "to", "serious", "and", ",", "occasionally", ",", "fatal", "hyperkalaemia", "."], "event_mentions": [{"id": "11250985_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 13, "end": 14}, "arguments": [{"entity_id": "11250985_2_Ent0", "role": "Subject", "text": "patients with chronic heart failure", "start": 1, "end": 6}, {"entity_id": "11250985_2_Ent1", "role": "Subject_Disorder", "text": "chronic heart failure", "start": 3, "end": 6}, {"entity_id": "11250985_2_Ent3", "role": "Treatment", "text": "spironolactone", "start": 7, "end": 8}, {"entity_id": "11250985_2_Ent4", "role": "Treatment_Drug", "text": "spironolactone", "start": 7, "end": 8}, {"entity_id": "11250985_2_Ent2", "role": "Effect", "text": "serious and , occasionally , fatal hyperkalaemia", "start": 15, "end": 22}]}], "entity_mentions": [{"id": "11250985_2_Ent0", "text": "patients with chronic heart failure", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11250985_2_Ent1", "text": "chronic heart failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "11250985_2_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11250985_2_Ent4", "text": "spironolactone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11250985_2_Ent2", "text": "serious and , occasionally , fatal hyperkalaemia", "entity_type": "Entity", "start": 15, "end": 22}], "lang": "en"}
{"doc_id": "11250985_3", "wnd_id": "11250985_3_1", "text": "In some cases this seems to happen because spironolactone causes diarrhoea .", "tokens": ["In", "some", "cases", "this", "seems", "to", "happen", "because", "spironolactone", "causes", "diarrhoea", "."], "event_mentions": [{"id": "11250985_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 9, "end": 10}, "arguments": [{"entity_id": "11250985_3_Ent1", "role": "Treatment", "text": "spironolactone", "start": 8, "end": 9}, {"entity_id": "11250985_3_Ent2", "role": "Treatment_Drug", "text": "spironolactone", "start": 8, "end": 9}, {"entity_id": "11250985_3_Ent0", "role": "Effect", "text": "diarrhoea", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11250985_3_Ent1", "text": "spironolactone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11250985_3_Ent2", "text": "spironolactone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11250985_3_Ent0", "text": "diarrhoea", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11283125_1", "wnd_id": "11283125_1_1", "text": "Value of high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol in increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma : results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial .", "tokens": ["Value", "of", "high", "-", "dose", "cytarabine", "during", "interval", "therapy", "of", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "-", "based", "protocol", "in", "increased", "-", "risk", "children", "with", "acute", "lymphoblastic", "leukemia", "and", "lymphoblastic", "lymphoma", ":", "results", "of", "the", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "randomized", "phase", "III", "trial", "."], "event_mentions": [{"id": "11283125_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Value", "start": 0, "end": 1}, "arguments": [{"entity_id": "11283125_1_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 2, "end": 5}, {"entity_id": "11283125_1_Ent2", "role": "Treatment", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "start": 2, "end": 19}, {"entity_id": "11283125_1_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 5, "end": 6}, {"entity_id": "11283125_1_Ent0", "role": "Subject", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "start": 20, "end": 31}, {"entity_id": "11283125_1_Ent1", "role": "Subject_Age", "text": "children", "start": 23, "end": 24}, {"entity_id": "11283125_1_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 25, "end": 28}, {"entity_id": "11283125_1_Ent4", "role": "Treatment_Disorder", "text": "lymphoblastic lymphoma", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "11283125_1_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11283125_1_Ent2", "text": "high - dose cytarabine during interval therapy of a Berlin - Frankfurt - Munster - based protocol", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "11283125_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11283125_1_Ent0", "text": "increased - risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "11283125_1_Ent1", "text": "children", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11283125_1_Ent3", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11283125_1_Ent4", "text": "lymphoblastic lymphoma", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "11328247_4", "wnd_id": "11328247_4_1", "text": "RESULTS : The patient , a 27 - year - old married Japanese woman with borderline personality disorder , developed an increased libido with the administration of fluvoxamine .", "tokens": ["RESULTS", ":", "The", "patient", ",", "a", "27", "-", "year", "-", "old", "married", "Japanese", "woman", "with", "borderline", "personality", "disorder", ",", "developed", "an", "increased", "libido", "with", "the", "administration", "of", "fluvoxamine", "."], "event_mentions": [{"id": "11328247_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "11328247_4_Ent0", "role": "Subject", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "start": 2, "end": 18}, {"entity_id": "11328247_4_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "11328247_4_Ent2", "role": "Subject_Race", "text": "Japanese", "start": 12, "end": 13}, {"entity_id": "11328247_4_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "11328247_4_Ent6", "role": "Treatment_Disorder", "text": "borderline personality disorder", "start": 15, "end": 18}, {"entity_id": "11328247_4_Ent4", "role": "Effect", "text": "increased libido", "start": 21, "end": 23}, {"entity_id": "11328247_4_Ent5", "role": "Treatment", "text": "administration of fluvoxamine", "start": 25, "end": 28}, {"entity_id": "11328247_4_Ent7", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "11328247_4_Ent0", "text": "The patient , a 27 - year - old married Japanese woman with borderline personality disorder", "entity_type": "Entity", "start": 2, "end": 18}, {"id": "11328247_4_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11328247_4_Ent2", "text": "Japanese", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11328247_4_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11328247_4_Ent6", "text": "borderline personality disorder", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11328247_4_Ent4", "text": "increased libido", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "11328247_4_Ent5", "text": "administration of fluvoxamine", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "11328247_4_Ent7", "text": "fluvoxamine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "11335880_1", "wnd_id": "11335880_1_1", "text": "CONCLUSIONS : This case report showed that the clinical appearance of Hashimoto 's disease after IFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology .", "tokens": ["CONCLUSIONS", ":", "This", "case", "report", "showed", "that", "the", "clinical", "appearance", "of", "Hashimoto", "'s", "disease", "after", "IFN", "-", "alpha", "therapy", "for", "chronic", "C", "hepatitis", "in", "our", "patient", "was", "associated", "with", "a", "specific", "genetic", "predisposition", "(", "DR5", ")", "for", "this", "pathology", "."], "event_mentions": [{"id": "11335880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "11335880_1_Ent2", "role": "Effect", "text": "clinical appearance of Hashimoto 's disease", "start": 8, "end": 14}, {"entity_id": "11335880_1_Ent3", "role": "Treatment", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 15, "end": 18}, {"entity_id": "11335880_1_Ent4", "role": "Treatment_Disorder", "text": "chronic C hepatitis", "start": 20, "end": 23}, {"entity_id": "11335880_1_Ent0", "role": "Subject", "text": "our patient", "start": 24, "end": 26}, {"entity_id": "11335880_1_Ent1", "role": "Subject_Disorder", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "start": 29, "end": 39}]}], "entity_mentions": [{"id": "11335880_1_Ent2", "text": "clinical appearance of Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "11335880_1_Ent3", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11335880_1_Ent4", "text": "chronic C hepatitis", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11335880_1_Ent0", "text": "our patient", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "11335880_1_Ent1", "text": "a specific genetic predisposition ( DR5 ) for this pathology", "entity_type": "Entity", "start": 29, "end": 39}], "lang": "en"}
{"doc_id": "11335880_3", "wnd_id": "11335880_3_1", "text": "Hashimoto 's disease during interferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease .", "tokens": ["Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "therapy", "in", "a", "patient", "with", "pre", "-", "treatment", "negative", "anti", "-", "thyroid", "autoantibodies", "and", "with", "the", "specific", "genetic", "susceptibility", "to", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "11335880_3_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 0, "end": 3}, {"entity_id": "11335880_3_Ent3", "role": "Treatment", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent0", "role": "Subject", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "start": 9, "end": 30}, {"entity_id": "11335880_3_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility to the thyroid disease", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "11335880_3_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11335880_3_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent0", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 9, "end": 30}, {"id": "11335880_3_Ent1", "text": "specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "11352235_2", "wnd_id": "11352235_2_1", "text": "Leflunomide - associated weight loss in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "weight", "loss", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "11352235_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11352235_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "11352235_2_Ent0", "role": "Effect", "text": "weight loss", "start": 3, "end": 5}, {"entity_id": "11352235_2_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "11352235_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11352235_2_Ent0", "text": "weight loss", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11352235_2_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "11352235_4", "wnd_id": "11352235_4_1", "text": "OBJECTIVE : To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center .", "tokens": ["OBJECTIVE", ":", "To", "determine", "the", "frequency", "of", "weight", "loss", "in", "patients", "treated", "with", "leflunomide", "for", "rheumatoid", "arthritis", "at", "an", "arthritis", "referral", "center", "."], "event_mentions": [{"id": "11352235_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "loss", "start": 8, "end": 9}, "arguments": [{"entity_id": "11352235_4_Ent1", "role": "Effect", "text": "weight loss", "start": 7, "end": 9}, {"entity_id": "11352235_4_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "11352235_4_Ent2", "role": "Treatment", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 13, "end": 14}, {"entity_id": "11352235_4_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11352235_4_Ent1", "text": "weight loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11352235_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11352235_4_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11352235_4_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11399735_4", "wnd_id": "11399735_4_1", "text": "We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine .", "tokens": ["We", "report", "a", "case", "of", "interstitial", "pulmonary", "disease", "that", "occurred", "together", "with", "lymphocytic", "colitis", "during", "treatment", "with", "ticlopidine", "."], "event_mentions": [{"id": "11399735_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "11399735_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "11399735_4_Ent1", "role": "Effect", "text": "interstitial pulmonary disease", "start": 5, "end": 8}, {"entity_id": "11399735_4_Ent2", "role": "Effect", "text": "lymphocytic colitis", "start": 12, "end": 14}, {"entity_id": "11399735_4_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 17, "end": 18}, {"entity_id": "11399735_4_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11399735_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11399735_4_Ent1", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11399735_4_Ent2", "text": "lymphocytic colitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11399735_4_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11399735_4_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11406880_3", "wnd_id": "11406880_3_1", "text": "A patient that received methadone for cancer - associated pain developed myoclonus as a side effect .", "tokens": ["A", "patient", "that", "received", "methadone", "for", "cancer", "-", "associated", "pain", "developed", "myoclonus", "as", "a", "side", "effect", "."], "event_mentions": [{"id": "11406880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11406880_3_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "11406880_3_Ent2", "role": "Treatment", "text": "methadone", "start": 4, "end": 5}, {"entity_id": "11406880_3_Ent4", "role": "Treatment_Drug", "text": "methadone", "start": 4, "end": 5}, {"entity_id": "11406880_3_Ent3", "role": "Treatment_Disorder", "text": "cancer - associated pain", "start": 6, "end": 10}, {"entity_id": "11406880_3_Ent1", "role": "Effect", "text": "myoclonus", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11406880_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11406880_3_Ent2", "text": "methadone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11406880_3_Ent4", "text": "methadone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11406880_3_Ent3", "text": "cancer - associated pain", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "11406880_3_Ent1", "text": "myoclonus", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11424102_1", "wnd_id": "11424102_1_1", "text": "Cutaneous seeding after ultrasound - guided percutaneous ethanol injection for treatment of hepatocellular carcinoma .", "tokens": ["Cutaneous", "seeding", "after", "ultrasound", "-", "guided", "percutaneous", "ethanol", "injection", "for", "treatment", "of", "hepatocellular", "carcinoma", "."], "event_mentions": [{"id": "11424102_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "11424102_1_Ent0", "role": "Effect", "text": "Cutaneous seeding", "start": 0, "end": 2}, {"entity_id": "11424102_1_Ent1", "role": "Treatment", "text": "ultrasound - guided percutaneous ethanol injection", "start": 3, "end": 9}, {"entity_id": "11424102_1_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 7, "end": 8}, {"entity_id": "11424102_1_Ent2", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "11424102_1_Ent4", "role": "Treatment_Disorder", "text": "hepatocellular carcinoma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11424102_1_Ent0", "text": "Cutaneous seeding", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11424102_1_Ent1", "text": "ultrasound - guided percutaneous ethanol injection", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11424102_1_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11424102_1_Ent2", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11424102_1_Ent4", "text": "hepatocellular carcinoma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11435808_2", "wnd_id": "11435808_2_1", "text": "Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability , a profound burst - suppression EEG pattern , and cranial nerve areflexia .", "tokens": ["Massive", "CBZ", "OD", "may", "produce", "a", "reversible", "encephalopathy", "that", "includes", "cortical", "hyperexcitability", ",", "a", "profound", "burst", "-", "suppression", "EEG", "pattern", ",", "and", "cranial", "nerve", "areflexia", "."], "event_mentions": [{"id": "11435808_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 4, "end": 5}, "arguments": [{"entity_id": "11435808_2_Ent1", "role": "Treatment", "text": "Massive CBZ OD", "start": 0, "end": 3}, {"entity_id": "11435808_2_Ent3", "role": "Treatment_Drug", "text": "CBZ", "start": 1, "end": 2}, {"entity_id": "11435808_2_Ent2", "role": "Treatment_Dosage", "text": "OD", "start": 2, "end": 3}, {"entity_id": "11435808_2_Ent0", "role": "Effect", "text": "reversible encephalopathy that includes cortical hyperexcitability , a profound burst - suppression EEG pattern , and cranial nerve areflexia", "start": 6, "end": 25}]}], "entity_mentions": [{"id": "11435808_2_Ent1", "text": "Massive CBZ OD", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11435808_2_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11435808_2_Ent2", "text": "OD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11435808_2_Ent0", "text": "reversible encephalopathy that includes cortical hyperexcitability , a profound burst - suppression EEG pattern , and cranial nerve areflexia", "entity_type": "Entity", "start": 6, "end": 25}], "lang": "en"}
{"doc_id": "11443640_2", "wnd_id": "11443640_2_1", "text": "To our knowledge this is the first report of pancytopenia due to MMI , where the usual hypoplasia found is replaced by massive plasmocytosis .", "tokens": ["To", "our", "knowledge", "this", "is", "the", "first", "report", "of", "pancytopenia", "due", "to", "MMI", ",", "where", "the", "usual", "hypoplasia", "found", "is", "replaced", "by", "massive", "plasmocytosis", "."], "event_mentions": [{"id": "11443640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 10, "end": 11}, "arguments": [{"entity_id": "11443640_2_Ent0", "role": "Effect", "text": "pancytopenia", "start": 9, "end": 10}, {"entity_id": "11443640_2_Ent1", "role": "Treatment", "text": "MMI", "start": 12, "end": 13}, {"entity_id": "11443640_2_Ent2", "role": "Treatment_Drug", "text": "MMI", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11443640_2_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11443640_2_Ent1", "text": "MMI", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11443640_2_Ent2", "text": "MMI", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11485141_2", "wnd_id": "11485141_2_1", "text": "CONCLUSIONS : We report the first case of gemcitabine - induced LABD .", "tokens": ["CONCLUSIONS", ":", "We", "report", "the", "first", "case", "of", "gemcitabine", "-", "induced", "LABD", "."], "event_mentions": [{"id": "11485141_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "11485141_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "11485141_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "11485141_2_Ent0", "role": "Effect", "text": "LABD", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11485141_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11485141_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11485141_2_Ent0", "text": "LABD", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11485141_3", "wnd_id": "11485141_3_1", "text": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine .", "tokens": ["Linear", "immunoglobulin", "A", "bullous", "dermatosis", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "11485141_3_Ent0", "role": "Effect", "text": "Linear immunoglobulin A bullous dermatosis", "start": 0, "end": 5}, {"entity_id": "11485141_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 7, "end": 8}, {"entity_id": "11485141_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11485141_3_Ent0", "text": "Linear immunoglobulin A bullous dermatosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11485141_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11485141_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11485141_4", "wnd_id": "11485141_4_1", "text": "OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by gemcitabine .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "linear", "immunoglobulin", "(", "Ig", ")", "A", "bullous", "dermatosis", "(", "LABD", ")", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "11485141_4_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "11485141_4_Ent1", "role": "Effect", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "start": 7, "end": 18}, {"entity_id": "11485141_4_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 20, "end": 21}, {"entity_id": "11485141_4_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11485141_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11485141_4_Ent1", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "11485141_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11485141_4_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11489400_1", "wnd_id": "11489400_1_1", "text": "Relief by naloxone of morphine - induced spasm of the sphincter of Oddi in a post - cholecystectomy patient .", "tokens": ["Relief", "by", "naloxone", "of", "morphine", "-", "induced", "spasm", "of", "the", "sphincter", "of", "Oddi", "in", "a", "post", "-", "cholecystectomy", "patient", "."], "event_mentions": [{"id": "11489400_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Relief", "start": 0, "end": 1}, "arguments": [{"entity_id": "11489400_1_Ent1", "role": "Treatment", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent2", "role": "Treatment_Disorder", "text": "morphine - induced spasm of the sphincter of Oddi", "start": 4, "end": 13}, {"entity_id": "11489400_1_Ent0", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}, {"id": "11489400_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11489400_1_Ent6", "role": "Treatment", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent7", "role": "Treatment_Drug", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent5", "role": "Effect", "text": "spasm of the sphincter of Oddi", "start": 7, "end": 13}, {"entity_id": "11489400_1_Ent4", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "11489400_1_Ent1", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent7", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent2", "text": "morphine - induced spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "11489400_1_Ent5", "text": "spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11489400_1_Ent0", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11489400_1_Ent4", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "11510798_1", "wnd_id": "11510798_1_1", "text": "Acute lung injury associated with 5 - fluorouracil and oxaliplatinum combined chemotherapy .", "tokens": ["Acute", "lung", "injury", "associated", "with", "5", "-", "fluorouracil", "and", "oxaliplatinum", "combined", "chemotherapy", "."], "event_mentions": [{"id": "11510798_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11510798_1_Ent0", "role": "Effect", "text": "Acute lung injury", "start": 0, "end": 3}, {"entity_id": "11510798_1_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent5", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "11510798_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "start": 5, "end": 12}, {"entity_id": "11510798_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent6", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 9, "end": 10}, {"entity_id": "11510798_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11510798_1_Ent0", "text": "Acute lung injury", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11510798_1_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11510798_1_Ent1", "text": "5 - fluorouracil and oxaliplatinum combined chemotherapy", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11510798_1_Ent2", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent6", "text": "oxaliplatinum", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11510798_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11518127_1", "wnd_id": "11518127_1_1", "text": "A 62 - year - old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "treated", "with", "pranlukast", "for", "2", "months", "developed", "interstitial", "pneumonitis", "with", "a", "high", "fever", "."], "event_mentions": [{"id": "11518127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11518127_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman", "start": 0, "end": 7}, {"entity_id": "11518127_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "11518127_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "11518127_1_Ent4", "role": "Treatment", "text": "treated with pranlukast for 2 months", "start": 7, "end": 13}, {"entity_id": "11518127_1_Ent5", "role": "Treatment_Drug", "text": "pranlukast", "start": 9, "end": 10}, {"entity_id": "11518127_1_Ent6", "role": "Treatment_Duration", "text": "2 months", "start": 11, "end": 13}, {"entity_id": "11518127_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis with a high fever", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "11518127_1_Ent0", "text": "A 62 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11518127_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11518127_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11518127_1_Ent4", "text": "treated with pranlukast for 2 months", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11518127_1_Ent5", "text": "pranlukast", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11518127_1_Ent6", "text": "2 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11518127_1_Ent3", "text": "interstitial pneumonitis with a high fever", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "11545487_1", "wnd_id": "11545487_1_1", "text": "An asymptomatic HIV - infected woman experienced right - sided renal colicky pain during treatment with indinavir .", "tokens": ["An", "asymptomatic", "HIV", "-", "infected", "woman", "experienced", "right", "-", "sided", "renal", "colicky", "pain", "during", "treatment", "with", "indinavir", "."], "event_mentions": [{"id": "11545487_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11545487_1_Ent0", "role": "Subject", "text": "An asymptomatic HIV - infected woman", "start": 0, "end": 6}, {"entity_id": "11545487_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 2, "end": 3}, {"entity_id": "11545487_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "11545487_1_Ent2", "role": "Effect", "text": "right - sided renal colicky pain", "start": 7, "end": 13}, {"entity_id": "11545487_1_Ent3", "role": "Treatment", "text": "indinavir", "start": 16, "end": 17}, {"entity_id": "11545487_1_Ent4", "role": "Treatment_Drug", "text": "indinavir", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11545487_1_Ent0", "text": "An asymptomatic HIV - infected woman", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11545487_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11545487_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_1_Ent2", "text": "right - sided renal colicky pain", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11545487_1_Ent3", "text": "indinavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11545487_1_Ent4", "text": "indinavir", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11545487_2", "wnd_id": "11545487_2_1", "text": "Indinavir - associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient .", "tokens": ["Indinavir", "-", "associated", "nephrolithiasis", "and", "chronic", "interstitial", "nephritis", "were", "the", "only", "possible", "causes", "identified", "in", "this", "patient", "."], "event_mentions": [{"id": "11545487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_2_Ent1", "role": "Treatment", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent2", "role": "Treatment_Drug", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent0", "role": "Effect", "text": "nephrolithiasis and chronic interstitial nephritis", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "11545487_2_Ent1", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent2", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent0", "text": "nephrolithiasis and chronic interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "11545487_7", "wnd_id": "11545487_7_1", "text": "We report a case of papillary necrosis in a patient treated with indinavir .", "tokens": ["We", "report", "a", "case", "of", "papillary", "necrosis", "in", "a", "patient", "treated", "with", "indinavir", "."], "event_mentions": [{"id": "11545487_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "11545487_7_Ent1", "role": "Effect", "text": "papillary necrosis", "start": 5, "end": 7}, {"entity_id": "11545487_7_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "11545487_7_Ent2", "role": "Treatment", "text": "indinavir", "start": 12, "end": 13}, {"entity_id": "11545487_7_Ent3", "role": "Treatment_Drug", "text": "indinavir", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11545487_7_Ent1", "text": "papillary necrosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11545487_7_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11545487_7_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11545487_7_Ent3", "text": "indinavir", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11573852_2", "wnd_id": "11573852_2_1", "text": "CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .", "tokens": ["CASE", "SUMMARY", ":", "A", "46", "-", "year", "-", "old", "African", "-", "American", "man", "experienced", "recurrent", "grand", "mal", "seizures", "during", "intravenous", "infusion", "of", "amphotericin", "B", ",", "then", "petit", "mal", "seizures", "as", "the", "infusion", "was", "stopped", "and", "the", "drug", "concentrations", "decreased", "with", "time", "."], "event_mentions": [{"id": "11573852_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "11573852_2_Ent0", "role": "Subject", "text": "A 46 - year - old African - American man", "start": 3, "end": 13}, {"entity_id": "11573852_2_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 4, "end": 9}, {"entity_id": "11573852_2_Ent2", "role": "Subject_Race", "text": "African - American", "start": 9, "end": 12}, {"entity_id": "11573852_2_Ent3", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "11573852_2_Ent4", "role": "Effect", "text": "recurrent grand mal seizures", "start": 14, "end": 18}, {"entity_id": "11573852_2_Ent6", "role": "Treatment_Route", "text": "intravenous infusion", "start": 19, "end": 21}, {"entity_id": "11573852_2_Ent5", "role": "Treatment", "text": "intravenous infusion of amphotericin B", "start": 19, "end": 24}, {"entity_id": "11573852_2_Ent7", "role": "Treatment_Drug", "text": "amphotericin B", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "11573852_2_Ent0", "text": "A 46 - year - old African - American man", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "11573852_2_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11573852_2_Ent2", "text": "African - American", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11573852_2_Ent3", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11573852_2_Ent4", "text": "recurrent grand mal seizures", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11573852_2_Ent6", "text": "intravenous infusion", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11573852_2_Ent5", "text": "intravenous infusion of amphotericin B", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "11573852_2_Ent7", "text": "amphotericin B", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "11573852_5", "wnd_id": "11573852_5_1", "text": "Didanosine also has a potential for inducing seizures .", "tokens": ["Didanosine", "also", "has", "a", "potential", "for", "inducing", "seizures", "."], "event_mentions": [{"id": "11573852_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 6, "end": 7}, "arguments": [{"entity_id": "11573852_5_Ent1", "role": "Treatment", "text": "Didanosine", "start": 0, "end": 1}, {"entity_id": "11573852_5_Ent2", "role": "Treatment_Drug", "text": "Didanosine", "start": 0, "end": 1}, {"entity_id": "11573852_5_Ent0", "role": "Effect", "text": "seizures", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11573852_5_Ent1", "text": "Didanosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11573852_5_Ent2", "text": "Didanosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11573852_5_Ent0", "text": "seizures", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11576059_2", "wnd_id": "11576059_2_1", "text": "We present the case of a 5 - year - old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration .", "tokens": ["We", "present", "the", "case", "of", "a", "5", "-", "year", "-", "old", "girl", "who", "developed", "bilateral", "vocal", "cord", "paralysis", "following", "preoperative", "peritonsillar", "bupivacaine", "infiltration", "."], "event_mentions": [{"id": "11576059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 18, "end": 19}, "arguments": [{"entity_id": "11576059_2_Ent0", "role": "Subject", "text": "a 5 - year - old girl", "start": 5, "end": 12}, {"entity_id": "11576059_2_Ent1", "role": "Subject_Age", "text": "5 - year - old", "start": 6, "end": 11}, {"entity_id": "11576059_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 11, "end": 12}, {"entity_id": "11576059_2_Ent3", "role": "Effect", "text": "bilateral vocal cord paralysis", "start": 14, "end": 18}, {"entity_id": "11576059_2_Ent4", "role": "Treatment", "text": "preoperative peritonsillar bupivacaine infiltration", "start": 19, "end": 23}, {"entity_id": "11576059_2_Ent6", "role": "Treatment_Route", "text": "peritonsillar", "start": 20, "end": 21}, {"entity_id": "11576059_2_Ent5", "role": "Treatment_Drug", "text": "bupivacaine", "start": 21, "end": 22}, {"entity_id": "11576059_2_Ent7", "role": "Treatment_Route", "text": "infiltration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11576059_2_Ent0", "text": "a 5 - year - old girl", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "11576059_2_Ent1", "text": "5 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11576059_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11576059_2_Ent3", "text": "bilateral vocal cord paralysis", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11576059_2_Ent4", "text": "preoperative peritonsillar bupivacaine infiltration", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "11576059_2_Ent6", "text": "peritonsillar", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11576059_2_Ent5", "text": "bupivacaine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11576059_2_Ent7", "text": "infiltration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11590881_1", "wnd_id": "11590881_1_1", "text": "Carbamazepine induced right bundle branch block in a Greenlandic patient .", "tokens": ["Carbamazepine", "induced", "right", "bundle", "branch", "block", "in", "a", "Greenlandic", "patient", "."], "event_mentions": [{"id": "11590881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11590881_1_Ent3", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "11590881_1_Ent4", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "11590881_1_Ent2", "role": "Effect", "text": "right bundle branch block", "start": 2, "end": 6}, {"entity_id": "11590881_1_Ent1", "role": "Subject_Race", "text": "Greenlandic", "start": 8, "end": 9}, {"entity_id": "11590881_1_Ent0", "role": "Subject", "text": "Greenlandic patient", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11590881_1_Ent3", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11590881_1_Ent4", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11590881_1_Ent2", "text": "right bundle branch block", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11590881_1_Ent1", "text": "Greenlandic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11590881_1_Ent0", "text": "Greenlandic patient", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11688826_2", "wnd_id": "11688826_2_1", "text": "Syndrome of inappropriate secretion of ADH ( SIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion .", "tokens": ["Syndrome", "of", "inappropriate", "secretion", "of", "ADH", "(", "SIADH", ")", "following", "cisplatin", "administration", "in", "a", "pulmonary", "adenocarcinoma", "patient", "with", "a", "malignant", "pleural", "effusion", "."], "event_mentions": [{"id": "11688826_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11688826_2_Ent2", "role": "Effect", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "start": 0, "end": 9}, {"entity_id": "11688826_2_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent0", "role": "Subject", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "start": 13, "end": 22}, {"entity_id": "11688826_2_Ent4", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 14, "end": 16}, {"entity_id": "11688826_2_Ent1", "role": "Subject_Disorder", "text": "malignant pleural effusion", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11688826_2_Ent2", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "11688826_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent0", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "11688826_2_Ent4", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11688826_2_Ent1", "text": "malignant pleural effusion", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11696132_1", "wnd_id": "11696132_1_1", "text": "After extensive neurological ' work up ' , we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid .", "tokens": ["After", "extensive", "neurological", "'", "work", "up", "'", ",", "we", "realized", "that", "the", "anisocoria", "was", "related", "to", "the", "transdermal", "scopolamine", "patch", "that", "we", "had", "prescribed", "for", "weaning", "off", "the", "opioid", "."], "event_mentions": [{"id": "11696132_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 14, "end": 15}, "arguments": [{"entity_id": "11696132_1_Ent0", "role": "Effect", "text": "anisocoria", "start": 12, "end": 13}, {"entity_id": "11696132_1_Ent3", "role": "Treatment_Route", "text": "transdermal", "start": 17, "end": 18}, {"entity_id": "11696132_1_Ent1", "role": "Treatment", "text": "transdermal scopolamine patch", "start": 17, "end": 20}, {"entity_id": "11696132_1_Ent2", "role": "Treatment_Drug", "text": "scopolamine", "start": 18, "end": 19}, {"entity_id": "11696132_1_Ent4", "role": "Treatment_Route", "text": "patch", "start": 19, "end": 20}, {"entity_id": "11696132_1_Ent5", "role": "Treatment_Disorder", "text": "weaning off the opioid", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "11696132_1_Ent0", "text": "anisocoria", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11696132_1_Ent3", "text": "transdermal", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11696132_1_Ent1", "text": "transdermal scopolamine patch", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11696132_1_Ent2", "text": "scopolamine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11696132_1_Ent4", "text": "patch", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11696132_1_Ent5", "text": "weaning off the opioid", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "11700998_1", "wnd_id": "11700998_1_1", "text": "De novo absence status of late onset following withdrawal of lorazepam : a case report .", "tokens": ["De", "novo", "absence", "status", "of", "late", "onset", "following", "withdrawal", "of", "lorazepam", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11700998_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "11700998_1_Ent0", "role": "Effect", "text": "De novo absence status of late onset", "start": 0, "end": 7}, {"entity_id": "11700998_1_Ent1", "role": "Treatment", "text": "withdrawal of lorazepam", "start": 8, "end": 11}, {"entity_id": "11700998_1_Ent2", "role": "Treatment_Drug", "text": "lorazepam", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11700998_1_Ent0", "text": "De novo absence status of late onset", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11700998_1_Ent1", "text": "withdrawal of lorazepam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11700998_1_Ent2", "text": "lorazepam", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11700998_2", "wnd_id": "11700998_2_1", "text": "The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam .", "tokens": ["The", "aim", "of", "this", "report", "is", "to", "describe", "the", "clinical", "and", "electroencephalographic", "findings", "seen", "in", "an", "elderly", "woman", "without", "previous", "history", "of", "seizures", "who", "developed", "a", "nonconvulsive", "generalized", "status", "epilepticus", "following", "acute", "withdrawal", "of", "lorazepam", "."], "event_mentions": [{"id": "11700998_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 30, "end": 31}, "arguments": [{"entity_id": "11700998_2_Ent0", "role": "Subject", "text": "an elderly woman", "start": 15, "end": 18}, {"entity_id": "11700998_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 16, "end": 17}, {"entity_id": "11700998_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 17, "end": 18}, {"entity_id": "11700998_2_Ent3", "role": "Effect", "text": "nonconvulsive generalized status epilepticus", "start": 26, "end": 30}, {"entity_id": "11700998_2_Ent4", "role": "Treatment", "text": "acute withdrawal of lorazepam", "start": 31, "end": 35}, {"entity_id": "11700998_2_Ent5", "role": "Treatment_Drug", "text": "lorazepam", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "11700998_2_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "11700998_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11700998_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11700998_2_Ent3", "text": "nonconvulsive generalized status epilepticus", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "11700998_2_Ent4", "text": "acute withdrawal of lorazepam", "entity_type": "Entity", "start": 31, "end": 35}, {"id": "11700998_2_Ent5", "text": "lorazepam", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "11720625_3", "wnd_id": "11720625_3_1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval have been known to cause TdP. However , clarithromycin is thought to be less frequently associated with drug induced TdP , because it inactivates hepatic cytochrome P - 450 to a lesser extent than erythromycin .", "tokens": ["Drug", "interactions", "between", "macrolide", "antibiotics", "such", "as", "erythomycin", "and", "pharmacologic", "agents", "that", "prolong", "the", "QT", "interval", "have", "been", "known", "to", "cause", "TdP.", "However", ",", "clarithromycin", "is", "thought", "to", "be", "less", "frequently", "associated", "with", "drug", "induced", "TdP", ",", "because", "it", "inactivates", "hepatic", "cytochrome", "P", "-", "450", "to", "a", "lesser", "extent", "than", "erythromycin", "."], "event_mentions": [{"id": "11720625_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 20, "end": 21}, "arguments": [{"entity_id": "11720625_3_Ent1", "role": "Treatment", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "start": 0, "end": 16}, {"entity_id": "11720625_3_Ent4", "role": "Treatment_Drug", "text": "macrolide antibiotics", "start": 3, "end": 5}, {"entity_id": "11720625_3_Ent2", "role": "Treatment_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent5", "role": "Combination_Drug", "text": "erythomycin", "start": 7, "end": 8}, {"entity_id": "11720625_3_Ent3", "role": "Treatment_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent6", "role": "Combination_Drug", "text": "pharmacologic agents", "start": 9, "end": 11}, {"entity_id": "11720625_3_Ent0", "role": "Effect", "text": "TdP.", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11720625_3_Ent1", "text": "Drug interactions between macrolide antibiotics such as erythomycin and pharmacologic agents that prolong the QT interval", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "11720625_3_Ent4", "text": "macrolide antibiotics", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11720625_3_Ent2", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent5", "text": "erythomycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11720625_3_Ent3", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent6", "text": "pharmacologic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11720625_3_Ent0", "text": "TdP.", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11720625_4", "wnd_id": "11720625_4_1", "text": "We describe a case of TdP caused by a drug interaction in a 76 - year - old woman taking long - term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis .", "tokens": ["We", "describe", "a", "case", "of", "TdP", "caused", "by", "a", "drug", "interaction", "in", "a", "76", "-", "year", "-", "old", "woman", "taking", "long", "-", "term", "disopyramide", "after", "she", "was", "given", "clarithromycin", "concomitantly", "for", "chronic", "bronchitis", "."], "event_mentions": [{"id": "11720625_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 19, "end": 20}, "arguments": [{"entity_id": "11720625_4_Ent3", "role": "Effect", "text": "TdP", "start": 5, "end": 6}, {"entity_id": "11720625_4_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 13, "end": 18}, {"entity_id": "11720625_4_Ent0", "role": "Subject", "text": "76 - year - old woman", "start": 13, "end": 19}, {"entity_id": "11720625_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}, {"entity_id": "11720625_4_Ent4", "role": "Treatment", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent7", "role": "Treatment_Drug", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent9", "role": "Combination_Drug", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent5", "role": "Treatment", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent8", "role": "Treatment_Drug", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent10", "role": "Combination_Drug", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent6", "role": "Treatment_Disorder", "text": "chronic bronchitis", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "11720625_4_Ent3", "text": "TdP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11720625_4_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "11720625_4_Ent0", "text": "76 - year - old woman", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "11720625_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11720625_4_Ent4", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent7", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent9", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent10", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent6", "text": "chronic bronchitis", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "11722307_3", "wnd_id": "11722307_3_1", "text": "METHOD : We describe three case - reports concerning haematological adverse effects of quetiapine .", "tokens": ["METHOD", ":", "We", "describe", "three", "case", "-", "reports", "concerning", "haematological", "adverse", "effects", "of", "quetiapine", "."], "event_mentions": [{"id": "11722307_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 10, "end": 12}, "arguments": [{"entity_id": "11722307_3_Ent0", "role": "Effect", "text": "haematological adverse effects", "start": 9, "end": 12}, {"entity_id": "11722307_3_Ent1", "role": "Treatment", "text": "quetiapine", "start": 13, "end": 14}, {"entity_id": "11722307_3_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11722307_3_Ent0", "text": "haematological adverse effects", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11722307_3_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11722307_3_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11737689_4", "wnd_id": "11737689_4_1", "text": "Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia .", "tokens": ["Painful", "neutrophilic", "skin", "lesions", "were", "observed", "in", "two", "children", "receiving", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "for", "treatment", "of", "idiopathic", "neutropenia", "."], "event_mentions": [{"id": "11737689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 5, "end": 6}, "arguments": [{"entity_id": "11737689_4_Ent3", "role": "Effect", "text": "Painful neutrophilic skin lesions", "start": 0, "end": 4}, {"entity_id": "11737689_4_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "11737689_4_Ent0", "role": "Subject", "text": "two children", "start": 7, "end": 9}, {"entity_id": "11737689_4_Ent2", "role": "Subject_Age", "text": "children", "start": 8, "end": 9}, {"entity_id": "11737689_4_Ent5", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 10, "end": 15}, {"entity_id": "11737689_4_Ent4", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 10, "end": 20}, {"entity_id": "11737689_4_Ent6", "role": "Treatment_Disorder", "text": "idiopathic neutropenia", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "11737689_4_Ent3", "text": "Painful neutrophilic skin lesions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11737689_4_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11737689_4_Ent0", "text": "two children", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11737689_4_Ent2", "text": "children", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11737689_4_Ent5", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11737689_4_Ent4", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "11737689_4_Ent6", "text": "idiopathic neutropenia", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "11737689_5", "wnd_id": "11737689_5_1", "text": "We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G - CSF therapy .", "tokens": ["We", "believe", "that", "these", "skin", "eruptions", "belong", "to", "a", "spectrum", "of", "neutrophilic", "dermatoses", "that", "can", "be", "induced", "or", "aggravated", "by", "G", "-", "CSF", "therapy", "."], "event_mentions": [{"id": "11737689_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "11737689_5_Ent0", "role": "Effect", "text": "skin eruptions", "start": 4, "end": 6}, {"entity_id": "11737689_5_Ent1", "role": "Treatment", "text": "G - CSF", "start": 20, "end": 23}, {"entity_id": "11737689_5_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "11737689_5_Ent0", "text": "skin eruptions", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11737689_5_Ent1", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11737689_5_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "11795358_1", "wnd_id": "11795358_1_1", "text": "However , in the mid - to - late 1980s , a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma .", "tokens": ["However", ",", "in", "the", "mid", "-", "to", "-", "late", "1980s", ",", "a", "series", "of", "letters", "to", "the", "editor", "and", "case", "reports", "announced", "an", "association", "between", "tamoxifen", "therapy", "in", "women", "with", "breast", "cancer", "and", "the", "development", "of", "endometrial", "carcinoma", "."], "event_mentions": [{"id": "11795358_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 34, "end": 35}, "arguments": [{"entity_id": "11795358_1_Ent3", "role": "Treatment", "text": "tamoxifen", "start": 25, "end": 26}, {"entity_id": "11795358_1_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 25, "end": 26}, {"entity_id": "11795358_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 28, "end": 29}, {"entity_id": "11795358_1_Ent0", "role": "Subject", "text": "women with breast cancer", "start": 28, "end": 32}, {"entity_id": "11795358_1_Ent5", "role": "Treatment_Disorder", "text": "breast cancer", "start": 30, "end": 32}, {"entity_id": "11795358_1_Ent2", "role": "Effect", "text": "endometrial carcinoma", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "11795358_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11795358_1_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11795358_1_Ent1", "text": "women", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11795358_1_Ent0", "text": "women with breast cancer", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "11795358_1_Ent5", "text": "breast cancer", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "11795358_1_Ent2", "text": "endometrial carcinoma", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "11804071_2", "wnd_id": "11804071_2_1", "text": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption .", "tokens": ["Isonicotinic", "acid", "hydrazide", "induced", "anagen", "effluvium", "and", "associated", "lichenoid", "eruption", "."], "event_mentions": [{"id": "11804071_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11804071_2_Ent1", "role": "Treatment", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent2", "role": "Treatment_Drug", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent0", "role": "Effect", "text": "anagen effluvium and associated lichenoid eruption", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "11804071_2_Ent1", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent2", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent0", "text": "anagen effluvium and associated lichenoid eruption", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "11816261_1", "wnd_id": "11816261_1_1", "text": "After a second dose of metoclopramide , these symptoms recurred and were associated with confusion , agitation , fever , diaphoresis , tachypnea , tachycardia , and hypertension .", "tokens": ["After", "a", "second", "dose", "of", "metoclopramide", ",", "these", "symptoms", "recurred", "and", "were", "associated", "with", "confusion", ",", "agitation", ",", "fever", ",", "diaphoresis", ",", "tachypnea", ",", "tachycardia", ",", "and", "hypertension", "."], "event_mentions": [{"id": "11816261_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "11816261_1_Ent1", "role": "Treatment", "text": "second dose of metoclopramide", "start": 2, "end": 6}, {"entity_id": "11816261_1_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 5, "end": 6}, {"entity_id": "11816261_1_Ent0", "role": "Effect", "text": "confusion , agitation , fever , diaphoresis , tachypnea , tachycardia , and hypertension", "start": 14, "end": 28}]}], "entity_mentions": [{"id": "11816261_1_Ent1", "text": "second dose of metoclopramide", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11816261_1_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11816261_1_Ent0", "text": "confusion , agitation , fever , diaphoresis , tachypnea , tachycardia , and hypertension", "entity_type": "Entity", "start": 14, "end": 28}], "lang": "en"}
{"doc_id": "11816261_5", "wnd_id": "11816261_5_1", "text": "She was administered metoclopramide because of nausea and , within 2 hours , developed agitation , dysarthria , diaphoresis , and a movement disorder .", "tokens": ["She", "was", "administered", "metoclopramide", "because", "of", "nausea", "and", ",", "within", "2", "hours", ",", "developed", "agitation", ",", "dysarthria", ",", "diaphoresis", ",", "and", "a", "movement", "disorder", "."], "event_mentions": [{"id": "11816261_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11816261_5_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 3, "end": 4}, {"entity_id": "11816261_5_Ent3", "role": "Treatment_Disorder", "text": "nausea", "start": 6, "end": 7}, {"entity_id": "11816261_5_Ent4", "role": "Treatment_Time_elapsed", "text": "within 2 hours", "start": 9, "end": 12}, {"entity_id": "11816261_5_Ent0", "role": "Effect", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "start": 14, "end": 24}]}], "entity_mentions": [{"id": "11816261_5_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11816261_5_Ent3", "text": "nausea", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11816261_5_Ent4", "text": "within 2 hours", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11816261_5_Ent0", "text": "agitation , dysarthria , diaphoresis , and a movement disorder", "entity_type": "Entity", "start": 14, "end": 24}], "lang": "en"}
{"doc_id": "11834188_4", "wnd_id": "11834188_4_1", "text": "We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test .", "tokens": ["We", "presented", "the", "case", "of", "a", "patient", "who", "developed", "a", "cutaneous", "reaction", "induced", "by", "captopril", "with", "positive", "patch", "test", "."], "event_mentions": [{"id": "11834188_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "11834188_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "11834188_4_Ent1", "role": "Effect", "text": "cutaneous reaction", "start": 10, "end": 12}, {"entity_id": "11834188_4_Ent2", "role": "Treatment", "text": "captopril", "start": 14, "end": 15}, {"entity_id": "11834188_4_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11834188_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11834188_4_Ent1", "text": "cutaneous reaction", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11834188_4_Ent2", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11834188_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "11837564_3", "wnd_id": "11837564_3_1", "text": "Warfarin - associated bleeding generally is considered deleterious ; however , in our patient it unmasked an early stage of colon cancer and thus may have saved the patient 's life .", "tokens": ["Warfarin", "-", "associated", "bleeding", "generally", "is", "considered", "deleterious", ";", "however", ",", "in", "our", "patient", "it", "unmasked", "an", "early", "stage", "of", "colon", "cancer", "and", "thus", "may", "have", "saved", "the", "patient", "'s", "life", "."], "event_mentions": [{"id": "11837564_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11837564_3_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_3_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "11837564_3_Ent0", "role": "Effect", "text": "bleeding", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11837564_3_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_3_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11837564_3_Ent0", "text": "bleeding", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11850606_2", "wnd_id": "11850606_2_1", "text": "In this case , interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B.", "tokens": ["In", "this", "case", ",", "interferon", "alpha", "induced", "polymyositis", "and", "cardiomyopathy", "is", "diagnosed", "in", "a", "33", "-", "yr", "-", "old", "male", "patient", "with", "history", "of", "chronic", "hepatitis", "B."], "event_mentions": [{"id": "11850606_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11850606_2_Ent4", "role": "Treatment", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "11850606_2_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "11850606_2_Ent3", "role": "Effect", "text": "polymyositis and cardiomyopathy", "start": 7, "end": 10}, {"entity_id": "11850606_2_Ent0", "role": "Subject", "text": "a 33 - yr - old male patient with history of chronic hepatitis B.", "start": 13, "end": 27}, {"entity_id": "11850606_2_Ent1", "role": "Subject_Age", "text": "33 - yr - old", "start": 14, "end": 19}, {"entity_id": "11850606_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 19, "end": 20}, {"entity_id": "11850606_2_Ent6", "role": "Treatment_Disorder", "text": "history of chronic hepatitis B.", "start": 22, "end": 27}]}], "entity_mentions": [{"id": "11850606_2_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11850606_2_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11850606_2_Ent3", "text": "polymyositis and cardiomyopathy", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11850606_2_Ent0", "text": "a 33 - yr - old male patient with history of chronic hepatitis B.", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "11850606_2_Ent1", "text": "33 - yr - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "11850606_2_Ent2", "text": "male", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11850606_2_Ent6", "text": "history of chronic hepatitis B.", "entity_type": "Entity", "start": 22, "end": 27}], "lang": "en"}
{"doc_id": "11850606_4", "wnd_id": "11850606_4_1", "text": "To treat hepatitis B , interferon alpha was administered until the proximal muscle weakness developed .", "tokens": ["To", "treat", "hepatitis", "B", ",", "interferon", "alpha", "was", "administered", "until", "the", "proximal", "muscle", "weakness", "developed", "."], "event_mentions": [{"id": "11850606_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "11850606_4_Ent2", "role": "Treatment_Disorder", "text": "hepatitis B", "start": 2, "end": 4}, {"entity_id": "11850606_4_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent0", "role": "Effect", "text": "proximal muscle weakness", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11850606_4_Ent2", "text": "hepatitis B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11850606_4_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent0", "text": "proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11876387_2", "wnd_id": "11876387_2_1", "text": "Since tamoxifen therapy can induce endometrial disorders , surveillance schemes of women taking tamoxifen have been recommended .", "tokens": ["Since", "tamoxifen", "therapy", "can", "induce", "endometrial", "disorders", ",", "surveillance", "schemes", "of", "women", "taking", "tamoxifen", "have", "been", "recommended", "."], "event_mentions": [{"id": "11876387_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 4, "end": 5}, "arguments": [{"entity_id": "11876387_2_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 1, "end": 2}, {"entity_id": "11876387_2_Ent3", "role": "Treatment", "text": "tamoxifen therapy", "start": 1, "end": 3}, {"entity_id": "11876387_2_Ent2", "role": "Effect", "text": "endometrial disorders", "start": 5, "end": 7}, {"entity_id": "11876387_2_Ent0", "role": "Subject", "text": "women", "start": 11, "end": 12}, {"entity_id": "11876387_2_Ent1", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11876387_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11876387_2_Ent3", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11876387_2_Ent2", "text": "endometrial disorders", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11876387_2_Ent0", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11876387_2_Ent1", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11881322_4", "wnd_id": "11881322_4_1", "text": "METHODS : Three patients with apparent itraconazole - induced liver injury were studied .", "tokens": ["METHODS", ":", "Three", "patients", "with", "apparent", "itraconazole", "-", "induced", "liver", "injury", "were", "studied", "."], "event_mentions": [{"id": "11881322_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "11881322_4_Ent1", "role": "Subject_Population", "text": "Three", "start": 2, "end": 3}, {"entity_id": "11881322_4_Ent0", "role": "Subject", "text": "Three patients", "start": 2, "end": 4}, {"entity_id": "11881322_4_Ent3", "role": "Treatment", "text": "itraconazole", "start": 6, "end": 7}, {"entity_id": "11881322_4_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 6, "end": 7}, {"entity_id": "11881322_4_Ent2", "role": "Effect", "text": "liver injury", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "11881322_4_Ent1", "text": "Three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_4_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11881322_4_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11881322_4_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11881322_4_Ent2", "text": "liver injury", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "11881322_8", "wnd_id": "11881322_8_1", "text": "With itraconazole , hepatotoxic reactions have only very rarely been reported , and histologic data are lacking .", "tokens": ["With", "itraconazole", ",", "hepatotoxic", "reactions", "have", "only", "very", "rarely", "been", "reported", ",", "and", "histologic", "data", "are", "lacking", "."], "event_mentions": [{"id": "11881322_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 10, "end": 11}, "arguments": [{"entity_id": "11881322_8_Ent1", "role": "Treatment", "text": "itraconazole", "start": 1, "end": 2}, {"entity_id": "11881322_8_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 1, "end": 2}, {"entity_id": "11881322_8_Ent0", "role": "Effect", "text": "hepatotoxic", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11881322_8_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_8_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_8_Ent0", "text": "hepatotoxic", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11886466_1", "wnd_id": "11886466_1_1", "text": "Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia .", "tokens": ["Thrombotic", "stroke", "associated", "with", "the", "use", "of", "porcine", "factor", "VIII", "in", "a", "patient", "with", "acquired", "haemophilia", "."], "event_mentions": [{"id": "11886466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11886466_1_Ent1", "role": "Effect", "text": "Thrombotic stroke", "start": 0, "end": 2}, {"entity_id": "11886466_1_Ent2", "role": "Treatment", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent3", "role": "Treatment_Drug", "text": "porcine factor VIII", "start": 7, "end": 10}, {"entity_id": "11886466_1_Ent0", "role": "Subject", "text": "patient with acquired haemophilia", "start": 12, "end": 16}, {"entity_id": "11886466_1_Ent4", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11886466_1_Ent1", "text": "Thrombotic stroke", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11886466_1_Ent2", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent3", "text": "porcine factor VIII", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11886466_1_Ent0", "text": "patient with acquired haemophilia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11886466_1_Ent4", "text": "acquired haemophilia", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11886466_3", "wnd_id": "11886466_3_1", "text": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII .", "tokens": ["We", "have", "recently", "encountered", "a", "patient", "with", "acquired", "haemophilia", "who", "developed", "a", "thrombotic", "left", "middle", "cerebral", "artery", "distribution", "stroke", "while", "being", "treated", "with", "pFVIII", "."], "event_mentions": [{"id": "11886466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11886466_3_Ent0", "role": "Subject", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "start": 5, "end": 19}, {"entity_id": "11886466_3_Ent3", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 7, "end": 9}, {"entity_id": "11886466_3_Ent1", "role": "Effect", "text": "thrombotic left middle cerebral artery distribution stroke", "start": 12, "end": 19}, {"entity_id": "11886466_3_Ent2", "role": "Treatment", "text": "pFVIII", "start": 23, "end": 24}, {"entity_id": "11886466_3_Ent4", "role": "Treatment_Drug", "text": "pFVIII", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11886466_3_Ent0", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11886466_3_Ent3", "text": "acquired haemophilia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11886466_3_Ent1", "text": "thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "11886466_3_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11886466_3_Ent4", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11903249_2", "wnd_id": "11903249_2_1", "text": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin .", "tokens": ["There", "have", "been", "more", "than", "20", "observations", "of", "the", "appearance", "or", "aggravation", "of", "this", "granulomatosis", "with", "interferon", "alfa", "and", "more", "recently", "with", "the", "combination", "of", "interferon", "alfa", "plus", "ribavirin", "."], "event_mentions": [{"id": "11903249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 15, "end": 16}, "arguments": [{"entity_id": "11903249_2_Ent0", "role": "Effect", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "start": 3, "end": 15}, {"entity_id": "11903249_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 16, "end": 18}, {"entity_id": "11903249_2_Ent1", "role": "Treatment", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "start": 16, "end": 29}, {"entity_id": "11903249_2_Ent3", "role": "Treatment_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent5", "role": "Combination_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 28, "end": 29}, {"entity_id": "11903249_2_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11903249_2_Ent0", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "11903249_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "11903249_2_Ent1", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "entity_type": "Entity", "start": 16, "end": 29}, {"id": "11903249_2_Ent3", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent5", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11903249_2_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11961411_3", "wnd_id": "11961411_3_1", "text": "To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN - beta therapy for the malignant melanoma .", "tokens": ["To", "our", "knowledge", "this", "is", "the", "first", "report", "that", "demonstrates", "histological", "abnormalities", "of", "the", "glomerulus", "associated", "with", "postoperative", "IFN", "-", "beta", "therapy", "for", "the", "malignant", "melanoma", "."], "event_mentions": [{"id": "11961411_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "11961411_3_Ent0", "role": "Effect", "text": "histological abnormalities of the glomerulus", "start": 10, "end": 15}, {"entity_id": "11961411_3_Ent1", "role": "Treatment", "text": "postoperative IFN - beta therapy", "start": 17, "end": 22}, {"entity_id": "11961411_3_Ent2", "role": "Treatment_Drug", "text": "IFN - beta", "start": 18, "end": 21}, {"entity_id": "11961411_3_Ent3", "role": "Treatment_Disorder", "text": "malignant melanoma", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "11961411_3_Ent0", "text": "histological abnormalities of the glomerulus", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11961411_3_Ent1", "text": "postoperative IFN - beta therapy", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "11961411_3_Ent2", "text": "IFN - beta", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "11961411_3_Ent3", "text": "malignant melanoma", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "11999915_4", "wnd_id": "11999915_4_1", "text": "The male patient was treated with 225 - mg / day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks .", "tokens": ["The", "male", "patient", "was", "treated", "with", "225", "-", "mg", "/", "day", "clozapine", "and", "the", "time", "to", "the", "diagnosis", "of", "agranulocytosis", "was", "6", "weeks", "."], "event_mentions": [{"id": "11999915_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosis", "start": 17, "end": 18}, "arguments": [{"entity_id": "11999915_4_Ent0", "role": "Subject", "text": "The male patient", "start": 0, "end": 3}, {"entity_id": "11999915_4_Ent1", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "11999915_4_Ent5", "role": "Treatment_Dosage", "text": "225 - mg / day", "start": 6, "end": 11}, {"entity_id": "11999915_4_Ent3", "role": "Treatment", "text": "225 - mg / day clozapine", "start": 6, "end": 12}, {"entity_id": "11999915_4_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "11999915_4_Ent2", "role": "Effect", "text": "agranulocytosis", "start": 19, "end": 20}, {"entity_id": "11999915_4_Ent6", "role": "Treatment_Duration", "text": "6 weeks", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11999915_4_Ent0", "text": "The male patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_4_Ent1", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11999915_4_Ent5", "text": "225 - mg / day", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11999915_4_Ent3", "text": "225 - mg / day clozapine", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11999915_4_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11999915_4_Ent2", "text": "agranulocytosis", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11999915_4_Ent6", "text": "6 weeks", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "12053072_2", "wnd_id": "12053072_2_1", "text": "We describe a patient who developed HUS after treatment with mitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "HUS", "after", "treatment", "with", "mitomycin", "C", "(", "total", "dose", "144", "mg", "/", "m2", ")", "due", "to", "a", "carcinoma", "of", "the", "ascending", "colon", "."], "event_mentions": [{"id": "12053072_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12053072_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12053072_2_Ent1", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "12053072_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 10, "end": 12}, {"entity_id": "12053072_2_Ent2", "role": "Treatment", "text": "mitomycin C ( total dose 144 mg / m2 )", "start": 10, "end": 20}, {"entity_id": "12053072_2_Ent4", "role": "Treatment_Dosage", "text": "144 mg / m2", "start": 15, "end": 19}, {"entity_id": "12053072_2_Ent5", "role": "Treatment_Disorder", "text": "carcinoma of the ascending colon", "start": 23, "end": 28}]}], "entity_mentions": [{"id": "12053072_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12053072_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12053072_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12053072_2_Ent2", "text": "mitomycin C ( total dose 144 mg / m2 )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "12053072_2_Ent4", "text": "144 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12053072_2_Ent5", "text": "carcinoma of the ascending colon", "entity_type": "Entity", "start": 23, "end": 28}], "lang": "en"}
{"doc_id": "12078977_1", "wnd_id": "12078977_1_1", "text": "A 31 - year - old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin , vinblastine and bleomycin for germ cell ovarian cancer stage Ic .", "tokens": ["A", "31", "-", "year", "-", "old", "female", "developed", "multiple", "episodes", "of", "grand", "mal", "seizures", "after", "combination", "chemotherapy", "with", "cisplatin", ",", "vinblastine", "and", "bleomycin", "for", "germ", "cell", "ovarian", "cancer", "stage", "Ic", "."], "event_mentions": [{"id": "12078977_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12078977_1_Ent0", "role": "Subject", "text": "A 31 - year - old female", "start": 0, "end": 7}, {"entity_id": "12078977_1_Ent1", "role": "Subject_Age", "text": "31 - year - old", "start": 1, "end": 6}, {"entity_id": "12078977_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "12078977_1_Ent3", "role": "Effect", "text": "multiple episodes of grand mal seizures", "start": 8, "end": 14}, {"entity_id": "12078977_1_Ent4", "role": "Treatment", "text": "combination chemotherapy with cisplatin , vinblastine and bleomycin", "start": 15, "end": 23}, {"entity_id": "12078977_1_Ent8", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "12078977_1_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "12078977_1_Ent7", "role": "Treatment_Drug", "text": "vinblastine", "start": 20, "end": 21}, {"entity_id": "12078977_1_Ent10", "role": "Combination_Drug", "text": "vinblastine", "start": 20, "end": 21}, {"entity_id": "12078977_1_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 22, "end": 23}, {"entity_id": "12078977_1_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 22, "end": 23}, {"entity_id": "12078977_1_Ent5", "role": "Treatment_Disorder", "text": "germ cell ovarian cancer stage Ic", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "12078977_1_Ent0", "text": "A 31 - year - old female", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12078977_1_Ent1", "text": "31 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12078977_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12078977_1_Ent3", "text": "multiple episodes of grand mal seizures", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12078977_1_Ent4", "text": "combination chemotherapy with cisplatin , vinblastine and bleomycin", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "12078977_1_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12078977_1_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12078977_1_Ent7", "text": "vinblastine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12078977_1_Ent10", "text": "vinblastine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12078977_1_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12078977_1_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12078977_1_Ent5", "text": "germ cell ovarian cancer stage Ic", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "12078977_2", "wnd_id": "12078977_2_1", "text": "Posterior leukoencephalopathy following cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary .", "tokens": ["Posterior", "leukoencephalopathy", "following", "cisplatin", ",", "bleomycin", "and", "vinblastine", "therapy", "for", "germ", "cell", "tumor", "of", "the", "ovary", "."], "event_mentions": [{"id": "12078977_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "12078977_2_Ent0", "role": "Effect", "text": "Posterior leukoencephalopathy", "start": 0, "end": 2}, {"entity_id": "12078977_2_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "12078977_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "12078977_2_Ent1", "role": "Treatment", "text": "cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary", "start": 3, "end": 16}, {"entity_id": "12078977_2_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "12078977_2_Ent7", "role": "Combination_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "12078977_2_Ent5", "role": "Treatment_Drug", "text": "vinblastine", "start": 7, "end": 8}, {"entity_id": "12078977_2_Ent6", "role": "Combination_Drug", "text": "vinblastine", "start": 7, "end": 8}, {"entity_id": "12078977_2_Ent2", "role": "Treatment_Disorder", "text": "germ cell tumor of the ovary", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "12078977_2_Ent0", "text": "Posterior leukoencephalopathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12078977_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12078977_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12078977_2_Ent1", "text": "cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "12078977_2_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12078977_2_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12078977_2_Ent5", "text": "vinblastine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12078977_2_Ent6", "text": "vinblastine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12078977_2_Ent2", "text": "germ cell tumor of the ovary", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "12086549_3", "wnd_id": "12086549_3_1", "text": "Subcutaneous IL - 2 is safe and well tolerated , with a mortality rate < 3 % .", "tokens": ["Subcutaneous", "IL", "-", "2", "is", "safe", "and", "well", "tolerated", ",", "with", "a", "mortality", "rate", "<", "3", "%", "."], "event_mentions": [{"id": "12086549_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "12086549_3_Ent2", "role": "Treatment_Route", "text": "Subcutaneous", "start": 0, "end": 1}, {"entity_id": "12086549_3_Ent1", "role": "Treatment", "text": "Subcutaneous IL - 2", "start": 0, "end": 4}, {"entity_id": "12086549_3_Ent3", "role": "Treatment_Drug", "text": "IL - 2", "start": 1, "end": 4}, {"entity_id": "12086549_3_Ent0", "role": "Effect", "text": "mortality rate < 3 %", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "12086549_3_Ent2", "text": "Subcutaneous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12086549_3_Ent1", "text": "Subcutaneous IL - 2", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12086549_3_Ent3", "text": "IL - 2", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12086549_3_Ent0", "text": "mortality rate < 3 %", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "12092878_2", "wnd_id": "12092878_2_1", "text": "A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non - haemorrhagic hypovolaemia is presented , with a discussion on the management and the use of allergy identification jewellery .", "tokens": ["A", "case", "of", "anaphylactoid", "reaction", "due", "solely", "to", "the", "use", "of", "Gelofusine", "in", "a", "patient", "with", "non", "-", "haemorrhagic", "hypovolaemia", "is", "presented", ",", "with", "a", "discussion", "on", "the", "management", "and", "the", "use", "of", "allergy", "identification", "jewellery", "."], "event_mentions": [{"id": "12092878_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 4, "end": 5}, "arguments": [{"entity_id": "12092878_2_Ent1", "role": "Effect", "text": "anaphylactoid", "start": 3, "end": 4}, {"entity_id": "12092878_2_Ent2", "role": "Treatment", "text": "Gelofusine", "start": 11, "end": 12}, {"entity_id": "12092878_2_Ent4", "role": "Treatment_Drug", "text": "Gelofusine", "start": 11, "end": 12}, {"entity_id": "12092878_2_Ent0", "role": "Subject", "text": "patient with non - haemorrhagic hypovolaemia", "start": 14, "end": 20}, {"entity_id": "12092878_2_Ent3", "role": "Treatment_Disorder", "text": "non - haemorrhagic hypovolaemia", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "12092878_2_Ent1", "text": "anaphylactoid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12092878_2_Ent2", "text": "Gelofusine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12092878_2_Ent4", "text": "Gelofusine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12092878_2_Ent0", "text": "patient with non - haemorrhagic hypovolaemia", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "12092878_2_Ent3", "text": "non - haemorrhagic hypovolaemia", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "12095907_2", "wnd_id": "12095907_2_1", "text": "Valproate - induced hyperammonemia as a cause of altered mental status .", "tokens": ["Valproate", "-", "induced", "hyperammonemia", "as", "a", "cause", "of", "altered", "mental", "status", "."], "event_mentions": [{"id": "12095907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12095907_2_Ent2", "role": "Treatment", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent3", "role": "Treatment_Drug", "text": "Valproate", "start": 0, "end": 1}, {"entity_id": "12095907_2_Ent1", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}, {"entity_id": "12095907_2_Ent0", "role": "Effect", "text": "altered mental status", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12095907_2_Ent2", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent3", "text": "Valproate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12095907_2_Ent1", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12095907_2_Ent0", "text": "altered mental status", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12111771_1", "wnd_id": "12111771_1_1", "text": "A 73 - year - old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ) .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "presented", "with", "fever", "and", "cough", "2", "weeks", "after", "completing", "the", "third", "cycle", "of", "fludarabine", "for", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "."], "event_mentions": [{"id": "12111771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "12111771_1_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "12111771_1_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "12111771_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "12111771_1_Ent3", "role": "Effect", "text": "fever and cough", "start": 9, "end": 12}, {"entity_id": "12111771_1_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 12, "end": 14}, {"entity_id": "12111771_1_Ent4", "role": "Treatment", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "start": 12, "end": 28}, {"entity_id": "12111771_1_Ent7", "role": "Treatment_Drug", "text": "fludarabine", "start": 20, "end": 21}, {"entity_id": "12111771_1_Ent5", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia ( CLL )", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "12111771_1_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12111771_1_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12111771_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12111771_1_Ent3", "text": "fever and cough", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12111771_1_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12111771_1_Ent4", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 12, "end": 28}, {"id": "12111771_1_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12111771_1_Ent5", "text": "chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "12163813_1", "wnd_id": "12163813_1_1", "text": "CONCLUSIONS : Peripheral administration of low - dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications .", "tokens": ["CONCLUSIONS", ":", "Peripheral", "administration", "of", "low", "-", "dose", "vasopressin", "for", "septic", "shock", "should", "be", "discouraged", "because", "of", "the", "risk", "of", "ischemic", "skin", "complications", "."], "event_mentions": [{"id": "12163813_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 18, "end": 19}, "arguments": [{"entity_id": "12163813_1_Ent5", "role": "Treatment_Route", "text": "Peripheral administration", "start": 2, "end": 4}, {"entity_id": "12163813_1_Ent1", "role": "Treatment", "text": "Peripheral administration of low - dose vasopressin", "start": 2, "end": 9}, {"entity_id": "12163813_1_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 5, "end": 8}, {"entity_id": "12163813_1_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_1_Ent2", "role": "Treatment_Disorder", "text": "septic shock", "start": 10, "end": 12}, {"entity_id": "12163813_1_Ent0", "role": "Effect", "text": "ischemic skin complications", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "12163813_1_Ent5", "text": "Peripheral administration", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12163813_1_Ent1", "text": "Peripheral administration of low - dose vasopressin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "12163813_1_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12163813_1_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_1_Ent2", "text": "septic shock", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12163813_1_Ent0", "text": "ischemic skin complications", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "12243603_1", "wnd_id": "12243603_1_1", "text": "Rhabdomyolysis with concurrent atorvastatin and diltiazem .", "tokens": ["Rhabdomyolysis", "with", "concurrent", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 1, "end": 2}, "arguments": [{"entity_id": "12243603_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_1_Ent2", "role": "Treatment", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent3", "role": "Treatment_Drug", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent5", "role": "Combination_Drug", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent1", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "12243603_1_Ent4", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "12243603_1_Ent6", "role": "Combination_Drug", "text": "diltiazem", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12243603_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_1_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent3", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent5", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_1_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_1_Ent6", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12243603_12", "wnd_id": "12243603_12_1", "text": "All patients beginning HMG - CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury ; particular attention should be paid to those patients who are taking medications that may interact .", "tokens": ["All", "patients", "beginning", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "should", "be", "counseled", "regarding", "the", "signs", "and", "symptoms", "of", "muscle", "injury", ";", "particular", "attention", "should", "be", "paid", "to", "those", "patients", "who", "are", "taking", "medications", "that", "may", "interact", "."], "event_mentions": [{"id": "12243603_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "regarding", "start": 12, "end": 13}, "arguments": [{"entity_id": "12243603_12_Ent0", "role": "Subject", "text": "All patients", "start": 0, "end": 2}, {"entity_id": "12243603_12_Ent2", "role": "Treatment", "text": "HMG - CoA reductase inhibitor", "start": 3, "end": 8}, {"entity_id": "12243603_12_Ent3", "role": "Treatment_Drug", "text": "HMG - CoA reductase inhibitor", "start": 3, "end": 8}, {"entity_id": "12243603_12_Ent1", "role": "Effect", "text": "the signs and symptoms of muscle injury", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "12243603_12_Ent0", "text": "All patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12243603_12_Ent2", "text": "HMG - CoA reductase inhibitor", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12243603_12_Ent3", "text": "HMG - CoA reductase inhibitor", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12243603_12_Ent1", "text": "the signs and symptoms of muscle injury", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "12397859_1", "wnd_id": "12397859_1_1", "text": "A case is presented of a patient who experienced benzodiazepine withdrawal symptoms on discontinuation of nefazodone , an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme .", "tokens": ["A", "case", "is", "presented", "of", "a", "patient", "who", "experienced", "benzodiazepine", "withdrawal", "symptoms", "on", "discontinuation", "of", "nefazodone", ",", "an", "antidepressant", "that", "inhibits", "the", "cytochrome", "P450", "3A4", "isoenzyme", "."], "event_mentions": [{"id": "12397859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 13, "end": 14}, "arguments": [{"entity_id": "12397859_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "12397859_1_Ent1", "role": "Effect", "text": "benzodiazepine withdrawal symptoms", "start": 9, "end": 12}, {"entity_id": "12397859_1_Ent2", "role": "Treatment", "text": "nefazodone", "start": 15, "end": 16}, {"entity_id": "12397859_1_Ent3", "role": "Treatment_Drug", "text": "nefazodone", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12397859_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12397859_1_Ent1", "text": "benzodiazepine withdrawal symptoms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12397859_1_Ent2", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12397859_1_Ent3", "text": "nefazodone", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12439602_2", "wnd_id": "12439602_2_1", "text": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report .", "tokens": ["Carboplatin", "hypersensitivity", "presenting", "as", "coronary", "vasospasm", "-", "a", "case", "report", "."], "event_mentions": [{"id": "12439602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 2, "end": 3}, "arguments": [{"entity_id": "12439602_2_Ent1", "role": "Treatment", "text": "Carboplatin", "start": 0, "end": 1}, {"entity_id": "12439602_2_Ent2", "role": "Treatment_Drug", "text": "Carboplatin", "start": 0, "end": 1}, {"entity_id": "12439602_2_Ent0", "role": "Effect", "text": "coronary vasospasm", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "12439602_2_Ent1", "text": "Carboplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12439602_2_Ent2", "text": "Carboplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12439602_2_Ent0", "text": "coronary vasospasm", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "12452753_1", "wnd_id": "12452753_1_1", "text": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week .", "tokens": ["Capecitabine", "was", "discontinued", "and", "the", "allergic", "reactions", "resolved", "after", "the", "woman", "took", "diphenhydramine", "for", "1", "week", "."], "event_mentions": [{"id": "12452753_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "took", "start": 11, "end": 12}, "arguments": [{"entity_id": "12452753_1_Ent2", "role": "Effect", "text": "Capecitabine was discontinued and the allergic reactions resolved", "start": 0, "end": 8}, {"entity_id": "12452753_1_Ent0", "role": "Subject", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent4", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 12, "end": 13}, {"entity_id": "12452753_1_Ent3", "role": "Treatment", "text": "diphenhydramine for 1 week", "start": 12, "end": 16}, {"entity_id": "12452753_1_Ent5", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12452753_1_Ent2", "text": "Capecitabine was discontinued and the allergic reactions resolved", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12452753_1_Ent0", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent4", "text": "diphenhydramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12452753_1_Ent3", "text": "diphenhydramine for 1 week", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12452753_1_Ent5", "text": "1 week", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12460237_1", "wnd_id": "12460237_1_1", "text": "Recurrent palmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia .", "tokens": ["Recurrent", "palmar", "-", "plantar", "erythrodysaesthesia", "following", "high", "-", "dose", "cytarabine", "treatment", "for", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "12460237_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 10, "end": 11}, "arguments": [{"entity_id": "12460237_1_Ent0", "role": "Effect", "text": "palmar - plantar erythrodysaesthesia", "start": 1, "end": 5}, {"entity_id": "12460237_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "12460237_1_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 6, "end": 10}, {"entity_id": "12460237_1_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 9, "end": 10}, {"entity_id": "12460237_1_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "12460237_1_Ent0", "text": "palmar - plantar erythrodysaesthesia", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12460237_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12460237_1_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12460237_1_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12460237_1_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "12477460_4", "wnd_id": "12477460_4_1", "text": "Ovarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under tamoxifen therapy for breast cancer : a case report .", "tokens": ["Ovarian", "endometrioid", "adenocarcinoma", "arising", "from", "an", "endometriotic", "cyst", "in", "a", "postmenopausal", "woman", "under", "tamoxifen", "therapy", "for", "breast", "cancer", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12477460_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 12, "end": 13}, "arguments": [{"entity_id": "12477460_4_Ent3", "role": "Effect", "text": "Ovarian endometrioid adenocarcinoma", "start": 0, "end": 3}, {"entity_id": "12477460_4_Ent0", "role": "Subject", "text": "a postmenopausal woman", "start": 9, "end": 12}, {"entity_id": "12477460_4_Ent1", "role": "Subject_Age", "text": "postmenopausal", "start": 10, "end": 11}, {"entity_id": "12477460_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "12477460_4_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "12477460_4_Ent4", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}, {"entity_id": "12477460_4_Ent6", "role": "Treatment_Disorder", "text": "breast cancer", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12477460_4_Ent3", "text": "Ovarian endometrioid adenocarcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12477460_4_Ent0", "text": "a postmenopausal woman", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12477460_4_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12477460_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12477460_4_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12477460_4_Ent4", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12477460_4_Ent6", "text": "breast cancer", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12488741_1", "wnd_id": "12488741_1_1", "text": "Clinical , spectroscopic , and imaging abnormalities resolved with discontinuation of metronidazole .", "tokens": ["Clinical", ",", "spectroscopic", ",", "and", "imaging", "abnormalities", "resolved", "with", "discontinuation", "of", "metronidazole", "."], "event_mentions": [{"id": "12488741_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "12488741_1_Ent0", "role": "Effect", "text": "Clinical , spectroscopic , and imaging abnormalities", "start": 0, "end": 7}, {"entity_id": "12488741_1_Ent1", "role": "Treatment", "text": "metronidazole", "start": 11, "end": 12}, {"entity_id": "12488741_1_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12488741_1_Ent0", "text": "Clinical , spectroscopic , and imaging abnormalities", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12488741_1_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12488741_1_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12494253_1", "wnd_id": "12494253_1_1", "text": "After nine previous uncomplicated cycles she developed severe anaphylaxis to cisplatin .", "tokens": ["After", "nine", "previous", "uncomplicated", "cycles", "she", "developed", "severe", "anaphylaxis", "to", "cisplatin", "."], "event_mentions": [{"id": "12494253_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "12494253_1_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "12494253_1_Ent1", "role": "Subject_Gender", "text": "she", "start": 5, "end": 6}, {"entity_id": "12494253_1_Ent2", "role": "Effect", "text": "severe anaphylaxis", "start": 7, "end": 9}, {"entity_id": "12494253_1_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "12494253_1_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12494253_1_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12494253_1_Ent1", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12494253_1_Ent2", "text": "severe anaphylaxis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12494253_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12494253_1_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12494253_2", "wnd_id": "12494253_2_1", "text": "Anaphylaxis to cisplatin following nine previous uncomplicated cycles .", "tokens": ["Anaphylaxis", "to", "cisplatin", "following", "nine", "previous", "uncomplicated", "cycles", "."], "event_mentions": [{"id": "12494253_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "12494253_2_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "12494253_2_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "12494253_2_Ent1", "role": "Treatment", "text": "cisplatin following nine previous uncomplicated cycles", "start": 2, "end": 8}, {"entity_id": "12494253_2_Ent3", "role": "Treatment_Duration", "text": "nine previous uncomplicated cycles", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "12494253_2_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12494253_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12494253_2_Ent1", "text": "cisplatin following nine previous uncomplicated cycles", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "12494253_2_Ent3", "text": "nine previous uncomplicated cycles", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "12503933_7", "wnd_id": "12503933_7_1", "text": "The most likely cause of liver failure in this patient was , therefore , clarithromycin , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure .", "tokens": ["The", "most", "likely", "cause", "of", "liver", "failure", "in", "this", "patient", "was", ",", "therefore", ",", "clarithromycin", ",", "which", "undergoes", "hepatic", "metabolism", "and", "has", "been", "reported", "to", "cause", "fulminant", "hepatic", "failure", "."], "event_mentions": [{"id": "12503933_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_7_Ent0", "role": "Effect", "text": "liver failure", "start": 5, "end": 7}, {"entity_id": "12503933_7_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 14, "end": 15}, {"entity_id": "12503933_7_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12503933_7_Ent0", "text": "liver failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12503933_7_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12503933_7_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12504711_2", "wnd_id": "12504711_2_1", "text": "CONCLUSION : Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine .", "tokens": ["CONCLUSION", ":", "Under", "certain", "circumstances", "topical", "brimonidine", "can", "cause", "paradoxical", "raised", "IOP", "necessitating", "vigilance", "in", "follow", "-", "up", "of", "patients", "on", "topical", "brimonidine", "."], "event_mentions": [{"id": "12504711_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "12504711_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 5, "end": 6}, {"entity_id": "12504711_2_Ent2", "role": "Treatment", "text": "topical brimonidine", "start": 5, "end": 7}, {"entity_id": "12504711_2_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 6, "end": 7}, {"entity_id": "12504711_2_Ent1", "role": "Effect", "text": "raised IOP", "start": 10, "end": 12}, {"entity_id": "12504711_2_Ent0", "role": "Subject", "text": "patients on topical brimonidine", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "12504711_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12504711_2_Ent2", "text": "topical brimonidine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12504711_2_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12504711_2_Ent1", "text": "raised IOP", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12504711_2_Ent0", "text": "patients on topical brimonidine", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "12540009_1", "wnd_id": "12540009_1_1", "text": "Doxycycline - induced hypoglycemia in a nondiabetic young man .", "tokens": ["Doxycycline", "-", "induced", "hypoglycemia", "in", "a", "nondiabetic", "young", "man", "."], "event_mentions": [{"id": "12540009_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12540009_1_Ent4", "role": "Treatment", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "12540009_1_Ent5", "role": "Treatment_Drug", "text": "Doxycycline", "start": 0, "end": 1}, {"entity_id": "12540009_1_Ent3", "role": "Effect", "text": "hypoglycemia", "start": 3, "end": 4}, {"entity_id": "12540009_1_Ent0", "role": "Subject", "text": "a nondiabetic young man", "start": 5, "end": 9}, {"entity_id": "12540009_1_Ent2", "role": "Subject_Age", "text": "young", "start": 7, "end": 8}, {"entity_id": "12540009_1_Ent1", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12540009_1_Ent4", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12540009_1_Ent5", "text": "Doxycycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12540009_1_Ent3", "text": "hypoglycemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12540009_1_Ent0", "text": "a nondiabetic young man", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12540009_1_Ent2", "text": "young", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12540009_1_Ent1", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12546343_3", "wnd_id": "12546343_3_1", "text": "He was later skin tested to confirm allergy to MTX .", "tokens": ["He", "was", "later", "skin", "tested", "to", "confirm", "allergy", "to", "MTX", "."], "event_mentions": [{"id": "12546343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 8, "end": 9}, "arguments": [{"entity_id": "12546343_3_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "12546343_3_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "12546343_3_Ent2", "role": "Effect", "text": "allergy", "start": 7, "end": 8}, {"entity_id": "12546343_3_Ent3", "role": "Treatment", "text": "MTX", "start": 9, "end": 10}, {"entity_id": "12546343_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12546343_3_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12546343_3_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12546343_3_Ent2", "text": "allergy", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12546343_3_Ent3", "text": "MTX", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12546343_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12587815_1", "wnd_id": "12587815_1_1", "text": "A 16 - year - old boy developed fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium .", "tokens": ["A", "16", "-", "year", "-", "old", "boy", "developed", "fever", ",", "generalized", "rigidity", ",", "leukocytosis", ",", "and", "increased", "serum", "transaminase", "and", "creatine", "kinase", "levels", "while", "receiving", "treatment", "with", "olanzapine", "and", "lithium", "."], "event_mentions": [{"id": "12587815_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 23, "end": 24}, "arguments": [{"entity_id": "12587815_1_Ent0", "role": "Subject", "text": "A 16 - year - old boy", "start": 0, "end": 7}, {"entity_id": "12587815_1_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 1, "end": 6}, {"entity_id": "12587815_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12587815_1_Ent3", "role": "Effect", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "start": 8, "end": 23}, {"entity_id": "12587815_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent4", "role": "Treatment", "text": "olanzapine and lithium", "start": 27, "end": 30}, {"entity_id": "12587815_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}, {"entity_id": "12587815_1_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12587815_1_Ent0", "text": "A 16 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12587815_1_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12587815_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12587815_1_Ent3", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "12587815_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent4", "text": "olanzapine and lithium", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12587815_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12587815_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12590235_2", "wnd_id": "12590235_2_1", "text": "Hepatotoxicity associated with 6 - thioguanine therapy for Crohn 's disease .", "tokens": ["Hepatotoxicity", "associated", "with", "6", "-", "thioguanine", "therapy", "for", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "12590235_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12590235_2_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "12590235_2_Ent1", "role": "Treatment", "text": "6 - thioguanine", "start": 3, "end": 6}, {"entity_id": "12590235_2_Ent2", "role": "Treatment_Drug", "text": "6 - thioguanine", "start": 3, "end": 6}, {"entity_id": "12590235_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "12590235_2_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12590235_2_Ent1", "text": "6 - thioguanine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12590235_2_Ent2", "text": "6 - thioguanine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "12590235_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "12590235_3", "wnd_id": "12590235_3_1", "text": "This case highlights the need to monitor liver enzymes in patients treated with 6 - TG and identifies the need for additional research focused on the mechanism of thiopurine - induced hepatic injury .", "tokens": ["This", "case", "highlights", "the", "need", "to", "monitor", "liver", "enzymes", "in", "patients", "treated", "with", "6", "-", "TG", "and", "identifies", "the", "need", "for", "additional", "research", "focused", "on", "the", "mechanism", "of", "thiopurine", "-", "induced", "hepatic", "injury", "."], "event_mentions": [{"id": "12590235_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "12590235_3_Ent0", "role": "Subject", "text": "patients treated with 6 - TG", "start": 10, "end": 16}, {"entity_id": "12590235_3_Ent2", "role": "Treatment", "text": "thiopurine", "start": 28, "end": 29}, {"entity_id": "12590235_3_Ent3", "role": "Treatment_Drug", "text": "thiopurine", "start": 28, "end": 29}, {"entity_id": "12590235_3_Ent1", "role": "Effect", "text": "hepatic injury", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "12590235_3_Ent0", "text": "patients treated with 6 - TG", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "12590235_3_Ent2", "text": "thiopurine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12590235_3_Ent3", "text": "thiopurine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12590235_3_Ent1", "text": "hepatic injury", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "12590235_5", "wnd_id": "12590235_5_1", "text": "We describe a case of significant elevation of serum transaminases in a patient treated with 6 - TG for a flare of Crohn 's disease .", "tokens": ["We", "describe", "a", "case", "of", "significant", "elevation", "of", "serum", "transaminases", "in", "a", "patient", "treated", "with", "6", "-", "TG", "for", "a", "flare", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "12590235_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "elevation", "start": 6, "end": 7}, "arguments": [{"entity_id": "12590235_5_Ent1", "role": "Effect", "text": "significant elevation of serum transaminases", "start": 5, "end": 10}, {"entity_id": "12590235_5_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "12590235_5_Ent2", "role": "Treatment", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent4", "role": "Treatment_Drug", "text": "6 - TG", "start": 15, "end": 18}, {"entity_id": "12590235_5_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "12590235_5_Ent1", "text": "significant elevation of serum transaminases", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12590235_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12590235_5_Ent2", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent4", "text": "6 - TG", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12590235_5_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "1261772_3", "wnd_id": "1261772_3_1", "text": "These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug .", "tokens": ["These", "observations", "indicate", "that", "submassive", "hepatic", "necrosis", "may", "result", "from", "treatment", "with", "propylthiouracil", "and", "are", "consistent", "with", "the", "notion", "that", "sensitization", "mechanisms", "may", "be", "responsible", "for", "the", "hepatic", "injury", "induced", "by", "this", "drug", "."], "event_mentions": [{"id": "1261772_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 8, "end": 9}, "arguments": [{"entity_id": "1261772_3_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 4, "end": 7}, {"entity_id": "1261772_3_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 12, "end": 13}, {"entity_id": "1261772_3_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1261772_3_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1261772_3_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1261772_3_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12625995_2", "wnd_id": "12625995_2_1", "text": "Clozapine - induced akathisia in children with schizophrenia .", "tokens": ["Clozapine", "-", "induced", "akathisia", "in", "children", "with", "schizophrenia", "."], "event_mentions": [{"id": "12625995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12625995_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent2", "role": "Effect", "text": "akathisia", "start": 3, "end": 4}, {"entity_id": "12625995_2_Ent1", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "12625995_2_Ent0", "role": "Subject", "text": "children with schizophrenia", "start": 5, "end": 8}, {"entity_id": "12625995_2_Ent5", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12625995_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_2_Ent1", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12625995_2_Ent0", "text": "children with schizophrenia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12625995_2_Ent5", "text": "schizophrenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12656748_2", "wnd_id": "12656748_2_1", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia .", "tokens": ["Emergence", "of", "Philadelphia", "positive", "chronic", "myeloid", "leukaemia", "during", "treatment", "with", "hydroxyurea", "for", "Philadelphia", "negative", "essential", "thrombocythaemia", "."], "event_mentions": [{"id": "12656748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "12656748_2_Ent0", "role": "Effect", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "start": 0, "end": 7}, {"entity_id": "12656748_2_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent3", "role": "Treatment_Disorder", "text": "Philadelphia negative essential thrombocythaemia", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "12656748_2_Ent0", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12656748_2_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent3", "text": "Philadelphia negative essential thrombocythaemia", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "12656748_3", "wnd_id": "12656748_3_1", "text": "There are no previous reports in the literature about the emergence of CML during treatment with hydroxyurea .", "tokens": ["There", "are", "no", "previous", "reports", "in", "the", "literature", "about", "the", "emergence", "of", "CML", "during", "treatment", "with", "hydroxyurea", "."], "event_mentions": [{"id": "12656748_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "12656748_3_Ent0", "role": "Effect", "text": "CML", "start": 12, "end": 13}, {"entity_id": "12656748_3_Ent1", "role": "Treatment", "text": "treatment with hydroxyurea", "start": 14, "end": 17}, {"entity_id": "12656748_3_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12656748_3_Ent0", "text": "CML", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12656748_3_Ent1", "text": "treatment with hydroxyurea", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "12656748_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12663440_2", "wnd_id": "12663440_2_1", "text": "Based on our previous demonstration that quinine could be used clinically to reverse P - glycoprotein - mediated resistance , we designed a multicenter , randomized trial aiming to determine whether quinine would improve the survival of adult patients ( 15 - 60 years old ) with de novo acute myelogenous leukemia ( AML ) .", "tokens": ["Based", "on", "our", "previous", "demonstration", "that", "quinine", "could", "be", "used", "clinically", "to", "reverse", "P", "-", "glycoprotein", "-", "mediated", "resistance", ",", "we", "designed", "a", "multicenter", ",", "randomized", "trial", "aiming", "to", "determine", "whether", "quinine", "would", "improve", "the", "survival", "of", "adult", "patients", "(", "15", "-", "60", "years", "old", ")", "with", "de", "novo", "acute", "myelogenous", "leukemia", "(", "AML", ")", "."], "event_mentions": [{"id": "12663440_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improve", "start": 33, "end": 34}, "arguments": [{"entity_id": "12663440_2_Ent4", "role": "Treatment", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "12663440_2_Ent5", "role": "Treatment_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "12663440_2_Ent3", "role": "Effect", "text": "reverse P - glycoprotein - mediated resistance", "start": 12, "end": 19}, {"entity_id": "12663440_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 37, "end": 38}, {"entity_id": "12663440_2_Ent0", "role": "Subject", "text": "adult patients ( 15 - 60 years old )", "start": 37, "end": 46}, {"entity_id": "12663440_2_Ent2", "role": "Subject_Age", "text": "15 - 60 years old", "start": 40, "end": 45}, {"entity_id": "12663440_2_Ent6", "role": "Treatment_Disorder", "text": "de novo acute myelogenous leukemia ( AML )", "start": 47, "end": 55}]}], "entity_mentions": [{"id": "12663440_2_Ent4", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12663440_2_Ent5", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12663440_2_Ent3", "text": "reverse P - glycoprotein - mediated resistance", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12663440_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "12663440_2_Ent0", "text": "adult patients ( 15 - 60 years old )", "entity_type": "Entity", "start": 37, "end": 46}, {"id": "12663440_2_Ent2", "text": "15 - 60 years old", "entity_type": "Entity", "start": 40, "end": 45}, {"id": "12663440_2_Ent6", "text": "de novo acute myelogenous leukemia ( AML )", "entity_type": "Entity", "start": 47, "end": 55}], "lang": "en"}
{"doc_id": "1267457_2", "wnd_id": "1267457_2_1", "text": "The patient received only the ophthalmic sulfonamide , and it was used for one day , but he developed Stevens - Johnson syndrome .", "tokens": ["The", "patient", "received", "only", "the", "ophthalmic", "sulfonamide", ",", "and", "it", "was", "used", "for", "one", "day", ",", "but", "he", "developed", "Stevens", "-", "Johnson", "syndrome", "."], "event_mentions": [{"id": "1267457_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "1267457_2_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "1267457_2_Ent5", "role": "Treatment_Route", "text": "ophthalmic", "start": 5, "end": 6}, {"entity_id": "1267457_2_Ent4", "role": "Treatment", "text": "ophthalmic sulfonamide , and it was used for one day", "start": 5, "end": 15}, {"entity_id": "1267457_2_Ent6", "role": "Treatment_Drug", "text": "sulfonamide", "start": 6, "end": 7}, {"entity_id": "1267457_2_Ent7", "role": "Treatment_Duration", "text": "one day", "start": 13, "end": 15}, {"entity_id": "1267457_2_Ent1", "role": "Subject", "text": "he", "start": 17, "end": 18}, {"entity_id": "1267457_2_Ent2", "role": "Subject_Gender", "text": "he", "start": 17, "end": 18}, {"entity_id": "1267457_2_Ent3", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "1267457_2_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1267457_2_Ent5", "text": "ophthalmic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1267457_2_Ent4", "text": "ophthalmic sulfonamide , and it was used for one day", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "1267457_2_Ent6", "text": "sulfonamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1267457_2_Ent7", "text": "one day", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "1267457_2_Ent1", "text": "he", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1267457_2_Ent2", "text": "he", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1267457_2_Ent3", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "12692521_2", "wnd_id": "12692521_2_1", "text": "We present two cases in which both patients suffered with CLS , which we believe was caused following administration of granulocyte colony - stimulating factor , to our knowledge not described in the intensive care patient previously .", "tokens": ["We", "present", "two", "cases", "in", "which", "both", "patients", "suffered", "with", "CLS", ",", "which", "we", "believe", "was", "caused", "following", "administration", "of", "granulocyte", "colony", "-", "stimulating", "factor", ",", "to", "our", "knowledge", "not", "described", "in", "the", "intensive", "care", "patient", "previously", "."], "event_mentions": [{"id": "12692521_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 18, "end": 19}, "arguments": [{"entity_id": "12692521_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12692521_2_Ent0", "role": "Subject", "text": "two cases in which both patients suffered with CLS", "start": 2, "end": 11}, {"entity_id": "12692521_2_Ent2", "role": "Effect", "text": "CLS", "start": 10, "end": 11}, {"entity_id": "12692521_2_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}, {"entity_id": "12692521_2_Ent4", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "12692521_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12692521_2_Ent0", "text": "two cases in which both patients suffered with CLS", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "12692521_2_Ent2", "text": "CLS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12692521_2_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "12692521_2_Ent4", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "12702914_2", "wnd_id": "12702914_2_1", "text": "Soon after introduction of insulin therapy , she developed severe anasarca , including marked peripheral oedema , ascites and pleural effusion .", "tokens": ["Soon", "after", "introduction", "of", "insulin", "therapy", ",", "she", "developed", "severe", "anasarca", ",", "including", "marked", "peripheral", "oedema", ",", "ascites", "and", "pleural", "effusion", "."], "event_mentions": [{"id": "12702914_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12702914_2_Ent3", "role": "Treatment", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent4", "role": "Treatment_Drug", "text": "insulin", "start": 4, "end": 5}, {"entity_id": "12702914_2_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "12702914_2_Ent2", "role": "Effect", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "start": 10, "end": 21}]}], "entity_mentions": [{"id": "12702914_2_Ent3", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent4", "text": "insulin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12702914_2_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12702914_2_Ent2", "text": "anasarca , including marked peripheral oedema , ascites and pleural effusion", "entity_type": "Entity", "start": 10, "end": 21}], "lang": "en"}
{"doc_id": "12702914_5", "wnd_id": "12702914_5_1", "text": "While 40 mg / day of prednisolone improved hepatic dysfunction dramatically , her diabetic milieu deteriorated seriously .", "tokens": ["While", "40", "mg", "/", "day", "of", "prednisolone", "improved", "hepatic", "dysfunction", "dramatically", ",", "her", "diabetic", "milieu", "deteriorated", "seriously", "."], "event_mentions": [{"id": "12702914_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 7, "end": 8}, "arguments": [{"entity_id": "12702914_5_Ent8", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 1, "end": 5}, {"entity_id": "12702914_5_Ent5", "role": "Treatment", "text": "40 mg / day of prednisolone", "start": 1, "end": 7}, {"entity_id": "12702914_5_Ent7", "role": "Treatment_Drug", "text": "prednisolone", "start": 6, "end": 7}, {"entity_id": "12702914_5_Ent6", "role": "Treatment_Disorder", "text": "hepatic dysfunction", "start": 8, "end": 10}]}, {"id": "12702914_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "deteriorated", "start": 15, "end": 16}, "arguments": [{"entity_id": "12702914_5_Ent4", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 1, "end": 5}, {"entity_id": "12702914_5_Ent1", "role": "Treatment", "text": "40 mg / day of prednisolone", "start": 1, "end": 7}, {"entity_id": "12702914_5_Ent3", "role": "Treatment_Drug", "text": "prednisolone", "start": 6, "end": 7}, {"entity_id": "12702914_5_Ent2", "role": "Treatment_Disorder", "text": "hepatic dysfunction", "start": 8, "end": 10}, {"entity_id": "12702914_5_Ent0", "role": "Effect", "text": "diabetic milieu deteriorated", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12702914_5_Ent4", "text": "40 mg / day", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12702914_5_Ent8", "text": "40 mg / day", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12702914_5_Ent1", "text": "40 mg / day of prednisolone", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "12702914_5_Ent5", "text": "40 mg / day of prednisolone", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "12702914_5_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12702914_5_Ent7", "text": "prednisolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12702914_5_Ent2", "text": "hepatic dysfunction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12702914_5_Ent6", "text": "hepatic dysfunction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12702914_5_Ent0", "text": "diabetic milieu deteriorated", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12707728_2", "wnd_id": "12707728_2_1", "text": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "acute", "cerebellar", "syndrome", "after", "prophylactic", "intrathecal", "methotrexate", "administration", "and", "recovered", "spontaneously", "."], "event_mentions": [{"id": "12707728_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12707728_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12707728_2_Ent1", "role": "Effect", "text": "acute cerebellar syndrome", "start": 6, "end": 9}, {"entity_id": "12707728_2_Ent2", "role": "Treatment", "text": "prophylactic intrathecal methotrexate administration", "start": 10, "end": 14}, {"entity_id": "12707728_2_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 11, "end": 12}, {"entity_id": "12707728_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12707728_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12707728_2_Ent1", "text": "acute cerebellar syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12707728_2_Ent2", "text": "prophylactic intrathecal methotrexate administration", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "12707728_2_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12707728_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12786839_3", "wnd_id": "12786839_3_1", "text": "We report two patients with infectious mononucleosis - like syndrome induced by salazosulfapyridine ( SASP ) .", "tokens": ["We", "report", "two", "patients", "with", "infectious", "mononucleosis", "-", "like", "syndrome", "induced", "by", "salazosulfapyridine", "(", "SASP", ")", "."], "event_mentions": [{"id": "12786839_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "12786839_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12786839_3_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "12786839_3_Ent2", "role": "Effect", "text": "infectious mononucleosis - like syndrome", "start": 5, "end": 10}, {"entity_id": "12786839_3_Ent4", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 12, "end": 13}, {"entity_id": "12786839_3_Ent3", "role": "Treatment", "text": "salazosulfapyridine ( SASP ) .", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "12786839_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12786839_3_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12786839_3_Ent2", "text": "infectious mononucleosis - like syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12786839_3_Ent4", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12786839_3_Ent3", "text": "salazosulfapyridine ( SASP ) .", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "12792223_3", "wnd_id": "12792223_3_1", "text": "Infliximab therapy may cause a lupus - like syndrome that is reversible upon discontinuing this agent .", "tokens": ["Infliximab", "therapy", "may", "cause", "a", "lupus", "-", "like", "syndrome", "that", "is", "reversible", "upon", "discontinuing", "this", "agent", "."], "event_mentions": [{"id": "12792223_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "12792223_3_Ent2", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "12792223_3_Ent1", "role": "Treatment", "text": "Infliximab therapy", "start": 0, "end": 2}, {"entity_id": "12792223_3_Ent0", "role": "Effect", "text": "lupus - like syndrome", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "12792223_3_Ent2", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12792223_3_Ent1", "text": "Infliximab therapy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12792223_3_Ent0", "text": "lupus - like syndrome", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "12796597_2", "wnd_id": "12796597_2_1", "text": "Despite the underlying hepatitis C , this case represents renal abnormalities consistent with IFNalpha therapy for CML .", "tokens": ["Despite", "the", "underlying", "hepatitis", "C", ",", "this", "case", "represents", "renal", "abnormalities", "consistent", "with", "IFNalpha", "therapy", "for", "CML", "."], "event_mentions": [{"id": "12796597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent", "start": 11, "end": 12}, "arguments": [{"entity_id": "12796597_2_Ent0", "role": "Subject", "text": "this case", "start": 6, "end": 8}, {"entity_id": "12796597_2_Ent1", "role": "Effect", "text": "renal abnormalities", "start": 9, "end": 11}, {"entity_id": "12796597_2_Ent3", "role": "Treatment_Drug", "text": "IFNalpha", "start": 13, "end": 14}, {"entity_id": "12796597_2_Ent2", "role": "Treatment", "text": "IFNalpha therapy", "start": 13, "end": 15}, {"entity_id": "12796597_2_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12796597_2_Ent0", "text": "this case", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "12796597_2_Ent1", "text": "renal abnormalities", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12796597_2_Ent3", "text": "IFNalpha", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12796597_2_Ent2", "text": "IFNalpha therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12796597_2_Ent4", "text": "CML", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12796597_3", "wnd_id": "12796597_3_1", "text": "Interferon - alpha - induced focal segmental glomerulosclerosis in chronic myelogenous leukemia : a case report and review of the literature .", "tokens": ["Interferon", "-", "alpha", "-", "induced", "focal", "segmental", "glomerulosclerosis", "in", "chronic", "myelogenous", "leukemia", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "12796597_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "12796597_3_Ent1", "role": "Treatment", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "12796597_3_Ent2", "role": "Treatment_Drug", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "12796597_3_Ent0", "role": "Effect", "text": "focal segmental glomerulosclerosis in chronic myelogenous leukemia", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "12796597_3_Ent1", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12796597_3_Ent2", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12796597_3_Ent0", "text": "focal segmental glomerulosclerosis in chronic myelogenous leukemia", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "12836099_1", "wnd_id": "12836099_1_1", "text": "Stevens - Johnson syndrome in a boy with nephrotic syndrome during prednisolone therapy .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "in", "a", "boy", "with", "nephrotic", "syndrome", "during", "prednisolone", "therapy", "."], "event_mentions": [{"id": "12836099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "12836099_1_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "12836099_1_Ent0", "role": "Subject", "text": "a boy with nephrotic syndrome", "start": 5, "end": 10}, {"entity_id": "12836099_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12836099_1_Ent5", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "12836099_1_Ent3", "role": "Treatment", "text": "prednisolone", "start": 11, "end": 12}, {"entity_id": "12836099_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12836099_1_Ent2", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12836099_1_Ent0", "text": "a boy with nephrotic syndrome", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12836099_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12836099_1_Ent5", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12836099_1_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12836099_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12851279_14", "wnd_id": "12851279_14_1", "text": "Treatment with tifacogin had no effect on all - cause mortality in patients with severe sepsis and high INR .", "tokens": ["Treatment", "with", "tifacogin", "had", "no", "effect", "on", "all", "-", "cause", "mortality", "in", "patients", "with", "severe", "sepsis", "and", "high", "INR", "."], "event_mentions": [{"id": "12851279_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 5, "end": 6}, "arguments": [{"entity_id": "12851279_14_Ent3", "role": "Treatment", "text": "tifacogin", "start": 2, "end": 3}, {"entity_id": "12851279_14_Ent5", "role": "Treatment_Drug", "text": "tifacogin", "start": 2, "end": 3}, {"entity_id": "12851279_14_Ent2", "role": "Effect", "text": "mortality", "start": 10, "end": 11}, {"entity_id": "12851279_14_Ent0", "role": "Subject", "text": "patients with severe sepsis and high INR", "start": 12, "end": 19}, {"entity_id": "12851279_14_Ent4", "role": "Treatment_Disorder", "text": "sepsis", "start": 15, "end": 16}, {"entity_id": "12851279_14_Ent1", "role": "Subject_Disorder", "text": "high INR", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "12851279_14_Ent3", "text": "tifacogin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12851279_14_Ent5", "text": "tifacogin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12851279_14_Ent2", "text": "mortality", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12851279_14_Ent0", "text": "patients with severe sepsis and high INR", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "12851279_14_Ent4", "text": "sepsis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12851279_14_Ent1", "text": "high INR", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "12852380_1", "wnd_id": "12852380_1_1", "text": "However , in order to avoid neuropathic side effects , patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug .", "tokens": ["However", ",", "in", "order", "to", "avoid", "neuropathic", "side", "effects", ",", "patients", "under", "thalidomide", "therapy", "should", "be", "monitored", "every", "6", "months", "with", "nerve", "conduction", "studies", "while", "taking", "the", "drug", "."], "event_mentions": [{"id": "12852380_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 11, "end": 12}, "arguments": [{"entity_id": "12852380_1_Ent1", "role": "Effect", "text": "neuropathic side effects", "start": 6, "end": 9}, {"entity_id": "12852380_1_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "12852380_1_Ent3", "role": "Treatment_Drug", "text": "thalidomide", "start": 12, "end": 13}, {"entity_id": "12852380_1_Ent2", "role": "Treatment", "text": "thalidomide therapy", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "12852380_1_Ent1", "text": "neuropathic side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12852380_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12852380_1_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12852380_1_Ent2", "text": "thalidomide therapy", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "12854039_6", "wnd_id": "12854039_6_1", "text": "PURPOSE : To describe bilateral optic neuritis that occurred as an adverse effect of recombinant and natural interferon alpha administration .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "optic", "neuritis", "that", "occurred", "as", "an", "adverse", "effect", "of", "recombinant", "and", "natural", "interferon", "alpha", "administration", "."], "event_mentions": [{"id": "12854039_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "12854039_6_Ent0", "role": "Effect", "text": "bilateral optic neuritis", "start": 4, "end": 7}, {"entity_id": "12854039_6_Ent2", "role": "Treatment_Drug", "text": "recombinant and natural interferon alpha", "start": 14, "end": 19}, {"entity_id": "12854039_6_Ent1", "role": "Treatment", "text": "recombinant and natural interferon alpha administration", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "12854039_6_Ent0", "text": "bilateral optic neuritis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12854039_6_Ent2", "text": "recombinant and natural interferon alpha", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "12854039_6_Ent1", "text": "recombinant and natural interferon alpha administration", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "12860350_2", "wnd_id": "12860350_2_1", "text": "We describe a premenopausal woman who , while having tamoxifen due to a diagnosis of in situ ductal carcinoma , developed endometriosis requiring surgery .", "tokens": ["We", "describe", "a", "premenopausal", "woman", "who", ",", "while", "having", "tamoxifen", "due", "to", "a", "diagnosis", "of", "in", "situ", "ductal", "carcinoma", ",", "developed", "endometriosis", "requiring", "surgery", "."], "event_mentions": [{"id": "12860350_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "12860350_2_Ent0", "role": "Subject", "text": "a premenopausal woman", "start": 2, "end": 5}, {"entity_id": "12860350_2_Ent2", "role": "Subject_Age", "text": "premenopausal", "start": 3, "end": 4}, {"entity_id": "12860350_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "12860350_2_Ent4", "role": "Treatment", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent6", "role": "Treatment_Disorder", "text": "in situ ductal carcinoma", "start": 15, "end": 19}, {"entity_id": "12860350_2_Ent3", "role": "Effect", "text": "endometriosis", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12860350_2_Ent0", "text": "a premenopausal woman", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12860350_2_Ent2", "text": "premenopausal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12860350_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12860350_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent6", "text": "in situ ductal carcinoma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12860350_2_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12875956_3", "wnd_id": "12875956_3_1", "text": "The psychotic behavior resolved completely soon after the discontinuation of levetiracetam .", "tokens": ["The", "psychotic", "behavior", "resolved", "completely", "soon", "after", "the", "discontinuation", "of", "levetiracetam", "."], "event_mentions": [{"id": "12875956_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 3, "end": 4}, "arguments": [{"entity_id": "12875956_3_Ent1", "role": "Treatment_Disorder", "text": "psychotic behavior", "start": 1, "end": 3}, {"entity_id": "12875956_3_Ent2", "role": "Treatment_Time_elapsed", "text": "soon after", "start": 5, "end": 7}, {"entity_id": "12875956_3_Ent0", "role": "Treatment", "text": "discontinuation of levetiracetam", "start": 8, "end": 11}, {"entity_id": "12875956_3_Ent3", "role": "Treatment_Drug", "text": "levetiracetam", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "12875956_3_Ent1", "text": "psychotic behavior", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12875956_3_Ent2", "text": "soon after", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12875956_3_Ent0", "text": "discontinuation of levetiracetam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12875956_3_Ent3", "text": "levetiracetam", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "12921505_4", "wnd_id": "12921505_4_1", "text": "OBJECTIVE : To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "significant", "hepatic", "and", "renal", "failure", "with", "the", "use", "of", "argatroban", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "requiring", "continuous", "veno", "-", "veno", "hemodialysis", "(", "CVVHD", ")", "."], "event_mentions": [{"id": "12921505_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "12921505_4_Ent2", "role": "Effect", "text": "significant hepatic and renal failure", "start": 7, "end": 12}, {"entity_id": "12921505_4_Ent3", "role": "Treatment", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent4", "role": "Treatment_Drug", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent0", "role": "Subject", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "start": 18, "end": 37}, {"entity_id": "12921505_4_Ent1", "role": "Subject_Disorder", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 21, "end": 28}]}, {"id": "12921505_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "12921505_4_Ent6", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent7", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent5", "role": "Effect", "text": "thrombocytopenia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12921505_4_Ent2", "text": "significant hepatic and renal failure", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12921505_4_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent4", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent0", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "entity_type": "Entity", "start": 18, "end": 37}, {"id": "12921505_4_Ent6", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent7", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent1", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12921505_4_Ent5", "text": "thrombocytopenia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "1295628_3", "wnd_id": "1295628_3_1", "text": "Clinical symptoms and leukopenia normalized after discontinuation of CBZ and administration of prednisolone at 40 mg .", "tokens": ["Clinical", "symptoms", "and", "leukopenia", "normalized", "after", "discontinuation", "of", "CBZ", "and", "administration", "of", "prednisolone", "at", "40", "mg", "."], "event_mentions": [{"id": "1295628_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "normalized", "start": 4, "end": 5}, "arguments": [{"entity_id": "1295628_3_Ent0", "role": "Effect", "text": "Clinical symptoms and leukopenia normalized", "start": 0, "end": 5}, {"entity_id": "1295628_3_Ent1", "role": "Treatment", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "start": 6, "end": 16}, {"entity_id": "1295628_3_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent5", "role": "Combination_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "1295628_3_Ent3", "role": "Treatment_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 12, "end": 13}, {"entity_id": "1295628_3_Ent4", "role": "Treatment_Dosage", "text": "40 mg", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1295628_3_Ent0", "text": "Clinical symptoms and leukopenia normalized", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1295628_3_Ent1", "text": "discontinuation of CBZ and administration of prednisolone at 40 mg", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "1295628_3_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent5", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1295628_3_Ent3", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1295628_3_Ent4", "text": "40 mg", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "1316047_1", "wnd_id": "1316047_1_1", "text": "Hemodynamic collapse following labetalol administration in preeclampsia .", "tokens": ["Hemodynamic", "collapse", "following", "labetalol", "administration", "in", "preeclampsia", "."], "event_mentions": [{"id": "1316047_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "1316047_1_Ent0", "role": "Effect", "text": "Hemodynamic collapse", "start": 0, "end": 2}, {"entity_id": "1316047_1_Ent1", "role": "Treatment", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent2", "role": "Treatment_Drug", "text": "labetalol", "start": 3, "end": 4}, {"entity_id": "1316047_1_Ent3", "role": "Treatment_Disorder", "text": "preeclampsia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1316047_1_Ent0", "text": "Hemodynamic collapse", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1316047_1_Ent1", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent2", "text": "labetalol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1316047_1_Ent3", "text": "preeclampsia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1348483_3", "wnd_id": "1348483_3_1", "text": "Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine .", "tokens": ["Thus", "cabergoline", "may", "cause", "similar", "pleuropulmonary", "abnormalities", "to", "bromocriptine", "."], "event_mentions": [{"id": "1348483_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "1348483_3_Ent2", "role": "Treatment", "text": "cabergoline", "start": 1, "end": 2}, {"entity_id": "1348483_3_Ent3", "role": "Treatment_Drug", "text": "cabergoline", "start": 1, "end": 2}, {"entity_id": "1348483_3_Ent0", "role": "Effect", "text": "pleuropulmonary abnormalities", "start": 5, "end": 7}, {"entity_id": "1348483_3_Ent1", "role": "Treatment", "text": "bromocriptine", "start": 8, "end": 9}, {"entity_id": "1348483_3_Ent4", "role": "Treatment_Drug", "text": "bromocriptine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1348483_3_Ent2", "text": "cabergoline", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1348483_3_Ent3", "text": "cabergoline", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1348483_3_Ent0", "text": "pleuropulmonary abnormalities", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1348483_3_Ent1", "text": "bromocriptine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1348483_3_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1359782_3", "wnd_id": "1359782_3_1", "text": "Sulfasalazine - induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy , despite the absence of pulmonary symptomatology .", "tokens": ["Sulfasalazine", "-", "induced", "lung", "disorder", "is", "an", "extremely", "rare", "entity", "which", "must", "be", "considered", "in", "all", "ulcerative", "colitis", "patients", "while", "on", "sulfasalazine", "therapy", ",", "despite", "the", "absence", "of", "pulmonary", "symptomatology", "."], "event_mentions": [{"id": "1359782_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1359782_3_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent2", "role": "Treatment_Disorder", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent0", "role": "Effect", "text": "lung disorder", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1359782_3_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent0", "text": "lung disorder", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1420650_3", "wnd_id": "1420650_3_1", "text": "We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .", "tokens": ["We", "consider", "asterixis", "to", "be", "an", "easily", "overlooked", "sign", "of", "neurotoxicity", ",", "which", "may", "occur", "even", "at", "low", "or", "moderate", "dosage", "levels", ",", "if", "certain", "drugs", "as", "lithium", "or", "clozapine", "are", "used", "in", "combination", "with", "CBZ", "."], "event_mentions": [{"id": "1420650_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 14, "end": 15}, "arguments": [{"entity_id": "1420650_3_Ent0", "role": "Effect", "text": "asterixis", "start": 2, "end": 3}, {"entity_id": "1420650_3_Ent1", "role": "Treatment", "text": "even at low or moderate dosage levels", "start": 15, "end": 22}, {"entity_id": "1420650_3_Ent6", "role": "Treatment_Dosage", "text": "low or moderate dosage", "start": 17, "end": 21}, {"entity_id": "1420650_3_Ent2", "role": "Treatment", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "start": 24, "end": 36}, {"entity_id": "1420650_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 27, "end": 28}, {"entity_id": "1420650_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent10", "role": "Combination_Drug", "text": "clozapine", "start": 29, "end": 30}, {"entity_id": "1420650_3_Ent3", "role": "Treatment_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent7", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}, {"entity_id": "1420650_3_Ent9", "role": "Combination_Drug", "text": "CBZ", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "1420650_3_Ent0", "text": "asterixis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1420650_3_Ent1", "text": "even at low or moderate dosage levels", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1420650_3_Ent6", "text": "low or moderate dosage", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "1420650_3_Ent2", "text": "certain drugs as lithium or clozapine are used in combination with CBZ", "entity_type": "Entity", "start": 24, "end": 36}, {"id": "1420650_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent8", "text": "lithium", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1420650_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent10", "text": "clozapine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "1420650_3_Ent3", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent7", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1420650_3_Ent9", "text": "CBZ", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "1422497_1", "wnd_id": "1422497_1_1", "text": "Encephalopathy and seizures induced by intravesical alum irrigations .", "tokens": ["Encephalopathy", "and", "seizures", "induced", "by", "intravesical", "alum", "irrigations", "."], "event_mentions": [{"id": "1422497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1422497_1_Ent0", "role": "Effect", "text": "Encephalopathy and seizures", "start": 0, "end": 3}, {"entity_id": "1422497_1_Ent3", "role": "Treatment_Route", "text": "intravesical", "start": 5, "end": 6}, {"entity_id": "1422497_1_Ent1", "role": "Treatment", "text": "intravesical alum irrigations", "start": 5, "end": 8}, {"entity_id": "1422497_1_Ent2", "role": "Treatment_Drug", "text": "alum", "start": 6, "end": 7}, {"entity_id": "1422497_1_Ent4", "role": "Treatment_Route", "text": "irrigations", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1422497_1_Ent0", "text": "Encephalopathy and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1422497_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1422497_1_Ent1", "text": "intravesical alum irrigations", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1422497_1_Ent2", "text": "alum", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1422497_1_Ent4", "text": "irrigations", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "14530108_4", "wnd_id": "14530108_4_1", "text": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated .", "tokens": ["The", "mechanism", "of", "RTA", "induced", "by", "FK506", "has", "not", "yet", "been", "clearly", "elucidated", "."], "event_mentions": [{"id": "14530108_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14530108_4_Ent0", "role": "Effect", "text": "RTA", "start": 3, "end": 4}, {"entity_id": "14530108_4_Ent1", "role": "Treatment", "text": "FK506", "start": 6, "end": 7}, {"entity_id": "14530108_4_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14530108_4_Ent0", "text": "RTA", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14530108_4_Ent1", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14530108_4_Ent2", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14561622_1", "wnd_id": "14561622_1_1", "text": "Neurotoxicity of intrathecal methotrexate : MR imaging findings .", "tokens": ["Neurotoxicity", "of", "intrathecal", "methotrexate", ":", "MR", "imaging", "findings", "."], "event_mentions": [{"id": "14561622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 1, "end": 2}, "arguments": [{"entity_id": "14561622_1_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "14561622_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "14561622_1_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 2, "end": 4}, {"entity_id": "14561622_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14561622_1_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14561622_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14561622_1_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "14561622_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14561622_3", "wnd_id": "14561622_3_1", "text": "We report a case of intrathecal methotrexate neurotoxicity manifesting as left arm weakness and aphasia .", "tokens": ["We", "report", "a", "case", "of", "intrathecal", "methotrexate", "neurotoxicity", "manifesting", "as", "left", "arm", "weakness", "and", "aphasia", "."], "event_mentions": [{"id": "14561622_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifesting", "start": 8, "end": 9}, "arguments": [{"entity_id": "14561622_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "14561622_3_Ent2", "role": "Treatment", "text": "intrathecal methotrexate neurotoxicity", "start": 5, "end": 8}, {"entity_id": "14561622_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "14561622_3_Ent1", "role": "Effect", "text": "left arm weakness and aphasia", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "14561622_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "14561622_3_Ent2", "text": "intrathecal methotrexate neurotoxicity", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14561622_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14561622_3_Ent1", "text": "left arm weakness and aphasia", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "14601701_3", "wnd_id": "14601701_3_1", "text": "The most commonly recognized toxic effect of ethambutol is optic neuropathy , which generally is considered uncommon and reversible in medical literature .", "tokens": ["The", "most", "commonly", "recognized", "toxic", "effect", "of", "ethambutol", "is", "optic", "neuropathy", ",", "which", "generally", "is", "considered", "uncommon", "and", "reversible", "in", "medical", "literature", "."], "event_mentions": [{"id": "14601701_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 5, "end": 6}, "arguments": [{"entity_id": "14601701_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 7, "end": 8}, {"entity_id": "14601701_3_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 7, "end": 8}, {"entity_id": "14601701_3_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14601701_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14601701_3_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14601701_3_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14601701_5", "wnd_id": "14601701_5_1", "text": "This case and a review of the literature show the severe and unpredictable nature of ethambutol toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring .", "tokens": ["This", "case", "and", "a", "review", "of", "the", "literature", "show", "the", "severe", "and", "unpredictable", "nature", "of", "ethambutol", "toxicity", "and", "its", "potential", "for", "irreversible", "vision", "loss", "despite", "careful", "ophthalmologic", "monitoring", "."], "event_mentions": [{"id": "14601701_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "unpredictable", "start": 12, "end": 13}, "arguments": [{"entity_id": "14601701_5_Ent1", "role": "Treatment", "text": "ethambutol", "start": 15, "end": 16}, {"entity_id": "14601701_5_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 15, "end": 16}, {"entity_id": "14601701_5_Ent0", "role": "Effect", "text": "irreversible vision loss", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "14601701_5_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14601701_5_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14601701_5_Ent0", "text": "irreversible vision loss", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "1467295_1", "wnd_id": "1467295_1_1", "text": "We describe a patient who developed NEH on three separate occasions provoked by two different chemotherapeutic agents -- cytarabine and mitoxantrone .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "NEH", "on", "three", "separate", "occasions", "provoked", "by", "two", "different", "chemotherapeutic", "agents", "--", "cytarabine", "and", "mitoxantrone", "."], "event_mentions": [{"id": "1467295_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 11, "end": 12}, "arguments": [{"entity_id": "1467295_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "1467295_1_Ent1", "role": "Effect", "text": "NEH", "start": 6, "end": 7}, {"entity_id": "1467295_1_Ent3", "role": "Treatment_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent5", "role": "Combination_Drug", "text": "cytarabine", "start": 18, "end": 19}, {"entity_id": "1467295_1_Ent2", "role": "Treatment", "text": "cytarabine and mitoxantrone", "start": 18, "end": 21}, {"entity_id": "1467295_1_Ent4", "role": "Treatment_Drug", "text": "mitoxantrone", "start": 20, "end": 21}, {"entity_id": "1467295_1_Ent6", "role": "Combination_Drug", "text": "mitoxantrone", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "1467295_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1467295_1_Ent1", "text": "NEH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1467295_1_Ent3", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1467295_1_Ent2", "text": "cytarabine and mitoxantrone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "1467295_1_Ent4", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1467295_1_Ent6", "text": "mitoxantrone", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14684937_2", "wnd_id": "14684937_2_1", "text": "Iatrogenic hypercalcemia due to vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics in a case of psoriasis .", "tokens": ["Iatrogenic", "hypercalcemia", "due", "to", "vitamin", "D3", "ointment", "(", "1,24(OH)2D3", ")", "combined", "with", "thiazide", "diuretics", "in", "a", "case", "of", "psoriasis", "."], "event_mentions": [{"id": "14684937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "14684937_2_Ent0", "role": "Effect", "text": "Iatrogenic hypercalcemia", "start": 0, "end": 2}, {"entity_id": "14684937_2_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent6", "role": "Combination_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent1", "role": "Treatment", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "start": 4, "end": 14}, {"entity_id": "14684937_2_Ent5", "role": "Treatment_Route", "text": "ointment", "start": 6, "end": 7}, {"entity_id": "14684937_2_Ent4", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14684937_2_Ent0", "text": "Iatrogenic hypercalcemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14684937_2_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent6", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent1", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "14684937_2_Ent5", "text": "ointment", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_2_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14697943_1", "wnd_id": "14697943_1_1", "text": "In conclusion , RSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or tacrolimus ) , even under monotherapy or with a low steroid dose .", "tokens": ["In", "conclusion", ",", "RSDS", "is", "a", "relevant", "osteoarticular", "complication", "in", "patients", "receiving", "either", "anticalcineurinic", "drug", "(", "CyA", "or", "tacrolimus", ")", ",", "even", "under", "monotherapy", "or", "with", "a", "low", "steroid", "dose", "."], "event_mentions": [{"id": "14697943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "osteoarticular complication", "start": 7, "end": 9}, "arguments": [{"entity_id": "14697943_1_Ent0", "role": "Effect", "text": "RSDS", "start": 3, "end": 4}, {"entity_id": "14697943_1_Ent1", "role": "Treatment", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "start": 13, "end": 20}, {"entity_id": "14697943_1_Ent2", "role": "Treatment_Drug", "text": "CyA", "start": 16, "end": 17}, {"entity_id": "14697943_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14697943_1_Ent0", "text": "RSDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14697943_1_Ent1", "text": "anticalcineurinic drug ( CyA or tacrolimus )", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "14697943_1_Ent2", "text": "CyA", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "14697943_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14711147_4", "wnd_id": "14711147_4_1", "text": "We present a case of photo - onycholysis in a patient treated with doxycycline for acne vulgaris .", "tokens": ["We", "present", "a", "case", "of", "photo", "-", "onycholysis", "in", "a", "patient", "treated", "with", "doxycycline", "for", "acne", "vulgaris", "."], "event_mentions": [{"id": "14711147_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "14711147_4_Ent1", "role": "Effect", "text": "photo - onycholysis", "start": 5, "end": 8}, {"entity_id": "14711147_4_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "14711147_4_Ent2", "role": "Treatment", "text": "doxycycline", "start": 13, "end": 14}, {"entity_id": "14711147_4_Ent3", "role": "Treatment_Drug", "text": "doxycycline", "start": 13, "end": 14}, {"entity_id": "14711147_4_Ent4", "role": "Treatment_Disorder", "text": "acne vulgaris", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14711147_4_Ent1", "text": "photo - onycholysis", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14711147_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "14711147_4_Ent2", "text": "doxycycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14711147_4_Ent3", "text": "doxycycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14711147_4_Ent4", "text": "acne vulgaris", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "14712320_5", "wnd_id": "14712320_5_1", "text": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin .", "tokens": ["Rhabdomyolysis", "can", "occur", "with", "all", "statins", "when", "used", "alone", "and", "particularly", "when", "combined", "with", "other", "drugs", "that", "are", "themselves", "myotoxic", "or", "that", "elevate", "the", "concentration", "of", "the", "statin", "."], "event_mentions": [{"id": "14712320_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "14712320_5_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "14712320_5_Ent1", "role": "Treatment", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent3", "role": "Treatment_Drug", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent2", "role": "Treatment", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "start": 14, "end": 28}]}], "entity_mentions": [{"id": "14712320_5_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14712320_5_Ent1", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent3", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent2", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "entity_type": "Entity", "start": 14, "end": 28}], "lang": "en"}
{"doc_id": "14712320_7", "wnd_id": "14712320_7_1", "text": "In this report , we describe a case of rhabdomyolysis and acute renal failure secondary to the interaction between danazol and simvastatin .", "tokens": ["In", "this", "report", ",", "we", "describe", "a", "case", "of", "rhabdomyolysis", "and", "acute", "renal", "failure", "secondary", "to", "the", "interaction", "between", "danazol", "and", "simvastatin", "."], "event_mentions": [{"id": "14712320_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 14, "end": 15}, "arguments": [{"entity_id": "14712320_7_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute renal failure", "start": 9, "end": 14}, {"entity_id": "14712320_7_Ent1", "role": "Treatment", "text": "interaction between danazol and simvastatin", "start": 17, "end": 22}, {"entity_id": "14712320_7_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent4", "role": "Combination_Drug", "text": "danazol", "start": 19, "end": 20}, {"entity_id": "14712320_7_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "14712320_7_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "14712320_7_Ent0", "text": "rhabdomyolysis and acute renal failure", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14712320_7_Ent1", "text": "interaction between danazol and simvastatin", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "14712320_7_Ent2", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent4", "text": "danazol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "14712320_7_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14712320_7_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "14723711_1", "wnd_id": "14723711_1_1", "text": "A new type of minocycline - induced cutaneous hyperpigmentation .", "tokens": ["A", "new", "type", "of", "minocycline", "-", "induced", "cutaneous", "hyperpigmentation", "."], "event_mentions": [{"id": "14723711_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "14723711_1_Ent1", "role": "Treatment", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_1_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 4, "end": 5}, {"entity_id": "14723711_1_Ent0", "role": "Effect", "text": "cutaneous hyperpigmentation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "14723711_1_Ent1", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_1_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14723711_1_Ent0", "text": "cutaneous hyperpigmentation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "14723711_2", "wnd_id": "14723711_2_1", "text": "Pigmentary disorders are recognized adverse effects of the semi - synthetic tetracycline derivative antibiotic , minocycline .", "tokens": ["Pigmentary", "disorders", "are", "recognized", "adverse", "effects", "of", "the", "semi", "-", "synthetic", "tetracycline", "derivative", "antibiotic", ",", "minocycline", "."], "event_mentions": [{"id": "14723711_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 4, "end": 5}, "arguments": [{"entity_id": "14723711_2_Ent0", "role": "Effect", "text": "Pigmentary disorders", "start": 0, "end": 2}, {"entity_id": "14723711_2_Ent1", "role": "Treatment", "text": "semi - synthetic tetracycline derivative antibiotic , minocycline", "start": 8, "end": 16}, {"entity_id": "14723711_2_Ent2", "role": "Treatment_Drug", "text": "minocycline", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "14723711_2_Ent0", "text": "Pigmentary disorders", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14723711_2_Ent1", "text": "semi - synthetic tetracycline derivative antibiotic , minocycline", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "14723711_2_Ent2", "text": "minocycline", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "14735388_1", "wnd_id": "14735388_1_1", "text": "Ciprofloxacin - induced toxic epidermal necrolysis in a patient with systemic lupus erythematosus .", "tokens": ["Ciprofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "a", "patient", "with", "systemic", "lupus", "erythematosus", "."], "event_mentions": [{"id": "14735388_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14735388_1_Ent2", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "14735388_1_Ent3", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "14735388_1_Ent1", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "14735388_1_Ent0", "role": "Subject", "text": "a patient with systemic lupus erythematosus .", "start": 7, "end": 14}, {"entity_id": "14735388_1_Ent4", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "14735388_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14735388_1_Ent3", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14735388_1_Ent1", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "14735388_1_Ent0", "text": "a patient with systemic lupus erythematosus .", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "14735388_1_Ent4", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "14740795_1", "wnd_id": "14740795_1_1", "text": "A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine .", "tokens": ["A", "56", "-", "year", "-", "old", "Caucasian", "man", "who", "received", "concomitant", "chemotherapy", "and", "radiation", "for", "head", "and", "neck", "cancer", "developed", "fever", "concurrent", "with", "the", "administration", "of", "amifostine", "."], "event_mentions": [{"id": "14740795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "14740795_1_Ent0", "role": "Subject", "text": "A 56 - year - old Caucasian man", "start": 0, "end": 8}, {"entity_id": "14740795_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "14740795_1_Ent2", "role": "Subject_Race", "text": "Caucasian", "start": 6, "end": 7}, {"entity_id": "14740795_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "14740795_1_Ent5", "role": "Treatment", "text": "concomitant chemotherapy and radiation for head and neck cancer", "start": 10, "end": 19}, {"entity_id": "14740795_1_Ent10", "role": "Treatment_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent13", "role": "Combination_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent9", "role": "Treatment_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent12", "role": "Combination_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent7", "role": "Treatment_Disorder", "text": "head and neck cancer", "start": 15, "end": 19}, {"entity_id": "14740795_1_Ent4", "role": "Effect", "text": "fever", "start": 20, "end": 21}, {"entity_id": "14740795_1_Ent6", "role": "Treatment", "text": "concurrent with the administration of amifostine", "start": 21, "end": 27}, {"entity_id": "14740795_1_Ent8", "role": "Treatment_Drug", "text": "amifostine", "start": 26, "end": 27}, {"entity_id": "14740795_1_Ent11", "role": "Combination_Drug", "text": "amifostine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "14740795_1_Ent0", "text": "A 56 - year - old Caucasian man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "14740795_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14740795_1_Ent2", "text": "Caucasian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14740795_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14740795_1_Ent5", "text": "concomitant chemotherapy and radiation for head and neck cancer", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "14740795_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent13", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent9", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent12", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent7", "text": "head and neck cancer", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "14740795_1_Ent4", "text": "fever", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14740795_1_Ent6", "text": "concurrent with the administration of amifostine", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "14740795_1_Ent8", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "14740795_1_Ent11", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "14742791_2", "wnd_id": "14742791_2_1", "text": "After 5 weeks of therapy , she stopped taking pantoprazole due to general malaise .", "tokens": ["After", "5", "weeks", "of", "therapy", ",", "she", "stopped", "taking", "pantoprazole", "due", "to", "general", "malaise", "."], "event_mentions": [{"id": "14742791_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 10, "end": 12}, "arguments": [{"entity_id": "14742791_2_Ent2", "role": "Treatment", "text": "After 5 weeks of therapy", "start": 0, "end": 5}, {"entity_id": "14742791_2_Ent3", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 1, "end": 3}, {"entity_id": "14742791_2_Ent1", "role": "Treatment", "text": "taking pantoprazole", "start": 8, "end": 10}, {"entity_id": "14742791_2_Ent4", "role": "Treatment_Drug", "text": "pantoprazole", "start": 9, "end": 10}, {"entity_id": "14742791_2_Ent0", "role": "Effect", "text": "general malaise", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14742791_2_Ent2", "text": "After 5 weeks of therapy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14742791_2_Ent3", "text": "5 weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14742791_2_Ent1", "text": "taking pantoprazole", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14742791_2_Ent4", "text": "pantoprazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14742791_2_Ent0", "text": "general malaise", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1477441_4", "wnd_id": "1477441_4_1", "text": "OBJECTIVE : To report two cases of fixed drug eruption induced by methylphenidate .", "tokens": ["OBJECTIVE", ":", "To", "report", "two", "cases", "of", "fixed", "drug", "eruption", "induced", "by", "methylphenidate", "."], "event_mentions": [{"id": "1477441_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "1477441_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "1477441_4_Ent0", "role": "Subject", "text": "two cases", "start": 4, "end": 6}, {"entity_id": "1477441_4_Ent2", "role": "Effect", "text": "fixed drug eruption", "start": 7, "end": 10}, {"entity_id": "1477441_4_Ent3", "role": "Treatment", "text": "methylphenidate", "start": 12, "end": 13}, {"entity_id": "1477441_4_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1477441_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1477441_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1477441_4_Ent2", "text": "fixed drug eruption", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1477441_4_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1477441_4_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "14960440_2", "wnd_id": "14960440_2_1", "text": "CASE REPORT : A woman of 80 years , on long - term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4.8 .", "tokens": ["CASE", "REPORT", ":", "A", "woman", "of", "80", "years", ",", "on", "long", "-", "term", "warfarin", "therapy", "presented", "with", "an", "acute", "dissecting", "thoracic", "aortic", "aneurysm", ";", "on", "investigation", "the", "only", "precipitating", "factor", "found", "was", "an", "international", "normalised", "ratio", "of", "4.8", "."], "event_mentions": [{"id": "14960440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "14960440_2_Ent0", "role": "Subject", "text": "A woman of 80 years", "start": 3, "end": 8}, {"entity_id": "14960440_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "14960440_2_Ent2", "role": "Subject_Age", "text": "80 years", "start": 6, "end": 8}, {"entity_id": "14960440_2_Ent4", "role": "Treatment", "text": "on long - term warfarin", "start": 9, "end": 14}, {"entity_id": "14960440_2_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "14960440_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14960440_2_Ent3", "role": "Effect", "text": "acute dissecting thoracic aortic aneurysm", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14960440_2_Ent0", "text": "A woman of 80 years", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14960440_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14960440_2_Ent2", "text": "80 years", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14960440_2_Ent4", "text": "on long - term warfarin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14960440_2_Ent5", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14960440_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14960440_2_Ent3", "text": "acute dissecting thoracic aortic aneurysm", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14964753_7", "wnd_id": "14964753_7_1", "text": "Ramipril - induced cutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before .", "tokens": ["Ramipril", "-", "induced", "cutaneous", "vasculitis", "is", "particularly", "rare", "and", "our", "case", "was", "atypical", "because", "the", "patient", "had", "tolerated", "lisinopril", "before", "."], "event_mentions": [{"id": "14964753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14964753_7_Ent3", "role": "Treatment", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent4", "role": "Treatment_Drug", "text": "Ramipril", "start": 0, "end": 1}, {"entity_id": "14964753_7_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}, {"entity_id": "14964753_7_Ent0", "role": "Subject", "text": "the patient had tolerated lisinopril before", "start": 14, "end": 20}, {"entity_id": "14964753_7_Ent1", "role": "Subject_Disorder", "text": "tolerated lisinopril", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14964753_7_Ent3", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent4", "text": "Ramipril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14964753_7_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14964753_7_Ent0", "text": "the patient had tolerated lisinopril before", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "14964753_7_Ent1", "text": "tolerated lisinopril", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "14968106_1", "wnd_id": "14968106_1_1", "text": "CONCLUSION : This is , to our knowledge , the first report of severe myelopathy following accidental intrathecal administration of doxorubicin .", "tokens": ["CONCLUSION", ":", "This", "is", ",", "to", "our", "knowledge", ",", "the", "first", "report", "of", "severe", "myelopathy", "following", "accidental", "intrathecal", "administration", "of", "doxorubicin", "."], "event_mentions": [{"id": "14968106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "14968106_1_Ent0", "role": "Effect", "text": "severe myelopathy", "start": 13, "end": 15}, {"entity_id": "14968106_1_Ent3", "role": "Treatment_Route", "text": "intrathecal administration", "start": 17, "end": 19}, {"entity_id": "14968106_1_Ent1", "role": "Treatment", "text": "intrathecal administration of doxorubicin", "start": 17, "end": 21}, {"entity_id": "14968106_1_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "14968106_1_Ent0", "text": "severe myelopathy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "14968106_1_Ent3", "text": "intrathecal administration", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14968106_1_Ent1", "text": "intrathecal administration of doxorubicin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "14968106_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "14971874_2", "wnd_id": "14971874_2_1", "text": "Thus , clinical recognition of sleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with infliximab .", "tokens": ["Thus", ",", "clinical", "recognition", "of", "sleep", "disordered", "breathing", "should", "be", "taken", "into", "account", "when", "rheumatoid", "arthritis", "patients", "are", "to", "be", "treated", "with", "infliximab", "."], "event_mentions": [{"id": "14971874_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 21, "end": 22}, "arguments": [{"entity_id": "14971874_2_Ent1", "role": "Effect", "text": "sleep disordered breathing", "start": 5, "end": 8}, {"entity_id": "14971874_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 14, "end": 16}, {"entity_id": "14971874_2_Ent0", "role": "Subject", "text": "rheumatoid arthritis patients", "start": 14, "end": 17}, {"entity_id": "14971874_2_Ent2", "role": "Treatment", "text": "infliximab", "start": 22, "end": 23}, {"entity_id": "14971874_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "14971874_2_Ent1", "text": "sleep disordered breathing", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14971874_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "14971874_2_Ent0", "text": "rheumatoid arthritis patients", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "14971874_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14971874_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "14996269_1", "wnd_id": "14996269_1_1", "text": "Hypernatraemia induced by sodium polystyrene sulphonate ( Kayexalate ) in two extremely low birth weight newborns .", "tokens": ["Hypernatraemia", "induced", "by", "sodium", "polystyrene", "sulphonate", "(", "Kayexalate", ")", "in", "two", "extremely", "low", "birth", "weight", "newborns", "."], "event_mentions": [{"id": "14996269_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 1, "end": 3}, "arguments": [{"entity_id": "14996269_1_Ent3", "role": "Effect", "text": "Hypernatraemia", "start": 0, "end": 1}, {"entity_id": "14996269_1_Ent5", "role": "Treatment_Drug", "text": "sodium polystyrene sulphonate ( Kayexalate", "start": 3, "end": 8}, {"entity_id": "14996269_1_Ent4", "role": "Treatment", "text": "sodium polystyrene sulphonate ( Kayexalate )", "start": 3, "end": 9}, {"entity_id": "14996269_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "14996269_1_Ent0", "role": "Subject", "text": "two extremely low birth weight newborns", "start": 10, "end": 16}, {"entity_id": "14996269_1_Ent2", "role": "Subject_Age", "text": "newborns", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "14996269_1_Ent3", "text": "Hypernatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14996269_1_Ent5", "text": "sodium polystyrene sulphonate ( Kayexalate", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14996269_1_Ent4", "text": "sodium polystyrene sulphonate ( Kayexalate )", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "14996269_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "14996269_1_Ent0", "text": "two extremely low birth weight newborns", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "14996269_1_Ent2", "text": "newborns", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "14996269_2", "wnd_id": "14996269_2_1", "text": "We describe two ELBW infants affected by hyperkalaemia , treated with Kayexalate , who developed serious hypernatraemia , that has never been reported before in preterm infants .", "tokens": ["We", "describe", "two", "ELBW", "infants", "affected", "by", "hyperkalaemia", ",", "treated", "with", "Kayexalate", ",", "who", "developed", "serious", "hypernatraemia", ",", "that", "has", "never", "been", "reported", "before", "in", "preterm", "infants", "."], "event_mentions": [{"id": "14996269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "14996269_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "14996269_2_Ent0", "role": "Subject", "text": "two ELBW infants affected by hyperkalaemia", "start": 2, "end": 8}, {"entity_id": "14996269_2_Ent3", "role": "Subject_Disorder", "text": "ELBW", "start": 3, "end": 4}, {"entity_id": "14996269_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 4, "end": 5}, {"entity_id": "14996269_2_Ent6", "role": "Treatment_Disorder", "text": "hyperkalaemia", "start": 7, "end": 8}, {"entity_id": "14996269_2_Ent5", "role": "Treatment", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 11, "end": 12}, {"entity_id": "14996269_2_Ent4", "role": "Effect", "text": "serious hypernatraemia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "14996269_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14996269_2_Ent0", "text": "two ELBW infants affected by hyperkalaemia", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "14996269_2_Ent3", "text": "ELBW", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14996269_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14996269_2_Ent6", "text": "hyperkalaemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14996269_2_Ent5", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14996269_2_Ent4", "text": "serious hypernatraemia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "14998226_7", "wnd_id": "14998226_7_1", "text": "Lovastatin also reportedly has caused increases in INR when coadministered with warfarin .", "tokens": ["Lovastatin", "also", "reportedly", "has", "caused", "increases", "in", "INR", "when", "coadministered", "with", "warfarin", "."], "event_mentions": [{"id": "14998226_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "14998226_7_Ent1", "role": "Treatment", "text": "Lovastatin", "start": 0, "end": 1}, {"entity_id": "14998226_7_Ent2", "role": "Treatment_Drug", "text": "Lovastatin", "start": 0, "end": 1}, {"entity_id": "14998226_7_Ent0", "role": "Effect", "text": "increases in INR", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "14998226_7_Ent1", "text": "Lovastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_7_Ent2", "text": "Lovastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_7_Ent0", "text": "increases in INR", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "15013892_3", "wnd_id": "15013892_3_1", "text": "RESULTS : A patient developed a bilaterally symmetric bull's - eye maculopathy 45 years after taking quinacrine for 18 months as prophylaxis against malaria .", "tokens": ["RESULTS", ":", "A", "patient", "developed", "a", "bilaterally", "symmetric", "bull's", "-", "eye", "maculopathy", "45", "years", "after", "taking", "quinacrine", "for", "18", "months", "as", "prophylaxis", "against", "malaria", "."], "event_mentions": [{"id": "15013892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_3_Ent0", "role": "Effect", "text": "A patient", "start": 2, "end": 4}, {"entity_id": "15013892_3_Ent1", "role": "Effect", "text": "bilaterally symmetric bull's - eye maculopathy", "start": 6, "end": 12}, {"entity_id": "15013892_3_Ent3", "role": "Treatment_Time_elapsed", "text": "45 years after", "start": 12, "end": 15}, {"entity_id": "15013892_3_Ent2", "role": "Treatment", "text": "45 years after taking quinacrine for 18 months", "start": 12, "end": 20}, {"entity_id": "15013892_3_Ent5", "role": "Treatment_Drug", "text": "quinacrine", "start": 16, "end": 17}, {"entity_id": "15013892_3_Ent4", "role": "Treatment_Time_elapsed", "text": "18 months", "start": 18, "end": 20}, {"entity_id": "15013892_3_Ent6", "role": "Treatment_Disorder", "text": "malaria", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15013892_3_Ent0", "text": "A patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15013892_3_Ent1", "text": "bilaterally symmetric bull's - eye maculopathy", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15013892_3_Ent3", "text": "45 years after", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15013892_3_Ent2", "text": "45 years after taking quinacrine for 18 months", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15013892_3_Ent5", "text": "quinacrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15013892_3_Ent4", "text": "18 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "15013892_3_Ent6", "text": "malaria", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15013892_4", "wnd_id": "15013892_4_1", "text": "The clinical picture was identical to that of chloroquine and hydroxychloroquine maculopathy .", "tokens": ["The", "clinical", "picture", "was", "identical", "to", "that", "of", "chloroquine", "and", "hydroxychloroquine", "maculopathy", "."], "event_mentions": [{"id": "15013892_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "identical", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_4_Ent2", "role": "Treatment_Drug", "text": "chloroquine", "start": 8, "end": 9}, {"entity_id": "15013892_4_Ent1", "role": "Treatment", "text": "chloroquine and hydroxychloroquine", "start": 8, "end": 11}, {"entity_id": "15013892_4_Ent3", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 10, "end": 11}, {"entity_id": "15013892_4_Ent0", "role": "Effect", "text": "maculopathy", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15013892_4_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15013892_4_Ent1", "text": "chloroquine and hydroxychloroquine", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15013892_4_Ent3", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15013892_4_Ent0", "text": "maculopathy", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15028328_3", "wnd_id": "15028328_3_1", "text": "The patient developed occipital infarcts and was found to have extremely elevated levels of PPA in his blood and dialysis fluid .", "tokens": ["The", "patient", "developed", "occipital", "infarcts", "and", "was", "found", "to", "have", "extremely", "elevated", "levels", "of", "PPA", "in", "his", "blood", "and", "dialysis", "fluid", "."], "event_mentions": [{"id": "15028328_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15028328_3_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "15028328_3_Ent1", "role": "Effect", "text": "occipital infarcts", "start": 3, "end": 5}, {"entity_id": "15028328_3_Ent2", "role": "Treatment", "text": "extremely elevated levels of PPA", "start": 10, "end": 15}, {"entity_id": "15028328_3_Ent3", "role": "Treatment_Drug", "text": "PPA", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15028328_3_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15028328_3_Ent1", "text": "occipital infarcts", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15028328_3_Ent2", "text": "extremely elevated levels of PPA", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15028328_3_Ent3", "text": "PPA", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15028964_3", "wnd_id": "15028964_3_1", "text": "Beyond the predictable pharmacokinetic drug - drug interaction requiring a significant warfarin dose reduction , the iodine - rich amiodarone affects the thyroid gland , causing overt hypothyroidism or thyrotoxicosis in 14% - 18 % of cases .", "tokens": ["Beyond", "the", "predictable", "pharmacokinetic", "drug", "-", "drug", "interaction", "requiring", "a", "significant", "warfarin", "dose", "reduction", ",", "the", "iodine", "-", "rich", "amiodarone", "affects", "the", "thyroid", "gland", ",", "causing", "overt", "hypothyroidism", "or", "thyrotoxicosis", "in", "14%", "-", "18", "%", "of", "cases", "."], "event_mentions": [{"id": "15028964_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 25, "end": 26}, "arguments": [{"entity_id": "15028964_3_Ent1", "role": "Treatment", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent2", "role": "Treatment_Drug", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent0", "role": "Effect", "text": "overt hypothyroidism or thyrotoxicosis", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "15028964_3_Ent1", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent2", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent0", "text": "overt hypothyroidism or thyrotoxicosis", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "15034704_3", "wnd_id": "15034704_3_1", "text": "Male volunteers ( n=12 ) participated in a randomised , two - period , crossover trial evaluating the effect of multiple doses of 600 mg rifampicin once daily for 7 days on repaglinide metabolism .", "tokens": ["Male", "volunteers", "(", "n=12", ")", "participated", "in", "a", "randomised", ",", "two", "-", "period", ",", "crossover", "trial", "evaluating", "the", "effect", "of", "multiple", "doses", "of", "600", "mg", "rifampicin", "once", "daily", "for", "7", "days", "on", "repaglinide", "metabolism", "."], "event_mentions": [{"id": "15034704_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 31, "end": 32}, "arguments": [{"entity_id": "15034704_3_Ent1", "role": "Subject_Gender", "text": "Male", "start": 0, "end": 1}, {"entity_id": "15034704_3_Ent0", "role": "Subject", "text": "Male volunteers ( n=12 )", "start": 0, "end": 5}, {"entity_id": "15034704_3_Ent2", "role": "Subject_Population", "text": "n=12", "start": 3, "end": 4}, {"entity_id": "15034704_3_Ent5", "role": "Treatment_Dosage", "text": "multiple doses of 600 mg", "start": 20, "end": 25}, {"entity_id": "15034704_3_Ent4", "role": "Treatment", "text": "multiple doses of 600 mg rifampicin once daily for 7 days", "start": 20, "end": 31}, {"entity_id": "15034704_3_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 25, "end": 26}, {"entity_id": "15034704_3_Ent7", "role": "Treatment_Freq", "text": "once daily", "start": 26, "end": 28}, {"entity_id": "15034704_3_Ent8", "role": "Treatment_Duration", "text": "7 days", "start": 29, "end": 31}, {"entity_id": "15034704_3_Ent3", "role": "Effect", "text": "repaglinide metabolism", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15034704_3_Ent1", "text": "Male", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15034704_3_Ent0", "text": "Male volunteers ( n=12 )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15034704_3_Ent2", "text": "n=12", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15034704_3_Ent5", "text": "multiple doses of 600 mg", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "15034704_3_Ent4", "text": "multiple doses of 600 mg rifampicin once daily for 7 days", "entity_type": "Entity", "start": 20, "end": 31}, {"id": "15034704_3_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15034704_3_Ent7", "text": "once daily", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15034704_3_Ent8", "text": "7 days", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15034704_3_Ent3", "text": "repaglinide metabolism", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "1504404_3", "wnd_id": "1504404_3_1", "text": "DATA SYNTHESIS : A 49 - year - old man developed symptoms of severe psychosis concomitant with ciprofloxacin ( 250 mg bid ) treatment .", "tokens": ["DATA", "SYNTHESIS", ":", "A", "49", "-", "year", "-", "old", "man", "developed", "symptoms", "of", "severe", "psychosis", "concomitant", "with", "ciprofloxacin", "(", "250", "mg", "bid", ")", "treatment", "."], "event_mentions": [{"id": "1504404_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "1504404_3_Ent0", "role": "Subject", "text": "A 49 - year - old man", "start": 3, "end": 10}, {"entity_id": "1504404_3_Ent1", "role": "Subject_Age", "text": "49 - year - old", "start": 4, "end": 9}, {"entity_id": "1504404_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "1504404_3_Ent3", "role": "Effect", "text": "psychosis", "start": 14, "end": 15}, {"entity_id": "1504404_3_Ent4", "role": "Treatment", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent5", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 17, "end": 18}, {"entity_id": "1504404_3_Ent6", "role": "Treatment_Dosage", "text": "250 mg bid", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "1504404_3_Ent0", "text": "A 49 - year - old man", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "1504404_3_Ent1", "text": "49 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1504404_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1504404_3_Ent3", "text": "psychosis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1504404_3_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1504404_3_Ent6", "text": "250 mg bid", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "15053046_2", "wnd_id": "15053046_2_1", "text": "Agranulocytosis is a rare adverse effect associated with prolonged vancomycin therapy , and is potentially serious , especially in end stage renal disease ( ESRD ) patients .", "tokens": ["Agranulocytosis", "is", "a", "rare", "adverse", "effect", "associated", "with", "prolonged", "vancomycin", "therapy", ",", "and", "is", "potentially", "serious", ",", "especially", "in", "end", "stage", "renal", "disease", "(", "ESRD", ")", "patients", "."], "event_mentions": [{"id": "15053046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15053046_2_Ent1", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "15053046_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 8, "end": 9}, {"entity_id": "15053046_2_Ent2", "role": "Treatment", "text": "prolonged vancomycin therapy", "start": 8, "end": 11}, {"entity_id": "15053046_2_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 9, "end": 10}, {"entity_id": "15053046_2_Ent5", "role": "Treatment_Disorder", "text": "end stage renal disease ( ESRD )", "start": 19, "end": 26}, {"entity_id": "15053046_2_Ent0", "role": "Subject", "text": "end stage renal disease ( ESRD ) patients", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "15053046_2_Ent1", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15053046_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15053046_2_Ent2", "text": "prolonged vancomycin therapy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15053046_2_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15053046_2_Ent5", "text": "end stage renal disease ( ESRD )", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15053046_2_Ent0", "text": "end stage renal disease ( ESRD ) patients", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "15053046_4", "wnd_id": "15053046_4_1", "text": "The agranulocytosis was rapidly resolved by granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin .", "tokens": ["The", "agranulocytosis", "was", "rapidly", "resolved", "by", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "therapy", "and", "by", "the", "discontinuation", "of", "vancomycin", "."], "event_mentions": [{"id": "15053046_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 4, "end": 5}, "arguments": [{"entity_id": "15053046_4_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 1, "end": 2}, {"entity_id": "15053046_4_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 6, "end": 11}, {"entity_id": "15053046_4_Ent1", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "start": 6, "end": 23}, {"entity_id": "15053046_4_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15053046_4_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15053046_4_Ent2", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15053046_4_Ent1", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "15053046_4_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15061230_1", "wnd_id": "15061230_1_1", "text": "It is very likely that the dexamethasone used in the antiemetic drug regimen contributed to the development of osteonecrosis in these patients .", "tokens": ["It", "is", "very", "likely", "that", "the", "dexamethasone", "used", "in", "the", "antiemetic", "drug", "regimen", "contributed", "to", "the", "development", "of", "osteonecrosis", "in", "these", "patients", "."], "event_mentions": [{"id": "15061230_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 13, "end": 14}, "arguments": [{"entity_id": "15061230_1_Ent2", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "15061230_1_Ent3", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "15061230_1_Ent1", "role": "Effect", "text": "osteonecrosis", "start": 18, "end": 19}, {"entity_id": "15061230_1_Ent0", "role": "Subject", "text": "these patients", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "15061230_1_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15061230_1_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15061230_1_Ent1", "text": "osteonecrosis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15061230_1_Ent0", "text": "these patients", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "150825_2", "wnd_id": "150825_2_1", "text": "A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime .", "tokens": ["A", "second", "episode", "of", "jaundice", "followed", "the", "intravaginal", "administration", "of", "a", "mixture", "of", "furazolidone", "and", "nifuroxime", "."], "event_mentions": [{"id": "150825_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 5, "end": 6}, "arguments": [{"entity_id": "150825_2_Ent0", "role": "Effect", "text": "jaundice", "start": 4, "end": 5}, {"entity_id": "150825_2_Ent4", "role": "Treatment_Route", "text": "intravaginal", "start": 7, "end": 8}, {"entity_id": "150825_2_Ent1", "role": "Treatment", "text": "intravaginal administration of a mixture of furazolidone and nifuroxime", "start": 7, "end": 16}, {"entity_id": "150825_2_Ent2", "role": "Treatment_Drug", "text": "furazolidone", "start": 13, "end": 14}, {"entity_id": "150825_2_Ent5", "role": "Combination_Drug", "text": "furazolidone", "start": 13, "end": 14}, {"entity_id": "150825_2_Ent3", "role": "Treatment_Drug", "text": "nifuroxime", "start": 15, "end": 16}, {"entity_id": "150825_2_Ent6", "role": "Combination_Drug", "text": "nifuroxime", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "150825_2_Ent0", "text": "jaundice", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "150825_2_Ent4", "text": "intravaginal", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "150825_2_Ent1", "text": "intravaginal administration of a mixture of furazolidone and nifuroxime", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "150825_2_Ent2", "text": "furazolidone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "150825_2_Ent5", "text": "furazolidone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "150825_2_Ent3", "text": "nifuroxime", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "150825_2_Ent6", "text": "nifuroxime", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1509179_3", "wnd_id": "1509179_3_1", "text": "This profile should trigger a \" red flag \" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors .", "tokens": ["This", "profile", "should", "trigger", "a", "\"", "red", "flag", "\"", "as", "to", "the", "possibility", "of", "phenobarbital", "behavioral", "side", "effects", "or", "exacerbation", "of", "preexisting", "maladaptive", "behaviors", "."], "event_mentions": [{"id": "1509179_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 3, "end": 4}, "arguments": [{"entity_id": "1509179_3_Ent1", "role": "Treatment", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent2", "role": "Treatment_Drug", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent0", "role": "Effect", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "1509179_3_Ent1", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent2", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent0", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "15107195_1", "wnd_id": "15107195_1_1", "text": "A case of heatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on clozapine monotherapy .", "tokens": ["A", "case", "of", "heatstroke", "is", "reported", "in", "a", "32", "-", "year", "-", "old", "man", "diagnosed", "with", "schizophrenia", "and", "on", "clozapine", "monotherapy", "."], "event_mentions": [{"id": "15107195_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 5, "end": 6}, "arguments": [{"entity_id": "15107195_1_Ent3", "role": "Effect", "text": "heatstroke", "start": 3, "end": 4}, {"entity_id": "15107195_1_Ent0", "role": "Subject", "text": "a 32 - year - old man diagnosed with schizophrenia", "start": 7, "end": 17}, {"entity_id": "15107195_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 8, "end": 13}, {"entity_id": "15107195_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "15107195_1_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "15107195_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 19, "end": 20}, {"entity_id": "15107195_1_Ent4", "role": "Treatment", "text": "clozapine monotherapy", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15107195_1_Ent3", "text": "heatstroke", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_1_Ent0", "text": "a 32 - year - old man diagnosed with schizophrenia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "15107195_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15107195_1_Ent2", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15107195_1_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15107195_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15107195_1_Ent4", "text": "clozapine monotherapy", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15157248_1", "wnd_id": "15157248_1_1", "text": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin .", "tokens": ["An", "immediate", "hemolytic", "reaction", "induced", "by", "repeated", "administration", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15157248_1_Ent0", "role": "Effect", "text": "immediate hemolytic reaction", "start": 1, "end": 4}, {"entity_id": "15157248_1_Ent2", "role": "Treatment_Freq", "text": "repeated", "start": 6, "end": 7}, {"entity_id": "15157248_1_Ent1", "role": "Treatment", "text": "repeated administration of oxaliplatin", "start": 6, "end": 10}, {"entity_id": "15157248_1_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15157248_1_Ent0", "text": "immediate hemolytic reaction", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15157248_1_Ent2", "text": "repeated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15157248_1_Ent1", "text": "repeated administration of oxaliplatin", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15157248_1_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15157248_2", "wnd_id": "15157248_2_1", "text": "CASE REPORT : We report a patient who developed a DAT - positive hemolytic episode after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin .", "tokens": ["CASE", "REPORT", ":", "We", "report", "a", "patient", "who", "developed", "a", "DAT", "-", "positive", "hemolytic", "episode", "after", "a", "red", "cell", "(", "RBC", ")", "transfusion", "was", "delivered", "during", "the", "infusion", "of", "her", "17th", "cycle", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "15157248_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15157248_2_Ent1", "role": "Effect", "text": "developed a DAT - positive hemolytic episode", "start": 8, "end": 15}, {"entity_id": "15157248_2_Ent4", "role": "Treatment_Drug", "text": "a red cell", "start": 16, "end": 19}, {"entity_id": "15157248_2_Ent9", "role": "Combination_Drug", "text": "a red cell", "start": 16, "end": 19}, {"entity_id": "15157248_2_Ent2", "role": "Treatment", "text": "a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin", "start": 16, "end": 34}, {"entity_id": "15157248_2_Ent6", "role": "Treatment_Route", "text": "transfusion", "start": 22, "end": 23}, {"entity_id": "15157248_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 27, "end": 28}, {"entity_id": "15157248_2_Ent7", "role": "Treatment_Duration", "text": "17th cycle", "start": 30, "end": 32}, {"entity_id": "15157248_2_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 33, "end": 34}, {"entity_id": "15157248_2_Ent8", "role": "Combination_Drug", "text": "oxaliplatin", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "15157248_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15157248_2_Ent1", "text": "developed a DAT - positive hemolytic episode", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "15157248_2_Ent4", "text": "a red cell", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15157248_2_Ent9", "text": "a red cell", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15157248_2_Ent2", "text": "a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin", "entity_type": "Entity", "start": 16, "end": 34}, {"id": "15157248_2_Ent6", "text": "transfusion", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15157248_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "15157248_2_Ent7", "text": "17th cycle", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "15157248_2_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15157248_2_Ent8", "text": "oxaliplatin", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "15162903_3", "wnd_id": "15162903_3_1", "text": "Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate .", "tokens": ["Fatal", "acute", "encephalomyelitis", "after", "a", "single", "dose", "of", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "15162903_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15162903_3_Ent0", "role": "Effect", "text": "Fatal acute encephalomyelitis", "start": 0, "end": 3}, {"entity_id": "15162903_3_Ent2", "role": "Treatment_Dosage", "text": "single dose", "start": 5, "end": 7}, {"entity_id": "15162903_3_Ent1", "role": "Treatment", "text": "single dose of intrathecal methotrexate", "start": 5, "end": 10}, {"entity_id": "15162903_3_Ent3", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "15162903_3_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15162903_3_Ent0", "text": "Fatal acute encephalomyelitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15162903_3_Ent2", "text": "single dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15162903_3_Ent1", "text": "single dose of intrathecal methotrexate", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15162903_3_Ent3", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15162903_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15224368_2", "wnd_id": "15224368_2_1", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim , a drug that causes increased neutrophil proliferation and differentiation .", "tokens": ["Sweet", "'s", "syndrome", "is", "an", "acute", "febrile", "neutrophilic", "dermatosis", "that", "is", "a", "known", "complication", "of", "the", "administration", "of", "filgrastim", ",", "a", "drug", "that", "causes", "increased", "neutrophil", "proliferation", "and", "differentiation", "."], "event_mentions": [{"id": "15224368_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 23, "end": 24}, "arguments": [{"entity_id": "15224368_2_Ent0", "role": "Effect", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "start": 0, "end": 9}, {"entity_id": "15224368_2_Ent2", "role": "Treatment", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent3", "role": "Treatment_Drug", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent1", "role": "Effect", "text": "increased neutrophil proliferation and differentiation", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "15224368_2_Ent0", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15224368_2_Ent2", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent3", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent1", "text": "increased neutrophil proliferation and differentiation", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "15266150_2", "wnd_id": "15266150_2_1", "text": "Increased lash length , thickness , and pigmentation are well - documented side effects of prostaglandin analog glaucoma drops .", "tokens": ["Increased", "lash", "length", ",", "thickness", ",", "and", "pigmentation", "are", "well", "-", "documented", "side", "effects", "of", "prostaglandin", "analog", "glaucoma", "drops", "."], "event_mentions": [{"id": "15266150_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "are", "start": 8, "end": 9}, "arguments": [{"entity_id": "15266150_2_Ent0", "role": "Effect", "text": "Increased lash length , thickness , and pigmentation", "start": 0, "end": 8}, {"entity_id": "15266150_2_Ent3", "role": "Treatment_Drug", "text": "prostaglandin analog", "start": 15, "end": 17}, {"entity_id": "15266150_2_Ent1", "role": "Treatment", "text": "prostaglandin analog glaucoma drops", "start": 15, "end": 19}, {"entity_id": "15266150_2_Ent4", "role": "Treatment_Disorder", "text": "glaucoma", "start": 17, "end": 18}, {"entity_id": "15266150_2_Ent2", "role": "Treatment_Route", "text": "drops", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "15266150_2_Ent0", "text": "Increased lash length , thickness , and pigmentation", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15266150_2_Ent3", "text": "prostaglandin analog", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15266150_2_Ent1", "text": "prostaglandin analog glaucoma drops", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "15266150_2_Ent4", "text": "glaucoma", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15266150_2_Ent2", "text": "drops", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15286697_1", "wnd_id": "15286697_1_1", "text": "Fatal pulmonary fibrosis associated with BCNU : the relative role of platelet - derived growth factor - B , insulin - like growth factor I , transforming growth factor - beta1 and cyclooxygenase - 2 .", "tokens": ["Fatal", "pulmonary", "fibrosis", "associated", "with", "BCNU", ":", "the", "relative", "role", "of", "platelet", "-", "derived", "growth", "factor", "-", "B", ",", "insulin", "-", "like", "growth", "factor", "I", ",", "transforming", "growth", "factor", "-", "beta1", "and", "cyclooxygenase", "-", "2", "."], "event_mentions": [{"id": "15286697_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15286697_1_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 1, "end": 3}, {"entity_id": "15286697_1_Ent1", "role": "Treatment", "text": "BCNU", "start": 5, "end": 6}, {"entity_id": "15286697_1_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15286697_1_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15286697_1_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15286697_1_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15286697_4", "wnd_id": "15286697_4_1", "text": "We further used immunohistochemistry ( IHC ) to examine the relative role of platelet - derived growth factor - B ( PDGF - B ) , insulin - like growth factor I ( IGF - I ) , transforming growth factor - beta1 ( TGF - beta1 ) and cyclooxygenase - 2 ( COX - 2 ) in the pathogenesis of BCNU - related pulmonary fibrosis .", "tokens": ["We", "further", "used", "immunohistochemistry", "(", "IHC", ")", "to", "examine", "the", "relative", "role", "of", "platelet", "-", "derived", "growth", "factor", "-", "B", "(", "PDGF", "-", "B", ")", ",", "insulin", "-", "like", "growth", "factor", "I", "(", "IGF", "-", "I", ")", ",", "transforming", "growth", "factor", "-", "beta1", "(", "TGF", "-", "beta1", ")", "and", "cyclooxygenase", "-", "2", "(", "COX", "-", "2", ")", "in", "the", "pathogenesis", "of", "BCNU", "-", "related", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "15286697_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 63, "end": 64}, "arguments": [{"entity_id": "15286697_4_Ent1", "role": "Treatment", "text": "BCNU", "start": 61, "end": 62}, {"entity_id": "15286697_4_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 61, "end": 62}, {"entity_id": "15286697_4_Ent0", "role": "Effect", "text": "pulmonary fibrosis", "start": 64, "end": 66}]}], "entity_mentions": [{"id": "15286697_4_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 61, "end": 62}, {"id": "15286697_4_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 61, "end": 62}, {"id": "15286697_4_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 64, "end": 66}], "lang": "en"}
{"doc_id": "15289139_2", "wnd_id": "15289139_2_1", "text": "METHODS : A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery developed a choroidal detachment 12 hours after initiation of therapy with dorzolamide eye drops .", "tokens": ["METHODS", ":", "A", "76", "-", "year", "-", "old", "woman", "with", "primary", "open", "-", "angle", "glaucoma", "and", "no", "history", "of", "ocular", "surgery", "developed", "a", "choroidal", "detachment", "12", "hours", "after", "initiation", "of", "therapy", "with", "dorzolamide", "eye", "drops", "."], "event_mentions": [{"id": "15289139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "15289139_2_Ent0", "role": "Subject", "text": "A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery", "start": 2, "end": 21}, {"entity_id": "15289139_2_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 3, "end": 8}, {"entity_id": "15289139_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15289139_2_Ent7", "role": "Treatment_Disorder", "text": "open - angle glaucoma", "start": 11, "end": 15}, {"entity_id": "15289139_2_Ent3", "role": "Effect", "text": "choroidal detachment", "start": 23, "end": 25}, {"entity_id": "15289139_2_Ent5", "role": "Treatment_Time_elapsed", "text": "12 hours", "start": 25, "end": 27}, {"entity_id": "15289139_2_Ent4", "role": "Treatment", "text": "12 hours after initiation of therapy with dorzolamide eye drops", "start": 25, "end": 35}, {"entity_id": "15289139_2_Ent6", "role": "Treatment_Drug", "text": "dorzolamide", "start": 32, "end": 33}, {"entity_id": "15289139_2_Ent8", "role": "Treatment_Route", "text": "eye drops", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "15289139_2_Ent0", "text": "A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery", "entity_type": "Entity", "start": 2, "end": 21}, {"id": "15289139_2_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15289139_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15289139_2_Ent7", "text": "open - angle glaucoma", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15289139_2_Ent3", "text": "choroidal detachment", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "15289139_2_Ent5", "text": "12 hours", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "15289139_2_Ent4", "text": "12 hours after initiation of therapy with dorzolamide eye drops", "entity_type": "Entity", "start": 25, "end": 35}, {"id": "15289139_2_Ent6", "text": "dorzolamide", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "15289139_2_Ent8", "text": "eye drops", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "15289139_3", "wnd_id": "15289139_3_1", "text": "We document the abrupt development of an extensive choroidal detachment after initiation of dorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma .", "tokens": ["We", "document", "the", "abrupt", "development", "of", "an", "extensive", "choroidal", "detachment", "after", "initiation", "of", "dorzolamide", "therapy", "in", "a", "surgically", "untreated", "eye", "with", "primary", "open", "-", "angle", "glaucoma", "."], "event_mentions": [{"id": "15289139_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 4, "end": 5}, "arguments": [{"entity_id": "15289139_3_Ent1", "role": "Effect", "text": "extensive choroidal detachment", "start": 7, "end": 10}, {"entity_id": "15289139_3_Ent3", "role": "Treatment_Drug", "text": "dorzolamide", "start": 13, "end": 14}, {"entity_id": "15289139_3_Ent2", "role": "Treatment", "text": "dorzolamide therapy", "start": 13, "end": 15}, {"entity_id": "15289139_3_Ent0", "role": "Subject", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}, {"entity_id": "15289139_3_Ent4", "role": "Treatment_Disorder", "text": "surgically untreated eye with primary open - angle glaucoma", "start": 17, "end": 26}]}], "entity_mentions": [{"id": "15289139_3_Ent1", "text": "extensive choroidal detachment", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15289139_3_Ent3", "text": "dorzolamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15289139_3_Ent2", "text": "dorzolamide therapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15289139_3_Ent0", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "15289139_3_Ent4", "text": "surgically untreated eye with primary open - angle glaucoma", "entity_type": "Entity", "start": 17, "end": 26}], "lang": "en"}
{"doc_id": "15304176_1", "wnd_id": "15304176_1_1", "text": "Lichen planus induced by hepatitis B vaccination : a new case and review of the literature .", "tokens": ["Lichen", "planus", "induced", "by", "hepatitis", "B", "vaccination", ":", "a", "new", "case", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15304176_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15304176_1_Ent0", "role": "Effect", "text": "Lichen planus", "start": 0, "end": 2}, {"entity_id": "15304176_1_Ent1", "role": "Treatment", "text": "hepatitis B vaccination", "start": 4, "end": 7}, {"entity_id": "15304176_1_Ent2", "role": "Treatment_Drug", "text": "hepatitis B vaccination", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15304176_1_Ent0", "text": "Lichen planus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15304176_1_Ent1", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15304176_1_Ent2", "text": "hepatitis B vaccination", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15307435_1", "wnd_id": "15307435_1_1", "text": "Case report : life - threatening hypoglycaemia associated with sulfadoxine - pyrimethamine , a commonly used antimalarial drug .", "tokens": ["Case", "report", ":", "life", "-", "threatening", "hypoglycaemia", "associated", "with", "sulfadoxine", "-", "pyrimethamine", ",", "a", "commonly", "used", "antimalarial", "drug", "."], "event_mentions": [{"id": "15307435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "15307435_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "15307435_1_Ent1", "role": "Effect", "text": "life - threatening hypoglycaemia", "start": 3, "end": 7}, {"entity_id": "15307435_1_Ent2", "role": "Treatment", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}, {"entity_id": "15307435_1_Ent3", "role": "Treatment_Drug", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15307435_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15307435_1_Ent1", "text": "life - threatening hypoglycaemia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15307435_1_Ent2", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15307435_1_Ent3", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15311565_1", "wnd_id": "15311565_1_1", "text": "Initial treatment with heparin was substituted with thrombolysis , which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage .", "tokens": ["Initial", "treatment", "with", "heparin", "was", "substituted", "with", "thrombolysis", ",", "which", "resulted", "in", "clinical", "improvement", "and", "dissolution", "of", "right", "heart", "thrombus", "but", "was", "followed", "by", "fatal", "intracerebral", "haemorrhage", "."], "event_mentions": [{"id": "15311565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 10, "end": 11}, "arguments": [{"entity_id": "15311565_1_Ent1", "role": "Treatment", "text": "thrombolysis", "start": 7, "end": 8}, {"entity_id": "15311565_1_Ent2", "role": "Treatment_Drug", "text": "thrombolysis", "start": 7, "end": 8}, {"entity_id": "15311565_1_Ent0", "role": "Effect", "text": "fatal intracerebral haemorrhage", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "15311565_1_Ent1", "text": "thrombolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15311565_1_Ent2", "text": "thrombolysis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15311565_1_Ent0", "text": "fatal intracerebral haemorrhage", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "15316423_3", "wnd_id": "15316423_3_1", "text": "The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to infliximab in the causation of the venous thrombosis in this case .", "tokens": ["The", "site", "of", "thrombosis", "and", "the", "chronological", "relationship", "with", "the", "IIR", "implicates", "a", "hypersensitivity", "to", "infliximab", "in", "the", "causation", "of", "the", "venous", "thrombosis", "in", "this", "case", "."], "event_mentions": [{"id": "15316423_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causation", "start": 18, "end": 19}, "arguments": [{"entity_id": "15316423_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "15316423_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "15316423_3_Ent0", "role": "Effect", "text": "venous thrombosis", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "15316423_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15316423_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15316423_3_Ent0", "text": "venous thrombosis", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "15331204_7", "wnd_id": "15331204_7_1", "text": "After 3 - to 13 - month period of therapy without indapamide , glucose levels of all patients decreased and diabetes disappeared .", "tokens": ["After", "3", "-", "to", "13", "-", "month", "period", "of", "therapy", "without", "indapamide", ",", "glucose", "levels", "of", "all", "patients", "decreased", "and", "diabetes", "disappeared", "."], "event_mentions": [{"id": "15331204_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "15331204_7_Ent3", "role": "Treatment_Time_elapsed", "text": "3 - to 13 - month", "start": 1, "end": 7}, {"entity_id": "15331204_7_Ent1", "role": "Treatment", "text": "3 - to 13 - month period of therapy without indapamide", "start": 1, "end": 12}, {"entity_id": "15331204_7_Ent2", "role": "Treatment_Drug", "text": "indapamide", "start": 11, "end": 12}, {"entity_id": "15331204_7_Ent0", "role": "Effect", "text": "glucose levels of all patients decreased and diabetes disappeared", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "15331204_7_Ent3", "text": "3 - to 13 - month", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "15331204_7_Ent1", "text": "3 - to 13 - month period of therapy without indapamide", "entity_type": "Entity", "start": 1, "end": 12}, {"id": "15331204_7_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15331204_7_Ent0", "text": "glucose levels of all patients decreased and diabetes disappeared", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "15331204_8", "wnd_id": "15331204_8_1", "text": "After stopping indapamide , glucose tolerance impairing may be reversed .", "tokens": ["After", "stopping", "indapamide", ",", "glucose", "tolerance", "impairing", "may", "be", "reversed", "."], "event_mentions": [{"id": "15331204_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopping", "start": 1, "end": 2}, "arguments": [{"entity_id": "15331204_8_Ent2", "role": "Treatment_Drug", "text": "indapamide", "start": 2, "end": 3}, {"entity_id": "15331204_8_Ent0", "role": "Treatment", "text": "indapamide , glucose tolerance impairing", "start": 2, "end": 7}, {"entity_id": "15331204_8_Ent1", "role": "Treatment_Disorder", "text": "glucose tolerance impairing", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15331204_8_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15331204_8_Ent0", "text": "indapamide , glucose tolerance impairing", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "15331204_8_Ent1", "text": "glucose tolerance impairing", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15338554_3", "wnd_id": "15338554_3_1", "text": "In addition to disease refractoriness , rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported .", "tokens": ["In", "addition", "to", "disease", "refractoriness", ",", "rare", "instances", "of", "disease", "progression", "from", "chronic", "phase", "to", "blast", "crisis", "during", "imatinib", "therapy", "have", "recently", "been", "anecdotally", "reported", "."], "event_mentions": [{"id": "15338554_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "15338554_3_Ent0", "role": "Effect", "text": "disease progression from chronic phase to blast crisis", "start": 9, "end": 17}, {"entity_id": "15338554_3_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "15338554_3_Ent1", "role": "Treatment", "text": "imatinib therapy", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "15338554_3_Ent0", "text": "disease progression from chronic phase to blast crisis", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "15338554_3_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15338554_3_Ent1", "text": "imatinib therapy", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "15362597_2", "wnd_id": "15362597_2_1", "text": "We present a case of a diabetic patient taking glyburide who was prescribed ciprofloxacin and developed prolonged hypoglycemia , which persisted for over 24 hours .", "tokens": ["We", "present", "a", "case", "of", "a", "diabetic", "patient", "taking", "glyburide", "who", "was", "prescribed", "ciprofloxacin", "and", "developed", "prolonged", "hypoglycemia", ",", "which", "persisted", "for", "over", "24", "hours", "."], "event_mentions": [{"id": "15362597_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "15362597_2_Ent0", "role": "Subject", "text": "a case of a diabetic patient taking glyburide", "start": 2, "end": 10}, {"entity_id": "15362597_2_Ent5", "role": "Treatment_Disorder", "text": "diabetic", "start": 6, "end": 7}, {"entity_id": "15362597_2_Ent3", "role": "Treatment_Drug", "text": "glyburide", "start": 9, "end": 10}, {"entity_id": "15362597_2_Ent6", "role": "Combination_Drug", "text": "glyburide", "start": 9, "end": 10}, {"entity_id": "15362597_2_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent7", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 13, "end": 14}, {"entity_id": "15362597_2_Ent1", "role": "Effect", "text": "prolonged hypoglycemia , which persisted for over 24 hours", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "15362597_2_Ent0", "text": "a case of a diabetic patient taking glyburide", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "15362597_2_Ent5", "text": "diabetic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15362597_2_Ent3", "text": "glyburide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15362597_2_Ent6", "text": "glyburide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15362597_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15362597_2_Ent1", "text": "prolonged hypoglycemia , which persisted for over 24 hours", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "15379082_2", "wnd_id": "15379082_2_1", "text": "Fulminant hepatic failure is a rare complication of disulfiram treatment for alcoholism .", "tokens": ["Fulminant", "hepatic", "failure", "is", "a", "rare", "complication", "of", "disulfiram", "treatment", "for", "alcoholism", "."], "event_mentions": [{"id": "15379082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_2_Ent0", "role": "Effect", "text": "Fulminant hepatic failure", "start": 0, "end": 3}, {"entity_id": "15379082_2_Ent1", "role": "Treatment", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 8, "end": 9}, {"entity_id": "15379082_2_Ent2", "role": "Treatment_Disorder", "text": "alcoholism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15379082_2_Ent0", "text": "Fulminant hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15379082_2_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15379082_2_Ent2", "text": "alcoholism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15379082_3", "wnd_id": "15379082_3_1", "text": "This case describes fulminant hepatic failure in a patient taking disulfiram with no previous liver disease and report of being compliant with alcohol abstinence .", "tokens": ["This", "case", "describes", "fulminant", "hepatic", "failure", "in", "a", "patient", "taking", "disulfiram", "with", "no", "previous", "liver", "disease", "and", "report", "of", "being", "compliant", "with", "alcohol", "abstinence", "."], "event_mentions": [{"id": "15379082_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "15379082_3_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}, {"entity_id": "15379082_3_Ent0", "role": "Subject", "text": "a patient", "start": 7, "end": 9}, {"entity_id": "15379082_3_Ent2", "role": "Treatment", "text": "disulfiram", "start": 10, "end": 11}, {"entity_id": "15379082_3_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "15379082_3_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15379082_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15379082_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15379082_3_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "15383642_11", "wnd_id": "15383642_11_1", "text": "The reaction in our patient appeared after tizanidine initiation and improved after both lisinopril and tizanidine were discontinued .", "tokens": ["The", "reaction", "in", "our", "patient", "appeared", "after", "tizanidine", "initiation", "and", "improved", "after", "both", "lisinopril", "and", "tizanidine", "were", "discontinued", "."], "event_mentions": [{"id": "15383642_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "15383642_11_Ent1", "role": "Effect", "text": "reaction", "start": 1, "end": 2}, {"entity_id": "15383642_11_Ent0", "role": "Subject", "text": "patient", "start": 4, "end": 5}, {"entity_id": "15383642_11_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 7, "end": 8}, {"entity_id": "15383642_11_Ent2", "role": "Treatment", "text": "tizanidine initiation", "start": 7, "end": 9}]}, {"id": "15383642_11_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 10, "end": 11}, "arguments": [{"entity_id": "15383642_11_Ent6", "role": "Treatment_Disorder", "text": "reaction", "start": 1, "end": 2}, {"entity_id": "15383642_11_Ent4", "role": "Subject", "text": "patient", "start": 4, "end": 5}, {"entity_id": "15383642_11_Ent5", "role": "Treatment", "text": "both lisinopril and tizanidine", "start": 12, "end": 16}, {"entity_id": "15383642_11_Ent7", "role": "Treatment_Drug", "text": "lisinopril", "start": 13, "end": 14}, {"entity_id": "15383642_11_Ent9", "role": "Combination_Drug", "text": "lisinopril", "start": 13, "end": 14}, {"entity_id": "15383642_11_Ent8", "role": "Treatment_Drug", "text": "tizanidine", "start": 15, "end": 16}, {"entity_id": "15383642_11_Ent10", "role": "Combination_Drug", "text": "tizanidine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15383642_11_Ent1", "text": "reaction", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15383642_11_Ent6", "text": "reaction", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15383642_11_Ent0", "text": "patient", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_11_Ent4", "text": "patient", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_11_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15383642_11_Ent2", "text": "tizanidine initiation", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15383642_11_Ent5", "text": "both lisinopril and tizanidine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15383642_11_Ent7", "text": "lisinopril", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_11_Ent9", "text": "lisinopril", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_11_Ent8", "text": "tizanidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15383642_11_Ent10", "text": "tizanidine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15383642_14", "wnd_id": "15383642_14_1", "text": "With its characteristics , tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin - converting enzyme inhibitor use .", "tokens": ["With", "its", "characteristics", ",", "tizanidine", "has", "the", "potential", "to", "compromise", "hemodynamic", "stability", "during", "concomitant", "angiotensin", "-", "converting", "enzyme", "inhibitor", "use", "."], "event_mentions": [{"id": "15383642_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "compromise", "start": 9, "end": 10}, "arguments": [{"entity_id": "15383642_14_Ent1", "role": "Treatment", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent0", "role": "Effect", "text": "compromise hemodynamic stability", "start": 9, "end": 12}, {"entity_id": "15383642_14_Ent2", "role": "Treatment", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "start": 12, "end": 20}, {"entity_id": "15383642_14_Ent4", "role": "Treatment_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}, {"entity_id": "15383642_14_Ent6", "role": "Combination_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "15383642_14_Ent1", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent0", "text": "compromise hemodynamic stability", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15383642_14_Ent2", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15383642_14_Ent4", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "15383642_14_Ent6", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "15383642_6", "wnd_id": "15383642_6_1", "text": "Three weeks later , the decerebrate rigidity and high BP remained , and tizanidine was initiated to see whether the decrease in muscle tone could facilitate hypertension control and motor recovery .", "tokens": ["Three", "weeks", "later", ",", "the", "decerebrate", "rigidity", "and", "high", "BP", "remained", ",", "and", "tizanidine", "was", "initiated", "to", "see", "whether", "the", "decrease", "in", "muscle", "tone", "could", "facilitate", "hypertension", "control", "and", "motor", "recovery", "."], "event_mentions": [{"id": "15383642_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 15, "end": 16}, "arguments": [{"entity_id": "15383642_6_Ent0", "role": "Subject", "text": "decerebrate rigidity and high BP", "start": 5, "end": 10}, {"entity_id": "15383642_6_Ent4", "role": "Treatment_Disorder", "text": "decerebrate rigidity and high BP", "start": 5, "end": 10}, {"entity_id": "15383642_6_Ent2", "role": "Treatment", "text": "tizanidine", "start": 13, "end": 14}, {"entity_id": "15383642_6_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 13, "end": 14}, {"entity_id": "15383642_6_Ent1", "role": "Effect", "text": "hypertension control and motor recovery", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "15383642_6_Ent0", "text": "decerebrate rigidity and high BP", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15383642_6_Ent4", "text": "decerebrate rigidity and high BP", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15383642_6_Ent2", "text": "tizanidine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_6_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_6_Ent1", "text": "hypertension control and motor recovery", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "15383642_9", "wnd_id": "15383642_9_1", "text": "Tizanidine was used again after her BP had stabilized , but did not produce similar problems .", "tokens": ["Tizanidine", "was", "used", "again", "after", "her", "BP", "had", "stabilized", ",", "but", "did", "not", "produce", "similar", "problems", "."], "event_mentions": [{"id": "15383642_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 13, "end": 14}, "arguments": [{"entity_id": "15383642_9_Ent1", "role": "Treatment", "text": "Tizanidine", "start": 0, "end": 1}, {"entity_id": "15383642_9_Ent2", "role": "Treatment_Drug", "text": "Tizanidine", "start": 0, "end": 1}, {"entity_id": "15383642_9_Ent0", "role": "Effect", "text": "problems", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15383642_9_Ent1", "text": "Tizanidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15383642_9_Ent2", "text": "Tizanidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15383642_9_Ent0", "text": "problems", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15454180_2", "wnd_id": "15454180_2_1", "text": "As linezolid has been shown to have hematologic side effects , blood count monitoring is recommended in patients receiving this drug for long - term therapy .", "tokens": ["As", "linezolid", "has", "been", "shown", "to", "have", "hematologic", "side", "effects", ",", "blood", "count", "monitoring", "is", "recommended", "in", "patients", "receiving", "this", "drug", "for", "long", "-", "term", "therapy", "."], "event_mentions": [{"id": "15454180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 6, "end": 7}, "arguments": [{"entity_id": "15454180_2_Ent1", "role": "Treatment", "text": "linezolid", "start": 1, "end": 2}, {"entity_id": "15454180_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 1, "end": 2}, {"entity_id": "15454180_2_Ent0", "role": "Effect", "text": "hematologic side effects", "start": 7, "end": 10}, {"entity_id": "15454180_2_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "15454180_2_Ent1", "text": "linezolid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15454180_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15454180_2_Ent0", "text": "hematologic side effects", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15454180_2_Ent3", "text": "long - term", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "15454180_3", "wnd_id": "15454180_3_1", "text": "Sideroblastic anemia due to linezolid in a patient with a left ventricular assist device .", "tokens": ["Sideroblastic", "anemia", "due", "to", "linezolid", "in", "a", "patient", "with", "a", "left", "ventricular", "assist", "device", "."], "event_mentions": [{"id": "15454180_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "15454180_3_Ent1", "role": "Effect", "text": "Sideroblastic anemia", "start": 0, "end": 2}, {"entity_id": "15454180_3_Ent2", "role": "Treatment", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "15454180_3_Ent0", "role": "Subject", "text": "patient with a left ventricular assist device", "start": 7, "end": 14}, {"entity_id": "15454180_3_Ent4", "role": "Treatment_Disorder", "text": "left ventricular assist device", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "15454180_3_Ent1", "text": "Sideroblastic anemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15454180_3_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15454180_3_Ent0", "text": "patient with a left ventricular assist device", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15454180_3_Ent4", "text": "left ventricular assist device", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "15461766_1", "wnd_id": "15461766_1_1", "text": "In this report , two newborns with congenital heart anomalies demonstrated the harlequin color change , one whose skin findings showed a course related to the dose of systemic prostaglandin E1 , suggesting a possible association .", "tokens": ["In", "this", "report", ",", "two", "newborns", "with", "congenital", "heart", "anomalies", "demonstrated", "the", "harlequin", "color", "change", ",", "one", "whose", "skin", "findings", "showed", "a", "course", "related", "to", "the", "dose", "of", "systemic", "prostaglandin", "E1", ",", "suggesting", "a", "possible", "association", "."], "event_mentions": [{"id": "15461766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 23, "end": 24}, "arguments": [{"entity_id": "15461766_1_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "15461766_1_Ent0", "role": "Subject", "text": "two newborns with congenital heart anomalies", "start": 4, "end": 10}, {"entity_id": "15461766_1_Ent2", "role": "Subject_Age", "text": "newborns", "start": 5, "end": 6}, {"entity_id": "15461766_1_Ent5", "role": "Treatment_Disorder", "text": "congenital heart anomalies", "start": 7, "end": 10}, {"entity_id": "15461766_1_Ent3", "role": "Effect", "text": "harlequin color change", "start": 12, "end": 15}, {"entity_id": "15461766_1_Ent4", "role": "Treatment", "text": "prostaglandin E1", "start": 29, "end": 31}, {"entity_id": "15461766_1_Ent6", "role": "Treatment_Drug", "text": "prostaglandin E1", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "15461766_1_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15461766_1_Ent0", "text": "two newborns with congenital heart anomalies", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15461766_1_Ent2", "text": "newborns", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15461766_1_Ent5", "text": "congenital heart anomalies", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15461766_1_Ent3", "text": "harlequin color change", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15461766_1_Ent4", "text": "prostaglandin E1", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "15461766_1_Ent6", "text": "prostaglandin E1", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "15463865_1", "wnd_id": "15463865_1_1", "text": "Ciprofloxacin - induced renal insufficiency in cystic fibrosis .", "tokens": ["Ciprofloxacin", "-", "induced", "renal", "insufficiency", "in", "cystic", "fibrosis", "."], "event_mentions": [{"id": "15463865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15463865_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15463865_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "15463865_1_Ent0", "role": "Effect", "text": "renal insufficiency", "start": 3, "end": 5}, {"entity_id": "15463865_1_Ent3", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15463865_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15463865_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15463865_1_Ent0", "text": "renal insufficiency", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15463865_1_Ent3", "text": "cystic fibrosis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15482394_4", "wnd_id": "15482394_4_1", "text": "In view of our experience in the present case , it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage .", "tokens": ["In", "view", "of", "our", "experience", "in", "the", "present", "case", ",", "it", "should", "be", "stressed", "that", "close", "monitoring", "of", "coagulation", "capacity", "is", "necessary", "in", "critically", "ill", "patients", "in", "order", "to", "avoid", "fatal", "haemorrhage", "after", "initiating", "warfarin", "therapy", "regardless", "of", "the", "dosage", "."], "event_mentions": [{"id": "15482394_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 32, "end": 33}, "arguments": [{"entity_id": "15482394_4_Ent0", "role": "Effect", "text": "haemorrhage", "start": 31, "end": 32}, {"entity_id": "15482394_4_Ent1", "role": "Treatment", "text": "initiating warfarin therapy regardless of the dosage", "start": 33, "end": 40}, {"entity_id": "15482394_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "15482394_4_Ent0", "text": "haemorrhage", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15482394_4_Ent1", "text": "initiating warfarin therapy regardless of the dosage", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "15482394_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "15494638_19", "wnd_id": "15494638_19_1", "text": "Knowledge regarding potential adverse effects of CAP is paramount and dose modification is indicated with development of neurotoxicity .", "tokens": ["Knowledge", "regarding", "potential", "adverse", "effects", "of", "CAP", "is", "paramount", "and", "dose", "modification", "is", "indicated", "with", "development", "of", "neurotoxicity", "."], "event_mentions": [{"id": "15494638_19_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 3, "end": 5}, "arguments": [{"entity_id": "15494638_19_Ent1", "role": "Treatment", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_19_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 6, "end": 7}, {"entity_id": "15494638_19_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15494638_19_Ent1", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_19_Ent2", "text": "CAP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15494638_19_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15494638_20", "wnd_id": "15494638_20_1", "text": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A , with no recurrence after reinitiating CAP alone at 2000 mg / m2 .", "tokens": ["Neurologic", "symptoms", "resolved", "after", "stopping", "CAP", "for", "4", "weeks", "in", "Patient", "A", ",", "with", "no", "recurrence", "after", "reinitiating", "CAP", "alone", "at", "2000", "mg", "/", "m2", "."], "event_mentions": [{"id": "15494638_20_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15494638_20_Ent0", "role": "Effect", "text": "Neurologic symptoms resolved", "start": 0, "end": 3}, {"entity_id": "15494638_20_Ent1", "role": "Treatment", "text": "stopping CAP for 4 weeks", "start": 4, "end": 9}, {"entity_id": "15494638_20_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 5, "end": 6}, {"entity_id": "15494638_20_Ent3", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15494638_20_Ent0", "text": "Neurologic symptoms resolved", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_20_Ent1", "text": "stopping CAP for 4 weeks", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15494638_20_Ent2", "text": "CAP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15494638_20_Ent3", "text": "4 weeks", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15516308_1", "wnd_id": "15516308_1_1", "text": "Fatal overdoses associated with quetiapine .", "tokens": ["Fatal", "overdoses", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15516308_1_Ent0", "role": "Effect", "text": "Fatal overdoses", "start": 0, "end": 2}, {"entity_id": "15516308_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 4, "end": 5}, {"entity_id": "15516308_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15516308_1_Ent0", "text": "Fatal overdoses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15516308_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15516308_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15516308_3", "wnd_id": "15516308_3_1", "text": "We present three cases from the Provincial Toxicology Center of British Columbia , Canada in which suicidal overdose deaths were associated with quetiapine .", "tokens": ["We", "present", "three", "cases", "from", "the", "Provincial", "Toxicology", "Center", "of", "British", "Columbia", ",", "Canada", "in", "which", "suicidal", "overdose", "deaths", "were", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15516308_3_Ent0", "role": "Effect", "text": "suicidal overdose deaths", "start": 16, "end": 19}, {"entity_id": "15516308_3_Ent1", "role": "Treatment", "text": "quetiapine", "start": 22, "end": 23}, {"entity_id": "15516308_3_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15516308_3_Ent0", "text": "suicidal overdose deaths", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15516308_3_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15516308_3_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15533031_2", "wnd_id": "15533031_2_1", "text": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine , a centrally acting analgesic and antispastic drug .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "increased", "cerebral", "cortical", "excitability", "following", "intoxication", "with", "flupirtine", ",", "a", "centrally", "acting", "analgesic", "and", "antispastic", "drug", "."], "event_mentions": [{"id": "15533031_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 12, "end": 13}, "arguments": [{"entity_id": "15533031_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15533031_2_Ent1", "role": "Effect", "text": "increased cerebral cortical excitability", "start": 8, "end": 12}, {"entity_id": "15533031_2_Ent2", "role": "Treatment", "text": "flupirtine", "start": 15, "end": 16}, {"entity_id": "15533031_2_Ent3", "role": "Treatment_Drug", "text": "flupirtine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15533031_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_2_Ent1", "text": "increased cerebral cortical excitability", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15533031_2_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15533031_2_Ent3", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15554737_1", "wnd_id": "15554737_1_1", "text": "In this article , we describe another case of subcutaneous changes following repeated glatiramer acetate injection , presented as localized panniculitis in the area around the injection sites , in a 46 - year - old female patient who was treated with glatiramer acetate for 18 months .", "tokens": ["In", "this", "article", ",", "we", "describe", "another", "case", "of", "subcutaneous", "changes", "following", "repeated", "glatiramer", "acetate", "injection", ",", "presented", "as", "localized", "panniculitis", "in", "the", "area", "around", "the", "injection", "sites", ",", "in", "a", "46", "-", "year", "-", "old", "female", "patient", "who", "was", "treated", "with", "glatiramer", "acetate", "for", "18", "months", "."], "event_mentions": [{"id": "15554737_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "15554737_1_Ent3", "role": "Effect", "text": "subcutaneous changes", "start": 9, "end": 11}, {"entity_id": "15554737_1_Ent5", "role": "Treatment", "text": "repeated glatiramer acetate injection", "start": 12, "end": 16}, {"entity_id": "15554737_1_Ent6", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 13, "end": 15}, {"entity_id": "15554737_1_Ent7", "role": "Treatment_Route", "text": "injection", "start": 15, "end": 16}, {"entity_id": "15554737_1_Ent4", "role": "Effect", "text": "presented as localized panniculitis in the area around the injection sites", "start": 17, "end": 28}, {"entity_id": "15554737_1_Ent0", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}]}, {"id": "15554737_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 40, "end": 41}, "arguments": [{"entity_id": "15554737_1_Ent8", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent9", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent10", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}, {"entity_id": "15554737_1_Ent12", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 42, "end": 44}, {"entity_id": "15554737_1_Ent11", "role": "Treatment", "text": "glatiramer acetate for 18 months", "start": 42, "end": 47}, {"entity_id": "15554737_1_Ent13", "role": "Treatment_Time_elapsed", "text": "18 months .", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "15554737_1_Ent3", "text": "subcutaneous changes", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15554737_1_Ent5", "text": "repeated glatiramer acetate injection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15554737_1_Ent6", "text": "glatiramer acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15554737_1_Ent7", "text": "injection", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15554737_1_Ent4", "text": "presented as localized panniculitis in the area around the injection sites", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "15554737_1_Ent0", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent8", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent9", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent2", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent10", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent12", "text": "glatiramer acetate", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "15554737_1_Ent11", "text": "glatiramer acetate for 18 months", "entity_type": "Entity", "start": 42, "end": 47}, {"id": "15554737_1_Ent13", "text": "18 months .", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "15554737_2", "wnd_id": "15554737_2_1", "text": "Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis .", "tokens": ["Localized", "panniculitis", "and", "subsequent", "lipoatrophy", "with", "subcutaneous", "glatiramer", "acetate", "(", "Copaxone", ")", "injection", "for", "the", "treatment", "of", "multiple", "sclerosis", "."], "event_mentions": [{"id": "15554737_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 5, "end": 6}, "arguments": [{"entity_id": "15554737_2_Ent0", "role": "Effect", "text": "Localized panniculitis and subsequent lipoatrophy", "start": 0, "end": 5}, {"entity_id": "15554737_2_Ent1", "role": "Treatment", "text": "subcutaneous glatiramer acetate ( Copaxone ) injection", "start": 6, "end": 13}, {"entity_id": "15554737_2_Ent2", "role": "Treatment_Drug", "text": "glatiramer acetate ( Copaxone )", "start": 7, "end": 12}, {"entity_id": "15554737_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}, {"entity_id": "15554737_2_Ent4", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15554737_2_Ent0", "text": "Localized panniculitis and subsequent lipoatrophy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15554737_2_Ent1", "text": "subcutaneous glatiramer acetate ( Copaxone ) injection", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "15554737_2_Ent2", "text": "glatiramer acetate ( Copaxone )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "15554737_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15554737_2_Ent4", "text": "multiple sclerosis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15571949_1", "wnd_id": "15571949_1_1", "text": "In four patients , thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing busulfan .", "tokens": ["In", "four", "patients", ",", "thrombosis", "occurred", "2", "-", "45", "days", "after", "severe", "hepatic", "veno", "-", "occlusive", "disease", "(", "HVOD", ")", "secondary", "to", "intensive", "chemotherapy", "containing", "busulfan", "."], "event_mentions": [{"id": "15571949_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 20, "end": 21}, "arguments": [{"entity_id": "15571949_1_Ent1", "role": "Subject_Population", "text": "four", "start": 1, "end": 2}, {"entity_id": "15571949_1_Ent0", "role": "Subject", "text": "four patients", "start": 1, "end": 3}, {"entity_id": "15571949_1_Ent2", "role": "Effect", "text": "thrombosis occurred", "start": 4, "end": 6}, {"entity_id": "15571949_1_Ent5", "role": "Treatment_Time_elapsed", "text": "2 - 45 days after", "start": 6, "end": 11}, {"entity_id": "15571949_1_Ent3", "role": "Effect", "text": "severe hepatic veno - occlusive disease ( HVOD )", "start": 11, "end": 20}, {"entity_id": "15571949_1_Ent4", "role": "Treatment", "text": "intensive chemotherapy containing busulfan", "start": 22, "end": 26}, {"entity_id": "15571949_1_Ent6", "role": "Treatment_Drug", "text": "busulfan", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15571949_1_Ent1", "text": "four", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15571949_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15571949_1_Ent2", "text": "thrombosis occurred", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15571949_1_Ent5", "text": "2 - 45 days after", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15571949_1_Ent3", "text": "severe hepatic veno - occlusive disease ( HVOD )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15571949_1_Ent4", "text": "intensive chemotherapy containing busulfan", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "15571949_1_Ent6", "text": "busulfan", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15588385_2", "wnd_id": "15588385_2_1", "text": "After an extensive review of the literature , we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with PTU - induced fulminant hepatitis .", "tokens": ["After", "an", "extensive", "review", "of", "the", "literature", ",", "we", "believe", "that", "this", "is", "the", "first", "communication", "of", "the", "successful", "use", "of", "amiodarone", "to", "control", "hyperthyroidism", "in", "a", "patient", "with", "PTU", "-", "induced", "fulminant", "hepatitis", "."], "event_mentions": [{"id": "15588385_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "control", "start": 23, "end": 24}, "arguments": [{"entity_id": "15588385_2_Ent2", "role": "Treatment", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 21, "end": 22}, {"entity_id": "15588385_2_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 24, "end": 25}, {"entity_id": "15588385_2_Ent0", "role": "Subject", "text": "a patient with PTU - induced fulminant hepatitis", "start": 26, "end": 34}, {"entity_id": "15588385_2_Ent1", "role": "Subject_Disorder", "text": "PTU - induced fulminant hepatitis", "start": 29, "end": 34}]}, {"id": "15588385_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 31, "end": 32}, "arguments": [{"entity_id": "15588385_2_Ent6", "role": "Treatment", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent7", "role": "Treatment_Drug", "text": "PTU", "start": 29, "end": 30}, {"entity_id": "15588385_2_Ent5", "role": "Effect", "text": "fulminant hepatitis", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "15588385_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15588385_2_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15588385_2_Ent0", "text": "a patient with PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "15588385_2_Ent6", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent7", "text": "PTU", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "15588385_2_Ent1", "text": "PTU - induced fulminant hepatitis", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "15588385_2_Ent5", "text": "fulminant hepatitis", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "15588385_4", "wnd_id": "15588385_4_1", "text": "We present a 20 - year - old woman with Basedow - Graves ' disease who developed PTU - induced fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy .", "tokens": ["We", "present", "a", "20", "-", "year", "-", "old", "woman", "with", "Basedow", "-", "Graves", "'", "disease", "who", "developed", "PTU", "-", "induced", "fulminant", "hepatitis", ",", "which", "progressed", "to", "acute", "hepatic", "failure", "with", "grade", "III", "hepatic", "encephalopathy", "."], "event_mentions": [{"id": "15588385_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "15588385_4_Ent0", "role": "Subject", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "start": 2, "end": 15}, {"entity_id": "15588385_4_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 3, "end": 8}, {"entity_id": "15588385_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15588385_4_Ent5", "role": "Treatment_Disorder", "text": "Basedow - Graves ' disease", "start": 10, "end": 15}, {"entity_id": "15588385_4_Ent4", "role": "Treatment", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent6", "role": "Treatment_Drug", "text": "PTU", "start": 17, "end": 18}, {"entity_id": "15588385_4_Ent3", "role": "Effect", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "start": 20, "end": 34}]}], "entity_mentions": [{"id": "15588385_4_Ent0", "text": "a 20 - year - old woman with Basedow - Graves ' disease", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "15588385_4_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15588385_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15588385_4_Ent5", "text": "Basedow - Graves ' disease", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15588385_4_Ent4", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent6", "text": "PTU", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15588385_4_Ent3", "text": "fulminant hepatitis , which progressed to acute hepatic failure with grade III hepatic encephalopathy", "entity_type": "Entity", "start": 20, "end": 34}], "lang": "en"}
{"doc_id": "15611427_4", "wnd_id": "15611427_4_1", "text": "The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity , detected by MxA expression after imiquimod therapy .", "tokens": ["The", "exacerbation", "of", "psoriasis", "was", "accompanied", "by", "a", "massive", "induction", "of", "lesional", "type", "I", "interferon", "activity", ",", "detected", "by", "MxA", "expression", "after", "imiquimod", "therapy", "."], "event_mentions": [{"id": "15611427_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detected", "start": 17, "end": 18}, "arguments": [{"entity_id": "15611427_4_Ent0", "role": "Effect", "text": "exacerbation of psoriasis", "start": 1, "end": 4}, {"entity_id": "15611427_4_Ent1", "role": "Effect", "text": "a massive induction of lesional type I interferon activity", "start": 7, "end": 16}, {"entity_id": "15611427_4_Ent2", "role": "Treatment", "text": "imiquimod", "start": 22, "end": 23}, {"entity_id": "15611427_4_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15611427_4_Ent0", "text": "exacerbation of psoriasis", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15611427_4_Ent1", "text": "a massive induction of lesional type I interferon activity", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15611427_4_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15611427_4_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15644988_1", "wnd_id": "15644988_1_1", "text": "Tardive dyskinesia in 2 patients treated with ziprasidone .", "tokens": ["Tardive", "dyskinesia", "in", "2", "patients", "treated", "with", "ziprasidone", "."], "event_mentions": [{"id": "15644988_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "15644988_1_Ent2", "role": "Effect", "text": "Tardive dyskinesia", "start": 0, "end": 2}, {"entity_id": "15644988_1_Ent1", "role": "Subject_Population", "text": "2", "start": 3, "end": 4}, {"entity_id": "15644988_1_Ent0", "role": "Subject", "text": "2 patients", "start": 3, "end": 5}, {"entity_id": "15644988_1_Ent3", "role": "Treatment", "text": "ziprasidone", "start": 7, "end": 8}, {"entity_id": "15644988_1_Ent4", "role": "Treatment_Drug", "text": "ziprasidone", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15644988_1_Ent2", "text": "Tardive dyskinesia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15644988_1_Ent1", "text": "2", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15644988_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15644988_1_Ent3", "text": "ziprasidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15644988_1_Ent4", "text": "ziprasidone", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15681911_2", "wnd_id": "15681911_2_1", "text": "OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop lower gastrointestinal symptoms when exposed to rofecoxib .", "tokens": ["OBJECTIVES", ":", "To", "describe", "clinical", "and", "pathologic", "findings", "in", "patients", "noted", "to", "develop", "lower", "gastrointestinal", "symptoms", "when", "exposed", "to", "rofecoxib", "."], "event_mentions": [{"id": "15681911_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 12, "end": 13}, "arguments": [{"entity_id": "15681911_2_Ent0", "role": "Subject", "text": "patients", "start": 9, "end": 10}, {"entity_id": "15681911_2_Ent1", "role": "Effect", "text": "lower gastrointestinal symptoms", "start": 13, "end": 16}, {"entity_id": "15681911_2_Ent2", "role": "Treatment", "text": "rofecoxib", "start": 19, "end": 20}, {"entity_id": "15681911_2_Ent3", "role": "Treatment_Drug", "text": "rofecoxib", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "15681911_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15681911_2_Ent1", "text": "lower gastrointestinal symptoms", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15681911_2_Ent2", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15681911_2_Ent3", "text": "rofecoxib", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "15694139_2", "wnd_id": "15694139_2_1", "text": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects .", "tokens": ["Thalidomide", "was", "withdrawn", "from", "world", "markets", "in", "1961", "following", "recognition", "of", "its", "teratogenic", "effects", "."], "event_mentions": [{"id": "15694139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "15694139_2_Ent1", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent2", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15694139_2_Ent1", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15694139_6", "wnd_id": "15694139_6_1", "text": "Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment , in the phenomenon of ' coasting ' .", "tokens": ["Thalidomide", "neuropathy", "is", "often", "associated", "with", "proximal", "weakness", "and", "may", "progress", "even", "after", "discontinuation", "of", "treatment", ",", "in", "the", "phenomenon", "of", "'", "coasting", "'", "."], "event_mentions": [{"id": "15694139_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15694139_6_Ent2", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_6_Ent3", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_6_Ent0", "role": "Effect", "text": "neuropathy", "start": 1, "end": 2}, {"entity_id": "15694139_6_Ent1", "role": "Effect", "text": "proximal weakness", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15694139_6_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_6_Ent3", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_6_Ent0", "text": "neuropathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15694139_6_Ent1", "text": "proximal weakness", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15729090_3", "wnd_id": "15729090_3_1", "text": "A 64 - year - old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine .", "tokens": ["A", "64", "-", "year", "-", "old", "man", "with", "schizophrenia", "developed", "myoclonic", "jerks", "when", "given", "higher", "doses", "of", "quetiapine", "."], "event_mentions": [{"id": "15729090_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "15729090_3_Ent0", "role": "Subject", "text": "A 64 - year - old man with schizophrenia", "start": 0, "end": 9}, {"entity_id": "15729090_3_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 1, "end": 6}, {"entity_id": "15729090_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "15729090_3_Ent5", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 8, "end": 9}, {"entity_id": "15729090_3_Ent3", "role": "Effect", "text": "myoclonic jerks", "start": 10, "end": 12}, {"entity_id": "15729090_3_Ent7", "role": "Treatment_Dosage", "text": "higher doses", "start": 14, "end": 16}, {"entity_id": "15729090_3_Ent4", "role": "Treatment", "text": "higher doses of quetiapine", "start": 14, "end": 18}, {"entity_id": "15729090_3_Ent6", "role": "Treatment_Drug", "text": "quetiapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15729090_3_Ent0", "text": "A 64 - year - old man with schizophrenia", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15729090_3_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15729090_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15729090_3_Ent5", "text": "schizophrenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15729090_3_Ent3", "text": "myoclonic jerks", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15729090_3_Ent7", "text": "higher doses", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15729090_3_Ent4", "text": "higher doses of quetiapine", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15729090_3_Ent6", "text": "quetiapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15760792_2", "wnd_id": "15760792_2_1", "text": "OBJECTIVE : To report the case of a young woman with Graves ' disease in whom ototoxicity developed because of propylthiouracil ( PTU) - induced antineutrophil cytoplasmic antibody ( ANCA) - associated vasculitis .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "case", "of", "a", "young", "woman", "with", "Graves", "'", "disease", "in", "whom", "ototoxicity", "developed", "because", "of", "propylthiouracil", "(", "PTU)", "-", "induced", "antineutrophil", "cytoplasmic", "antibody", "(", "ANCA)", "-", "associated", "vasculitis", "."], "event_mentions": [{"id": "15760792_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 24, "end": 25}, "arguments": [{"entity_id": "15760792_2_Ent1", "role": "Subject_Age", "text": "young", "start": 8, "end": 9}, {"entity_id": "15760792_2_Ent0", "role": "Subject", "text": "young woman with Graves ' disease", "start": 8, "end": 14}, {"entity_id": "15760792_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15760792_2_Ent6", "role": "Treatment_Disorder", "text": "Graves ' disease", "start": 11, "end": 14}, {"entity_id": "15760792_2_Ent3", "role": "Effect", "text": "ototoxicity developed", "start": 16, "end": 18}, {"entity_id": "15760792_2_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 20, "end": 21}, {"entity_id": "15760792_2_Ent4", "role": "Treatment", "text": "propylthiouracil ( PTU)", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "15760792_2_Ent1", "text": "young", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15760792_2_Ent0", "text": "young woman with Graves ' disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "15760792_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15760792_2_Ent6", "text": "Graves ' disease", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15760792_2_Ent3", "text": "ototoxicity developed", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15760792_2_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15760792_2_Ent4", "text": "propylthiouracil ( PTU)", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "15760792_3", "wnd_id": "15760792_3_1", "text": "Propylthiouracil - induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies .", "tokens": ["Propylthiouracil", "-", "induced", "sensorineural", "hearing", "loss", "associated", "with", "antineutrophil", "cytoplasmic", "antibodies", "."], "event_mentions": [{"id": "15760792_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15760792_3_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent0", "role": "Effect", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "start": 3, "end": 11}]}], "entity_mentions": [{"id": "15760792_3_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent0", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "entity_type": "Entity", "start": 3, "end": 11}], "lang": "en"}
{"doc_id": "15770343_2", "wnd_id": "15770343_2_1", "text": "During the anti - tuberculous therapy , visual loss can be related to ethambutol toxicity or the tuberculosis infection itself .", "tokens": ["During", "the", "anti", "-", "tuberculous", "therapy", ",", "visual", "loss", "can", "be", "related", "to", "ethambutol", "toxicity", "or", "the", "tuberculosis", "infection", "itself", "."], "event_mentions": [{"id": "15770343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "15770343_2_Ent0", "role": "Effect", "text": "visual loss", "start": 7, "end": 9}, {"entity_id": "15770343_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis infection", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15770343_2_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15770343_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent3", "text": "tuberculosis infection", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15773973_2", "wnd_id": "15773973_2_1", "text": "It is well - recognized that flucloxacillin may occasionally result in fatal hepatic injury .", "tokens": ["It", "is", "well", "-", "recognized", "that", "flucloxacillin", "may", "occasionally", "result", "in", "fatal", "hepatic", "injury", "."], "event_mentions": [{"id": "15773973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 9, "end": 10}, "arguments": [{"entity_id": "15773973_2_Ent1", "role": "Treatment", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent2", "role": "Treatment_Drug", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent0", "role": "Effect", "text": "hepatic injury", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15773973_2_Ent1", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent2", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent0", "text": "hepatic injury", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15785053_3", "wnd_id": "15785053_3_1", "text": "We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus .", "tokens": ["We", "report", "the", "first", "histopathologically", "documented", "case", "of", "oral", "mucosa", "pigmentation", "after", "OLP", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "15785053_3_Ent0", "role": "Effect", "text": "oral mucosa pigmentation", "start": 8, "end": 11}, {"entity_id": "15785053_3_Ent3", "role": "Treatment_Disorder", "text": "OLP", "start": 12, "end": 13}, {"entity_id": "15785053_3_Ent4", "role": "Treatment_Route", "text": "topical", "start": 15, "end": 16}, {"entity_id": "15785053_3_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 15, "end": 17}, {"entity_id": "15785053_3_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "15785053_3_Ent0", "text": "oral mucosa pigmentation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15785053_3_Ent3", "text": "OLP", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15785053_3_Ent4", "text": "topical", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15785053_3_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15785053_3_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15806568_1", "wnd_id": "15806568_1_1", "text": "In this study , we report on three individual patients who received BTX - B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX - B at remote sites .", "tokens": ["In", "this", "study", ",", "we", "report", "on", "three", "individual", "patients", "who", "received", "BTX", "-", "B", "and", "who", "subsequently", "developed", "parasympathetic", "dysfunction", "of", "the", "visual", "system", "after", "injections", "of", "BTX", "-", "B", "at", "remote", "sites", "."], "event_mentions": [{"id": "15806568_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "15806568_1_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "15806568_1_Ent0", "role": "Subject", "text": "three individual patients", "start": 7, "end": 10}, {"entity_id": "15806568_1_Ent3", "role": "Treatment", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent5", "role": "Treatment_Drug", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent2", "role": "Effect", "text": "parasympathetic dysfunction of the visual system", "start": 19, "end": 25}, {"entity_id": "15806568_1_Ent4", "role": "Treatment", "text": "BTX - B", "start": 28, "end": 31}, {"entity_id": "15806568_1_Ent6", "role": "Treatment_Drug", "text": "BTX - B", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "15806568_1_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15806568_1_Ent0", "text": "three individual patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15806568_1_Ent3", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent5", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent2", "text": "parasympathetic dysfunction of the visual system", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "15806568_1_Ent4", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "15806568_1_Ent6", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "15806568_3", "wnd_id": "15806568_3_1", "text": "Visual system side effects caused by parasympathetic dysfunction after botulinum toxin type B injections .", "tokens": ["Visual", "system", "side", "effects", "caused", "by", "parasympathetic", "dysfunction", "after", "botulinum", "toxin", "type", "B", "injections", "."], "event_mentions": [{"id": "15806568_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "15806568_3_Ent0", "role": "Effect", "text": "Visual system side effects caused by parasympathetic dysfunction", "start": 0, "end": 8}, {"entity_id": "15806568_3_Ent2", "role": "Treatment_Drug", "text": "botulinum toxin type B", "start": 9, "end": 13}, {"entity_id": "15806568_3_Ent1", "role": "Treatment", "text": "botulinum toxin type B injections", "start": 9, "end": 14}, {"entity_id": "15806568_3_Ent3", "role": "Treatment_Route", "text": "injections", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15806568_3_Ent0", "text": "Visual system side effects caused by parasympathetic dysfunction", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15806568_3_Ent2", "text": "botulinum toxin type B", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15806568_3_Ent1", "text": "botulinum toxin type B injections", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15806568_3_Ent3", "text": "injections", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15823103_1", "wnd_id": "15823103_1_1", "text": "Carboplatin hypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer .", "tokens": ["Carboplatin", "hypersensitivity", "induced", "by", "low", "-", "dose", "paclitaxel", "/", "carboplatin", "in", "multiple", "platinum", "-", "treated", "patients", "with", "recurrent", "ovarian", "cancer", "."], "event_mentions": [{"id": "15823103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15823103_1_Ent1", "role": "Effect", "text": "Carboplatin hypersensitivity", "start": 0, "end": 2}, {"entity_id": "15823103_1_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 4, "end": 7}, {"entity_id": "15823103_1_Ent2", "role": "Treatment", "text": "low - dose paclitaxel / carboplatin", "start": 4, "end": 10}, {"entity_id": "15823103_1_Ent3", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent8", "role": "Combination_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent9", "role": "Combination_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent0", "role": "Subject", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "start": 11, "end": 20}, {"entity_id": "15823103_1_Ent5", "role": "Treatment_Drug", "text": "platinum", "start": 12, "end": 13}, {"entity_id": "15823103_1_Ent7", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "15823103_1_Ent1", "text": "Carboplatin hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15823103_1_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15823103_1_Ent2", "text": "low - dose paclitaxel / carboplatin", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15823103_1_Ent3", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent8", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent9", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent0", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15823103_1_Ent5", "text": "platinum", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15823103_1_Ent7", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "15823103_4", "wnd_id": "15823103_4_1", "text": "We report five cases of carboplatin ( CBDCA ) hypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy .", "tokens": ["We", "report", "five", "cases", "of", "carboplatin", "(", "CBDCA", ")", "hypersensitivity", "after", "weekly", "low", "-", "dose", "paclitaxel", "(", "60", "mg", "/", "m2)/CBDCA", "(", "area", "under", "the", "concentration", "curve", "=", "2", ")", "therapy", "in", "patients", "with", "recurrent", "ovarian", "cancer", "receiving", "multiple", "platinum", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "15823103_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "15823103_4_Ent1", "role": "Subject_Population", "text": "five", "start": 2, "end": 3}, {"entity_id": "15823103_4_Ent7", "role": "Treatment_Drug", "text": "carboplatin", "start": 5, "end": 6}, {"entity_id": "15823103_4_Ent2", "role": "Effect", "text": "carboplatin ( CBDCA ) hypersensitivity", "start": 5, "end": 10}, {"entity_id": "15823103_4_Ent11", "role": "Treatment_Freq", "text": "weekly", "start": 11, "end": 12}, {"entity_id": "15823103_4_Ent3", "role": "Treatment", "text": "weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy", "start": 11, "end": 31}, {"entity_id": "15823103_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 12, "end": 15}, {"entity_id": "15823103_4_Ent5", "role": "Treatment_Drug", "text": "paclitaxel", "start": 15, "end": 16}, {"entity_id": "15823103_4_Ent14", "role": "Combination_Drug", "text": "paclitaxel", "start": 15, "end": 16}, {"entity_id": "15823103_4_Ent10", "role": "Treatment_Dosage", "text": "60 mg / m2)/CBDCA", "start": 17, "end": 21}, {"entity_id": "15823103_4_Ent6", "role": "Treatment_Drug", "text": "m2)/CBDCA", "start": 20, "end": 21}, {"entity_id": "15823103_4_Ent15", "role": "Combination_Drug", "text": "m2)/CBDCA", "start": 20, "end": 21}, {"entity_id": "15823103_4_Ent0", "role": "Subject", "text": "patients with recurrent ovarian cancer", "start": 32, "end": 37}, {"entity_id": "15823103_4_Ent12", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 34, "end": 37}, {"entity_id": "15823103_4_Ent4", "role": "Treatment", "text": "multiple platinum - based chemotherapy", "start": 38, "end": 43}, {"entity_id": "15823103_4_Ent8", "role": "Treatment_Drug", "text": "platinum", "start": 39, "end": 40}, {"entity_id": "15823103_4_Ent16", "role": "Combination_Drug", "text": "platinum", "start": 39, "end": 40}, {"entity_id": "15823103_4_Ent13", "role": "Treatment_Route", "text": "chemotherapy", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "15823103_4_Ent1", "text": "five", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15823103_4_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15823103_4_Ent2", "text": "carboplatin ( CBDCA ) hypersensitivity", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15823103_4_Ent11", "text": "weekly", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15823103_4_Ent3", "text": "weekly low - dose paclitaxel ( 60 mg / m2)/CBDCA ( area under the concentration curve = 2 ) therapy", "entity_type": "Entity", "start": 11, "end": 31}, {"id": "15823103_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15823103_4_Ent5", "text": "paclitaxel", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15823103_4_Ent14", "text": "paclitaxel", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15823103_4_Ent10", "text": "60 mg / m2)/CBDCA", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "15823103_4_Ent6", "text": "m2)/CBDCA", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15823103_4_Ent15", "text": "m2)/CBDCA", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15823103_4_Ent0", "text": "patients with recurrent ovarian cancer", "entity_type": "Entity", "start": 32, "end": 37}, {"id": "15823103_4_Ent12", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 34, "end": 37}, {"id": "15823103_4_Ent4", "text": "multiple platinum - based chemotherapy", "entity_type": "Entity", "start": 38, "end": 43}, {"id": "15823103_4_Ent8", "text": "platinum", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15823103_4_Ent16", "text": "platinum", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15823103_4_Ent13", "text": "chemotherapy", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "15827071_10", "wnd_id": "15827071_10_1", "text": "The following day , the patient developed anxiety , panic attacks , tremors , tachycardia , and hypertension that persisted throughout linezolid treatment .", "tokens": ["The", "following", "day", ",", "the", "patient", "developed", "anxiety", ",", "panic", "attacks", ",", "tremors", ",", "tachycardia", ",", "and", "hypertension", "that", "persisted", "throughout", "linezolid", "treatment", "."], "event_mentions": [{"id": "15827071_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "15827071_10_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "15827071_10_Ent1", "role": "Effect", "text": "anxiety , panic attacks , tremors , tachycardia , and hypertension", "start": 7, "end": 18}, {"entity_id": "15827071_10_Ent2", "role": "Treatment", "text": "linezolid", "start": 21, "end": 22}, {"entity_id": "15827071_10_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15827071_10_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15827071_10_Ent1", "text": "anxiety , panic attacks , tremors , tachycardia , and hypertension", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "15827071_10_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15827071_10_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15827071_13", "wnd_id": "15827071_13_1", "text": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid , generally within 1 - 3 days .", "tokens": ["A", "review", "of", "published", "case", "reports", "showed", "a", "short", "time", "to", "onset", "of", "symptoms", "following", "the", "introduction", "of", "linezolid", ",", "generally", "within", "1", "-", "3", "days", "."], "event_mentions": [{"id": "15827071_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 14, "end": 15}, "arguments": [{"entity_id": "15827071_13_Ent0", "role": "Effect", "text": "a short time to onset of symptoms", "start": 7, "end": 14}, {"entity_id": "15827071_13_Ent1", "role": "Treatment", "text": "introduction of linezolid , generally within 1 - 3 days", "start": 16, "end": 26}, {"entity_id": "15827071_13_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 18, "end": 19}, {"entity_id": "15827071_13_Ent3", "role": "Treatment_Time_elapsed", "text": "within 1 - 3 days", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "15827071_13_Ent0", "text": "a short time to onset of symptoms", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15827071_13_Ent1", "text": "introduction of linezolid , generally within 1 - 3 days", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15827071_13_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15827071_13_Ent3", "text": "within 1 - 3 days", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "15827071_4", "wnd_id": "15827071_4_1", "text": "A 38 - year - old white female with cystic fibrosis treated with venlafaxine 300 mg / day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection .", "tokens": ["A", "38", "-", "year", "-", "old", "white", "female", "with", "cystic", "fibrosis", "treated", "with", "venlafaxine", "300", "mg", "/", "day", "for", "one", "year", "was", "prescribed", "linezolid", "600", "mg", "intravenously", "every", "12", "hours", "for", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "(", "MRSA", ")", "pulmonary", "infection", "."], "event_mentions": [{"id": "15827071_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15827071_4_Ent0", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent1", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent5", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 9, "end": 11}, {"entity_id": "15827071_4_Ent7", "role": "Treatment_Drug", "text": "venlafaxine", "start": 13, "end": 14}, {"entity_id": "15827071_4_Ent4", "role": "Treatment", "text": "venlafaxine 300 mg / day for one year", "start": 13, "end": 21}, {"entity_id": "15827071_4_Ent6", "role": "Treatment_Dosage", "text": "300 mg / day", "start": 14, "end": 18}, {"entity_id": "15827071_4_Ent8", "role": "Treatment_Duration", "text": "one year", "start": 19, "end": 21}]}, {"id": "15827071_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 31, "end": 32}, "arguments": [{"entity_id": "15827071_4_Ent9", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent10", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent11", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent12", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent15", "role": "Treatment_Drug", "text": "linezolid", "start": 23, "end": 24}, {"entity_id": "15827071_4_Ent13", "role": "Treatment", "text": "linezolid 600 mg intravenously every 12 hours", "start": 23, "end": 30}, {"entity_id": "15827071_4_Ent16", "role": "Treatment_Dosage", "text": "600 mg", "start": 24, "end": 26}, {"entity_id": "15827071_4_Ent18", "role": "Treatment_Route", "text": "intravenously", "start": 26, "end": 27}, {"entity_id": "15827071_4_Ent17", "role": "Treatment_Freq", "text": "every 12 hours", "start": 27, "end": 30}, {"entity_id": "15827071_4_Ent14", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "start": 33, "end": 43}]}], "entity_mentions": [{"id": "15827071_4_Ent0", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent9", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent1", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent10", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent11", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent12", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent5", "text": "cystic fibrosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15827071_4_Ent7", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15827071_4_Ent4", "text": "venlafaxine 300 mg / day for one year", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "15827071_4_Ent6", "text": "300 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15827071_4_Ent8", "text": "one year", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15827071_4_Ent15", "text": "linezolid", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15827071_4_Ent13", "text": "linezolid 600 mg intravenously every 12 hours", "entity_type": "Entity", "start": 23, "end": 30}, {"id": "15827071_4_Ent16", "text": "600 mg", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15827071_4_Ent18", "text": "intravenously", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15827071_4_Ent17", "text": "every 12 hours", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "15827071_4_Ent14", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "entity_type": "Entity", "start": 33, "end": 43}], "lang": "en"}
{"doc_id": "15840734_2", "wnd_id": "15840734_2_1", "text": "OBJECTIVE : To report a case of neuroleptic malignant syndrome ( NMS ) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "(", "NMS", ")", "associated", "with", "fluphenazine", "in", "a", "schizophrenic", "patient", "and", "review", "the", "literature", "related", "to", "this", "condition", "."], "event_mentions": [{"id": "15840734_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "15840734_2_Ent1", "role": "Effect", "text": "a case of neuroleptic malignant syndrome ( NMS )", "start": 4, "end": 13}, {"entity_id": "15840734_2_Ent2", "role": "Treatment", "text": "fluphenazine", "start": 15, "end": 16}, {"entity_id": "15840734_2_Ent4", "role": "Treatment_Drug", "text": "fluphenazine", "start": 15, "end": 16}, {"entity_id": "15840734_2_Ent3", "role": "Treatment_Disorder", "text": "schizophrenic", "start": 18, "end": 19}, {"entity_id": "15840734_2_Ent0", "role": "Subject", "text": "schizophrenic patient", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "15840734_2_Ent1", "text": "a case of neuroleptic malignant syndrome ( NMS )", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15840734_2_Ent2", "text": "fluphenazine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15840734_2_Ent4", "text": "fluphenazine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15840734_2_Ent3", "text": "schizophrenic", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15840734_2_Ent0", "text": "schizophrenic patient", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "1584367_2", "wnd_id": "1584367_2_1", "text": "We propose a mechanism of vancomycin - induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE .", "tokens": ["We", "propose", "a", "mechanism", "of", "vancomycin", "-", "induced", "mast", "cell", "degranulation", "and", "subsequent", "release", "of", "eosinophil", "chemotactic", "factor", "as", "a", "cause", "of", "CSFE", "."], "event_mentions": [{"id": "1584367_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1584367_2_Ent1", "role": "Treatment", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent0", "role": "Effect", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "start": 8, "end": 23}]}], "entity_mentions": [{"id": "1584367_2_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent0", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "entity_type": "Entity", "start": 8, "end": 23}], "lang": "en"}
{"doc_id": "15878975_4", "wnd_id": "15878975_4_1", "text": "The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti - D IGIV treatment .", "tokens": ["The", "purpose", "of", "this", "review", "is", "to", "increase", "awareness", "among", "physicians", "and", "other", "health", "care", "professionals", "that", "DIC", "may", "be", "a", "rare", "but", "potentially", "severe", "complication", "of", "anti", "-", "D", "IGIV", "treatment", "."], "event_mentions": [{"id": "15878975_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 25, "end": 26}, "arguments": [{"entity_id": "15878975_4_Ent0", "role": "Effect", "text": "DIC", "start": 17, "end": 18}, {"entity_id": "15878975_4_Ent1", "role": "Treatment", "text": "anti - D IGIV", "start": 27, "end": 31}, {"entity_id": "15878975_4_Ent2", "role": "Treatment_Drug", "text": "anti - D IGIV", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "15878975_4_Ent0", "text": "DIC", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15878975_4_Ent1", "text": "anti - D IGIV", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "15878975_4_Ent2", "text": "anti - D IGIV", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "15895899_2", "wnd_id": "15895899_2_1", "text": "Drug - induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy .", "tokens": ["Drug", "-", "induced", "agranulocytosis", "during", "treatment", "with", "infliximab", "in", "enteropathic", "spondyloarthropathy", "."], "event_mentions": [{"id": "15895899_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15895899_2_Ent0", "role": "Effect", "text": "Drug - induced agranulocytosis", "start": 0, "end": 4}, {"entity_id": "15895899_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent3", "role": "Treatment_Disorder", "text": "enteropathic spondyloarthropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15895899_2_Ent0", "text": "Drug - induced agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15895899_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent3", "text": "enteropathic spondyloarthropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15895899_3", "wnd_id": "15895899_3_1", "text": "These data indicated that infliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis .", "tokens": ["These", "data", "indicated", "that", "infliximab", "possibly", "triggered", "production", "of", "granulocyte", "and", "neutrophil", "autoantibodies", "with", "resultant", "autoimmune", "agranulocytosis", "."], "event_mentions": [{"id": "15895899_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 6, "end": 7}, "arguments": [{"entity_id": "15895899_3_Ent1", "role": "Treatment", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "15895899_3_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 4, "end": 5}, {"entity_id": "15895899_3_Ent0", "role": "Effect", "text": "production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "15895899_3_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_3_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_3_Ent0", "text": "production of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "15907341_2", "wnd_id": "15907341_2_1", "text": "Six patients developed peripheral neuropathy and five patients bone marrow depression , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of linezolid .", "tokens": ["Six", "patients", "developed", "peripheral", "neuropathy", "and", "five", "patients", "bone", "marrow", "depression", ",", "blood", "transfusions", "were", "given", "to", "three", "patients", "and", "in", "all", "five", "patients", "bone", "marrow", "function", "normalized", "after", "cessation", "of", "linezolid", "."], "event_mentions": [{"id": "15907341_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15907341_2_Ent6", "role": "Subject_Population", "text": "Six", "start": 0, "end": 1}, {"entity_id": "15907341_2_Ent5", "role": "Subject", "text": "Six patients", "start": 0, "end": 2}, {"entity_id": "15907341_2_Ent7", "role": "Effect", "text": "peripheral neuropathy", "start": 3, "end": 5}, {"entity_id": "15907341_2_Ent8", "role": "Treatment", "text": "linezolid", "start": 31, "end": 32}, {"entity_id": "15907341_2_Ent9", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15907341_2_Ent11", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "15907341_2_Ent10", "role": "Subject", "text": "five patients", "start": 6, "end": 8}, {"entity_id": "15907341_2_Ent12", "role": "Effect", "text": "bone marrow depression", "start": 8, "end": 11}, {"entity_id": "15907341_2_Ent13", "role": "Treatment", "text": "linezolid", "start": 31, "end": 32}, {"entity_id": "15907341_2_Ent14", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt3", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 15, "end": 16}, "arguments": [{"entity_id": "15907341_2_Ent17", "role": "Treatment", "text": "blood transfusions", "start": 12, "end": 14}, {"entity_id": "15907341_2_Ent16", "role": "Subject_Population", "text": "three", "start": 17, "end": 18}, {"entity_id": "15907341_2_Ent15", "role": "Subject", "text": "three patients", "start": 17, "end": 19}, {"entity_id": "15907341_2_Ent18", "role": "Treatment", "text": "cessation of linezolid", "start": 29, "end": 32}, {"entity_id": "15907341_2_Ent19", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}, {"id": "15907341_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "normalized", "start": 27, "end": 28}, "arguments": [{"entity_id": "15907341_2_Ent3", "role": "Treatment_Disorder", "text": "bone marrow depression", "start": 8, "end": 11}, {"entity_id": "15907341_2_Ent0", "role": "Subject", "text": "all five patients", "start": 21, "end": 24}, {"entity_id": "15907341_2_Ent1", "role": "Subject_Population", "text": "five", "start": 22, "end": 23}, {"entity_id": "15907341_2_Ent2", "role": "Treatment", "text": "cessation of linezolid", "start": 29, "end": 32}, {"entity_id": "15907341_2_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "15907341_2_Ent6", "text": "Six", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15907341_2_Ent5", "text": "Six patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15907341_2_Ent7", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15907341_2_Ent11", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15907341_2_Ent10", "text": "five patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15907341_2_Ent3", "text": "bone marrow depression", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15907341_2_Ent12", "text": "bone marrow depression", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15907341_2_Ent17", "text": "blood transfusions", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "15907341_2_Ent16", "text": "three", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15907341_2_Ent15", "text": "three patients", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "15907341_2_Ent0", "text": "all five patients", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "15907341_2_Ent1", "text": "five", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15907341_2_Ent2", "text": "cessation of linezolid", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "15907341_2_Ent18", "text": "cessation of linezolid", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "15907341_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent8", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent9", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent13", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent14", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15907341_2_Ent19", "text": "linezolid", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "15944830_6", "wnd_id": "15944830_6_1", "text": "With the use of optical coherence tomography ( OCT ) , two patients with IFN - associated retinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed .", "tokens": ["With", "the", "use", "of", "optical", "coherence", "tomography", "(", "OCT", ")", ",", "two", "patients", "with", "IFN", "-", "associated", "retinopathy", "who", "had", "developed", "macular", "edema", "and", "reduced", "visual", "acuity", "during", "the", "clinical", "course", "of", "IFN", "therapy", "were", "observed", "."], "event_mentions": [{"id": "15944830_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "15944830_6_Ent2", "role": "Treatment", "text": "IFN", "start": 14, "end": 15}, {"entity_id": "15944830_6_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 14, "end": 15}, {"entity_id": "15944830_6_Ent0", "role": "Effect", "text": "retinopathy", "start": 17, "end": 18}, {"entity_id": "15944830_6_Ent1", "role": "Effect", "text": "macular edema and reduced visual acuity", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "15944830_6_Ent2", "text": "IFN", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15944830_6_Ent3", "text": "IFN", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15944830_6_Ent0", "text": "retinopathy", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15944830_6_Ent1", "text": "macular edema and reduced visual acuity", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "15961942_2", "wnd_id": "15961942_2_1", "text": "OBJECTIVE : To report the late development of immune - mediated diabetes mellitus after completion of alfa - interferon therapy for hepatitis C in an Asian patient .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "late", "development", "of", "immune", "-", "mediated", "diabetes", "mellitus", "after", "completion", "of", "alfa", "-", "interferon", "therapy", "for", "hepatitis", "C", "in", "an", "Asian", "patient", "."], "event_mentions": [{"id": "15961942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "15961942_2_Ent2", "role": "Effect", "text": "the late development of immune - mediated diabetes mellitus", "start": 4, "end": 13}, {"entity_id": "15961942_2_Ent3", "role": "Treatment", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent4", "role": "Treatment_Drug", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 21, "end": 23}, {"entity_id": "15961942_2_Ent0", "role": "Subject", "text": "an Asian patient", "start": 24, "end": 27}, {"entity_id": "15961942_2_Ent1", "role": "Subject_Race", "text": "Asian", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15961942_2_Ent2", "text": "the late development of immune - mediated diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15961942_2_Ent3", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent4", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15961942_2_Ent0", "text": "an Asian patient", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "15961942_2_Ent1", "text": "Asian", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15977922_3", "wnd_id": "15977922_3_1", "text": "We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis , tegaserod use , and irritable bowel syndrome .", "tokens": ["We", "describe", "the", "development", "of", "ischemic", "colitis", "in", "a", "woman", "who", "was", "treated", "with", "tegaserod", "and", "review", "the", "relationship", "among", "ischemic", "colitis", ",", "tegaserod", "use", ",", "and", "irritable", "bowel", "syndrome", "."], "event_mentions": [{"id": "15977922_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 3, "end": 4}, "arguments": [{"entity_id": "15977922_3_Ent2", "role": "Effect", "text": "ischemic colitis", "start": 5, "end": 7}, {"entity_id": "15977922_3_Ent0", "role": "Subject", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "15977922_3_Ent3", "role": "Treatment", "text": "tegaserod", "start": 14, "end": 15}, {"entity_id": "15977922_3_Ent4", "role": "Treatment_Drug", "text": "tegaserod", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15977922_3_Ent2", "text": "ischemic colitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15977922_3_Ent0", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15977922_3_Ent3", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15977922_3_Ent4", "text": "tegaserod", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16001348_2", "wnd_id": "16001348_2_1", "text": "A 57 - year - old man developed chronic , watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease .", "tokens": ["A", "57", "-", "year", "-", "old", "man", "developed", "chronic", ",", "watery", "diarrhea", "four", "weeks", "after", "Helicobacter", "pylori", "eradication", "therapy", "including", "lansoprazole", "followed", "by", "lansoprazole", "monotherapy", "for", "gastroesophageal", "reflux", "disease", "."], "event_mentions": [{"id": "16001348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16001348_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "16001348_2_Ent0", "role": "Subject", "text": "57 - year - old man", "start": 1, "end": 7}, {"entity_id": "16001348_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "16001348_2_Ent3", "role": "Effect", "text": "chronic , watery diarrhea", "start": 8, "end": 12}, {"entity_id": "16001348_2_Ent8", "role": "Treatment_Time_elapsed", "text": "four weeks", "start": 12, "end": 14}, {"entity_id": "16001348_2_Ent4", "role": "Treatment", "text": "four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "start": 12, "end": 29}, {"entity_id": "16001348_2_Ent6", "role": "Treatment_Drug", "text": "lansoprazole", "start": 20, "end": 21}, {"entity_id": "16001348_2_Ent9", "role": "Combination_Drug", "text": "lansoprazole", "start": 20, "end": 21}, {"entity_id": "16001348_2_Ent7", "role": "Treatment_Drug", "text": "lansoprazole", "start": 23, "end": 24}, {"entity_id": "16001348_2_Ent10", "role": "Combination_Drug", "text": "lansoprazole", "start": 23, "end": 24}, {"entity_id": "16001348_2_Ent5", "role": "Treatment_Disorder", "text": "gastroesophageal reflux disease", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "16001348_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16001348_2_Ent0", "text": "57 - year - old man", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16001348_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16001348_2_Ent3", "text": "chronic , watery diarrhea", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "16001348_2_Ent8", "text": "four weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16001348_2_Ent4", "text": "four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "16001348_2_Ent6", "text": "lansoprazole", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16001348_2_Ent9", "text": "lansoprazole", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16001348_2_Ent7", "text": "lansoprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16001348_2_Ent10", "text": "lansoprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16001348_2_Ent5", "text": "gastroesophageal reflux disease", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "16005413_2", "wnd_id": "16005413_2_1", "text": "To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome ( SS ) , mechanism of the interaction , and the spectrum of SS in elderly residents of a long - term care facility .", "tokens": ["To", "describe", "the", "potential", "for", "interaction", "between", "opioids", "and", "serotonergic", "antidepressants", "leading", "to", "the", "development", "of", "serotonin", "syndrome", "(", "SS", ")", ",", "mechanism", "of", "the", "interaction", ",", "and", "the", "spectrum", "of", "SS", "in", "elderly", "residents", "of", "a", "long", "-", "term", "care", "facility", "."], "event_mentions": [{"id": "16005413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 11, "end": 12}, "arguments": [{"entity_id": "16005413_2_Ent3", "role": "Treatment", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent5", "role": "Treatment_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent7", "role": "Combination_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent4", "role": "Treatment", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent6", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent8", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 16, "end": 18}, {"entity_id": "16005413_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 33, "end": 34}, {"entity_id": "16005413_2_Ent0", "role": "Subject", "text": "elderly residents", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "16005413_2_Ent3", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent5", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent7", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent4", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent8", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16005413_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "16005413_2_Ent0", "text": "elderly residents", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "16005413_9", "wnd_id": "16005413_9_1", "text": "While many can benefit from coadministration of serotonergic antidepressants and opioids , it appears that some individuals are at increased risk for SS .", "tokens": ["While", "many", "can", "benefit", "from", "coadministration", "of", "serotonergic", "antidepressants", "and", "opioids", ",", "it", "appears", "that", "some", "individuals", "are", "at", "increased", "risk", "for", "SS", "."], "event_mentions": [{"id": "16005413_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 20, "end": 21}, "arguments": [{"entity_id": "16005413_9_Ent2", "role": "Treatment", "text": "coadministration of serotonergic antidepressants and opioids", "start": 5, "end": 11}, {"entity_id": "16005413_9_Ent3", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent6", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent4", "role": "Treatment_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent5", "role": "Combination_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent0", "role": "Subject", "text": "some individuals", "start": 15, "end": 17}, {"entity_id": "16005413_9_Ent1", "role": "Effect", "text": "SS", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16005413_9_Ent2", "text": "coadministration of serotonergic antidepressants and opioids", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16005413_9_Ent3", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent4", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent5", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent0", "text": "some individuals", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16005413_9_Ent1", "text": "SS", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16008658_1", "wnd_id": "16008658_1_1", "text": "46 - year - old woman developed painful ulcers over her lower abdomen in the form of reticulate erythema after injecting interferon beta - 1b subcutaneously for multiple sclerosis .", "tokens": ["46", "-", "year", "-", "old", "woman", "developed", "painful", "ulcers", "over", "her", "lower", "abdomen", "in", "the", "form", "of", "reticulate", "erythema", "after", "injecting", "interferon", "beta", "-", "1b", "subcutaneously", "for", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16008658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "16008658_1_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 0, "end": 5}, {"entity_id": "16008658_1_Ent0", "role": "Subject", "text": "46 - year - old woman", "start": 0, "end": 6}, {"entity_id": "16008658_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "16008658_1_Ent3", "role": "Effect", "text": "painful ulcers over her lower abdomen in the form of reticulate erythema", "start": 7, "end": 19}, {"entity_id": "16008658_1_Ent6", "role": "Treatment_Route", "text": "injecting", "start": 20, "end": 21}, {"entity_id": "16008658_1_Ent4", "role": "Treatment", "text": "injecting interferon beta - 1b subcutaneously", "start": 20, "end": 26}, {"entity_id": "16008658_1_Ent5", "role": "Treatment_Drug", "text": "interferon beta - 1b", "start": 21, "end": 25}, {"entity_id": "16008658_1_Ent7", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "16008658_1_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16008658_1_Ent0", "text": "46 - year - old woman", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "16008658_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16008658_1_Ent3", "text": "painful ulcers over her lower abdomen in the form of reticulate erythema", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "16008658_1_Ent6", "text": "injecting", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16008658_1_Ent4", "text": "injecting interferon beta - 1b subcutaneously", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "16008658_1_Ent5", "text": "interferon beta - 1b", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16008658_1_Ent7", "text": "multiple sclerosis", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "16018164_4", "wnd_id": "16018164_4_1", "text": "Since 1979 , over 30 published case reports have documented the relationship between phenylpropanolamine and stroke .", "tokens": ["Since", "1979", ",", "over", "30", "published", "case", "reports", "have", "documented", "the", "relationship", "between", "phenylpropanolamine", "and", "stroke", "."], "event_mentions": [{"id": "16018164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 11, "end": 12}, "arguments": [{"entity_id": "16018164_4_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent0", "role": "Effect", "text": "stroke", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_4_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent0", "text": "stroke", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1602800_1", "wnd_id": "1602800_1_1", "text": "Pulmonary leukostasis secondary to all - trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse .", "tokens": ["Pulmonary", "leukostasis", "secondary", "to", "all", "-", "trans", "retinoic", "acid", "in", "the", "treatment", "of", "acute", "promyelocytic", "leukemia", "in", "first", "relapse", "."], "event_mentions": [{"id": "1602800_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "1602800_1_Ent0", "role": "Effect", "text": "Pulmonary leukostasis", "start": 0, "end": 2}, {"entity_id": "1602800_1_Ent1", "role": "Treatment", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "1602800_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 4, "end": 9}, {"entity_id": "1602800_1_Ent2", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia in first relapse", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "1602800_1_Ent0", "text": "Pulmonary leukostasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1602800_1_Ent1", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1602800_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1602800_1_Ent2", "text": "acute promyelocytic leukemia in first relapse", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "16029707_2", "wnd_id": "16029707_2_1", "text": "METHODS : A 79 - year - old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy .", "tokens": ["METHODS", ":", "A", "79", "-", "year", "-", "old", "woman", "being", "treated", "with", "imiquimod", "5", "days", "per", "week", "for", "a", "nodular", "basal", "cell", "developed", "a", "verrucous", "plaque", "over", "the", "treatment", "area", "after", "7", "weeks", "of", "therapy", "."], "event_mentions": [{"id": "16029707_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "16029707_2_Ent0", "role": "Subject", "text": "A 79 - year - old woman", "start": 2, "end": 9}, {"entity_id": "16029707_2_Ent1", "role": "Subject_Age", "text": "79 - year - old", "start": 3, "end": 8}, {"entity_id": "16029707_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "16029707_2_Ent7", "role": "Treatment_Drug", "text": "imiquimod", "start": 12, "end": 13}, {"entity_id": "16029707_2_Ent4", "role": "Treatment", "text": "imiquimod 5 days per week", "start": 12, "end": 17}, {"entity_id": "16029707_2_Ent8", "role": "Treatment_Freq", "text": "5 days per week", "start": 13, "end": 17}, {"entity_id": "16029707_2_Ent6", "role": "Treatment_Disorder", "text": "nodular basal cell", "start": 19, "end": 22}, {"entity_id": "16029707_2_Ent3", "role": "Effect", "text": "verrucous plaque", "start": 24, "end": 26}, {"entity_id": "16029707_2_Ent5", "role": "Treatment", "text": "after 7 weeks", "start": 30, "end": 33}, {"entity_id": "16029707_2_Ent9", "role": "Treatment_Time_elapsed", "text": "7 weeks", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "16029707_2_Ent0", "text": "A 79 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "16029707_2_Ent1", "text": "79 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16029707_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16029707_2_Ent7", "text": "imiquimod", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16029707_2_Ent4", "text": "imiquimod 5 days per week", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "16029707_2_Ent8", "text": "5 days per week", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16029707_2_Ent6", "text": "nodular basal cell", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16029707_2_Ent3", "text": "verrucous plaque", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "16029707_2_Ent5", "text": "after 7 weeks", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "16029707_2_Ent9", "text": "7 weeks", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "16029707_3", "wnd_id": "16029707_3_1", "text": "The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy .", "tokens": ["The", "multiple", "comedones", "and", "ruptured", "epidermoid", "cysts", "are", "newly", "reported", "adverse", "effects", "of", "imiquimod", "therapy", "."], "event_mentions": [{"id": "16029707_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "16029707_3_Ent0", "role": "Effect", "text": "multiple comedones and ruptured epidermoid cysts", "start": 1, "end": 7}, {"entity_id": "16029707_3_Ent2", "role": "Treatment_Drug", "text": "imiquimod", "start": 13, "end": 14}, {"entity_id": "16029707_3_Ent1", "role": "Treatment", "text": "imiquimod therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16029707_3_Ent0", "text": "multiple comedones and ruptured epidermoid cysts", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16029707_3_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16029707_3_Ent1", "text": "imiquimod therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16062101_4", "wnd_id": "16062101_4_1", "text": "The authors think that although lamivudine is widely used and well tolerated , it can cause ADRs , which are reversible after drug withdrawal .", "tokens": ["The", "authors", "think", "that", "although", "lamivudine", "is", "widely", "used", "and", "well", "tolerated", ",", "it", "can", "cause", "ADRs", ",", "which", "are", "reversible", "after", "drug", "withdrawal", "."], "event_mentions": [{"id": "16062101_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "16062101_4_Ent1", "role": "Treatment", "text": "lamivudine", "start": 5, "end": 6}, {"entity_id": "16062101_4_Ent2", "role": "Treatment_Drug", "text": "lamivudine", "start": 5, "end": 6}, {"entity_id": "16062101_4_Ent0", "role": "Effect", "text": "ADRs", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16062101_4_Ent1", "text": "lamivudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16062101_4_Ent2", "text": "lamivudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16062101_4_Ent0", "text": "ADRs", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16116136_4", "wnd_id": "16116136_4_1", "text": "Primary CNS lymphoma regressed on withdrawal of MM .", "tokens": ["Primary", "CNS", "lymphoma", "regressed", "on", "withdrawal", "of", "MM", "."], "event_mentions": [{"id": "16116136_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "regressed", "start": 3, "end": 4}, "arguments": [{"entity_id": "16116136_4_Ent0", "role": "Effect", "text": "Primary CNS lymphoma", "start": 0, "end": 3}, {"entity_id": "16116136_4_Ent1", "role": "Treatment", "text": "withdrawal of MM", "start": 5, "end": 8}, {"entity_id": "16116136_4_Ent2", "role": "Treatment_Drug", "text": "MM", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16116136_4_Ent0", "text": "Primary CNS lymphoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16116136_4_Ent1", "text": "withdrawal of MM", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16116136_4_Ent2", "text": "MM", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16119501_2", "wnd_id": "16119501_2_1", "text": "Baclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit .", "tokens": ["Baclofen", "withdrawal", "syndrome", "resulting", "from", "underdosing", "of", "oral", "baclofen", "should", "be", "considered", "as", "a", "potential", "source", "of", "prolonged", "fever", "in", "the", "intensive", "care", "unit", "."], "event_mentions": [{"id": "16119501_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "16119501_2_Ent0", "role": "Effect", "text": "Baclofen withdrawal syndrome", "start": 0, "end": 3}, {"entity_id": "16119501_2_Ent2", "role": "Treatment", "text": "underdosing of oral baclofen", "start": 5, "end": 9}, {"entity_id": "16119501_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 7, "end": 8}, {"entity_id": "16119501_2_Ent4", "role": "Treatment_Drug", "text": "baclofen", "start": 8, "end": 9}, {"entity_id": "16119501_2_Ent1", "role": "Effect", "text": "prolonged fever in the intensive care unit", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "16119501_2_Ent0", "text": "Baclofen withdrawal syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16119501_2_Ent2", "text": "underdosing of oral baclofen", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16119501_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16119501_2_Ent4", "text": "baclofen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16119501_2_Ent1", "text": "prolonged fever in the intensive care unit", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "16132305_2", "wnd_id": "16132305_2_1", "text": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia .", "tokens": ["We", "report", "a", "case", "of", "an", "infant", "with", "complex", "congenital", "heart", "disease", "who", "was", "placed", "on", "captopril", "for", "afterload", "reduction", "following", "cardiac", "surgery", "and", "subsequently", "developed", "pulmonary", "infiltrates", "with", "eosinophilia", "."], "event_mentions": [{"id": "16132305_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "16132305_2_Ent0", "role": "Subject", "text": "an infant with complex congenital heart disease", "start": 5, "end": 12}, {"entity_id": "16132305_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "16132305_2_Ent5", "role": "Treatment_Disorder", "text": "congenital heart disease", "start": 9, "end": 12}, {"entity_id": "16132305_2_Ent3", "role": "Treatment", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "16132305_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "16132305_2_Ent2", "role": "Effect", "text": "pulmonary infiltrates with eosinophilia", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "16132305_2_Ent0", "text": "an infant with complex congenital heart disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "16132305_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_2_Ent5", "text": "congenital heart disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16132305_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16132305_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16132305_2_Ent2", "text": "pulmonary infiltrates with eosinophilia", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "16146480_2", "wnd_id": "16146480_2_1", "text": "Since elevated cortisol levels in Cushing 's disease poses a threat for pancreatitis , there is a possibility that patients with Cushing 's disease might be more prone to acute pancreatitis following propofol administration .", "tokens": ["Since", "elevated", "cortisol", "levels", "in", "Cushing", "'s", "disease", "poses", "a", "threat", "for", "pancreatitis", ",", "there", "is", "a", "possibility", "that", "patients", "with", "Cushing", "'s", "disease", "might", "be", "more", "prone", "to", "acute", "pancreatitis", "following", "propofol", "administration", "."], "event_mentions": [{"id": "16146480_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 31, "end": 32}, "arguments": [{"entity_id": "16146480_2_Ent0", "role": "Subject", "text": "patients with Cushing 's disease", "start": 19, "end": 24}, {"entity_id": "16146480_2_Ent4", "role": "Treatment_Disorder", "text": "Cushing 's disease", "start": 21, "end": 24}, {"entity_id": "16146480_2_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 29, "end": 31}, {"entity_id": "16146480_2_Ent2", "role": "Treatment", "text": "propofol", "start": 32, "end": 33}, {"entity_id": "16146480_2_Ent3", "role": "Treatment_Drug", "text": "propofol", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "16146480_2_Ent0", "text": "patients with Cushing 's disease", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "16146480_2_Ent4", "text": "Cushing 's disease", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "16146480_2_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16146480_2_Ent2", "text": "propofol", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16146480_2_Ent3", "text": "propofol", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "16164579_1", "wnd_id": "16164579_1_1", "text": "A 51 - year old physically fit woman experienced angio - oedema and hypotensive shock after irbesartan ingestion requiring noradrenaline infusion .", "tokens": ["A", "51", "-", "year", "old", "physically", "fit", "woman", "experienced", "angio", "-", "oedema", "and", "hypotensive", "shock", "after", "irbesartan", "ingestion", "requiring", "noradrenaline", "infusion", "."], "event_mentions": [{"id": "16164579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 8, "end": 9}, "arguments": [{"entity_id": "16164579_1_Ent0", "role": "Subject", "text": "A 51 - year old physically fit woman", "start": 0, "end": 8}, {"entity_id": "16164579_1_Ent1", "role": "Subject_Age", "text": "51 - year old", "start": 1, "end": 5}, {"entity_id": "16164579_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16164579_1_Ent3", "role": "Effect", "text": "angio - oedema and hypotensive shock", "start": 9, "end": 15}, {"entity_id": "16164579_1_Ent5", "role": "Treatment_Drug", "text": "irbesartan", "start": 16, "end": 17}, {"entity_id": "16164579_1_Ent4", "role": "Treatment", "text": "irbesartan ingestion", "start": 16, "end": 18}, {"entity_id": "16164579_1_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16164579_1_Ent0", "text": "A 51 - year old physically fit woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16164579_1_Ent1", "text": "51 - year old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "16164579_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16164579_1_Ent3", "text": "angio - oedema and hypotensive shock", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "16164579_1_Ent5", "text": "irbesartan", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16164579_1_Ent4", "text": "irbesartan ingestion", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16164579_1_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16176119_2", "wnd_id": "16176119_2_1", "text": "Gefitinib ( IRESSA , ZD1839 ) , an epidermal growth factor receptor tyrosine kinase inhibitor , has been approved in several countries for the treatment of advanced non - small - cell lung cancer .", "tokens": ["Gefitinib", "(", "IRESSA", ",", "ZD1839", ")", ",", "an", "epidermal", "growth", "factor", "receptor", "tyrosine", "kinase", "inhibitor", ",", "has", "been", "approved", "in", "several", "countries", "for", "the", "treatment", "of", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", "."], "event_mentions": [{"id": "16176119_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 24, "end": 25}, "arguments": [{"entity_id": "16176119_2_Ent0", "role": "Treatment", "text": "Gefitinib", "start": 0, "end": 1}, {"entity_id": "16176119_2_Ent2", "role": "Treatment_Drug", "text": "Gefitinib", "start": 0, "end": 1}, {"entity_id": "16176119_2_Ent3", "role": "Treatment_Drug", "text": "IRESSA", "start": 2, "end": 3}, {"entity_id": "16176119_2_Ent4", "role": "Treatment_Drug", "text": "ZD1839", "start": 4, "end": 5}, {"entity_id": "16176119_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor tyrosine kinase inhibitor", "start": 8, "end": 15}, {"entity_id": "16176119_2_Ent1", "role": "Treatment_Disorder", "text": "advanced non - small - cell lung cancer", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "16176119_2_Ent0", "text": "Gefitinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16176119_2_Ent2", "text": "Gefitinib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16176119_2_Ent3", "text": "IRESSA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16176119_2_Ent4", "text": "ZD1839", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16176119_2_Ent5", "text": "epidermal growth factor receptor tyrosine kinase inhibitor", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "16176119_2_Ent1", "text": "advanced non - small - cell lung cancer", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "16181292_2", "wnd_id": "16181292_2_1", "text": "Severe loss of vision after removal of cataract caused by intravitreal triamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration .", "tokens": ["Severe", "loss", "of", "vision", "after", "removal", "of", "cataract", "caused", "by", "intravitreal", "triamcinolone", "in", "combination", "with", "photodynamic", "therapy", "for", "exudative", "age", "-", "related", "macular", "degeneration", "."], "event_mentions": [{"id": "16181292_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "16181292_2_Ent0", "role": "Effect", "text": "Severe loss of vision", "start": 0, "end": 4}, {"entity_id": "16181292_2_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone", "start": 10, "end": 12}, {"entity_id": "16181292_2_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent6", "role": "Combination_Drug", "text": "triamcinolone", "start": 11, "end": 12}, {"entity_id": "16181292_2_Ent2", "role": "Treatment", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent4", "role": "Treatment_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent7", "role": "Combination_Drug", "text": "photodynamic", "start": 15, "end": 16}, {"entity_id": "16181292_2_Ent5", "role": "Treatment_Disorder", "text": "exudative age - related macular degeneration", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "16181292_2_Ent0", "text": "Severe loss of vision", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16181292_2_Ent1", "text": "intravitreal triamcinolone", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16181292_2_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent6", "text": "triamcinolone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16181292_2_Ent2", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent4", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent7", "text": "photodynamic", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16181292_2_Ent5", "text": "exudative age - related macular degeneration", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "16196187_1", "wnd_id": "16196187_1_1", "text": "Acute myocardial ischemia following accidental intravenous administration of epinephrine in high concentration .", "tokens": ["Acute", "myocardial", "ischemia", "following", "accidental", "intravenous", "administration", "of", "epinephrine", "in", "high", "concentration", "."], "event_mentions": [{"id": "16196187_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "16196187_1_Ent0", "role": "Effect", "text": "Acute myocardial ischemia", "start": 0, "end": 3}, {"entity_id": "16196187_1_Ent1", "role": "Treatment", "text": "accidental intravenous administration of epinephrine in high concentration", "start": 4, "end": 12}, {"entity_id": "16196187_1_Ent2", "role": "Treatment_Route", "text": "intravenous administration", "start": 5, "end": 7}, {"entity_id": "16196187_1_Ent3", "role": "Treatment_Drug", "text": "epinephrine", "start": 8, "end": 9}, {"entity_id": "16196187_1_Ent4", "role": "Treatment_Dosage", "text": "high concentration", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "16196187_1_Ent0", "text": "Acute myocardial ischemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16196187_1_Ent1", "text": "accidental intravenous administration of epinephrine in high concentration", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "16196187_1_Ent2", "text": "intravenous administration", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16196187_1_Ent3", "text": "epinephrine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16196187_1_Ent4", "text": "high concentration", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "16216617_2", "wnd_id": "16216617_2_1", "text": "While on a maximal dose of phenylephrine she developed prominent positive U waves , which disappeared with the cessation of the drug .", "tokens": ["While", "on", "a", "maximal", "dose", "of", "phenylephrine", "she", "developed", "prominent", "positive", "U", "waves", ",", "which", "disappeared", "with", "the", "cessation", "of", "the", "drug", "."], "event_mentions": [{"id": "16216617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16216617_2_Ent4", "role": "Treatment_Dosage", "text": "maximal dose", "start": 3, "end": 5}, {"entity_id": "16216617_2_Ent3", "role": "Treatment", "text": "maximal dose of phenylephrine", "start": 3, "end": 7}, {"entity_id": "16216617_2_Ent5", "role": "Treatment_Drug", "text": "phenylephrine", "start": 6, "end": 7}, {"entity_id": "16216617_2_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "16216617_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "16216617_2_Ent2", "role": "Effect", "text": "positive U waves", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "16216617_2_Ent4", "text": "maximal dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16216617_2_Ent3", "text": "maximal dose of phenylephrine", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16216617_2_Ent5", "text": "phenylephrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16216617_2_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16216617_2_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16216617_2_Ent2", "text": "positive U waves", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "16221163_8", "wnd_id": "16221163_8_1", "text": "Hepatoxicity is a rare complication of SRL therapy and may be connected with some diagnostic and/or therapeutic problems .", "tokens": ["Hepatoxicity", "is", "a", "rare", "complication", "of", "SRL", "therapy", "and", "may", "be", "connected", "with", "some", "diagnostic", "and/or", "therapeutic", "problems", "."], "event_mentions": [{"id": "16221163_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "is", "start": 1, "end": 2}, "arguments": [{"entity_id": "16221163_8_Ent0", "role": "Effect", "text": "Hepatoxicity", "start": 0, "end": 1}, {"entity_id": "16221163_8_Ent2", "role": "Treatment_Drug", "text": "SRL", "start": 6, "end": 7}, {"entity_id": "16221163_8_Ent1", "role": "Treatment", "text": "SRL therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16221163_8_Ent0", "text": "Hepatoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16221163_8_Ent2", "text": "SRL", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16221163_8_Ent1", "text": "SRL therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16237130_1", "wnd_id": "16237130_1_1", "text": "Capecitabine - induced multifocal leukoencephalopathy : a report of five cases .", "tokens": ["Capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", ":", "a", "report", "of", "five", "cases", "."], "event_mentions": [{"id": "16237130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16237130_1_Ent3", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent4", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent2", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 3, "end": 5}, {"entity_id": "16237130_1_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "16237130_1_Ent0", "role": "Subject", "text": "five cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16237130_1_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent4", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent2", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16237130_1_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16237130_1_Ent0", "text": "five cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16237130_2", "wnd_id": "16237130_2_1", "text": "The authors report five additional cases of capecitabine - induced multifocal leukoencephalopathy .", "tokens": ["The", "authors", "report", "five", "additional", "cases", "of", "capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", "."], "event_mentions": [{"id": "16237130_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "16237130_2_Ent1", "role": "Treatment", "text": "capecitabine", "start": 7, "end": 8}, {"entity_id": "16237130_2_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 7, "end": 8}, {"entity_id": "16237130_2_Ent0", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "16237130_2_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16237130_2_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16237130_2_Ent0", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "16239768_3", "wnd_id": "16239768_3_1", "text": "Venlafaxine - induced urinary incontinence resolved after switching to sertraline .", "tokens": ["Venlafaxine", "-", "induced", "urinary", "incontinence", "resolved", "after", "switching", "to", "sertraline", "."], "event_mentions": [{"id": "16239768_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16239768_3_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "16239768_3_Ent0", "role": "Effect", "text": "urinary incontinence", "start": 3, "end": 5}]}, {"id": "16239768_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "16239768_3_Ent4", "role": "Treatment_Disorder", "text": "Venlafaxine - induced urinary incontinence", "start": 0, "end": 5}, {"entity_id": "16239768_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 9, "end": 10}, {"entity_id": "16239768_3_Ent5", "role": "Treatment_Drug", "text": "sertraline", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16239768_3_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16239768_3_Ent4", "text": "Venlafaxine - induced urinary incontinence", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16239768_3_Ent0", "text": "urinary incontinence", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16239768_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16239768_3_Ent5", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16268429_1", "wnd_id": "16268429_1_1", "text": "In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury .", "tokens": ["In", "this", "case", "senna", "was", "likely", "the", "cause", "of", "a", "subacute", "cholestatic", "hepatitis", "exemplifying", "again", "the", "potential", "role", "of", "herbal", "related", "liver", "injury", "."], "event_mentions": [{"id": "16268429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_1_Ent2", "role": "Treatment", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent0", "role": "Effect", "text": "a subacute cholestatic hepatitis", "start": 9, "end": 13}, {"entity_id": "16268429_1_Ent1", "role": "Effect", "text": "herbal related liver injury", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "16268429_1_Ent2", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent3", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent0", "text": "a subacute cholestatic hepatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16268429_1_Ent1", "text": "herbal related liver injury", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "16268429_2", "wnd_id": "16268429_2_1", "text": "Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation .", "tokens": ["Subacute", "cholestatic", "hepatitis", "likely", "related", "to", "the", "use", "of", "senna", "for", "chronic", "constipation", "."], "event_mentions": [{"id": "16268429_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 4, "end": 6}, "arguments": [{"entity_id": "16268429_2_Ent0", "role": "Effect", "text": "Subacute cholestatic hepatitis", "start": 0, "end": 3}, {"entity_id": "16268429_2_Ent1", "role": "Treatment", "text": "use of senna", "start": 7, "end": 10}, {"entity_id": "16268429_2_Ent2", "role": "Treatment_Drug", "text": "senna", "start": 9, "end": 10}, {"entity_id": "16268429_2_Ent3", "role": "Treatment_Disorder", "text": "chronic constipation .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16268429_2_Ent0", "text": "Subacute cholestatic hepatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16268429_2_Ent1", "text": "use of senna", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16268429_2_Ent2", "text": "senna", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16268429_2_Ent3", "text": "chronic constipation .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16268429_3", "wnd_id": "16268429_3_1", "text": "We report a case of senna - induced cholestatic hepatitis which was not diagnosed at presentation .", "tokens": ["We", "report", "a", "case", "of", "senna", "-", "induced", "cholestatic", "hepatitis", "which", "was", "not", "diagnosed", "at", "presentation", "."], "event_mentions": [{"id": "16268429_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16268429_3_Ent2", "role": "Treatment", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent1", "role": "Effect", "text": "cholestatic hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16268429_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16268429_3_Ent2", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent3", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent1", "text": "cholestatic hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16288069_4", "wnd_id": "16288069_4_1", "text": "The patient described feeling cold with worsening headache and chills approximately one hour after infusion of the first dose of penicillin .", "tokens": ["The", "patient", "described", "feeling", "cold", "with", "worsening", "headache", "and", "chills", "approximately", "one", "hour", "after", "infusion", "of", "the", "first", "dose", "of", "penicillin", "."], "event_mentions": [{"id": "16288069_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "16288069_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "16288069_4_Ent1", "role": "Effect", "text": "feeling cold with worsening headache and chills", "start": 3, "end": 10}, {"entity_id": "16288069_4_Ent3", "role": "Treatment_Time_elapsed", "text": "one hour", "start": 11, "end": 13}, {"entity_id": "16288069_4_Ent2", "role": "Treatment", "text": "one hour after infusion of the first dose of penicillin", "start": 11, "end": 21}, {"entity_id": "16288069_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 14, "end": 15}, {"entity_id": "16288069_4_Ent5", "role": "Treatment_Drug", "text": "penicillin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "16288069_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16288069_4_Ent1", "text": "feeling cold with worsening headache and chills", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "16288069_4_Ent3", "text": "one hour", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16288069_4_Ent2", "text": "one hour after infusion of the first dose of penicillin", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "16288069_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16288069_4_Ent5", "text": "penicillin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "16298824_3", "wnd_id": "16298824_3_1", "text": "ARDS is rarely associated with rituximab infusion for lympho - proliferative disorders , but it should be considered by those administering rituximab , especially when a patient develops severe pulmonary symptoms soon after infusion .", "tokens": ["ARDS", "is", "rarely", "associated", "with", "rituximab", "infusion", "for", "lympho", "-", "proliferative", "disorders", ",", "but", "it", "should", "be", "considered", "by", "those", "administering", "rituximab", ",", "especially", "when", "a", "patient", "develops", "severe", "pulmonary", "symptoms", "soon", "after", "infusion", "."], "event_mentions": [{"id": "16298824_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 32, "end": 33}, "arguments": [{"entity_id": "16298824_3_Ent1", "role": "Effect", "text": "ARDS", "start": 0, "end": 1}, {"entity_id": "16298824_3_Ent4", "role": "Treatment", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "16298824_3_Ent6", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "16298824_3_Ent0", "role": "Subject", "text": "a patient", "start": 25, "end": 27}, {"entity_id": "16298824_3_Ent2", "role": "Effect", "text": "severe pulmonary symptoms", "start": 28, "end": 31}, {"entity_id": "16298824_3_Ent3", "role": "Treatment", "text": "infusion", "start": 33, "end": 34}, {"entity_id": "16298824_3_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "16298824_3_Ent1", "text": "ARDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16298824_3_Ent4", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16298824_3_Ent6", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16298824_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16298824_3_Ent2", "text": "severe pulmonary symptoms", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "16298824_3_Ent3", "text": "infusion", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "16298824_3_Ent5", "text": "infusion", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "16298824_5", "wnd_id": "16298824_5_1", "text": "Progressive hypoxemia mandated endotracheal intubation 1 week after rituximab administration and led to death 4 weeks after admission .", "tokens": ["Progressive", "hypoxemia", "mandated", "endotracheal", "intubation", "1", "week", "after", "rituximab", "administration", "and", "led", "to", "death", "4", "weeks", "after", "admission", "."], "event_mentions": [{"id": "16298824_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "16298824_5_Ent0", "role": "Effect", "text": "Progressive hypoxemia", "start": 0, "end": 2}, {"entity_id": "16298824_5_Ent4", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 5, "end": 7}, {"entity_id": "16298824_5_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}, {"entity_id": "16298824_5_Ent2", "role": "Treatment", "text": "rituximab administration", "start": 8, "end": 10}, {"entity_id": "16298824_5_Ent1", "role": "Effect", "text": "led to death", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16298824_5_Ent0", "text": "Progressive hypoxemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16298824_5_Ent4", "text": "1 week", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16298824_5_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16298824_5_Ent2", "text": "rituximab administration", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16298824_5_Ent1", "text": "led to death", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16313549_1", "wnd_id": "16313549_1_1", "text": "Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma .", "tokens": ["Symptomatic", "hypocalcaemia", "and", "renal", "impairment", "associated", "with", "bisphosphonate", "treatment", "in", "patients", "with", "multiple", "myeloma", "."], "event_mentions": [{"id": "16313549_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "16313549_1_Ent1", "role": "Effect", "text": "Symptomatic hypocalcaemia and renal impairment", "start": 0, "end": 5}, {"entity_id": "16313549_1_Ent3", "role": "Treatment_Drug", "text": "bisphosphonate", "start": 7, "end": 8}, {"entity_id": "16313549_1_Ent2", "role": "Treatment", "text": "bisphosphonate treatment", "start": 7, "end": 9}, {"entity_id": "16313549_1_Ent0", "role": "Subject", "text": "patients with multiple myeloma", "start": 10, "end": 14}, {"entity_id": "16313549_1_Ent4", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16313549_1_Ent1", "text": "Symptomatic hypocalcaemia and renal impairment", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16313549_1_Ent3", "text": "bisphosphonate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16313549_1_Ent2", "text": "bisphosphonate treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16313549_1_Ent0", "text": "patients with multiple myeloma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16313549_1_Ent4", "text": "multiple myeloma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16317298_1", "wnd_id": "16317298_1_1", "text": "Gemcitabine - related radiation recall in a patient with pancreatic cancer .", "tokens": ["Gemcitabine", "-", "related", "radiation", "recall", "in", "a", "patient", "with", "pancreatic", "cancer", "."], "event_mentions": [{"id": "16317298_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "16317298_1_Ent2", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_1_Ent3", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_1_Ent1", "role": "Effect", "text": "radiation recall", "start": 3, "end": 5}, {"entity_id": "16317298_1_Ent0", "role": "Subject", "text": "a patient with pancreatic cancer", "start": 6, "end": 11}, {"entity_id": "16317298_1_Ent4", "role": "Treatment_Disorder", "text": "pancreatic cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16317298_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_1_Ent3", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_1_Ent1", "text": "radiation recall", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16317298_1_Ent0", "text": "a patient with pancreatic cancer", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16317298_1_Ent4", "text": "pancreatic cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16317298_5", "wnd_id": "16317298_5_1", "text": "We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to radiation - recall related to gemcitabine and review literature .", "tokens": ["We", "report", "a", "patient", "with", "inoperable", "pancreatic", "cancer", "who", "developed", "gastrointestinal", "bleeding", "secondary", "to", "radiation", "-", "recall", "related", "to", "gemcitabine", "and", "review", "literature", "."], "event_mentions": [{"id": "16317298_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "16317298_5_Ent0", "role": "Subject", "text": "a patient with inoperable pancreatic cancer", "start": 2, "end": 8}, {"entity_id": "16317298_5_Ent4", "role": "Treatment_Disorder", "text": "inoperable pancreatic cancer", "start": 5, "end": 8}, {"entity_id": "16317298_5_Ent1", "role": "Effect", "text": "gastrointestinal bleeding", "start": 10, "end": 12}, {"entity_id": "16317298_5_Ent2", "role": "Effect", "text": "radiation - recall", "start": 14, "end": 17}, {"entity_id": "16317298_5_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 19, "end": 20}, {"entity_id": "16317298_5_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16317298_5_Ent0", "text": "a patient with inoperable pancreatic cancer", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16317298_5_Ent4", "text": "inoperable pancreatic cancer", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16317298_5_Ent1", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16317298_5_Ent2", "text": "radiation - recall", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "16317298_5_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16317298_5_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16341621_2", "wnd_id": "16341621_2_1", "text": "The authors present a case report of a granulomatous reaction leading to urethral prolapse , 3 months after the transurethral injection of calcium hydroxylapatite .", "tokens": ["The", "authors", "present", "a", "case", "report", "of", "a", "granulomatous", "reaction", "leading", "to", "urethral", "prolapse", ",", "3", "months", "after", "the", "transurethral", "injection", "of", "calcium", "hydroxylapatite", "."], "event_mentions": [{"id": "16341621_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "16341621_2_Ent0", "role": "Subject", "text": "a case report", "start": 3, "end": 6}, {"entity_id": "16341621_2_Ent1", "role": "Effect", "text": "granulomatous reaction", "start": 8, "end": 10}, {"entity_id": "16341621_2_Ent2", "role": "Effect", "text": "urethral prolapse", "start": 12, "end": 14}, {"entity_id": "16341621_2_Ent4", "role": "Treatment_Time_elapsed", "text": "3 months", "start": 15, "end": 17}, {"entity_id": "16341621_2_Ent3", "role": "Treatment", "text": "3 months after the transurethral injection of calcium hydroxylapatite", "start": 15, "end": 24}, {"entity_id": "16341621_2_Ent5", "role": "Treatment_Route", "text": "transurethral injection", "start": 19, "end": 21}, {"entity_id": "16341621_2_Ent6", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "16341621_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "16341621_2_Ent1", "text": "granulomatous reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16341621_2_Ent2", "text": "urethral prolapse", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16341621_2_Ent4", "text": "3 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16341621_2_Ent3", "text": "3 months after the transurethral injection of calcium hydroxylapatite", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "16341621_2_Ent5", "text": "transurethral injection", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16341621_2_Ent6", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "16357738_2", "wnd_id": "16357738_2_1", "text": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine .", "tokens": ["Reversible", "posterior", "leukoencephalopathy", "syndrome", "in", "systemic", "lupus", "erythematosus", "with", "thrombocytopenia", "treated", "with", "cyclosporine", "."], "event_mentions": [{"id": "16357738_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16357738_2_Ent2", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus with thrombocytopenia", "start": 5, "end": 10}, {"entity_id": "16357738_2_Ent0", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "16357738_2_Ent1", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16357738_2_Ent2", "text": "systemic lupus erythematosus with thrombocytopenia", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16357738_2_Ent0", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16371793_1", "wnd_id": "16371793_1_1", "text": "Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty .", "tokens": ["Intravitreal", "triamcinolone", "acetonide", "for", "persisting", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "16371793_1_Ent3", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "16371793_1_Ent0", "role": "Treatment", "text": "Intravitreal triamcinolone acetonide", "start": 0, "end": 3}, {"entity_id": "16371793_1_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 1, "end": 3}, {"entity_id": "16371793_1_Ent1", "role": "Treatment_Disorder", "text": "persisting cystoid macular edema", "start": 4, "end": 8}]}, {"id": "16371793_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "16371793_1_Ent4", "role": "Effect", "text": "persisting cystoid macular edema", "start": 4, "end": 8}, {"entity_id": "16371793_1_Ent5", "role": "Treatment", "text": "penetrating keratoplasty", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16371793_1_Ent3", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16371793_1_Ent0", "text": "Intravitreal triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16371793_1_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16371793_1_Ent1", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent4", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent5", "text": "penetrating keratoplasty", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16396068_1", "wnd_id": "16396068_1_1", "text": "Trimethoprim - sulfamethoxazole - induced aseptic meningitis .", "tokens": ["Trimethoprim", "-", "sulfamethoxazole", "-", "induced", "aseptic", "meningitis", "."], "event_mentions": [{"id": "16396068_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16396068_1_Ent1", "role": "Treatment", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent2", "role": "Treatment_Drug", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent0", "role": "Effect", "text": "aseptic meningitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16396068_1_Ent1", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent2", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent0", "text": "aseptic meningitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16411025_1", "wnd_id": "16411025_1_1", "text": "DESIGN : We reviewed the medical records of four patients , who were seen by us between July 2000 and February 2004 for sudden onset of a central neurological syndrome within days of intrathecal MTX .", "tokens": ["DESIGN", ":", "We", "reviewed", "the", "medical", "records", "of", "four", "patients", ",", "who", "were", "seen", "by", "us", "between", "July", "2000", "and", "February", "2004", "for", "sudden", "onset", "of", "a", "central", "neurological", "syndrome", "within", "days", "of", "intrathecal", "MTX", "."], "event_mentions": [{"id": "16411025_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intrathecal", "start": 33, "end": 34}, "arguments": [{"entity_id": "16411025_1_Ent0", "role": "Subject", "text": "medical records of four patients", "start": 5, "end": 10}, {"entity_id": "16411025_1_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "16411025_1_Ent2", "role": "Effect", "text": "a central neurological syndrome", "start": 26, "end": 30}, {"entity_id": "16411025_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within days", "start": 30, "end": 32}, {"entity_id": "16411025_1_Ent3", "role": "Treatment", "text": "MTX", "start": 34, "end": 35}, {"entity_id": "16411025_1_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16411025_1_Ent0", "text": "medical records of four patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16411025_1_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16411025_1_Ent2", "text": "a central neurological syndrome", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "16411025_1_Ent5", "text": "within days", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "16411025_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16411025_1_Ent4", "text": "MTX", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16416684_1", "wnd_id": "16416684_1_1", "text": "This is a rare case of ARDS associated with lithium intoxication .", "tokens": ["This", "is", "a", "rare", "case", "of", "ARDS", "associated", "with", "lithium", "intoxication", "."], "event_mentions": [{"id": "16416684_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16416684_1_Ent0", "role": "Effect", "text": "ARDS", "start": 6, "end": 7}, {"entity_id": "16416684_1_Ent1", "role": "Treatment", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "16416684_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16416684_1_Ent0", "text": "ARDS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16416684_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16416684_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "1642627_2", "wnd_id": "1642627_2_1", "text": "Triazolam - induced nocturnal bingeing with amnesia .", "tokens": ["Triazolam", "-", "induced", "nocturnal", "bingeing", "with", "amnesia", "."], "event_mentions": [{"id": "1642627_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1642627_2_Ent1", "role": "Treatment", "text": "Triazolam", "start": 0, "end": 1}, {"entity_id": "1642627_2_Ent2", "role": "Treatment_Drug", "text": "Triazolam", "start": 0, "end": 1}, {"entity_id": "1642627_2_Ent0", "role": "Effect", "text": "nocturnal bingeing with amnesia", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "1642627_2_Ent1", "text": "Triazolam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1642627_2_Ent2", "text": "Triazolam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1642627_2_Ent0", "text": "nocturnal bingeing with amnesia", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "16436462_1", "wnd_id": "16436462_1_1", "text": "Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer .", "tokens": ["Neutropenic", "colitis", "during", "standard", "dose", "combination", "chemotherapy", "with", "nedaplatin", "and", "irinotecan", "for", "testicular", "cancer", "."], "event_mentions": [{"id": "16436462_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "16436462_1_Ent0", "role": "Effect", "text": "Neutropenic colitis", "start": 0, "end": 2}, {"entity_id": "16436462_1_Ent3", "role": "Treatment_Dosage", "text": "standard dose", "start": 3, "end": 5}, {"entity_id": "16436462_1_Ent1", "role": "Treatment", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "start": 3, "end": 14}, {"entity_id": "16436462_1_Ent4", "role": "Treatment_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent6", "role": "Combination_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent5", "role": "Treatment_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent7", "role": "Combination_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent2", "role": "Treatment_Disorder", "text": "testicular cancer", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16436462_1_Ent0", "text": "Neutropenic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16436462_1_Ent3", "text": "standard dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16436462_1_Ent1", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "16436462_1_Ent4", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent6", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent7", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent2", "text": "testicular cancer", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16449538_3", "wnd_id": "16449538_3_1", "text": "CONCLUSIONS : Among the many presentations of ifosfamide neurotoxicity , clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent .", "tokens": ["CONCLUSIONS", ":", "Among", "the", "many", "presentations", "of", "ifosfamide", "neurotoxicity", ",", "clinicians", "should", "consider", "NCSE", "as", "a", "possible", "explanation", "for", "changes", "in", "consciousness", "in", "a", "patient", "receiving", "this", "agent", "."], "event_mentions": [{"id": "16449538_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 25, "end": 26}, "arguments": [{"entity_id": "16449538_3_Ent4", "role": "Treatment", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "16449538_3_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 7, "end": 8}, {"entity_id": "16449538_3_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 8, "end": 9}, {"entity_id": "16449538_3_Ent2", "role": "Effect", "text": "NCSE", "start": 13, "end": 14}, {"entity_id": "16449538_3_Ent3", "role": "Effect", "text": "changes in consciousness", "start": 19, "end": 22}, {"entity_id": "16449538_3_Ent0", "role": "Subject", "text": "a patient", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "16449538_3_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16449538_3_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16449538_3_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16449538_3_Ent2", "text": "NCSE", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16449538_3_Ent3", "text": "changes in consciousness", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16449538_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "16498048_1", "wnd_id": "16498048_1_1", "text": "Autoimmune thyroid disease is a common side - effect of interferon - alpha ( IFN - alpha ) treatment of viral hepatitis C.", "tokens": ["Autoimmune", "thyroid", "disease", "is", "a", "common", "side", "-", "effect", "of", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "of", "viral", "hepatitis", "C."], "event_mentions": [{"id": "16498048_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effect", "start": 6, "end": 9}, "arguments": [{"entity_id": "16498048_1_Ent0", "role": "Effect", "text": "Autoimmune thyroid disease", "start": 0, "end": 3}, {"entity_id": "16498048_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 10, "end": 13}, {"entity_id": "16498048_1_Ent1", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha )", "start": 10, "end": 18}, {"entity_id": "16498048_1_Ent3", "role": "Treatment_Disorder", "text": "viral hepatitis C.", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "16498048_1_Ent0", "text": "Autoimmune thyroid disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16498048_1_Ent1", "text": "interferon - alpha ( IFN - alpha )", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "16498048_1_Ent3", "text": "viral hepatitis C.", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "16498048_4", "wnd_id": "16498048_4_1", "text": "Interferon - alpha - induced hyperthyroidism : a three - stage evolution from silent thyroiditis towards Graves ' disease .", "tokens": ["Interferon", "-", "alpha", "-", "induced", "hyperthyroidism", ":", "a", "three", "-", "stage", "evolution", "from", "silent", "thyroiditis", "towards", "Graves", "'", "disease", "."], "event_mentions": [{"id": "16498048_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16498048_4_Ent2", "role": "Treatment", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "16498048_4_Ent3", "role": "Treatment_Drug", "text": "Interferon - alpha", "start": 0, "end": 3}, {"entity_id": "16498048_4_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 5, "end": 6}, {"entity_id": "16498048_4_Ent1", "role": "Effect", "text": "Graves ' disease", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "16498048_4_Ent2", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_4_Ent3", "text": "Interferon - alpha", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16498048_4_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16498048_4_Ent1", "text": "Graves ' disease", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "16511396_3", "wnd_id": "16511396_3_1", "text": "This case underscores problems in clinical management with sulfadiazine hypersensitivity , potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis .", "tokens": ["This", "case", "underscores", "problems", "in", "clinical", "management", "with", "sulfadiazine", "hypersensitivity", ",", "potential", "immunosuppression", "from", "corticosteroids", "and", "selection", "of", "medications", "for", "recurrences", "of", "toxoplasmic", "chorioretinitis", "."], "event_mentions": [{"id": "16511396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hypersensitivity", "start": 9, "end": 10}, "arguments": [{"entity_id": "16511396_3_Ent1", "role": "Treatment", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent2", "role": "Treatment_Drug", "text": "sulfadiazine", "start": 8, "end": 9}, {"entity_id": "16511396_3_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 9, "end": 10}]}, {"id": "16511396_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 13, "end": 14}, "arguments": [{"entity_id": "16511396_3_Ent3", "role": "Effect", "text": "immunosuppression", "start": 12, "end": 13}, {"entity_id": "16511396_3_Ent4", "role": "Treatment", "text": "corticosteroids", "start": 14, "end": 15}, {"entity_id": "16511396_3_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16511396_3_Ent1", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent2", "text": "sulfadiazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16511396_3_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16511396_3_Ent3", "text": "immunosuppression", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16511396_3_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16511396_3_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16515630_1", "wnd_id": "16515630_1_1", "text": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer .", "tokens": ["Fatal", "lung", "fibrosis", "caused", "by", "paclitaxel", "toxicity", "has", "not", "been", "reported", "In", "this", "report", ",", "we", "describe", "the", "case", "of", "a", "62", "-", "year", "-", "old", "woman", "who", "received", "six", "cycles", "of", "paclitaxel", "and", "carboplatin", "as", "combination", "chemotherapy", "for", "advanced", "ovarian", "cancer", "."], "event_mentions": [{"id": "16515630_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 28, "end": 29}, "arguments": [{"entity_id": "16515630_1_Ent4", "role": "Effect", "text": "Fatal lung fibrosis", "start": 0, "end": 3}, {"entity_id": "16515630_1_Ent2", "role": "Subject_Age", "text": "62 - year - old", "start": 21, "end": 26}, {"entity_id": "16515630_1_Ent0", "role": "Subject", "text": "62 - year - old woman", "start": 21, "end": 27}, {"entity_id": "16515630_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 26, "end": 27}, {"entity_id": "16515630_1_Ent6", "role": "Treatment_Dosage", "text": "six cycles", "start": 29, "end": 31}, {"entity_id": "16515630_1_Ent5", "role": "Treatment", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "start": 29, "end": 38}, {"entity_id": "16515630_1_Ent7", "role": "Treatment_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent11", "role": "Combination_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent8", "role": "Treatment_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent12", "role": "Combination_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent10", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}, {"entity_id": "16515630_1_Ent1", "role": "Subject", "text": "advanced ovarian cancer", "start": 39, "end": 42}, {"entity_id": "16515630_1_Ent9", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16515630_1_Ent4", "text": "Fatal lung fibrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16515630_1_Ent2", "text": "62 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "16515630_1_Ent0", "text": "62 - year - old woman", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "16515630_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16515630_1_Ent6", "text": "six cycles", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16515630_1_Ent5", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "16515630_1_Ent7", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent11", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent8", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent12", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16515630_1_Ent1", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "16515630_1_Ent9", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16537817_1", "wnd_id": "16537817_1_1", "text": "Simvastatin - amiodarone interaction resulting in rhabdomyolysis , azotemia , and possible hepatotoxicity .", "tokens": ["Simvastatin", "-", "amiodarone", "interaction", "resulting", "in", "rhabdomyolysis", ",", "azotemia", ",", "and", "possible", "hepatotoxicity", "."], "event_mentions": [{"id": "16537817_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 4, "end": 5}, "arguments": [{"entity_id": "16537817_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent1", "role": "Treatment", "text": "Simvastatin - amiodarone interaction", "start": 0, "end": 4}, {"entity_id": "16537817_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent0", "role": "Effect", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "16537817_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent1", "text": "Simvastatin - amiodarone interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16537817_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent0", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "1655228_2", "wnd_id": "1655228_2_1", "text": "Myocardial ischemia associated with high - dose carmustine infusion .", "tokens": ["Myocardial", "ischemia", "associated", "with", "high", "-", "dose", "carmustine", "infusion", "."], "event_mentions": [{"id": "1655228_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "1655228_2_Ent0", "role": "Effect", "text": "Myocardial ischemia", "start": 0, "end": 2}, {"entity_id": "1655228_2_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 4, "end": 7}, {"entity_id": "1655228_2_Ent1", "role": "Treatment", "text": "high - dose carmustine infusion", "start": 4, "end": 9}, {"entity_id": "1655228_2_Ent3", "role": "Treatment_Drug", "text": "carmustine", "start": 7, "end": 8}, {"entity_id": "1655228_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1655228_2_Ent0", "text": "Myocardial ischemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1655228_2_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1655228_2_Ent1", "text": "high - dose carmustine infusion", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "1655228_2_Ent3", "text": "carmustine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1655228_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1655228_3", "wnd_id": "1655228_3_1", "text": "Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of myocardial ischemia during and immediately after BCNU infusion .", "tokens": ["Three", "patients", "are", "reported", "without", "a", "history", "of", "angina", "pectoris", "who", "had", "clinical", "and", "electrocardiographic", "evidence", "of", "myocardial", "ischemia", "during", "and", "immediately", "after", "BCNU", "infusion", "."], "event_mentions": [{"id": "1655228_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 11, "end": 12}, "arguments": [{"entity_id": "1655228_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "1655228_3_Ent0", "role": "Subject", "text": "Three patients are reported without a history of angina pectoris", "start": 0, "end": 10}, {"entity_id": "1655228_3_Ent2", "role": "Effect", "text": "myocardial ischemia", "start": 17, "end": 19}, {"entity_id": "1655228_3_Ent3", "role": "Treatment", "text": "during and immediately after BCNU infusion", "start": 19, "end": 25}, {"entity_id": "1655228_3_Ent5", "role": "Treatment_Time_elapsed", "text": "immediately after", "start": 21, "end": 23}, {"entity_id": "1655228_3_Ent4", "role": "Treatment_Drug", "text": "BCNU", "start": 23, "end": 24}, {"entity_id": "1655228_3_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "1655228_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1655228_3_Ent0", "text": "Three patients are reported without a history of angina pectoris", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "1655228_3_Ent2", "text": "myocardial ischemia", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "1655228_3_Ent3", "text": "during and immediately after BCNU infusion", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "1655228_3_Ent5", "text": "immediately after", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1655228_3_Ent4", "text": "BCNU", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "1655228_3_Ent6", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16609346_1", "wnd_id": "16609346_1_1", "text": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment , but this association is not well described .", "tokens": ["A", "few", "recent", "individual", "case", "reports", "have", "suggested", "that", "a", "myasthenic", "syndrome", "may", "be", "associated", "with", "statin", "treatment", ",", "but", "this", "association", "is", "not", "well", "described", "."], "event_mentions": [{"id": "16609346_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "16609346_1_Ent0", "role": "Subject", "text": "A few recent individual case", "start": 0, "end": 5}, {"entity_id": "16609346_1_Ent1", "role": "Effect", "text": "myasthenic syndrome", "start": 10, "end": 12}, {"entity_id": "16609346_1_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 16, "end": 17}, {"entity_id": "16609346_1_Ent2", "role": "Treatment", "text": "statin treatment", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16609346_1_Ent0", "text": "A few recent individual case", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16609346_1_Ent1", "text": "myasthenic syndrome", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16609346_1_Ent3", "text": "statin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16609346_1_Ent2", "text": "statin treatment", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16609346_3", "wnd_id": "16609346_3_1", "text": "We report 4 patients who developed symptoms of myasthenia gravis within 2 weeks of starting treatment with a statin drug .", "tokens": ["We", "report", "4", "patients", "who", "developed", "symptoms", "of", "myasthenia", "gravis", "within", "2", "weeks", "of", "starting", "treatment", "with", "a", "statin", "drug", "."], "event_mentions": [{"id": "16609346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "16609346_3_Ent1", "role": "Subject_Population", "text": "4", "start": 2, "end": 3}, {"entity_id": "16609346_3_Ent0", "role": "Subject", "text": "4 patients", "start": 2, "end": 4}, {"entity_id": "16609346_3_Ent2", "role": "Effect", "text": "symptoms of myasthenia gravis", "start": 6, "end": 10}, {"entity_id": "16609346_3_Ent3", "role": "Treatment", "text": "within 2 weeks of starting treatment with a statin", "start": 10, "end": 19}, {"entity_id": "16609346_3_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 11, "end": 13}, {"entity_id": "16609346_3_Ent4", "role": "Treatment_Drug", "text": "statin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16609346_3_Ent1", "text": "4", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16609346_3_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16609346_3_Ent2", "text": "symptoms of myasthenia gravis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16609346_3_Ent3", "text": "within 2 weeks of starting treatment with a statin", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "16609346_3_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16609346_3_Ent4", "text": "statin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16615675_1", "wnd_id": "16615675_1_1", "text": "After excluding other causes of long QT syndrome , the HCQ was suspected as the cause of her ventricular tachycardia .", "tokens": ["After", "excluding", "other", "causes", "of", "long", "QT", "syndrome", ",", "the", "HCQ", "was", "suspected", "as", "the", "cause", "of", "her", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "16615675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 12, "end": 13}, "arguments": [{"entity_id": "16615675_1_Ent3", "role": "Treatment", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent4", "role": "Treatment_Drug", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent0", "role": "Subject", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent1", "role": "Subject_Gender", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent2", "role": "Effect", "text": "ventricular tachycardia", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16615675_1_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent4", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent0", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent1", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent2", "text": "ventricular tachycardia", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16615675_2", "wnd_id": "16615675_2_1", "text": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia .", "tokens": ["Chronic", "hydroxychloroquine", "use", "associated", "with", "QT", "prolongation", "and", "refractory", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "16615675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16615675_2_Ent1", "role": "Treatment", "text": "Chronic hydroxychloroquine", "start": 0, "end": 2}, {"entity_id": "16615675_2_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 1, "end": 2}, {"entity_id": "16615675_2_Ent0", "role": "Effect", "text": "QT prolongation and refractory ventricular arrhythmia", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "16615675_2_Ent1", "text": "Chronic hydroxychloroquine", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16615675_2_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16615675_2_Ent0", "text": "QT prolongation and refractory ventricular arrhythmia", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "16615675_3", "wnd_id": "16615675_3_1", "text": "CONCLUSION : The chronic use of HCQ for rheumatic diseases , or as an anti - malarial drug , should be balanced against the risk of developing potentially lethal cardiac arrhythmias .", "tokens": ["CONCLUSION", ":", "The", "chronic", "use", "of", "HCQ", "for", "rheumatic", "diseases", ",", "or", "as", "an", "anti", "-", "malarial", "drug", ",", "should", "be", "balanced", "against", "the", "risk", "of", "developing", "potentially", "lethal", "cardiac", "arrhythmias", "."], "event_mentions": [{"id": "16615675_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "against", "start": 22, "end": 23}, "arguments": [{"entity_id": "16615675_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 3, "end": 4}, {"entity_id": "16615675_3_Ent1", "role": "Treatment", "text": "chronic use of HCQ", "start": 3, "end": 7}, {"entity_id": "16615675_3_Ent3", "role": "Treatment_Drug", "text": "HCQ", "start": 6, "end": 7}, {"entity_id": "16615675_3_Ent2", "role": "Treatment_Disorder", "text": "rheumatic diseases", "start": 8, "end": 10}, {"entity_id": "16615675_3_Ent0", "role": "Effect", "text": "lethal cardiac arrhythmias", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "16615675_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16615675_3_Ent1", "text": "chronic use of HCQ", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16615675_3_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16615675_3_Ent2", "text": "rheumatic diseases", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16615675_3_Ent0", "text": "lethal cardiac arrhythmias", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "16623611_1", "wnd_id": "16623611_1_1", "text": "Case report : lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine .", "tokens": ["Case", "report", ":", "lack", "of", "control", "of", "diabetes", "and", "weight", "gain", "in", "a", "patient", "on", "initiation", "and", "rechallenge", "of", "therapy", "with", "olanzapine", "."], "event_mentions": [{"id": "16623611_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "initiation and rechallenge", "start": 15, "end": 18}, "arguments": [{"entity_id": "16623611_1_Ent1", "role": "Effect", "text": "diabetes", "start": 7, "end": 8}, {"entity_id": "16623611_1_Ent2", "role": "Effect", "text": "weight gain", "start": 9, "end": 11}, {"entity_id": "16623611_1_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "16623611_1_Ent3", "role": "Treatment", "text": "olanzapine", "start": 21, "end": 22}, {"entity_id": "16623611_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16623611_1_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16623611_1_Ent2", "text": "weight gain", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16623611_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16623611_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16623611_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16623611_2", "wnd_id": "16623611_2_1", "text": "The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of olanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and weight gain .", "tokens": ["The", "following", "is", "a", "case", "report", "analysis", "intended", "to", "draw", "attention", "to", "the", "need", "for", "better", "care", "coordination", "by", "describing", "the", "observed", "relationship", "of", "olanzapine", "to", "metabolic", "changes", "manifested", "as", "uncontrolled", "diabetes", "mellitus", "and", "weight", "gain", "."], "event_mentions": [{"id": "16623611_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 22, "end": 23}, "arguments": [{"entity_id": "16623611_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 24, "end": 25}, {"entity_id": "16623611_2_Ent0", "role": "Effect", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "start": 26, "end": 36}]}], "entity_mentions": [{"id": "16623611_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16623611_2_Ent0", "text": "metabolic changes manifested as uncontrolled diabetes mellitus and weight gain", "entity_type": "Entity", "start": 26, "end": 36}], "lang": "en"}
{"doc_id": "16641839_3", "wnd_id": "16641839_3_1", "text": "Cutaneous eruptions occur in 3 % of individuals administered carbamazepine .", "tokens": ["Cutaneous", "eruptions", "occur", "in", "3", "%", "of", "individuals", "administered", "carbamazepine", "."], "event_mentions": [{"id": "16641839_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "16641839_3_Ent0", "role": "Effect", "text": "Cutaneous eruptions", "start": 0, "end": 2}, {"entity_id": "16641839_3_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 9, "end": 10}, {"entity_id": "16641839_3_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "16641839_3_Ent0", "text": "Cutaneous eruptions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16641839_3_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16641839_3_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16641839_5", "wnd_id": "16641839_5_1", "text": "We report the case of a 27 - year - old Indian woman who developed maculopapular rash and angioedema secondary to carbamazepine administration .", "tokens": ["We", "report", "the", "case", "of", "a", "27", "-", "year", "-", "old", "Indian", "woman", "who", "developed", "maculopapular", "rash", "and", "angioedema", "secondary", "to", "carbamazepine", "administration", "."], "event_mentions": [{"id": "16641839_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "16641839_5_Ent0", "role": "Subject", "text": "a 27 - year - old Indian woman", "start": 5, "end": 13}, {"entity_id": "16641839_5_Ent1", "role": "Subject_Age", "text": "27 - year - old", "start": 6, "end": 11}, {"entity_id": "16641839_5_Ent2", "role": "Subject_Race", "text": "Indian", "start": 11, "end": 12}, {"entity_id": "16641839_5_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "16641839_5_Ent4", "role": "Effect", "text": "maculopapular rash and angioedema", "start": 15, "end": 19}, {"entity_id": "16641839_5_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 21, "end": 22}, {"entity_id": "16641839_5_Ent5", "role": "Treatment", "text": "carbamazepine administration", "start": 21, "end": 23}, {"entity_id": "16641839_5_Ent7", "role": "Treatment_Route", "text": "administration", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16641839_5_Ent0", "text": "a 27 - year - old Indian woman", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "16641839_5_Ent1", "text": "27 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16641839_5_Ent2", "text": "Indian", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16641839_5_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_5_Ent4", "text": "maculopapular rash and angioedema", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "16641839_5_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16641839_5_Ent5", "text": "carbamazepine administration", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16641839_5_Ent7", "text": "administration", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16649344_3", "wnd_id": "16649344_3_1", "text": "Sirolimus works differently from the immunosuppressants currently available , and except for increased lipid levels , the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus .", "tokens": ["Sirolimus", "works", "differently", "from", "the", "immunosuppressants", "currently", "available", ",", "and", "except", "for", "increased", "lipid", "levels", ",", "the", "adverse", "reaction", "profile", "of", "sirolimus", "does", "not", "appear", "to", "overlap", "to", "any", "great", "extent", "with", "that", "associated", "with", "cyclosporine", "or", "tacrolimus", "."], "event_mentions": [{"id": "16649344_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "16649344_3_Ent2", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16649344_3_Ent1", "role": "Treatment", "text": "Sirolimus works differently from the immunosuppressants currently available", "start": 0, "end": 8}, {"entity_id": "16649344_3_Ent3", "role": "Treatment_Drug", "text": "immunosuppressants", "start": 5, "end": 6}, {"entity_id": "16649344_3_Ent0", "role": "Effect", "text": "increased lipid levels", "start": 12, "end": 15}, {"entity_id": "16649344_3_Ent4", "role": "Treatment_Drug", "text": "sirolimus", "start": 21, "end": 22}, {"entity_id": "16649344_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "16649344_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "16649344_3_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16649344_3_Ent1", "text": "Sirolimus works differently from the immunosuppressants currently available", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16649344_3_Ent3", "text": "immunosuppressants", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16649344_3_Ent0", "text": "increased lipid levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16649344_3_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16649344_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16649344_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "16678268_1", "wnd_id": "16678268_1_1", "text": "Severe adenovirus pneumonia ( AVP ) following infliximab infusion for the treatment of Crohn 's disease .", "tokens": ["Severe", "adenovirus", "pneumonia", "(", "AVP", ")", "following", "infliximab", "infusion", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "16678268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "16678268_1_Ent0", "role": "Effect", "text": "adenovirus pneumonia", "start": 1, "end": 3}, {"entity_id": "16678268_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16678268_1_Ent1", "role": "Treatment", "text": "infliximab infusion", "start": 7, "end": 9}, {"entity_id": "16678268_1_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "16678268_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16678268_1_Ent0", "text": "adenovirus pneumonia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16678268_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16678268_1_Ent1", "text": "infliximab infusion", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_1_Ent3", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16678268_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16678268_2", "wnd_id": "16678268_2_1", "text": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn 's disease ( CD ) .", "tokens": ["We", "report", "a", "case", "of", "severe", "AVP", "three", "weeks", "following", "the", "administration", "of", "infliximab", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "(", "CD", ")", "."], "event_mentions": [{"id": "16678268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "16678268_2_Ent0", "role": "Effect", "text": "AVP", "start": 6, "end": 7}, {"entity_id": "16678268_2_Ent2", "role": "Treatment_Time_elapsed", "text": "three weeks", "start": 7, "end": 9}, {"entity_id": "16678268_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16678268_2_Ent0", "text": "AVP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16678268_2_Ent2", "text": "three weeks", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16680561_10", "wnd_id": "16680561_10_1", "text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .", "tokens": ["Fewer", "subjects", "reported", "adverse", "events", "following", "treatment", "with", "desipramine", "alone", "than", "when", "receiving", "desipramine", "with", "cinacalcet", "(", "33", "versus", "86", "%", ")", ",", "the", "most", "frequent", "of", "which", "(", "nausea", "and", "headache", ")", "have", "been", "reported", "for", "patients", "treated", "with", "either", "desipramine", "or", "cinacalcet", "."], "event_mentions": [{"id": "16680561_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 35, "end": 36}, "arguments": [{"entity_id": "16680561_10_Ent5", "role": "Treatment_Drug", "text": "desipramine", "start": 8, "end": 9}, {"entity_id": "16680561_10_Ent6", "role": "Treatment_Drug", "text": "desipramine", "start": 13, "end": 14}, {"entity_id": "16680561_10_Ent8", "role": "Combination_Drug", "text": "desipramine", "start": 13, "end": 14}, {"entity_id": "16680561_10_Ent7", "role": "Treatment_Drug", "text": "cinacalcet", "start": 15, "end": 16}, {"entity_id": "16680561_10_Ent9", "role": "Combination_Drug", "text": "cinacalcet", "start": 15, "end": 16}, {"entity_id": "16680561_10_Ent1", "role": "Effect", "text": "nausea and headache", "start": 29, "end": 32}, {"entity_id": "16680561_10_Ent0", "role": "Subject", "text": "patients", "start": 37, "end": 38}, {"entity_id": "16680561_10_Ent3", "role": "Treatment_Drug", "text": "desipramine", "start": 41, "end": 42}, {"entity_id": "16680561_10_Ent2", "role": "Treatment", "text": "desipramine or cinacalcet", "start": 41, "end": 44}, {"entity_id": "16680561_10_Ent4", "role": "Treatment_Drug", "text": "cinacalcet", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "16680561_10_Ent5", "text": "desipramine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16680561_10_Ent6", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16680561_10_Ent8", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16680561_10_Ent7", "text": "cinacalcet", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16680561_10_Ent9", "text": "cinacalcet", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16680561_10_Ent1", "text": "nausea and headache", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "16680561_10_Ent0", "text": "patients", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16680561_10_Ent3", "text": "desipramine", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "16680561_10_Ent2", "text": "desipramine or cinacalcet", "entity_type": "Entity", "start": 41, "end": 44}, {"id": "16680561_10_Ent4", "text": "cinacalcet", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "16682062_2", "wnd_id": "16682062_2_1", "text": "To our knowledge , this is the first case of ivermectin - induced severe liver disease published in the literature .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "ivermectin", "-", "induced", "severe", "liver", "disease", "published", "in", "the", "literature", "."], "event_mentions": [{"id": "16682062_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16682062_2_Ent1", "role": "Treatment", "text": "ivermectin", "start": 10, "end": 11}, {"entity_id": "16682062_2_Ent2", "role": "Treatment_Drug", "text": "ivermectin", "start": 10, "end": 11}, {"entity_id": "16682062_2_Ent0", "role": "Effect", "text": "severe liver disease", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "16682062_2_Ent1", "text": "ivermectin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16682062_2_Ent2", "text": "ivermectin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16682062_2_Ent0", "text": "severe liver disease", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "16682062_3", "wnd_id": "16682062_3_1", "text": "We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis , identified 1 month after a single dose of ivermectin .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "originally", "from", "Cameroon", "who", "was", "infected", "by", "the", "L.", "loa", "parasite", "and", "developed", "severe", "hepatitis", ",", "identified", "1", "month", "after", "a", "single", "dose", "of", "ivermectin", "."], "event_mentions": [{"id": "16682062_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "16682062_3_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "16682062_3_Ent0", "role": "Subject", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "start": 6, "end": 23}, {"entity_id": "16682062_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16682062_3_Ent3", "role": "Subject_Race", "text": "Cameroon", "start": 14, "end": 15}, {"entity_id": "16682062_3_Ent6", "role": "Treatment_Disorder", "text": "infected by the L. loa parasite", "start": 17, "end": 23}, {"entity_id": "16682062_3_Ent4", "role": "Effect", "text": "severe hepatitis", "start": 25, "end": 27}, {"entity_id": "16682062_3_Ent7", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 29, "end": 31}, {"entity_id": "16682062_3_Ent5", "role": "Treatment", "text": "1 month after a single dose of ivermectin", "start": 29, "end": 37}, {"entity_id": "16682062_3_Ent8", "role": "Treatment_Dosage", "text": "single dose", "start": 33, "end": 35}, {"entity_id": "16682062_3_Ent9", "role": "Treatment_Drug", "text": "ivermectin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16682062_3_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16682062_3_Ent0", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "16682062_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16682062_3_Ent3", "text": "Cameroon", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16682062_3_Ent6", "text": "infected by the L. loa parasite", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "16682062_3_Ent4", "text": "severe hepatitis", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16682062_3_Ent7", "text": "1 month", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16682062_3_Ent5", "text": "1 month after a single dose of ivermectin", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "16682062_3_Ent8", "text": "single dose", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "16682062_3_Ent9", "text": "ivermectin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16688722_2", "wnd_id": "16688722_2_1", "text": "We report a 53 - year - old - man who developed rippling muscle disease ( RMD ) 2 months after starting simvastatin therapy for hypercholesterolemia .", "tokens": ["We", "report", "a", "53", "-", "year", "-", "old", "-", "man", "who", "developed", "rippling", "muscle", "disease", "(", "RMD", ")", "2", "months", "after", "starting", "simvastatin", "therapy", "for", "hypercholesterolemia", "."], "event_mentions": [{"id": "16688722_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16688722_2_Ent0", "role": "Subject", "text": "a 53 - year - old - man", "start": 2, "end": 10}, {"entity_id": "16688722_2_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 3, "end": 8}, {"entity_id": "16688722_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "16688722_2_Ent3", "role": "Effect", "text": "rippling muscle disease ( RMD )", "start": 12, "end": 18}, {"entity_id": "16688722_2_Ent7", "role": "Treatment_Time_elapsed", "text": "2 months", "start": 18, "end": 20}, {"entity_id": "16688722_2_Ent4", "role": "Treatment", "text": "2 months after starting simvastatin therapy", "start": 18, "end": 24}, {"entity_id": "16688722_2_Ent6", "role": "Treatment_Drug", "text": "simvastatin", "start": 22, "end": 23}, {"entity_id": "16688722_2_Ent5", "role": "Treatment_Disorder", "text": "hypercholesterolemia", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "16688722_2_Ent0", "text": "a 53 - year - old - man", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "16688722_2_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16688722_2_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16688722_2_Ent3", "text": "rippling muscle disease ( RMD )", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "16688722_2_Ent7", "text": "2 months", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "16688722_2_Ent4", "text": "2 months after starting simvastatin therapy", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "16688722_2_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16688722_2_Ent5", "text": "hypercholesterolemia", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16718947_2", "wnd_id": "16718947_2_1", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism was receiving warfarin to prevent thromboembolic complications ; her international normalized ratio ( INR ) had been stable for 1 month .", "tokens": ["53", "-", "year", "-", "old", "woman", "with", "a", "history", "of", "deep", "vein", "thrombosis", "and", "pulmonary", "embolism", "was", "receiving", "warfarin", "to", "prevent", "thromboembolic", "complications", ";", "her", "international", "normalized", "ratio", "(", "INR", ")", "had", "been", "stable", "for", "1", "month", "."], "event_mentions": [{"id": "16718947_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 20, "end": 21}, "arguments": [{"entity_id": "16718947_2_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 0, "end": 5}, {"entity_id": "16718947_2_Ent0", "role": "Subject", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism", "start": 0, "end": 16}, {"entity_id": "16718947_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 5, "end": 6}, {"entity_id": "16718947_2_Ent5", "role": "Treatment_Disorder", "text": "deep vein thrombosis", "start": 10, "end": 13}, {"entity_id": "16718947_2_Ent6", "role": "Treatment_Disorder", "text": "pulmonary embolism", "start": 14, "end": 16}, {"entity_id": "16718947_2_Ent3", "role": "Treatment", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "16718947_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 18, "end": 19}, {"entity_id": "16718947_2_Ent7", "role": "Treatment_Disorder", "text": "thromboembolic complications ;", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "16718947_2_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16718947_2_Ent0", "text": "53 - year - old woman with a history of deep vein thrombosis and pulmonary embolism", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "16718947_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16718947_2_Ent5", "text": "deep vein thrombosis", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16718947_2_Ent6", "text": "pulmonary embolism", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16718947_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16718947_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16718947_2_Ent7", "text": "thromboembolic complications ;", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "16718947_3", "wnd_id": "16718947_3_1", "text": "Extended - release tolterodine 4 mg / day was then prescribed to manage overactive bladder .", "tokens": ["Extended", "-", "release", "tolterodine", "4", "mg", "/", "day", "was", "then", "prescribed", "to", "manage", "overactive", "bladder", "."], "event_mentions": [{"id": "16718947_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 10, "end": 11}, "arguments": [{"entity_id": "16718947_3_Ent2", "role": "Treatment_Drug", "text": "Extended - release tolterodine", "start": 0, "end": 4}, {"entity_id": "16718947_3_Ent0", "role": "Treatment", "text": "Extended - release tolterodine 4 mg / day", "start": 0, "end": 8}, {"entity_id": "16718947_3_Ent3", "role": "Treatment_Dosage", "text": "4 mg / day", "start": 4, "end": 8}, {"entity_id": "16718947_3_Ent1", "role": "Treatment_Disorder", "text": "overactive bladder", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16718947_3_Ent2", "text": "Extended - release tolterodine", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16718947_3_Ent0", "text": "Extended - release tolterodine 4 mg / day", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16718947_3_Ent3", "text": "4 mg / day", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16718947_3_Ent1", "text": "overactive bladder", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16757971_1", "wnd_id": "16757971_1_1", "text": "DIAGNOSIS : Severe temozolomide - induced immunosuppression , exacerbated by corticosteroids , with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes , and cutaneous Kaposi 's sarcoma .", "tokens": ["DIAGNOSIS", ":", "Severe", "temozolomide", "-", "induced", "immunosuppression", ",", "exacerbated", "by", "corticosteroids", ",", "with", "profound", "T", "-", "cell", "lymphocytopenia", "and", "simultaneous", "opportunistic", "infections", "with", "Pneumocystis", "jiroveci", "pneumonia", ",", "brain", "abscess", "with", "Listeria", "monocytogenes", ",", "and", "cutaneous", "Kaposi", "'s", "sarcoma", "."], "event_mentions": [{"id": "16757971_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "16757971_1_Ent5", "role": "Treatment", "text": "temozolomide", "start": 3, "end": 4}, {"entity_id": "16757971_1_Ent7", "role": "Treatment_Drug", "text": "temozolomide", "start": 3, "end": 4}, {"entity_id": "16757971_1_Ent10", "role": "Combination_Drug", "text": "temozolomide", "start": 3, "end": 4}, {"entity_id": "16757971_1_Ent0", "role": "Effect", "text": "immunosuppression", "start": 6, "end": 7}, {"entity_id": "16757971_1_Ent6", "role": "Treatment", "text": "exacerbated by corticosteroids", "start": 8, "end": 11}, {"entity_id": "16757971_1_Ent8", "role": "Treatment_Drug", "text": "corticosteroids", "start": 10, "end": 11}, {"entity_id": "16757971_1_Ent9", "role": "Combination_Drug", "text": "corticosteroids", "start": 10, "end": 11}, {"entity_id": "16757971_1_Ent1", "role": "Effect", "text": "T - cell lymphocytopenia", "start": 14, "end": 18}, {"entity_id": "16757971_1_Ent2", "role": "Effect", "text": "Pneumocystis jiroveci pneumonia", "start": 23, "end": 26}, {"entity_id": "16757971_1_Ent3", "role": "Effect", "text": "brain abscess with Listeria monocytogenes", "start": 27, "end": 32}, {"entity_id": "16757971_1_Ent4", "role": "Effect", "text": "cutaneous Kaposi 's sarcoma", "start": 34, "end": 38}]}], "entity_mentions": [{"id": "16757971_1_Ent5", "text": "temozolomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16757971_1_Ent7", "text": "temozolomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16757971_1_Ent10", "text": "temozolomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16757971_1_Ent0", "text": "immunosuppression", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16757971_1_Ent6", "text": "exacerbated by corticosteroids", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "16757971_1_Ent8", "text": "corticosteroids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16757971_1_Ent9", "text": "corticosteroids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16757971_1_Ent1", "text": "T - cell lymphocytopenia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "16757971_1_Ent2", "text": "Pneumocystis jiroveci pneumonia", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "16757971_1_Ent3", "text": "brain abscess with Listeria monocytogenes", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "16757971_1_Ent4", "text": "cutaneous Kaposi 's sarcoma", "entity_type": "Entity", "start": 34, "end": 38}], "lang": "en"}
{"doc_id": "16843118_1", "wnd_id": "16843118_1_1", "text": "Acute generalized exanthematous pustulosis caused by morphine , confirmed by positive patch test and lymphocyte transformation test .", "tokens": ["Acute", "generalized", "exanthematous", "pustulosis", "caused", "by", "morphine", ",", "confirmed", "by", "positive", "patch", "test", "and", "lymphocyte", "transformation", "test", "."], "event_mentions": [{"id": "16843118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "16843118_1_Ent0", "role": "Effect", "text": "Acute generalized exanthematous pustulosis", "start": 0, "end": 4}, {"entity_id": "16843118_1_Ent1", "role": "Treatment", "text": "morphine", "start": 6, "end": 7}, {"entity_id": "16843118_1_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "16843118_1_Ent0", "text": "Acute generalized exanthematous pustulosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16843118_1_Ent1", "text": "morphine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16843118_1_Ent2", "text": "morphine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "16863495_1", "wnd_id": "16863495_1_1", "text": "Olanzapine - associated neuroleptic malignant syndrome .", "tokens": ["Olanzapine", "-", "associated", "neuroleptic", "malignant", "syndrome", "."], "event_mentions": [{"id": "16863495_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16863495_1_Ent1", "role": "Treatment", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "16863495_1_Ent2", "role": "Treatment_Drug", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "16863495_1_Ent0", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "16863495_1_Ent1", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16863495_1_Ent2", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16863495_1_Ent0", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "16889287_1", "wnd_id": "16889287_1_1", "text": "It may cause a severe adverse drug reaction with multiorgan involvement known as dapsone hypersensitivity syndrome .", "tokens": ["It", "may", "cause", "a", "severe", "adverse", "drug", "reaction", "with", "multiorgan", "involvement", "known", "as", "dapsone", "hypersensitivity", "syndrome", "."], "event_mentions": [{"id": "16889287_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "16889287_1_Ent1", "role": "Effect", "text": "a severe adverse drug reaction", "start": 3, "end": 8}, {"entity_id": "16889287_1_Ent2", "role": "Treatment", "text": "dapsone", "start": 13, "end": 14}, {"entity_id": "16889287_1_Ent3", "role": "Treatment_Drug", "text": "dapsone", "start": 13, "end": 14}, {"entity_id": "16889287_1_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "16889287_1_Ent1", "text": "a severe adverse drug reaction", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16889287_1_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16889287_1_Ent3", "text": "dapsone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16889287_1_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "16901609_1", "wnd_id": "16901609_1_1", "text": "Anaphylaxis to intrathecal diamorphine .", "tokens": ["Anaphylaxis", "to", "intrathecal", "diamorphine", "."], "event_mentions": [{"id": "16901609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16901609_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "16901609_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "16901609_1_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 2, "end": 4}, {"entity_id": "16901609_1_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16901609_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16901609_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16901609_1_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16901609_1_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16948177_2", "wnd_id": "16948177_2_1", "text": "Moreover , these findings suggest that the incidence of BOOP following rituximab therapy may be higher than has been previously appreciated .", "tokens": ["Moreover", ",", "these", "findings", "suggest", "that", "the", "incidence", "of", "BOOP", "following", "rituximab", "therapy", "may", "be", "higher", "than", "has", "been", "previously", "appreciated", "."], "event_mentions": [{"id": "16948177_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "16948177_2_Ent0", "role": "Effect", "text": "BOOP", "start": 9, "end": 10}, {"entity_id": "16948177_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "16948177_2_Ent1", "role": "Treatment", "text": "rituximab therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "16948177_2_Ent0", "text": "BOOP", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16948177_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16948177_2_Ent1", "text": "rituximab therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "16960880_3", "wnd_id": "16960880_3_1", "text": "Native arterial thrombosis , though recognized as a severe complication of thrombin injection , has not been well described in the literature .", "tokens": ["Native", "arterial", "thrombosis", ",", "though", "recognized", "as", "a", "severe", "complication", "of", "thrombin", "injection", ",", "has", "not", "been", "well", "described", "in", "the", "literature", "."], "event_mentions": [{"id": "16960880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "16960880_3_Ent0", "role": "Effect", "text": "Native arterial thrombosis", "start": 0, "end": 3}, {"entity_id": "16960880_3_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 11, "end": 12}, {"entity_id": "16960880_3_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 11, "end": 13}, {"entity_id": "16960880_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16960880_3_Ent0", "text": "Native arterial thrombosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16960880_3_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16960880_3_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16960880_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16968538_2", "wnd_id": "16968538_2_1", "text": "BACKGROUND : Oxaliplatin is a platinum derivative , which is used in the treatment of colorectal cancer .", "tokens": ["BACKGROUND", ":", "Oxaliplatin", "is", "a", "platinum", "derivative", ",", "which", "is", "used", "in", "the", "treatment", "of", "colorectal", "cancer", "."], "event_mentions": [{"id": "16968538_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "16968538_2_Ent1", "role": "Treatment_Drug", "text": "Oxaliplatin", "start": 2, "end": 3}, {"entity_id": "16968538_2_Ent0", "role": "Treatment", "text": "Oxaliplatin is a platinum derivative", "start": 2, "end": 7}, {"entity_id": "16968538_2_Ent2", "role": "Treatment_Drug", "text": "platinum derivative", "start": 5, "end": 7}, {"entity_id": "16968538_2_Ent3", "role": "Treatment_Disorder", "text": "colorectal cancer", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16968538_2_Ent1", "text": "Oxaliplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16968538_2_Ent0", "text": "Oxaliplatin is a platinum derivative", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "16968538_2_Ent2", "text": "platinum derivative", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16968538_2_Ent3", "text": "colorectal cancer", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16968538_4", "wnd_id": "16968538_4_1", "text": "We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin .", "tokens": ["We", "present", "a", "case", "of", "hemolytic", "-", "uremic", "syndrome", "that", "developed", "during", "the", "4th", "cycle", "of", "combination", "chemotherapy", "with", "oxaliplatin", ",", "5", "-", "fluorouracil", "and", "leucovorin", "."], "event_mentions": [{"id": "16968538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "16968538_4_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 5, "end": 9}, {"entity_id": "16968538_4_Ent1", "role": "Treatment", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "start": 11, "end": 26}, {"entity_id": "16968538_4_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 19, "end": 20}, {"entity_id": "16968538_4_Ent3", "role": "Treatment_Drug", "text": "fluorouracil", "start": 23, "end": 24}, {"entity_id": "16968538_4_Ent4", "role": "Treatment_Drug", "text": "leucovorin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "16968538_4_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16968538_4_Ent1", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "16968538_4_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16968538_4_Ent3", "text": "fluorouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16968538_4_Ent4", "text": "leucovorin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16978752_3", "wnd_id": "16978752_3_1", "text": "Second , we report a case of neutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and thiazide .", "tokens": ["Second", ",", "we", "report", "a", "case", "of", "neutropenia", ",", "which", "proved", "to", "be", "fatal", "in", "a", "schizophrenia", "patient", "receiving", "olanzapine", "and", "thiazide", "."], "event_mentions": [{"id": "16978752_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "16978752_3_Ent1", "role": "Effect", "text": "neutropenia", "start": 7, "end": 8}, {"entity_id": "16978752_3_Ent0", "role": "Subject", "text": "a schizophrenia patient", "start": 15, "end": 18}, {"entity_id": "16978752_3_Ent3", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "16978752_3_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent6", "role": "Combination_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "16978752_3_Ent2", "role": "Treatment", "text": "olanzapine and thiazide", "start": 19, "end": 22}, {"entity_id": "16978752_3_Ent5", "role": "Treatment_Drug", "text": "thiazide", "start": 21, "end": 22}, {"entity_id": "16978752_3_Ent7", "role": "Combination_Drug", "text": "thiazide", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16978752_3_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16978752_3_Ent0", "text": "a schizophrenia patient", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16978752_3_Ent3", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16978752_3_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent6", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16978752_3_Ent2", "text": "olanzapine and thiazide", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16978752_3_Ent5", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16978752_3_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16997047_2", "wnd_id": "16997047_2_1", "text": "In this case , unlike those previously reported , hyponatremia recurred 5 months after switching from citalopram to mirtazapine , which is believed to be a safe antidepressant .", "tokens": ["In", "this", "case", ",", "unlike", "those", "previously", "reported", ",", "hyponatremia", "recurred", "5", "months", "after", "switching", "from", "citalopram", "to", "mirtazapine", ",", "which", "is", "believed", "to", "be", "a", "safe", "antidepressant", "."], "event_mentions": [{"id": "16997047_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "16997047_2_Ent0", "role": "Effect", "text": "hyponatremia", "start": 9, "end": 10}, {"entity_id": "16997047_2_Ent4", "role": "Treatment_Time_elapsed", "text": "5 months", "start": 11, "end": 13}, {"entity_id": "16997047_2_Ent1", "role": "Treatment", "text": "switching from citalopram to mirtazapine", "start": 14, "end": 19}, {"entity_id": "16997047_2_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 16, "end": 17}, {"entity_id": "16997047_2_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16997047_2_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16997047_2_Ent4", "text": "5 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16997047_2_Ent1", "text": "switching from citalopram to mirtazapine", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "16997047_2_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16997047_2_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17039658_1", "wnd_id": "17039658_1_1", "text": "An intertrigo - like eruption from pegylated liposomal doxorubicin .", "tokens": ["An", "intertrigo", "-", "like", "eruption", "from", "pegylated", "liposomal", "doxorubicin", "."], "event_mentions": [{"id": "17039658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 5, "end": 6}, "arguments": [{"entity_id": "17039658_1_Ent0", "role": "Effect", "text": "intertrigo - like eruption", "start": 1, "end": 5}, {"entity_id": "17039658_1_Ent1", "role": "Treatment", "text": "pegylated liposomal doxorubicin", "start": 6, "end": 9}, {"entity_id": "17039658_1_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17039658_1_Ent0", "text": "intertrigo - like eruption", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "17039658_1_Ent1", "text": "pegylated liposomal doxorubicin", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17039658_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17044380_2", "wnd_id": "17044380_2_1", "text": "Warfarin - induced skin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis .", "tokens": ["Warfarin", "-", "induced", "skin", "necrosis", "and", "heparin", "-", "induced", "thrombocytopenia", "following", "mitral", "valve", "replacement", "for", "marantic", "endocarditis", "."], "event_mentions": [{"id": "17044380_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17044380_2_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent2", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "17044380_2_Ent0", "role": "Effect", "text": "skin necrosis", "start": 3, "end": 5}]}, {"id": "17044380_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17044380_2_Ent4", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent6", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "17044380_2_Ent3", "role": "Effect", "text": "thrombocytopenia", "start": 9, "end": 10}, {"entity_id": "17044380_2_Ent5", "role": "Treatment_Disorder", "text": "marantic endocarditis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17044380_2_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent2", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17044380_2_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17044380_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent6", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17044380_2_Ent3", "text": "thrombocytopenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17044380_2_Ent5", "text": "marantic endocarditis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17060191_1", "wnd_id": "17060191_1_1", "text": "Premature closure of the ductus arteriosus : variable response among monozygotic twins after in utero exposure to indomethacin .", "tokens": ["Premature", "closure", "of", "the", "ductus", "arteriosus", ":", "variable", "response", "among", "monozygotic", "twins", "after", "in", "utero", "exposure", "to", "indomethacin", "."], "event_mentions": [{"id": "17060191_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17060191_1_Ent1", "role": "Effect", "text": "Premature closure of the ductus arteriosus", "start": 0, "end": 6}, {"entity_id": "17060191_1_Ent0", "role": "Subject", "text": "monozygotic twins", "start": 10, "end": 12}, {"entity_id": "17060191_1_Ent4", "role": "Treatment_Route", "text": "in utero exposure", "start": 13, "end": 16}, {"entity_id": "17060191_1_Ent2", "role": "Treatment", "text": "in utero exposure to indomethacin", "start": 13, "end": 18}, {"entity_id": "17060191_1_Ent3", "role": "Treatment_Drug", "text": "indomethacin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17060191_1_Ent1", "text": "Premature closure of the ductus arteriosus", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17060191_1_Ent0", "text": "monozygotic twins", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17060191_1_Ent4", "text": "in utero exposure", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17060191_1_Ent2", "text": "in utero exposure to indomethacin", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17060191_1_Ent3", "text": "indomethacin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17060191_2", "wnd_id": "17060191_2_1", "text": "Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects , including premature closure of the ductus arteriosus .", "tokens": ["Exposure", "of", "the", "fetus", "to", "indomethacin", "by", "administration", "of", "the", "drug", "to", "the", "mother", "may", "cause", "many", "side", "effects", ",", "including", "premature", "closure", "of", "the", "ductus", "arteriosus", "."], "event_mentions": [{"id": "17060191_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 17, "end": 19}, "arguments": [{"entity_id": "17060191_2_Ent0", "role": "Subject", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent1", "role": "Subject_Age", "text": "fetus", "start": 3, "end": 4}, {"entity_id": "17060191_2_Ent3", "role": "Treatment", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent4", "role": "Treatment_Drug", "text": "indomethacin", "start": 5, "end": 6}, {"entity_id": "17060191_2_Ent2", "role": "Effect", "text": "premature closure of the ductus arteriosus", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "17060191_2_Ent0", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent1", "text": "fetus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17060191_2_Ent3", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent4", "text": "indomethacin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17060191_2_Ent2", "text": "premature closure of the ductus arteriosus", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "17060191_5", "wnd_id": "17060191_5_1", "text": "This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to ductal closure in response to indomethacin exposure .", "tokens": ["This", "selective", "closure", "of", "the", "ductus", "arteriosus", "suggests", "that", "the", "affected", "twin", "was", "predisposed", "to", "hypoxia", "and", "thus", "was", "more", "susceptible", "to", "ductal", "closure", "in", "response", "to", "indomethacin", "exposure", "."], "event_mentions": [{"id": "17060191_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 25, "end": 26}, "arguments": [{"entity_id": "17060191_5_Ent0", "role": "Effect", "text": "ductal closure", "start": 22, "end": 24}, {"entity_id": "17060191_5_Ent2", "role": "Treatment_Drug", "text": "indomethacin", "start": 27, "end": 28}, {"entity_id": "17060191_5_Ent1", "role": "Treatment", "text": "indomethacin exposure", "start": 27, "end": 29}, {"entity_id": "17060191_5_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17060191_5_Ent0", "text": "ductal closure", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17060191_5_Ent2", "text": "indomethacin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17060191_5_Ent1", "text": "indomethacin exposure", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "17060191_5_Ent3", "text": "exposure", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17083890_8", "wnd_id": "17083890_8_1", "text": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy , which further pointed out towards adriamycin and vincristine as possible etiologic agents .", "tokens": ["All", "changes", "disappeared", "4", "months", "after", "the", "discontinuation", "of", "VAD", "chemotherapy", ",", "which", "further", "pointed", "out", "towards", "adriamycin", "and", "vincristine", "as", "possible", "etiologic", "agents", "."], "event_mentions": [{"id": "17083890_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "etiologic agents", "start": 22, "end": 24}, "arguments": [{"entity_id": "17083890_8_Ent0", "role": "Effect", "text": "All changes", "start": 0, "end": 2}, {"entity_id": "17083890_8_Ent2", "role": "Treatment_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent4", "role": "Combination_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent1", "role": "Treatment", "text": "adriamycin and vincristine", "start": 17, "end": 20}, {"entity_id": "17083890_8_Ent3", "role": "Treatment_Drug", "text": "vincristine", "start": 19, "end": 20}, {"entity_id": "17083890_8_Ent5", "role": "Combination_Drug", "text": "vincristine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17083890_8_Ent0", "text": "All changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17083890_8_Ent2", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent4", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent1", "text": "adriamycin and vincristine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17083890_8_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17083890_8_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17083900_2", "wnd_id": "17083900_2_1", "text": "We report a case of acute generalized exanthematous pustulosis ( AGEP ) in a 50 - year - old woman that was attributed to the ingestion of nimesulide .", "tokens": ["We", "report", "a", "case", "of", "acute", "generalized", "exanthematous", "pustulosis", "(", "AGEP", ")", "in", "a", "50", "-", "year", "-", "old", "woman", "that", "was", "attributed", "to", "the", "ingestion", "of", "nimesulide", "."], "event_mentions": [{"id": "17083900_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "attributed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17083900_2_Ent3", "role": "Effect", "text": "acute generalized exanthematous pustulosis ( AGEP )", "start": 5, "end": 12}, {"entity_id": "17083900_2_Ent0", "role": "Subject", "text": "a 50 - year - old woman", "start": 13, "end": 20}, {"entity_id": "17083900_2_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 14, "end": 19}, {"entity_id": "17083900_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "17083900_2_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 25, "end": 26}, {"entity_id": "17083900_2_Ent4", "role": "Treatment", "text": "ingestion of nimesulide", "start": 25, "end": 28}, {"entity_id": "17083900_2_Ent5", "role": "Treatment_Drug", "text": "nimesulide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "17083900_2_Ent3", "text": "acute generalized exanthematous pustulosis ( AGEP )", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "17083900_2_Ent0", "text": "a 50 - year - old woman", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "17083900_2_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "17083900_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17083900_2_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17083900_2_Ent4", "text": "ingestion of nimesulide", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "17083900_2_Ent5", "text": "nimesulide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "17090724_1", "wnd_id": "17090724_1_1", "text": "DISCUSSION : Amphotericin B deoxycholate has been reported to produce significant cardiac toxicity , with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease , even when administered in conventional dosages and infusion rates .", "tokens": ["DISCUSSION", ":", "Amphotericin", "B", "deoxycholate", "has", "been", "reported", "to", "produce", "significant", "cardiac", "toxicity", ",", "with", "ventricular", "arrhythmias", "and", "bradycardia", "reported", "in", "overdoses", "in", "children", "and", "in", "adults", "with", "preexisting", "cardiac", "disease", ",", "even", "when", "administered", "in", "conventional", "dosages", "and", "infusion", "rates", "."], "event_mentions": [{"id": "17090724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 9, "end": 10}, "arguments": [{"entity_id": "17090724_1_Ent4", "role": "Treatment", "text": "Amphotericin B deoxycholate", "start": 2, "end": 5}, {"entity_id": "17090724_1_Ent6", "role": "Treatment_Drug", "text": "Amphotericin B deoxycholate", "start": 2, "end": 5}, {"entity_id": "17090724_1_Ent3", "role": "Effect", "text": "cardiac toxicity , with ventricular arrhythmias and bradycardia", "start": 11, "end": 19}, {"entity_id": "17090724_1_Ent1", "role": "Subject_Age", "text": "in children and in adults", "start": 22, "end": 27}, {"entity_id": "17090724_1_Ent0", "role": "Subject", "text": "in children and in adults with preexisting cardiac disease", "start": 22, "end": 31}, {"entity_id": "17090724_1_Ent2", "role": "Subject_Disorder", "text": "preexisting cardiac disease", "start": 28, "end": 31}, {"entity_id": "17090724_1_Ent7", "role": "Treatment_Dosage", "text": "conventional dosages", "start": 36, "end": 38}, {"entity_id": "17090724_1_Ent5", "role": "Treatment", "text": "conventional dosages and infusion rates", "start": 36, "end": 41}, {"entity_id": "17090724_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "17090724_1_Ent4", "text": "Amphotericin B deoxycholate", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17090724_1_Ent6", "text": "Amphotericin B deoxycholate", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17090724_1_Ent3", "text": "cardiac toxicity , with ventricular arrhythmias and bradycardia", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "17090724_1_Ent1", "text": "in children and in adults", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "17090724_1_Ent0", "text": "in children and in adults with preexisting cardiac disease", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "17090724_1_Ent2", "text": "preexisting cardiac disease", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "17090724_1_Ent7", "text": "conventional dosages", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "17090724_1_Ent5", "text": "conventional dosages and infusion rates", "entity_type": "Entity", "start": 36, "end": 41}, {"id": "17090724_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "17090724_2", "wnd_id": "17090724_2_1", "text": "OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a fatal cardiac arrhythmia after an acute overdose of amphotericin B and to review its toxicity .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "clinical", "course", "of", "a", "woman", "with", "cryptococcal", "meningitis", "and", "no", "previous", "cardiac", "disease", "who", "developed", "a", "fatal", "cardiac", "arrhythmia", "after", "an", "acute", "overdose", "of", "amphotericin", "B", "and", "to", "review", "its", "toxicity", "."], "event_mentions": [{"id": "17090724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "17090724_2_Ent0", "role": "Subject", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "start": 8, "end": 18}, {"entity_id": "17090724_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "17090724_2_Ent4", "role": "Treatment_Disorder", "text": "cryptococcal meningitis", "start": 11, "end": 13}, {"entity_id": "17090724_2_Ent2", "role": "Effect", "text": "a fatal cardiac arrhythmia", "start": 20, "end": 24}, {"entity_id": "17090724_2_Ent3", "role": "Treatment", "text": "an acute overdose of amphotericin B", "start": 25, "end": 31}, {"entity_id": "17090724_2_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 27, "end": 28}, {"entity_id": "17090724_2_Ent5", "role": "Treatment_Drug", "text": "amphotericin B", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17090724_2_Ent0", "text": "a woman with cryptococcal meningitis and no previous cardiac disease", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17090724_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17090724_2_Ent4", "text": "cryptococcal meningitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17090724_2_Ent2", "text": "a fatal cardiac arrhythmia", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "17090724_2_Ent3", "text": "an acute overdose of amphotericin B", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17090724_2_Ent6", "text": "overdose", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17090724_2_Ent5", "text": "amphotericin B", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "17122225_1", "wnd_id": "17122225_1_1", "text": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs .", "tokens": ["Serotonin", "syndrome", "from", "the", "interaction", "of", "cyclobenzaprine", "with", "other", "serotoninergic", "drugs", "."], "event_mentions": [{"id": "17122225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "17122225_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_1_Ent1", "role": "Treatment", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "start": 4, "end": 11}, {"entity_id": "17122225_1_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 6, "end": 7}, {"entity_id": "17122225_1_Ent3", "role": "Treatment_Drug", "text": "serotoninergic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17122225_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_1_Ent1", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17122225_1_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17122225_1_Ent3", "text": "serotoninergic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17122225_5", "wnd_id": "17122225_5_1", "text": "In both cases , symptoms of autonomic instability and severe agitation started within hours of initiation of cyclobenzaprine and fully resolved within 3 days after discontinuing the proserotoninergic drugs .", "tokens": ["In", "both", "cases", ",", "symptoms", "of", "autonomic", "instability", "and", "severe", "agitation", "started", "within", "hours", "of", "initiation", "of", "cyclobenzaprine", "and", "fully", "resolved", "within", "3", "days", "after", "discontinuing", "the", "proserotoninergic", "drugs", "."], "event_mentions": [{"id": "17122225_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "started", "start": 11, "end": 12}, "arguments": [{"entity_id": "17122225_5_Ent0", "role": "Effect", "text": "symptoms of autonomic instability and severe agitation", "start": 4, "end": 11}, {"entity_id": "17122225_5_Ent3", "role": "Treatment_Time_elapsed", "text": "within hours of initiation", "start": 12, "end": 16}, {"entity_id": "17122225_5_Ent1", "role": "Treatment", "text": "within hours of initiation of cyclobenzaprine", "start": 12, "end": 18}, {"entity_id": "17122225_5_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17122225_5_Ent0", "text": "symptoms of autonomic instability and severe agitation", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17122225_5_Ent3", "text": "within hours of initiation", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17122225_5_Ent1", "text": "within hours of initiation of cyclobenzaprine", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "17122225_5_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17123120_1", "wnd_id": "17123120_1_1", "text": "Tacrolimus - induced HUS : an unusual cause of acute renal failure in nephrotic syndrome .", "tokens": ["Tacrolimus", "-", "induced", "HUS", ":", "an", "unusual", "cause", "of", "acute", "renal", "failure", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17123120_1_Ent1", "role": "Treatment", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent0", "role": "Effect", "text": "HUS", "start": 3, "end": 4}, {"entity_id": "17123120_1_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_1_Ent1", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent0", "text": "HUS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17123120_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17123120_2", "wnd_id": "17123120_2_1", "text": "Thus , tacrolimus - induced HUS is a rare cause of ARF in nephrotic syndrome .", "tokens": ["Thus", ",", "tacrolimus", "-", "induced", "HUS", "is", "a", "rare", "cause", "of", "ARF", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17123120_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent2", "role": "Treatment_Drug", "text": "tacrolimus", "start": 2, "end": 3}, {"entity_id": "17123120_2_Ent0", "role": "Effect", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "17123120_2_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent2", "text": "tacrolimus", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17123120_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17123120_2_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17163271_2", "wnd_id": "17163271_2_1", "text": "In this report , a patient who had undergone a renal transplantation as a result of malignant hypertension , and who was on immunosuppressive therapy consisting of cyclosporin , prednisone and azathioprine , developed thrombosis of the central retinal vein 5 years following the transplantation .", "tokens": ["In", "this", "report", ",", "a", "patient", "who", "had", "undergone", "a", "renal", "transplantation", "as", "a", "result", "of", "malignant", "hypertension", ",", "and", "who", "was", "on", "immunosuppressive", "therapy", "consisting", "of", "cyclosporin", ",", "prednisone", "and", "azathioprine", ",", "developed", "thrombosis", "of", "the", "central", "retinal", "vein", "5", "years", "following", "the", "transplantation", "."], "event_mentions": [{"id": "17163271_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 33, "end": 34}, "arguments": [{"entity_id": "17163271_2_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "17163271_2_Ent4", "role": "Treatment", "text": "undergone a renal transplantation as a result of malignant hypertension", "start": 8, "end": 18}, {"entity_id": "17163271_2_Ent1", "role": "Subject_Disorder", "text": "malignant hypertension", "start": 16, "end": 18}, {"entity_id": "17163271_2_Ent3", "role": "Treatment", "text": "on immunosuppressive therapy consisting of cyclosporin , prednisone and azathioprine", "start": 22, "end": 32}, {"entity_id": "17163271_2_Ent5", "role": "Treatment_Drug", "text": "cyclosporin", "start": 27, "end": 28}, {"entity_id": "17163271_2_Ent9", "role": "Combination_Drug", "text": "cyclosporin", "start": 27, "end": 28}, {"entity_id": "17163271_2_Ent6", "role": "Treatment_Drug", "text": "prednisone", "start": 29, "end": 30}, {"entity_id": "17163271_2_Ent10", "role": "Combination_Drug", "text": "prednisone", "start": 29, "end": 30}, {"entity_id": "17163271_2_Ent7", "role": "Treatment_Drug", "text": "azathioprine", "start": 31, "end": 32}, {"entity_id": "17163271_2_Ent11", "role": "Combination_Drug", "text": "azathioprine", "start": 31, "end": 32}, {"entity_id": "17163271_2_Ent2", "role": "Effect", "text": "thrombosis of the central retinal vein", "start": 34, "end": 40}, {"entity_id": "17163271_2_Ent8", "role": "Treatment_Time_elapsed", "text": "5 years", "start": 40, "end": 42}]}], "entity_mentions": [{"id": "17163271_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17163271_2_Ent4", "text": "undergone a renal transplantation as a result of malignant hypertension", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "17163271_2_Ent1", "text": "malignant hypertension", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17163271_2_Ent3", "text": "on immunosuppressive therapy consisting of cyclosporin , prednisone and azathioprine", "entity_type": "Entity", "start": 22, "end": 32}, {"id": "17163271_2_Ent5", "text": "cyclosporin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17163271_2_Ent9", "text": "cyclosporin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17163271_2_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17163271_2_Ent10", "text": "prednisone", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17163271_2_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "17163271_2_Ent11", "text": "azathioprine", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "17163271_2_Ent2", "text": "thrombosis of the central retinal vein", "entity_type": "Entity", "start": 34, "end": 40}, {"id": "17163271_2_Ent8", "text": "5 years", "entity_type": "Entity", "start": 40, "end": 42}], "lang": "en"}
{"doc_id": "17167851_2", "wnd_id": "17167851_2_1", "text": "Three male patients aged 78 - 83 years are presented , in whom severe hepatotoxic reactions emerged after CPA administration .", "tokens": ["Three", "male", "patients", "aged", "78", "-", "83", "years", "are", "presented", ",", "in", "whom", "severe", "hepatotoxic", "reactions", "emerged", "after", "CPA", "administration", "."], "event_mentions": [{"id": "17167851_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "17167851_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "17167851_2_Ent0", "role": "Subject", "text": "Three male patients aged 78 - 83 years", "start": 0, "end": 8}, {"entity_id": "17167851_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "17167851_2_Ent3", "role": "Subject_Age", "text": "78 - 83 years", "start": 4, "end": 8}, {"entity_id": "17167851_2_Ent4", "role": "Effect", "text": "severe hepatotoxic reactions", "start": 13, "end": 16}, {"entity_id": "17167851_2_Ent5", "role": "Treatment", "text": "CPA", "start": 18, "end": 19}, {"entity_id": "17167851_2_Ent6", "role": "Treatment_Drug", "text": "CPA", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17167851_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17167851_2_Ent0", "text": "Three male patients aged 78 - 83 years", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17167851_2_Ent2", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17167851_2_Ent3", "text": "78 - 83 years", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17167851_2_Ent4", "text": "severe hepatotoxic reactions", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17167851_2_Ent5", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17167851_2_Ent6", "text": "CPA", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17182354_3", "wnd_id": "17182354_3_1", "text": "Methylphenidate ( Ritalin) - associated cataract and glaucoma .", "tokens": ["Methylphenidate", "(", "Ritalin)", "-", "associated", "cataract", "and", "glaucoma", "."], "event_mentions": [{"id": "17182354_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17182354_3_Ent2", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "17182354_3_Ent1", "role": "Treatment", "text": "Methylphenidate ( Ritalin)", "start": 0, "end": 3}, {"entity_id": "17182354_3_Ent0", "role": "Effect", "text": "cataract and glaucoma", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "17182354_3_Ent2", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17182354_3_Ent1", "text": "Methylphenidate ( Ritalin)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17182354_3_Ent0", "text": "cataract and glaucoma", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "17188061_1", "wnd_id": "17188061_1_1", "text": "CONCLUSIONS : We report a typical symptoms of Charles - Bonnet syndrome ( CBS ) in patients with severe AMD after intravitreal Avastin - injections .", "tokens": ["CONCLUSIONS", ":", "We", "report", "a", "typical", "symptoms", "of", "Charles", "-", "Bonnet", "syndrome", "(", "CBS", ")", "in", "patients", "with", "severe", "AMD", "after", "intravitreal", "Avastin", "-", "injections", "."], "event_mentions": [{"id": "17188061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "17188061_1_Ent1", "role": "Effect", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "start": 5, "end": 15}, {"entity_id": "17188061_1_Ent0", "role": "Subject", "text": "patients with severe AMD", "start": 16, "end": 20}, {"entity_id": "17188061_1_Ent6", "role": "Treatment_Disorder", "text": "AMD", "start": 19, "end": 20}, {"entity_id": "17188061_1_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 21, "end": 22}, {"entity_id": "17188061_1_Ent2", "role": "Treatment", "text": "intravitreal Avastin - injections", "start": 21, "end": 25}, {"entity_id": "17188061_1_Ent3", "role": "Treatment_Drug", "text": "Avastin", "start": 22, "end": 23}, {"entity_id": "17188061_1_Ent5", "role": "Treatment_Route", "text": "injections", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17188061_1_Ent1", "text": "typical symptoms of Charles - Bonnet syndrome ( CBS )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "17188061_1_Ent0", "text": "patients with severe AMD", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17188061_1_Ent6", "text": "AMD", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17188061_1_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17188061_1_Ent2", "text": "intravitreal Avastin - injections", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17188061_1_Ent3", "text": "Avastin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17188061_1_Ent5", "text": "injections", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17224428_1", "wnd_id": "17224428_1_1", "text": "Cardiac hypersensitivity and myopericarditis have been reported during long - term treatment with mesalazine .", "tokens": ["Cardiac", "hypersensitivity", "and", "myopericarditis", "have", "been", "reported", "during", "long", "-", "term", "treatment", "with", "mesalazine", "."], "event_mentions": [{"id": "17224428_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "17224428_1_Ent0", "role": "Effect", "text": "Cardiac hypersensitivity and myopericarditis", "start": 0, "end": 4}, {"entity_id": "17224428_1_Ent2", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "17224428_1_Ent1", "role": "Treatment", "text": "long - term treatment with mesalazine", "start": 8, "end": 14}, {"entity_id": "17224428_1_Ent3", "role": "Treatment_Drug", "text": "mesalazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17224428_1_Ent0", "text": "Cardiac hypersensitivity and myopericarditis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17224428_1_Ent2", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17224428_1_Ent1", "text": "long - term treatment with mesalazine", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17224428_1_Ent3", "text": "mesalazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17224428_2", "wnd_id": "17224428_2_1", "text": "We report the case of a man , treated with mesalazine for Crohn 's disease who developed drug - induced pericarditis .", "tokens": ["We", "report", "the", "case", "of", "a", "man", ",", "treated", "with", "mesalazine", "for", "Crohn", "'s", "disease", "who", "developed", "drug", "-", "induced", "pericarditis", "."], "event_mentions": [{"id": "17224428_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "17224428_2_Ent0", "role": "Subject", "text": "a man", "start": 5, "end": 7}, {"entity_id": "17224428_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17224428_2_Ent3", "role": "Treatment", "text": "mesalazine", "start": 10, "end": 11}, {"entity_id": "17224428_2_Ent5", "role": "Treatment_Drug", "text": "mesalazine", "start": 10, "end": 11}, {"entity_id": "17224428_2_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 12, "end": 15}, {"entity_id": "17224428_2_Ent2", "role": "Effect", "text": "drug - induced pericarditis", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "17224428_2_Ent0", "text": "a man", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17224428_2_Ent1", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17224428_2_Ent3", "text": "mesalazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17224428_2_Ent5", "text": "mesalazine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17224428_2_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17224428_2_Ent2", "text": "drug - induced pericarditis", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "17228132_6", "wnd_id": "17228132_6_1", "text": "CONCLUSIONS : Acute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or erlotinib .", "tokens": ["CONCLUSIONS", ":", "Acute", "severe", "hepatitis", "though", "rare", "is", "occasionally", "observed", "with", "EGFR", "inhibitors", "gefitinib", "or", "erlotinib", "."], "event_mentions": [{"id": "17228132_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 9, "end": 10}, "arguments": [{"entity_id": "17228132_6_Ent0", "role": "Effect", "text": "Acute severe hepatitis", "start": 2, "end": 5}, {"entity_id": "17228132_6_Ent1", "role": "Treatment", "text": "EGFR inhibitors gefitinib or erlotinib", "start": 11, "end": 16}, {"entity_id": "17228132_6_Ent2", "role": "Treatment_Drug", "text": "gefitinib", "start": 13, "end": 14}, {"entity_id": "17228132_6_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17228132_6_Ent0", "text": "Acute severe hepatitis", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17228132_6_Ent1", "text": "EGFR inhibitors gefitinib or erlotinib", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "17228132_6_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17228132_6_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1722991_9", "wnd_id": "1722991_9_1", "text": "This experience supports the hypothesis that heparin can be readministered early to patients with heparin - associated thrombocytopenia and thrombosis , provided antiplatelet therapy is given .", "tokens": ["This", "experience", "supports", "the", "hypothesis", "that", "heparin", "can", "be", "readministered", "early", "to", "patients", "with", "heparin", "-", "associated", "thrombocytopenia", "and", "thrombosis", ",", "provided", "antiplatelet", "therapy", "is", "given", "."], "event_mentions": [{"id": "1722991_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "readministered", "start": 9, "end": 10}, "arguments": [{"entity_id": "1722991_9_Ent0", "role": "Treatment", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent6", "role": "Combination_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "1722991_9_Ent2", "role": "Treatment_Disorder", "text": "heparin - associated thrombocytopenia", "start": 14, "end": 18}, {"entity_id": "1722991_9_Ent4", "role": "Treatment_Drug", "text": "antiplatelet", "start": 22, "end": 23}, {"entity_id": "1722991_9_Ent5", "role": "Combination_Drug", "text": "antiplatelet", "start": 22, "end": 23}, {"entity_id": "1722991_9_Ent1", "role": "Treatment", "text": "antiplatelet therapy is given", "start": 22, "end": 26}]}, {"id": "1722991_9_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "1722991_9_Ent8", "role": "Treatment", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "1722991_9_Ent9", "role": "Treatment_Drug", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "1722991_9_Ent7", "role": "Effect", "text": "thrombocytopenia and thrombosis", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "1722991_9_Ent0", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent3", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent6", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1722991_9_Ent8", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1722991_9_Ent9", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1722991_9_Ent2", "text": "heparin - associated thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1722991_9_Ent7", "text": "thrombocytopenia and thrombosis", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "1722991_9_Ent4", "text": "antiplatelet", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1722991_9_Ent5", "text": "antiplatelet", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1722991_9_Ent1", "text": "antiplatelet therapy is given", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "17260498_5", "wnd_id": "17260498_5_1", "text": "Even though only a few cases of this adverse event have been reported in the literature , severe docetaxel - induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms .", "tokens": ["Even", "though", "only", "a", "few", "cases", "of", "this", "adverse", "event", "have", "been", "reported", "in", "the", "literature", ",", "severe", "docetaxel", "-", "induced", "pulmonary", "toxicity", "needs", "to", "be", "considered", "in", "the", "differential", "diagnosis", "when", "such", "patients", "present", "with", "respiratory", "symptoms", "."], "event_mentions": [{"id": "17260498_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "17260498_5_Ent2", "role": "Treatment", "text": "docetaxel", "start": 18, "end": 19}, {"entity_id": "17260498_5_Ent3", "role": "Treatment_Drug", "text": "docetaxel", "start": 18, "end": 19}, {"entity_id": "17260498_5_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 21, "end": 23}, {"entity_id": "17260498_5_Ent1", "role": "Effect", "text": "respiratory symptoms", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "17260498_5_Ent2", "text": "docetaxel", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17260498_5_Ent3", "text": "docetaxel", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17260498_5_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17260498_5_Ent1", "text": "respiratory symptoms", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "17266059_2", "wnd_id": "17266059_2_1", "text": "Thrombotic thrombocytopenic purpura induced by trimethoprim - sulfamethoxazole in a Jehovah 's Witness .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "induced", "by", "trimethoprim", "-", "sulfamethoxazole", "in", "a", "Jehovah", "'s", "Witness", "."], "event_mentions": [{"id": "17266059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17266059_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura", "start": 0, "end": 3}, {"entity_id": "17266059_2_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim - sulfamethoxazole", "start": 5, "end": 8}, {"entity_id": "17266059_2_Ent0", "role": "Subject", "text": "a Jehovah 's Witness", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "17266059_2_Ent1", "text": "Thrombotic thrombocytopenic purpura", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17266059_2_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent3", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "17266059_2_Ent0", "text": "a Jehovah 's Witness", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "17275666_2", "wnd_id": "17275666_2_1", "text": "Valproic acid is commonly and effectively used in the treatment of idiopathic generalized epilepsies , including juvenile absence epilepsy .", "tokens": ["Valproic", "acid", "is", "commonly", "and", "effectively", "used", "in", "the", "treatment", "of", "idiopathic", "generalized", "epilepsies", ",", "including", "juvenile", "absence", "epilepsy", "."], "event_mentions": [{"id": "17275666_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 6, "end": 7}, "arguments": [{"entity_id": "17275666_2_Ent0", "role": "Treatment", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "17275666_2_Ent1", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "17275666_2_Ent2", "role": "Treatment_Disorder", "text": "idiopathic generalized epilepsies", "start": 11, "end": 14}, {"entity_id": "17275666_2_Ent3", "role": "Treatment_Disorder", "text": "juvenile absence epilepsy", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "17275666_2_Ent0", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17275666_2_Ent1", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17275666_2_Ent2", "text": "idiopathic generalized epilepsies", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17275666_2_Ent3", "text": "juvenile absence epilepsy", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "17275666_4", "wnd_id": "17275666_4_1", "text": "Similar to antiarrhythmic drugs aggravating particular arrhythmias , antiepileptic drugs can paradoxically induce new seizure types or exacerbate existing ones .", "tokens": ["Similar", "to", "antiarrhythmic", "drugs", "aggravating", "particular", "arrhythmias", ",", "antiepileptic", "drugs", "can", "paradoxically", "induce", "new", "seizure", "types", "or", "exacerbate", "existing", "ones", "."], "event_mentions": [{"id": "17275666_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 12, "end": 13}, "arguments": [{"entity_id": "17275666_4_Ent2", "role": "Treatment_Drug", "text": "antiarrhythmic drugs", "start": 2, "end": 4}, {"entity_id": "17275666_4_Ent1", "role": "Treatment", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent3", "role": "Treatment_Drug", "text": "antiepileptic drugs", "start": 8, "end": 10}, {"entity_id": "17275666_4_Ent0", "role": "Effect", "text": "new seizure types or exacerbate existing ones", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "17275666_4_Ent2", "text": "antiarrhythmic drugs", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17275666_4_Ent1", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent3", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17275666_4_Ent0", "text": "new seizure types or exacerbate existing ones", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "17298107_1", "wnd_id": "17298107_1_1", "text": "The patient 's arthritis flared after the second infusion of infliximab , which was discontinued .", "tokens": ["The", "patient", "'s", "arthritis", "flared", "after", "the", "second", "infusion", "of", "infliximab", ",", "which", "was", "discontinued", "."], "event_mentions": [{"id": "17298107_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "17298107_1_Ent0", "role": "Subject", "text": "patient 's", "start": 1, "end": 3}, {"entity_id": "17298107_1_Ent1", "role": "Effect", "text": "arthritis flared", "start": 3, "end": 5}, {"entity_id": "17298107_1_Ent5", "role": "Treatment_Time_elapsed", "text": "second", "start": 7, "end": 8}, {"entity_id": "17298107_1_Ent2", "role": "Treatment", "text": "second infusion of infliximab", "start": 7, "end": 11}, {"entity_id": "17298107_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}, {"entity_id": "17298107_1_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17298107_1_Ent0", "text": "patient 's", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17298107_1_Ent1", "text": "arthritis flared", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17298107_1_Ent5", "text": "second", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17298107_1_Ent2", "text": "second infusion of infliximab", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "17298107_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17298107_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17316891_1", "wnd_id": "17316891_1_1", "text": "We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed status epilepticus shortly after receiving cisplatin and gemcitabine chemotherapy .", "tokens": ["We", "describe", "the", "case", "of", "a", "50", "-", "year", "-", "old", "woman", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "who", "developed", "status", "epilepticus", "shortly", "after", "receiving", "cisplatin", "and", "gemcitabine", "chemotherapy", "."], "event_mentions": [{"id": "17316891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "17316891_1_Ent0", "role": "Subject", "text": "a 50 - year - old woman with advanced non - small cell lung cancer", "start": 5, "end": 20}, {"entity_id": "17316891_1_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 6, "end": 11}, {"entity_id": "17316891_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "17316891_1_Ent7", "role": "Treatment_Disorder", "text": "lung cancer", "start": 18, "end": 20}, {"entity_id": "17316891_1_Ent3", "role": "Effect", "text": "status epilepticus", "start": 22, "end": 24}, {"entity_id": "17316891_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "17316891_1_Ent9", "role": "Combination_Drug", "text": "cisplatin", "start": 27, "end": 28}, {"entity_id": "17316891_1_Ent4", "role": "Treatment", "text": "cisplatin and gemcitabine chemotherapy", "start": 27, "end": 31}, {"entity_id": "17316891_1_Ent6", "role": "Treatment_Drug", "text": "gemcitabine", "start": 29, "end": 30}, {"entity_id": "17316891_1_Ent10", "role": "Combination_Drug", "text": "gemcitabine", "start": 29, "end": 30}, {"entity_id": "17316891_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "17316891_1_Ent0", "text": "a 50 - year - old woman with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 5, "end": 20}, {"id": "17316891_1_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17316891_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17316891_1_Ent7", "text": "lung cancer", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "17316891_1_Ent3", "text": "status epilepticus", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "17316891_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17316891_1_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17316891_1_Ent4", "text": "cisplatin and gemcitabine chemotherapy", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "17316891_1_Ent6", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17316891_1_Ent10", "text": "gemcitabine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "17316891_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "17329303_10", "wnd_id": "17329303_10_1", "text": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate .", "tokens": ["Functional", "regulation", "of", "certain", "neuroreceptors", "during", "risperidone", "treatment", "may", "lead", "to", "altered", "behavioural", "responses", "upon", "switching", "to", "methylphenidate", "."], "event_mentions": [{"id": "17329303_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 9, "end": 10}, "arguments": [{"entity_id": "17329303_10_Ent1", "role": "Treatment", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent0", "role": "Effect", "text": "altered behavioural responses", "start": 11, "end": 14}, {"entity_id": "17329303_10_Ent2", "role": "Treatment", "text": "switching to methylphenidate", "start": 15, "end": 18}, {"entity_id": "17329303_10_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17329303_10_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent0", "text": "altered behavioural responses", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17329303_10_Ent2", "text": "switching to methylphenidate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17329303_10_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17329303_9", "wnd_id": "17329303_9_1", "text": "In all the cases described here , it is only with the discontinuation of methylphenidate that the adverse reactions resolved and readministration of methylphenidate in two patients did not produce any adverse effect after a drug - free interval .", "tokens": ["In", "all", "the", "cases", "described", "here", ",", "it", "is", "only", "with", "the", "discontinuation", "of", "methylphenidate", "that", "the", "adverse", "reactions", "resolved", "and", "readministration", "of", "methylphenidate", "in", "two", "patients", "did", "not", "produce", "any", "adverse", "effect", "after", "a", "drug", "-", "free", "interval", "."], "event_mentions": [{"id": "17329303_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 19, "end": 20}, "arguments": [{"entity_id": "17329303_9_Ent1", "role": "Treatment", "text": "discontinuation of methylphenidate", "start": 12, "end": 15}, {"entity_id": "17329303_9_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 14, "end": 15}, {"entity_id": "17329303_9_Ent0", "role": "Effect", "text": "adverse reactions", "start": 17, "end": 19}]}, {"id": "17329303_9_Evt1", "event_type": "Adverse_event", "trigger": {"text": "produce", "start": 29, "end": 30}, "arguments": [{"entity_id": "17329303_9_Ent6", "role": "Treatment", "text": "methylphenidate", "start": 23, "end": 24}, {"entity_id": "17329303_9_Ent7", "role": "Treatment_Drug", "text": "methylphenidate", "start": 23, "end": 24}, {"entity_id": "17329303_9_Ent4", "role": "Subject_Population", "text": "two", "start": 25, "end": 26}, {"entity_id": "17329303_9_Ent3", "role": "Subject", "text": "two patients", "start": 25, "end": 27}, {"entity_id": "17329303_9_Ent5", "role": "Effect", "text": "adverse effect after a drug - free interval", "start": 31, "end": 39}]}], "entity_mentions": [{"id": "17329303_9_Ent1", "text": "discontinuation of methylphenidate", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17329303_9_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17329303_9_Ent0", "text": "adverse reactions", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17329303_9_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17329303_9_Ent7", "text": "methylphenidate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17329303_9_Ent4", "text": "two", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17329303_9_Ent3", "text": "two patients", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17329303_9_Ent5", "text": "adverse effect after a drug - free interval", "entity_type": "Entity", "start": 31, "end": 39}], "lang": "en"}
{"doc_id": "17331261_2", "wnd_id": "17331261_2_1", "text": "CONCLUSION : Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and deterioration of pulmonary function following the use of tobramycin by inhalation or by intravenous administration .", "tokens": ["CONCLUSION", ":", "Hypersensitivity", "reaction", "should", "be", "considered", "in", "patients", "who", "develop", "recurrent", "eosinophilia", "and", "deterioration", "of", "pulmonary", "function", "following", "the", "use", "of", "tobramycin", "by", "inhalation", "or", "by", "intravenous", "administration", "."], "event_mentions": [{"id": "17331261_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 10, "end": 11}, "arguments": [{"entity_id": "17331261_2_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "17331261_2_Ent1", "role": "Effect", "text": "recurrent eosinophilia and deterioration of pulmonary function", "start": 11, "end": 18}, {"entity_id": "17331261_2_Ent2", "role": "Treatment", "text": "use of tobramycin by inhalation or by intravenous administration", "start": 20, "end": 29}, {"entity_id": "17331261_2_Ent3", "role": "Treatment_Drug", "text": "tobramycin", "start": 22, "end": 23}, {"entity_id": "17331261_2_Ent4", "role": "Treatment_Route", "text": "inhalation", "start": 24, "end": 25}, {"entity_id": "17331261_2_Ent5", "role": "Treatment_Route", "text": "intravenous administration .", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "17331261_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17331261_2_Ent1", "text": "recurrent eosinophilia and deterioration of pulmonary function", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "17331261_2_Ent2", "text": "use of tobramycin by inhalation or by intravenous administration", "entity_type": "Entity", "start": 20, "end": 29}, {"id": "17331261_2_Ent3", "text": "tobramycin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17331261_2_Ent4", "text": "inhalation", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17331261_2_Ent5", "text": "intravenous administration .", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "17352036_1", "wnd_id": "17352036_1_1", "text": "Adverse effects of amiodarone including pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases are well understood .", "tokens": ["Adverse", "effects", "of", "amiodarone", "including", "pulmonary", "toxicity", ",", "hepatotoxicity", ",", "aggravation", "of", "arrhythmia", ",", "and", "thyroid", "diseases", "are", "well", "understood", "."], "event_mentions": [{"id": "17352036_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "including", "start": 4, "end": 5}, "arguments": [{"entity_id": "17352036_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "17352036_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "17352036_1_Ent0", "role": "Effect", "text": "pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases", "start": 5, "end": 17}]}], "entity_mentions": [{"id": "17352036_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17352036_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17352036_1_Ent0", "text": "pulmonary toxicity , hepatotoxicity , aggravation of arrhythmia , and thyroid diseases", "entity_type": "Entity", "start": 5, "end": 17}], "lang": "en"}
{"doc_id": "17352036_4", "wnd_id": "17352036_4_1", "text": "We report a patient who developed acute pancreatitis during amiodarone therapy .", "tokens": ["We", "report", "a", "patient", "who", "developed", "acute", "pancreatitis", "during", "amiodarone", "therapy", "."], "event_mentions": [{"id": "17352036_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "17352036_4_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "17352036_4_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 6, "end": 8}, {"entity_id": "17352036_4_Ent2", "role": "Treatment", "text": "amiodarone", "start": 9, "end": 10}, {"entity_id": "17352036_4_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17352036_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17352036_4_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17352036_4_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17352036_4_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17364199_14", "wnd_id": "17364199_14_1", "text": "DISCUSSION : To our knowledge this is the first reported case of tuberculous uveitis following treatment with etanercept .", "tokens": ["DISCUSSION", ":", "To", "our", "knowledge", "this", "is", "the", "first", "reported", "case", "of", "tuberculous", "uveitis", "following", "treatment", "with", "etanercept", "."], "event_mentions": [{"id": "17364199_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 16, "end": 17}, "arguments": [{"entity_id": "17364199_14_Ent0", "role": "Effect", "text": "tuberculous uveitis", "start": 12, "end": 14}, {"entity_id": "17364199_14_Ent1", "role": "Treatment", "text": "etanercept", "start": 17, "end": 18}, {"entity_id": "17364199_14_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17364199_14_Ent0", "text": "tuberculous uveitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "17364199_14_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17364199_14_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17373180_1", "wnd_id": "17373180_1_1", "text": "Infliximab and its serious adverse effects are discussed , and other cases of osteomyelitis with infliximab use are also reviewed .", "tokens": ["Infliximab", "and", "its", "serious", "adverse", "effects", "are", "discussed", ",", "and", "other", "cases", "of", "osteomyelitis", "with", "infliximab", "use", "are", "also", "reviewed", "."], "event_mentions": [{"id": "17373180_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 14, "end": 15}, "arguments": [{"entity_id": "17373180_1_Ent3", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "17373180_1_Ent0", "role": "Effect", "text": "osteomyelitis", "start": 13, "end": 14}, {"entity_id": "17373180_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "17373180_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17373180_1_Ent3", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17373180_1_Ent0", "text": "osteomyelitis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17373180_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17373180_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "17381671_9", "wnd_id": "17381671_9_1", "text": "CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome , following initiation of fentanyl , and all symptoms and signs resolved following discontinuation of fentanyl .", "tokens": ["CASE", "SUMMARY", ":", "A", "65", "-", "year", "-", "old", "patient", "chronically", "treated", "with", "the", "selective", "serotonin", "reuptake", "inhibitor", "(", "SSRI", ")", "citalopram", "developed", "confusion", ",", "agitation", ",", "tachycardia", ",", "tremors", ",", "myoclonic", "jerks", "and", "unsteady", "gait", ",", "consistent", "with", "serotonin", "syndrome", ",", "following", "initiation", "of", "fentanyl", ",", "and", "all", "symptoms", "and", "signs", "resolved", "following", "discontinuation", "of", "fentanyl", "."], "event_mentions": [{"id": "17381671_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17381671_9_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 4, "end": 9}, {"entity_id": "17381671_9_Ent0", "role": "Subject", "text": "65 - year - old patient", "start": 4, "end": 10}, {"entity_id": "17381671_9_Ent7", "role": "Treatment_Duration", "text": "chronically", "start": 10, "end": 11}, {"entity_id": "17381671_9_Ent3", "role": "Treatment", "text": "chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram", "start": 10, "end": 22}, {"entity_id": "17381671_9_Ent6", "role": "Treatment_Drug", "text": "citalopram", "start": 21, "end": 22}, {"entity_id": "17381671_9_Ent9", "role": "Combination_Drug", "text": "citalopram", "start": 21, "end": 22}, {"entity_id": "17381671_9_Ent2", "role": "Effect", "text": "confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome", "start": 23, "end": 41}, {"entity_id": "17381671_9_Ent4", "role": "Treatment", "text": "following initiation of fentanyl", "start": 42, "end": 46}, {"entity_id": "17381671_9_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 45, "end": 46}, {"entity_id": "17381671_9_Ent8", "role": "Combination_Drug", "text": "fentanyl", "start": 45, "end": 46}]}], "entity_mentions": [{"id": "17381671_9_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "17381671_9_Ent0", "text": "65 - year - old patient", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "17381671_9_Ent7", "text": "chronically", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17381671_9_Ent3", "text": "chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram", "entity_type": "Entity", "start": 10, "end": 22}, {"id": "17381671_9_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17381671_9_Ent9", "text": "citalopram", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17381671_9_Ent2", "text": "confusion , agitation , tachycardia , tremors , myoclonic jerks and unsteady gait , consistent with serotonin syndrome", "entity_type": "Entity", "start": 23, "end": 41}, {"id": "17381671_9_Ent4", "text": "following initiation of fentanyl", "entity_type": "Entity", "start": 42, "end": 46}, {"id": "17381671_9_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 45, "end": 46}, {"id": "17381671_9_Ent8", "text": "fentanyl", "entity_type": "Entity", "start": 45, "end": 46}], "lang": "en"}
{"doc_id": "17383767_4", "wnd_id": "17383767_4_1", "text": "We report a case in which a potential drug interaction resulted in elevated phenytoin levels after initiation of erlotinib therapy in a patient who was receiving phenytoin .", "tokens": ["We", "report", "a", "case", "in", "which", "a", "potential", "drug", "interaction", "resulted", "in", "elevated", "phenytoin", "levels", "after", "initiation", "of", "erlotinib", "therapy", "in", "a", "patient", "who", "was", "receiving", "phenytoin", "."], "event_mentions": [{"id": "17383767_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 10, "end": 12}, "arguments": [{"entity_id": "17383767_4_Ent2", "role": "Treatment", "text": "a potential drug interaction", "start": 6, "end": 10}, {"entity_id": "17383767_4_Ent1", "role": "Effect", "text": "elevated phenytoin levels", "start": 12, "end": 15}, {"entity_id": "17383767_4_Ent3", "role": "Treatment", "text": "initiation of erlotinib therapy", "start": 16, "end": 20}, {"entity_id": "17383767_4_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 18, "end": 19}, {"entity_id": "17383767_4_Ent7", "role": "Combination_Drug", "text": "erlotinib", "start": 18, "end": 19}, {"entity_id": "17383767_4_Ent0", "role": "Subject", "text": "a patient", "start": 21, "end": 23}, {"entity_id": "17383767_4_Ent4", "role": "Treatment", "text": "receiving phenytoin", "start": 25, "end": 27}, {"entity_id": "17383767_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 26, "end": 27}, {"entity_id": "17383767_4_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "17383767_4_Ent2", "text": "a potential drug interaction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "17383767_4_Ent1", "text": "elevated phenytoin levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17383767_4_Ent3", "text": "initiation of erlotinib therapy", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17383767_4_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17383767_4_Ent7", "text": "erlotinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17383767_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17383767_4_Ent4", "text": "receiving phenytoin", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17383767_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17383767_4_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "17387702_1", "wnd_id": "17387702_1_1", "text": "Renal failure after high - dose methotrexate in a child homozygous for MTHFR C677 T polymorphism .", "tokens": ["Renal", "failure", "after", "high", "-", "dose", "methotrexate", "in", "a", "child", "homozygous", "for", "MTHFR", "C677", "T", "polymorphism", "."], "event_mentions": [{"id": "17387702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17387702_1_Ent3", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "17387702_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 3, "end": 6}, {"entity_id": "17387702_1_Ent4", "role": "Treatment", "text": "high - dose methotrexate", "start": 3, "end": 7}, {"entity_id": "17387702_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "17387702_1_Ent0", "role": "Subject", "text": "a child homozygous for MTHFR C677 T polymorphism", "start": 8, "end": 16}, {"entity_id": "17387702_1_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "17387702_1_Ent2", "role": "Subject_Disorder", "text": "homozygous for MTHFR C677 T polymorphism", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "17387702_1_Ent3", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17387702_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17387702_1_Ent4", "text": "high - dose methotrexate", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "17387702_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17387702_1_Ent0", "text": "a child homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "17387702_1_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17387702_1_Ent2", "text": "homozygous for MTHFR C677 T polymorphism", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "17404582_3", "wnd_id": "17404582_3_1", "text": "We report a 71 - year male with castration - resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment .", "tokens": ["We", "report", "a", "71", "-", "year", "male", "with", "castration", "-", "resistant", "metastatic", "prostate", "cancer", "who", "was", "treated", "with", "weekly", "docetaxel", "for", "12", "weeks", "and", "developed", "significant", "eye", "irritation", "and", "dryness", "during", "treatment", "."], "event_mentions": [{"id": "17404582_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "17404582_3_Ent0", "role": "Subject", "text": "a 71 - year male with castration - resistant metastatic prostate cancer", "start": 2, "end": 14}, {"entity_id": "17404582_3_Ent1", "role": "Subject_Age", "text": "71 - year", "start": 3, "end": 6}, {"entity_id": "17404582_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "17404582_3_Ent5", "role": "Treatment_Disorder", "text": "castration - resistant metastatic prostate cancer", "start": 8, "end": 14}, {"entity_id": "17404582_3_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 18, "end": 19}, {"entity_id": "17404582_3_Ent4", "role": "Treatment", "text": "weekly docetaxel for 12 weeks", "start": 18, "end": 23}, {"entity_id": "17404582_3_Ent6", "role": "Treatment_Drug", "text": "docetaxel", "start": 19, "end": 20}, {"entity_id": "17404582_3_Ent8", "role": "Treatment_Duration", "text": "12 weeks", "start": 21, "end": 23}, {"entity_id": "17404582_3_Ent3", "role": "Effect", "text": "significant eye irritation and dryness", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "17404582_3_Ent0", "text": "a 71 - year male with castration - resistant metastatic prostate cancer", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "17404582_3_Ent1", "text": "71 - year", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17404582_3_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17404582_3_Ent5", "text": "castration - resistant metastatic prostate cancer", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17404582_3_Ent7", "text": "weekly", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17404582_3_Ent4", "text": "weekly docetaxel for 12 weeks", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "17404582_3_Ent6", "text": "docetaxel", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17404582_3_Ent8", "text": "12 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17404582_3_Ent3", "text": "significant eye irritation and dryness", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "17420198_10", "wnd_id": "17420198_10_1", "text": "Facial , tongue , and arm movements were first reported approximately five weeks after the initiation of aripiprazole .", "tokens": ["Facial", ",", "tongue", ",", "and", "arm", "movements", "were", "first", "reported", "approximately", "five", "weeks", "after", "the", "initiation", "of", "aripiprazole", "."], "event_mentions": [{"id": "17420198_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "17420198_10_Ent0", "role": "Effect", "text": "Facial , tongue , and arm movements", "start": 0, "end": 7}, {"entity_id": "17420198_10_Ent2", "role": "Treatment_Time_elapsed", "text": "five weeks", "start": 11, "end": 13}, {"entity_id": "17420198_10_Ent1", "role": "Treatment", "text": "initiation of aripiprazole", "start": 15, "end": 18}, {"entity_id": "17420198_10_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17420198_10_Ent0", "text": "Facial , tongue , and arm movements", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "17420198_10_Ent2", "text": "five weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17420198_10_Ent1", "text": "initiation of aripiprazole", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17420198_10_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17420198_18", "wnd_id": "17420198_18_1", "text": "Aripiprazole was subsequently discontinued secondary to its lack of efficacy for OCD and the development of a movement disorder .", "tokens": ["Aripiprazole", "was", "subsequently", "discontinued", "secondary", "to", "its", "lack", "of", "efficacy", "for", "OCD", "and", "the", "development", "of", "a", "movement", "disorder", "."], "event_mentions": [{"id": "17420198_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 14, "end": 15}, "arguments": [{"entity_id": "17420198_18_Ent1", "role": "Treatment", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent3", "role": "Treatment_Drug", "text": "Aripiprazole", "start": 0, "end": 1}, {"entity_id": "17420198_18_Ent2", "role": "Treatment_Disorder", "text": "OCD", "start": 11, "end": 12}, {"entity_id": "17420198_18_Ent0", "role": "Effect", "text": "a movement disorder", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "17420198_18_Ent1", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent3", "text": "Aripiprazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17420198_18_Ent2", "text": "OCD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_18_Ent0", "text": "a movement disorder", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "17426073_1", "wnd_id": "17426073_1_1", "text": "CONCLUSIONS : For all patients with vancomycin - induced neutropenia , possible cross - reactivity of teicoplanin should be monitored .", "tokens": ["CONCLUSIONS", ":", "For", "all", "patients", "with", "vancomycin", "-", "induced", "neutropenia", ",", "possible", "cross", "-", "reactivity", "of", "teicoplanin", "should", "be", "monitored", "."], "event_mentions": [{"id": "17426073_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17426073_1_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "17426073_1_Ent2", "role": "Treatment", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent6", "role": "Combination_Drug", "text": "vancomycin", "start": 6, "end": 7}, {"entity_id": "17426073_1_Ent1", "role": "Effect", "text": "neutropenia", "start": 9, "end": 10}, {"entity_id": "17426073_1_Ent4", "role": "Treatment_Drug", "text": "teicoplanin", "start": 16, "end": 17}, {"entity_id": "17426073_1_Ent5", "role": "Combination_Drug", "text": "teicoplanin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17426073_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17426073_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent6", "text": "vancomycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17426073_1_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17426073_1_Ent4", "text": "teicoplanin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17426073_1_Ent5", "text": "teicoplanin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17444802_4", "wnd_id": "17444802_4_1", "text": "RESULTS : An 81 - year - old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye .", "tokens": ["RESULTS", ":", "An", "81", "-", "year", "-", "old", "man", "with", "a", "history", "of", "neoplasies", "of", "the", "colon", "and", "prostate", "and", "anticoagulant", "treatment", "was", "referred", "for", "treatment", "of", "an", "ocular", "surface", "neoplasia", "on", "his", "left", "eye", "."], "event_mentions": [{"id": "17444802_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "referred", "start": 23, "end": 24}, "arguments": [{"entity_id": "17444802_4_Ent0", "role": "Subject", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "start": 2, "end": 19}, {"entity_id": "17444802_4_Ent1", "role": "Subject_Age", "text": "81 - year - old", "start": 3, "end": 8}, {"entity_id": "17444802_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "17444802_4_Ent6", "role": "Treatment_Disorder", "text": "neoplasies of the colon and prostate", "start": 13, "end": 19}, {"entity_id": "17444802_4_Ent4", "role": "Treatment", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent5", "role": "Treatment_Drug", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent3", "role": "Effect", "text": "an ocular surface neoplasia on his left eye", "start": 27, "end": 35}]}], "entity_mentions": [{"id": "17444802_4_Ent0", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "17444802_4_Ent1", "text": "81 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17444802_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17444802_4_Ent6", "text": "neoplasies of the colon and prostate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "17444802_4_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent5", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent3", "text": "an ocular surface neoplasia on his left eye", "entity_type": "Entity", "start": 27, "end": 35}], "lang": "en"}
{"doc_id": "17458405_1", "wnd_id": "17458405_1_1", "text": "Ezetimibe - induced acute pancreatitis .", "tokens": ["Ezetimibe", "-", "induced", "acute", "pancreatitis", "."], "event_mentions": [{"id": "17458405_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17458405_1_Ent1", "role": "Treatment", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent2", "role": "Treatment_Drug", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17458405_1_Ent1", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent2", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1747495_2", "wnd_id": "1747495_2_1", "text": "A case of liver damage following treatment with Danazol for fibrocystic breast disease is reported .", "tokens": ["A", "case", "of", "liver", "damage", "following", "treatment", "with", "Danazol", "for", "fibrocystic", "breast", "disease", "is", "reported", "."], "event_mentions": [{"id": "1747495_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "1747495_2_Ent0", "role": "Effect", "text": "liver damage", "start": 3, "end": 5}, {"entity_id": "1747495_2_Ent1", "role": "Treatment", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent2", "role": "Treatment_Drug", "text": "Danazol", "start": 8, "end": 9}, {"entity_id": "1747495_2_Ent3", "role": "Treatment_Disorder", "text": "fibrocystic breast disease", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1747495_2_Ent0", "text": "liver damage", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1747495_2_Ent1", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent2", "text": "Danazol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1747495_2_Ent3", "text": "fibrocystic breast disease", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "17494808_1", "wnd_id": "17494808_1_1", "text": "Hypersensitivity pneumonitis - like syndrome associated with the use of lenalidomide .", "tokens": ["Hypersensitivity", "pneumonitis", "-", "like", "syndrome", "associated", "with", "the", "use", "of", "lenalidomide", "."], "event_mentions": [{"id": "17494808_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17494808_1_Ent0", "role": "Effect", "text": "Hypersensitivity pneumonitis - like syndrome", "start": 0, "end": 5}, {"entity_id": "17494808_1_Ent1", "role": "Treatment", "text": "lenalidomide", "start": 10, "end": 11}, {"entity_id": "17494808_1_Ent2", "role": "Treatment_Drug", "text": "lenalidomide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17494808_1_Ent0", "text": "Hypersensitivity pneumonitis - like syndrome", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17494808_1_Ent1", "text": "lenalidomide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17494808_1_Ent2", "text": "lenalidomide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17504225_2", "wnd_id": "17504225_2_1", "text": "Bacterial infection is a frequent event in renal transplant recipients and often requires the use of antimicrobial agents .", "tokens": ["Bacterial", "infection", "is", "a", "frequent", "event", "in", "renal", "transplant", "recipients", "and", "often", "requires", "the", "use", "of", "antimicrobial", "agents", "."], "event_mentions": [{"id": "17504225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "event", "start": 5, "end": 6}, "arguments": [{"entity_id": "17504225_2_Ent2", "role": "Effect", "text": "Bacterial infection", "start": 0, "end": 2}, {"entity_id": "17504225_2_Ent1", "role": "Subject_Disorder", "text": "renal transplant", "start": 7, "end": 9}, {"entity_id": "17504225_2_Ent0", "role": "Subject", "text": "renal transplant recipients", "start": 7, "end": 10}, {"entity_id": "17504225_2_Ent3", "role": "Treatment", "text": "antimicrobial agents", "start": 16, "end": 18}, {"entity_id": "17504225_2_Ent4", "role": "Treatment_Drug", "text": "antimicrobial agents", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "17504225_2_Ent2", "text": "Bacterial infection", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17504225_2_Ent1", "text": "renal transplant", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17504225_2_Ent0", "text": "renal transplant recipients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "17504225_2_Ent3", "text": "antimicrobial agents", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17504225_2_Ent4", "text": "antimicrobial agents", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "1751354_3", "wnd_id": "1751354_3_1", "text": "We report four patients , three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon - alpha .", "tokens": ["We", "report", "four", "patients", ",", "three", "of", "whom", "first", "developed", "psoriasis", "and", "one", "who", "had", "an", "aggravation", "of", "the", "condition", "during", "treatment", "with", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "1751354_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "1751354_3_Ent5", "role": "Subject", "text": "three", "start": 5, "end": 6}, {"entity_id": "1751354_3_Ent6", "role": "Subject_Population", "text": "three", "start": 5, "end": 6}, {"entity_id": "1751354_3_Ent7", "role": "Effect", "text": "psoriasis", "start": 10, "end": 11}, {"entity_id": "1751354_3_Ent8", "role": "Treatment", "text": "interferon - alpha", "start": 23, "end": 26}, {"entity_id": "1751354_3_Ent9", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 23, "end": 26}]}, {"id": "1751354_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 22, "end": 23}, "arguments": [{"entity_id": "1751354_3_Ent0", "role": "Subject", "text": "one", "start": 12, "end": 13}, {"entity_id": "1751354_3_Ent1", "role": "Subject_Population", "text": "one", "start": 12, "end": 13}, {"entity_id": "1751354_3_Ent2", "role": "Effect", "text": "had an aggravation of the condition", "start": 14, "end": 20}, {"entity_id": "1751354_3_Ent3", "role": "Treatment", "text": "interferon - alpha", "start": 23, "end": 26}, {"entity_id": "1751354_3_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "1751354_3_Ent5", "text": "three", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1751354_3_Ent6", "text": "three", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1751354_3_Ent7", "text": "psoriasis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1751354_3_Ent0", "text": "one", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1751354_3_Ent1", "text": "one", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1751354_3_Ent2", "text": "had an aggravation of the condition", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "1751354_3_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "1751354_3_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "1751354_3_Ent8", "text": "interferon - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "1751354_3_Ent9", "text": "interferon - alpha", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "17526968_2", "wnd_id": "17526968_2_1", "text": "Hyperpigmentation is one of the cutaneous side effects of chemotherapautic agents , but it is usually accepted as a cosmetic problem .", "tokens": ["Hyperpigmentation", "is", "one", "of", "the", "cutaneous", "side", "effects", "of", "chemotherapautic", "agents", ",", "but", "it", "is", "usually", "accepted", "as", "a", "cosmetic", "problem", "."], "event_mentions": [{"id": "17526968_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "17526968_2_Ent0", "role": "Effect", "text": "Hyperpigmentation", "start": 0, "end": 1}, {"entity_id": "17526968_2_Ent1", "role": "Treatment", "text": "chemotherapautic agents", "start": 9, "end": 11}, {"entity_id": "17526968_2_Ent2", "role": "Treatment_Drug", "text": "chemotherapautic agents", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17526968_2_Ent0", "text": "Hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_2_Ent1", "text": "chemotherapautic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17526968_2_Ent2", "text": "chemotherapautic agents", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17547624_1", "wnd_id": "17547624_1_1", "text": "Brugada type electrocardiographic changes induced by concomitant use of lithium and propafenone in patient with Wolff - Parkinson - White syndrome .", "tokens": ["Brugada", "type", "electrocardiographic", "changes", "induced", "by", "concomitant", "use", "of", "lithium", "and", "propafenone", "in", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "."], "event_mentions": [{"id": "17547624_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17547624_1_Ent1", "role": "Effect", "text": "Brugada type electrocardiographic changes", "start": 0, "end": 4}, {"entity_id": "17547624_1_Ent2", "role": "Treatment", "text": "concomitant use of lithium and propafenone", "start": 6, "end": 12}, {"entity_id": "17547624_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent6", "role": "Combination_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17547624_1_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 11, "end": 12}, {"entity_id": "17547624_1_Ent0", "role": "Subject", "text": "patient with Wolff - Parkinson - White syndrome", "start": 13, "end": 21}, {"entity_id": "17547624_1_Ent3", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "17547624_1_Ent1", "text": "Brugada type electrocardiographic changes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17547624_1_Ent2", "text": "concomitant use of lithium and propafenone", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "17547624_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17547624_1_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17547624_1_Ent0", "text": "patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "17547624_1_Ent3", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "17547624_2", "wnd_id": "17547624_2_1", "text": "We report a case of ST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels .", "tokens": ["We", "report", "a", "case", "of", "ST", "elevation", "in", "right", "precordial", "leads", "compatible", "with", "type", "1", "Brugada", "syndrome", "following", "administration", "of", "propafenone", "in", "a", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "who", "was", "receiving", "lithium", "at", "concentrations", "within", "therapeutic", "levels", "."], "event_mentions": [{"id": "17547624_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 17, "end": 18}, "arguments": [{"entity_id": "17547624_2_Ent1", "role": "Effect", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "start": 5, "end": 17}, {"entity_id": "17547624_2_Ent2", "role": "Treatment", "text": "administration of propafenone", "start": 18, "end": 21}, {"entity_id": "17547624_2_Ent4", "role": "Treatment_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent7", "role": "Combination_Drug", "text": "propafenone", "start": 20, "end": 21}, {"entity_id": "17547624_2_Ent0", "role": "Subject", "text": "a patient with Wolff - Parkinson - White syndrome", "start": 22, "end": 31}, {"entity_id": "17547624_2_Ent6", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 25, "end": 31}, {"entity_id": "17547624_2_Ent3", "role": "Treatment", "text": "receiving lithium at concentrations within therapeutic levels", "start": 33, "end": 40}, {"entity_id": "17547624_2_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 34, "end": 35}, {"entity_id": "17547624_2_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "17547624_2_Ent1", "text": "ST elevation in right precordial leads compatible with type 1 Brugada syndrome", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "17547624_2_Ent2", "text": "administration of propafenone", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17547624_2_Ent4", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17547624_2_Ent0", "text": "a patient with Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "17547624_2_Ent6", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "17547624_2_Ent3", "text": "receiving lithium at concentrations within therapeutic levels", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "17547624_2_Ent5", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17547624_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "17556909_2", "wnd_id": "17556909_2_1", "text": "Paralytic ileus in patients undergoing bortezomib treatment has been reported , although a definite attribution to bortezomib administration has not been established .", "tokens": ["Paralytic", "ileus", "in", "patients", "undergoing", "bortezomib", "treatment", "has", "been", "reported", ",", "although", "a", "definite", "attribution", "to", "bortezomib", "administration", "has", "not", "been", "established", "."], "event_mentions": [{"id": "17556909_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "17556909_2_Ent1", "role": "Effect", "text": "Paralytic ileus", "start": 0, "end": 2}, {"entity_id": "17556909_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "17556909_2_Ent3", "role": "Treatment_Drug", "text": "bortezomib", "start": 5, "end": 6}, {"entity_id": "17556909_2_Ent2", "role": "Treatment", "text": "bortezomib treatment", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17556909_2_Ent1", "text": "Paralytic ileus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17556909_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_2_Ent3", "text": "bortezomib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17556909_2_Ent2", "text": "bortezomib treatment", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17556909_3", "wnd_id": "17556909_3_1", "text": "We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy , which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation , suggesting a direct causal relationship .", "tokens": ["We", "report", "a", "myeloma", "patient", "who", "developed", "severe", "paralytic", "ileus", "during", "bortezomib", "therapy", ",", "which", "presented", "in", "the", "context", "of", "progressive", "constipation", "without", "other", "known", "causes", "and", "which", "regressed", "promptly", "with", "medical", "management", "after", "drug", "cessation", ",", "suggesting", "a", "direct", "causal", "relationship", "."], "event_mentions": [{"id": "17556909_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "17556909_3_Ent0", "role": "Subject", "text": "a myeloma patient", "start": 2, "end": 5}, {"entity_id": "17556909_3_Ent4", "role": "Treatment_Disorder", "text": "myeloma", "start": 3, "end": 4}, {"entity_id": "17556909_3_Ent1", "role": "Effect", "text": "paralytic ileus", "start": 8, "end": 10}, {"entity_id": "17556909_3_Ent5", "role": "Treatment_Drug", "text": "bortezomib", "start": 11, "end": 12}, {"entity_id": "17556909_3_Ent3", "role": "Treatment", "text": "bortezomib therapy", "start": 11, "end": 13}, {"entity_id": "17556909_3_Ent2", "role": "Effect", "text": "presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation", "start": 15, "end": 36}]}], "entity_mentions": [{"id": "17556909_3_Ent0", "text": "a myeloma patient", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17556909_3_Ent4", "text": "myeloma", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_3_Ent1", "text": "paralytic ileus", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17556909_3_Ent5", "text": "bortezomib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17556909_3_Ent3", "text": "bortezomib therapy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17556909_3_Ent2", "text": "presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation", "entity_type": "Entity", "start": 15, "end": 36}], "lang": "en"}
{"doc_id": "17610180_1", "wnd_id": "17610180_1_1", "text": "The clinical symptoms of gastric mucosa foveolar hyperplasia due to long - term PGE1 therapy simulate hypertrophic pyloric stenosis .", "tokens": ["The", "clinical", "symptoms", "of", "gastric", "mucosa", "foveolar", "hyperplasia", "due", "to", "long", "-", "term", "PGE1", "therapy", "simulate", "hypertrophic", "pyloric", "stenosis", "."], "event_mentions": [{"id": "17610180_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "17610180_1_Ent0", "role": "Effect", "text": "gastric mucosa foveolar hyperplasia", "start": 4, "end": 8}, {"entity_id": "17610180_1_Ent4", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "17610180_1_Ent2", "role": "Treatment", "text": "long - term PGE1 therapy", "start": 10, "end": 15}, {"entity_id": "17610180_1_Ent3", "role": "Treatment_Drug", "text": "PGE1", "start": 13, "end": 14}, {"entity_id": "17610180_1_Ent1", "role": "Effect", "text": "simulate hypertrophic pyloric stenosis", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "17610180_1_Ent0", "text": "gastric mucosa foveolar hyperplasia", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17610180_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "17610180_1_Ent2", "text": "long - term PGE1 therapy", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "17610180_1_Ent3", "text": "PGE1", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17610180_1_Ent1", "text": "simulate hypertrophic pyloric stenosis", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "17610180_2", "wnd_id": "17610180_2_1", "text": "The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy .", "tokens": ["The", "results", "of", "the", "ultrasound", "examination", "combined", "with", "clinical", "anamnesis", "allowed", "diagnosis", "of", "gastric", "mucosa", "foveolar", "hyperplasia", "due", "to", "prolonged", "PGE1", "therapy", "."], "event_mentions": [{"id": "17610180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 17, "end": 18}, "arguments": [{"entity_id": "17610180_2_Ent0", "role": "Effect", "text": "gastric mucosa foveolar hyperplasia", "start": 13, "end": 17}, {"entity_id": "17610180_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 19, "end": 20}, {"entity_id": "17610180_2_Ent1", "role": "Treatment", "text": "prolonged PGE1 therapy", "start": 19, "end": 22}, {"entity_id": "17610180_2_Ent2", "role": "Treatment_Drug", "text": "PGE1", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17610180_2_Ent0", "text": "gastric mucosa foveolar hyperplasia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "17610180_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17610180_2_Ent1", "text": "prolonged PGE1 therapy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "17610180_2_Ent2", "text": "PGE1", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17619811_2", "wnd_id": "17619811_2_1", "text": "A case of colchicine - induced rhabdomyolysis is reported .", "tokens": ["A", "case", "of", "colchicine", "-", "induced", "rhabdomyolysis", "is", "reported", "."], "event_mentions": [{"id": "17619811_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17619811_2_Ent1", "role": "Treatment", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 3, "end": 4}, {"entity_id": "17619811_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17619811_2_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17619811_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17619811_3", "wnd_id": "17619811_3_1", "text": "Colchicine - induced rhabdomyolysis is a rare complication , and the postulated mechanisms and risk factors for this severe complication are discussed .", "tokens": ["Colchicine", "-", "induced", "rhabdomyolysis", "is", "a", "rare", "complication", ",", "and", "the", "postulated", "mechanisms", "and", "risk", "factors", "for", "this", "severe", "complication", "are", "discussed", "."], "event_mentions": [{"id": "17619811_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17619811_3_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_3_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "17619811_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "17619811_3_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_3_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17619811_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "1765991_1", "wnd_id": "1765991_1_1", "text": "Induction of systemic lupus erythematosus by interferon - gamma in a patient with rheumatoid arthritis .", "tokens": ["Induction", "of", "systemic", "lupus", "erythematosus", "by", "interferon", "-", "gamma", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "1765991_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "1765991_1_Ent1", "role": "Effect", "text": "systemic lupus erythematosus", "start": 2, "end": 5}, {"entity_id": "1765991_1_Ent2", "role": "Treatment", "text": "interferon - gamma", "start": 6, "end": 9}, {"entity_id": "1765991_1_Ent3", "role": "Treatment_Drug", "text": "interferon - gamma", "start": 6, "end": 9}, {"entity_id": "1765991_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 10, "end": 15}, {"entity_id": "1765991_1_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "1765991_1_Ent1", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "1765991_1_Ent2", "text": "interferon - gamma", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1765991_1_Ent3", "text": "interferon - gamma", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1765991_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "1765991_1_Ent4", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "1765991_4", "wnd_id": "1765991_4_1", "text": "We assume that rIFN - gamma induced the de novo development of SLE in our patient .", "tokens": ["We", "assume", "that", "rIFN", "-", "gamma", "induced", "the", "de", "novo", "development", "of", "SLE", "in", "our", "patient", "."], "event_mentions": [{"id": "1765991_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "1765991_4_Ent2", "role": "Treatment", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent3", "role": "Treatment_Drug", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent1", "role": "Effect", "text": "the de novo development of SLE", "start": 7, "end": 13}, {"entity_id": "1765991_4_Ent0", "role": "Subject", "text": "our patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1765991_4_Ent2", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent3", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent1", "text": "the de novo development of SLE", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "1765991_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "17671884_1", "wnd_id": "17671884_1_1", "text": "Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone .", "tokens": ["Red", "blood", "cell", "anemia", "in", "a", "patient", "with", "pemphigus", "vulgaris", "induced", "by", "the", "use", "of", "mycophenolate", "mofetil", "and", "prednisone", "."], "event_mentions": [{"id": "17671884_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17671884_1_Ent1", "role": "Effect", "text": "Red blood cell anemia", "start": 0, "end": 4}, {"entity_id": "17671884_1_Ent0", "role": "Subject", "text": "a patient with pemphigus vulgaris", "start": 5, "end": 10}, {"entity_id": "17671884_1_Ent3", "role": "Treatment_Disorder", "text": "pemphigus vulgaris", "start": 8, "end": 10}, {"entity_id": "17671884_1_Ent4", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 15, "end": 17}, {"entity_id": "17671884_1_Ent6", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 15, "end": 17}, {"entity_id": "17671884_1_Ent2", "role": "Treatment", "text": "mycophenolate mofetil and prednisone", "start": 15, "end": 19}, {"entity_id": "17671884_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "17671884_1_Ent7", "role": "Combination_Drug", "text": "prednisone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17671884_1_Ent1", "text": "Red blood cell anemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17671884_1_Ent0", "text": "a patient with pemphigus vulgaris", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17671884_1_Ent3", "text": "pemphigus vulgaris", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17671884_1_Ent4", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17671884_1_Ent6", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17671884_1_Ent2", "text": "mycophenolate mofetil and prednisone", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "17671884_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17675030_1", "wnd_id": "17675030_1_1", "text": "A search of the United States Food and Drug Administration 's Adverse Event Reporting System identified nine cases of oxcarbazepine - associated angioedema in pediatric patients aged 16 years and younger .", "tokens": ["A", "search", "of", "the", "United", "States", "Food", "and", "Drug", "Administration", "'s", "Adverse", "Event", "Reporting", "System", "identified", "nine", "cases", "of", "oxcarbazepine", "-", "associated", "angioedema", "in", "pediatric", "patients", "aged", "16", "years", "and", "younger", "."], "event_mentions": [{"id": "17675030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "17675030_1_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 19, "end": 20}, {"entity_id": "17675030_1_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 19, "end": 20}, {"entity_id": "17675030_1_Ent3", "role": "Effect", "text": "angioedema", "start": 22, "end": 23}, {"entity_id": "17675030_1_Ent2", "role": "Subject_Disorder", "text": "pediatric", "start": 24, "end": 25}, {"entity_id": "17675030_1_Ent0", "role": "Subject", "text": "pediatric patients aged 16 years and younger", "start": 24, "end": 31}, {"entity_id": "17675030_1_Ent1", "role": "Subject_Age", "text": "16 years and younger", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "17675030_1_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17675030_1_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17675030_1_Ent3", "text": "angioedema", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17675030_1_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17675030_1_Ent0", "text": "pediatric patients aged 16 years and younger", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "17675030_1_Ent1", "text": "16 years and younger", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "17697264_2", "wnd_id": "17697264_2_1", "text": "One case of tacrolimus - induced hepatic VOD developing after lung transplantation ( LT ) has been recently reported .", "tokens": ["One", "case", "of", "tacrolimus", "-", "induced", "hepatic", "VOD", "developing", "after", "lung", "transplantation", "(", "LT", ")", "has", "been", "recently", "reported", "."], "event_mentions": [{"id": "17697264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17697264_2_Ent1", "role": "Treatment", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 3, "end": 4}, {"entity_id": "17697264_2_Ent0", "role": "Effect", "text": "hepatic VOD", "start": 6, "end": 8}, {"entity_id": "17697264_2_Ent2", "role": "Treatment", "text": "after lung transplantation ( LT )", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "17697264_2_Ent1", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17697264_2_Ent0", "text": "hepatic VOD", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17697264_2_Ent2", "text": "after lung transplantation ( LT )", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "17710018_2", "wnd_id": "17710018_2_1", "text": "Because etoposide - induced pulmonary toxicity is an uncommon but serious adverse event , clinicians must be vigilant about the possibility of it , so that the optimal treatment can start as soon as possible .", "tokens": ["Because", "etoposide", "-", "induced", "pulmonary", "toxicity", "is", "an", "uncommon", "but", "serious", "adverse", "event", ",", "clinicians", "must", "be", "vigilant", "about", "the", "possibility", "of", "it", ",", "so", "that", "the", "optimal", "treatment", "can", "start", "as", "soon", "as", "possible", "."], "event_mentions": [{"id": "17710018_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17710018_2_Ent1", "role": "Treatment", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "17710018_2_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "17710018_3", "wnd_id": "17710018_3_1", "text": "PET scintigraphy of etoposide - induced pulmonary toxicity .", "tokens": ["PET", "scintigraphy", "of", "etoposide", "-", "induced", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17710018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17710018_3_Ent1", "role": "Treatment", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 3, "end": 4}, {"entity_id": "17710018_3_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "17710018_3_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17710018_3_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "17725438_1", "wnd_id": "17725438_1_1", "text": "Here , we report a case of RFP - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Here", ",", "we", "report", "a", "case", "of", "RFP", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "17725438_1_Ent1", "role": "Treatment", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent2", "role": "Treatment_Drug", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "17725438_1_Ent1", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent2", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "17725438_2", "wnd_id": "17725438_2_1", "text": "Rifampin - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Rifampin", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17725438_2_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "17725438_2_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "17763133_2", "wnd_id": "17763133_2_1", "text": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function .", "tokens": ["Discontinuation", "of", "simvastatin", "and", "cyclosporine", "resulted", "in", "resolution", "of", "rhabdomyolysis", "and", "normalization", "of", "renal", "function", "."], "event_mentions": [{"id": "17763133_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 5, "end": 6}, "arguments": [{"entity_id": "17763133_2_Ent1", "role": "Treatment", "text": "Discontinuation of simvastatin and cyclosporine", "start": 0, "end": 5}, {"entity_id": "17763133_2_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "17763133_2_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 4, "end": 5}, {"entity_id": "17763133_2_Ent2", "role": "Treatment_Disorder", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "17763133_2_Ent0", "role": "Effect", "text": "normalization of renal function", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "17763133_2_Ent1", "text": "Discontinuation of simvastatin and cyclosporine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17763133_2_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17763133_2_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17763133_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17763133_2_Ent0", "text": "normalization of renal function", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "17823522_1", "wnd_id": "17823522_1_1", "text": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment .", "tokens": ["Generalized", "lichen", "nitidus", "with", "involvement", "of", "the", "palms", "following", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "17823522_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17823522_1_Ent0", "role": "Effect", "text": "Generalized lichen nitidus with involvement of the palms", "start": 0, "end": 8}, {"entity_id": "17823522_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 9, "end": 11}, {"entity_id": "17823522_1_Ent1", "role": "Treatment", "text": "interferon alpha treatment", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17823522_1_Ent0", "text": "Generalized lichen nitidus with involvement of the palms", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17823522_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17823522_1_Ent1", "text": "interferon alpha treatment", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17852449_1", "wnd_id": "17852449_1_1", "text": "Outcome of pregnancy in women treated with all - trans retinoic acid ; a case report and review of literature .", "tokens": ["Outcome", "of", "pregnancy", "in", "women", "treated", "with", "all", "-", "trans", "retinoic", "acid", ";", "a", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "17852449_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17852449_1_Ent4", "role": "Treatment_Disorder", "text": "pregnancy", "start": 2, "end": 3}, {"entity_id": "17852449_1_Ent0", "role": "Subject", "text": "pregnancy in women", "start": 2, "end": 5}, {"entity_id": "17852449_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 4, "end": 5}, {"entity_id": "17852449_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 7, "end": 12}, {"entity_id": "17852449_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17852449_1_Ent4", "text": "pregnancy", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17852449_1_Ent0", "text": "pregnancy in women", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17852449_1_Ent1", "text": "women", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17852449_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17852449_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17852449_2", "wnd_id": "17852449_2_1", "text": "All - trans - retinoic acid ( ATRA ) has been proved to be an effective treatment for acute promyelocytic leukemia ( APL ) , inducing remission in more than 90 % of cases .", "tokens": ["All", "-", "trans", "-", "retinoic", "acid", "(", "ATRA", ")", "has", "been", "proved", "to", "be", "an", "effective", "treatment", "for", "acute", "promyelocytic", "leukemia", "(", "APL", ")", ",", "inducing", "remission", "in", "more", "than", "90", "%", "of", "cases", "."], "event_mentions": [{"id": "17852449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "proved", "start": 11, "end": 12}, "arguments": [{"entity_id": "17852449_2_Ent4", "role": "Treatment_Drug", "text": "All - trans - retinoic acid", "start": 0, "end": 6}, {"entity_id": "17852449_2_Ent2", "role": "Treatment", "text": "All - trans - retinoic acid ( ATRA )", "start": 0, "end": 9}, {"entity_id": "17852449_2_Ent3", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia ( APL )", "start": 18, "end": 24}, {"entity_id": "17852449_2_Ent1", "role": "Subject_Population", "text": "more than 90 %", "start": 28, "end": 32}, {"entity_id": "17852449_2_Ent0", "role": "Subject", "text": "more than 90 % of cases", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "17852449_2_Ent4", "text": "All - trans - retinoic acid", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17852449_2_Ent2", "text": "All - trans - retinoic acid ( ATRA )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "17852449_2_Ent3", "text": "acute promyelocytic leukemia ( APL )", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "17852449_2_Ent1", "text": "more than 90 %", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "17852449_2_Ent0", "text": "more than 90 % of cases", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "17876386_1", "wnd_id": "17876386_1_1", "text": "It has been reported that fluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause torsade de pointes .", "tokens": ["It", "has", "been", "reported", "that", "fluoroquinolone", "antimicrobials", "prolong", "the", "corrected", "QT", "interval", "but", "rarely", "cause", "torsade", "de", "pointes", "."], "event_mentions": [{"id": "17876386_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "prolong", "start": 7, "end": 8}, "arguments": [{"entity_id": "17876386_1_Ent2", "role": "Treatment_Drug", "text": "fluoroquinolone", "start": 5, "end": 6}, {"entity_id": "17876386_1_Ent1", "role": "Treatment", "text": "fluoroquinolone antimicrobials", "start": 5, "end": 7}, {"entity_id": "17876386_1_Ent0", "role": "Effect", "text": "corrected QT interval but rarely cause torsade de pointes", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "17876386_1_Ent2", "text": "fluoroquinolone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17876386_1_Ent1", "text": "fluoroquinolone antimicrobials", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17876386_1_Ent0", "text": "corrected QT interval but rarely cause torsade de pointes", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "17921794_3", "wnd_id": "17921794_3_1", "text": "The concomitant use , however , of colchicine and statin has been associated with the rapid onset of muscle weakness .", "tokens": ["The", "concomitant", "use", ",", "however", ",", "of", "colchicine", "and", "statin", "has", "been", "associated", "with", "the", "rapid", "onset", "of", "muscle", "weakness", "."], "event_mentions": [{"id": "17921794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "17921794_3_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "17921794_3_Ent4", "role": "Combination_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "17921794_3_Ent1", "role": "Treatment", "text": "colchicine and statin", "start": 7, "end": 10}, {"entity_id": "17921794_3_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 9, "end": 10}, {"entity_id": "17921794_3_Ent5", "role": "Combination_Drug", "text": "statin", "start": 9, "end": 10}, {"entity_id": "17921794_3_Ent0", "role": "Effect", "text": "the rapid onset of muscle weakness", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "17921794_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17921794_3_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17921794_3_Ent1", "text": "colchicine and statin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "17921794_3_Ent3", "text": "statin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17921794_3_Ent5", "text": "statin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17921794_3_Ent0", "text": "the rapid onset of muscle weakness", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "17921794_4", "wnd_id": "17921794_4_1", "text": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "mild", "chronic", "renal", "insufficiency", "who", "had", "been", "taking", "simvastatin", "for", "over", "a", "year", "and", "developed", "acute", "weakness", "within", "3", "weeks", "after", "the", "start", "of", "treatment", "with", "colchicine", "for", "acute", "gouty", "bursitis", "."], "event_mentions": [{"id": "17921794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17921794_4_Ent0", "role": "Subject", "text": "a patient with mild chronic renal insufficiency", "start": 5, "end": 12}, {"entity_id": "17921794_4_Ent1", "role": "Subject_Disorder", "text": "mild chronic renal insufficiency", "start": 8, "end": 12}, {"entity_id": "17921794_4_Ent3", "role": "Treatment", "text": "taking simvastatin for over a year", "start": 15, "end": 21}, {"entity_id": "17921794_4_Ent6", "role": "Treatment_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent10", "role": "Combination_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent8", "role": "Treatment_Time_elapsed", "text": "over a year", "start": 18, "end": 21}, {"entity_id": "17921794_4_Ent2", "role": "Effect", "text": "acute weakness", "start": 23, "end": 25}, {"entity_id": "17921794_4_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 26, "end": 28}, {"entity_id": "17921794_4_Ent4", "role": "Treatment", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "start": 26, "end": 39}, {"entity_id": "17921794_4_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent11", "role": "Combination_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent5", "role": "Treatment_Disorder", "text": "acute gouty bursitis", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "17921794_4_Ent0", "text": "a patient with mild chronic renal insufficiency", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "17921794_4_Ent1", "text": "mild chronic renal insufficiency", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17921794_4_Ent3", "text": "taking simvastatin for over a year", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "17921794_4_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent10", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent8", "text": "over a year", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17921794_4_Ent2", "text": "acute weakness", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "17921794_4_Ent9", "text": "3 weeks", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "17921794_4_Ent4", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "entity_type": "Entity", "start": 26, "end": 39}, {"id": "17921794_4_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent11", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent5", "text": "acute gouty bursitis", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "1792646_1", "wnd_id": "1792646_1_1", "text": "Pneumocystis carinii pneumonia as a complication of methotrexate treatment of asthma .", "tokens": ["Pneumocystis", "carinii", "pneumonia", "as", "a", "complication", "of", "methotrexate", "treatment", "of", "asthma", "."], "event_mentions": [{"id": "1792646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "1792646_1_Ent0", "role": "Effect", "text": "Pneumocystis carinii pneumonia", "start": 0, "end": 3}, {"entity_id": "1792646_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 7, "end": 8}, {"entity_id": "1792646_1_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "1792646_1_Ent0", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1792646_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1792646_1_Ent3", "text": "asthma", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17937473_1", "wnd_id": "17937473_1_1", "text": "Eleven patients developed infection requiring hospitalization while taking leflunomide including : lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ) .", "tokens": ["Eleven", "patients", "developed", "infection", "requiring", "hospitalization", "while", "taking", "leflunomide", "including", ":", "lower", "respiratory", "tract", "infections", "(", "3", ")", ",", "cellulitis", "(", "2", ")", ",", "disseminated", "herpes", "zoster", "(", "2", ")", ",", "probable", "TB", "liver", "(", "1", ")", ",", "abdominal", "sepsis", "(", "1", ")", ",", "mycotic", "aneurysm", "(", "1", ")", "and", "gastroenteritis", "(", "1", ")", "."], "event_mentions": [{"id": "17937473_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_1_Ent1", "role": "Subject_Population", "text": "Eleven", "start": 0, "end": 1}, {"entity_id": "17937473_1_Ent0", "role": "Subject", "text": "Eleven patients", "start": 0, "end": 2}, {"entity_id": "17937473_1_Ent2", "role": "Effect", "text": "infection", "start": 3, "end": 4}, {"entity_id": "17937473_1_Ent4", "role": "Treatment", "text": "leflunomide", "start": 8, "end": 9}, {"entity_id": "17937473_1_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 8, "end": 9}, {"entity_id": "17937473_1_Ent3", "role": "Effect", "text": "lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 )", "start": 11, "end": 54}]}], "entity_mentions": [{"id": "17937473_1_Ent1", "text": "Eleven", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_1_Ent0", "text": "Eleven patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17937473_1_Ent2", "text": "infection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_1_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17937473_1_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17937473_1_Ent3", "text": "lower respiratory tract infections ( 3 ) , cellulitis ( 2 ) , disseminated herpes zoster ( 2 ) , probable TB liver ( 1 ) , abdominal sepsis ( 1 ) , mycotic aneurysm ( 1 ) and gastroenteritis ( 1 )", "entity_type": "Entity", "start": 11, "end": 54}], "lang": "en"}
{"doc_id": "17937473_2", "wnd_id": "17937473_2_1", "text": "Leflunomide - associated infections in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "infections", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17937473_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent2", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent0", "role": "Effect", "text": "infections", "start": 3, "end": 4}, {"entity_id": "17937473_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17937473_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent0", "text": "infections", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17987285_12", "wnd_id": "17987285_12_1", "text": "Caution should be exercised , especially in patients who are given voriconazole or fluconazole during long - lasting fentanyl treatment , because insidiously elevated fentanyl concentration may lead to respiratory depression .", "tokens": ["Caution", "should", "be", "exercised", ",", "especially", "in", "patients", "who", "are", "given", "voriconazole", "or", "fluconazole", "during", "long", "-", "lasting", "fentanyl", "treatment", ",", "because", "insidiously", "elevated", "fentanyl", "concentration", "may", "lead", "to", "respiratory", "depression", "."], "event_mentions": [{"id": "17987285_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 27, "end": 28}, "arguments": [{"entity_id": "17987285_12_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "17987285_12_Ent3", "role": "Treatment_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "17987285_12_Ent6", "role": "Combination_Drug", "text": "voriconazole", "start": 11, "end": 12}, {"entity_id": "17987285_12_Ent4", "role": "Treatment_Drug", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "17987285_12_Ent7", "role": "Combination_Drug", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "17987285_12_Ent2", "role": "Treatment", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17987285_12_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 24, "end": 25}, {"entity_id": "17987285_12_Ent1", "role": "Effect", "text": "respiratory depression", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17987285_12_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17987285_12_Ent3", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17987285_12_Ent6", "text": "voriconazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17987285_12_Ent4", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17987285_12_Ent7", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17987285_12_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17987285_12_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17987285_12_Ent1", "text": "respiratory depression", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "17987285_3", "wnd_id": "17987285_3_1", "text": "Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions .", "tokens": ["Recent", "reports", "suggest", "that", "concomitant", "administration", "of", "CYP3A", "inhibitors", "with", "fentanyl", "may", "lead", "to", "dangerous", "drug", "interactions", "."], "event_mentions": [{"id": "17987285_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 12, "end": 13}, "arguments": [{"entity_id": "17987285_3_Ent1", "role": "Treatment", "text": "concomitant administration of CYP3A inhibitors with fentanyl", "start": 4, "end": 11}, {"entity_id": "17987285_3_Ent2", "role": "Treatment_Drug", "text": "CYP3A inhibitors", "start": 7, "end": 9}, {"entity_id": "17987285_3_Ent4", "role": "Combination_Drug", "text": "CYP3A inhibitors", "start": 7, "end": 9}, {"entity_id": "17987285_3_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 10, "end": 11}, {"entity_id": "17987285_3_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 10, "end": 11}, {"entity_id": "17987285_3_Ent0", "role": "Effect", "text": "drug interactions", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17987285_3_Ent1", "text": "concomitant administration of CYP3A inhibitors with fentanyl", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17987285_3_Ent2", "text": "CYP3A inhibitors", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17987285_3_Ent4", "text": "CYP3A inhibitors", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17987285_3_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17987285_3_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17987285_3_Ent0", "text": "drug interactions", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18025525_11", "wnd_id": "18025525_11_1", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz is contraindicated due to the clinically significant effect of efavirenz on voriconazole pharmacokinetics .", "tokens": ["Coadministration", "of", "200", "mg", "bid", "voriconazole", "with", "400", "mg", "(", "or", "higher", ")", "qd", "efavirenz", "is", "contraindicated", "due", "to", "the", "clinically", "significant", "effect", "of", "efavirenz", "on", "voriconazole", "pharmacokinetics", "."], "event_mentions": [{"id": "18025525_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contraindicated", "start": 16, "end": 17}, "arguments": [{"entity_id": "18025525_11_Ent1", "role": "Treatment", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz", "start": 0, "end": 15}, {"entity_id": "18025525_11_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 2, "end": 4}, {"entity_id": "18025525_11_Ent5", "role": "Treatment_Drug", "text": "voriconazole", "start": 5, "end": 6}, {"entity_id": "18025525_11_Ent9", "role": "Combination_Drug", "text": "voriconazole", "start": 5, "end": 6}, {"entity_id": "18025525_11_Ent4", "role": "Treatment_Dosage", "text": "400 mg", "start": 7, "end": 9}, {"entity_id": "18025525_11_Ent6", "role": "Treatment_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "18025525_11_Ent10", "role": "Combination_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "18025525_11_Ent0", "role": "Effect", "text": "clinically significant effect", "start": 20, "end": 23}, {"entity_id": "18025525_11_Ent7", "role": "Treatment_Drug", "text": "efavirenz", "start": 24, "end": 25}, {"entity_id": "18025525_11_Ent2", "role": "Treatment", "text": "efavirenz on voriconazole", "start": 24, "end": 27}, {"entity_id": "18025525_11_Ent8", "role": "Treatment_Drug", "text": "voriconazole", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18025525_11_Ent1", "text": "Coadministration of 200 mg bid voriconazole with 400 mg ( or higher ) qd efavirenz", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "18025525_11_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18025525_11_Ent5", "text": "voriconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18025525_11_Ent9", "text": "voriconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18025525_11_Ent4", "text": "400 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18025525_11_Ent6", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18025525_11_Ent10", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18025525_11_Ent0", "text": "clinically significant effect", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "18025525_11_Ent7", "text": "efavirenz", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18025525_11_Ent2", "text": "efavirenz on voriconazole", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18025525_11_Ent8", "text": "voriconazole", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18034202_1", "wnd_id": "18034202_1_1", "text": "We report a case of a patient with rheumatoid arthritis treated with low - dose methotrexate ( 15 mg / week ) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "rheumatoid", "arthritis", "treated", "with", "low", "-", "dose", "methotrexate", "(", "15", "mg", "/", "week", ")", "who", "developed", "infection", "with", "both", "M.", "tuberculosis", "and", "M.", "chelonae", "after", "the", "revision", "of", "a", "prosthetic", "hip", "."], "event_mentions": [{"id": "18034202_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "18034202_1_Ent0", "role": "Subject", "text": "patient with rheumatoid arthritis", "start": 6, "end": 10}, {"entity_id": "18034202_1_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}, {"entity_id": "18034202_1_Ent2", "role": "Treatment", "text": "low - dose methotrexate ( 15 mg / week )", "start": 12, "end": 22}, {"entity_id": "18034202_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "18034202_1_Ent3", "role": "Treatment_Dosage", "text": "15 mg / week", "start": 17, "end": 21}, {"entity_id": "18034202_1_Ent1", "role": "Effect", "text": "infection with both M. tuberculosis and M. chelonae", "start": 24, "end": 32}]}], "entity_mentions": [{"id": "18034202_1_Ent0", "text": "patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18034202_1_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18034202_1_Ent2", "text": "low - dose methotrexate ( 15 mg / week )", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18034202_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18034202_1_Ent3", "text": "15 mg / week", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18034202_1_Ent1", "text": "infection with both M. tuberculosis and M. chelonae", "entity_type": "Entity", "start": 24, "end": 32}], "lang": "en"}
{"doc_id": "18067642_1", "wnd_id": "18067642_1_1", "text": "Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case , it is reasonable to presume that this histopathology is associated with amiodarone - induced hypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder .", "tokens": ["Although", "it", "is", "difficult", "to", "be", "certain", "of", "the", "direct", "link", "of", "amiodarone", "on", "the", "basis", "of", "a", "single", "case", ",", "it", "is", "reasonable", "to", "presume", "that", "this", "histopathology", "is", "associated", "with", "amiodarone", "-", "induced", "hypothyroidism", "and", "that", "involution", "changes", "represent", "the", "hypofunctional", "status", "of", "this", "drug", "-", "induced", "disorder", "."], "event_mentions": [{"id": "18067642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 34, "end": 35}, "arguments": [{"entity_id": "18067642_1_Ent5", "role": "Treatment_Drug", "text": "amiodarone", "start": 12, "end": 13}, {"entity_id": "18067642_1_Ent0", "role": "Subject", "text": "a single case", "start": 17, "end": 20}, {"entity_id": "18067642_1_Ent1", "role": "Subject_Population", "text": "single", "start": 18, "end": 19}, {"entity_id": "18067642_1_Ent3", "role": "Treatment", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 32, "end": 33}, {"entity_id": "18067642_1_Ent2", "role": "Effect", "text": "hypothyroidism", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "18067642_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18067642_1_Ent0", "text": "a single case", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18067642_1_Ent1", "text": "single", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18067642_1_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18067642_1_Ent2", "text": "hypothyroidism", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "18067642_2", "wnd_id": "18067642_2_1", "text": "Amiodarone is well recognized as an anti - arrhythmic drug containing a high dose of iodine with considerable potential to cause thyroid dysfunction .", "tokens": ["Amiodarone", "is", "well", "recognized", "as", "an", "anti", "-", "arrhythmic", "drug", "containing", "a", "high", "dose", "of", "iodine", "with", "considerable", "potential", "to", "cause", "thyroid", "dysfunction", "."], "event_mentions": [{"id": "18067642_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recognized", "start": 3, "end": 4}, "arguments": [{"entity_id": "18067642_2_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "18067642_2_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "18067642_2_Ent0", "role": "Effect", "text": "potential to cause thyroid dysfunction", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "18067642_2_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18067642_2_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18067642_2_Ent0", "text": "potential to cause thyroid dysfunction", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "18094347_1", "wnd_id": "18094347_1_1", "text": "According to the Naranjo probability scale , the papular eruption was probably caused by methotrexate .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "the", "papular", "eruption", "was", "probably", "caused", "by", "methotrexate", "."], "event_mentions": [{"id": "18094347_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "18094347_1_Ent0", "role": "Effect", "text": "papular eruption", "start": 8, "end": 10}, {"entity_id": "18094347_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18094347_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18094347_1_Ent0", "text": "papular eruption", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18094347_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18094347_6", "wnd_id": "18094347_6_1", "text": "OBJECTIVE : To report a case of a diffuse papular eruption following treatment of psoriasis with methotrexate injections .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "a", "diffuse", "papular", "eruption", "following", "treatment", "of", "psoriasis", "with", "methotrexate", "injections", "."], "event_mentions": [{"id": "18094347_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "18094347_6_Ent0", "role": "Effect", "text": "diffuse papular eruption", "start": 8, "end": 11}, {"entity_id": "18094347_6_Ent4", "role": "Treatment_Disorder", "text": "psoriasis", "start": 14, "end": 15}, {"entity_id": "18094347_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "18094347_6_Ent1", "role": "Treatment", "text": "methotrexate injections", "start": 16, "end": 18}, {"entity_id": "18094347_6_Ent3", "role": "Treatment_Route", "text": "injections", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "18094347_6_Ent0", "text": "diffuse papular eruption", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "18094347_6_Ent4", "text": "psoriasis", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18094347_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18094347_6_Ent1", "text": "methotrexate injections", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "18094347_6_Ent3", "text": "injections", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "18094347_8", "wnd_id": "18094347_8_1", "text": "Ten hours after the second methotrexate injection , the patient experienced a diffuse pruritic papular eruption located mainly on the limbs .", "tokens": ["Ten", "hours", "after", "the", "second", "methotrexate", "injection", ",", "the", "patient", "experienced", "a", "diffuse", "pruritic", "papular", "eruption", "located", "mainly", "on", "the", "limbs", "."], "event_mentions": [{"id": "18094347_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "18094347_8_Ent5", "role": "Treatment_Time_elapsed", "text": "Ten hours", "start": 0, "end": 2}, {"entity_id": "18094347_8_Ent2", "role": "Treatment", "text": "Ten hours after the second methotrexate injection", "start": 0, "end": 7}, {"entity_id": "18094347_8_Ent6", "role": "Treatment_Time_elapsed", "text": "second", "start": 4, "end": 5}, {"entity_id": "18094347_8_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18094347_8_Ent4", "role": "Treatment_Route", "text": "injection", "start": 6, "end": 7}, {"entity_id": "18094347_8_Ent0", "role": "Subject", "text": "the patient", "start": 8, "end": 10}, {"entity_id": "18094347_8_Ent1", "role": "Effect", "text": "diffuse pruritic papular eruption located mainly on the limbs", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "18094347_8_Ent5", "text": "Ten hours", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18094347_8_Ent2", "text": "Ten hours after the second methotrexate injection", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18094347_8_Ent6", "text": "second", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18094347_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18094347_8_Ent4", "text": "injection", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18094347_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_8_Ent1", "text": "diffuse pruritic papular eruption located mainly on the limbs", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "18176653_2", "wnd_id": "18176653_2_1", "text": "AIM : The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine ( NVP ) .", "tokens": ["AIM", ":", "The", "aim", "of", "this", "article", "is", "to", "present", "the", "clinical", "characteristics", "and", "management", "of", "an", "oral", "adverse", "effect", "stemming", "from", "the", "use", "of", "the", "antiretroviral", "medication", "Nevirapine", "(", "NVP", ")", "."], "event_mentions": [{"id": "18176653_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 21, "end": 22}, "arguments": [{"entity_id": "18176653_2_Ent0", "role": "Effect", "text": "adverse effect", "start": 18, "end": 20}, {"entity_id": "18176653_2_Ent1", "role": "Treatment", "text": "antiretroviral medication Nevirapine ( NVP )", "start": 26, "end": 32}, {"entity_id": "18176653_2_Ent2", "role": "Treatment_Drug", "text": "Nevirapine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18176653_2_Ent0", "text": "adverse effect", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18176653_2_Ent1", "text": "antiretroviral medication Nevirapine ( NVP )", "entity_type": "Entity", "start": 26, "end": 32}, {"id": "18176653_2_Ent2", "text": "Nevirapine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18176653_3", "wnd_id": "18176653_3_1", "text": "BACKGROUND : NVP is a non - nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus ( HIV ) infection .", "tokens": ["BACKGROUND", ":", "NVP", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection", "."], "event_mentions": [{"id": "18176653_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 11, "end": 12}, "arguments": [{"entity_id": "18176653_3_Ent0", "role": "Treatment", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent2", "role": "Treatment_Drug", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent1", "role": "Treatment_Disorder", "text": "Human Immunodeficiency Virus ( HIV ) infection", "start": 16, "end": 23}]}], "entity_mentions": [{"id": "18176653_3_Ent0", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent2", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent1", "text": "Human Immunodeficiency Virus ( HIV ) infection", "entity_type": "Entity", "start": 16, "end": 23}], "lang": "en"}
{"doc_id": "18191947_3", "wnd_id": "18191947_3_1", "text": "We describe longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy following methotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ) , presenting with right - sided paralysis and aphasia after second consolidation with intrathecal triple - drug therapy given intrathecally .", "tokens": ["We", "describe", "longitudinal", "diffusion", "-", "weighted", "MRI", "findings", "of", "sub", "-", "acute", "leukoencephalopathy", "following", "methotrexate", "therapy", "in", "a", "24", "-", "year", "-", "old", "man", "diagnosed", "with", "pre", "-", "B", "-", "cell", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", ",", "presenting", "with", "right", "-", "sided", "paralysis", "and", "aphasia", "after", "second", "consolidation", "with", "intrathecal", "triple", "-", "drug", "therapy", "given", "intrathecally", "."], "event_mentions": [{"id": "18191947_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18191947_3_Ent3", "role": "Effect", "text": "longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy", "start": 2, "end": 13}, {"entity_id": "18191947_3_Ent4", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18191947_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18191947_3_Ent0", "role": "Subject", "text": "a 24 - year - old man", "start": 17, "end": 24}, {"entity_id": "18191947_3_Ent1", "role": "Subject_Age", "text": "24 - year - old", "start": 18, "end": 23}, {"entity_id": "18191947_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}]}, {"id": "18191947_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 46, "end": 47}, "arguments": [{"entity_id": "18191947_3_Ent6", "role": "Subject", "text": "a 24 - year - old man", "start": 17, "end": 24}, {"entity_id": "18191947_3_Ent7", "role": "Subject_Age", "text": "24 - year - old", "start": 18, "end": 23}, {"entity_id": "18191947_3_Ent8", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}, {"entity_id": "18191947_3_Ent11", "role": "Treatment_Disorder", "text": "pre - B - cell acute lymphoblastic leukemia ( ALL )", "start": 26, "end": 37}, {"entity_id": "18191947_3_Ent9", "role": "Effect", "text": "presenting with right - sided paralysis and aphasia", "start": 38, "end": 46}, {"entity_id": "18191947_3_Ent10", "role": "Treatment", "text": "second consolidation with intrathecal triple - drug therapy given intrathecally", "start": 47, "end": 57}, {"entity_id": "18191947_3_Ent12", "role": "Treatment_Route", "text": "intrathecally", "start": 56, "end": 57}]}], "entity_mentions": [{"id": "18191947_3_Ent3", "text": "longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "18191947_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18191947_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18191947_3_Ent0", "text": "a 24 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "18191947_3_Ent6", "text": "a 24 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "18191947_3_Ent1", "text": "24 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18191947_3_Ent7", "text": "24 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18191947_3_Ent2", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18191947_3_Ent8", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18191947_3_Ent11", "text": "pre - B - cell acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 26, "end": 37}, {"id": "18191947_3_Ent9", "text": "presenting with right - sided paralysis and aphasia", "entity_type": "Entity", "start": 38, "end": 46}, {"id": "18191947_3_Ent10", "text": "second consolidation with intrathecal triple - drug therapy given intrathecally", "entity_type": "Entity", "start": 47, "end": 57}, {"id": "18191947_3_Ent12", "text": "intrathecally", "entity_type": "Entity", "start": 56, "end": 57}], "lang": "en"}
{"doc_id": "18252776_1", "wnd_id": "18252776_1_1", "text": "Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel ( dual ) anti - platelet therapy with a high morbidity and mortality .", "tokens": ["Upper", "gastrointestinal", "haemorrhage", "is", "a", "serious", "complication", "of", "aspirin", "and", "clopidogrel", "(", "dual", ")", "anti", "-", "platelet", "therapy", "with", "a", "high", "morbidity", "and", "mortality", "."], "event_mentions": [{"id": "18252776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "18252776_1_Ent0", "role": "Effect", "text": "Upper gastrointestinal haemorrhage", "start": 0, "end": 3}, {"entity_id": "18252776_1_Ent1", "role": "Treatment", "text": "aspirin and clopidogrel ( dual )", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "18252776_1_Ent0", "text": "Upper gastrointestinal haemorrhage", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18252776_1_Ent1", "text": "aspirin and clopidogrel ( dual )", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "18262450_11", "wnd_id": "18262450_11_1", "text": "Oxycodone - gabapentin co - administration was associated with less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 ) .", "tokens": ["Oxycodone", "-", "gabapentin", "co", "-", "administration", "was", "associated", "with", "less", "escape", "medication", "use", "(", "P", "=", "0.03", ")", "and", "fewer", "nights", "of", "disturbed", "sleep", "(", "P", "<", "0.05", ")", "."], "event_mentions": [{"id": "18262450_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "18262450_11_Ent3", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_11_Ent4", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_11_Ent1", "role": "Treatment", "text": "Oxycodone - gabapentin co - administration", "start": 0, "end": 6}, {"entity_id": "18262450_11_Ent2", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_11_Ent5", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_11_Ent0", "role": "Effect", "text": "less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 )", "start": 9, "end": 29}]}], "entity_mentions": [{"id": "18262450_11_Ent3", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_11_Ent4", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_11_Ent1", "text": "Oxycodone - gabapentin co - administration", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18262450_11_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_11_Ent5", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_11_Ent0", "text": "less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 )", "entity_type": "Entity", "start": 9, "end": 29}], "lang": "en"}
{"doc_id": "18262450_14", "wnd_id": "18262450_14_1", "text": "This study provides the first evidence that co - administration of prolonged - release oxycodone and existing gabapentin therapy has a clinically meaningful effect in painful diabetic neuropathy .", "tokens": ["This", "study", "provides", "the", "first", "evidence", "that", "co", "-", "administration", "of", "prolonged", "-", "release", "oxycodone", "and", "existing", "gabapentin", "therapy", "has", "a", "clinically", "meaningful", "effect", "in", "painful", "diabetic", "neuropathy", "."], "event_mentions": [{"id": "18262450_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has", "start": 19, "end": 20}, "arguments": [{"entity_id": "18262450_14_Ent1", "role": "Treatment", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "start": 7, "end": 19}, {"entity_id": "18262450_14_Ent3", "role": "Treatment_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent5", "role": "Combination_Drug", "text": "oxycodone", "start": 14, "end": 15}, {"entity_id": "18262450_14_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 17, "end": 18}, {"entity_id": "18262450_14_Ent0", "role": "Effect", "text": "clinically meaningful effect", "start": 21, "end": 24}, {"entity_id": "18262450_14_Ent2", "role": "Treatment_Disorder", "text": "painful diabetic neuropathy", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "18262450_14_Ent1", "text": "co - administration of prolonged - release oxycodone and existing gabapentin therapy", "entity_type": "Entity", "start": 7, "end": 19}, {"id": "18262450_14_Ent3", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18262450_14_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18262450_14_Ent0", "text": "clinically meaningful effect", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18262450_14_Ent2", "text": "painful diabetic neuropathy", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "18262450_8", "wnd_id": "18262450_8_1", "text": "Oxycodone - gabapentin reduced pain score by 33 % from baseline to end of treatment .", "tokens": ["Oxycodone", "-", "gabapentin", "reduced", "pain", "score", "by", "33", "%", "from", "baseline", "to", "end", "of", "treatment", "."], "event_mentions": [{"id": "18262450_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18262450_8_Ent3", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent5", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent1", "role": "Treatment", "text": "Oxycodone - gabapentin", "start": 0, "end": 3}, {"entity_id": "18262450_8_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent0", "role": "Effect", "text": "reduced pain score by 33 % from baseline", "start": 3, "end": 11}, {"entity_id": "18262450_8_Ent2", "role": "Treatment_Disorder", "text": "pain", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18262450_8_Ent3", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent5", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent1", "text": "Oxycodone - gabapentin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18262450_8_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent0", "text": "reduced pain score by 33 % from baseline", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18262450_8_Ent2", "text": "pain", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1827039_1", "wnd_id": "1827039_1_1", "text": "Severe hepatocellular dysfunction following cyproterone acetate therapy .", "tokens": ["Severe", "hepatocellular", "dysfunction", "following", "cyproterone", "acetate", "therapy", "."], "event_mentions": [{"id": "1827039_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "1827039_1_Ent0", "role": "Effect", "text": "Severe hepatocellular dysfunction", "start": 0, "end": 3}, {"entity_id": "1827039_1_Ent1", "role": "Treatment", "text": "cyproterone acetate", "start": 4, "end": 6}, {"entity_id": "1827039_1_Ent2", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "1827039_1_Ent0", "text": "Severe hepatocellular dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1827039_1_Ent1", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1827039_1_Ent2", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "18294121_1", "wnd_id": "18294121_1_1", "text": "According to the Naranjo adverse drug reaction probability scale , the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable ( score of 6 ) .", "tokens": ["According", "to", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "the", "likelihood", "that", "temozolomide", "was", "responsible", "for", "the", "adverse", "drug", "reaction", "of", "fever", "was", "probable", "(", "score", "of", "6", ")", "."], "event_mentions": [{"id": "18294121_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse drug reaction", "start": 18, "end": 21}, "arguments": [{"entity_id": "18294121_1_Ent1", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent0", "role": "Effect", "text": "fever", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18294121_1_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18294121_3", "wnd_id": "18294121_3_1", "text": "Due to the severity of the rash , temozolomide was permanently discontinued .", "tokens": ["Due", "to", "the", "severity", "of", "the", "rash", ",", "temozolomide", "was", "permanently", "discontinued", "."], "event_mentions": [{"id": "18294121_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Due", "start": 0, "end": 1}, "arguments": [{"entity_id": "18294121_3_Ent0", "role": "Effect", "text": "rash", "start": 6, "end": 7}, {"entity_id": "18294121_3_Ent1", "role": "Treatment", "text": "temozolomide", "start": 8, "end": 9}, {"entity_id": "18294121_3_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18294121_3_Ent0", "text": "rash", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18294121_3_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18294121_3_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18294121_4", "wnd_id": "18294121_4_1", "text": "Temozolomide - induced desquamative skin rash in a patient with metastatic melanoma .", "tokens": ["Temozolomide", "-", "induced", "desquamative", "skin", "rash", "in", "a", "patient", "with", "metastatic", "melanoma", "."], "event_mentions": [{"id": "18294121_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18294121_4_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent1", "role": "Effect", "text": "desquamative skin rash", "start": 3, "end": 6}, {"entity_id": "18294121_4_Ent0", "role": "Subject", "text": "a patient with metastatic melanoma", "start": 7, "end": 12}, {"entity_id": "18294121_4_Ent4", "role": "Treatment_Disorder", "text": "metastatic melanoma", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18294121_4_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent1", "text": "desquamative skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18294121_4_Ent0", "text": "a patient with metastatic melanoma", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18294121_4_Ent4", "text": "metastatic melanoma", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18343993_1", "wnd_id": "18343993_1_1", "text": "A diagnosis of trastuzumab - induced pneumonitis was made .", "tokens": ["A", "diagnosis", "of", "trastuzumab", "-", "induced", "pneumonitis", "was", "made", "."], "event_mentions": [{"id": "18343993_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18343993_1_Ent1", "role": "Treatment", "text": "trastuzumab", "start": 3, "end": 4}, {"entity_id": "18343993_1_Ent2", "role": "Treatment_Drug", "text": "trastuzumab", "start": 3, "end": 4}, {"entity_id": "18343993_1_Ent0", "role": "Effect", "text": "pneumonitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18343993_1_Ent1", "text": "trastuzumab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18343993_1_Ent2", "text": "trastuzumab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18343993_1_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1834424_1", "wnd_id": "1834424_1_1", "text": "A 30 - year - old pharmacist suffered from acute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ) .", "tokens": ["A", "30", "-", "year", "-", "old", "pharmacist", "suffered", "from", "acute", "allergic", "contact", "dermatitis", "due", "to", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "(", "NBD", "-", "Cl", ")", "."], "event_mentions": [{"id": "1834424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 7, "end": 8}, "arguments": [{"entity_id": "1834424_1_Ent0", "role": "Subject", "text": "A 30 - year - old pharmacist", "start": 0, "end": 7}, {"entity_id": "1834424_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 1, "end": 6}, {"entity_id": "1834424_1_Ent2", "role": "Effect", "text": "acute allergic contact dermatitis", "start": 9, "end": 13}, {"entity_id": "1834424_1_Ent4", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 15, "end": 22}, {"entity_id": "1834424_1_Ent3", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "1834424_1_Ent0", "text": "A 30 - year - old pharmacist", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1834424_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1834424_1_Ent2", "text": "acute allergic contact dermatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1834424_1_Ent4", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "1834424_1_Ent3", "text": "4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl )", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "18347524_1", "wnd_id": "18347524_1_1", "text": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis .", "tokens": ["Diffuse", "alveolar", "hemorrhage", "after", "leflunomide", "therapy", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18347524_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18347524_1_Ent1", "role": "Effect", "text": "Diffuse alveolar hemorrhage", "start": 0, "end": 3}, {"entity_id": "18347524_1_Ent2", "role": "Treatment", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18347524_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18347524_1_Ent1", "text": "Diffuse alveolar hemorrhage", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18347524_1_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18347524_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18364401_5", "wnd_id": "18364401_5_1", "text": "There have been numerous case reports of hyperglycemia with olanzapine in the literature , but none reported hyperglycemia within days of initiation of the medication .", "tokens": ["There", "have", "been", "numerous", "case", "reports", "of", "hyperglycemia", "with", "olanzapine", "in", "the", "literature", ",", "but", "none", "reported", "hyperglycemia", "within", "days", "of", "initiation", "of", "the", "medication", "."], "event_mentions": [{"id": "18364401_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "18364401_5_Ent0", "role": "Effect", "text": "hyperglycemia", "start": 7, "end": 8}, {"entity_id": "18364401_5_Ent1", "role": "Treatment", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18364401_5_Ent3", "role": "Treatment_Time_elapsed", "text": "within days of initiation", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "18364401_5_Ent0", "text": "hyperglycemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18364401_5_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_5_Ent3", "text": "within days of initiation", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "18379937_2", "wnd_id": "18379937_2_1", "text": "PURPOSE : To report a case of bilateral anterior uveitis associated with ovulation induction therapy using clomiphene citrate .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "bilateral", "anterior", "uveitis", "associated", "with", "ovulation", "induction", "therapy", "using", "clomiphene", "citrate", "."], "event_mentions": [{"id": "18379937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "18379937_2_Ent0", "role": "Subject", "text": "case", "start": 5, "end": 6}, {"entity_id": "18379937_2_Ent1", "role": "Effect", "text": "bilateral anterior uveitis", "start": 7, "end": 10}, {"entity_id": "18379937_2_Ent2", "role": "Treatment", "text": "ovulation induction therapy using clomiphene citrate", "start": 12, "end": 18}, {"entity_id": "18379937_2_Ent3", "role": "Treatment_Drug", "text": "clomiphene citrate", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "18379937_2_Ent0", "text": "case", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18379937_2_Ent1", "text": "bilateral anterior uveitis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18379937_2_Ent2", "text": "ovulation induction therapy using clomiphene citrate", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18379937_2_Ent3", "text": "clomiphene citrate", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "18396749_3", "wnd_id": "18396749_3_1", "text": "The case of a patient under tibolone therapy for two years who developed a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome following a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions is reported .", "tokens": ["The", "case", "of", "a", "patient", "under", "tibolone", "therapy", "for", "two", "years", "who", "developed", "a", "mixed", "-", "type", "liver", "injury", "with", "prolonged", "cholestasis", "and", "features", "of", "the", "vanishing", "bile", "duct", "syndrome", "following", "a", "ten", "weeks", "treatment", "with", "St.", "John", "wort", "(", "Hypericum", "Perforatum", ")", "infusions", "is", "reported", "."], "event_mentions": [{"id": "18396749_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "18396749_3_Ent0", "role": "Subject", "text": "a patient under tibolone therapy", "start": 3, "end": 8}, {"entity_id": "18396749_3_Ent2", "role": "Treatment", "text": "under tibolone therapy", "start": 5, "end": 8}, {"entity_id": "18396749_3_Ent5", "role": "Treatment_Drug", "text": "tibolone", "start": 6, "end": 7}, {"entity_id": "18396749_3_Ent8", "role": "Combination_Drug", "text": "tibolone", "start": 6, "end": 7}, {"entity_id": "18396749_3_Ent1", "role": "Effect", "text": "a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome", "start": 13, "end": 30}, {"entity_id": "18396749_3_Ent3", "role": "Treatment", "text": "a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions", "start": 31, "end": 44}, {"entity_id": "18396749_3_Ent7", "role": "Treatment_Duration", "text": "ten weeks", "start": 32, "end": 34}, {"entity_id": "18396749_3_Ent4", "role": "Treatment_Drug", "text": "Hypericum Perforatum", "start": 40, "end": 42}, {"entity_id": "18396749_3_Ent9", "role": "Combination_Drug", "text": "Hypericum Perforatum", "start": 40, "end": 42}, {"entity_id": "18396749_3_Ent6", "role": "Treatment_Route", "text": "infusions", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "18396749_3_Ent0", "text": "a patient under tibolone therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18396749_3_Ent2", "text": "under tibolone therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18396749_3_Ent5", "text": "tibolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18396749_3_Ent8", "text": "tibolone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18396749_3_Ent1", "text": "a mixed - type liver injury with prolonged cholestasis and features of the vanishing bile duct syndrome", "entity_type": "Entity", "start": 13, "end": 30}, {"id": "18396749_3_Ent3", "text": "a ten weeks treatment with St. John wort ( Hypericum Perforatum ) infusions", "entity_type": "Entity", "start": 31, "end": 44}, {"id": "18396749_3_Ent7", "text": "ten weeks", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_3_Ent4", "text": "Hypericum Perforatum", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "18396749_3_Ent9", "text": "Hypericum Perforatum", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "18396749_3_Ent6", "text": "infusions", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "18421192_3", "wnd_id": "18421192_3_1", "text": "Type 1 diabetes mellitus provoked by peginterferon alpha - 2b plus ribavirin treatment for chronic hepatitis C.", "tokens": ["Type", "1", "diabetes", "mellitus", "provoked", "by", "peginterferon", "alpha", "-", "2b", "plus", "ribavirin", "treatment", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "18421192_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "18421192_3_Ent0", "role": "Effect", "text": "Type 1 diabetes mellitus", "start": 0, "end": 4}, {"entity_id": "18421192_3_Ent2", "role": "Treatment_Drug", "text": "peginterferon alpha - 2b", "start": 6, "end": 10}, {"entity_id": "18421192_3_Ent6", "role": "Combination_Drug", "text": "peginterferon alpha - 2b", "start": 6, "end": 10}, {"entity_id": "18421192_3_Ent1", "role": "Treatment", "text": "peginterferon alpha - 2b plus ribavirin treatment", "start": 6, "end": 13}, {"entity_id": "18421192_3_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_3_Ent5", "role": "Combination_Drug", "text": "ribavirin", "start": 11, "end": 12}, {"entity_id": "18421192_3_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "18421192_3_Ent0", "text": "Type 1 diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18421192_3_Ent2", "text": "peginterferon alpha - 2b", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18421192_3_Ent6", "text": "peginterferon alpha - 2b", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18421192_3_Ent1", "text": "peginterferon alpha - 2b plus ribavirin treatment", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18421192_3_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_3_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18421192_3_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "18425523_3", "wnd_id": "18425523_3_1", "text": "Ocular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3 , and 1 month after the first ranibizumab in patient 2 .", "tokens": ["Ocular", "hypertension", "occurred", "1", "month", "after", "the", "second", "ranibizumab", "injection", "in", "patients", "1", "and", "3", ",", "and", "1", "month", "after", "the", "first", "ranibizumab", "in", "patient", "2", "."], "event_mentions": [{"id": "18425523_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 2, "end": 3}, "arguments": [{"entity_id": "18425523_3_Ent2", "role": "Effect", "text": "Ocular hypertension", "start": 0, "end": 2}, {"entity_id": "18425523_3_Ent6", "role": "Treatment_Time_elapsed", "text": "1 month after the second", "start": 3, "end": 8}, {"entity_id": "18425523_3_Ent3", "role": "Treatment", "text": "1 month after the second ranibizumab injection", "start": 3, "end": 10}, {"entity_id": "18425523_3_Ent4", "role": "Treatment_Drug", "text": "ranibizumab", "start": 8, "end": 9}, {"entity_id": "18425523_3_Ent8", "role": "Treatment_Route", "text": "injection", "start": 9, "end": 10}, {"entity_id": "18425523_3_Ent0", "role": "Subject", "text": "patients 1 and 3", "start": 11, "end": 15}, {"entity_id": "18425523_3_Ent7", "role": "Treatment_Time_elapsed", "text": "1 month after the first", "start": 17, "end": 22}, {"entity_id": "18425523_3_Ent5", "role": "Treatment_Drug", "text": "ranibizumab", "start": 22, "end": 23}, {"entity_id": "18425523_3_Ent1", "role": "Subject", "text": "in patient 2", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "18425523_3_Ent2", "text": "Ocular hypertension", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18425523_3_Ent6", "text": "1 month after the second", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18425523_3_Ent3", "text": "1 month after the second ranibizumab injection", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18425523_3_Ent4", "text": "ranibizumab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18425523_3_Ent8", "text": "injection", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18425523_3_Ent0", "text": "patients 1 and 3", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "18425523_3_Ent7", "text": "1 month after the first", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "18425523_3_Ent5", "text": "ranibizumab", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18425523_3_Ent1", "text": "in patient 2", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "18453852_10", "wnd_id": "18453852_10_1", "text": "After addition of lopinavir / ritonavir , eight volunteers suffered from both nausea and vomiting , one from nausea only , and one from vomiting only .", "tokens": ["After", "addition", "of", "lopinavir", "/", "ritonavir", ",", "eight", "volunteers", "suffered", "from", "both", "nausea", "and", "vomiting", ",", "one", "from", "nausea", "only", ",", "and", "one", "from", "vomiting", "only", "."], "event_mentions": [{"id": "18453852_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent4", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent6", "role": "Combination_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent3", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent5", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent7", "role": "Combination_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent1", "role": "Subject_Population", "text": "eight", "start": 7, "end": 8}, {"entity_id": "18453852_10_Ent0", "role": "Subject", "text": "eight volunteers", "start": 7, "end": 9}, {"entity_id": "18453852_10_Ent2", "role": "Effect", "text": "nausea and vomiting", "start": 12, "end": 15}]}, {"id": "18453852_10_Evt1", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent12", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent11", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent13", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent8", "role": "Subject", "text": "one", "start": 22, "end": 23}, {"entity_id": "18453852_10_Ent9", "role": "Subject_Population", "text": "one", "start": 22, "end": 23}, {"entity_id": "18453852_10_Ent10", "role": "Effect", "text": "vomiting", "start": 24, "end": 25}]}, {"id": "18453852_10_Evt2", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "18453852_10_Ent18", "role": "Treatment_Drug", "text": "lopinavir", "start": 3, "end": 4}, {"entity_id": "18453852_10_Ent17", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 3, "end": 6}, {"entity_id": "18453852_10_Ent19", "role": "Treatment_Drug", "text": "ritonavir", "start": 5, "end": 6}, {"entity_id": "18453852_10_Ent14", "role": "Subject", "text": "one", "start": 16, "end": 17}, {"entity_id": "18453852_10_Ent15", "role": "Subject_Population", "text": "one", "start": 16, "end": 17}, {"entity_id": "18453852_10_Ent16", "role": "Effect", "text": "nausea", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "18453852_10_Ent4", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent6", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent12", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent18", "text": "lopinavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18453852_10_Ent3", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent11", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent17", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18453852_10_Ent5", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent7", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent13", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent19", "text": "ritonavir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18453852_10_Ent1", "text": "eight", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18453852_10_Ent0", "text": "eight volunteers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18453852_10_Ent2", "text": "nausea and vomiting", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18453852_10_Ent14", "text": "one", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_10_Ent15", "text": "one", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_10_Ent16", "text": "nausea", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18453852_10_Ent8", "text": "one", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18453852_10_Ent9", "text": "one", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "18453852_10_Ent10", "text": "vomiting", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18453852_14", "wnd_id": "18453852_14_1", "text": "The study showed a high incidence of adverse events when a higher than standard dose of the new lopinavir / ritonavir tablets was combined with rifampicin .", "tokens": ["The", "study", "showed", "a", "high", "incidence", "of", "adverse", "events", "when", "a", "higher", "than", "standard", "dose", "of", "the", "new", "lopinavir", "/", "ritonavir", "tablets", "was", "combined", "with", "rifampicin", "."], "event_mentions": [{"id": "18453852_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "when", "start": 9, "end": 10}, "arguments": [{"entity_id": "18453852_14_Ent0", "role": "Effect", "text": "adverse events", "start": 7, "end": 9}, {"entity_id": "18453852_14_Ent2", "role": "Treatment_Dosage", "text": "higher than standard dose", "start": 11, "end": 15}, {"entity_id": "18453852_14_Ent1", "role": "Treatment", "text": "higher than standard dose of the new lopinavir / ritonavir tablets was combined with rifampicin", "start": 11, "end": 26}, {"entity_id": "18453852_14_Ent4", "role": "Treatment_Drug", "text": "lopinavir", "start": 18, "end": 19}, {"entity_id": "18453852_14_Ent7", "role": "Combination_Drug", "text": "lopinavir", "start": 18, "end": 19}, {"entity_id": "18453852_14_Ent5", "role": "Treatment_Drug", "text": "ritonavir", "start": 20, "end": 21}, {"entity_id": "18453852_14_Ent6", "role": "Combination_Drug", "text": "ritonavir", "start": 20, "end": 21}, {"entity_id": "18453852_14_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 25, "end": 26}, {"entity_id": "18453852_14_Ent8", "role": "Combination_Drug", "text": "rifampicin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "18453852_14_Ent0", "text": "adverse events", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18453852_14_Ent2", "text": "higher than standard dose", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "18453852_14_Ent1", "text": "higher than standard dose of the new lopinavir / ritonavir tablets was combined with rifampicin", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "18453852_14_Ent4", "text": "lopinavir", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18453852_14_Ent7", "text": "lopinavir", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18453852_14_Ent5", "text": "ritonavir", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18453852_14_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18453852_14_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18453852_14_Ent8", "text": "rifampicin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "18453852_16", "wnd_id": "18453852_16_1", "text": "Liver function should be carefully monitored when rifampicin and lopinavir / ritonavir are combined in patients .", "tokens": ["Liver", "function", "should", "be", "carefully", "monitored", "when", "rifampicin", "and", "lopinavir", "/", "ritonavir", "are", "combined", "in", "patients", "."], "event_mentions": [{"id": "18453852_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "when", "start": 6, "end": 7}, "arguments": [{"entity_id": "18453852_16_Ent1", "role": "Effect", "text": "Liver function should be carefully monitored", "start": 0, "end": 6}, {"entity_id": "18453852_16_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 7, "end": 8}, {"entity_id": "18453852_16_Ent5", "role": "Combination_Drug", "text": "rifampicin", "start": 7, "end": 8}, {"entity_id": "18453852_16_Ent2", "role": "Treatment", "text": "rifampicin and lopinavir / ritonavir are combined", "start": 7, "end": 14}, {"entity_id": "18453852_16_Ent4", "role": "Treatment_Drug", "text": "lopinavir / ritonavir", "start": 9, "end": 12}, {"entity_id": "18453852_16_Ent6", "role": "Combination_Drug", "text": "lopinavir / ritonavir", "start": 9, "end": 12}, {"entity_id": "18453852_16_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18453852_16_Ent1", "text": "Liver function should be carefully monitored", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18453852_16_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18453852_16_Ent5", "text": "rifampicin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18453852_16_Ent2", "text": "rifampicin and lopinavir / ritonavir are combined", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "18453852_16_Ent4", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18453852_16_Ent6", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18453852_16_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18459568_1", "wnd_id": "18459568_1_1", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with tamoxifen for breast cancer .", "tokens": ["Gastric", "tumor", ",", "endometrial", "carcinoma", "and", "cervical", "adenocarcinoma", "in", "situ", "were", "detected", "after", "treatment", "with", "tamoxifen", "for", "breast", "cancer", "."], "event_mentions": [{"id": "18459568_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detected", "start": 11, "end": 12}, "arguments": [{"entity_id": "18459568_1_Ent0", "role": "Effect", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ", "start": 0, "end": 10}, {"entity_id": "18459568_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 15, "end": 16}, {"entity_id": "18459568_1_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 15, "end": 16}, {"entity_id": "18459568_1_Ent2", "role": "Treatment_Disorder", "text": "breast cancer", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18459568_1_Ent0", "text": "Gastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "18459568_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18459568_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18459568_1_Ent2", "text": "breast cancer", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18476934_3", "wnd_id": "18476934_3_1", "text": "We report a 4 - year - old girl who presented with acute bilateral blindness , a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis .", "tokens": ["We", "report", "a", "4", "-", "year", "-", "old", "girl", "who", "presented", "with", "acute", "bilateral", "blindness", ",", "a", "focal", "seizure", "and", "hypertension", "10", "days", "after", "commencing", "oxybutynin", "to", "treat", "enuresis", "."], "event_mentions": [{"id": "18476934_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "18476934_3_Ent0", "role": "Subject", "text": "a 4 - year - old girl", "start": 2, "end": 9}, {"entity_id": "18476934_3_Ent1", "role": "Subject_Age", "text": "4 - year - old", "start": 3, "end": 8}, {"entity_id": "18476934_3_Ent2", "role": "Subject_Gender", "text": "girl", "start": 8, "end": 9}, {"entity_id": "18476934_3_Ent3", "role": "Effect", "text": "acute bilateral blindness , a focal seizure and hypertension", "start": 12, "end": 21}, {"entity_id": "18476934_3_Ent5", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 21, "end": 23}, {"entity_id": "18476934_3_Ent4", "role": "Treatment", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent6", "role": "Treatment_Drug", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent7", "role": "Treatment_Disorder", "text": "enuresis", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18476934_3_Ent0", "text": "a 4 - year - old girl", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "18476934_3_Ent1", "text": "4 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18476934_3_Ent2", "text": "girl", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18476934_3_Ent3", "text": "acute bilateral blindness , a focal seizure and hypertension", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "18476934_3_Ent5", "text": "10 days", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "18476934_3_Ent4", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent6", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent7", "text": "enuresis", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18504683_1", "wnd_id": "18504683_1_1", "text": "L - asparaginase - induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children .", "tokens": ["L", "-", "asparaginase", "-", "induced", "posterior", "reversible", "encephalopathy", "syndrome", "during", "acute", "lymphoblastic", "leukemia", "treatment", "in", "children", "."], "event_mentions": [{"id": "18504683_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18504683_1_Ent3", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent4", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent2", "role": "Effect", "text": "posterior reversible encephalopathy syndrome", "start": 5, "end": 9}, {"entity_id": "18504683_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 10, "end": 13}, {"entity_id": "18504683_1_Ent0", "role": "Subject", "text": "children", "start": 15, "end": 16}, {"entity_id": "18504683_1_Ent1", "role": "Subject_Age", "text": "children", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18504683_1_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent2", "text": "posterior reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18504683_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18504683_1_Ent0", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18504683_1_Ent1", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18504683_2", "wnd_id": "18504683_2_1", "text": "The purpose of this article is to present the first case - series of posterior reversible encephalopathy syndrome ( PRES ) associated with L - asparaginase treatment .", "tokens": ["The", "purpose", "of", "this", "article", "is", "to", "present", "the", "first", "case", "-", "series", "of", "posterior", "reversible", "encephalopathy", "syndrome", "(", "PRES", ")", "associated", "with", "L", "-", "asparaginase", "treatment", "."], "event_mentions": [{"id": "18504683_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "18504683_2_Ent0", "role": "Effect", "text": "posterior reversible encephalopathy syndrome ( PRES )", "start": 14, "end": 21}, {"entity_id": "18504683_2_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 23, "end": 26}, {"entity_id": "18504683_2_Ent1", "role": "Treatment", "text": "L - asparaginase treatment", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "18504683_2_Ent0", "text": "posterior reversible encephalopathy syndrome ( PRES )", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "18504683_2_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "18504683_2_Ent1", "text": "L - asparaginase treatment", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "18505911_13", "wnd_id": "18505911_13_1", "text": "This case report and several others point toward azathioprine as a clinically significant inducer of warfarin resistance .", "tokens": ["This", "case", "report", "and", "several", "others", "point", "toward", "azathioprine", "as", "a", "clinically", "significant", "inducer", "of", "warfarin", "resistance", "."], "event_mentions": [{"id": "18505911_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducer", "start": 13, "end": 14}, "arguments": [{"entity_id": "18505911_13_Ent1", "role": "Treatment", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent3", "role": "Treatment_Drug", "text": "azathioprine", "start": 8, "end": 9}, {"entity_id": "18505911_13_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 15, "end": 16}, {"entity_id": "18505911_13_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "18505911_13_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18505911_13_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18505911_13_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18505911_2", "wnd_id": "18505911_2_1", "text": "To describe a case of azathioprine - induced warfarin resistance , present a literature review on warfarin - azathioprine interactions , and provide recommendations on appropriate management of this clinically significant interaction .", "tokens": ["To", "describe", "a", "case", "of", "azathioprine", "-", "induced", "warfarin", "resistance", ",", "present", "a", "literature", "review", "on", "warfarin", "-", "azathioprine", "interactions", ",", "and", "provide", "recommendations", "on", "appropriate", "management", "of", "this", "clinically", "significant", "interaction", "."], "event_mentions": [{"id": "18505911_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "18505911_2_Ent1", "role": "Treatment", "text": "azathioprine", "start": 5, "end": 6}, {"entity_id": "18505911_2_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 5, "end": 6}, {"entity_id": "18505911_2_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "18505911_2_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18505911_2_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18505911_2_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "18505911_4", "wnd_id": "18505911_4_1", "text": "She was treated with an average weekly warfarin dose of 39 mg ( 5.5 mg daily ) prior to beginning azathioprine therapy .", "tokens": ["She", "was", "treated", "with", "an", "average", "weekly", "warfarin", "dose", "of", "39", "mg", "(", "5.5", "mg", "daily", ")", "prior", "to", "beginning", "azathioprine", "therapy", "."], "event_mentions": [{"id": "18505911_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "18505911_4_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "18505911_4_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "18505911_4_Ent2", "role": "Treatment", "text": "average weekly warfarin dose of 39 mg ( 5.5 mg daily ) prior to beginning azathioprine therapy", "start": 5, "end": 22}, {"entity_id": "18505911_4_Ent5", "role": "Treatment_Freq", "text": "weekly", "start": 6, "end": 7}, {"entity_id": "18505911_4_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "18505911_4_Ent7", "role": "Treatment_Dosage", "text": "39 mg", "start": 10, "end": 12}, {"entity_id": "18505911_4_Ent8", "role": "Treatment_Dosage", "text": "5.5 mg", "start": 13, "end": 15}, {"entity_id": "18505911_4_Ent6", "role": "Treatment_Freq", "text": "daily", "start": 15, "end": 16}, {"entity_id": "18505911_4_Ent4", "role": "Treatment_Drug", "text": "azathioprine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18505911_4_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_4_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_4_Ent2", "text": "average weekly warfarin dose of 39 mg ( 5.5 mg daily ) prior to beginning azathioprine therapy", "entity_type": "Entity", "start": 5, "end": 22}, {"id": "18505911_4_Ent5", "text": "weekly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18505911_4_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18505911_4_Ent7", "text": "39 mg", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18505911_4_Ent8", "text": "5.5 mg", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "18505911_4_Ent6", "text": "daily", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18505911_4_Ent4", "text": "azathioprine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18505911_9", "wnd_id": "18505911_9_1", "text": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale , and a possible causative agent according to the Drug Interaction Probability Scale .", "tokens": ["Azathioprine", "was", "the", "probable", "causative", "agent", "of", "warfarin", "resistance", "according", "to", "the", "Naranjo", "probability", "scale", ",", "and", "a", "possible", "causative", "agent", "according", "to", "the", "Drug", "Interaction", "Probability", "Scale", "."], "event_mentions": [{"id": "18505911_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causative agent", "start": 4, "end": 6}, "arguments": [{"entity_id": "18505911_9_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "18505911_9_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "18515982_6", "wnd_id": "18515982_6_1", "text": "We believe that the acute renal failure in our patient was associated with anastrozole .", "tokens": ["We", "believe", "that", "the", "acute", "renal", "failure", "in", "our", "patient", "was", "associated", "with", "anastrozole", "."], "event_mentions": [{"id": "18515982_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "18515982_6_Ent1", "role": "Effect", "text": "acute renal failure", "start": 4, "end": 7}, {"entity_id": "18515982_6_Ent0", "role": "Subject", "text": "patient", "start": 9, "end": 10}, {"entity_id": "18515982_6_Ent2", "role": "Treatment", "text": "anastrozole", "start": 13, "end": 14}, {"entity_id": "18515982_6_Ent3", "role": "Treatment_Drug", "text": "anastrozole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18515982_6_Ent1", "text": "acute renal failure", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18515982_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18515982_6_Ent2", "text": "anastrozole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18515982_6_Ent3", "text": "anastrozole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18523232_4", "wnd_id": "18523232_4_1", "text": "OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced hepatitis .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "occurrence", "of", "acute", "cytolytic", "hepatitis", "in", "a", "patient", "exposed", "to", "pulse", "itraconazole", "therapy", "for", "24", "weeks", "and", "provide", "a", "concise", "review", "of", "the", "literature", "on", "cases", "of", "itraconazole", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "18523232_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed to", "start": 13, "end": 15}, "arguments": [{"entity_id": "18523232_4_Ent1", "role": "Effect", "text": "acute cytolytic hepatitis", "start": 7, "end": 10}, {"entity_id": "18523232_4_Ent0", "role": "Subject", "text": "a patient", "start": 11, "end": 13}, {"entity_id": "18523232_4_Ent2", "role": "Treatment", "text": "pulse itraconazole therapy for 24 weeks", "start": 15, "end": 21}, {"entity_id": "18523232_4_Ent3", "role": "Treatment_Drug", "text": "itraconazole", "start": 16, "end": 17}, {"entity_id": "18523232_4_Ent4", "role": "Treatment_Time_elapsed", "text": "24 weeks", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "18523232_4_Ent1", "text": "acute cytolytic hepatitis", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18523232_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18523232_4_Ent2", "text": "pulse itraconazole therapy for 24 weeks", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "18523232_4_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18523232_4_Ent4", "text": "24 weeks", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "18562412_6", "wnd_id": "18562412_6_1", "text": "The third patient had been suffering from serious akathisia while on risperidone , and was cured after switching to olanzapine , but thereafter the patient suffered from RLS at nighttime .", "tokens": ["The", "third", "patient", "had", "been", "suffering", "from", "serious", "akathisia", "while", "on", "risperidone", ",", "and", "was", "cured", "after", "switching", "to", "olanzapine", ",", "but", "thereafter", "the", "patient", "suffered", "from", "RLS", "at", "nighttime", "."], "event_mentions": [{"id": "18562412_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 5, "end": 6}, "arguments": [{"entity_id": "18562412_6_Ent0", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent1", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent2", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "18562412_6_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}]}, {"id": "18562412_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 25, "end": 26}, "arguments": [{"entity_id": "18562412_6_Ent4", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent7", "role": "Treatment_Disorder", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent6", "role": "Treatment", "text": "switching to olanzapine", "start": 17, "end": 20}, {"entity_id": "18562412_6_Ent8", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "18562412_6_Ent5", "role": "Effect", "text": "RLS at nighttime", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "18562412_6_Ent0", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent4", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent7", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent6", "text": "switching to olanzapine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18562412_6_Ent8", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18562412_6_Ent5", "text": "RLS at nighttime", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "18585545_2", "wnd_id": "18585545_2_1", "text": "CONCLUSION : The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors , are known for their potential to cause central nervous system - related adverse effects , including headache , dizziness and insomnia .", "tokens": ["CONCLUSION", ":", "The", "new", "quinolone", "derivatives", "(", "levofloxacin", ",", "sparfloxacin", ",", "grepafloxacin", ",", "trovafloxacin", ",", "gatifloxacin", "and", "moxifloxacin", ")", ",", "also", "called", "gyrase", "inhibitors", ",", "are", "known", "for", "their", "potential", "to", "cause", "central", "nervous", "system", "-", "related", "adverse", "effects", ",", "including", "headache", ",", "dizziness", "and", "insomnia", "."], "event_mentions": [{"id": "18585545_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 31, "end": 32}, "arguments": [{"entity_id": "18585545_2_Ent1", "role": "Treatment", "text": "The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors", "start": 2, "end": 24}, {"entity_id": "18585545_2_Ent2", "role": "Treatment_Drug", "text": "levofloxacin", "start": 7, "end": 8}, {"entity_id": "18585545_2_Ent3", "role": "Treatment_Drug", "text": "sparfloxacin", "start": 9, "end": 10}, {"entity_id": "18585545_2_Ent4", "role": "Treatment_Drug", "text": "grepafloxacin", "start": 11, "end": 12}, {"entity_id": "18585545_2_Ent5", "role": "Treatment_Drug", "text": "trovafloxacin", "start": 13, "end": 14}, {"entity_id": "18585545_2_Ent6", "role": "Treatment_Drug", "text": "gatifloxacin", "start": 15, "end": 16}, {"entity_id": "18585545_2_Ent7", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 17, "end": 18}, {"entity_id": "18585545_2_Ent0", "role": "Effect", "text": "central nervous system - related adverse effects , including headache , dizziness and insomnia", "start": 32, "end": 46}]}], "entity_mentions": [{"id": "18585545_2_Ent1", "text": "The new quinolone derivatives ( levofloxacin , sparfloxacin , grepafloxacin , trovafloxacin , gatifloxacin and moxifloxacin ) , also called gyrase inhibitors", "entity_type": "Entity", "start": 2, "end": 24}, {"id": "18585545_2_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18585545_2_Ent3", "text": "sparfloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18585545_2_Ent4", "text": "grepafloxacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18585545_2_Ent5", "text": "trovafloxacin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18585545_2_Ent6", "text": "gatifloxacin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18585545_2_Ent7", "text": "moxifloxacin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18585545_2_Ent0", "text": "central nervous system - related adverse effects , including headache , dizziness and insomnia", "entity_type": "Entity", "start": 32, "end": 46}], "lang": "en"}
{"doc_id": "18622319_1", "wnd_id": "18622319_1_1", "text": "Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy .", "tokens": ["Spontaneous", "nasal", "septal", "perforation", "with", "antiangiogenic", "bevacizumab", "therapy", "."], "event_mentions": [{"id": "18622319_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "18622319_1_Ent0", "role": "Effect", "text": "Spontaneous nasal septal perforation", "start": 0, "end": 4}, {"entity_id": "18622319_1_Ent1", "role": "Treatment", "text": "antiangiogenic bevacizumab therapy", "start": 5, "end": 8}, {"entity_id": "18622319_1_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18622319_1_Ent0", "text": "Spontaneous nasal septal perforation", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18622319_1_Ent1", "text": "antiangiogenic bevacizumab therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18622319_1_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18622319_2", "wnd_id": "18622319_2_1", "text": "Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies .", "tokens": ["Otolaryngologists", "should", "be", "made", "aware", "of", "a", "newer", "cause", "of", "nasal", "septal", "perforations", "resulting", "from", "the", "more", "recent", "antiangiogenic", "therapy", "used", "to", "treat", "malignancies", "."], "event_mentions": [{"id": "18622319_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 13, "end": 14}, "arguments": [{"entity_id": "18622319_2_Ent0", "role": "Effect", "text": "nasal septal perforations", "start": 10, "end": 13}, {"entity_id": "18622319_2_Ent1", "role": "Treatment", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent2", "role": "Treatment_Drug", "text": "the more recent antiangiogenic therapy", "start": 15, "end": 20}, {"entity_id": "18622319_2_Ent3", "role": "Treatment_Disorder", "text": "malignancies", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18622319_2_Ent0", "text": "nasal septal perforations", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18622319_2_Ent1", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent2", "text": "the more recent antiangiogenic therapy", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "18622319_2_Ent3", "text": "malignancies", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18622319_4", "wnd_id": "18622319_4_1", "text": "Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis .", "tokens": ["Bevacizumab", "is", "a", "recently", "developed", "monoclonal", "antibody", "against", "vascular", "endothelial", "growth", "factor", "receptor", "used", "to", "inhibit", "angiogenesis", "."], "event_mentions": [{"id": "18622319_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit", "start": 15, "end": 16}, "arguments": [{"entity_id": "18622319_4_Ent2", "role": "Treatment_Drug", "text": "Bevacizumab", "start": 0, "end": 1}, {"entity_id": "18622319_4_Ent0", "role": "Treatment", "text": "Bevacizumab is a recently developed monoclonal antibody", "start": 0, "end": 7}, {"entity_id": "18622319_4_Ent1", "role": "Treatment_Disorder", "text": "angiogenesis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18622319_4_Ent2", "text": "Bevacizumab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18622319_4_Ent0", "text": "Bevacizumab is a recently developed monoclonal antibody", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18622319_4_Ent1", "text": "angiogenesis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18628507_4", "wnd_id": "18628507_4_1", "text": "To our knowledge , this is the first report of an angio - oedema associated with VRC .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "an", "angio", "-", "oedema", "associated", "with", "VRC", "."], "event_mentions": [{"id": "18628507_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "18628507_4_Ent0", "role": "Effect", "text": "angio - oedema", "start": 11, "end": 14}, {"entity_id": "18628507_4_Ent1", "role": "Treatment", "text": "VRC", "start": 16, "end": 17}, {"entity_id": "18628507_4_Ent2", "role": "Treatment_Drug", "text": "VRC", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18628507_4_Ent0", "text": "angio - oedema", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18628507_4_Ent1", "text": "VRC", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18628507_4_Ent2", "text": "VRC", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18628507_5", "wnd_id": "18628507_5_1", "text": "Voriconazole ( VRC ) has not previously been reported to cause angio - oedema .", "tokens": ["Voriconazole", "(", "VRC", ")", "has", "not", "previously", "been", "reported", "to", "cause", "angio", "-", "oedema", "."], "event_mentions": [{"id": "18628507_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "18628507_5_Ent2", "role": "Treatment_Drug", "text": "Voriconazole", "start": 0, "end": 1}, {"entity_id": "18628507_5_Ent1", "role": "Treatment", "text": "Voriconazole ( VRC )", "start": 0, "end": 4}, {"entity_id": "18628507_5_Ent0", "role": "Effect", "text": "angio - oedema", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "18628507_5_Ent2", "text": "Voriconazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18628507_5_Ent1", "text": "Voriconazole ( VRC )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18628507_5_Ent0", "text": "angio - oedema", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "18665833_1", "wnd_id": "18665833_1_1", "text": "Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency .", "tokens": ["Stuttering", "priapism", "complicating", "warfarin", "therapy", "in", "a", "patient", "with", "protein", "C", "deficiency", "."], "event_mentions": [{"id": "18665833_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "18665833_1_Ent1", "role": "Effect", "text": "Stuttering priapism", "start": 0, "end": 2}, {"entity_id": "18665833_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "18665833_1_Ent0", "role": "Subject", "text": "a patient with protein C deficiency", "start": 6, "end": 12}, {"entity_id": "18665833_1_Ent3", "role": "Treatment_Disorder", "text": "protein C deficiency", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "18665833_1_Ent1", "text": "Stuttering priapism", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18665833_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18665833_1_Ent0", "text": "a patient with protein C deficiency", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "18665833_1_Ent3", "text": "protein C deficiency", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "18675768_13", "wnd_id": "18675768_13_1", "text": "This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "18675768_13_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent1", "role": "Treatment", "text": "propafenone and citalopram", "start": 10, "end": 13}, {"entity_id": "18675768_13_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent2", "role": "Treatment", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent0", "role": "Effect", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 16, "end": 31}]}], "entity_mentions": [{"id": "18675768_13_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent1", "text": "propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18675768_13_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent0", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 16, "end": 31}], "lang": "en"}
{"doc_id": "18675768_15", "wnd_id": "18675768_15_1", "text": "CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["CONCLUSIONS", ":", "This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 17, "end": 18}, "arguments": [{"entity_id": "18675768_15_Ent1", "role": "Treatment", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "18675768_15_Ent2", "role": "Treatment", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 14, "end": 15}, {"entity_id": "18675768_15_Ent0", "role": "Effect", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 19, "end": 33}]}], "entity_mentions": [{"id": "18675768_15_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_15_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18675768_15_Ent0", "text": "adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 19, "end": 33}], "lang": "en"}
{"doc_id": "18691992_6", "wnd_id": "18691992_6_1", "text": "OBJECTIVE : The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment , and to describe a successful therapeutic approach using imiquimod 5 % .", "tokens": ["OBJECTIVE", ":", "The", "purpose", "of", "this", "study", "was", "to", "report", "the", "concomitant", "occurrence", "of", "multiple", "squamous", "cell", "carcinomas", "and", "diffuse", "nail", "hyperpigmentation", "associated", "with", "hydroxyurea", "treatment", ",", "and", "to", "describe", "a", "successful", "therapeutic", "approach", "using", "imiquimod", "5", "%", "."], "event_mentions": [{"id": "18691992_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 22, "end": 23}, "arguments": [{"entity_id": "18691992_6_Ent0", "role": "Effect", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "start": 14, "end": 22}, {"entity_id": "18691992_6_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 24, "end": 25}, {"entity_id": "18691992_6_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18691992_6_Ent0", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "18691992_6_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18691992_6_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18717612_3", "wnd_id": "18717612_3_1", "text": "We report the first case of a 54 - year - old Turkish woman who presented with ceftriaxone - induced FDE .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "54", "-", "year", "-", "old", "Turkish", "woman", "who", "presented", "with", "ceftriaxone", "-", "induced", "FDE", "."], "event_mentions": [{"id": "18717612_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18717612_3_Ent0", "role": "Subject", "text": "a 54 - year - old Turkish woman", "start": 6, "end": 14}, {"entity_id": "18717612_3_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 7, "end": 12}, {"entity_id": "18717612_3_Ent2", "role": "Subject_Race", "text": "Turkish", "start": 12, "end": 13}, {"entity_id": "18717612_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "18717612_3_Ent5", "role": "Treatment", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent6", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent4", "role": "Effect", "text": "FDE", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18717612_3_Ent0", "text": "a 54 - year - old Turkish woman", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "18717612_3_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18717612_3_Ent2", "text": "Turkish", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18717612_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18717612_3_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent6", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent4", "text": "FDE", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18751717_1", "wnd_id": "18751717_1_1", "text": "Acute syphilitic posterior placoid chorioretinitis following intravitreal triamcinolone acetonide injection .", "tokens": ["Acute", "syphilitic", "posterior", "placoid", "chorioretinitis", "following", "intravitreal", "triamcinolone", "acetonide", "injection", "."], "event_mentions": [{"id": "18751717_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "18751717_1_Ent0", "role": "Effect", "text": "Acute syphilitic posterior placoid chorioretinitis", "start": 0, "end": 5}, {"entity_id": "18751717_1_Ent2", "role": "Treatment_Route", "text": "intravitreal", "start": 6, "end": 7}, {"entity_id": "18751717_1_Ent1", "role": "Treatment", "text": "intravitreal triamcinolone acetonide injection", "start": 6, "end": 10}, {"entity_id": "18751717_1_Ent4", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 7, "end": 9}, {"entity_id": "18751717_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18751717_1_Ent0", "text": "Acute syphilitic posterior placoid chorioretinitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18751717_1_Ent2", "text": "intravitreal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18751717_1_Ent1", "text": "intravitreal triamcinolone acetonide injection", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18751717_1_Ent4", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18751717_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18751717_3", "wnd_id": "18751717_3_1", "text": "CONCLUSIONS : The fundus picture shown in these cases may be typical of ASPPC after IVTA injection .", "tokens": ["CONCLUSIONS", ":", "The", "fundus", "picture", "shown", "in", "these", "cases", "may", "be", "typical", "of", "ASPPC", "after", "IVTA", "injection", "."], "event_mentions": [{"id": "18751717_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "18751717_3_Ent0", "role": "Effect", "text": "ASPPC", "start": 13, "end": 14}, {"entity_id": "18751717_3_Ent2", "role": "Treatment_Drug", "text": "IVTA", "start": 15, "end": 16}, {"entity_id": "18751717_3_Ent1", "role": "Treatment", "text": "IVTA injection", "start": 15, "end": 17}, {"entity_id": "18751717_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18751717_3_Ent0", "text": "ASPPC", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18751717_3_Ent2", "text": "IVTA", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18751717_3_Ent1", "text": "IVTA injection", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18751717_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18755414_1", "wnd_id": "18755414_1_1", "text": "Hemorrhage from a falx meningioma after internal use of low - dose aspirin .", "tokens": ["Hemorrhage", "from", "a", "falx", "meningioma", "after", "internal", "use", "of", "low", "-", "dose", "aspirin", "."], "event_mentions": [{"id": "18755414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "18755414_1_Ent0", "role": "Effect", "text": "Hemorrhage from a falx meningioma", "start": 0, "end": 5}, {"entity_id": "18755414_1_Ent5", "role": "Treatment_Disorder", "text": "falx meningioma", "start": 3, "end": 5}, {"entity_id": "18755414_1_Ent4", "role": "Treatment_Route", "text": "internal", "start": 6, "end": 7}, {"entity_id": "18755414_1_Ent1", "role": "Treatment", "text": "internal use of low - dose aspirin", "start": 6, "end": 13}, {"entity_id": "18755414_1_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 9, "end": 12}, {"entity_id": "18755414_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18755414_1_Ent0", "text": "Hemorrhage from a falx meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18755414_1_Ent5", "text": "falx meningioma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18755414_1_Ent4", "text": "internal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_1_Ent1", "text": "internal use of low - dose aspirin", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18755414_1_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18755414_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18765315_5", "wnd_id": "18765315_5_1", "text": "We reviewed the records of 3 patients with lymphoproliferative disorders who experienced acute coronary syndromes associated with their initial infusion of rituximab .", "tokens": ["We", "reviewed", "the", "records", "of", "3", "patients", "with", "lymphoproliferative", "disorders", "who", "experienced", "acute", "coronary", "syndromes", "associated", "with", "their", "initial", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "18765315_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "18765315_5_Ent1", "role": "Subject_Population", "text": "3", "start": 5, "end": 6}, {"entity_id": "18765315_5_Ent0", "role": "Subject", "text": "3 patients with lymphoproliferative disorders", "start": 5, "end": 10}, {"entity_id": "18765315_5_Ent4", "role": "Treatment_Disorder", "text": "lymphoproliferative disorders", "start": 8, "end": 10}, {"entity_id": "18765315_5_Ent2", "role": "Effect", "text": "acute coronary syndromes", "start": 12, "end": 15}, {"entity_id": "18765315_5_Ent3", "role": "Treatment", "text": "their initial infusion of rituximab", "start": 17, "end": 22}, {"entity_id": "18765315_5_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "18765315_5_Ent5", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18765315_5_Ent1", "text": "3", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18765315_5_Ent0", "text": "3 patients with lymphoproliferative disorders", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18765315_5_Ent4", "text": "lymphoproliferative disorders", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18765315_5_Ent2", "text": "acute coronary syndromes", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18765315_5_Ent3", "text": "their initial infusion of rituximab", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "18765315_5_Ent6", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18765315_5_Ent5", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18795_1", "wnd_id": "18795_1_1", "text": "A 10 - year - old asthmatic boy began to suffer from urticarial rash and moderately severe bronchospasm after 8 weeks ' treatment with disodium cromoglycate .", "tokens": ["A", "10", "-", "year", "-", "old", "asthmatic", "boy", "began", "to", "suffer", "from", "urticarial", "rash", "and", "moderately", "severe", "bronchospasm", "after", "8", "weeks", "'", "treatment", "with", "disodium", "cromoglycate", "."], "event_mentions": [{"id": "18795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "18795_1_Ent0", "role": "Subject", "text": "A 10 - year - old asthmatic boy", "start": 0, "end": 8}, {"entity_id": "18795_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 1, "end": 6}, {"entity_id": "18795_1_Ent7", "role": "Treatment_Disorder", "text": "asthmatic", "start": 6, "end": 7}, {"entity_id": "18795_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 7, "end": 8}, {"entity_id": "18795_1_Ent3", "role": "Effect", "text": "urticarial rash and moderately severe bronchospasm", "start": 12, "end": 18}, {"entity_id": "18795_1_Ent5", "role": "Treatment_Time_elapsed", "text": "8 weeks '", "start": 19, "end": 22}, {"entity_id": "18795_1_Ent4", "role": "Treatment", "text": "8 weeks ' treatment with disodium cromoglycate", "start": 19, "end": 26}, {"entity_id": "18795_1_Ent6", "role": "Treatment_Drug", "text": "disodium cromoglycate", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "18795_1_Ent0", "text": "A 10 - year - old asthmatic boy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18795_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18795_1_Ent7", "text": "asthmatic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18795_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18795_1_Ent3", "text": "urticarial rash and moderately severe bronchospasm", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18795_1_Ent5", "text": "8 weeks '", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "18795_1_Ent4", "text": "8 weeks ' treatment with disodium cromoglycate", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "18795_1_Ent6", "text": "disodium cromoglycate", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "18805724_1", "wnd_id": "18805724_1_1", "text": "DISCUSSION : The main adverse effects of leflunomide consist of diarrhea , nausea , liver enzyme elevation , hypertension , alopecia , and allergic skin reactions .", "tokens": ["DISCUSSION", ":", "The", "main", "adverse", "effects", "of", "leflunomide", "consist", "of", "diarrhea", ",", "nausea", ",", "liver", "enzyme", "elevation", ",", "hypertension", ",", "alopecia", ",", "and", "allergic", "skin", "reactions", "."], "event_mentions": [{"id": "18805724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effects", "start": 5, "end": 6}, "arguments": [{"entity_id": "18805724_1_Ent1", "role": "Treatment", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "18805724_1_Ent2", "role": "Treatment_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "18805724_1_Ent0", "role": "Effect", "text": "diarrhea , nausea , liver enzyme elevation , hypertension , alopecia , and allergic skin reactions", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "18805724_1_Ent1", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18805724_1_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18805724_1_Ent0", "text": "diarrhea , nausea , liver enzyme elevation , hypertension , alopecia , and allergic skin reactions", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "18805724_2", "wnd_id": "18805724_2_1", "text": "Leflunomide - induced toxic epidermal necrolysis in a patient with rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18805724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18805724_2_Ent2", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent4", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent1", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "18805724_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18805724_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18805724_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent4", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent1", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18805724_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18805724_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18810448_2", "wnd_id": "18810448_2_1", "text": "Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy .", "tokens": ["Thymic", "enlargement", "in", "a", "patient", "with", "juvenile", "idiopathic", "arthritis", "during", "etanercept", "therapy", "."], "event_mentions": [{"id": "18810448_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 9, "end": 10}, "arguments": [{"entity_id": "18810448_2_Ent2", "role": "Effect", "text": "Thymic enlargement", "start": 0, "end": 2}, {"entity_id": "18810448_2_Ent0", "role": "Subject", "text": "a patient with juvenile idiopathic arthritis", "start": 3, "end": 9}, {"entity_id": "18810448_2_Ent1", "role": "Subject_Age", "text": "juvenile", "start": 6, "end": 7}, {"entity_id": "18810448_2_Ent5", "role": "Treatment_Disorder", "text": "idiopathic arthritis", "start": 7, "end": 9}, {"entity_id": "18810448_2_Ent3", "role": "Treatment", "text": "etanercept", "start": 10, "end": 11}, {"entity_id": "18810448_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18810448_2_Ent2", "text": "Thymic enlargement", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18810448_2_Ent0", "text": "a patient with juvenile idiopathic arthritis", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "18810448_2_Ent1", "text": "juvenile", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18810448_2_Ent5", "text": "idiopathic arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18810448_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18810448_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18812562_5", "wnd_id": "18812562_5_1", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours according to impaired renal function , was immediately started ; to avoid further nephrotoxicity , immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours .", "tokens": ["Intravenous", "fluconazole", "400", "mg", ",", "followed", "by", "100", "mg", "every", "24", "hours", "according", "to", "impaired", "renal", "function", ",", "was", "immediately", "started", ";", "to", "avoid", "further", "nephrotoxicity", ",", "immunosuppressant", "therapy", "was", "switched", "from", "cyclosporine", "plus", "mycophenolate", "mofetil", "to", "oral", "everolimus", "0.75", "mg", "every", "12", "hours", "."], "event_mentions": [{"id": "18812562_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "avoid", "start": 23, "end": 24}, "arguments": [{"entity_id": "18812562_5_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "18812562_5_Ent0", "role": "Treatment", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "start": 0, "end": 12}, {"entity_id": "18812562_5_Ent8", "role": "Treatment_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent13", "role": "Combination_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent10", "role": "Treatment_Dosage", "text": "400 mg , followed by 100 mg every 24 hours", "start": 2, "end": 12}, {"entity_id": "18812562_5_Ent2", "role": "Treatment_Disorder", "text": "nephrotoxicity", "start": 25, "end": 26}, {"entity_id": "18812562_5_Ent1", "role": "Treatment", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "start": 27, "end": 44}, {"entity_id": "18812562_5_Ent7", "role": "Treatment_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent6", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent12", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent3", "role": "Treatment_Route", "text": "oral", "start": 37, "end": 38}, {"entity_id": "18812562_5_Ent5", "role": "Treatment_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent14", "role": "Combination_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent9", "role": "Treatment_Dosage", "text": "0.75 mg every 12 hours", "start": 39, "end": 44}]}], "entity_mentions": [{"id": "18812562_5_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18812562_5_Ent0", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "18812562_5_Ent8", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent13", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent10", "text": "400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18812562_5_Ent2", "text": "nephrotoxicity", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18812562_5_Ent1", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "entity_type": "Entity", "start": 27, "end": 44}, {"id": "18812562_5_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent6", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent12", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent3", "text": "oral", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18812562_5_Ent5", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent14", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent9", "text": "0.75 mg every 12 hours", "entity_type": "Entity", "start": 39, "end": 44}], "lang": "en"}
{"doc_id": "18854289_1", "wnd_id": "18854289_1_1", "text": "Consolidation therapy with bortezomib / lenalidomide/ dexamethasone versus bortezomib / dexamethasone after a dexamethasone - based induction regimen in patients with multiple myeloma : a randomized phase III trial .", "tokens": ["Consolidation", "therapy", "with", "bortezomib", "/", "lenalidomide/", "dexamethasone", "versus", "bortezomib", "/", "dexamethasone", "after", "a", "dexamethasone", "-", "based", "induction", "regimen", "in", "patients", "with", "multiple", "myeloma", ":", "a", "randomized", "phase", "III", "trial", "."], "event_mentions": [{"id": "18854289_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 18, "end": 19}, "arguments": [{"entity_id": "18854289_1_Ent1", "role": "Treatment", "text": "Consolidation therapy with bortezomib / lenalidomide/ dexamethasone versus bortezomib / dexamethasone after a dexamethasone - based induction regimen", "start": 0, "end": 18}, {"entity_id": "18854289_1_Ent3", "role": "Treatment_Drug", "text": "bortezomib", "start": 3, "end": 4}, {"entity_id": "18854289_1_Ent8", "role": "Combination_Drug", "text": "bortezomib", "start": 3, "end": 4}, {"entity_id": "18854289_1_Ent4", "role": "Treatment_Drug", "text": "lenalidomide/", "start": 5, "end": 6}, {"entity_id": "18854289_1_Ent9", "role": "Combination_Drug", "text": "lenalidomide/", "start": 5, "end": 6}, {"entity_id": "18854289_1_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "18854289_1_Ent10", "role": "Combination_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "18854289_1_Ent6", "role": "Treatment_Drug", "text": "bortezomib", "start": 8, "end": 9}, {"entity_id": "18854289_1_Ent11", "role": "Combination_Drug", "text": "bortezomib", "start": 8, "end": 9}, {"entity_id": "18854289_1_Ent7", "role": "Treatment_Drug", "text": "dexamethasone", "start": 10, "end": 11}, {"entity_id": "18854289_1_Ent12", "role": "Combination_Drug", "text": "dexamethasone", "start": 10, "end": 11}, {"entity_id": "18854289_1_Ent0", "role": "Subject", "text": "patients with multiple myeloma", "start": 19, "end": 23}, {"entity_id": "18854289_1_Ent2", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "18854289_1_Ent1", "text": "Consolidation therapy with bortezomib / lenalidomide/ dexamethasone versus bortezomib / dexamethasone after a dexamethasone - based induction regimen", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "18854289_1_Ent3", "text": "bortezomib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18854289_1_Ent8", "text": "bortezomib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18854289_1_Ent4", "text": "lenalidomide/", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18854289_1_Ent9", "text": "lenalidomide/", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18854289_1_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18854289_1_Ent10", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18854289_1_Ent6", "text": "bortezomib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18854289_1_Ent11", "text": "bortezomib", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18854289_1_Ent7", "text": "dexamethasone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18854289_1_Ent12", "text": "dexamethasone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18854289_1_Ent0", "text": "patients with multiple myeloma", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "18854289_1_Ent2", "text": "multiple myeloma", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "18855892_3", "wnd_id": "18855892_3_1", "text": "In patients with methotrexate - induced anaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression .", "tokens": ["In", "patients", "with", "methotrexate", "-", "induced", "anaphylaxis", ",", "discontinuation", "of", "treatment", "may", "increase", "the", "risk", "of", "death", "due", "to", "cancer", "progression", "."], "event_mentions": [{"id": "18855892_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "18855892_3_Ent5", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "18855892_3_Ent4", "role": "Effect", "text": "anaphylaxis", "start": 6, "end": 7}]}, {"id": "18855892_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinuation", "start": 8, "end": 9}, "arguments": [{"entity_id": "18855892_3_Ent0", "role": "Subject", "text": "In patients with methotrexate - induced anaphylaxis", "start": 0, "end": 7}, {"entity_id": "18855892_3_Ent3", "role": "Treatment_Disorder", "text": "methotrexate - induced anaphylaxis", "start": 3, "end": 7}, {"entity_id": "18855892_3_Ent2", "role": "Treatment", "text": "treatment", "start": 10, "end": 11}, {"entity_id": "18855892_3_Ent1", "role": "Effect", "text": "death due to cancer progression", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "18855892_3_Ent0", "text": "In patients with methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18855892_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18855892_3_Ent3", "text": "methotrexate - induced anaphylaxis", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18855892_3_Ent4", "text": "anaphylaxis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18855892_3_Ent2", "text": "treatment", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18855892_3_Ent1", "text": "death due to cancer progression", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "1893404_2", "wnd_id": "1893404_2_1", "text": "Diabetes Mellitus was observed in a patient given carbamazepine .", "tokens": ["Diabetes", "Mellitus", "was", "observed", "in", "a", "patient", "given", "carbamazepine", "."], "event_mentions": [{"id": "1893404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 7, "end": 8}, "arguments": [{"entity_id": "1893404_2_Ent1", "role": "Effect", "text": "Diabetes Mellitus", "start": 0, "end": 2}, {"entity_id": "1893404_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "1893404_2_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 8, "end": 9}, {"entity_id": "1893404_2_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1893404_2_Ent1", "text": "Diabetes Mellitus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1893404_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1893404_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1893404_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18957000_1", "wnd_id": "18957000_1_1", "text": "Although heparin - dependent antibodies ( HDAs ) typically manifest with thrombocytopenia as in heparin - induced thrombocytopenia ( HIT ) , they may also manifest with preserved platelet counts .", "tokens": ["Although", "heparin", "-", "dependent", "antibodies", "(", "HDAs", ")", "typically", "manifest", "with", "thrombocytopenia", "as", "in", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", ",", "they", "may", "also", "manifest", "with", "preserved", "platelet", "counts", "."], "event_mentions": [{"id": "18957000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifest", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "18957000_1_Ent1", "role": "Treatment", "text": "heparin - dependent antibodies ( HDAs )", "start": 1, "end": 8}, {"entity_id": "18957000_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18957000_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18957000_1_Ent1", "text": "heparin - dependent antibodies ( HDAs )", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "18957000_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18991509_1", "wnd_id": "18991509_1_1", "text": "Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir .", "tokens": ["Iatrogenic", "Cushing", "syndrome", "after", "epidural", "triamcinolone", "injections", "in", "an", "HIV", "type", "1", "-", "infected", "patient", "receiving", "therapy", "with", "ritonavir", "-", "lopinavir", "."], "event_mentions": [{"id": "18991509_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18991509_1_Ent1", "role": "Effect", "text": "Iatrogenic Cushing syndrome", "start": 0, "end": 3}, {"entity_id": "18991509_1_Ent5", "role": "Treatment_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent8", "role": "Combination_Drug", "text": "epidural triamcinolone", "start": 4, "end": 6}, {"entity_id": "18991509_1_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 4, "end": 7}, {"entity_id": "18991509_1_Ent7", "role": "Treatment_Route", "text": "injections", "start": 6, "end": 7}, {"entity_id": "18991509_1_Ent0", "role": "Subject", "text": "an HIV type 1 - infected patient", "start": 8, "end": 15}, {"entity_id": "18991509_1_Ent4", "role": "Treatment_Disorder", "text": "HIV type 1", "start": 9, "end": 12}, {"entity_id": "18991509_1_Ent2", "role": "Treatment", "text": "receiving therapy with ritonavir - lopinavir", "start": 15, "end": 21}, {"entity_id": "18991509_1_Ent6", "role": "Treatment_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}, {"entity_id": "18991509_1_Ent9", "role": "Combination_Drug", "text": "ritonavir - lopinavir", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "18991509_1_Ent1", "text": "Iatrogenic Cushing syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18991509_1_Ent5", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent8", "text": "epidural triamcinolone", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18991509_1_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18991509_1_Ent7", "text": "injections", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18991509_1_Ent0", "text": "an HIV type 1 - infected patient", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "18991509_1_Ent4", "text": "HIV type 1", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18991509_1_Ent2", "text": "receiving therapy with ritonavir - lopinavir", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "18991509_1_Ent6", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "18991509_1_Ent9", "text": "ritonavir - lopinavir", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "19003750_2", "wnd_id": "19003750_2_1", "text": "Acute ischaemia of the leg following accidental intra - arterial injection of dissolved flunitrazepam tablets .", "tokens": ["Acute", "ischaemia", "of", "the", "leg", "following", "accidental", "intra", "-", "arterial", "injection", "of", "dissolved", "flunitrazepam", "tablets", "."], "event_mentions": [{"id": "19003750_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "19003750_2_Ent0", "role": "Effect", "text": "Acute ischaemia of the leg", "start": 0, "end": 5}, {"entity_id": "19003750_2_Ent1", "role": "Treatment", "text": "intra - arterial injection of dissolved flunitrazepam tablets", "start": 7, "end": 15}, {"entity_id": "19003750_2_Ent2", "role": "Treatment_Route", "text": "injection", "start": 10, "end": 11}, {"entity_id": "19003750_2_Ent3", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19003750_2_Ent0", "text": "Acute ischaemia of the leg", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19003750_2_Ent1", "text": "intra - arterial injection of dissolved flunitrazepam tablets", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "19003750_2_Ent2", "text": "injection", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_2_Ent3", "text": "flunitrazepam", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19018868_1", "wnd_id": "19018868_1_1", "text": "A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma .", "tokens": ["A", "case", "of", "severe", "aplastic", "anemia", "secondary", "to", "treatment", "with", "lenalidomide", "for", "multiple", "myeloma", "."], "event_mentions": [{"id": "19018868_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "19018868_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "19018868_1_Ent1", "role": "Effect", "text": "severe aplastic anemia", "start": 3, "end": 6}, {"entity_id": "19018868_1_Ent4", "role": "Treatment_Drug", "text": "lenalidomide", "start": 10, "end": 11}, {"entity_id": "19018868_1_Ent2", "role": "Treatment", "text": "lenalidomide for multiple myeloma", "start": 10, "end": 14}, {"entity_id": "19018868_1_Ent3", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "19018868_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19018868_1_Ent1", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "19018868_1_Ent4", "text": "lenalidomide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19018868_1_Ent2", "text": "lenalidomide for multiple myeloma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "19018868_1_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "19034138_4", "wnd_id": "19034138_4_1", "text": "Corneal endothelial dysfunction associated with amantadine toxicity .", "tokens": ["Corneal", "endothelial", "dysfunction", "associated", "with", "amantadine", "toxicity", "."], "event_mentions": [{"id": "19034138_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_4_Ent0", "role": "Effect", "text": "Corneal endothelial dysfunction", "start": 0, "end": 3}, {"entity_id": "19034138_4_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "19034138_4_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "19034138_4_Ent0", "text": "Corneal endothelial dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19034138_4_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19034138_4_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "19034138_5", "wnd_id": "19034138_5_1", "text": "PURPOSE : To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term amantadine .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "corneal", "endothelial", "dysfunction", "in", "a", "patient", "with", "Parkinson", "disease", "who", "was", "treated", "with", "long", "-", "term", "amantadine", "."], "event_mentions": [{"id": "19034138_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "19034138_5_Ent1", "role": "Effect", "text": "bilateral corneal endothelial dysfunction", "start": 4, "end": 8}, {"entity_id": "19034138_5_Ent0", "role": "Subject", "text": "a patient with Parkinson disease", "start": 9, "end": 14}, {"entity_id": "19034138_5_Ent3", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 12, "end": 14}, {"entity_id": "19034138_5_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 18, "end": 21}, {"entity_id": "19034138_5_Ent2", "role": "Treatment", "text": "long - term amantadine", "start": 18, "end": 22}, {"entity_id": "19034138_5_Ent4", "role": "Treatment_Drug", "text": "amantadine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19034138_5_Ent1", "text": "bilateral corneal endothelial dysfunction", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19034138_5_Ent0", "text": "a patient with Parkinson disease", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19034138_5_Ent3", "text": "Parkinson disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19034138_5_Ent5", "text": "long - term", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19034138_5_Ent2", "text": "long - term amantadine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "19034138_5_Ent4", "text": "amantadine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19058340_1", "wnd_id": "19058340_1_1", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten - month treatment of methotrexate .", "tokens": ["A", "52", "year", "-", "old", "male", "patient", "diagnosed", "of", "ankylosing", "spondylitis", "presented", "with", "an", "iron", "deficiency", "anemia", "after", "a", "ten", "-", "month", "treatment", "of", "methotrexate", "."], "event_mentions": [{"id": "19058340_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 11, "end": 12}, "arguments": [{"entity_id": "19058340_1_Ent0", "role": "Subject", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "start": 0, "end": 11}, {"entity_id": "19058340_1_Ent1", "role": "Subject_Age", "text": "52 year - old", "start": 1, "end": 5}, {"entity_id": "19058340_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "19058340_1_Ent7", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}, {"entity_id": "19058340_1_Ent3", "role": "Effect", "text": "an iron deficiency anemia", "start": 13, "end": 17}, {"entity_id": "19058340_1_Ent4", "role": "Treatment", "text": "a ten - month treatment of methotrexate", "start": 18, "end": 25}, {"entity_id": "19058340_1_Ent5", "role": "Treatment_Time_elapsed", "text": "ten - month", "start": 19, "end": 22}, {"entity_id": "19058340_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19058340_1_Ent0", "text": "A 52 year - old male patient diagnosed of ankylosing spondylitis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "19058340_1_Ent1", "text": "52 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19058340_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19058340_1_Ent7", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19058340_1_Ent3", "text": "an iron deficiency anemia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "19058340_1_Ent4", "text": "a ten - month treatment of methotrexate", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "19058340_1_Ent5", "text": "ten - month", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19058340_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19104709_1", "wnd_id": "19104709_1_1", "text": "IFNalpha - induced recurrence of Graves ' disease ten years after thyroidectomy in chronic viral hepatitis C.", "tokens": ["IFNalpha", "-", "induced", "recurrence", "of", "Graves", "'", "disease", "ten", "years", "after", "thyroidectomy", "in", "chronic", "viral", "hepatitis", "C."], "event_mentions": [{"id": "19104709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19104709_1_Ent1", "role": "Treatment", "text": "IFNalpha", "start": 0, "end": 1}, {"entity_id": "19104709_1_Ent4", "role": "Treatment_Drug", "text": "IFNalpha", "start": 0, "end": 1}, {"entity_id": "19104709_1_Ent0", "role": "Effect", "text": "recurrence of Graves ' disease", "start": 3, "end": 8}, {"entity_id": "19104709_1_Ent2", "role": "Treatment", "text": "ten years after thyroidectomy", "start": 8, "end": 12}, {"entity_id": "19104709_1_Ent3", "role": "Treatment_Disorder", "text": "chronic viral hepatitis C.", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "19104709_1_Ent1", "text": "IFNalpha", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19104709_1_Ent4", "text": "IFNalpha", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19104709_1_Ent0", "text": "recurrence of Graves ' disease", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19104709_1_Ent2", "text": "ten years after thyroidectomy", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "19104709_1_Ent3", "text": "chronic viral hepatitis C.", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "19104709_3", "wnd_id": "19104709_3_1", "text": "We report the case of a 51 - year - old man in whom IFN - alpha treatment was followed by recurrence of Graves ' disease 10 years after thyroidectomy was performed and the patient was declared cured .", "tokens": ["We", "report", "the", "case", "of", "a", "51", "-", "year", "-", "old", "man", "in", "whom", "IFN", "-", "alpha", "treatment", "was", "followed", "by", "recurrence", "of", "Graves", "'", "disease", "10", "years", "after", "thyroidectomy", "was", "performed", "and", "the", "patient", "was", "declared", "cured", "."], "event_mentions": [{"id": "19104709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 19, "end": 20}, "arguments": [{"entity_id": "19104709_3_Ent0", "role": "Subject", "text": "a 51 - year - old man", "start": 5, "end": 12}, {"entity_id": "19104709_3_Ent1", "role": "Subject_Age", "text": "51 - year - old", "start": 6, "end": 11}, {"entity_id": "19104709_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "19104709_3_Ent6", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 14, "end": 17}, {"entity_id": "19104709_3_Ent4", "role": "Treatment", "text": "IFN - alpha treatment", "start": 14, "end": 18}, {"entity_id": "19104709_3_Ent3", "role": "Effect", "text": "recurrence of Graves ' disease", "start": 21, "end": 26}, {"entity_id": "19104709_3_Ent5", "role": "Treatment", "text": "10 years after thyroidectomy", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "19104709_3_Ent0", "text": "a 51 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19104709_3_Ent1", "text": "51 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19104709_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19104709_3_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19104709_3_Ent4", "text": "IFN - alpha treatment", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "19104709_3_Ent3", "text": "recurrence of Graves ' disease", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "19104709_3_Ent5", "text": "10 years after thyroidectomy", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "19122478_1", "wnd_id": "19122478_1_1", "text": "Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia .", "tokens": ["Drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "after", "chlorambucil", "treatment", "in", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "19122478_1_Ent0", "role": "Effect", "text": "Drug rash with eosinophilia and systemic symptoms", "start": 0, "end": 7}, {"entity_id": "19122478_1_Ent1", "role": "Treatment", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 8, "end": 9}, {"entity_id": "19122478_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19122478_1_Ent0", "text": "Drug rash with eosinophilia and systemic symptoms", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19122478_1_Ent1", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19122478_1_Ent3", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19145124_1", "wnd_id": "19145124_1_1", "text": "Multifocal electroretinographic abnormalities in ethambutol - induced visual loss .", "tokens": ["Multifocal", "electroretinographic", "abnormalities", "in", "ethambutol", "-", "induced", "visual", "loss", "."], "event_mentions": [{"id": "19145124_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "19145124_1_Ent1", "role": "Treatment", "text": "ethambutol", "start": 4, "end": 5}, {"entity_id": "19145124_1_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 4, "end": 5}, {"entity_id": "19145124_1_Ent0", "role": "Effect", "text": "visual loss", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "19145124_1_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19145124_1_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19145124_1_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "19212144_1", "wnd_id": "19212144_1_1", "text": "A 58 - year - old man with advanced renal cell carcinoma developed grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency five days after temsirolimus infusion .", "tokens": ["A", "58", "-", "year", "-", "old", "man", "with", "advanced", "renal", "cell", "carcinoma", "developed", "grade", "3", "proteinuria", "(", "8.5", "g/24", "h", ")", "without", "microscopic", "hematuria", "or", "renal", "insufficiency", "five", "days", "after", "temsirolimus", "infusion", "."], "event_mentions": [{"id": "19212144_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "19212144_1_Ent0", "role": "Subject", "text": "A 58 - year - old man with advanced renal cell carcinoma", "start": 0, "end": 12}, {"entity_id": "19212144_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "19212144_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19212144_1_Ent5", "role": "Treatment_Disorder", "text": "renal cell carcinoma", "start": 9, "end": 12}, {"entity_id": "19212144_1_Ent3", "role": "Effect", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "start": 13, "end": 27}, {"entity_id": "19212144_1_Ent6", "role": "Treatment_Time_elapsed", "text": "five days", "start": 27, "end": 29}, {"entity_id": "19212144_1_Ent4", "role": "Treatment", "text": "five days after temsirolimus infusion", "start": 27, "end": 32}, {"entity_id": "19212144_1_Ent7", "role": "Treatment_Drug", "text": "temsirolimus", "start": 30, "end": 31}, {"entity_id": "19212144_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19212144_1_Ent0", "text": "A 58 - year - old man with advanced renal cell carcinoma", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "19212144_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19212144_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19212144_1_Ent5", "text": "renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "19212144_1_Ent3", "text": "grade 3 proteinuria ( 8.5 g/24 h ) without microscopic hematuria or renal insufficiency", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "19212144_1_Ent6", "text": "five days", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "19212144_1_Ent4", "text": "five days after temsirolimus infusion", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "19212144_1_Ent7", "text": "temsirolimus", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19212144_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19224802_5", "wnd_id": "19224802_5_1", "text": "We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i.v .", "tokens": ["We", "report", "on", "three", "cases", "wherein", "treatment", "of", "dexmedetomidine", "-", "induced", "bradycardia", "with", "i.v", "."], "event_mentions": [{"id": "19224802_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19224802_5_Ent1", "role": "Treatment", "text": "treatment of dexmedetomidine", "start": 6, "end": 9}, {"entity_id": "19224802_5_Ent2", "role": "Treatment_Drug", "text": "dexmedetomidine", "start": 8, "end": 9}, {"entity_id": "19224802_5_Ent0", "role": "Effect", "text": "bradycardia with i.v", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19224802_5_Ent1", "text": "treatment of dexmedetomidine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19224802_5_Ent2", "text": "dexmedetomidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19224802_5_Ent0", "text": "bradycardia with i.v", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19226083_4", "wnd_id": "19226083_4_1", "text": "There are several documented case reports of serotonin toxicity when used with selective serotonin reuptake inhibitors .", "tokens": ["There", "are", "several", "documented", "case", "reports", "of", "serotonin", "toxicity", "when", "used", "with", "selective", "serotonin", "reuptake", "inhibitors", "."], "event_mentions": [{"id": "19226083_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 5, "end": 6}, "arguments": [{"entity_id": "19226083_4_Ent1", "role": "Subject_Population", "text": "several", "start": 2, "end": 3}, {"entity_id": "19226083_4_Ent0", "role": "Subject", "text": "several documented case", "start": 2, "end": 5}, {"entity_id": "19226083_4_Ent5", "role": "Treatment_Drug", "text": "serotonin", "start": 7, "end": 8}, {"entity_id": "19226083_4_Ent7", "role": "Combination_Drug", "text": "serotonin", "start": 7, "end": 8}, {"entity_id": "19226083_4_Ent2", "role": "Effect", "text": "serotonin toxicity", "start": 7, "end": 9}, {"entity_id": "19226083_4_Ent3", "role": "Treatment", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}, {"entity_id": "19226083_4_Ent4", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}, {"entity_id": "19226083_4_Ent6", "role": "Combination_Drug", "text": "selective serotonin reuptake inhibitors", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "19226083_4_Ent1", "text": "several", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19226083_4_Ent0", "text": "several documented case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19226083_4_Ent5", "text": "serotonin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19226083_4_Ent7", "text": "serotonin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19226083_4_Ent2", "text": "serotonin toxicity", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19226083_4_Ent3", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "19226083_4_Ent4", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "19226083_4_Ent6", "text": "selective serotonin reuptake inhibitors", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "19249953_10", "wnd_id": "19249953_10_1", "text": "To our knowledge , however , this is the first case report of a possible sitagliptin - lovastatin interaction that may have caused rhabdomyolysis .", "tokens": ["To", "our", "knowledge", ",", "however", ",", "this", "is", "the", "first", "case", "report", "of", "a", "possible", "sitagliptin", "-", "lovastatin", "interaction", "that", "may", "have", "caused", "rhabdomyolysis", "."], "event_mentions": [{"id": "19249953_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 22, "end": 23}, "arguments": [{"entity_id": "19249953_10_Ent2", "role": "Treatment_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent5", "role": "Combination_Drug", "text": "sitagliptin", "start": 15, "end": 16}, {"entity_id": "19249953_10_Ent1", "role": "Treatment", "text": "sitagliptin - lovastatin interaction", "start": 15, "end": 19}, {"entity_id": "19249953_10_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 17, "end": 18}, {"entity_id": "19249953_10_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "19249953_10_Ent2", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent5", "text": "sitagliptin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19249953_10_Ent1", "text": "sitagliptin - lovastatin interaction", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19249953_10_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19249953_10_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "19249953_7", "wnd_id": "19249953_7_1", "text": "As it had been 10 months since her last dosage adjustment of diltiazem , it was unlikely that the statin - induced rhabdomyolysis was precipitated by diltiazem .", "tokens": ["As", "it", "had", "been", "10", "months", "since", "her", "last", "dosage", "adjustment", "of", "diltiazem", ",", "it", "was", "unlikely", "that", "the", "statin", "-", "induced", "rhabdomyolysis", "was", "precipitated", "by", "diltiazem", "."], "event_mentions": [{"id": "19249953_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 24, "end": 25}, "arguments": [{"entity_id": "19249953_7_Ent0", "role": "Effect", "text": "statin - induced rhabdomyolysis", "start": 19, "end": 23}, {"entity_id": "19249953_7_Ent1", "role": "Treatment", "text": "diltiazem", "start": 26, "end": 27}, {"entity_id": "19249953_7_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19249953_7_Ent0", "text": "statin - induced rhabdomyolysis", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19249953_7_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19249953_7_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19266307_2", "wnd_id": "19266307_2_1", "text": "MATERIALS AND METHODS : We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin .", "tokens": ["MATERIALS", "AND", "METHODS", ":", "We", "present", "two", "cases", "of", "significant", "morbidity", "related", "to", "primary", "and", "secondary", "perforation", "of", "the", "bladder", "following", "two", "instillations", "of", "epirubicin", "."], "event_mentions": [{"id": "19266307_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "19266307_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "19266307_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "19266307_2_Ent2", "role": "Effect", "text": "significant morbidity related to primary and secondary perforation of the bladder", "start": 9, "end": 20}, {"entity_id": "19266307_2_Ent3", "role": "Treatment", "text": "two instillations of epirubicin", "start": 21, "end": 25}, {"entity_id": "19266307_2_Ent4", "role": "Treatment_Route", "text": "instillations", "start": 22, "end": 23}, {"entity_id": "19266307_2_Ent5", "role": "Treatment_Drug", "text": "epirubicin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19266307_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19266307_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19266307_2_Ent2", "text": "significant morbidity related to primary and secondary perforation of the bladder", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "19266307_2_Ent3", "text": "two instillations of epirubicin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19266307_2_Ent4", "text": "instillations", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19266307_2_Ent5", "text": "epirubicin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19281746_1", "wnd_id": "19281746_1_1", "text": "Aliskiren - associated acute renal failure with hyperkalemia .", "tokens": ["Aliskiren", "-", "associated", "acute", "renal", "failure", "with", "hyperkalemia", "."], "event_mentions": [{"id": "19281746_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19281746_1_Ent1", "role": "Treatment", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent2", "role": "Treatment_Drug", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "19281746_1_Ent1", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent2", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "19281746_2", "wnd_id": "19281746_2_1", "text": "We report the first case of acute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor aliskiren .", "tokens": ["We", "report", "the", "first", "case", "of", "acute", "renal", "failure", "with", "hyperkalemia", "associated", "with", "the", "recently", "marketed", "direct", "renin", "inhibitor", "aliskiren", "."], "event_mentions": [{"id": "19281746_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "19281746_2_Ent0", "role": "Effect", "text": "acute renal failure with hyperkalemia", "start": 6, "end": 11}, {"entity_id": "19281746_2_Ent1", "role": "Treatment", "text": "renin inhibitor aliskiren", "start": 17, "end": 20}, {"entity_id": "19281746_2_Ent2", "role": "Treatment_Drug", "text": "aliskiren", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19281746_2_Ent0", "text": "acute renal failure with hyperkalemia", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19281746_2_Ent1", "text": "renin inhibitor aliskiren", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "19281746_2_Ent2", "text": "aliskiren", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19299370_2", "wnd_id": "19299370_2_1", "text": "CONCLUSION : A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose .", "tokens": ["CONCLUSION", ":", "A", "woman", "receiving", "enoxaparin", "every", "12", "hours", "developed", "signs", "and", "symptoms", "of", "hepatotoxicity", "after", "the", "second", "dose", "."], "event_mentions": [{"id": "19299370_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19299370_2_Ent0", "role": "Subject", "text": "A woman", "start": 2, "end": 4}, {"entity_id": "19299370_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 3, "end": 4}, {"entity_id": "19299370_2_Ent5", "role": "Treatment_Drug", "text": "enoxaparin", "start": 5, "end": 6}, {"entity_id": "19299370_2_Ent3", "role": "Treatment", "text": "enoxaparin every 12 hours", "start": 5, "end": 9}, {"entity_id": "19299370_2_Ent6", "role": "Treatment_Freq", "text": "every 12 hours", "start": 6, "end": 9}, {"entity_id": "19299370_2_Ent2", "role": "Effect", "text": "signs and symptoms of hepatotoxicity", "start": 10, "end": 15}, {"entity_id": "19299370_2_Ent4", "role": "Treatment", "text": "after the second dose", "start": 15, "end": 19}, {"entity_id": "19299370_2_Ent7", "role": "Treatment_Dosage", "text": "the second dose .", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "19299370_2_Ent0", "text": "A woman", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19299370_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19299370_2_Ent5", "text": "enoxaparin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19299370_2_Ent3", "text": "enoxaparin every 12 hours", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19299370_2_Ent6", "text": "every 12 hours", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19299370_2_Ent2", "text": "signs and symptoms of hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "19299370_2_Ent4", "text": "after the second dose", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19299370_2_Ent7", "text": "the second dose .", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "19318596_4", "wnd_id": "19318596_4_1", "text": "With the first cyclosporine dose , the patient complained of leg pain that was most severe during the cyclosporine infusion .", "tokens": ["With", "the", "first", "cyclosporine", "dose", ",", "the", "patient", "complained", "of", "leg", "pain", "that", "was", "most", "severe", "during", "the", "cyclosporine", "infusion", "."], "event_mentions": [{"id": "19318596_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 8, "end": 9}, "arguments": [{"entity_id": "19318596_4_Ent0", "role": "Subject", "text": "With", "start": 0, "end": 1}, {"entity_id": "19318596_4_Ent2", "role": "Treatment", "text": "first cyclosporine dose", "start": 2, "end": 5}, {"entity_id": "19318596_4_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 3, "end": 4}, {"entity_id": "19318596_4_Ent1", "role": "Effect", "text": "leg pain", "start": 10, "end": 12}, {"entity_id": "19318596_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19318596_4_Ent0", "text": "With", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_4_Ent2", "text": "first cyclosporine dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19318596_4_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19318596_4_Ent1", "text": "leg pain", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19318596_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19331262_4", "wnd_id": "19331262_4_1", "text": "This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome .", "tokens": ["This", "report", "describes", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "due", "to", "risperidone", "in", "a", "child", "with", "Joubert", "syndrome", "."], "event_mentions": [{"id": "19331262_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 9, "end": 11}, "arguments": [{"entity_id": "19331262_4_Ent2", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 6, "end": 9}, {"entity_id": "19331262_4_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "19331262_4_Ent0", "role": "Subject", "text": "a child with Joubert syndrome", "start": 13, "end": 18}, {"entity_id": "19331262_4_Ent1", "role": "Subject_Age", "text": "child", "start": 14, "end": 15}, {"entity_id": "19331262_4_Ent4", "role": "Treatment_Disorder", "text": "Joubert syndrome", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19331262_4_Ent2", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19331262_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19331262_4_Ent0", "text": "a child with Joubert syndrome", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19331262_4_Ent1", "text": "child", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19331262_4_Ent4", "text": "Joubert syndrome", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "19354059_1", "wnd_id": "19354059_1_1", "text": "The most common complication of warfarin use is adverse bleeding .", "tokens": ["The", "most", "common", "complication", "of", "warfarin", "use", "is", "adverse", "bleeding", "."], "event_mentions": [{"id": "19354059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 6, "end": 7}, "arguments": [{"entity_id": "19354059_1_Ent1", "role": "Treatment", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "19354059_1_Ent0", "role": "Effect", "text": "adverse bleeding", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19354059_1_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19354059_1_Ent0", "text": "adverse bleeding", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19365885_3", "wnd_id": "19365885_3_1", "text": "In these patients , long - acting octreotide may trigger serious hypoglycemia .", "tokens": ["In", "these", "patients", ",", "long", "-", "acting", "octreotide", "may", "trigger", "serious", "hypoglycemia", "."], "event_mentions": [{"id": "19365885_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 9, "end": 10}, "arguments": [{"entity_id": "19365885_3_Ent0", "role": "Subject", "text": "these patients", "start": 1, "end": 3}, {"entity_id": "19365885_3_Ent2", "role": "Treatment", "text": "long - acting octreotide", "start": 4, "end": 8}, {"entity_id": "19365885_3_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 7, "end": 8}, {"entity_id": "19365885_3_Ent1", "role": "Effect", "text": "serious hypoglycemia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "19365885_3_Ent0", "text": "these patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19365885_3_Ent2", "text": "long - acting octreotide", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19365885_3_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19365885_3_Ent1", "text": "serious hypoglycemia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "19390192_1", "wnd_id": "19390192_1_1", "text": "Leukopenia due to parvovirus B19 in a Crohn 's disease patient using azathioprine .", "tokens": ["Leukopenia", "due", "to", "parvovirus", "B19", "in", "a", "Crohn", "'s", "disease", "patient", "using", "azathioprine", "."], "event_mentions": [{"id": "19390192_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19390192_1_Ent2", "role": "Effect", "text": "Leukopenia", "start": 0, "end": 1}, {"entity_id": "19390192_1_Ent1", "role": "Subject_Disorder", "text": "parvovirus B19", "start": 3, "end": 5}, {"entity_id": "19390192_1_Ent0", "role": "Subject", "text": "parvovirus B19 in a Crohn 's disease patient", "start": 3, "end": 11}, {"entity_id": "19390192_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 7, "end": 10}, {"entity_id": "19390192_1_Ent3", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "19390192_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19390192_1_Ent2", "text": "Leukopenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19390192_1_Ent1", "text": "parvovirus B19", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19390192_1_Ent0", "text": "parvovirus B19 in a Crohn 's disease patient", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "19390192_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19390192_1_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19390192_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19402273_2", "wnd_id": "19402273_2_1", "text": "Isoniazid induced gynaecomastia : a case report .", "tokens": ["Isoniazid", "induced", "gynaecomastia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19402273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19402273_2_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent0", "role": "Effect", "text": "gynaecomastia", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "19402273_2_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent0", "text": "gynaecomastia", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "19423610_3", "wnd_id": "19423610_3_1", "text": "We noted that the delirium resembled serotonin toxicity and that the patient had been taking paroxetine until 2 days before surgery .", "tokens": ["We", "noted", "that", "the", "delirium", "resembled", "serotonin", "toxicity", "and", "that", "the", "patient", "had", "been", "taking", "paroxetine", "until", "2", "days", "before", "surgery", "."], "event_mentions": [{"id": "19423610_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 14, "end": 15}, "arguments": [{"entity_id": "19423610_3_Ent0", "role": "Effect", "text": "delirium resembled serotonin toxicity", "start": 4, "end": 8}, {"entity_id": "19423610_3_Ent2", "role": "Treatment_Drug", "text": "paroxetine", "start": 15, "end": 16}, {"entity_id": "19423610_3_Ent1", "role": "Treatment", "text": "paroxetine until 2 days before surgery", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "19423610_3_Ent0", "text": "delirium resembled serotonin toxicity", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19423610_3_Ent2", "text": "paroxetine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19423610_3_Ent1", "text": "paroxetine until 2 days before surgery", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "19434733_2", "wnd_id": "19434733_2_1", "text": "The risk of developing sAML is estimated to be between 1 % and 5 % , 2 - 20 years after exposure to etoposide but may also be related to cumulative drug doses , treatment schedules , host factors and co - administration of other antineoplastic agents .", "tokens": ["The", "risk", "of", "developing", "sAML", "is", "estimated", "to", "be", "between", "1", "%", "and", "5", "%", ",", "2", "-", "20", "years", "after", "exposure", "to", "etoposide", "but", "may", "also", "be", "related", "to", "cumulative", "drug", "doses", ",", "treatment", "schedules", ",", "host", "factors", "and", "co", "-", "administration", "of", "other", "antineoplastic", "agents", "."], "event_mentions": [{"id": "19434733_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "19434733_2_Ent0", "role": "Effect", "text": "sAML", "start": 4, "end": 5}, {"entity_id": "19434733_2_Ent3", "role": "Treatment_Time_elapsed", "text": "2 - 20 years", "start": 16, "end": 20}, {"entity_id": "19434733_2_Ent1", "role": "Treatment", "text": "2 - 20 years after exposure to etoposide", "start": 16, "end": 24}, {"entity_id": "19434733_2_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "19434733_2_Ent0", "text": "sAML", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19434733_2_Ent3", "text": "2 - 20 years", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "19434733_2_Ent1", "text": "2 - 20 years after exposure to etoposide", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "19434733_2_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "19499966_3", "wnd_id": "19499966_3_1", "text": "Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma .", "tokens": ["Onset", "of", "male", "gynaecomastia", "in", "a", "patient", "treated", "with", "sunitinib", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19499966_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Onset", "start": 0, "end": 1}, "arguments": [{"entity_id": "19499966_3_Ent0", "role": "Subject", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 2, "end": 3}, {"entity_id": "19499966_3_Ent3", "role": "Effect", "text": "gynaecomastia", "start": 3, "end": 4}, {"entity_id": "19499966_3_Ent1", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "19499966_3_Ent6", "role": "Treatment_Drug", "text": "sunitinib", "start": 9, "end": 10}, {"entity_id": "19499966_3_Ent4", "role": "Treatment", "text": "sunitinib for metastatic renal cell carcinoma", "start": 9, "end": 15}, {"entity_id": "19499966_3_Ent5", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "19499966_3_Ent0", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent2", "text": "male", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19499966_3_Ent3", "text": "gynaecomastia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19499966_3_Ent1", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19499966_3_Ent6", "text": "sunitinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19499966_3_Ent4", "text": "sunitinib for metastatic renal cell carcinoma", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "19499966_3_Ent5", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "19520277_1", "wnd_id": "19520277_1_1", "text": "Stupor and fast activity on electroencephalography in a child treated with valproate .", "tokens": ["Stupor", "and", "fast", "activity", "on", "electroencephalography", "in", "a", "child", "treated", "with", "valproate", "."], "event_mentions": [{"id": "19520277_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "19520277_1_Ent2", "role": "Effect", "text": "Stupor", "start": 0, "end": 1}, {"entity_id": "19520277_1_Ent3", "role": "Effect", "text": "fast activity on electroencephalography", "start": 2, "end": 6}, {"entity_id": "19520277_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "19520277_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "19520277_1_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19520277_1_Ent2", "text": "Stupor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19520277_1_Ent3", "text": "fast activity on electroencephalography", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19520277_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19520277_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19520277_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19531695_11", "wnd_id": "19531695_11_1", "text": "A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .", "tokens": ["A", "MEDLINE", "search", "(", "1966", "-", "January", "2009", ")", "revealed", "one", "in", "vivo", "pharmacokinetic", "study", "on", "the", "interaction", "between", "flecainide", ",", "a", "CYP2D6", "substrate", ",", "and", "paroxetine", ",", "a", "CYP2D6", "inhibitor", ",", "as", "well", "as", "3", "case", "reports", "of", "flecainide", "-", "induced", "delirium", "."], "event_mentions": [{"id": "19531695_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 41, "end": 42}, "arguments": [{"entity_id": "19531695_11_Ent1", "role": "Subject_Population", "text": "3", "start": 35, "end": 36}, {"entity_id": "19531695_11_Ent0", "role": "Subject", "text": "3 case reports", "start": 35, "end": 38}, {"entity_id": "19531695_11_Ent3", "role": "Treatment", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent2", "role": "Effect", "text": "delirium", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "19531695_11_Ent1", "text": "3", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19531695_11_Ent0", "text": "3 case reports", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "19531695_11_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent2", "text": "delirium", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "19531695_14", "wnd_id": "19531695_14_1", "text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .", "tokens": ["Because", "toxicity", "may", "occur", "when", "flecainide", "is", "prescribed", "with", "paroxetine", "and", "other", "potent", "CYP2D6", "inhibitors", ",", "flecainide", "plasma", "concentrations", "should", "be", "monitored", "closely", "with", "commencement", "of", "CYP2D6", "inhibitors", "."], "event_mentions": [{"id": "19531695_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 3, "end": 4}, "arguments": [{"entity_id": "19531695_14_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "19531695_14_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent4", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent1", "role": "Treatment", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "start": 5, "end": 15}, {"entity_id": "19531695_14_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 9, "end": 10}, {"entity_id": "19531695_14_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19531695_14_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_14_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent1", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "19531695_14_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531695_14_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19555801_2", "wnd_id": "19555801_2_1", "text": "We report a patient of organic bipolar affective disorder who developed hiccups with the atypical antipsychotic aripiprazole .", "tokens": ["We", "report", "a", "patient", "of", "organic", "bipolar", "affective", "disorder", "who", "developed", "hiccups", "with", "the", "atypical", "antipsychotic", "aripiprazole", "."], "event_mentions": [{"id": "19555801_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "19555801_2_Ent0", "role": "Subject", "text": "a patient of organic bipolar affective disorder", "start": 2, "end": 9}, {"entity_id": "19555801_2_Ent3", "role": "Treatment_Disorder", "text": "organic bipolar affective disorder", "start": 5, "end": 9}, {"entity_id": "19555801_2_Ent1", "role": "Effect", "text": "hiccups", "start": 11, "end": 12}, {"entity_id": "19555801_2_Ent2", "role": "Treatment", "text": "the atypical antipsychotic aripiprazole", "start": 13, "end": 17}, {"entity_id": "19555801_2_Ent4", "role": "Treatment_Drug", "text": "aripiprazole", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19555801_2_Ent0", "text": "a patient of organic bipolar affective disorder", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "19555801_2_Ent3", "text": "organic bipolar affective disorder", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19555801_2_Ent1", "text": "hiccups", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19555801_2_Ent2", "text": "the atypical antipsychotic aripiprazole", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "19555801_2_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "19567656_1", "wnd_id": "19567656_1_1", "text": "CONCLUSIONS : This patient 's rhabdomyolysis was probably induced by sertraline therapy .", "tokens": ["CONCLUSIONS", ":", "This", "patient", "'s", "rhabdomyolysis", "was", "probably", "induced", "by", "sertraline", "therapy", "."], "event_mentions": [{"id": "19567656_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19567656_1_Ent0", "role": "Subject", "text": "This patient", "start": 2, "end": 4}, {"entity_id": "19567656_1_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "19567656_1_Ent2", "role": "Treatment", "text": "sertraline", "start": 10, "end": 11}, {"entity_id": "19567656_1_Ent3", "role": "Treatment_Drug", "text": "sertraline", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19567656_1_Ent0", "text": "This patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19567656_1_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19567656_1_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_1_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19648225_1", "wnd_id": "19648225_1_1", "text": "Can ketamine prescribed for pain cause damage to the urinary tract ?", "tokens": ["Can", "ketamine", "prescribed", "for", "pain", "cause", "damage", "to", "the", "urinary", "tract", "?"], "event_mentions": [{"id": "19648225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 5, "end": 6}, "arguments": [{"entity_id": "19648225_1_Ent1", "role": "Treatment", "text": "ketamine", "start": 1, "end": 2}, {"entity_id": "19648225_1_Ent3", "role": "Treatment_Drug", "text": "ketamine", "start": 1, "end": 2}, {"entity_id": "19648225_1_Ent2", "role": "Treatment_Disorder", "text": "pain", "start": 4, "end": 5}, {"entity_id": "19648225_1_Ent0", "role": "Effect", "text": "damage to the urinary tract", "start": 6, "end": 11}]}], "entity_mentions": [{"id": "19648225_1_Ent1", "text": "ketamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19648225_1_Ent3", "text": "ketamine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19648225_1_Ent2", "text": "pain", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19648225_1_Ent0", "text": "damage to the urinary tract", "entity_type": "Entity", "start": 6, "end": 11}], "lang": "en"}
{"doc_id": "19653965_1", "wnd_id": "19653965_1_1", "text": "These two cases highlight the importance of considering lopinavir / ritonavir induced arrhythmias when dealing with HIV - positive individuals .", "tokens": ["These", "two", "cases", "highlight", "the", "importance", "of", "considering", "lopinavir", "/", "ritonavir", "induced", "arrhythmias", "when", "dealing", "with", "HIV", "-", "positive", "individuals", "."], "event_mentions": [{"id": "19653965_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "19653965_1_Ent3", "role": "Treatment_Drug", "text": "lopinavir", "start": 8, "end": 9}, {"entity_id": "19653965_1_Ent6", "role": "Combination_Drug", "text": "lopinavir", "start": 8, "end": 9}, {"entity_id": "19653965_1_Ent2", "role": "Treatment", "text": "lopinavir / ritonavir", "start": 8, "end": 11}, {"entity_id": "19653965_1_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 10, "end": 11}, {"entity_id": "19653965_1_Ent7", "role": "Combination_Drug", "text": "ritonavir", "start": 10, "end": 11}, {"entity_id": "19653965_1_Ent1", "role": "Effect", "text": "arrhythmias", "start": 12, "end": 13}, {"entity_id": "19653965_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 16, "end": 17}, {"entity_id": "19653965_1_Ent0", "role": "Subject", "text": "HIV - positive individuals", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "19653965_1_Ent3", "text": "lopinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19653965_1_Ent6", "text": "lopinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19653965_1_Ent2", "text": "lopinavir / ritonavir", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "19653965_1_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19653965_1_Ent7", "text": "ritonavir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19653965_1_Ent1", "text": "arrhythmias", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19653965_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19653965_1_Ent0", "text": "HIV - positive individuals", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "19667003_1", "wnd_id": "19667003_1_1", "text": "Carbamazepine - induced hyperammonemia .", "tokens": ["Carbamazepine", "-", "induced", "hyperammonemia", "."], "event_mentions": [{"id": "19667003_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19667003_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "19667003_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "19667003_1_Ent0", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "19667003_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_1_Ent0", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "19667003_14", "wnd_id": "19667003_14_1", "text": "CONCLUSION : A 26 - year - old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy .", "tokens": ["CONCLUSION", ":", "A", "26", "-", "year", "-", "old", "man", "with", "bipolar", "disorder", "developed", "hyperammonemia", "three", "weeks", "after", "initiating", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "19667003_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "19667003_14_Ent0", "role": "Subject", "text": "A 26 - year - old man with bipolar disorder", "start": 2, "end": 12}, {"entity_id": "19667003_14_Ent1", "role": "Subject_Age", "text": "26 - year - old", "start": 3, "end": 8}, {"entity_id": "19667003_14_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19667003_14_Ent7", "role": "Treatment_Disorder", "text": "bipolar disorder", "start": 10, "end": 12}, {"entity_id": "19667003_14_Ent3", "role": "Effect", "text": "hyperammonemia", "start": 13, "end": 14}, {"entity_id": "19667003_14_Ent5", "role": "Treatment_Time_elapsed", "text": "three weeks", "start": 14, "end": 16}, {"entity_id": "19667003_14_Ent4", "role": "Treatment", "text": "three weeks after initiating carbamazepine therapy", "start": 14, "end": 20}, {"entity_id": "19667003_14_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19667003_14_Ent0", "text": "A 26 - year - old man with bipolar disorder", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "19667003_14_Ent1", "text": "26 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19667003_14_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_14_Ent7", "text": "bipolar disorder", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_14_Ent3", "text": "hyperammonemia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19667003_14_Ent5", "text": "three weeks", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19667003_14_Ent4", "text": "three weeks after initiating carbamazepine therapy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "19667003_14_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "19669617_1", "wnd_id": "19669617_1_1", "text": "A 65 - year - old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat , 1 week after the fourth dose of adalimumab .", "tokens": ["A", "65", "-", "year", "-", "old", "female", "patient", "presented", "with", "jaundice", "followed", "2", "days", "later", "by", "severe", "dyspnea", "and", "tachypnea", "which", "worsened", "when", "patient", "was", "lying", "flat", ",", "1", "week", "after", "the", "fourth", "dose", "of", "adalimumab", "."], "event_mentions": [{"id": "19669617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 8, "end": 9}, "arguments": [{"entity_id": "19669617_1_Ent0", "role": "Subject", "text": "A 65 - year - old female patient", "start": 0, "end": 8}, {"entity_id": "19669617_1_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "19669617_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "19669617_1_Ent3", "role": "Effect", "text": "jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat", "start": 10, "end": 27}, {"entity_id": "19669617_1_Ent6", "role": "Treatment_Time_elapsed", "text": "1 week after", "start": 28, "end": 31}, {"entity_id": "19669617_1_Ent4", "role": "Treatment", "text": "1 week after the fourth dose of adalimumab", "start": 28, "end": 36}, {"entity_id": "19669617_1_Ent7", "role": "Treatment_Dosage", "text": "fourth dose", "start": 32, "end": 34}, {"entity_id": "19669617_1_Ent5", "role": "Treatment_Drug", "text": "adalimumab", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "19669617_1_Ent0", "text": "A 65 - year - old female patient", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "19669617_1_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19669617_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19669617_1_Ent3", "text": "jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat", "entity_type": "Entity", "start": 10, "end": 27}, {"id": "19669617_1_Ent6", "text": "1 week after", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "19669617_1_Ent4", "text": "1 week after the fourth dose of adalimumab", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "19669617_1_Ent7", "text": "fourth dose", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "19669617_1_Ent5", "text": "adalimumab", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "19733945_1", "wnd_id": "19733945_1_1", "text": "Linezolid - associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome .", "tokens": ["Linezolid", "-", "associated", "acute", "interstitial", "nephritis", "and", "drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "(", "DRESS", ")", "syndrome", "."], "event_mentions": [{"id": "19733945_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19733945_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19733945_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19733945_1_Ent0", "role": "Effect", "text": "acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "start": 3, "end": 18}]}], "entity_mentions": [{"id": "19733945_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19733945_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19733945_1_Ent0", "text": "acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 3, "end": 18}], "lang": "en"}
{"doc_id": "19745701_4", "wnd_id": "19745701_4_1", "text": "To our knowledge , this is the first case of spontaneous remission of MTX - associated gastric LPD after discontinuation of MTX therapy .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "spontaneous", "remission", "of", "MTX", "-", "associated", "gastric", "LPD", "after", "discontinuation", "of", "MTX", "therapy", "."], "event_mentions": [{"id": "19745701_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "19745701_4_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "19745701_4_Ent2", "role": "Treatment", "text": "MTX", "start": 13, "end": 14}, {"entity_id": "19745701_4_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 13, "end": 14}, {"entity_id": "19745701_4_Ent1", "role": "Effect", "text": "gastric LPD", "start": 16, "end": 18}, {"entity_id": "19745701_4_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19745701_4_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19745701_4_Ent2", "text": "MTX", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19745701_4_Ent3", "text": "MTX", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19745701_4_Ent1", "text": "gastric LPD", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "19745701_4_Ent4", "text": "MTX", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1977935_4", "wnd_id": "1977935_4_1", "text": "This report describes the first association ( exclusive of drug overdose ) of symptomatic torsades de pointes occurring with the use of terfenadine in a patient who was taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone .", "tokens": ["This", "report", "describes", "the", "first", "association", "(", "exclusive", "of", "drug", "overdose", ")", "of", "symptomatic", "torsades", "de", "pointes", "occurring", "with", "the", "use", "of", "terfenadine", "in", "a", "patient", "who", "was", "taking", "the", "recommended", "prescribed", "dose", "of", "this", "drug", "in", "addition", "to", "cefaclor", ",", "ketoconazole", ",", "and", "medroxyprogesterone", "."], "event_mentions": [{"id": "1977935_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 17, "end": 18}, "arguments": [{"entity_id": "1977935_4_Ent1", "role": "Effect", "text": "symptomatic torsades de pointes", "start": 13, "end": 17}, {"entity_id": "1977935_4_Ent2", "role": "Treatment", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent7", "role": "Treatment_Drug", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent8", "role": "Combination_Drug", "text": "terfenadine", "start": 22, "end": 23}, {"entity_id": "1977935_4_Ent0", "role": "Subject", "text": "a patient", "start": 24, "end": 26}, {"entity_id": "1977935_4_Ent3", "role": "Treatment", "text": "taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone", "start": 28, "end": 45}, {"entity_id": "1977935_4_Ent4", "role": "Treatment_Drug", "text": "cefaclor", "start": 39, "end": 40}, {"entity_id": "1977935_4_Ent9", "role": "Combination_Drug", "text": "cefaclor", "start": 39, "end": 40}, {"entity_id": "1977935_4_Ent5", "role": "Treatment_Drug", "text": "ketoconazole", "start": 41, "end": 42}, {"entity_id": "1977935_4_Ent10", "role": "Combination_Drug", "text": "ketoconazole", "start": 41, "end": 42}, {"entity_id": "1977935_4_Ent6", "role": "Treatment_Drug", "text": "medroxyprogesterone", "start": 44, "end": 45}, {"entity_id": "1977935_4_Ent11", "role": "Combination_Drug", "text": "medroxyprogesterone", "start": 44, "end": 45}]}], "entity_mentions": [{"id": "1977935_4_Ent1", "text": "symptomatic torsades de pointes", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "1977935_4_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent7", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent8", "text": "terfenadine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1977935_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "1977935_4_Ent3", "text": "taking the recommended prescribed dose of this drug in addition to cefaclor , ketoconazole , and medroxyprogesterone", "entity_type": "Entity", "start": 28, "end": 45}, {"id": "1977935_4_Ent4", "text": "cefaclor", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "1977935_4_Ent9", "text": "cefaclor", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "1977935_4_Ent5", "text": "ketoconazole", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "1977935_4_Ent10", "text": "ketoconazole", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "1977935_4_Ent6", "text": "medroxyprogesterone", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "1977935_4_Ent11", "text": "medroxyprogesterone", "entity_type": "Entity", "start": 44, "end": 45}], "lang": "en"}
{"doc_id": "19782276_1", "wnd_id": "19782276_1_1", "text": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy .", "tokens": ["Fulminant", "fatal", "cardiotoxicity", "following", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "19782276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19782276_1_Ent0", "role": "Effect", "text": "Fulminant fatal cardiotoxicity", "start": 0, "end": 3}, {"entity_id": "19782276_1_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "19782276_1_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19782276_1_Ent0", "text": "Fulminant fatal cardiotoxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19782276_1_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19782276_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19798640_1", "wnd_id": "19798640_1_1", "text": "A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( PCNSL ) after having received 21 doses of natalizumab monotherapy .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "relapsing", "-", "remitting", "multiple", "sclerosis", "(", "MS", ")", "developed", "primary", "central", "nervous", "system", "lymphoma", "(", "PCNSL", ")", "after", "having", "received", "21", "doses", "of", "natalizumab", "monotherapy", "."], "event_mentions": [{"id": "19798640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "19798640_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "19798640_1_Ent0", "role": "Subject", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "start": 1, "end": 16}, {"entity_id": "19798640_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "19798640_1_Ent5", "role": "Treatment_Disorder", "text": "relapsing - remitting multiple sclerosis ( MS )", "start": 8, "end": 16}, {"entity_id": "19798640_1_Ent3", "role": "Effect", "text": "primary central nervous system lymphoma ( PCNSL )", "start": 17, "end": 25}, {"entity_id": "19798640_1_Ent6", "role": "Treatment_Dosage", "text": "21 doses", "start": 28, "end": 30}, {"entity_id": "19798640_1_Ent4", "role": "Treatment", "text": "21 doses of natalizumab monotherapy", "start": 28, "end": 33}, {"entity_id": "19798640_1_Ent7", "role": "Treatment_Drug", "text": "natalizumab", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19798640_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19798640_1_Ent0", "text": "40 - year - old man with relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 1, "end": 16}, {"id": "19798640_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19798640_1_Ent5", "text": "relapsing - remitting multiple sclerosis ( MS )", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "19798640_1_Ent3", "text": "primary central nervous system lymphoma ( PCNSL )", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "19798640_1_Ent6", "text": "21 doses", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "19798640_1_Ent4", "text": "21 doses of natalizumab monotherapy", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "19798640_1_Ent7", "text": "natalizumab", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19826099_1", "wnd_id": "19826099_1_1", "text": "OBJECTIVE : To report a case of severe apnea in an infant exposed to lamotrigine through breast - feeding .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "severe", "apnea", "in", "an", "infant", "exposed", "to", "lamotrigine", "through", "breast", "-", "feeding", "."], "event_mentions": [{"id": "19826099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "19826099_1_Ent2", "role": "Effect", "text": "severe apnea", "start": 7, "end": 9}, {"entity_id": "19826099_1_Ent0", "role": "Subject", "text": "an infant", "start": 10, "end": 12}, {"entity_id": "19826099_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 11, "end": 12}, {"entity_id": "19826099_1_Ent3", "role": "Treatment", "text": "exposed to lamotrigine through breast - feeding", "start": 12, "end": 19}, {"entity_id": "19826099_1_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "19826099_1_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "19826099_1_Ent2", "text": "severe apnea", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19826099_1_Ent0", "text": "an infant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19826099_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19826099_1_Ent3", "text": "exposed to lamotrigine through breast - feeding", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19826099_1_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19826099_1_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "19892516_4", "wnd_id": "19892516_4_1", "text": "In one patient the vasculitis resolved after termination of the ciprofloxacin therapy ; in the other patient the ciprofloxacin - induced hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation .", "tokens": ["In", "one", "patient", "the", "vasculitis", "resolved", "after", "termination", "of", "the", "ciprofloxacin", "therapy", ";", "in", "the", "other", "patient", "the", "ciprofloxacin", "-", "induced", "hemorrhagic", "vasculitis", "was", "superimposed", "on", "a", "severe", "forefoot", "infection", ",", "leading", "to", "progressive", "gangrene", "and", "a", "below", "-", "knee", "amputation", "."], "event_mentions": [{"id": "19892516_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "19892516_4_Ent5", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "19892516_4_Ent4", "role": "Subject", "text": "one patient the vasculitis", "start": 1, "end": 5}, {"entity_id": "19892516_4_Ent8", "role": "Treatment_Disorder", "text": "vasculitis", "start": 4, "end": 5}, {"entity_id": "19892516_4_Ent6", "role": "Treatment", "text": "termination of the ciprofloxacin therapy", "start": 7, "end": 12}, {"entity_id": "19892516_4_Ent7", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}, {"id": "19892516_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "19892516_4_Ent0", "role": "Subject", "text": "patient", "start": 16, "end": 17}, {"entity_id": "19892516_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 18, "end": 19}, {"entity_id": "19892516_4_Ent1", "role": "Effect", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "start": 21, "end": 41}]}], "entity_mentions": [{"id": "19892516_4_Ent5", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19892516_4_Ent4", "text": "one patient the vasculitis", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19892516_4_Ent8", "text": "vasculitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19892516_4_Ent6", "text": "termination of the ciprofloxacin therapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "19892516_4_Ent7", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19892516_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19892516_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19892516_4_Ent1", "text": "hemorrhagic vasculitis was superimposed on a severe forefoot infection , leading to progressive gangrene and a below - knee amputation", "entity_type": "Entity", "start": 21, "end": 41}], "lang": "en"}
{"doc_id": "19904536_1", "wnd_id": "19904536_1_1", "text": "Fatal gemcitabine - induced pulmonary toxicity in metastatic gallbladder adenocarcinoma .", "tokens": ["Fatal", "gemcitabine", "-", "induced", "pulmonary", "toxicity", "in", "metastatic", "gallbladder", "adenocarcinoma", "."], "event_mentions": [{"id": "19904536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19904536_1_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_1_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_1_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}, {"entity_id": "19904536_1_Ent3", "role": "Treatment_Disorder", "text": "metastatic gallbladder adenocarcinoma", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "19904536_1_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_1_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19904536_1_Ent3", "text": "metastatic gallbladder adenocarcinoma", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "19904536_10", "wnd_id": "19904536_10_1", "text": "A helicoidal CT scan showed diffuse and severe interstitial pneumonitis , and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug - induced toxicity .", "tokens": ["A", "helicoidal", "CT", "scan", "showed", "diffuse", "and", "severe", "interstitial", "pneumonitis", ",", "and", "lung", "biopsy", "confirmed", "accelerated", "usual", "interstitial", "pneumonia", "consistent", "with", "drug", "-", "induced", "toxicity", "."], "event_mentions": [{"id": "19904536_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "19904536_10_Ent0", "role": "Effect", "text": "diffuse and severe interstitial pneumonitis", "start": 5, "end": 10}, {"entity_id": "19904536_10_Ent1", "role": "Effect", "text": "accelerated usual interstitial pneumonia", "start": 15, "end": 19}, {"entity_id": "19904536_10_Ent3", "role": "Treatment", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent4", "role": "Treatment_Drug", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent2", "role": "Effect", "text": "toxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19904536_10_Ent0", "text": "diffuse and severe interstitial pneumonitis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19904536_10_Ent1", "text": "accelerated usual interstitial pneumonia", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19904536_10_Ent3", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent4", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent2", "text": "toxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19904536_13", "wnd_id": "19904536_13_1", "text": "Gemcitabine - induced pulmonary toxicity is usually a dramatic condition .", "tokens": ["Gemcitabine", "-", "induced", "pulmonary", "toxicity", "is", "usually", "a", "dramatic", "condition", "."], "event_mentions": [{"id": "19904536_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19904536_13_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19904536_13_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19904536_2", "wnd_id": "19904536_2_1", "text": "Gemcitabine is a chemotherapy agent that may cause unpredictable side effects .", "tokens": ["Gemcitabine", "is", "a", "chemotherapy", "agent", "that", "may", "cause", "unpredictable", "side", "effects", "."], "event_mentions": [{"id": "19904536_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "19904536_2_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent0", "role": "Effect", "text": "unpredictable side effects", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "19904536_2_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent0", "text": "unpredictable side effects", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "19915794_1", "wnd_id": "19915794_1_1", "text": "He had hypokalemia ( K 2.3 mmol / L ) induced by licorice and also had received disopyramide for arrhythmia , bicalutamide for prostate cancer , and silodosin for prostate hypertrophy .", "tokens": ["He", "had", "hypokalemia", "(", "K", "2.3", "mmol", "/", "L", ")", "induced", "by", "licorice", "and", "also", "had", "received", "disopyramide", "for", "arrhythmia", ",", "bicalutamide", "for", "prostate", "cancer", ",", "and", "silodosin", "for", "prostate", "hypertrophy", "."], "event_mentions": [{"id": "19915794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19915794_1_Ent0", "role": "Effect", "text": "hypokalemia ( K 2.3 mmol / L )", "start": 2, "end": 10}, {"entity_id": "19915794_1_Ent2", "role": "Treatment_Drug", "text": "licorice", "start": 12, "end": 13}, {"entity_id": "19915794_1_Ent12", "role": "Combination_Drug", "text": "licorice", "start": 12, "end": 13}, {"entity_id": "19915794_1_Ent1", "role": "Treatment", "text": "licorice and also had received disopyramide for arrhythmia , bicalutamide for prostate cancer , and silodosin for prostate hypertrophy", "start": 12, "end": 31}, {"entity_id": "19915794_1_Ent3", "role": "Treatment_Drug", "text": "disopyramide", "start": 17, "end": 18}, {"entity_id": "19915794_1_Ent9", "role": "Combination_Drug", "text": "disopyramide", "start": 17, "end": 18}, {"entity_id": "19915794_1_Ent8", "role": "Treatment_Disorder", "text": "arrhythmia", "start": 19, "end": 20}, {"entity_id": "19915794_1_Ent4", "role": "Treatment_Drug", "text": "bicalutamide", "start": 21, "end": 22}, {"entity_id": "19915794_1_Ent10", "role": "Combination_Drug", "text": "bicalutamide", "start": 21, "end": 22}, {"entity_id": "19915794_1_Ent7", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 23, "end": 25}, {"entity_id": "19915794_1_Ent5", "role": "Treatment_Drug", "text": "silodosin", "start": 27, "end": 28}, {"entity_id": "19915794_1_Ent11", "role": "Combination_Drug", "text": "silodosin", "start": 27, "end": 28}, {"entity_id": "19915794_1_Ent6", "role": "Treatment_Disorder", "text": "prostate hypertrophy", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "19915794_1_Ent0", "text": "hypokalemia ( K 2.3 mmol / L )", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "19915794_1_Ent2", "text": "licorice", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19915794_1_Ent12", "text": "licorice", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19915794_1_Ent1", "text": "licorice and also had received disopyramide for arrhythmia , bicalutamide for prostate cancer , and silodosin for prostate hypertrophy", "entity_type": "Entity", "start": 12, "end": 31}, {"id": "19915794_1_Ent3", "text": "disopyramide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19915794_1_Ent9", "text": "disopyramide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19915794_1_Ent8", "text": "arrhythmia", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19915794_1_Ent4", "text": "bicalutamide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19915794_1_Ent10", "text": "bicalutamide", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19915794_1_Ent7", "text": "prostate cancer", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "19915794_1_Ent5", "text": "silodosin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19915794_1_Ent11", "text": "silodosin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19915794_1_Ent6", "text": "prostate hypertrophy", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "19915794_4", "wnd_id": "19915794_4_1", "text": "We report an 82 - year - old man who developed ventricular tachycardia and Torsades de Pointes ( TdP ) after oral administration of garenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones , for pneumonia .", "tokens": ["We", "report", "an", "82", "-", "year", "-", "old", "man", "who", "developed", "ventricular", "tachycardia", "and", "Torsades", "de", "Pointes", "(", "TdP", ")", "after", "oral", "administration", "of", "garenoxacin", ",", "a", "novel", "quinolone", "antibiotic", "agent", "that", "differs", "from", "the", "third", "-", "generation", "quinolones", ",", "for", "pneumonia", "."], "event_mentions": [{"id": "19915794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "19915794_4_Ent0", "role": "Subject", "text": "an 82 - year - old man", "start": 2, "end": 9}, {"entity_id": "19915794_4_Ent1", "role": "Subject_Age", "text": "82 - year - old", "start": 3, "end": 8}, {"entity_id": "19915794_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19915794_4_Ent3", "role": "Effect", "text": "ventricular tachycardia and Torsades de Pointes ( TdP )", "start": 11, "end": 20}, {"entity_id": "19915794_4_Ent6", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "19915794_4_Ent4", "role": "Treatment", "text": "oral administration of garenoxacin", "start": 21, "end": 25}, {"entity_id": "19915794_4_Ent7", "role": "Treatment_Drug", "text": "garenoxacin", "start": 24, "end": 25}, {"entity_id": "19915794_4_Ent5", "role": "Treatment_Disorder", "text": "pneumonia", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "19915794_4_Ent0", "text": "an 82 - year - old man", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "19915794_4_Ent1", "text": "82 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19915794_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_4_Ent3", "text": "ventricular tachycardia and Torsades de Pointes ( TdP )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "19915794_4_Ent6", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19915794_4_Ent4", "text": "oral administration of garenoxacin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19915794_4_Ent7", "text": "garenoxacin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19915794_4_Ent5", "text": "pneumonia", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "19934385_3", "wnd_id": "19934385_3_1", "text": "A 34 - year - old HIV - infected man who had recently initiated efavirenz - based antiretroviral therapy was diagnosed with disseminated Histoplasma capsulatum infection .", "tokens": ["A", "34", "-", "year", "-", "old", "HIV", "-", "infected", "man", "who", "had", "recently", "initiated", "efavirenz", "-", "based", "antiretroviral", "therapy", "was", "diagnosed", "with", "disseminated", "Histoplasma", "capsulatum", "infection", "."], "event_mentions": [{"id": "19934385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 13, "end": 14}, "arguments": [{"entity_id": "19934385_3_Ent0", "role": "Subject", "text": "A 34 - year - old HIV - infected man", "start": 0, "end": 10}, {"entity_id": "19934385_3_Ent2", "role": "Subject_Age", "text": "34 - year - old", "start": 1, "end": 6}, {"entity_id": "19934385_3_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "19934385_3_Ent3", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "19934385_3_Ent4", "role": "Treatment", "text": "initiated efavirenz - based antiretroviral therapy", "start": 13, "end": 19}, {"entity_id": "19934385_3_Ent6", "role": "Treatment_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent8", "role": "Combination_Drug", "text": "efavirenz", "start": 14, "end": 15}, {"entity_id": "19934385_3_Ent7", "role": "Treatment_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent9", "role": "Combination_Drug", "text": "antiretroviral", "start": 17, "end": 18}, {"entity_id": "19934385_3_Ent1", "role": "Subject_Disorder", "text": "disseminated Histoplasma capsulatum infection", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "19934385_3_Ent0", "text": "A 34 - year - old HIV - infected man", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "19934385_3_Ent2", "text": "34 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19934385_3_Ent5", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19934385_3_Ent3", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19934385_3_Ent4", "text": "initiated efavirenz - based antiretroviral therapy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "19934385_3_Ent6", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent8", "text": "efavirenz", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19934385_3_Ent7", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent9", "text": "antiretroviral", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "19934385_3_Ent1", "text": "disseminated Histoplasma capsulatum infection", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "20009973_2", "wnd_id": "20009973_2_1", "text": "Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis , synovitis , and possible vasculitis , after receiving all - trans retinoic acid therapy .", "tokens": ["Here", "we", "report", "a", "patient", "with", "newly", "diagnosed", "acute", "promyelocytic", "leukemia", "who", "developed", "acute", "focal", "myositis", ",", "synovitis", ",", "and", "possible", "vasculitis", ",", "after", "receiving", "all", "-", "trans", "retinoic", "acid", "therapy", "."], "event_mentions": [{"id": "20009973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "20009973_2_Ent0", "role": "Subject", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "start": 3, "end": 11}, {"entity_id": "20009973_2_Ent3", "role": "Treatment_Disorder", "text": "acute promyelocytic leukemia", "start": 8, "end": 11}, {"entity_id": "20009973_2_Ent1", "role": "Effect", "text": "acute focal myositis , synovitis , and possible vasculitis", "start": 13, "end": 22}, {"entity_id": "20009973_2_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 25, "end": 30}, {"entity_id": "20009973_2_Ent4", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "20009973_2_Ent0", "text": "a patient with newly diagnosed acute promyelocytic leukemia", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "20009973_2_Ent3", "text": "acute promyelocytic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20009973_2_Ent1", "text": "acute focal myositis , synovitis , and possible vasculitis", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "20009973_2_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "20009973_2_Ent4", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "20065266_1", "wnd_id": "20065266_1_1", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension in a patient treated with trimethoprim - sulfamethoxazole .", "tokens": ["Aseptic", "meningitis", ",", "hemolytic", "anemia", ",", "hepatitis", ",", "and", "orthostatic", "hypotension", "in", "a", "patient", "treated", "with", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "20065266_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "20065266_1_Ent1", "role": "Effect", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension", "start": 0, "end": 11}, {"entity_id": "20065266_1_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "20065266_1_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "20065266_1_Ent5", "role": "Combination_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "20065266_1_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 16, "end": 19}, {"entity_id": "20065266_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}, {"entity_id": "20065266_1_Ent6", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20065266_1_Ent1", "text": "Aseptic meningitis , hemolytic anemia , hepatitis , and orthostatic hypotension", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "20065266_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "20065266_1_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20065266_1_Ent5", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20065266_1_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "20065266_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20065266_1_Ent6", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2006943_1", "wnd_id": "2006943_1_1", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block ) during ritodrine therapy for preterm labor .", "tokens": ["Type", "I", "second", "-", "degree", "AV", "block", "(", "Mobitz", "type", "I", ",", "Wenckebach", "AV", "block", ")", "during", "ritodrine", "therapy", "for", "preterm", "labor", "."], "event_mentions": [{"id": "2006943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 16, "end": 17}, "arguments": [{"entity_id": "2006943_1_Ent0", "role": "Effect", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "start": 0, "end": 16}, {"entity_id": "2006943_1_Ent1", "role": "Treatment", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent3", "role": "Treatment_Drug", "text": "ritodrine", "start": 17, "end": 18}, {"entity_id": "2006943_1_Ent2", "role": "Treatment_Disorder", "text": "preterm labor", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "2006943_1_Ent0", "text": "Type I second - degree AV block ( Mobitz type I , Wenckebach AV block )", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "2006943_1_Ent1", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent3", "text": "ritodrine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2006943_1_Ent2", "text": "preterm labor", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "20110001_4", "wnd_id": "20110001_4_1", "text": "OBJECTIVE : We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib .", "tokens": ["OBJECTIVE", ":", "We", "report", "a", "case", "of", "cutaneous", "KS", "lesions", "in", "a", "patient", "affected", "by", "CML", "treated", "with", "imatinib", "."], "event_mentions": [{"id": "20110001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "20110001_4_Ent1", "role": "Effect", "text": "cutaneous KS lesions", "start": 7, "end": 10}, {"entity_id": "20110001_4_Ent0", "role": "Subject", "text": "a patient affected by CML", "start": 11, "end": 16}, {"entity_id": "20110001_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 15, "end": 16}, {"entity_id": "20110001_4_Ent2", "role": "Treatment", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "20110001_4_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20110001_4_Ent1", "text": "cutaneous KS lesions", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20110001_4_Ent0", "text": "a patient affected by CML", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "20110001_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20110001_4_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20110001_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "20120657_3", "wnd_id": "20120657_3_1", "text": "Zidovudine induced pure red cell aplasia : a case report .", "tokens": ["Zidovudine", "induced", "pure", "red", "cell", "aplasia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "20120657_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "20120657_3_Ent2", "role": "Treatment", "text": "Zidovudine", "start": 0, "end": 1}, {"entity_id": "20120657_3_Ent3", "role": "Treatment_Drug", "text": "Zidovudine", "start": 0, "end": 1}, {"entity_id": "20120657_3_Ent1", "role": "Effect", "text": "pure red cell aplasia", "start": 2, "end": 6}, {"entity_id": "20120657_3_Ent0", "role": "Subject", "text": "a case", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "20120657_3_Ent2", "text": "Zidovudine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20120657_3_Ent3", "text": "Zidovudine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20120657_3_Ent1", "text": "pure red cell aplasia", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "20120657_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "20130478_1", "wnd_id": "20130478_1_1", "text": "Introduction of etanercept was also clinically effective but followed by development of severe heart failure .", "tokens": ["Introduction", "of", "etanercept", "was", "also", "clinically", "effective", "but", "followed", "by", "development", "of", "severe", "heart", "failure", "."], "event_mentions": [{"id": "20130478_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 10, "end": 11}, "arguments": [{"entity_id": "20130478_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 2, "end": 3}, {"entity_id": "20130478_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 2, "end": 3}, {"entity_id": "20130478_1_Ent0", "role": "Effect", "text": "severe heart failure .", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "20130478_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20130478_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20130478_1_Ent0", "text": "severe heart failure .", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "20171144_1", "wnd_id": "20171144_1_1", "text": "Common adverse events ( frequency 10 % ) of lacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence ) .", "tokens": ["Common", "adverse", "events", "(", "frequency", "10", "%", ")", "of", "lacosamide", "doses", "up", "to", "600", "mg", "/", "day", "include", "nonspecific", "central", "nervous", "system", "effects", "(", "e.g.", ",", "dizziness", ",", "ataxia", ",", "diplopia", ",", "and", "somnolence", ")", "."], "event_mentions": [{"id": "20171144_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "include", "start": 17, "end": 18}, "arguments": [{"entity_id": "20171144_1_Ent2", "role": "Treatment_Drug", "text": "lacosamide", "start": 9, "end": 10}, {"entity_id": "20171144_1_Ent1", "role": "Treatment", "text": "lacosamide doses up to 600 mg / day", "start": 9, "end": 17}, {"entity_id": "20171144_1_Ent3", "role": "Treatment_Dosage", "text": "600 mg / day", "start": 13, "end": 17}, {"entity_id": "20171144_1_Ent0", "role": "Effect", "text": "nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence )", "start": 18, "end": 35}]}], "entity_mentions": [{"id": "20171144_1_Ent2", "text": "lacosamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20171144_1_Ent1", "text": "lacosamide doses up to 600 mg / day", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "20171144_1_Ent3", "text": "600 mg / day", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "20171144_1_Ent0", "text": "nonspecific central nervous system effects ( e.g. , dizziness , ataxia , diplopia , and somnolence )", "entity_type": "Entity", "start": 18, "end": 35}], "lang": "en"}
{"doc_id": "20178709_1", "wnd_id": "20178709_1_1", "text": "A case of aseptic pleuropericarditis in a patient with chronic plaque psoriasis under methotrexate therapy .", "tokens": ["A", "case", "of", "aseptic", "pleuropericarditis", "in", "a", "patient", "with", "chronic", "plaque", "psoriasis", "under", "methotrexate", "therapy", "."], "event_mentions": [{"id": "20178709_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "20178709_1_Ent1", "role": "Effect", "text": "aseptic pleuropericarditis", "start": 3, "end": 5}, {"entity_id": "20178709_1_Ent0", "role": "Subject", "text": "a patient with chronic plaque psoriasis", "start": 6, "end": 12}, {"entity_id": "20178709_1_Ent4", "role": "Treatment_Disorder", "text": "chronic plaque psoriasis", "start": 9, "end": 12}, {"entity_id": "20178709_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}, {"entity_id": "20178709_1_Ent2", "role": "Treatment", "text": "methotrexate therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "20178709_1_Ent1", "text": "aseptic pleuropericarditis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20178709_1_Ent0", "text": "a patient with chronic plaque psoriasis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "20178709_1_Ent4", "text": "chronic plaque psoriasis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "20178709_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20178709_1_Ent2", "text": "methotrexate therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "20178709_3", "wnd_id": "20178709_3_1", "text": "We report here a rare case of pleuropericarditis due to methotrexate .", "tokens": ["We", "report", "here", "a", "rare", "case", "of", "pleuropericarditis", "due", "to", "methotrexate", "."], "event_mentions": [{"id": "20178709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "20178709_3_Ent0", "role": "Subject", "text": "a rare case", "start": 3, "end": 6}, {"entity_id": "20178709_3_Ent1", "role": "Effect", "text": "pleuropericarditis", "start": 7, "end": 8}, {"entity_id": "20178709_3_Ent2", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "20178709_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20178709_3_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20178709_3_Ent1", "text": "pleuropericarditis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20178709_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20178709_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20199429_1", "wnd_id": "20199429_1_1", "text": "Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature , and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to bisabolol - a component of the Aquaphor emollient they were using to treat their atopic dermatitis .", "tokens": ["Only", "two", "case", "reports", "of", "adults", "with", "allergic", "contact", "dermatitis", "to", "this", "chemical", "exist", "in", "the", "literature", ",", "and", "we", "describe", "three", "more", "cases", "of", "children", "with", "recalcitrant", "atopic", "dermatitis", "found", "to", "have", "potential", "allergic", "contact", "dermatitis", "to", "bisabolol", "-", "a", "component", "of", "the", "Aquaphor", "emollient", "they", "were", "using", "to", "treat", "their", "atopic", "dermatitis", "."], "event_mentions": [{"id": "20199429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 32, "end": 33}, "arguments": [{"entity_id": "20199429_1_Ent1", "role": "Subject_Population", "text": "three", "start": 21, "end": 22}, {"entity_id": "20199429_1_Ent0", "role": "Subject", "text": "three more cases of children with recalcitrant atopic dermatitis", "start": 21, "end": 30}, {"entity_id": "20199429_1_Ent2", "role": "Subject_Age", "text": "children", "start": 25, "end": 26}, {"entity_id": "20199429_1_Ent5", "role": "Treatment_Disorder", "text": "recalcitrant atopic dermatitis", "start": 27, "end": 30}, {"entity_id": "20199429_1_Ent3", "role": "Effect", "text": "potential allergic contact dermatitis", "start": 33, "end": 37}, {"entity_id": "20199429_1_Ent6", "role": "Treatment_Drug", "text": "bisabolol", "start": 38, "end": 39}, {"entity_id": "20199429_1_Ent4", "role": "Treatment", "text": "bisabolol - a component of the Aquaphor emollient", "start": 38, "end": 46}]}], "entity_mentions": [{"id": "20199429_1_Ent1", "text": "three", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "20199429_1_Ent0", "text": "three more cases of children with recalcitrant atopic dermatitis", "entity_type": "Entity", "start": 21, "end": 30}, {"id": "20199429_1_Ent2", "text": "children", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "20199429_1_Ent5", "text": "recalcitrant atopic dermatitis", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20199429_1_Ent3", "text": "potential allergic contact dermatitis", "entity_type": "Entity", "start": 33, "end": 37}, {"id": "20199429_1_Ent6", "text": "bisabolol", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "20199429_1_Ent4", "text": "bisabolol - a component of the Aquaphor emollient", "entity_type": "Entity", "start": 38, "end": 46}], "lang": "en"}
{"doc_id": "20203465_1", "wnd_id": "20203465_1_1", "text": "Case report : acute renal failure after administering intravenous immunoglobulin .", "tokens": ["Case", "report", ":", "acute", "renal", "failure", "after", "administering", "intravenous", "immunoglobulin", "."], "event_mentions": [{"id": "20203465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "20203465_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}, {"entity_id": "20203465_1_Ent1", "role": "Treatment", "text": "administering intravenous immunoglobulin", "start": 7, "end": 10}, {"entity_id": "20203465_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "20203465_1_Ent2", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "20203465_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20203465_1_Ent1", "text": "administering intravenous immunoglobulin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20203465_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "20203465_1_Ent2", "text": "immunoglobulin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20234160_3", "wnd_id": "20234160_3_1", "text": "We report a case of a 23 - year - old man who developed a vancomycin - induced anaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection .", "tokens": ["We", "report", "a", "case", "of", "a", "23", "-", "year", "-", "old", "man", "who", "developed", "a", "vancomycin", "-", "induced", "anaphylactic", "reaction", "in", "the", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infection", "."], "event_mentions": [{"id": "20234160_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "20234160_3_Ent0", "role": "Subject", "text": "a 23 - year - old man", "start": 5, "end": 12}, {"entity_id": "20234160_3_Ent1", "role": "Subject_Age", "text": "23 - year - old", "start": 6, "end": 11}, {"entity_id": "20234160_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "20234160_3_Ent3", "role": "Effect", "text": "a vancomycin - induced anaphylactic reaction", "start": 14, "end": 20}, {"entity_id": "20234160_3_Ent4", "role": "Treatment", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 15, "end": 16}, {"entity_id": "20234160_3_Ent6", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infection", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "20234160_3_Ent0", "text": "a 23 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "20234160_3_Ent1", "text": "23 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20234160_3_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20234160_3_Ent3", "text": "a vancomycin - induced anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20234160_3_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20234160_3_Ent6", "text": "methicillin - resistant Staphylococcus aureus infection", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "20298401_1", "wnd_id": "20298401_1_1", "text": "Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis .", "tokens": ["Fatal", "interstitial", "lung", "disease", "after", "erlotinib", "administration", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "20298401_1_Ent2", "role": "Effect", "text": "interstitial lung disease", "start": 1, "end": 4}, {"entity_id": "20298401_1_Ent3", "role": "Treatment", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 8, "end": 13}, {"entity_id": "20298401_1_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20298401_1_Ent2", "text": "interstitial lung disease", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "20298401_1_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20298401_1_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "20298401_2", "wnd_id": "20298401_2_1", "text": "INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ) , few case reports on erlotinib - induced ILD have been issued .", "tokens": ["INTRODUCTION", ":", "Although", "gefitinib", "used", "for", "the", "treatment", "of", "non", "-", "small", "-", "cell", "lung", "cancer", "is", "a", "well", "-", "known", "cause", "of", "interstitial", "lung", "disease", "(", "ILD", ")", ",", "few", "case", "reports", "on", "erlotinib", "-", "induced", "ILD", "have", "been", "issued", "."], "event_mentions": [{"id": "20298401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 21, "end": 22}, "arguments": [{"entity_id": "20298401_2_Ent1", "role": "Treatment", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent3", "role": "Treatment_Drug", "text": "gefitinib", "start": 3, "end": 4}, {"entity_id": "20298401_2_Ent2", "role": "Treatment_Disorder", "text": "non - small - cell lung cancer", "start": 9, "end": 16}, {"entity_id": "20298401_2_Ent0", "role": "Effect", "text": "interstitial lung disease ( ILD )", "start": 23, "end": 29}]}, {"id": "20298401_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 36, "end": 37}, "arguments": [{"entity_id": "20298401_2_Ent5", "role": "Treatment", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent6", "role": "Treatment_Drug", "text": "erlotinib", "start": 34, "end": 35}, {"entity_id": "20298401_2_Ent4", "role": "Effect", "text": "ILD", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "20298401_2_Ent1", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent3", "text": "gefitinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20298401_2_Ent2", "text": "non - small - cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "20298401_2_Ent0", "text": "interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "20298401_2_Ent5", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent6", "text": "erlotinib", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "20298401_2_Ent4", "text": "ILD", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "20298401_5", "wnd_id": "20298401_5_1", "text": "RESULTS : We recently experienced a case of fatal erlotinib - induced ILD , diagnosed based on clinical and radiologic findings , which occurred in a patient with radiation fibrosis .", "tokens": ["RESULTS", ":", "We", "recently", "experienced", "a", "case", "of", "fatal", "erlotinib", "-", "induced", "ILD", ",", "diagnosed", "based", "on", "clinical", "and", "radiologic", "findings", ",", "which", "occurred", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "20298401_5_Ent3", "role": "Treatment", "text": "erlotinib", "start": 9, "end": 10}, {"entity_id": "20298401_5_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 9, "end": 10}, {"entity_id": "20298401_5_Ent2", "role": "Effect", "text": "ILD", "start": 12, "end": 13}, {"entity_id": "20298401_5_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 25, "end": 30}, {"entity_id": "20298401_5_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "20298401_5_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20298401_5_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20298401_5_Ent2", "text": "ILD", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20298401_5_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "20298401_5_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "20298401_7", "wnd_id": "20298401_7_1", "text": "Six days after taking erlotinib , a chest radiograph showed rapid progression of reticular infiltration in both lung fields .", "tokens": ["Six", "days", "after", "taking", "erlotinib", ",", "a", "chest", "radiograph", "showed", "rapid", "progression", "of", "reticular", "infiltration", "in", "both", "lung", "fields", "."], "event_mentions": [{"id": "20298401_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "20298401_7_Ent1", "role": "Treatment", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent3", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent2", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent0", "role": "Effect", "text": "rapid progression of reticular infiltration in both lung fields", "start": 10, "end": 19}]}], "entity_mentions": [{"id": "20298401_7_Ent1", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent3", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent0", "text": "rapid progression of reticular infiltration in both lung fields", "entity_type": "Entity", "start": 10, "end": 19}], "lang": "en"}
{"doc_id": "20456080_4", "wnd_id": "20456080_4_1", "text": "Corticosteroid injections are commonly used as effective treatments for a variety of pain disorders .", "tokens": ["Corticosteroid", "injections", "are", "commonly", "used", "as", "effective", "treatments", "for", "a", "variety", "of", "pain", "disorders", "."], "event_mentions": [{"id": "20456080_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatments", "start": 7, "end": 8}, "arguments": [{"entity_id": "20456080_4_Ent1", "role": "Treatment_Drug", "text": "Corticosteroid", "start": 0, "end": 1}, {"entity_id": "20456080_4_Ent0", "role": "Treatment", "text": "Corticosteroid injections", "start": 0, "end": 2}, {"entity_id": "20456080_4_Ent2", "role": "Treatment_Route", "text": "injections", "start": 1, "end": 2}, {"entity_id": "20456080_4_Ent3", "role": "Treatment_Disorder", "text": "pain disorders", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "20456080_4_Ent1", "text": "Corticosteroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20456080_4_Ent0", "text": "Corticosteroid injections", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20456080_4_Ent2", "text": "injections", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20456080_4_Ent3", "text": "pain disorders", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "20465622_1", "wnd_id": "20465622_1_1", "text": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors .", "tokens": ["Severe", "aphthous", "stomatitis", "associated", "with", "oral", "calcineurin", "and", "mTOR", "inhibitors", "."], "event_mentions": [{"id": "20465622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "20465622_1_Ent0", "role": "Effect", "text": "Severe aphthous stomatitis", "start": 0, "end": 3}, {"entity_id": "20465622_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 5, "end": 6}, {"entity_id": "20465622_1_Ent1", "role": "Treatment", "text": "oral calcineurin and mTOR inhibitors", "start": 5, "end": 10}, {"entity_id": "20465622_1_Ent4", "role": "Treatment_Drug", "text": "calcineurin", "start": 6, "end": 7}, {"entity_id": "20465622_1_Ent5", "role": "Combination_Drug", "text": "calcineurin", "start": 6, "end": 7}, {"entity_id": "20465622_1_Ent3", "role": "Treatment_Drug", "text": "mTOR inhibitors", "start": 8, "end": 10}, {"entity_id": "20465622_1_Ent6", "role": "Combination_Drug", "text": "mTOR inhibitors", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "20465622_1_Ent0", "text": "Severe aphthous stomatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20465622_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20465622_1_Ent1", "text": "oral calcineurin and mTOR inhibitors", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "20465622_1_Ent4", "text": "calcineurin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20465622_1_Ent5", "text": "calcineurin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20465622_1_Ent3", "text": "mTOR inhibitors", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20465622_1_Ent6", "text": "mTOR inhibitors", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "20628041_2", "wnd_id": "20628041_2_1", "text": "To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant - like syndrome ( NMLS ) in a polytrauma patient with Parkinson 's disease ( PD ) .", "tokens": ["To", "describe", "a", "probable", "interaction", "between", "enteral", "feeds", "and", "levodopa", "leading", "to", "neuroleptic", "malignant", "-", "like", "syndrome", "(", "NMLS", ")", "in", "a", "polytrauma", "patient", "with", "Parkinson", "'s", "disease", "(", "PD", ")", "."], "event_mentions": [{"id": "20628041_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 10, "end": 11}, "arguments": [{"entity_id": "20628041_2_Ent3", "role": "Treatment", "text": "interaction between enteral feeds and levodopa", "start": 4, "end": 10}, {"entity_id": "20628041_2_Ent5", "role": "Treatment_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent7", "role": "Combination_Drug", "text": "enteral feeds", "start": 6, "end": 8}, {"entity_id": "20628041_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent8", "role": "Combination_Drug", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "20628041_2_Ent2", "role": "Effect", "text": "neuroleptic malignant - like syndrome ( NMLS )", "start": 12, "end": 20}, {"entity_id": "20628041_2_Ent0", "role": "Subject", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "start": 21, "end": 31}, {"entity_id": "20628041_2_Ent1", "role": "Subject_Disorder", "text": "polytrauma", "start": 22, "end": 23}, {"entity_id": "20628041_2_Ent6", "role": "Treatment_Disorder", "text": "Parkinson 's disease ( PD )", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "20628041_2_Ent3", "text": "interaction between enteral feeds and levodopa", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "20628041_2_Ent5", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent7", "text": "enteral feeds", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "20628041_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent8", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "20628041_2_Ent2", "text": "neuroleptic malignant - like syndrome ( NMLS )", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "20628041_2_Ent0", "text": "a polytrauma patient with Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "20628041_2_Ent1", "text": "polytrauma", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20628041_2_Ent6", "text": "Parkinson 's disease ( PD )", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "20628041_5", "wnd_id": "20628041_5_1", "text": "His PD medications ( pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily ) were administered via nasogastric tube .", "tokens": ["His", "PD", "medications", "(", "pramipexole", ",", "entacapone", ",", "and", "immediate", "-", "release", "levodopa", "/", "carbidopa", "100", "mg/25", "mg", ",", "1.5", "tablets", "4", "times", "daily", ")", "were", "administered", "via", "nasogastric", "tube", "."], "event_mentions": [{"id": "20628041_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 26, "end": 27}, "arguments": [{"entity_id": "20628041_5_Ent1", "role": "Subject_Gender", "text": "His", "start": 0, "end": 1}, {"entity_id": "20628041_5_Ent0", "role": "Subject", "text": "His PD", "start": 0, "end": 2}, {"entity_id": "20628041_5_Ent4", "role": "Treatment_Disorder", "text": "PD", "start": 1, "end": 2}, {"entity_id": "20628041_5_Ent5", "role": "Treatment_Drug", "text": "pramipexole", "start": 4, "end": 5}, {"entity_id": "20628041_5_Ent14", "role": "Combination_Drug", "text": "pramipexole", "start": 4, "end": 5}, {"entity_id": "20628041_5_Ent2", "role": "Treatment", "text": "pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily", "start": 4, "end": 24}, {"entity_id": "20628041_5_Ent6", "role": "Treatment_Drug", "text": "entacapone", "start": 6, "end": 7}, {"entity_id": "20628041_5_Ent15", "role": "Combination_Drug", "text": "entacapone", "start": 6, "end": 7}, {"entity_id": "20628041_5_Ent7", "role": "Treatment_Drug", "text": "levodopa", "start": 12, "end": 13}, {"entity_id": "20628041_5_Ent16", "role": "Combination_Drug", "text": "levodopa", "start": 12, "end": 13}, {"entity_id": "20628041_5_Ent8", "role": "Treatment_Drug", "text": "carbidopa", "start": 14, "end": 15}, {"entity_id": "20628041_5_Ent17", "role": "Combination_Drug", "text": "carbidopa", "start": 14, "end": 15}, {"entity_id": "20628041_5_Ent9", "role": "Treatment_Dosage", "text": "100 mg/25", "start": 15, "end": 17}, {"entity_id": "20628041_5_Ent10", "role": "Treatment_Dosage", "text": "mg/25 mg", "start": 16, "end": 18}, {"entity_id": "20628041_5_Ent11", "role": "Treatment_Dosage", "text": "1.5 tablets", "start": 19, "end": 21}, {"entity_id": "20628041_5_Ent12", "role": "Treatment_Freq", "text": "4 times daily", "start": 21, "end": 24}, {"entity_id": "20628041_5_Ent3", "role": "Treatment", "text": "via nasogastric tube", "start": 27, "end": 30}, {"entity_id": "20628041_5_Ent13", "role": "Treatment_Route", "text": "nasogastric tube", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "20628041_5_Ent1", "text": "His", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20628041_5_Ent0", "text": "His PD", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20628041_5_Ent4", "text": "PD", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20628041_5_Ent5", "text": "pramipexole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20628041_5_Ent14", "text": "pramipexole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20628041_5_Ent2", "text": "pramipexole , entacapone , and immediate - release levodopa / carbidopa 100 mg/25 mg , 1.5 tablets 4 times daily", "entity_type": "Entity", "start": 4, "end": 24}, {"id": "20628041_5_Ent6", "text": "entacapone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20628041_5_Ent15", "text": "entacapone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20628041_5_Ent7", "text": "levodopa", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20628041_5_Ent16", "text": "levodopa", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20628041_5_Ent8", "text": "carbidopa", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20628041_5_Ent17", "text": "carbidopa", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "20628041_5_Ent9", "text": "100 mg/25", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "20628041_5_Ent10", "text": "mg/25 mg", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "20628041_5_Ent11", "text": "1.5 tablets", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "20628041_5_Ent12", "text": "4 times daily", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "20628041_5_Ent3", "text": "via nasogastric tube", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "20628041_5_Ent13", "text": "nasogastric tube", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "20666169_9", "wnd_id": "20666169_9_1", "text": "We presume the cause for multiple organ failure could be the result of drug - drug interaction , atorvastatin and verapamil , as verapamil is known to increase the serum concentration of atorvastatin significantly .", "tokens": ["We", "presume", "the", "cause", "for", "multiple", "organ", "failure", "could", "be", "the", "result", "of", "drug", "-", "drug", "interaction", ",", "atorvastatin", "and", "verapamil", ",", "as", "verapamil", "is", "known", "to", "increase", "the", "serum", "concentration", "of", "atorvastatin", "significantly", "."], "event_mentions": [{"id": "20666169_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "20666169_9_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 5, "end": 8}, {"entity_id": "20666169_9_Ent1", "role": "Treatment", "text": "interaction , atorvastatin and verapamil", "start": 16, "end": 21}, {"entity_id": "20666169_9_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 20, "end": 21}, {"entity_id": "20666169_9_Ent5", "role": "Combination_Drug", "text": "verapamil", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "20666169_9_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20666169_9_Ent1", "text": "interaction , atorvastatin and verapamil", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "20666169_9_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20666169_9_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "20925534_13", "wnd_id": "20925534_13_1", "text": "The two groups did not differ significantly in the rate of serious adverse events , though the risk of diarrhea was increased with omeprazole .", "tokens": ["The", "two", "groups", "did", "not", "differ", "significantly", "in", "the", "rate", "of", "serious", "adverse", "events", ",", "though", "the", "risk", "of", "diarrhea", "was", "increased", "with", "omeprazole", "."], "event_mentions": [{"id": "20925534_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 21, "end": 22}, "arguments": [{"entity_id": "20925534_13_Ent0", "role": "Effect", "text": "risk of diarrhea was increased", "start": 17, "end": 22}, {"entity_id": "20925534_13_Ent1", "role": "Treatment", "text": "omeprazole", "start": 23, "end": 24}, {"entity_id": "20925534_13_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "20925534_13_Ent0", "text": "risk of diarrhea was increased", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "20925534_13_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "20925534_13_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "20925534_15", "wnd_id": "20925534_15_1", "text": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole , but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI .", "tokens": ["There", "was", "no", "apparent", "cardiovascular", "interaction", "between", "clopidogrel", "and", "omeprazole", ",", "but", "our", "results", "do", "not", "rule", "out", "a", "clinically", "meaningful", "difference", "in", "cardiovascular", "events", "due", "to", "use", "of", "a", "PPI", "."], "event_mentions": [{"id": "20925534_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 25, "end": 26}, "arguments": [{"entity_id": "20925534_15_Ent0", "role": "Effect", "text": "cardiovascular", "start": 23, "end": 24}, {"entity_id": "20925534_15_Ent1", "role": "Treatment", "text": "PPI", "start": 30, "end": 31}, {"entity_id": "20925534_15_Ent2", "role": "Treatment_Drug", "text": "PPI", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "20925534_15_Ent0", "text": "cardiovascular", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "20925534_15_Ent1", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "20925534_15_Ent2", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "21045170_9", "wnd_id": "21045170_9_1", "text": "When these cells are exposed to nicotinic acid , an exaggerated immune response is produced that may lead to pain , redness , and swelling at the injection site .", "tokens": ["When", "these", "cells", "are", "exposed", "to", "nicotinic", "acid", ",", "an", "exaggerated", "immune", "response", "is", "produced", "that", "may", "lead", "to", "pain", ",", "redness", ",", "and", "swelling", "at", "the", "injection", "site", "."], "event_mentions": [{"id": "21045170_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 14, "end": 15}, "arguments": [{"entity_id": "21045170_9_Ent2", "role": "Treatment", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent3", "role": "Treatment_Drug", "text": "nicotinic acid", "start": 6, "end": 8}, {"entity_id": "21045170_9_Ent0", "role": "Effect", "text": "exaggerated immune response", "start": 10, "end": 13}, {"entity_id": "21045170_9_Ent1", "role": "Effect", "text": "pain , redness , and swelling at the injection site", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "21045170_9_Ent2", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent3", "text": "nicotinic acid", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "21045170_9_Ent0", "text": "exaggerated immune response", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "21045170_9_Ent1", "text": "pain , redness , and swelling at the injection site", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "2104570_1", "wnd_id": "2104570_1_1", "text": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma .", "tokens": ["Secondary", "hematologic", "neoplasm", "after", "intravesical", "chemotherapy", "for", "superficial", "bladder", "carcinoma", "."], "event_mentions": [{"id": "2104570_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "2104570_1_Ent0", "role": "Effect", "text": "Secondary hematologic neoplasm", "start": 0, "end": 3}, {"entity_id": "2104570_1_Ent3", "role": "Treatment_Drug", "text": "intravesical", "start": 4, "end": 5}, {"entity_id": "2104570_1_Ent1", "role": "Treatment", "text": "intravesical chemotherapy", "start": 4, "end": 6}, {"entity_id": "2104570_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 5, "end": 6}, {"entity_id": "2104570_1_Ent2", "role": "Treatment_Disorder", "text": "bladder carcinoma", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "2104570_1_Ent0", "text": "Secondary hematologic neoplasm", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2104570_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2104570_1_Ent1", "text": "intravesical chemotherapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2104570_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2104570_1_Ent2", "text": "bladder carcinoma", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2104570_2", "wnd_id": "2104570_2_1", "text": "Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid , doxorubicin , and mitomycin C.", "tokens": ["Two", "cases", "are", "reported", "of", "patients", "who", "developed", "a", "hematologic", "malignancy", "several", "years", "after", "intravesical", "chemotherapy", "of", "superficial", "bladder", "cancer", "with", "etoglucid", ",", "doxorubicin", ",", "and", "mitomycin", "C."], "event_mentions": [{"id": "2104570_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "2104570_2_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "2104570_2_Ent1", "role": "Effect", "text": "a hematologic malignancy", "start": 8, "end": 11}, {"entity_id": "2104570_2_Ent8", "role": "Treatment_Time_elapsed", "text": "several years after", "start": 11, "end": 14}, {"entity_id": "2104570_2_Ent2", "role": "Treatment", "text": "several years after intravesical chemotherapy", "start": 11, "end": 16}, {"entity_id": "2104570_2_Ent9", "role": "Treatment_Route", "text": "intravesical", "start": 14, "end": 15}, {"entity_id": "2104570_2_Ent7", "role": "Treatment_Disorder", "text": "superficial bladder cancer", "start": 17, "end": 20}, {"entity_id": "2104570_2_Ent3", "role": "Treatment", "text": "with etoglucid , doxorubicin , and mitomycin C.", "start": 20, "end": 28}, {"entity_id": "2104570_2_Ent4", "role": "Treatment_Drug", "text": "etoglucid", "start": 21, "end": 22}, {"entity_id": "2104570_2_Ent12", "role": "Combination_Drug", "text": "etoglucid", "start": 21, "end": 22}, {"entity_id": "2104570_2_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 23, "end": 24}, {"entity_id": "2104570_2_Ent11", "role": "Combination_Drug", "text": "doxorubicin", "start": 23, "end": 24}, {"entity_id": "2104570_2_Ent6", "role": "Treatment_Drug", "text": "mitomycin C.", "start": 26, "end": 28}, {"entity_id": "2104570_2_Ent10", "role": "Combination_Drug", "text": "mitomycin C.", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "2104570_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2104570_2_Ent1", "text": "a hematologic malignancy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2104570_2_Ent8", "text": "several years after", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "2104570_2_Ent2", "text": "several years after intravesical chemotherapy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "2104570_2_Ent9", "text": "intravesical", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2104570_2_Ent7", "text": "superficial bladder cancer", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "2104570_2_Ent3", "text": "with etoglucid , doxorubicin , and mitomycin C.", "entity_type": "Entity", "start": 20, "end": 28}, {"id": "2104570_2_Ent4", "text": "etoglucid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2104570_2_Ent12", "text": "etoglucid", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2104570_2_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2104570_2_Ent11", "text": "doxorubicin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2104570_2_Ent6", "text": "mitomycin C.", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "2104570_2_Ent10", "text": "mitomycin C.", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "2113320_2", "wnd_id": "2113320_2_1", "text": "Subglottic stenosis in Wegener 's granulomatosis : development during cyclophosphamide treatment with response to carbon dioxide laser therapy .", "tokens": ["Subglottic", "stenosis", "in", "Wegener", "'s", "granulomatosis", ":", "development", "during", "cyclophosphamide", "treatment", "with", "response", "to", "carbon", "dioxide", "laser", "therapy", "."], "event_mentions": [{"id": "2113320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "2113320_2_Ent0", "role": "Effect", "text": "Subglottic stenosis in Wegener 's granulomatosis", "start": 0, "end": 6}, {"entity_id": "2113320_2_Ent3", "role": "Treatment_Disorder", "text": "Wegener 's granulomatosis", "start": 3, "end": 6}, {"entity_id": "2113320_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 9, "end": 10}, {"entity_id": "2113320_2_Ent1", "role": "Treatment", "text": "cyclophosphamide treatment with response to carbon dioxide laser therapy", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "2113320_2_Ent0", "text": "Subglottic stenosis in Wegener 's granulomatosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2113320_2_Ent3", "text": "Wegener 's granulomatosis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2113320_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2113320_2_Ent1", "text": "cyclophosphamide treatment with response to carbon dioxide laser therapy", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "2116935_1", "wnd_id": "2116935_1_1", "text": "Splenic hemorrhage : a complication of tissue plasminogen activator treatment .", "tokens": ["Splenic", "hemorrhage", ":", "a", "complication", "of", "tissue", "plasminogen", "activator", "treatment", "."], "event_mentions": [{"id": "2116935_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication of", "start": 4, "end": 6}, "arguments": [{"entity_id": "2116935_1_Ent0", "role": "Effect", "text": "Splenic hemorrhage", "start": 0, "end": 2}, {"entity_id": "2116935_1_Ent2", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 6, "end": 9}, {"entity_id": "2116935_1_Ent1", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "2116935_1_Ent0", "text": "Splenic hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2116935_1_Ent2", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2116935_1_Ent1", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "21330680_1", "wnd_id": "21330680_1_1", "text": "Olanzapine - induced parkinsonism associated with smoking cessation .", "tokens": ["Olanzapine", "-", "induced", "parkinsonism", "associated", "with", "smoking", "cessation", "."], "event_mentions": [{"id": "21330680_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "21330680_1_Ent2", "role": "Treatment", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "21330680_1_Ent3", "role": "Treatment_Drug", "text": "Olanzapine", "start": 0, "end": 1}, {"entity_id": "21330680_1_Ent0", "role": "Effect", "text": "parkinsonism", "start": 3, "end": 4}, {"entity_id": "21330680_1_Ent1", "role": "Treatment", "text": "associated with smoking cessation", "start": 4, "end": 8}, {"entity_id": "21330680_1_Ent4", "role": "Treatment_Dosage", "text": "cessation", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "21330680_1_Ent2", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21330680_1_Ent3", "text": "Olanzapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21330680_1_Ent0", "text": "parkinsonism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21330680_1_Ent1", "text": "associated with smoking cessation", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "21330680_1_Ent4", "text": "cessation", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "21350204_12", "wnd_id": "21350204_12_1", "text": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio < 1.7 and may reduce the risk of poor functional outcome .", "tokens": ["The", "results", "from", "the", "present", "study", "suggest", "that", "tissue", "plasminogen", "activator", "treatment", "appears", "to", "be", "safe", "in", "patients", "with", "acute", "ischemic", "stroke", "taking", "warfarin", "with", "an", "international", "normalized", "ratio", "<", "1.7", "and", "may", "reduce", "the", "risk", "of", "poor", "functional", "outcome", "."], "event_mentions": [{"id": "21350204_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "appears", "start": 12, "end": 13}, "arguments": [{"entity_id": "21350204_12_Ent5", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent7", "role": "Combination_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent3", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 8, "end": 12}, {"entity_id": "21350204_12_Ent0", "role": "Subject", "text": "patients with acute ischemic stroke", "start": 17, "end": 22}, {"entity_id": "21350204_12_Ent4", "role": "Treatment_Disorder", "text": "acute ischemic stroke", "start": 19, "end": 22}, {"entity_id": "21350204_12_Ent2", "role": "Treatment", "text": "taking warfarin with an international normalized ratio < 1.7", "start": 22, "end": 31}, {"entity_id": "21350204_12_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent1", "role": "Effect", "text": "may reduce the risk of poor functional outcome", "start": 32, "end": 40}]}], "entity_mentions": [{"id": "21350204_12_Ent5", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent7", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent3", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21350204_12_Ent0", "text": "patients with acute ischemic stroke", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21350204_12_Ent4", "text": "acute ischemic stroke", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21350204_12_Ent2", "text": "taking warfarin with an international normalized ratio < 1.7", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "21350204_12_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent1", "text": "may reduce the risk of poor functional outcome", "entity_type": "Entity", "start": 32, "end": 40}], "lang": "en"}
{"doc_id": "21448111_6", "wnd_id": "21448111_6_1", "text": "We can conclude that in this case , as in many others , akathisia as a possible adverse effect of psychopharmacs was very hard to identify .", "tokens": ["We", "can", "conclude", "that", "in", "this", "case", ",", "as", "in", "many", "others", ",", "akathisia", "as", "a", "possible", "adverse", "effect", "of", "psychopharmacs", "was", "very", "hard", "to", "identify", "."], "event_mentions": [{"id": "21448111_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 17, "end": 19}, "arguments": [{"entity_id": "21448111_6_Ent0", "role": "Subject", "text": "this case", "start": 5, "end": 7}, {"entity_id": "21448111_6_Ent1", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "21448111_6_Ent2", "role": "Treatment", "text": "psychopharmacs", "start": 20, "end": 21}, {"entity_id": "21448111_6_Ent3", "role": "Treatment_Drug", "text": "psychopharmacs", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21448111_6_Ent0", "text": "this case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "21448111_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_6_Ent2", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_6_Ent3", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21512888_7", "wnd_id": "21512888_7_1", "text": "Patient was on warfarin for a prior deep venous thrombosis .", "tokens": ["Patient", "was", "on", "warfarin", "for", "a", "prior", "deep", "venous", "thrombosis", "."], "event_mentions": [{"id": "21512888_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "21512888_7_Ent0", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent1", "role": "Treatment_Disorder", "text": "a prior deep venous thrombosis", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "21512888_7_Ent0", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent1", "text": "a prior deep venous thrombosis", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "21515865_11", "wnd_id": "21515865_11_1", "text": "According to the Drug Interaction Probability Scale , the development of supratherapeutic INRs was probably associated with concomitant acetaminophen and moxifloxacin use .", "tokens": ["According", "to", "the", "Drug", "Interaction", "Probability", "Scale", ",", "the", "development", "of", "supratherapeutic", "INRs", "was", "probably", "associated", "with", "concomitant", "acetaminophen", "and", "moxifloxacin", "use", "."], "event_mentions": [{"id": "21515865_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "21515865_11_Ent0", "role": "Effect", "text": "development of supratherapeutic INRs", "start": 9, "end": 13}, {"entity_id": "21515865_11_Ent1", "role": "Treatment", "text": "concomitant acetaminophen and moxifloxacin use", "start": 17, "end": 22}, {"entity_id": "21515865_11_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent4", "role": "Combination_Drug", "text": "acetaminophen", "start": 18, "end": 19}, {"entity_id": "21515865_11_Ent2", "role": "Treatment_Drug", "text": "moxifloxacin", "start": 20, "end": 21}, {"entity_id": "21515865_11_Ent5", "role": "Combination_Drug", "text": "moxifloxacin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21515865_11_Ent0", "text": "development of supratherapeutic INRs", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "21515865_11_Ent1", "text": "concomitant acetaminophen and moxifloxacin use", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21515865_11_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent4", "text": "acetaminophen", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21515865_11_Ent2", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21515865_11_Ent5", "text": "moxifloxacin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21515865_4", "wnd_id": "21515865_4_1", "text": "On the day before this visit , he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer .", "tokens": ["On", "the", "day", "before", "this", "visit", ",", "he", "had", "received", "the", "third", "of", "six", "serial", "weekly", "BCG", "bladder", "instillations", "for", "the", "treatment", "of", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 9, "end": 10}, "arguments": [{"entity_id": "21515865_4_Ent0", "role": "Subject", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent2", "role": "Subject_Gender", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent3", "role": "Treatment", "text": "the third of six serial weekly BCG bladder instillations", "start": 10, "end": 19}, {"entity_id": "21515865_4_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 15, "end": 16}, {"entity_id": "21515865_4_Ent6", "role": "Treatment_Drug", "text": "BCG", "start": 16, "end": 17}, {"entity_id": "21515865_4_Ent4", "role": "Treatment_Route", "text": "bladder instillations", "start": 17, "end": 19}, {"entity_id": "21515865_4_Ent1", "role": "Subject", "text": "bladder cancer", "start": 23, "end": 25}, {"entity_id": "21515865_4_Ent5", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "21515865_4_Ent0", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent2", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent3", "text": "the third of six serial weekly BCG bladder instillations", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "21515865_4_Ent7", "text": "weekly", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21515865_4_Ent6", "text": "BCG", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21515865_4_Ent4", "text": "bladder instillations", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21515865_4_Ent1", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21515865_4_Ent5", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2154663_1", "wnd_id": "2154663_1_1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy , and the rash resolved .", "tokens": ["Aminoglutethimide", "was", "discontinued", "until", "completion", "of", "radiotherapy", ",", "and", "the", "rash", "resolved", "."], "event_mentions": [{"id": "2154663_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "and", "start": 8, "end": 9}, "arguments": [{"entity_id": "2154663_1_Ent2", "role": "Treatment_Drug", "text": "Aminoglutethimide", "start": 0, "end": 1}, {"entity_id": "2154663_1_Ent1", "role": "Treatment", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "start": 0, "end": 7}, {"entity_id": "2154663_1_Ent0", "role": "Effect", "text": "the rash resolved", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2154663_1_Ent2", "text": "Aminoglutethimide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2154663_1_Ent1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2154663_1_Ent0", "text": "the rash resolved", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "21597286_2", "wnd_id": "21597286_2_1", "text": "We report a case of a potential drug - drug interaction in a woman treated by a first injection of high - dose methotrexate for a T - lymphoblastic lymphoma .", "tokens": ["We", "report", "a", "case", "of", "a", "potential", "drug", "-", "drug", "interaction", "in", "a", "woman", "treated", "by", "a", "first", "injection", "of", "high", "-", "dose", "methotrexate", "for", "a", "T", "-", "lymphoblastic", "lymphoma", "."], "event_mentions": [{"id": "21597286_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 14, "end": 15}, "arguments": [{"entity_id": "21597286_2_Ent0", "role": "Subject", "text": "a woman", "start": 12, "end": 14}, {"entity_id": "21597286_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "21597286_2_Ent2", "role": "Treatment", "text": "a first injection of high - dose methotrexate", "start": 16, "end": 24}, {"entity_id": "21597286_2_Ent4", "role": "Treatment_Route", "text": "injection", "start": 18, "end": 19}, {"entity_id": "21597286_2_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 20, "end": 23}, {"entity_id": "21597286_2_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "21597286_2_Ent3", "role": "Treatment_Disorder", "text": "a T - lymphoblastic lymphoma", "start": 25, "end": 30}]}], "entity_mentions": [{"id": "21597286_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "21597286_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21597286_2_Ent2", "text": "a first injection of high - dose methotrexate", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "21597286_2_Ent4", "text": "injection", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "21597286_2_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "21597286_2_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21597286_2_Ent3", "text": "a T - lymphoblastic lymphoma", "entity_type": "Entity", "start": 25, "end": 30}], "lang": "en"}
{"doc_id": "21712512_1", "wnd_id": "21712512_1_1", "text": "Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis - related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor .", "tokens": ["Rapid", "onset", "of", "iatrogenic", "adrenal", "insufficiency", "in", "a", "patient", "with", "cystic", "fibrosis", "-", "related", "liver", "disease", "treated", "with", "inhaled", "corticosteroids", "and", "a", "moderate", "CYP3A4", "inhibitor", "."], "event_mentions": [{"id": "21712512_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 1, "end": 2}, "arguments": [{"entity_id": "21712512_1_Ent2", "role": "Effect", "text": "iatrogenic adrenal insufficiency", "start": 3, "end": 6}, {"entity_id": "21712512_1_Ent0", "role": "Subject", "text": "a patient with cystic fibrosis - related liver disease", "start": 7, "end": 16}, {"entity_id": "21712512_1_Ent1", "role": "Subject_Disorder", "text": "cystic fibrosis - related liver disease", "start": 10, "end": 16}, {"entity_id": "21712512_1_Ent4", "role": "Treatment_Drug", "text": "inhaled corticosteroids", "start": 18, "end": 20}, {"entity_id": "21712512_1_Ent6", "role": "Combination_Drug", "text": "inhaled corticosteroids", "start": 18, "end": 20}, {"entity_id": "21712512_1_Ent3", "role": "Treatment", "text": "inhaled corticosteroids and a moderate CYP3A4 inhibitor", "start": 18, "end": 25}, {"entity_id": "21712512_1_Ent5", "role": "Treatment_Drug", "text": "CYP3A4 inhibitor .", "start": 23, "end": 26}, {"entity_id": "21712512_1_Ent7", "role": "Combination_Drug", "text": "CYP3A4 inhibitor .", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "21712512_1_Ent2", "text": "iatrogenic adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "21712512_1_Ent0", "text": "a patient with cystic fibrosis - related liver disease", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "21712512_1_Ent1", "text": "cystic fibrosis - related liver disease", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "21712512_1_Ent4", "text": "inhaled corticosteroids", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "21712512_1_Ent6", "text": "inhaled corticosteroids", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "21712512_1_Ent3", "text": "inhaled corticosteroids and a moderate CYP3A4 inhibitor", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "21712512_1_Ent5", "text": "CYP3A4 inhibitor .", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "21712512_1_Ent7", "text": "CYP3A4 inhibitor .", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "21751692_3", "wnd_id": "21751692_3_1", "text": "We retrospectively reviewed the records of 7 pediatric oncology patients who received low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy .", "tokens": ["We", "retrospectively", "reviewed", "the", "records", "of", "7", "pediatric", "oncology", "patients", "who", "received", "low", "-", "dose", "ketamine", "in", "conjunction", "with", "propofol", "for", "total", "intravenous", "anesthesia", "(", "TIVA", ")", "repeatedly", "for", "radiation", "therapy", "."], "event_mentions": [{"id": "21751692_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "21751692_3_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_3_Ent0", "role": "Subject", "text": "7 pediatric oncology patients", "start": 6, "end": 10}, {"entity_id": "21751692_3_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 7, "end": 8}, {"entity_id": "21751692_3_Ent7", "role": "Treatment_Disorder", "text": "oncology", "start": 8, "end": 9}, {"entity_id": "21751692_3_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 12, "end": 15}, {"entity_id": "21751692_3_Ent3", "role": "Treatment", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "start": 12, "end": 31}, {"entity_id": "21751692_3_Ent5", "role": "Treatment_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent9", "role": "Combination_Drug", "text": "ketamine", "start": 15, "end": 16}, {"entity_id": "21751692_3_Ent4", "role": "Treatment_Drug", "text": "propofol", "start": 19, "end": 20}, {"entity_id": "21751692_3_Ent8", "role": "Combination_Drug", "text": "propofol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "21751692_3_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_3_Ent0", "text": "7 pediatric oncology patients", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "21751692_3_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751692_3_Ent7", "text": "oncology", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21751692_3_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "21751692_3_Ent3", "text": "low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy", "entity_type": "Entity", "start": 12, "end": 31}, {"id": "21751692_3_Ent5", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent9", "text": "ketamine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21751692_3_Ent4", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "21751692_3_Ent8", "text": "propofol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "2196696_1", "wnd_id": "2196696_1_1", "text": "Disulfiram - induced hepatitis .", "tokens": ["Disulfiram", "-", "induced", "hepatitis", "."], "event_mentions": [{"id": "2196696_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2196696_1_Ent1", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "2196696_1_Ent2", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "2196696_1_Ent0", "role": "Effect", "text": "hepatitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2196696_1_Ent1", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2196696_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2196696_1_Ent0", "text": "hepatitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2196696_3", "wnd_id": "2196696_3_1", "text": "We reported a case of disulfiram - induced hepatitis with unique clinical features and compared our case with others in the literature .", "tokens": ["We", "reported", "a", "case", "of", "disulfiram", "-", "induced", "hepatitis", "with", "unique", "clinical", "features", "and", "compared", "our", "case", "with", "others", "in", "the", "literature", "."], "event_mentions": [{"id": "2196696_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2196696_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "2196696_3_Ent2", "role": "Treatment", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent1", "role": "Effect", "text": "hepatitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2196696_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2196696_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "22010004_1", "wnd_id": "22010004_1_1", "text": "Critically elevated INR in a patient on warfarin after increase in extended - release niacin dose .", "tokens": ["Critically", "elevated", "INR", "in", "a", "patient", "on", "warfarin", "after", "increase", "in", "extended", "-", "release", "niacin", "dose", "."], "event_mentions": [{"id": "22010004_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "22010004_1_Ent1", "role": "Effect", "text": "elevated INR", "start": 1, "end": 3}, {"entity_id": "22010004_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "22010004_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent6", "role": "Treatment_Dosage", "text": "increase in", "start": 9, "end": 11}, {"entity_id": "22010004_1_Ent3", "role": "Treatment", "text": "increase in extended - release niacin dose", "start": 9, "end": 16}, {"entity_id": "22010004_1_Ent5", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "22010004_1_Ent7", "role": "Treatment_Dosage", "text": "dose", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "22010004_1_Ent1", "text": "elevated INR", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22010004_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "22010004_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent6", "text": "increase in", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "22010004_1_Ent3", "text": "increase in extended - release niacin dose", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "22010004_1_Ent5", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22010004_1_Ent7", "text": "dose", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "22010004_2", "wnd_id": "22010004_2_1", "text": "To report a case of a probable interaction between warfarin and extended - release niacin that may have led to synergistic coagulopathy and to inform health care providers of a need for more frequent monitoring of international normalized ratio ( INR ) in patients taking these drugs concomitantly .", "tokens": ["To", "report", "a", "case", "of", "a", "probable", "interaction", "between", "warfarin", "and", "extended", "-", "release", "niacin", "that", "may", "have", "led", "to", "synergistic", "coagulopathy", "and", "to", "inform", "health", "care", "providers", "of", "a", "need", "for", "more", "frequent", "monitoring", "of", "international", "normalized", "ratio", "(", "INR", ")", "in", "patients", "taking", "these", "drugs", "concomitantly", "."], "event_mentions": [{"id": "22010004_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 18, "end": 19}, "arguments": [{"entity_id": "22010004_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "22010004_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "22010004_2_Ent1", "role": "Treatment", "text": "warfarin and extended - release niacin", "start": 9, "end": 15}, {"entity_id": "22010004_2_Ent3", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "22010004_2_Ent4", "role": "Combination_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "22010004_2_Ent0", "role": "Effect", "text": "synergistic coagulopathy", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "22010004_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "22010004_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "22010004_2_Ent1", "text": "warfarin and extended - release niacin", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "22010004_2_Ent3", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22010004_2_Ent4", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22010004_2_Ent0", "text": "synergistic coagulopathy", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "22047557_1", "wnd_id": "22047557_1_1", "text": "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation .", "tokens": ["A", "CFTR", "potentiator", "in", "patients", "with", "cystic", "fibrosis", "and", "the", "G551D", "mutation", "."], "event_mentions": [{"id": "22047557_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "22047557_1_Ent2", "role": "Treatment", "text": "CFTR potentiator", "start": 1, "end": 3}, {"entity_id": "22047557_1_Ent4", "role": "Treatment_Drug", "text": "CFTR potentiator", "start": 1, "end": 3}, {"entity_id": "22047557_1_Ent0", "role": "Subject", "text": "patients with cystic fibrosis and the G551D mutation", "start": 4, "end": 12}, {"entity_id": "22047557_1_Ent3", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 6, "end": 8}, {"entity_id": "22047557_1_Ent1", "role": "Subject_Disorder", "text": "G551D mutation", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "22047557_1_Ent2", "text": "CFTR potentiator", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22047557_1_Ent4", "text": "CFTR potentiator", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22047557_1_Ent0", "text": "patients with cystic fibrosis and the G551D mutation", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "22047557_1_Ent3", "text": "cystic fibrosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "22047557_1_Ent1", "text": "G551D mutation", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "22233409_4", "wnd_id": "22233409_4_1", "text": "We report the case of a patient with chronic hepatitis C infection who developed severe anaemia during antiviral treatment with peginterferon alfa / ribavirin when oseltamivir was added to treat influenza .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "chronic", "hepatitis", "C", "infection", "who", "developed", "severe", "anaemia", "during", "antiviral", "treatment", "with", "peginterferon", "alfa", "/", "ribavirin", "when", "oseltamivir", "was", "added", "to", "treat", "influenza", "."], "event_mentions": [{"id": "22233409_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "22233409_4_Ent0", "role": "Subject", "text": "a patient with chronic hepatitis C infection", "start": 5, "end": 12}, {"entity_id": "22233409_4_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C infection", "start": 8, "end": 12}, {"entity_id": "22233409_4_Ent1", "role": "Effect", "text": "severe anaemia", "start": 14, "end": 16}, {"entity_id": "22233409_4_Ent6", "role": "Treatment_Drug", "text": "peginterferon alfa", "start": 20, "end": 22}, {"entity_id": "22233409_4_Ent9", "role": "Combination_Drug", "text": "peginterferon alfa", "start": 20, "end": 22}, {"entity_id": "22233409_4_Ent2", "role": "Treatment", "text": "peginterferon alfa / ribavirin", "start": 20, "end": 24}, {"entity_id": "22233409_4_Ent7", "role": "Treatment_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "22233409_4_Ent10", "role": "Combination_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "22233409_4_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent8", "role": "Treatment_Drug", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent11", "role": "Combination_Drug", "text": "oseltamivir", "start": 25, "end": 26}, {"entity_id": "22233409_4_Ent5", "role": "Treatment_Disorder", "text": "influenza", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "22233409_4_Ent0", "text": "a patient with chronic hepatitis C infection", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "22233409_4_Ent4", "text": "chronic hepatitis C infection", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "22233409_4_Ent1", "text": "severe anaemia", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "22233409_4_Ent6", "text": "peginterferon alfa", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "22233409_4_Ent9", "text": "peginterferon alfa", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "22233409_4_Ent2", "text": "peginterferon alfa / ribavirin", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22233409_4_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "22233409_4_Ent10", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "22233409_4_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent8", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent11", "text": "oseltamivir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22233409_4_Ent5", "text": "influenza", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "22372628_1", "wnd_id": "22372628_1_1", "text": "Long - term safety and efficacy in patients with uncontrolled partial - onset seizures treated with adjunctive lacosamide : results from a Phase III open - label extension trial .", "tokens": ["Long", "-", "term", "safety", "and", "efficacy", "in", "patients", "with", "uncontrolled", "partial", "-", "onset", "seizures", "treated", "with", "adjunctive", "lacosamide", ":", "results", "from", "a", "Phase", "III", "open", "-", "label", "extension", "trial", "."], "event_mentions": [{"id": "22372628_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 14, "end": 15}, "arguments": [{"entity_id": "22372628_1_Ent0", "role": "Subject", "text": "patients with uncontrolled partial - onset seizures", "start": 7, "end": 14}, {"entity_id": "22372628_1_Ent3", "role": "Treatment_Disorder", "text": "uncontrolled partial - onset seizures", "start": 9, "end": 14}, {"entity_id": "22372628_1_Ent1", "role": "Treatment", "text": "adjunctive lacosamide", "start": 16, "end": 18}, {"entity_id": "22372628_1_Ent2", "role": "Treatment_Drug", "text": "lacosamide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "22372628_1_Ent0", "text": "patients with uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "22372628_1_Ent3", "text": "uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "22372628_1_Ent1", "text": "adjunctive lacosamide", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "22372628_1_Ent2", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "22372628_2", "wnd_id": "22372628_2_1", "text": "To evaluate the long - term ( up to 5 years exposure ) safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial - onset seizures taking one to three concomitant antiepileptic drugs ( AEDs ) in open - label extension trial SP756 ( NCT00522275 ) .", "tokens": ["To", "evaluate", "the", "long", "-", "term", "(", "up", "to", "5", "years", "exposure", ")", "safety", "and", "efficacy", "of", "lacosamide", "as", "adjunctive", "therapy", "in", "patients", "with", "uncontrolled", "partial", "-", "onset", "seizures", "taking", "one", "to", "three", "concomitant", "antiepileptic", "drugs", "(", "AEDs", ")", "in", "open", "-", "label", "extension", "trial", "SP756", "(", "NCT00522275", ")", "."], "event_mentions": [{"id": "22372628_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 21, "end": 22}, "arguments": [{"entity_id": "22372628_2_Ent0", "role": "Treatment", "text": "long - term ( up to 5 years exposure )", "start": 3, "end": 13}, {"entity_id": "22372628_2_Ent6", "role": "Treatment_Duration", "text": "long - term ( up to 5 years exposure )", "start": 3, "end": 13}, {"entity_id": "22372628_2_Ent4", "role": "Treatment_Drug", "text": "lacosamide", "start": 17, "end": 18}, {"entity_id": "22372628_2_Ent7", "role": "Combination_Drug", "text": "lacosamide", "start": 17, "end": 18}, {"entity_id": "22372628_2_Ent1", "role": "Treatment", "text": "lacosamide as adjunctive therapy", "start": 17, "end": 21}, {"entity_id": "22372628_2_Ent3", "role": "Treatment_Disorder", "text": "uncontrolled partial - onset seizures", "start": 24, "end": 29}, {"entity_id": "22372628_2_Ent2", "role": "Treatment", "text": "taking one to three concomitant antiepileptic drugs ( AEDs )", "start": 29, "end": 39}, {"entity_id": "22372628_2_Ent5", "role": "Treatment_Drug", "text": "antiepileptic drugs", "start": 34, "end": 36}, {"entity_id": "22372628_2_Ent8", "role": "Combination_Drug", "text": "antiepileptic drugs", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "22372628_2_Ent0", "text": "long - term ( up to 5 years exposure )", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "22372628_2_Ent6", "text": "long - term ( up to 5 years exposure )", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "22372628_2_Ent4", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22372628_2_Ent7", "text": "lacosamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22372628_2_Ent1", "text": "lacosamide as adjunctive therapy", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "22372628_2_Ent3", "text": "uncontrolled partial - onset seizures", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "22372628_2_Ent2", "text": "taking one to three concomitant antiepileptic drugs ( AEDs )", "entity_type": "Entity", "start": 29, "end": 39}, {"id": "22372628_2_Ent5", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "22372628_2_Ent8", "text": "antiepileptic drugs", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "22550162_1", "wnd_id": "22550162_1_1", "text": "Suspected methotrexate toxicity from omeprazole : a case review of carboxypeptidase G2 use in a methotrexate - experienced patient with methotrexate toxicity and a review of the literature .", "tokens": ["Suspected", "methotrexate", "toxicity", "from", "omeprazole", ":", "a", "case", "review", "of", "carboxypeptidase", "G2", "use", "in", "a", "methotrexate", "-", "experienced", "patient", "with", "methotrexate", "toxicity", "and", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "22550162_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 3, "end": 4}, "arguments": [{"entity_id": "22550162_1_Ent0", "role": "Effect", "text": "methotrexate toxicity", "start": 1, "end": 3}, {"entity_id": "22550162_1_Ent1", "role": "Treatment", "text": "omeprazole", "start": 4, "end": 5}, {"entity_id": "22550162_1_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 4, "end": 5}]}, {"id": "22550162_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "use", "start": 12, "end": 13}, "arguments": [{"entity_id": "22550162_1_Ent4", "role": "Treatment", "text": "carboxypeptidase G2", "start": 10, "end": 12}, {"entity_id": "22550162_1_Ent6", "role": "Treatment_Drug", "text": "carboxypeptidase G2", "start": 10, "end": 12}, {"entity_id": "22550162_1_Ent3", "role": "Subject", "text": "methotrexate - experienced patient", "start": 15, "end": 19}, {"entity_id": "22550162_1_Ent5", "role": "Treatment_Disorder", "text": "methotrexate toxicity", "start": 20, "end": 22}]}, {"id": "22550162_1_Evt2", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 21, "end": 22}, "arguments": [{"entity_id": "22550162_1_Ent8", "role": "Treatment", "text": "methotrexate", "start": 20, "end": 21}, {"entity_id": "22550162_1_Ent9", "role": "Treatment_Drug", "text": "methotrexate", "start": 20, "end": 21}, {"entity_id": "22550162_1_Ent7", "role": "Effect", "text": "toxicity", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "22550162_1_Ent0", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22550162_1_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22550162_1_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22550162_1_Ent4", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22550162_1_Ent6", "text": "carboxypeptidase G2", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22550162_1_Ent3", "text": "methotrexate - experienced patient", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "22550162_1_Ent8", "text": "methotrexate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "22550162_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "22550162_1_Ent5", "text": "methotrexate toxicity", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "22550162_1_Ent7", "text": "toxicity", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "22791547_3", "wnd_id": "22791547_3_1", "text": "In this article , the authors report a 7 - year - old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention - deficit / hyperactivity disorder ; he was also receiving sodium valproate treatment for epilepsy .", "tokens": ["In", "this", "article", ",", "the", "authors", "report", "a", "7", "-", "year", "-", "old", "male", "patient", "who", "presented", "with", "orofacial", "and", "limb", "dyskinesia", "after", "his", "first", "dose", "of", "methylphenidate", "treatment", "for", "a", "diagnosis", "of", "attention", "-", "deficit", "/", "hyperactivity", "disorder", ";", "he", "was", "also", "receiving", "sodium", "valproate", "treatment", "for", "epilepsy", "."], "event_mentions": [{"id": "22791547_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "22791547_3_Ent0", "role": "Subject", "text": "a 7 - year - old male patient", "start": 7, "end": 15}, {"entity_id": "22791547_3_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 8, "end": 13}, {"entity_id": "22791547_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "22791547_3_Ent3", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 18, "end": 22}, {"entity_id": "22791547_3_Ent6", "role": "Treatment_Time_elapsed", "text": "first dose", "start": 24, "end": 26}, {"entity_id": "22791547_3_Ent4", "role": "Treatment", "text": "first dose of methylphenidate", "start": 24, "end": 28}, {"entity_id": "22791547_3_Ent7", "role": "Treatment_Drug", "text": "methylphenidate", "start": 27, "end": 28}, {"entity_id": "22791547_3_Ent5", "role": "Treatment_Disorder", "text": "attention - deficit / hyperactivity disorder", "start": 33, "end": 39}]}, {"id": "22791547_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 43, "end": 44}, "arguments": [{"entity_id": "22791547_3_Ent8", "role": "Subject", "text": "a 7 - year - old male patient", "start": 7, "end": 15}, {"entity_id": "22791547_3_Ent9", "role": "Subject_Age", "text": "7 - year - old", "start": 8, "end": 13}, {"entity_id": "22791547_3_Ent10", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "22791547_3_Ent11", "role": "Treatment", "text": "sodium valproate", "start": 44, "end": 46}, {"entity_id": "22791547_3_Ent13", "role": "Treatment_Drug", "text": "sodium valproate", "start": 44, "end": 46}, {"entity_id": "22791547_3_Ent12", "role": "Treatment_Disorder", "text": "epilepsy", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "22791547_3_Ent0", "text": "a 7 - year - old male patient", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "22791547_3_Ent8", "text": "a 7 - year - old male patient", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "22791547_3_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "22791547_3_Ent9", "text": "7 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "22791547_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22791547_3_Ent10", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22791547_3_Ent3", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "22791547_3_Ent6", "text": "first dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "22791547_3_Ent4", "text": "first dose of methylphenidate", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "22791547_3_Ent7", "text": "methylphenidate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "22791547_3_Ent5", "text": "attention - deficit / hyperactivity disorder", "entity_type": "Entity", "start": 33, "end": 39}, {"id": "22791547_3_Ent11", "text": "sodium valproate", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "22791547_3_Ent13", "text": "sodium valproate", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "22791547_3_Ent12", "text": "epilepsy", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "22791547_5", "wnd_id": "22791547_5_1", "text": "Although limb dyskinesia after methylphenidate is a commonly reported side effect , to the authors ' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate .", "tokens": ["Although", "limb", "dyskinesia", "after", "methylphenidate", "is", "a", "commonly", "reported", "side", "effect", ",", "to", "the", "authors", "'", "knowledge", "this", "is", "only", "the", "second", "reported", "case", "to", "develop", "both", "orofacial", "and", "limb", "dyskinesia", "in", "the", "acute", "period", "after", "the", "first", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "22791547_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "22791547_5_Ent3", "role": "Treatment_Drug", "text": "methylphenidate", "start": 4, "end": 5}, {"entity_id": "22791547_5_Ent0", "role": "Subject", "text": "the second reported case", "start": 20, "end": 24}, {"entity_id": "22791547_5_Ent1", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 27, "end": 31}, {"entity_id": "22791547_5_Ent2", "role": "Treatment", "text": "methylphenidate", "start": 40, "end": 41}, {"entity_id": "22791547_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "22791547_5_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22791547_5_Ent0", "text": "the second reported case", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22791547_5_Ent1", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "22791547_5_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "22791547_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "228648_1", "wnd_id": "228648_1_1", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ) .", "tokens": ["Prenatal", "cytomegalovirus", "(", "CMV", ")", "infection", "associated", "with", "severe", "brain", "damage", "was", "detected", "in", "an", "infant", "whose", "mother", "had", "been", "treated", "with", "prednisolone", "and", "azathioprine", "for", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "."], "event_mentions": [{"id": "228648_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "228648_1_Ent2", "role": "Effect", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "start": 0, "end": 11}, {"entity_id": "228648_1_Ent0", "role": "Subject", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "start": 14, "end": 32}, {"entity_id": "228648_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 15, "end": 16}, {"entity_id": "228648_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 22, "end": 25}, {"entity_id": "228648_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 24, "end": 25}, {"entity_id": "228648_1_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "228648_1_Ent2", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "228648_1_Ent0", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "228648_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "228648_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "228648_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "228648_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2302898_1", "wnd_id": "2302898_1_1", "text": "Diazepam use by pregnant women can be associated with a later presentation of withdrawal symptoms in the neonate than that induced by the use of other drugs .", "tokens": ["Diazepam", "use", "by", "pregnant", "women", "can", "be", "associated", "with", "a", "later", "presentation", "of", "withdrawal", "symptoms", "in", "the", "neonate", "than", "that", "induced", "by", "the", "use", "of", "other", "drugs", "."], "event_mentions": [{"id": "2302898_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2302898_1_Ent3", "role": "Treatment", "text": "Diazepam", "start": 0, "end": 1}, {"entity_id": "2302898_1_Ent4", "role": "Treatment_Drug", "text": "Diazepam", "start": 0, "end": 1}, {"entity_id": "2302898_1_Ent2", "role": "Effect", "text": "later presentation of withdrawal symptoms in the neonate", "start": 10, "end": 18}, {"entity_id": "2302898_1_Ent0", "role": "Subject", "text": "neonate", "start": 17, "end": 18}, {"entity_id": "2302898_1_Ent1", "role": "Subject_Age", "text": "neonate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "2302898_1_Ent3", "text": "Diazepam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2302898_1_Ent4", "text": "Diazepam", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2302898_1_Ent2", "text": "later presentation of withdrawal symptoms in the neonate", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "2302898_1_Ent0", "text": "neonate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2302898_1_Ent1", "text": "neonate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2305654_2", "wnd_id": "2305654_2_1", "text": "We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening pseudo - obstruction of the colon , a variant of adynamic ileus , while being treated with intravenous nimodipine .", "tokens": ["We", "report", "on", "a", "patient", "with", "subarachnoid", "haemorrhage", "who", "developed", "an", "acute", "life", "-", "threatening", "pseudo", "-", "obstruction", "of", "the", "colon", ",", "a", "variant", "of", "adynamic", "ileus", ",", "while", "being", "treated", "with", "intravenous", "nimodipine", "."], "event_mentions": [{"id": "2305654_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "2305654_2_Ent0", "role": "Subject", "text": "patient with subarachnoid haemorrhage", "start": 4, "end": 8}, {"entity_id": "2305654_2_Ent3", "role": "Treatment_Disorder", "text": "subarachnoid haemorrhage", "start": 6, "end": 8}, {"entity_id": "2305654_2_Ent1", "role": "Effect", "text": "pseudo - obstruction of the colon", "start": 15, "end": 21}, {"entity_id": "2305654_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 32, "end": 33}, {"entity_id": "2305654_2_Ent2", "role": "Treatment", "text": "intravenous nimodipine", "start": 32, "end": 34}, {"entity_id": "2305654_2_Ent4", "role": "Treatment_Drug", "text": "nimodipine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "2305654_2_Ent0", "text": "patient with subarachnoid haemorrhage", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "2305654_2_Ent3", "text": "subarachnoid haemorrhage", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2305654_2_Ent1", "text": "pseudo - obstruction of the colon", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "2305654_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "2305654_2_Ent2", "text": "intravenous nimodipine", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "2305654_2_Ent4", "text": "nimodipine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "2316232_2", "wnd_id": "2316232_2_1", "text": "Symptomatic hypoglycemia secondary to a glipizide - trimethoprim / sulfamethoxazole drug interaction .", "tokens": ["Symptomatic", "hypoglycemia", "secondary", "to", "a", "glipizide", "-", "trimethoprim", "/", "sulfamethoxazole", "drug", "interaction", "."], "event_mentions": [{"id": "2316232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "2316232_2_Ent0", "role": "Effect", "text": "Symptomatic hypoglycemia", "start": 0, "end": 2}, {"entity_id": "2316232_2_Ent2", "role": "Treatment_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent5", "role": "Combination_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent1", "role": "Treatment", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "start": 5, "end": 12}, {"entity_id": "2316232_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}, {"entity_id": "2316232_2_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2316232_2_Ent0", "text": "Symptomatic hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2316232_2_Ent2", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent5", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent1", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "2316232_2_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2316232_2_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2320800_6", "wnd_id": "2320800_6_1", "text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .", "tokens": ["Ifosfamide", "is", "a", "known", "nephrotoxic", "drug", "with", "demonstrated", "tubulopathies", "."], "event_mentions": [{"id": "2320800_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "2320800_6_Ent1", "role": "Treatment", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent2", "role": "Treatment_Drug", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent0", "role": "Effect", "text": "tubulopathies", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2320800_6_Ent1", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent2", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent0", "text": "tubulopathies", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2327115_1", "wnd_id": "2327115_1_1", "text": "Ciprofloxacin is one drug that has been reported to cause interstitial nephritis .", "tokens": ["Ciprofloxacin", "is", "one", "drug", "that", "has", "been", "reported", "to", "cause", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_1_Ent1", "role": "Treatment", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent2", "role": "Treatment_Drug", "text": "Ciprofloxacin", "start": 0, "end": 1}, {"entity_id": "2327115_1_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_1_Ent1", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent2", "text": "Ciprofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2327115_1_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2327115_3", "wnd_id": "2327115_3_1", "text": "Suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["Suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2327115_3_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 1, "end": 2}, {"entity_id": "2327115_3_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2327115_3_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2327115_3_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "2332596_2", "wnd_id": "2332596_2_1", "text": "Severe hepatotoxicity from phenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "tokens": ["Severe", "hepatotoxicity", "from", "phenobarbital", "occurred", "in", "an", "infant", "boy", "who", "had", "a", "complicated", "illness", "with", "chronic", "bilateral", "subdural", "hematomas", "and", "sepsis", "."], "event_mentions": [{"id": "2332596_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "2332596_2_Ent3", "role": "Effect", "text": "Severe hepatotoxicity", "start": 0, "end": 2}, {"entity_id": "2332596_2_Ent4", "role": "Treatment", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "2332596_2_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "2332596_2_Ent0", "role": "Subject", "text": "an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "start": 6, "end": 22}, {"entity_id": "2332596_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 7, "end": 8}, {"entity_id": "2332596_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "2332596_2_Ent6", "role": "Treatment_Disorder", "text": "chronic bilateral subdural hematomas", "start": 15, "end": 19}, {"entity_id": "2332596_2_Ent7", "role": "Treatment_Disorder", "text": "sepsis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2332596_2_Ent3", "text": "Severe hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2332596_2_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2332596_2_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2332596_2_Ent0", "text": "an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis .", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "2332596_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2332596_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2332596_2_Ent6", "text": "chronic bilateral subdural hematomas", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2332596_2_Ent7", "text": "sepsis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "23552010_1", "wnd_id": "23552010_1_1", "text": "Acute angioedema response to topical 5 - fluorouracil therapy .", "tokens": ["Acute", "angioedema", "response", "to", "topical", "5", "-", "fluorouracil", "therapy", "."], "event_mentions": [{"id": "23552010_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 2, "end": 3}, "arguments": [{"entity_id": "23552010_1_Ent0", "role": "Effect", "text": "angioedema", "start": 1, "end": 2}, {"entity_id": "23552010_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "23552010_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "23552010_1_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "23552010_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "23552010_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "23774436_2", "wnd_id": "23774436_2_1", "text": "A 4 - month regimen of gatifloxacin with rifampin , isoniazid , and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial ( OFLOTUB ) .", "tokens": ["A", "4", "-", "month", "regimen", "of", "gatifloxacin", "with", "rifampin", ",", "isoniazid", ",", "and", "pyrazinamide", "is", "being", "evaluated", "for", "the", "treatment", "of", "tuberculosis", "in", "a", "phase", "3", "randomized", "controlled", "trial", "(", "OFLOTUB", ")", "."], "event_mentions": [{"id": "23774436_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 19, "end": 20}, "arguments": [{"entity_id": "23774436_2_Ent0", "role": "Treatment", "text": "gatifloxacin", "start": 6, "end": 7}, {"entity_id": "23774436_2_Ent4", "role": "Treatment_Drug", "text": "gatifloxacin", "start": 6, "end": 7}, {"entity_id": "23774436_2_Ent1", "role": "Treatment", "text": "rifampin", "start": 8, "end": 9}, {"entity_id": "23774436_2_Ent5", "role": "Treatment_Drug", "text": "rifampin", "start": 8, "end": 9}, {"entity_id": "23774436_2_Ent2", "role": "Treatment", "text": "isoniazid", "start": 10, "end": 11}, {"entity_id": "23774436_2_Ent6", "role": "Treatment_Drug", "text": "isoniazid", "start": 10, "end": 11}, {"entity_id": "23774436_2_Ent9", "role": "Combination_Drug", "text": "isoniazid", "start": 10, "end": 11}, {"entity_id": "23774436_2_Ent3", "role": "Treatment", "text": "pyrazinamide", "start": 13, "end": 14}, {"entity_id": "23774436_2_Ent7", "role": "Treatment_Drug", "text": "pyrazinamide", "start": 13, "end": 14}, {"entity_id": "23774436_2_Ent10", "role": "Combination_Drug", "text": "pyrazinamide", "start": 13, "end": 14}, {"entity_id": "23774436_2_Ent8", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "23774436_2_Ent0", "text": "gatifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23774436_2_Ent4", "text": "gatifloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23774436_2_Ent1", "text": "rifampin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "23774436_2_Ent5", "text": "rifampin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "23774436_2_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23774436_2_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23774436_2_Ent9", "text": "isoniazid", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23774436_2_Ent3", "text": "pyrazinamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "23774436_2_Ent7", "text": "pyrazinamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "23774436_2_Ent10", "text": "pyrazinamide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "23774436_2_Ent8", "text": "tuberculosis", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "23970584_3", "wnd_id": "23970584_3_1", "text": "A 55 - year - old HIV - positive African woman received a single epidural triamcinolone injection for pain relief of postherpetic neuralgia .", "tokens": ["A", "55", "-", "year", "-", "old", "HIV", "-", "positive", "African", "woman", "received", "a", "single", "epidural", "triamcinolone", "injection", "for", "pain", "relief", "of", "postherpetic", "neuralgia", "."], "event_mentions": [{"id": "23970584_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 11, "end": 12}, "arguments": [{"entity_id": "23970584_3_Ent0", "role": "Subject", "text": "A 55 - year - old HIV - positive African woman", "start": 0, "end": 11}, {"entity_id": "23970584_3_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 1, "end": 6}, {"entity_id": "23970584_3_Ent2", "role": "Subject_Disorder", "text": "HIV", "start": 6, "end": 7}, {"entity_id": "23970584_3_Ent3", "role": "Subject_Race", "text": "African", "start": 9, "end": 10}, {"entity_id": "23970584_3_Ent4", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "23970584_3_Ent5", "role": "Treatment", "text": "a single epidural triamcinolone injection", "start": 12, "end": 17}, {"entity_id": "23970584_3_Ent7", "role": "Treatment_Drug", "text": "triamcinolone", "start": 15, "end": 16}, {"entity_id": "23970584_3_Ent8", "role": "Treatment_Route", "text": "injection", "start": 16, "end": 17}, {"entity_id": "23970584_3_Ent6", "role": "Treatment_Disorder", "text": "pain relief of postherpetic neuralgia", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "23970584_3_Ent0", "text": "A 55 - year - old HIV - positive African woman", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "23970584_3_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "23970584_3_Ent2", "text": "HIV", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_3_Ent3", "text": "African", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "23970584_3_Ent4", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23970584_3_Ent5", "text": "a single epidural triamcinolone injection", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23970584_3_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23970584_3_Ent8", "text": "injection", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "23970584_3_Ent6", "text": "pain relief of postherpetic neuralgia", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "2417800_2", "wnd_id": "2417800_2_1", "text": "Autopsy findings were consistent with bleomycin and oxygen - induced pulmonary damage .", "tokens": ["Autopsy", "findings", "were", "consistent", "with", "bleomycin", "and", "oxygen", "-", "induced", "pulmonary", "damage", "."], "event_mentions": [{"id": "2417800_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2417800_2_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "2417800_2_Ent5", "role": "Combination_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "2417800_2_Ent1", "role": "Treatment", "text": "bleomycin and oxygen", "start": 5, "end": 8}, {"entity_id": "2417800_2_Ent2", "role": "Treatment_Drug", "text": "oxygen", "start": 7, "end": 8}, {"entity_id": "2417800_2_Ent4", "role": "Combination_Drug", "text": "oxygen", "start": 7, "end": 8}, {"entity_id": "2417800_2_Ent0", "role": "Effect", "text": "pulmonary damage", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2417800_2_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2417800_2_Ent5", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2417800_2_Ent1", "text": "bleomycin and oxygen", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2417800_2_Ent2", "text": "oxygen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2417800_2_Ent4", "text": "oxygen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2417800_2_Ent0", "text": "pulmonary damage", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2429270_3", "wnd_id": "2429270_3_1", "text": "In addition , the tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after procainamide .", "tokens": ["In", "addition", ",", "the", "tachycardia", "persisted", "and", "was", "repeatedly", "spontaneously", "reinitiated", "for", "prolonged", "periods", "after", "procainamide", "."], "event_mentions": [{"id": "2429270_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "2429270_3_Ent0", "role": "Effect", "text": "tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods", "start": 4, "end": 14}, {"entity_id": "2429270_3_Ent1", "role": "Treatment", "text": "procainamide", "start": 15, "end": 16}, {"entity_id": "2429270_3_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2429270_3_Ent0", "text": "tachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "2429270_3_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2429270_3_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "24429012_2", "wnd_id": "24429012_2_1", "text": "A case report of a sharp rise in International Normalized Ratio ( INR ) values during a patient 's concomitant use of warfarin and the antineoplastic agent vismodegib is presented .", "tokens": ["A", "case", "report", "of", "a", "sharp", "rise", "in", "International", "Normalized", "Ratio", "(", "INR", ")", "values", "during", "a", "patient", "'s", "concomitant", "use", "of", "warfarin", "and", "the", "antineoplastic", "agent", "vismodegib", "is", "presented", "."], "event_mentions": [{"id": "24429012_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 15, "end": 16}, "arguments": [{"entity_id": "24429012_2_Ent1", "role": "Effect", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "start": 4, "end": 15}, {"entity_id": "24429012_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "24429012_2_Ent2", "role": "Treatment", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "start": 19, "end": 28}, {"entity_id": "24429012_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 22, "end": 23}, {"entity_id": "24429012_2_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 27, "end": 28}, {"entity_id": "24429012_2_Ent6", "role": "Combination_Drug", "text": "vismodegib", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24429012_2_Ent1", "text": "a sharp rise in International Normalized Ratio ( INR ) values", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "24429012_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "24429012_2_Ent2", "text": "concomitant use of warfarin and the antineoplastic agent vismodegib", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "24429012_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "24429012_2_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24429012_2_Ent6", "text": "vismodegib", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "24429012_9", "wnd_id": "24429012_9_1", "text": "Since its introduction in 2012 , vismodegib has been implicated as a possible factor in seven reports of patient deaths .", "tokens": ["Since", "its", "introduction", "in", "2012", ",", "vismodegib", "has", "been", "implicated", "as", "a", "possible", "factor", "in", "seven", "reports", "of", "patient", "deaths", "."], "event_mentions": [{"id": "24429012_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 9, "end": 10}, "arguments": [{"entity_id": "24429012_9_Ent3", "role": "Treatment", "text": "vismodegib", "start": 6, "end": 7}, {"entity_id": "24429012_9_Ent4", "role": "Treatment_Drug", "text": "vismodegib", "start": 6, "end": 7}, {"entity_id": "24429012_9_Ent1", "role": "Subject_Population", "text": "seven", "start": 15, "end": 16}, {"entity_id": "24429012_9_Ent0", "role": "Subject", "text": "seven reports of patient", "start": 15, "end": 19}, {"entity_id": "24429012_9_Ent2", "role": "Effect", "text": "deaths", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "24429012_9_Ent3", "text": "vismodegib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "24429012_9_Ent4", "text": "vismodegib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "24429012_9_Ent1", "text": "seven", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "24429012_9_Ent0", "text": "seven reports of patient", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "24429012_9_Ent2", "text": "deaths", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "2442958_3", "wnd_id": "2442958_3_1", "text": "This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( PDES ) for prostatic cancer .", "tokens": ["This", "paper", "reports", "an", "autopsy", "case", "of", "a", "78", "-", "year", "-", "old", "male", "with", "multiple", "nodules", "in", "the", "liver", "developed", "after", "long", "-", "termed", "administration", "of", "phosphate", "diethylstilbestrol", "(", "PDES", ")", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2442958_3_Ent0", "role": "Subject", "text": "an autopsy case of a 78 - year - old male", "start": 3, "end": 14}, {"entity_id": "2442958_3_Ent2", "role": "Subject_Age", "text": "78 - year - old", "start": 8, "end": 13}, {"entity_id": "2442958_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "2442958_3_Ent4", "role": "Effect", "text": "multiple nodules in the liver", "start": 15, "end": 20}, {"entity_id": "2442958_3_Ent7", "role": "Treatment_Drug", "text": "phosphate diethylstilbestrol", "start": 27, "end": 29}, {"entity_id": "2442958_3_Ent5", "role": "Treatment", "text": "phosphate diethylstilbestrol ( PDES )", "start": 27, "end": 32}, {"entity_id": "2442958_3_Ent1", "role": "Subject", "text": "prostatic cancer", "start": 33, "end": 35}, {"entity_id": "2442958_3_Ent6", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2442958_3_Ent0", "text": "an autopsy case of a 78 - year - old male", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "2442958_3_Ent2", "text": "78 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2442958_3_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2442958_3_Ent4", "text": "multiple nodules in the liver", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "2442958_3_Ent7", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "2442958_3_Ent5", "text": "phosphate diethylstilbestrol ( PDES )", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "2442958_3_Ent1", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "2442958_3_Ent6", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2461837_1", "wnd_id": "2461837_1_1", "text": "Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin , this is , to our knowledge , the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients .", "tokens": ["Although", "this", "type", "of", "hyperpigmentation", "has", "been", "previously", "seen", "in", "patients", "with", "cancer", "who", "are", "receiving", "bleomycin", ",", "this", "is", ",", "to", "our", "knowledge", ",", "the", "first", "reported", "case", "of", "bleomycin", "-", "induced", "hyperpigmentation", "in", "an", "AIDS", "patient", "and", "should", "be", "added", "to", "the", "growing", "list", "of", "cutaneous", "eruptions", "seen", "in", "these", "patients", "."], "event_mentions": [{"id": "2461837_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 32, "end": 33}, "arguments": [{"entity_id": "2461837_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 30, "end": 31}, {"entity_id": "2461837_1_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 30, "end": 31}, {"entity_id": "2461837_1_Ent1", "role": "Effect", "text": "hyperpigmentation", "start": 33, "end": 34}, {"entity_id": "2461837_1_Ent0", "role": "Subject", "text": "an AIDS patient", "start": 35, "end": 38}, {"entity_id": "2461837_1_Ent4", "role": "Treatment_Disorder", "text": "AIDS", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "2461837_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "2461837_1_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "2461837_1_Ent1", "text": "hyperpigmentation", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "2461837_1_Ent0", "text": "an AIDS patient", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2461837_1_Ent4", "text": "AIDS", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "24791374_2", "wnd_id": "24791374_2_1", "text": "We describe a rare case of severe drug - drug interaction between propafenone and mirtazapine leading to propafenone toxicity .", "tokens": ["We", "describe", "a", "rare", "case", "of", "severe", "drug", "-", "drug", "interaction", "between", "propafenone", "and", "mirtazapine", "leading", "to", "propafenone", "toxicity", "."], "event_mentions": [{"id": "24791374_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 15, "end": 16}, "arguments": [{"entity_id": "24791374_2_Ent0", "role": "Subject", "text": "a rare case", "start": 2, "end": 5}, {"entity_id": "24791374_2_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "24791374_2_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 12, "end": 13}, {"entity_id": "24791374_2_Ent2", "role": "Treatment", "text": "propafenone and mirtazapine", "start": 12, "end": 15}, {"entity_id": "24791374_2_Ent4", "role": "Treatment_Drug", "text": "mirtazapine", "start": 14, "end": 15}, {"entity_id": "24791374_2_Ent6", "role": "Combination_Drug", "text": "mirtazapine", "start": 14, "end": 15}, {"entity_id": "24791374_2_Ent1", "role": "Effect", "text": "propafenone toxicity", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "24791374_2_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "24791374_2_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24791374_2_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24791374_2_Ent2", "text": "propafenone and mirtazapine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "24791374_2_Ent4", "text": "mirtazapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24791374_2_Ent6", "text": "mirtazapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "24791374_2_Ent1", "text": "propafenone toxicity", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "24791374_6", "wnd_id": "24791374_6_1", "text": "Propafenone is an established class IC antiarrhythmic drug commonly used in the treatment of atrial fibrillation .", "tokens": ["Propafenone", "is", "an", "established", "class", "IC", "antiarrhythmic", "drug", "commonly", "used", "in", "the", "treatment", "of", "atrial", "fibrillation", "."], "event_mentions": [{"id": "24791374_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "24791374_6_Ent0", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent2", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "24791374_6_Ent1", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "24791374_6_Ent0", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent2", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24791374_6_Ent1", "text": "atrial fibrillation", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "24801976_1", "wnd_id": "24801976_1_1", "text": "Pain management discussion forum : serious interaction among frequently used drugs for chronic pain .", "tokens": ["Pain", "management", "discussion", "forum", ":", "serious", "interaction", "among", "frequently", "used", "drugs", "for", "chronic", "pain", "."], "event_mentions": [{"id": "24801976_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "among", "start": 7, "end": 8}, "arguments": [{"entity_id": "24801976_1_Ent0", "role": "Effect", "text": "serious interaction", "start": 5, "end": 7}, {"entity_id": "24801976_1_Ent3", "role": "Treatment_Freq", "text": "frequently", "start": 8, "end": 9}, {"entity_id": "24801976_1_Ent1", "role": "Treatment", "text": "frequently used drugs", "start": 8, "end": 11}, {"entity_id": "24801976_1_Ent4", "role": "Treatment_Drug", "text": "drugs", "start": 10, "end": 11}, {"entity_id": "24801976_1_Ent2", "role": "Treatment_Disorder", "text": "chronic pain", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "24801976_1_Ent0", "text": "serious interaction", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24801976_1_Ent3", "text": "frequently", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "24801976_1_Ent1", "text": "frequently used drugs", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24801976_1_Ent4", "text": "drugs", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24801976_1_Ent2", "text": "chronic pain", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "2483959_4", "wnd_id": "2483959_4_1", "text": "While the mechanism of dextran - associated renal failure remains unsolved , plasma exchange seems to be effective therapy .", "tokens": ["While", "the", "mechanism", "of", "dextran", "-", "associated", "renal", "failure", "remains", "unsolved", ",", "plasma", "exchange", "seems", "to", "be", "effective", "therapy", "."], "event_mentions": [{"id": "2483959_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "2483959_4_Ent1", "role": "Treatment", "text": "dextran", "start": 4, "end": 5}, {"entity_id": "2483959_4_Ent2", "role": "Treatment_Drug", "text": "dextran", "start": 4, "end": 5}, {"entity_id": "2483959_4_Ent0", "role": "Effect", "text": "renal failure", "start": 7, "end": 9}]}, {"id": "2483959_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 17, "end": 18}, "arguments": [{"entity_id": "2483959_4_Ent5", "role": "Treatment_Disorder", "text": "dextran - associated renal failure", "start": 4, "end": 9}, {"entity_id": "2483959_4_Ent3", "role": "Treatment", "text": "plasma exchange", "start": 12, "end": 14}, {"entity_id": "2483959_4_Ent4", "role": "Treatment_Drug", "text": "plasma exchange", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2483959_4_Ent1", "text": "dextran", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2483959_4_Ent2", "text": "dextran", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2483959_4_Ent5", "text": "dextran - associated renal failure", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2483959_4_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2483959_4_Ent3", "text": "plasma exchange", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2483959_4_Ent4", "text": "plasma exchange", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "24846936_2", "wnd_id": "24846936_2_1", "text": "This is the first report of a fatal outcome from serotonin toxicity , precipitated by an interaction between methylene blue and venlafaxine .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "fatal", "outcome", "from", "serotonin", "toxicity", ",", "precipitated", "by", "an", "interaction", "between", "methylene", "blue", "and", "venlafaxine", "."], "event_mentions": [{"id": "24846936_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 13, "end": 14}, "arguments": [{"entity_id": "24846936_2_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 10, "end": 12}, {"entity_id": "24846936_2_Ent1", "role": "Treatment", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent3", "role": "Treatment_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent5", "role": "Combination_Drug", "text": "methylene blue", "start": 18, "end": 20}, {"entity_id": "24846936_2_Ent2", "role": "Treatment", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "24846936_2_Ent6", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "24846936_2_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "24846936_2_Ent1", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent3", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent5", "text": "methylene blue", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "24846936_2_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "24846936_2_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "24927617_1", "wnd_id": "24927617_1_1", "text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .", "tokens": ["Rhabdomyolysis", "in", "a", "hepatitis", "C", "virus", "infected", "patient", "treated", "with", "telaprevir", "and", "simvastatin", "."], "event_mentions": [{"id": "24927617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "24927617_1_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "24927617_1_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C virus", "start": 3, "end": 6}, {"entity_id": "24927617_1_Ent0", "role": "Subject", "text": "hepatitis C virus infected patient", "start": 3, "end": 8}, {"entity_id": "24927617_1_Ent3", "role": "Treatment_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent6", "role": "Combination_Drug", "text": "telaprevir", "start": 10, "end": 11}, {"entity_id": "24927617_1_Ent2", "role": "Treatment", "text": "telaprevir and simvastatin", "start": 10, "end": 13}, {"entity_id": "24927617_1_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 12, "end": 13}, {"entity_id": "24927617_1_Ent7", "role": "Combination_Drug", "text": "simvastatin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "24927617_1_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24927617_1_Ent5", "text": "hepatitis C virus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24927617_1_Ent0", "text": "hepatitis C virus infected patient", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "24927617_1_Ent3", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent6", "text": "telaprevir", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24927617_1_Ent2", "text": "telaprevir and simvastatin", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "24927617_1_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "24927617_1_Ent7", "text": "simvastatin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "2523364_2", "wnd_id": "2523364_2_1", "text": "A 57 - year - old man developed morphea while taking bromocriptine .", "tokens": ["A", "57", "-", "year", "-", "old", "man", "developed", "morphea", "while", "taking", "bromocriptine", "."], "event_mentions": [{"id": "2523364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 10, "end": 11}, "arguments": [{"entity_id": "2523364_2_Ent0", "role": "Subject", "text": "A 57 - year - old man", "start": 0, "end": 7}, {"entity_id": "2523364_2_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "2523364_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "2523364_2_Ent3", "role": "Effect", "text": "morphea", "start": 8, "end": 9}, {"entity_id": "2523364_2_Ent4", "role": "Treatment", "text": "bromocriptine", "start": 11, "end": 12}, {"entity_id": "2523364_2_Ent5", "role": "Treatment_Drug", "text": "bromocriptine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "2523364_2_Ent0", "text": "A 57 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2523364_2_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2523364_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2523364_2_Ent3", "text": "morphea", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2523364_2_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2523364_2_Ent5", "text": "bromocriptine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "25295553_2", "wnd_id": "25295553_2_1", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties and is approved for treatment of generalized anxiety disorder .", "tokens": ["Pregabalin", "is", "an", "antiepileptic", "drug", "with", "anti", "-", "anxiety", "properties", "and", "is", "approved", "for", "treatment", "of", "generalized", "anxiety", "disorder", "."], "event_mentions": [{"id": "25295553_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "25295553_2_Ent1", "role": "Treatment_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_2_Ent0", "role": "Treatment", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties", "start": 0, "end": 10}, {"entity_id": "25295553_2_Ent2", "role": "Treatment_Disorder", "text": "generalized anxiety disorder", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "25295553_2_Ent1", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_2_Ent0", "text": "Pregabalin is an antiepileptic drug with anti - anxiety properties", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "25295553_2_Ent2", "text": "generalized anxiety disorder", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "25295553_4", "wnd_id": "25295553_4_1", "text": "Pregabalin was added to clozapine in 2 patients with schizophrenia , who both suffered from severe anxiety symptoms .", "tokens": ["Pregabalin", "was", "added", "to", "clozapine", "in", "2", "patients", "with", "schizophrenia", ",", "who", "both", "suffered", "from", "severe", "anxiety", "symptoms", "."], "event_mentions": [{"id": "25295553_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "25295553_4_Ent4", "role": "Treatment_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_4_Ent7", "role": "Combination_Drug", "text": "Pregabalin", "start": 0, "end": 1}, {"entity_id": "25295553_4_Ent2", "role": "Treatment", "text": "Pregabalin was added to clozapine", "start": 0, "end": 5}, {"entity_id": "25295553_4_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "25295553_4_Ent8", "role": "Combination_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "25295553_4_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "25295553_4_Ent0", "role": "Subject", "text": "2 patients with schizophrenia , who both suffered from severe anxiety symptoms", "start": 6, "end": 18}, {"entity_id": "25295553_4_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 9, "end": 10}, {"entity_id": "25295553_4_Ent5", "role": "Treatment_Disorder", "text": "anxiety symptoms", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "25295553_4_Ent4", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_4_Ent7", "text": "Pregabalin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_4_Ent2", "text": "Pregabalin was added to clozapine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "25295553_4_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "25295553_4_Ent8", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "25295553_4_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25295553_4_Ent0", "text": "2 patients with schizophrenia , who both suffered from severe anxiety symptoms", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "25295553_4_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25295553_4_Ent5", "text": "anxiety symptoms", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "2532694_2", "wnd_id": "2532694_2_1", "text": "Dapsone - induced erythroderma with Beau 's lines .", "tokens": ["Dapsone", "-", "induced", "erythroderma", "with", "Beau", "'s", "lines", "."], "event_mentions": [{"id": "2532694_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2532694_2_Ent1", "role": "Treatment", "text": "Dapsone", "start": 0, "end": 1}, {"entity_id": "2532694_2_Ent2", "role": "Treatment_Drug", "text": "Dapsone", "start": 0, "end": 1}, {"entity_id": "2532694_2_Ent0", "role": "Effect", "text": "erythroderma with Beau 's lines", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "2532694_2_Ent1", "text": "Dapsone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2532694_2_Ent2", "text": "Dapsone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2532694_2_Ent0", "text": "erythroderma with Beau 's lines", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "2549018_4", "wnd_id": "2549018_4_1", "text": "The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced \" jitteriness \" may be identical .", "tokens": ["The", "authors", "suggest", "that", "fluoxetine", "-", "induced", "akathisia", "may", "be", "caused", "by", "serotonergically", "mediated", "inhibition", "of", "dopaminergic", "neurotransmission", "and", "that", "the", "pathophysiology", "of", "fluoxetine", "-", "induced", "akathisia", "and", "tricyclic", "antidepressant", "-", "induced", "\"", "jitteriness", "\"", "may", "be", "identical", "."], "event_mentions": [{"id": "2549018_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "2549018_4_Ent1", "role": "Treatment", "text": "fluoxetine", "start": 4, "end": 5}, {"entity_id": "2549018_4_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 4, "end": 5}, {"entity_id": "2549018_4_Ent0", "role": "Effect", "text": "akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission", "start": 7, "end": 18}]}], "entity_mentions": [{"id": "2549018_4_Ent1", "text": "fluoxetine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2549018_4_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2549018_4_Ent0", "text": "akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission", "entity_type": "Entity", "start": 7, "end": 18}], "lang": "en"}
{"doc_id": "25515435_1", "wnd_id": "25515435_1_1", "text": "Warfarin and boceprevir interaction causing subtherapeutic international normalized ratio : a case report .", "tokens": ["Warfarin", "and", "boceprevir", "interaction", "causing", "subtherapeutic", "international", "normalized", "ratio", ":", "a", "case", "report", "."], "event_mentions": [{"id": "25515435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 4, "end": 5}, "arguments": [{"entity_id": "25515435_1_Ent1", "role": "Treatment", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent3", "role": "Treatment_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent5", "role": "Combination_Drug", "text": "Warfarin", "start": 0, "end": 1}, {"entity_id": "25515435_1_Ent2", "role": "Treatment", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent4", "role": "Treatment_Drug", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent6", "role": "Combination_Drug", "text": "boceprevir", "start": 2, "end": 3}, {"entity_id": "25515435_1_Ent0", "role": "Effect", "text": "subtherapeutic international normalized ratio", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "25515435_1_Ent1", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent3", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent5", "text": "Warfarin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25515435_1_Ent2", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent4", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent6", "text": "boceprevir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "25515435_1_Ent0", "text": "subtherapeutic international normalized ratio", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "25538343_1", "wnd_id": "25538343_1_1", "text": "Duloxetine - induced hyponatremia in an elderly patient treated with thiazide diuretics .", "tokens": ["Duloxetine", "-", "induced", "hyponatremia", "in", "an", "elderly", "patient", "treated", "with", "thiazide", "diuretics", "."], "event_mentions": [{"id": "25538343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "25538343_1_Ent3", "role": "Treatment", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent4", "role": "Treatment_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent7", "role": "Combination_Drug", "text": "Duloxetine", "start": 0, "end": 1}, {"entity_id": "25538343_1_Ent2", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}, {"entity_id": "25538343_1_Ent0", "role": "Subject", "text": "an elderly patient treated with thiazide diuretics", "start": 5, "end": 12}, {"entity_id": "25538343_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "25538343_1_Ent5", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}, {"entity_id": "25538343_1_Ent6", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "25538343_1_Ent3", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent4", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent7", "text": "Duloxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_1_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "25538343_1_Ent0", "text": "an elderly patient treated with thiazide diuretics", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "25538343_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25538343_1_Ent5", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "25538343_1_Ent6", "text": "thiazide diuretics", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "25540831_4", "wnd_id": "25540831_4_1", "text": "We report a typical case of transient serotonin syndrome secondary to tramadol - Citalopram combination .", "tokens": ["We", "report", "a", "typical", "case", "of", "transient", "serotonin", "syndrome", "secondary", "to", "tramadol", "-", "Citalopram", "combination", "."], "event_mentions": [{"id": "25540831_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "25540831_4_Ent0", "role": "Subject", "text": "a typical case", "start": 2, "end": 5}, {"entity_id": "25540831_4_Ent1", "role": "Effect", "text": "transient serotonin syndrome", "start": 6, "end": 9}, {"entity_id": "25540831_4_Ent3", "role": "Treatment_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent5", "role": "Combination_Drug", "text": "tramadol", "start": 11, "end": 12}, {"entity_id": "25540831_4_Ent2", "role": "Treatment", "text": "tramadol - Citalopram combination", "start": 11, "end": 15}, {"entity_id": "25540831_4_Ent4", "role": "Treatment_Drug", "text": "Citalopram", "start": 13, "end": 14}, {"entity_id": "25540831_4_Ent6", "role": "Combination_Drug", "text": "Citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "25540831_4_Ent0", "text": "a typical case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "25540831_4_Ent1", "text": "transient serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "25540831_4_Ent3", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent5", "text": "tramadol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25540831_4_Ent2", "text": "tramadol - Citalopram combination", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "25540831_4_Ent4", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "25540831_4_Ent6", "text": "Citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2616440_2", "wnd_id": "2616440_2_1", "text": "We report the case of a patient with multiple myeloma who developed acute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous cyclophosphamide .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "multiple", "myeloma", "who", "developed", "acute", "life", "-", "threatening", "water", "intoxication", "following", "treatment", "with", "oral", "indomethacin", "and", "low", "dose", "intravenous", "cyclophosphamide", "."], "event_mentions": [{"id": "2616440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "2616440_2_Ent0", "role": "Subject", "text": "a patient with multiple myeloma", "start": 5, "end": 10}, {"entity_id": "2616440_2_Ent3", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 8, "end": 10}, {"entity_id": "2616440_2_Ent1", "role": "Effect", "text": "acute life - threatening water intoxication", "start": 12, "end": 18}, {"entity_id": "2616440_2_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "2616440_2_Ent2", "role": "Treatment", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "start": 21, "end": 28}, {"entity_id": "2616440_2_Ent6", "role": "Treatment_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent9", "role": "Combination_Drug", "text": "indomethacin", "start": 22, "end": 23}, {"entity_id": "2616440_2_Ent8", "role": "Treatment_Dosage", "text": "low dose", "start": 24, "end": 26}, {"entity_id": "2616440_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 26, "end": 27}, {"entity_id": "2616440_2_Ent7", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "2616440_2_Ent10", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "2616440_2_Ent0", "text": "a patient with multiple myeloma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "2616440_2_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2616440_2_Ent1", "text": "acute life - threatening water intoxication", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2616440_2_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2616440_2_Ent2", "text": "oral indomethacin and low dose intravenous cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "2616440_2_Ent6", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent9", "text": "indomethacin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2616440_2_Ent8", "text": "low dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "2616440_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "2616440_2_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "2616440_2_Ent10", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "2719905_1", "wnd_id": "2719905_1_1", "text": "Long lasting respiratory depression induced by morphine - 6 - glucuronide ?", "tokens": ["Long", "lasting", "respiratory", "depression", "induced", "by", "morphine", "-", "6", "-", "glucuronide", "?"], "event_mentions": [{"id": "2719905_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2719905_1_Ent0", "role": "Effect", "text": "Long lasting respiratory depression", "start": 0, "end": 4}, {"entity_id": "2719905_1_Ent1", "role": "Treatment", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}, {"entity_id": "2719905_1_Ent2", "role": "Treatment_Drug", "text": "morphine - 6 - glucuronide", "start": 6, "end": 11}]}], "entity_mentions": [{"id": "2719905_1_Ent0", "text": "Long lasting respiratory depression", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2719905_1_Ent1", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "2719905_1_Ent2", "text": "morphine - 6 - glucuronide", "entity_type": "Entity", "start": 6, "end": 11}], "lang": "en"}
{"doc_id": "2738729_1", "wnd_id": "2738729_1_1", "text": "We present the first case of WES in an infant born to a mother taking haloperidol during her pregnancy .", "tokens": ["We", "present", "the", "first", "case", "of", "WES", "in", "an", "infant", "born", "to", "a", "mother", "taking", "haloperidol", "during", "her", "pregnancy", "."], "event_mentions": [{"id": "2738729_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "case", "start": 4, "end": 5}, "arguments": [{"entity_id": "2738729_1_Ent2", "role": "Effect", "text": "WES", "start": 6, "end": 7}, {"entity_id": "2738729_1_Ent0", "role": "Subject", "text": "an infant born to a mother", "start": 8, "end": 14}, {"entity_id": "2738729_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 9, "end": 10}, {"entity_id": "2738729_1_Ent3", "role": "Treatment", "text": "haloperidol", "start": 15, "end": 16}, {"entity_id": "2738729_1_Ent4", "role": "Treatment_Drug", "text": "haloperidol", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2738729_1_Ent2", "text": "WES", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2738729_1_Ent0", "text": "an infant born to a mother", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "2738729_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2738729_1_Ent3", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2738729_1_Ent4", "text": "haloperidol", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2768785_2", "wnd_id": "2768785_2_1", "text": "We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy .", "tokens": ["We", "present", "two", "children", "with", "acute", "lymphocytic", "leukemia", "who", "developed", "leukoencephalopathy", "following", "administration", "of", "a", "combination", "of", "intravenous", "ara", "=", "C", "and", "methotrexate", "during", "the", "consolidation", "phase", "of", "chemotherapy", "."], "event_mentions": [{"id": "2768785_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "2768785_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "2768785_2_Ent0", "role": "Subject", "text": "two children with acute lymphocytic leukemia", "start": 2, "end": 8}, {"entity_id": "2768785_2_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "2768785_2_Ent5", "role": "Treatment_Disorder", "text": "acute lymphocytic leukemia", "start": 5, "end": 8}, {"entity_id": "2768785_2_Ent3", "role": "Effect", "text": "leukoencephalopathy", "start": 10, "end": 11}, {"entity_id": "2768785_2_Ent4", "role": "Treatment", "text": "administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy", "start": 12, "end": 29}, {"entity_id": "2768785_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 17, "end": 18}, {"entity_id": "2768785_2_Ent7", "role": "Treatment_Drug", "text": "ara = C", "start": 18, "end": 21}, {"entity_id": "2768785_2_Ent9", "role": "Combination_Drug", "text": "ara = C", "start": 18, "end": 21}, {"entity_id": "2768785_2_Ent8", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "2768785_2_Ent10", "role": "Combination_Drug", "text": "methotrexate", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "2768785_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2768785_2_Ent0", "text": "two children with acute lymphocytic leukemia", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "2768785_2_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2768785_2_Ent5", "text": "acute lymphocytic leukemia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "2768785_2_Ent3", "text": "leukoencephalopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2768785_2_Ent4", "text": "administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "2768785_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2768785_2_Ent7", "text": "ara = C", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "2768785_2_Ent9", "text": "ara = C", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "2768785_2_Ent8", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2768785_2_Ent10", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "2863342_1", "wnd_id": "2863342_1_1", "text": "Sulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease ( IBD ) in adults .", "tokens": ["Sulfasalazine", "has", "been", "associated", "with", "bronchopulmonary", "complications", "of", "inflammatory", "bowel", "disease", "(", "IBD", ")", "in", "adults", "."], "event_mentions": [{"id": "2863342_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2863342_1_Ent3", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2863342_1_Ent4", "role": "Treatment_Drug", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2863342_1_Ent2", "role": "Effect", "text": "bronchopulmonary complications of inflammatory bowel disease ( IBD )", "start": 5, "end": 14}, {"entity_id": "2863342_1_Ent0", "role": "Subject", "text": "adults", "start": 15, "end": 16}, {"entity_id": "2863342_1_Ent1", "role": "Subject_Age", "text": "adults", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2863342_1_Ent3", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2863342_1_Ent4", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2863342_1_Ent2", "text": "bronchopulmonary complications of inflammatory bowel disease ( IBD )", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "2863342_1_Ent0", "text": "adults", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2863342_1_Ent1", "text": "adults", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2894766_1", "wnd_id": "2894766_1_1", "text": "It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .", "tokens": ["It", "is", "suggested", "that", "the", "patient", "had", "sulfasalazine", "-", "induced", "lupus", ",", "which", "manifested", "with", "serositis", "and", "pulmonary", "parenchymal", "involvement", "in", "the", "absence", "of", "joint", "symptoms", "."], "event_mentions": [{"id": "2894766_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2894766_1_Ent1", "role": "Treatment", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent2", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 7, "end": 8}, {"entity_id": "2894766_1_Ent0", "role": "Effect", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "start": 10, "end": 26}]}], "entity_mentions": [{"id": "2894766_1_Ent1", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent2", "text": "sulfasalazine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2894766_1_Ent0", "text": "lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms", "entity_type": "Entity", "start": 10, "end": 26}], "lang": "en"}
{"doc_id": "2894766_3", "wnd_id": "2894766_3_1", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .", "tokens": ["Pneumonitis", ",", "bilateral", "pleural", "effusions", ",", "echocardiographic", "evidence", "of", "cardiac", "tamponade", ",", "and", "positive", "autoantibodies", "developed", "in", "a", "43", "-", "year", "-", "old", "man", ",", "who", "was", "receiving", "long", "-", "term", "sulfasalazine", "therapy", "for", "chronic", "ulcerative", "colitis", "."], "event_mentions": [{"id": "2894766_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2894766_3_Ent3", "role": "Effect", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "start": 0, "end": 15}, {"entity_id": "2894766_3_Ent0", "role": "Subject", "text": "a 43 - year - old man", "start": 17, "end": 24}, {"entity_id": "2894766_3_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 18, "end": 23}, {"entity_id": "2894766_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}, {"entity_id": "2894766_3_Ent4", "role": "Treatment", "text": "long - term sulfasalazine", "start": 28, "end": 32}, {"entity_id": "2894766_3_Ent6", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 31, "end": 32}, {"entity_id": "2894766_3_Ent5", "role": "Treatment_Disorder", "text": "chronic ulcerative colitis", "start": 34, "end": 37}]}], "entity_mentions": [{"id": "2894766_3_Ent3", "text": "Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2894766_3_Ent0", "text": "a 43 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "2894766_3_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "2894766_3_Ent2", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2894766_3_Ent4", "text": "long - term sulfasalazine", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "2894766_3_Ent6", "text": "sulfasalazine", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2894766_3_Ent5", "text": "chronic ulcerative colitis", "entity_type": "Entity", "start": 34, "end": 37}], "lang": "en"}
{"doc_id": "2894766_4", "wnd_id": "2894766_4_1", "text": "Sulfasalazine - induced lupus erythematosus .", "tokens": ["Sulfasalazine", "-", "induced", "lupus", "erythematosus", "."], "event_mentions": [{"id": "2894766_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2894766_4_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2894766_4_Ent2", "role": "Treatment_Drug", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "2894766_4_Ent0", "role": "Effect", "text": "lupus erythematosus", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "2894766_4_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2894766_4_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2894766_4_Ent0", "text": "lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2924444_1", "wnd_id": "2924444_1_1", "text": "Acute myocardial infarction due to coronary spasm associated with L - thyroxine therapy .", "tokens": ["Acute", "myocardial", "infarction", "due", "to", "coronary", "spasm", "associated", "with", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2924444_1_Ent0", "role": "Effect", "text": "Acute myocardial infarction due to coronary spasm", "start": 0, "end": 7}, {"entity_id": "2924444_1_Ent1", "role": "Treatment", "text": "L - thyroxine", "start": 9, "end": 12}, {"entity_id": "2924444_1_Ent2", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2924444_1_Ent0", "text": "Acute myocardial infarction due to coronary spasm", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2924444_1_Ent1", "text": "L - thyroxine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2924444_1_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "2924444_8", "wnd_id": "2924444_8_1", "text": "We believe this is the first report of myocardial infarction due to coronary spasm , demonstrated by angiography associated with L - thyroxine therapy .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "myocardial", "infarction", "due", "to", "coronary", "spasm", ",", "demonstrated", "by", "angiography", "associated", "with", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "2924444_8_Ent0", "role": "Effect", "text": "myocardial infarction", "start": 8, "end": 10}, {"entity_id": "2924444_8_Ent1", "role": "Effect", "text": "coronary spasm", "start": 12, "end": 14}, {"entity_id": "2924444_8_Ent2", "role": "Treatment", "text": "L - thyroxine", "start": 20, "end": 23}, {"entity_id": "2924444_8_Ent3", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "2924444_8_Ent0", "text": "myocardial infarction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2924444_8_Ent1", "text": "coronary spasm", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2924444_8_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "2924444_8_Ent3", "text": "L - thyroxine", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "2935070_2", "wnd_id": "2935070_2_1", "text": "However , there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis .", "tokens": ["However", ",", "there", "are", "few", "reports", "in", "the", "literature", "of", "ampicillin", "as", "a", "cause", "of", "acute", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2935070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "2935070_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent0", "role": "Effect", "text": "acute interstitial nephritis", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2935070_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent0", "text": "acute interstitial nephritis", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2935070_4", "wnd_id": "2935070_4_1", "text": "The diagnosis was based on the rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy finding , following the administration of ampicillin .", "tokens": ["The", "diagnosis", "was", "based", "on", "the", "rapid", "onset", "of", "renal", "failure", ",", "presence", "of", "eosinophilia", ",", "skin", "rash", ",", "and", "characteristic", "renal", "biopsy", "finding", ",", "following", "the", "administration", "of", "ampicillin", "."], "event_mentions": [{"id": "2935070_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 25, "end": 26}, "arguments": [{"entity_id": "2935070_4_Ent0", "role": "Effect", "text": "rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy", "start": 6, "end": 23}, {"entity_id": "2935070_4_Ent1", "role": "Treatment", "text": "ampicillin", "start": 29, "end": 30}, {"entity_id": "2935070_4_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "2935070_4_Ent0", "text": "rapid onset of renal failure , presence of eosinophilia , skin rash , and characteristic renal biopsy", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "2935070_4_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "2935070_4_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "3067748_2", "wnd_id": "3067748_2_1", "text": "Histological examination of the dacryolith suggested its derivation from breakdown products of adrenaline .", "tokens": ["Histological", "examination", "of", "the", "dacryolith", "suggested", "its", "derivation", "from", "breakdown", "products", "of", "adrenaline", "."], "event_mentions": [{"id": "3067748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 8, "end": 9}, "arguments": [{"entity_id": "3067748_2_Ent0", "role": "Effect", "text": "dacryolith", "start": 4, "end": 5}, {"entity_id": "3067748_2_Ent1", "role": "Treatment", "text": "breakdown products of adrenaline", "start": 9, "end": 13}, {"entity_id": "3067748_2_Ent2", "role": "Treatment_Drug", "text": "adrenaline", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "3067748_2_Ent0", "text": "dacryolith", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3067748_2_Ent1", "text": "breakdown products of adrenaline", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3067748_2_Ent2", "text": "adrenaline", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3084231_2", "wnd_id": "3084231_2_1", "text": "Reversible valproic acid - induced dementia : a case report .", "tokens": ["Reversible", "valproic", "acid", "-", "induced", "dementia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "3084231_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3084231_2_Ent1", "role": "Treatment", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 1, "end": 3}, {"entity_id": "3084231_2_Ent0", "role": "Effect", "text": "dementia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3084231_2_Ent1", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3084231_2_Ent0", "text": "dementia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3115809_1", "wnd_id": "3115809_1_1", "text": "A patient developed optic neuropathy while being treated with isoniazid and ethambutol .", "tokens": ["A", "patient", "developed", "optic", "neuropathy", "while", "being", "treated", "with", "isoniazid", "and", "ethambutol", "."], "event_mentions": [{"id": "3115809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "3115809_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3115809_1_Ent1", "role": "Effect", "text": "optic neuropathy", "start": 3, "end": 5}, {"entity_id": "3115809_1_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent5", "role": "Combination_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "3115809_1_Ent2", "role": "Treatment", "text": "isoniazid and ethambutol", "start": 9, "end": 12}, {"entity_id": "3115809_1_Ent4", "role": "Treatment_Drug", "text": "ethambutol", "start": 11, "end": 12}, {"entity_id": "3115809_1_Ent6", "role": "Combination_Drug", "text": "ethambutol", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3115809_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3115809_1_Ent1", "text": "optic neuropathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3115809_1_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent5", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3115809_1_Ent2", "text": "isoniazid and ethambutol", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3115809_1_Ent4", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3115809_1_Ent6", "text": "ethambutol", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3115809_2", "wnd_id": "3115809_2_1", "text": "A well - recognized complication of ethambutol use is optic neuropathy , but the potential ocular toxicity of isoniazid is often overlooked .", "tokens": ["A", "well", "-", "recognized", "complication", "of", "ethambutol", "use", "is", "optic", "neuropathy", ",", "but", "the", "potential", "ocular", "toxicity", "of", "isoniazid", "is", "often", "overlooked", "."], "event_mentions": [{"id": "3115809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "3115809_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 6, "end": 7}, {"entity_id": "3115809_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 6, "end": 7}, {"entity_id": "3115809_2_Ent0", "role": "Effect", "text": "optic neuropathy", "start": 9, "end": 11}]}, {"id": "3115809_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 16, "end": 17}, "arguments": [{"entity_id": "3115809_2_Ent3", "role": "Effect", "text": "ocular toxicity", "start": 15, "end": 17}, {"entity_id": "3115809_2_Ent4", "role": "Treatment", "text": "isoniazid", "start": 18, "end": 19}, {"entity_id": "3115809_2_Ent5", "role": "Treatment_Drug", "text": "isoniazid", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "3115809_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3115809_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3115809_2_Ent0", "text": "optic neuropathy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3115809_2_Ent3", "text": "ocular toxicity", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3115809_2_Ent4", "text": "isoniazid", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3115809_2_Ent5", "text": "isoniazid", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "3124393_1", "wnd_id": "3124393_1_1", "text": "A woman 38 - year - old , suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal Depo - Medrol , developed a spastic paraparesis at the lower limbs .", "tokens": ["A", "woman", "38", "-", "year", "-", "old", ",", "suffering", "for", "about", "ten", "years", "from", "multiple", "sclerosis", "and", "treated", "with", "repeated", "therapy", "cycles", "of", "intrathecal", "Depo", "-", "Medrol", ",", "developed", "a", "spastic", "paraparesis", "at", "the", "lower", "limbs", "."], "event_mentions": [{"id": "3124393_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "3124393_1_Ent0", "role": "Subject", "text": "A woman 38 - year - old , suffering for about ten years from multiple sclerosis", "start": 0, "end": 16}, {"entity_id": "3124393_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "3124393_1_Ent2", "role": "Subject_Age", "text": "38 - year - old", "start": 2, "end": 7}, {"entity_id": "3124393_1_Ent6", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 14, "end": 16}, {"entity_id": "3124393_1_Ent8", "role": "Treatment_Freq", "text": "repeated", "start": 19, "end": 20}, {"entity_id": "3124393_1_Ent4", "role": "Treatment", "text": "repeated therapy cycles of intrathecal Depo - Medrol", "start": 19, "end": 27}, {"entity_id": "3124393_1_Ent7", "role": "Treatment_Route", "text": "intrathecal", "start": 23, "end": 24}, {"entity_id": "3124393_1_Ent5", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 24, "end": 27}, {"entity_id": "3124393_1_Ent3", "role": "Effect", "text": "a spastic paraparesis at the lower limbs", "start": 29, "end": 36}]}], "entity_mentions": [{"id": "3124393_1_Ent0", "text": "A woman 38 - year - old , suffering for about ten years from multiple sclerosis", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "3124393_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3124393_1_Ent2", "text": "38 - year - old", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "3124393_1_Ent6", "text": "multiple sclerosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3124393_1_Ent8", "text": "repeated", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3124393_1_Ent4", "text": "repeated therapy cycles of intrathecal Depo - Medrol", "entity_type": "Entity", "start": 19, "end": 27}, {"id": "3124393_1_Ent7", "text": "intrathecal", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3124393_1_Ent5", "text": "Depo - Medrol", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "3124393_1_Ent3", "text": "a spastic paraparesis at the lower limbs", "entity_type": "Entity", "start": 29, "end": 36}], "lang": "en"}
{"doc_id": "3124393_2", "wnd_id": "3124393_2_1", "text": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol .", "tokens": ["Calcification", "and", "ossification", "of", "the", "spinal", "arachnoid", "after", "intrathecal", "administration", "of", "Depo", "-", "Medrol", "."], "event_mentions": [{"id": "3124393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3124393_2_Ent0", "role": "Effect", "text": "Calcification and ossification of the spinal arachnoid", "start": 0, "end": 7}, {"entity_id": "3124393_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "3124393_2_Ent1", "role": "Treatment", "text": "intrathecal administration of Depo - Medrol", "start": 8, "end": 14}, {"entity_id": "3124393_2_Ent3", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "3124393_2_Ent0", "text": "Calcification and ossification of the spinal arachnoid", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3124393_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3124393_2_Ent1", "text": "intrathecal administration of Depo - Medrol", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3124393_2_Ent3", "text": "Depo - Medrol", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "3136101_1", "wnd_id": "3136101_1_1", "text": "Hyperkalemia as a late side effect of prolonged adrenocorticotropic hormone therapy for infantile spasms .", "tokens": ["Hyperkalemia", "as", "a", "late", "side", "effect", "of", "prolonged", "adrenocorticotropic", "hormone", "therapy", "for", "infantile", "spasms", "."], "event_mentions": [{"id": "3136101_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "3136101_1_Ent2", "role": "Effect", "text": "Hyperkalemia", "start": 0, "end": 1}, {"entity_id": "3136101_1_Ent3", "role": "Treatment", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent5", "role": "Treatment_Drug", "text": "adrenocorticotropic hormone", "start": 8, "end": 10}, {"entity_id": "3136101_1_Ent1", "role": "Subject_Age", "text": "infantile", "start": 12, "end": 13}, {"entity_id": "3136101_1_Ent0", "role": "Subject", "text": "infantile spasms", "start": 12, "end": 14}, {"entity_id": "3136101_1_Ent4", "role": "Treatment_Disorder", "text": "infantile spasms", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3136101_1_Ent2", "text": "Hyperkalemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3136101_1_Ent3", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent5", "text": "adrenocorticotropic hormone", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3136101_1_Ent1", "text": "infantile", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3136101_1_Ent0", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3136101_1_Ent4", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3156465_1", "wnd_id": "3156465_1_1", "text": "Isotretinoin , a drug used for the treatment of acne , has been shown to have teratogenic effects .", "tokens": ["Isotretinoin", ",", "a", "drug", "used", "for", "the", "treatment", "of", "acne", ",", "has", "been", "shown", "to", "have", "teratogenic", "effects", "."], "event_mentions": [{"id": "3156465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 15, "end": 16}, "arguments": [{"entity_id": "3156465_1_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_1_Ent3", "role": "Treatment_Disorder", "text": "acne", "start": 9, "end": 10}, {"entity_id": "3156465_1_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3156465_1_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_1_Ent3", "text": "acne", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3156465_1_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3195622_3", "wnd_id": "3195622_3_1", "text": "Case report : dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider .", "tokens": ["Case", "report", ":", "dapsone", "hypersensitivity", "syndrome", "associated", "with", "treatment", "of", "the", "bite", "of", "a", "brown", "recluse", "spider", "."], "event_mentions": [{"id": "3195622_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "3195622_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3195622_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3259776_2", "wnd_id": "3259776_2_1", "text": "Thrombo - embolic complication after streptokinase therapy of pulmonary emboli .", "tokens": ["Thrombo", "-", "embolic", "complication", "after", "streptokinase", "therapy", "of", "pulmonary", "emboli", "."], "event_mentions": [{"id": "3259776_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3259776_2_Ent0", "role": "Effect", "text": "Thrombo - embolic complication", "start": 0, "end": 4}, {"entity_id": "3259776_2_Ent1", "role": "Treatment", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent3", "role": "Treatment_Disorder", "text": "pulmonary emboli .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "3259776_2_Ent0", "text": "Thrombo - embolic complication", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3259776_2_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent3", "text": "pulmonary emboli .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "3301251_2", "wnd_id": "3301251_2_1", "text": "Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity .", "tokens": ["Hepatotoxicity", "associated", "with", "choline", "magnesium", "trisalicylate", ":", "case", "report", "and", "review", "of", "salicylate", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "3301251_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "3301251_2_Ent1", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "3301251_2_Ent2", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent3", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent0", "role": "Subject", "text": "case", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3301251_2_Ent1", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_2_Ent2", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent3", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent0", "text": "case", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3301251_3", "wnd_id": "3301251_3_1", "text": "Salicylate - induced hepatotoxicity is reviewed .", "tokens": ["Salicylate", "-", "induced", "hepatotoxicity", "is", "reviewed", "."], "event_mentions": [{"id": "3301251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3301251_3_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent2", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3301251_3_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent2", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3301251_4", "wnd_id": "3301251_4_1", "text": "They continued to rise for five more days before salicylate hepatotoxicity was suspected .", "tokens": ["They", "continued", "to", "rise", "for", "five", "more", "days", "before", "salicylate", "hepatotoxicity", "was", "suspected", "."], "event_mentions": [{"id": "3301251_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 12, "end": 13}, "arguments": [{"entity_id": "3301251_4_Ent1", "role": "Treatment", "text": "salicylate", "start": 9, "end": 10}, {"entity_id": "3301251_4_Ent2", "role": "Treatment_Drug", "text": "salicylate", "start": 9, "end": 10}, {"entity_id": "3301251_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3301251_4_Ent1", "text": "salicylate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_4_Ent2", "text": "salicylate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3335488_1", "wnd_id": "3335488_1_1", "text": "The observations suggest that testicular swelling and pain are side effects of desipramine .", "tokens": ["The", "observations", "suggest", "that", "testicular", "swelling", "and", "pain", "are", "side", "effects", "of", "desipramine", "."], "event_mentions": [{"id": "3335488_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 9, "end": 11}, "arguments": [{"entity_id": "3335488_1_Ent0", "role": "Effect", "text": "testicular swelling and pain", "start": 4, "end": 8}, {"entity_id": "3335488_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 12, "end": 13}, {"entity_id": "3335488_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "3335488_1_Ent0", "text": "testicular swelling and pain", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3335488_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3335488_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3365032_1", "wnd_id": "3365032_1_1", "text": "A patient is presented with typical hyperthyroidism , who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day ) .", "tokens": ["A", "patient", "is", "presented", "with", "typical", "hyperthyroidism", ",", "who", "developed", "a", "severe", "proximal", "muscle", "weakness", "and", "a", "raised", "creatine", "phosphokinase", "after", "treatment", "for", "hyperthyroidism", "with", "propylthiouracil", "(", "100", "mg", "orally", ",", "three", "times", "a", "day", ")", "."], "event_mentions": [{"id": "3365032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "3365032_1_Ent0", "role": "Subject", "text": "A patient is presented with typical hyperthyroidism", "start": 0, "end": 7}, {"entity_id": "3365032_1_Ent4", "role": "Treatment_Disorder", "text": "typical hyperthyroidism", "start": 5, "end": 7}, {"entity_id": "3365032_1_Ent1", "role": "Effect", "text": "severe proximal muscle weakness and a raised creatine phosphokinase", "start": 11, "end": 20}, {"entity_id": "3365032_1_Ent2", "role": "Treatment", "text": "treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day )", "start": 21, "end": 36}, {"entity_id": "3365032_1_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 23, "end": 24}, {"entity_id": "3365032_1_Ent5", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 25, "end": 26}, {"entity_id": "3365032_1_Ent6", "role": "Treatment_Dosage", "text": "100 mg", "start": 27, "end": 29}, {"entity_id": "3365032_1_Ent7", "role": "Treatment_Route", "text": "orally", "start": 29, "end": 30}, {"entity_id": "3365032_1_Ent8", "role": "Treatment_Freq", "text": "three times a day", "start": 31, "end": 35}]}], "entity_mentions": [{"id": "3365032_1_Ent0", "text": "A patient is presented with typical hyperthyroidism", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3365032_1_Ent4", "text": "typical hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3365032_1_Ent1", "text": "severe proximal muscle weakness and a raised creatine phosphokinase", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "3365032_1_Ent2", "text": "treatment for hyperthyroidism with propylthiouracil ( 100 mg orally , three times a day )", "entity_type": "Entity", "start": 21, "end": 36}, {"id": "3365032_1_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3365032_1_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3365032_1_Ent6", "text": "100 mg", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "3365032_1_Ent7", "text": "orally", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "3365032_1_Ent8", "text": "three times a day", "entity_type": "Entity", "start": 31, "end": 35}], "lang": "en"}
{"doc_id": "3379435_3", "wnd_id": "3379435_3_1", "text": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate .", "tokens": ["Three", "senile", "patients", "developed", "fatal", "acute", "encephalopathy", "while", "receiving", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3379435_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "3379435_3_Ent0", "role": "Subject", "text": "Three senile patients", "start": 0, "end": 3}, {"entity_id": "3379435_3_Ent2", "role": "Subject_Age", "text": "senile", "start": 1, "end": 2}, {"entity_id": "3379435_3_Ent3", "role": "Effect", "text": "encephalopathy", "start": 6, "end": 7}, {"entity_id": "3379435_3_Ent4", "role": "Treatment", "text": "calcium hopantenate", "start": 9, "end": 11}, {"entity_id": "3379435_3_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3379435_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3379435_3_Ent0", "text": "Three senile patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3379435_3_Ent2", "text": "senile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3379435_3_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3379435_3_Ent4", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3379435_3_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3397227_1", "wnd_id": "3397227_1_1", "text": "Anhedonic ejaculation with desipramine .", "tokens": ["Anhedonic", "ejaculation", "with", "desipramine", "."], "event_mentions": [{"id": "3397227_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "3397227_1_Ent0", "role": "Effect", "text": "Anhedonic ejaculation", "start": 0, "end": 2}, {"entity_id": "3397227_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 3, "end": 4}, {"entity_id": "3397227_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3397227_1_Ent0", "text": "Anhedonic ejaculation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3397227_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3397227_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3397227_2", "wnd_id": "3397227_2_1", "text": "We report two patients with anhedonic ejaculation ( ejaculation without orgasm ) associated with initiation of treatment with desipramine .", "tokens": ["We", "report", "two", "patients", "with", "anhedonic", "ejaculation", "(", "ejaculation", "without", "orgasm", ")", "associated", "with", "initiation", "of", "treatment", "with", "desipramine", "."], "event_mentions": [{"id": "3397227_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "3397227_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "3397227_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "3397227_2_Ent2", "role": "Effect", "text": "anhedonic ejaculation ( ejaculation without orgasm )", "start": 5, "end": 12}, {"entity_id": "3397227_2_Ent3", "role": "Treatment", "text": "desipramine", "start": 18, "end": 19}, {"entity_id": "3397227_2_Ent4", "role": "Treatment_Drug", "text": "desipramine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "3397227_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3397227_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3397227_2_Ent2", "text": "anhedonic ejaculation ( ejaculation without orgasm )", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "3397227_2_Ent3", "text": "desipramine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3397227_2_Ent4", "text": "desipramine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "3405528_1", "wnd_id": "3405528_1_1", "text": "A case of halothane induced hepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity .", "tokens": ["A", "case", "of", "halothane", "induced", "hepatitis", "is", "reported", "in", "a", "middle", "aged", "woman", "who", "underwent", "gastric", "surgery", "for", "morbid", "obesity", "."], "event_mentions": [{"id": "3405528_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3405528_1_Ent4", "role": "Treatment", "text": "halothane", "start": 3, "end": 4}, {"entity_id": "3405528_1_Ent6", "role": "Treatment_Drug", "text": "halothane", "start": 3, "end": 4}, {"entity_id": "3405528_1_Ent3", "role": "Effect", "text": "hepatitis", "start": 5, "end": 6}, {"entity_id": "3405528_1_Ent0", "role": "Subject", "text": "a middle aged woman", "start": 9, "end": 13}, {"entity_id": "3405528_1_Ent1", "role": "Subject_Age", "text": "middle aged", "start": 10, "end": 12}, {"entity_id": "3405528_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "3405528_1_Ent5", "role": "Treatment", "text": "gastric surgery for morbid obesity", "start": 15, "end": 20}, {"entity_id": "3405528_1_Ent7", "role": "Treatment_Disorder", "text": "morbid obesity", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "3405528_1_Ent4", "text": "halothane", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3405528_1_Ent6", "text": "halothane", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3405528_1_Ent3", "text": "hepatitis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3405528_1_Ent0", "text": "a middle aged woman", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3405528_1_Ent1", "text": "middle aged", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3405528_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3405528_1_Ent5", "text": "gastric surgery for morbid obesity", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "3405528_1_Ent7", "text": "morbid obesity", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "3438585_6", "wnd_id": "3438585_6_1", "text": "This case supports the view that in gold - induced pneumonitis a prolonged treatment with corticosteroids may be necessary , as lung function continued to improve .", "tokens": ["This", "case", "supports", "the", "view", "that", "in", "gold", "-", "induced", "pneumonitis", "a", "prolonged", "treatment", "with", "corticosteroids", "may", "be", "necessary", ",", "as", "lung", "function", "continued", "to", "improve", "."], "event_mentions": [{"id": "3438585_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "as", "start": 20, "end": 21}, "arguments": [{"entity_id": "3438585_6_Ent1", "role": "Treatment_Disorder", "text": "in gold - induced pneumonitis", "start": 6, "end": 11}, {"entity_id": "3438585_6_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 7, "end": 8}, {"entity_id": "3438585_6_Ent0", "role": "Treatment", "text": "a prolonged treatment with corticosteroids", "start": 11, "end": 16}, {"entity_id": "3438585_6_Ent3", "role": "Treatment_Drug", "text": "corticosteroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3438585_6_Ent1", "text": "in gold - induced pneumonitis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3438585_6_Ent2", "text": "gold", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3438585_6_Ent0", "text": "a prolonged treatment with corticosteroids", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "3438585_6_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3465489_1", "wnd_id": "3465489_1_1", "text": "Pharmacokinetic determinants of 6 - mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia .", "tokens": ["Pharmacokinetic", "determinants", "of", "6", "-", "mercaptopurine", "myelotoxicity", "and", "therapeutic", "failure", "in", "children", "with", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "3465489_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "3465489_1_Ent3", "role": "Treatment", "text": "6 - mercaptopurine", "start": 3, "end": 6}, {"entity_id": "3465489_1_Ent4", "role": "Treatment_Drug", "text": "6 - mercaptopurine", "start": 3, "end": 6}, {"entity_id": "3465489_1_Ent2", "role": "Effect", "text": "myelotoxicity and therapeutic failure", "start": 6, "end": 10}, {"entity_id": "3465489_1_Ent1", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}, {"entity_id": "3465489_1_Ent0", "role": "Subject", "text": "children with acute lymphoblastic leukemia", "start": 11, "end": 16}, {"entity_id": "3465489_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "3465489_1_Ent3", "text": "6 - mercaptopurine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3465489_1_Ent4", "text": "6 - mercaptopurine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3465489_1_Ent2", "text": "myelotoxicity and therapeutic failure", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3465489_1_Ent1", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3465489_1_Ent0", "text": "children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "3465489_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "3470173_4", "wnd_id": "3470173_4_1", "text": "The neurotoxicity seen with HDARAC is dose - related and has occurred in up to 60 percent of treated patients .", "tokens": ["The", "neurotoxicity", "seen", "with", "HDARAC", "is", "dose", "-", "related", "and", "has", "occurred", "in", "up", "to", "60", "percent", "of", "treated", "patients", "."], "event_mentions": [{"id": "3470173_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 8, "end": 9}, "arguments": [{"entity_id": "3470173_4_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "3470173_4_Ent3", "role": "Treatment", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent4", "role": "Treatment_Drug", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent1", "role": "Subject_Population", "text": "60 percent", "start": 15, "end": 17}, {"entity_id": "3470173_4_Ent0", "role": "Subject", "text": "60 percent of treated patients", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "3470173_4_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3470173_4_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent4", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent1", "text": "60 percent", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3470173_4_Ent0", "text": "60 percent of treated patients", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "3485422_1", "wnd_id": "3485422_1_1", "text": "Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin .", "tokens": ["Macular", "infarction", "after", "endophthalmitis", "treated", "with", "vitrectomy", "and", "intravitreal", "gentamicin", "."], "event_mentions": [{"id": "3485422_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3485422_1_Ent0", "role": "Effect", "text": "Macular infarction", "start": 0, "end": 2}, {"entity_id": "3485422_1_Ent2", "role": "Treatment_Disorder", "text": "endophthalmitis", "start": 3, "end": 4}, {"entity_id": "3485422_1_Ent1", "role": "Treatment", "text": "endophthalmitis treated with vitrectomy and intravitreal gentamicin", "start": 3, "end": 10}, {"entity_id": "3485422_1_Ent3", "role": "Treatment_Route", "text": "vitrectomy and intravitreal", "start": 6, "end": 9}, {"entity_id": "3485422_1_Ent4", "role": "Treatment_Drug", "text": "gentamicin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "3485422_1_Ent0", "text": "Macular infarction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3485422_1_Ent2", "text": "endophthalmitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3485422_1_Ent1", "text": "endophthalmitis treated with vitrectomy and intravitreal gentamicin", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "3485422_1_Ent3", "text": "vitrectomy and intravitreal", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3485422_1_Ent4", "text": "gentamicin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "3485422_2", "wnd_id": "3485422_2_1", "text": "We are concerned that the macular lesion was a retinal toxic effect of gentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug .", "tokens": ["We", "are", "concerned", "that", "the", "macular", "lesion", "was", "a", "retinal", "toxic", "effect", "of", "gentamicin", "because", "of", "the", "recent", "description", "of", "similar", "lesions", "occurring", "after", "the", "inadvertent", "intraocular", "injection", "of", "massive", "doses", "of", "this", "drug", "."], "event_mentions": [{"id": "3485422_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 12, "end": 13}, "arguments": [{"entity_id": "3485422_2_Ent0", "role": "Effect", "text": "macular lesion", "start": 5, "end": 7}, {"entity_id": "3485422_2_Ent1", "role": "Treatment", "text": "gentamicin", "start": 13, "end": 14}, {"entity_id": "3485422_2_Ent2", "role": "Treatment_Drug", "text": "gentamicin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3485422_2_Ent0", "text": "macular lesion", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3485422_2_Ent1", "text": "gentamicin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3485422_2_Ent2", "text": "gentamicin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3508194_1", "wnd_id": "3508194_1_1", "text": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion .", "tokens": ["Transient", "leucopenia", "and", "thrombocytopenia", "associated", "with", "sodium", "nitroprusside", "infusion", "."], "event_mentions": [{"id": "3508194_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "3508194_1_Ent0", "role": "Effect", "text": "Transient leucopenia and thrombocytopenia", "start": 0, "end": 4}, {"entity_id": "3508194_1_Ent3", "role": "Treatment_Drug", "text": "sodium nitroprusside", "start": 6, "end": 8}, {"entity_id": "3508194_1_Ent1", "role": "Treatment", "text": "sodium nitroprusside infusion", "start": 6, "end": 9}, {"entity_id": "3508194_1_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3508194_1_Ent0", "text": "Transient leucopenia and thrombocytopenia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3508194_1_Ent3", "text": "sodium nitroprusside", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3508194_1_Ent1", "text": "sodium nitroprusside infusion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3508194_1_Ent2", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3513544_3", "wnd_id": "3513544_3_1", "text": "With the increasing use of Cyclosporine A in transplant patients , the incidence of herpes esophagitis may increase .", "tokens": ["With", "the", "increasing", "use", "of", "Cyclosporine", "A", "in", "transplant", "patients", ",", "the", "incidence", "of", "herpes", "esophagitis", "may", "increase", "."], "event_mentions": [{"id": "3513544_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 12, "end": 13}, "arguments": [{"entity_id": "3513544_3_Ent3", "role": "Treatment", "text": "Cyclosporine A", "start": 5, "end": 7}, {"entity_id": "3513544_3_Ent4", "role": "Treatment_Drug", "text": "Cyclosporine A", "start": 5, "end": 7}, {"entity_id": "3513544_3_Ent1", "role": "Subject_Disorder", "text": "transplant", "start": 8, "end": 9}, {"entity_id": "3513544_3_Ent0", "role": "Subject", "text": "transplant patients", "start": 8, "end": 10}, {"entity_id": "3513544_3_Ent2", "role": "Effect", "text": "herpes esophagitis may increase .", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "3513544_3_Ent3", "text": "Cyclosporine A", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_3_Ent4", "text": "Cyclosporine A", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3513544_3_Ent1", "text": "transplant", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3513544_3_Ent0", "text": "transplant patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3513544_3_Ent2", "text": "herpes esophagitis may increase .", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "3558331_1", "wnd_id": "3558331_1_1", "text": "Amoxapine - induced cognitive impairment in two patients .", "tokens": ["Amoxapine", "-", "induced", "cognitive", "impairment", "in", "two", "patients", "."], "event_mentions": [{"id": "3558331_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3558331_1_Ent3", "role": "Treatment", "text": "Amoxapine", "start": 0, "end": 1}, {"entity_id": "3558331_1_Ent4", "role": "Treatment_Drug", "text": "Amoxapine", "start": 0, "end": 1}, {"entity_id": "3558331_1_Ent2", "role": "Effect", "text": "cognitive impairment", "start": 3, "end": 5}, {"entity_id": "3558331_1_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "3558331_1_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "3558331_1_Ent3", "text": "Amoxapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3558331_1_Ent4", "text": "Amoxapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3558331_1_Ent2", "text": "cognitive impairment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3558331_1_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3558331_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3569037_1", "wnd_id": "3569037_1_1", "text": "A brief review of reported cases of chloramphenicol hypersensitivity in the English - language literature , as well as possible alternative explanations in this case , are provided .", "tokens": ["A", "brief", "review", "of", "reported", "cases", "of", "chloramphenicol", "hypersensitivity", "in", "the", "English", "-", "language", "literature", ",", "as", "well", "as", "possible", "alternative", "explanations", "in", "this", "case", ",", "are", "provided", "."], "event_mentions": [{"id": "3569037_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "3569037_1_Ent1", "role": "Treatment", "text": "chloramphenicol", "start": 7, "end": 8}, {"entity_id": "3569037_1_Ent2", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 7, "end": 8}, {"entity_id": "3569037_1_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3569037_1_Ent1", "text": "chloramphenicol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3569037_1_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3569037_1_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3569037_3", "wnd_id": "3569037_3_1", "text": "Hypersensitivity reactions due to chloramphenicol are rarely reported in the literature .", "tokens": ["Hypersensitivity", "reactions", "due", "to", "chloramphenicol", "are", "rarely", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "3569037_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "3569037_3_Ent0", "role": "Effect", "text": "Hypersensitivity reactions", "start": 0, "end": 2}, {"entity_id": "3569037_3_Ent1", "role": "Treatment", "text": "chloramphenicol", "start": 4, "end": 5}, {"entity_id": "3569037_3_Ent2", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3569037_3_Ent0", "text": "Hypersensitivity reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3569037_3_Ent1", "text": "chloramphenicol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3569037_3_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3586163_2", "wnd_id": "3586163_2_1", "text": "Upper tract urothelial malignancy after cyclophosphamide therapy : a case report and literature review .", "tokens": ["Upper", "tract", "urothelial", "malignancy", "after", "cyclophosphamide", "therapy", ":", "a", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "3586163_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3586163_2_Ent0", "role": "Effect", "text": "Upper tract urothelial malignancy", "start": 0, "end": 4}, {"entity_id": "3586163_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 5, "end": 6}, {"entity_id": "3586163_2_Ent1", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "3586163_2_Ent0", "text": "Upper tract urothelial malignancy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3586163_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3586163_2_Ent1", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "3586163_3", "wnd_id": "3586163_3_1", "text": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin 's lymphoma .", "tokens": ["We", "report", "an", "unusual", "case", "of", "simultaneous", "transitional", "cell", "carcinoma", "of", "the", "renal", "pelvis", "and", "distal", "ureter", "without", "transitional", "cell", "carcinoma", "of", "the", "bladder", "occurring", "after", "chronic", "cyclophosphamide", "therapy", "for", "nonHodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "3586163_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "3586163_3_Ent0", "role": "Effect", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "start": 6, "end": 24}, {"entity_id": "3586163_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 26, "end": 27}, {"entity_id": "3586163_3_Ent1", "role": "Treatment", "text": "chronic cyclophosphamide therapy", "start": 26, "end": 29}, {"entity_id": "3586163_3_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "3586163_3_Ent3", "role": "Treatment_Disorder", "text": "nonHodgkin 's lymphoma", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "3586163_3_Ent0", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "3586163_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3586163_3_Ent1", "text": "chronic cyclophosphamide therapy", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "3586163_3_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3586163_3_Ent3", "text": "nonHodgkin 's lymphoma", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "3620420_4", "wnd_id": "3620420_4_1", "text": "We report here such a case with bilateral Mooren 's ulcer that failed to respond to local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine .", "tokens": ["We", "report", "here", "such", "a", "case", "with", "bilateral", "Mooren", "'s", "ulcer", "that", "failed", "to", "respond", "to", "local", "therapy", "with", "topical", "corticosteroids", ",", "silver", "nitrate", ",", "and", "conjunctival", "resection", ",", "as", "well", "as", "systemic", "immunosuppression", "with", "corticosteroids", ",", "cyclophosphamide", ",", "and", "azathioprine", "."], "event_mentions": [{"id": "3620420_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "respond", "start": 14, "end": 15}, "arguments": [{"entity_id": "3620420_4_Ent0", "role": "Subject", "text": "a case with bilateral Mooren 's ulcer", "start": 4, "end": 11}, {"entity_id": "3620420_4_Ent7", "role": "Treatment_Disorder", "text": "bilateral Mooren 's ulcer", "start": 7, "end": 11}, {"entity_id": "3620420_4_Ent1", "role": "Treatment", "text": "local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine", "start": 16, "end": 41}, {"entity_id": "3620420_4_Ent8", "role": "Treatment_Route", "text": "topical", "start": 19, "end": 20}, {"entity_id": "3620420_4_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "3620420_4_Ent9", "role": "Combination_Drug", "text": "corticosteroids", "start": 20, "end": 21}, {"entity_id": "3620420_4_Ent3", "role": "Treatment_Drug", "text": "silver nitrate", "start": 22, "end": 24}, {"entity_id": "3620420_4_Ent10", "role": "Combination_Drug", "text": "silver nitrate", "start": 22, "end": 24}, {"entity_id": "3620420_4_Ent4", "role": "Treatment_Drug", "text": "corticosteroids", "start": 35, "end": 36}, {"entity_id": "3620420_4_Ent11", "role": "Combination_Drug", "text": "corticosteroids", "start": 35, "end": 36}, {"entity_id": "3620420_4_Ent5", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 37, "end": 38}, {"entity_id": "3620420_4_Ent12", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 37, "end": 38}, {"entity_id": "3620420_4_Ent6", "role": "Treatment_Drug", "text": "azathioprine", "start": 40, "end": 41}, {"entity_id": "3620420_4_Ent13", "role": "Combination_Drug", "text": "azathioprine", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "3620420_4_Ent0", "text": "a case with bilateral Mooren 's ulcer", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "3620420_4_Ent7", "text": "bilateral Mooren 's ulcer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3620420_4_Ent1", "text": "local therapy with topical corticosteroids , silver nitrate , and conjunctival resection , as well as systemic immunosuppression with corticosteroids , cyclophosphamide , and azathioprine", "entity_type": "Entity", "start": 16, "end": 41}, {"id": "3620420_4_Ent8", "text": "topical", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3620420_4_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3620420_4_Ent9", "text": "corticosteroids", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3620420_4_Ent3", "text": "silver nitrate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "3620420_4_Ent10", "text": "silver nitrate", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "3620420_4_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3620420_4_Ent11", "text": "corticosteroids", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3620420_4_Ent5", "text": "cyclophosphamide", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "3620420_4_Ent12", "text": "cyclophosphamide", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "3620420_4_Ent6", "text": "azathioprine", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "3620420_4_Ent13", "text": "azathioprine", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "3677571_16", "wnd_id": "3677571_16_1", "text": "Phenytoin was discontinued after admission ; however , phenytoin 1 g i.v . was given for a tonic - clonic seizure two days after admission , after which swelling of the face and legs and pruritus developed .", "tokens": ["Phenytoin", "was", "discontinued", "after", "admission", ";", "however", ",", "phenytoin", "1", "g", "i.v", ".", "was", "given", "for", "a", "tonic", "-", "clonic", "seizure", "two", "days", "after", "admission", ",", "after", "which", "swelling", "of", "the", "face", "and", "legs", "and", "pruritus", "developed", "."], "event_mentions": [{"id": "3677571_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 36, "end": 37}, "arguments": [{"entity_id": "3677571_16_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "3677571_16_Ent1", "role": "Treatment", "text": "phenytoin 1 g i.v .", "start": 8, "end": 13}, {"entity_id": "3677571_16_Ent4", "role": "Treatment_Dosage", "text": "1 g", "start": 9, "end": 11}, {"entity_id": "3677571_16_Ent5", "role": "Treatment_Route", "text": "i.v .", "start": 11, "end": 13}, {"entity_id": "3677571_16_Ent2", "role": "Treatment_Disorder", "text": "a tonic - clonic seizure", "start": 16, "end": 21}, {"entity_id": "3677571_16_Ent0", "role": "Effect", "text": "swelling of the face and legs and pruritus", "start": 28, "end": 36}]}], "entity_mentions": [{"id": "3677571_16_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3677571_16_Ent1", "text": "phenytoin 1 g i.v .", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "3677571_16_Ent4", "text": "1 g", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3677571_16_Ent5", "text": "i.v .", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3677571_16_Ent2", "text": "a tonic - clonic seizure", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "3677571_16_Ent0", "text": "swelling of the face and legs and pruritus", "entity_type": "Entity", "start": 28, "end": 36}], "lang": "en"}
{"doc_id": "3720318_1", "wnd_id": "3720318_1_1", "text": "Noncardiogenic pulmonary edema during intrabiliary infusion of mono - octanoin .", "tokens": ["Noncardiogenic", "pulmonary", "edema", "during", "intrabiliary", "infusion", "of", "mono", "-", "octanoin", "."], "event_mentions": [{"id": "3720318_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3720318_1_Ent0", "role": "Effect", "text": "Noncardiogenic pulmonary edema", "start": 0, "end": 3}, {"entity_id": "3720318_1_Ent2", "role": "Treatment_Route", "text": "intrabiliary infusion", "start": 4, "end": 6}, {"entity_id": "3720318_1_Ent1", "role": "Treatment", "text": "intrabiliary infusion of mono - octanoin", "start": 4, "end": 10}, {"entity_id": "3720318_1_Ent3", "role": "Treatment_Drug", "text": "mono - octanoin", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "3720318_1_Ent0", "text": "Noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3720318_1_Ent2", "text": "intrabiliary infusion", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3720318_1_Ent1", "text": "intrabiliary infusion of mono - octanoin", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "3720318_1_Ent3", "text": "mono - octanoin", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "3732375_2", "wnd_id": "3732375_2_1", "text": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine .", "tokens": ["A", "case", "is", "reported", "of", "theophylline", "intoxication", "due", "to", "a", "dramatic", "decrease", "in", "theophylline", "clearance", "following", "concomitant", "administration", "of", "viloxazine", "."], "event_mentions": [{"id": "3732375_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "3732375_2_Ent0", "role": "Effect", "text": "theophylline intoxication", "start": 5, "end": 7}, {"entity_id": "3732375_2_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 13, "end": 14}, {"entity_id": "3732375_2_Ent5", "role": "Combination_Drug", "text": "theophylline", "start": 13, "end": 14}, {"entity_id": "3732375_2_Ent1", "role": "Treatment", "text": "concomitant administration of viloxazine", "start": 16, "end": 20}, {"entity_id": "3732375_2_Ent3", "role": "Treatment_Drug", "text": "viloxazine", "start": 19, "end": 20}, {"entity_id": "3732375_2_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "3732375_2_Ent0", "text": "theophylline intoxication", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3732375_2_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3732375_2_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3732375_2_Ent1", "text": "concomitant administration of viloxazine", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "3732375_2_Ent3", "text": "viloxazine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3732375_2_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "3753891_1", "wnd_id": "3753891_1_1", "text": "Acute myocardial necrosis during administration of amsacrine .", "tokens": ["Acute", "myocardial", "necrosis", "during", "administration", "of", "amsacrine", "."], "event_mentions": [{"id": "3753891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3753891_1_Ent0", "role": "Effect", "text": "Acute myocardial necrosis", "start": 0, "end": 3}, {"entity_id": "3753891_1_Ent1", "role": "Treatment", "text": "amsacrine", "start": 6, "end": 7}, {"entity_id": "3753891_1_Ent2", "role": "Treatment_Drug", "text": "amsacrine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3753891_1_Ent0", "text": "Acute myocardial necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3753891_1_Ent1", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3753891_1_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3753891_3", "wnd_id": "3753891_3_1", "text": "The authors report a case of focal myocardial necrosis , presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug , amsacrine , in a patient without coronary artery disease .", "tokens": ["The", "authors", "report", "a", "case", "of", "focal", "myocardial", "necrosis", ",", "presenting", "clinically", "as", "an", "acute", "myocardial", "infarction", "during", "the", "administration", "of", "the", "antineoplastic", "drug", ",", "amsacrine", ",", "in", "a", "patient", "without", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "3753891_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "3753891_3_Ent1", "role": "Effect", "text": "focal myocardial necrosis , presenting clinically as an acute myocardial infarction", "start": 6, "end": 17}, {"entity_id": "3753891_3_Ent2", "role": "Treatment", "text": "amsacrine", "start": 25, "end": 26}, {"entity_id": "3753891_3_Ent3", "role": "Treatment_Drug", "text": "amsacrine", "start": 25, "end": 26}, {"entity_id": "3753891_3_Ent0", "role": "Subject", "text": "a patient without coronary artery disease", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "3753891_3_Ent1", "text": "focal myocardial necrosis , presenting clinically as an acute myocardial infarction", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "3753891_3_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3753891_3_Ent3", "text": "amsacrine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3753891_3_Ent0", "text": "a patient without coronary artery disease", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "3767790_1", "wnd_id": "3767790_1_1", "text": "Duodenal ulceration : a complication of tolazoline therapy .", "tokens": ["Duodenal", "ulceration", ":", "a", "complication", "of", "tolazoline", "therapy", "."], "event_mentions": [{"id": "3767790_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "3767790_1_Ent0", "role": "Effect", "text": "Duodenal ulceration", "start": 0, "end": 2}, {"entity_id": "3767790_1_Ent1", "role": "Treatment", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "3767790_1_Ent2", "role": "Treatment_Drug", "text": "tolazoline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3767790_1_Ent0", "text": "Duodenal ulceration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3767790_1_Ent1", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3767790_1_Ent2", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3767790_2", "wnd_id": "3767790_2_1", "text": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation .", "tokens": ["Two", "patients", "who", "were", "receiving", "Tolazoline", "by", "infusion", "developed", "duodenal", "ulceration", "and", "subsequent", "intestinal", "perforation", "."], "event_mentions": [{"id": "3767790_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "3767790_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3767790_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "3767790_2_Ent3", "role": "Treatment", "text": "receiving Tolazoline by infusion", "start": 4, "end": 8}, {"entity_id": "3767790_2_Ent4", "role": "Treatment_Drug", "text": "Tolazoline", "start": 5, "end": 6}, {"entity_id": "3767790_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 7, "end": 8}, {"entity_id": "3767790_2_Ent2", "role": "Effect", "text": "duodenal ulceration and subsequent intestinal perforation", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "3767790_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3767790_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3767790_2_Ent3", "text": "receiving Tolazoline by infusion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3767790_2_Ent4", "text": "Tolazoline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3767790_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3767790_2_Ent2", "text": "duodenal ulceration and subsequent intestinal perforation", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "3899068_1", "wnd_id": "3899068_1_1", "text": "Ototoxicity as a result of cis - platinum administration is well documented .", "tokens": ["Ototoxicity", "as", "a", "result", "of", "cis", "-", "platinum", "administration", "is", "well", "documented", "."], "event_mentions": [{"id": "3899068_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 3, "end": 4}, "arguments": [{"entity_id": "3899068_1_Ent0", "role": "Effect", "text": "Ototoxicity", "start": 0, "end": 1}, {"entity_id": "3899068_1_Ent2", "role": "Treatment_Drug", "text": "cis - platinum", "start": 5, "end": 8}, {"entity_id": "3899068_1_Ent1", "role": "Treatment", "text": "cis - platinum administration", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "3899068_1_Ent0", "text": "Ototoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3899068_1_Ent2", "text": "cis - platinum", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "3899068_1_Ent1", "text": "cis - platinum administration", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "3947272_3", "wnd_id": "3947272_3_1", "text": "Myasthenic patients receiving ampicillin should be closely monitored for possible acute exacerbations .", "tokens": ["Myasthenic", "patients", "receiving", "ampicillin", "should", "be", "closely", "monitored", "for", "possible", "acute", "exacerbations", "."], "event_mentions": [{"id": "3947272_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 2, "end": 3}, "arguments": [{"entity_id": "3947272_3_Ent3", "role": "Treatment_Disorder", "text": "Myasthenic", "start": 0, "end": 1}, {"entity_id": "3947272_3_Ent0", "role": "Subject", "text": "Myasthenic patients", "start": 0, "end": 2}, {"entity_id": "3947272_3_Ent2", "role": "Treatment", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "3947272_3_Ent4", "role": "Treatment_Drug", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "3947272_3_Ent1", "role": "Effect", "text": "acute exacerbations", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "3947272_3_Ent3", "text": "Myasthenic", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_3_Ent0", "text": "Myasthenic patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3947272_3_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3947272_3_Ent4", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3947272_3_Ent1", "text": "acute exacerbations", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "3947272_4", "wnd_id": "3947272_4_1", "text": "One patient had severe temporary weakness after an ampicillin sodium challenge .", "tokens": ["One", "patient", "had", "severe", "temporary", "weakness", "after", "an", "ampicillin", "sodium", "challenge", "."], "event_mentions": [{"id": "3947272_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "3947272_4_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "3947272_4_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "3947272_4_Ent2", "role": "Effect", "text": "temporary weakness", "start": 4, "end": 6}, {"entity_id": "3947272_4_Ent3", "role": "Treatment", "text": "an ampicillin sodium challenge", "start": 7, "end": 11}, {"entity_id": "3947272_4_Ent4", "role": "Treatment_Drug", "text": "ampicillin sodium", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3947272_4_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3947272_4_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3947272_4_Ent2", "text": "temporary weakness", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3947272_4_Ent3", "text": "an ampicillin sodium challenge", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3947272_4_Ent4", "text": "ampicillin sodium", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3967536_1", "wnd_id": "3967536_1_1", "text": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension .", "tokens": ["Hypotension", "and", "sinus", "arrest", "with", "nifedipine", "in", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "3967536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "3967536_1_Ent0", "role": "Effect", "text": "Hypotension and sinus arrest", "start": 0, "end": 4}, {"entity_id": "3967536_1_Ent1", "role": "Treatment", "text": "nifedipine", "start": 5, "end": 6}, {"entity_id": "3967536_1_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 5, "end": 6}, {"entity_id": "3967536_1_Ent3", "role": "Treatment_Disorder", "text": "pulmonary hypertension", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "3967536_1_Ent0", "text": "Hypotension and sinus arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3967536_1_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3967536_1_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3967536_1_Ent3", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "3970339_2", "wnd_id": "3970339_2_1", "text": "Ischaemia following selfadministered intra - arterial injection of methylphenidate and diamorphine .", "tokens": ["Ischaemia", "following", "selfadministered", "intra", "-", "arterial", "injection", "of", "methylphenidate", "and", "diamorphine", "."], "event_mentions": [{"id": "3970339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "3970339_2_Ent0", "role": "Effect", "text": "Ischaemia", "start": 0, "end": 1}, {"entity_id": "3970339_2_Ent1", "role": "Treatment", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "start": 2, "end": 11}, {"entity_id": "3970339_2_Ent4", "role": "Treatment_Route", "text": "intra - arterial injection", "start": 3, "end": 7}, {"entity_id": "3970339_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent5", "role": "Combination_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 10, "end": 11}, {"entity_id": "3970339_2_Ent6", "role": "Combination_Drug", "text": "diamorphine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3970339_2_Ent0", "text": "Ischaemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3970339_2_Ent1", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "3970339_2_Ent4", "text": "intra - arterial injection", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3970339_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent5", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3970339_2_Ent6", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3977377_1", "wnd_id": "3977377_1_1", "text": "Chronic photosensitivity associated with hydrochlorothiazide ingestion occurred in four patients .", "tokens": ["Chronic", "photosensitivity", "associated", "with", "hydrochlorothiazide", "ingestion", "occurred", "in", "four", "patients", "."], "event_mentions": [{"id": "3977377_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "3977377_1_Ent2", "role": "Effect", "text": "Chronic photosensitivity", "start": 0, "end": 2}, {"entity_id": "3977377_1_Ent4", "role": "Treatment_Drug", "text": "hydrochlorothiazide", "start": 4, "end": 5}, {"entity_id": "3977377_1_Ent3", "role": "Treatment", "text": "hydrochlorothiazide ingestion", "start": 4, "end": 6}, {"entity_id": "3977377_1_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 5, "end": 6}, {"entity_id": "3977377_1_Ent1", "role": "Subject_Population", "text": "four", "start": 8, "end": 9}, {"entity_id": "3977377_1_Ent0", "role": "Subject", "text": "four patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3977377_1_Ent2", "text": "Chronic photosensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3977377_1_Ent4", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3977377_1_Ent3", "text": "hydrochlorothiazide ingestion", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3977377_1_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3977377_1_Ent1", "text": "four", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3977377_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3982906_1", "wnd_id": "3982906_1_1", "text": "Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia .", "tokens": ["Cardiac", "decompensation", "following", "verapamil", "therapy", "in", "infants", "with", "supraventricular", "tachycardia", "."], "event_mentions": [{"id": "3982906_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3982906_1_Ent2", "role": "Effect", "text": "Cardiac decompensation", "start": 0, "end": 2}, {"entity_id": "3982906_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "3982906_1_Ent3", "role": "Treatment", "text": "verapamil therapy", "start": 3, "end": 5}, {"entity_id": "3982906_1_Ent1", "role": "Subject_Age", "text": "infants", "start": 6, "end": 7}, {"entity_id": "3982906_1_Ent0", "role": "Subject", "text": "infants with supraventricular tachycardia", "start": 6, "end": 10}, {"entity_id": "3982906_1_Ent4", "role": "Treatment_Disorder", "text": "supraventricular tachycardia", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3982906_1_Ent2", "text": "Cardiac decompensation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3982906_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3982906_1_Ent3", "text": "verapamil therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3982906_1_Ent1", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3982906_1_Ent0", "text": "infants with supraventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3982906_1_Ent4", "text": "supraventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3997294_2", "wnd_id": "3997294_2_1", "text": "Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .", "tokens": ["Review", "of", "this", "and", "previously", "reported", "cases", "indicates", "the", "need", "for", "early", "diagnosis", "of", "amiodarone", "pneumonitis", ",", "immediate", "withdrawal", "of", "amiodarone", ",", "and", "prompt", "but", "continued", "steroid", "therapy", "to", "ensure", "full", "recovery", "."], "event_mentions": [{"id": "3997294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 13, "end": 14}, "arguments": [{"entity_id": "3997294_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "3997294_2_Ent0", "role": "Effect", "text": "pneumonitis", "start": 15, "end": 16}]}, {"id": "3997294_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovery", "start": 31, "end": 32}, "arguments": [{"entity_id": "3997294_2_Ent4", "role": "Treatment_Disorder", "text": "pneumonitis", "start": 15, "end": 16}, {"entity_id": "3997294_2_Ent3", "role": "Treatment", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "start": 17, "end": 28}, {"entity_id": "3997294_2_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "3997294_2_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3997294_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3997294_2_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent4", "text": "pneumonitis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3997294_2_Ent3", "text": "immediate withdrawal of amiodarone , and prompt but continued steroid therapy", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "3997294_2_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "3997294_2_Ent5", "text": "steroid", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "4014301_1", "wnd_id": "4014301_1_1", "text": "Insulin - induced cardiac failure .", "tokens": ["Insulin", "-", "induced", "cardiac", "failure", "."], "event_mentions": [{"id": "4014301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4014301_1_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent2", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "4014301_1_Ent0", "role": "Effect", "text": "cardiac failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "4014301_1_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent2", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4014301_1_Ent0", "text": "cardiac failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "4018433_2", "wnd_id": "4018433_2_1", "text": "Administration of pyridoxine to an infant after a long period of convulsions was followed by acute hypotonia .", "tokens": ["Administration", "of", "pyridoxine", "to", "an", "infant", "after", "a", "long", "period", "of", "convulsions", "was", "followed", "by", "acute", "hypotonia", "."], "event_mentions": [{"id": "4018433_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 13, "end": 14}, "arguments": [{"entity_id": "4018433_2_Ent3", "role": "Treatment", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent4", "role": "Treatment_Drug", "text": "pyridoxine", "start": 2, "end": 3}, {"entity_id": "4018433_2_Ent0", "role": "Subject", "text": "an infant", "start": 4, "end": 6}, {"entity_id": "4018433_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 5, "end": 6}, {"entity_id": "4018433_2_Ent5", "role": "Treatment_Disorder", "text": "convulsions", "start": 11, "end": 12}, {"entity_id": "4018433_2_Ent2", "role": "Effect", "text": "acute hypotonia", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "4018433_2_Ent3", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent4", "text": "pyridoxine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "4018433_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "4018433_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4018433_2_Ent5", "text": "convulsions", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4018433_2_Ent2", "text": "acute hypotonia", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "4031907_2", "wnd_id": "4031907_2_1", "text": "Isoniazid inhibits the conversion of tryptophan to niacin and may induce pellagra , particularly in poorly nourished patients .", "tokens": ["Isoniazid", "inhibits", "the", "conversion", "of", "tryptophan", "to", "niacin", "and", "may", "induce", "pellagra", ",", "particularly", "in", "poorly", "nourished", "patients", "."], "event_mentions": [{"id": "4031907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 10, "end": 11}, "arguments": [{"entity_id": "4031907_2_Ent3", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "4031907_2_Ent4", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "4031907_2_Ent2", "role": "Effect", "text": "pellagra", "start": 11, "end": 12}, {"entity_id": "4031907_2_Ent1", "role": "Subject_Disorder", "text": "poorly nourished", "start": 15, "end": 17}, {"entity_id": "4031907_2_Ent0", "role": "Subject", "text": "poorly nourished patients", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "4031907_2_Ent3", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4031907_2_Ent4", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4031907_2_Ent2", "text": "pellagra", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4031907_2_Ent1", "text": "poorly nourished", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "4031907_2_Ent0", "text": "poorly nourished patients", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "4036917_2", "wnd_id": "4036917_2_1", "text": "Reye syndrome ( RS ) is believed to occur infrequently among children receiving long - term aspirin therapy .", "tokens": ["Reye", "syndrome", "(", "RS", ")", "is", "believed", "to", "occur", "infrequently", "among", "children", "receiving", "long", "-", "term", "aspirin", "therapy", "."], "event_mentions": [{"id": "4036917_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 8, "end": 9}, "arguments": [{"entity_id": "4036917_2_Ent2", "role": "Effect", "text": "Reye syndrome ( RS )", "start": 0, "end": 5}, {"entity_id": "4036917_2_Ent0", "role": "Subject", "text": "children", "start": 11, "end": 12}, {"entity_id": "4036917_2_Ent1", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}, {"entity_id": "4036917_2_Ent3", "role": "Treatment", "text": "long - term aspirin", "start": 13, "end": 17}, {"entity_id": "4036917_2_Ent4", "role": "Treatment_Drug", "text": "aspirin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "4036917_2_Ent2", "text": "Reye syndrome ( RS )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "4036917_2_Ent0", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_2_Ent1", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_2_Ent3", "text": "long - term aspirin", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "4036917_2_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "4066622_2", "wnd_id": "4066622_2_1", "text": "The calcium channel blockers are a group of drugs that have recently become available for the treatment of angina .", "tokens": ["The", "calcium", "channel", "blockers", "are", "a", "group", "of", "drugs", "that", "have", "recently", "become", "available", "for", "the", "treatment", "of", "angina", "."], "event_mentions": [{"id": "4066622_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "4066622_2_Ent0", "role": "Treatment", "text": "calcium channel blockers", "start": 1, "end": 4}, {"entity_id": "4066622_2_Ent2", "role": "Treatment_Drug", "text": "calcium channel blockers", "start": 1, "end": 4}, {"entity_id": "4066622_2_Ent1", "role": "Treatment_Disorder", "text": "angina", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "4066622_2_Ent0", "text": "calcium channel blockers", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4066622_2_Ent2", "text": "calcium channel blockers", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4066622_2_Ent1", "text": "angina", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "4075534_3", "wnd_id": "4075534_3_1", "text": "Two reports of spindle coma are noted with alcohol and imipramine .", "tokens": ["Two", "reports", "of", "spindle", "coma", "are", "noted", "with", "alcohol", "and", "imipramine", "."], "event_mentions": [{"id": "4075534_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 6, "end": 7}, "arguments": [{"entity_id": "4075534_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "4075534_3_Ent0", "role": "Subject", "text": "Two reports", "start": 0, "end": 2}, {"entity_id": "4075534_3_Ent2", "role": "Effect", "text": "spindle coma", "start": 3, "end": 5}, {"entity_id": "4075534_3_Ent4", "role": "Treatment_Drug", "text": "alcohol", "start": 8, "end": 9}, {"entity_id": "4075534_3_Ent6", "role": "Combination_Drug", "text": "alcohol", "start": 8, "end": 9}, {"entity_id": "4075534_3_Ent3", "role": "Treatment", "text": "alcohol and imipramine", "start": 8, "end": 11}, {"entity_id": "4075534_3_Ent5", "role": "Treatment_Drug", "text": "imipramine", "start": 10, "end": 11}, {"entity_id": "4075534_3_Ent7", "role": "Combination_Drug", "text": "imipramine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "4075534_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4075534_3_Ent0", "text": "Two reports", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4075534_3_Ent2", "text": "spindle coma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "4075534_3_Ent4", "text": "alcohol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "4075534_3_Ent6", "text": "alcohol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "4075534_3_Ent3", "text": "alcohol and imipramine", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "4075534_3_Ent5", "text": "imipramine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "4075534_3_Ent7", "text": "imipramine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "412488_2", "wnd_id": "412488_2_1", "text": "Three patients developed proteinuria following gold therapy for rheumatoid arthritis .", "tokens": ["Three", "patients", "developed", "proteinuria", "following", "gold", "therapy", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "412488_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "412488_2_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "412488_2_Ent2", "role": "Effect", "text": "proteinuria", "start": 3, "end": 4}, {"entity_id": "412488_2_Ent3", "role": "Treatment", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent5", "role": "Treatment_Drug", "text": "gold", "start": 5, "end": 6}, {"entity_id": "412488_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "412488_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "412488_2_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "412488_2_Ent2", "text": "proteinuria", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "412488_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent5", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "412488_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "424824_3", "wnd_id": "424824_3_1", "text": "It is suggested therefore that methotrexate be added to the list of agents capable of inducing diffuse interstitial pulmonary fibrosis .", "tokens": ["It", "is", "suggested", "therefore", "that", "methotrexate", "be", "added", "to", "the", "list", "of", "agents", "capable", "of", "inducing", "diffuse", "interstitial", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "424824_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 15, "end": 16}, "arguments": [{"entity_id": "424824_3_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "424824_3_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "424824_3_Ent0", "role": "Effect", "text": "diffuse interstitial pulmonary fibrosis", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "424824_3_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "424824_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "424824_3_Ent0", "text": "diffuse interstitial pulmonary fibrosis", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "424824_4", "wnd_id": "424824_4_1", "text": "Methotrexate - induced diffuse interstitial pulmonary fibrosis .", "tokens": ["Methotrexate", "-", "induced", "diffuse", "interstitial", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "424824_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "424824_4_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "424824_4_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "424824_4_Ent0", "role": "Effect", "text": "diffuse interstitial pulmonary fibrosis", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "424824_4_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "424824_4_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "424824_4_Ent0", "text": "diffuse interstitial pulmonary fibrosis", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "440873_4", "wnd_id": "440873_4_1", "text": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use .", "tokens": ["We", "have", "cared", "for", "three", "children", "in", "whom", "four", "episodes", "of", "dystonia", "proceeding", "to", "opisthotonus", "occurred", "in", "association", "with", "carbamazepine", "use", "."], "event_mentions": [{"id": "440873_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 15, "end": 16}, "arguments": [{"entity_id": "440873_4_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "440873_4_Ent0", "role": "Subject", "text": "three children", "start": 4, "end": 6}, {"entity_id": "440873_4_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "440873_4_Ent3", "role": "Effect", "text": "four episodes of dystonia proceeding to opisthotonus", "start": 8, "end": 15}, {"entity_id": "440873_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 19, "end": 20}, {"entity_id": "440873_4_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "440873_4_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "440873_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "440873_4_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "440873_4_Ent3", "text": "four episodes of dystonia proceeding to opisthotonus", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "440873_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "440873_4_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "448845_3", "wnd_id": "448845_3_1", "text": "Several case reports of aplastic anemia with use of acetazolamide , and two cases with use of methazolamide , have appeared in the literature .", "tokens": ["Several", "case", "reports", "of", "aplastic", "anemia", "with", "use", "of", "acetazolamide", ",", "and", "two", "cases", "with", "use", "of", "methazolamide", ",", "have", "appeared", "in", "the", "literature", "."], "event_mentions": [{"id": "448845_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 2, "end": 3}, "arguments": [{"entity_id": "448845_3_Ent1", "role": "Subject_Population", "text": "Several", "start": 0, "end": 1}, {"entity_id": "448845_3_Ent0", "role": "Subject", "text": "Several case", "start": 0, "end": 2}, {"entity_id": "448845_3_Ent2", "role": "Effect", "text": "aplastic anemia", "start": 4, "end": 6}, {"entity_id": "448845_3_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 9, "end": 10}, {"entity_id": "448845_3_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "448845_3_Ent1", "text": "Several", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "448845_3_Ent0", "text": "Several case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "448845_3_Ent2", "text": "aplastic anemia", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "448845_3_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "448845_3_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "515777_1", "wnd_id": "515777_1_1", "text": "Hyperglycemia and diabetic coma : possible relationship to diuretic - propranolol therapy .", "tokens": ["Hyperglycemia", "and", "diabetic", "coma", ":", "possible", "relationship", "to", "diuretic", "-", "propranolol", "therapy", "."], "event_mentions": [{"id": "515777_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 7, "end": 8}, "arguments": [{"entity_id": "515777_1_Ent0", "role": "Effect", "text": "Hyperglycemia and diabetic coma", "start": 0, "end": 4}, {"entity_id": "515777_1_Ent1", "role": "Treatment", "text": "propranolol", "start": 10, "end": 11}, {"entity_id": "515777_1_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "515777_1_Ent0", "text": "Hyperglycemia and diabetic coma", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "515777_1_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "515777_1_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "515777_2", "wnd_id": "515777_2_1", "text": "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol .", "tokens": ["Two", "patients", "developed", "diabetic", "coma", "when", "taking", "a", "combination", "of", "a", "thiazide", "diuretic", "and", "propranolol", "."], "event_mentions": [{"id": "515777_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "515777_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "515777_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "515777_2_Ent2", "role": "Effect", "text": "diabetic coma", "start": 3, "end": 5}, {"entity_id": "515777_2_Ent3", "role": "Treatment", "text": "a combination of a thiazide diuretic and propranolol", "start": 7, "end": 15}, {"entity_id": "515777_2_Ent4", "role": "Treatment_Drug", "text": "thiazide", "start": 11, "end": 12}, {"entity_id": "515777_2_Ent6", "role": "Combination_Drug", "text": "thiazide", "start": 11, "end": 12}, {"entity_id": "515777_2_Ent5", "role": "Treatment_Drug", "text": "propranolol", "start": 14, "end": 15}, {"entity_id": "515777_2_Ent7", "role": "Combination_Drug", "text": "propranolol", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "515777_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "515777_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "515777_2_Ent2", "text": "diabetic coma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "515777_2_Ent3", "text": "a combination of a thiazide diuretic and propranolol", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "515777_2_Ent4", "text": "thiazide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "515777_2_Ent6", "text": "thiazide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "515777_2_Ent5", "text": "propranolol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "515777_2_Ent7", "text": "propranolol", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "536461_1", "wnd_id": "536461_1_1", "text": "Five cases of clindamycin - associated pseudomembranous colitis in leukaemic patients are reported .", "tokens": ["Five", "cases", "of", "clindamycin", "-", "associated", "pseudomembranous", "colitis", "in", "leukaemic", "patients", "are", "reported", "."], "event_mentions": [{"id": "536461_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "536461_1_Ent3", "role": "Treatment", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent4", "role": "Treatment_Drug", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent2", "role": "Effect", "text": "pseudomembranous colitis", "start": 6, "end": 8}, {"entity_id": "536461_1_Ent1", "role": "Subject_Disorder", "text": "leukaemic", "start": 9, "end": 10}, {"entity_id": "536461_1_Ent0", "role": "Subject", "text": "leukaemic patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "536461_1_Ent3", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent4", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent2", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "536461_1_Ent1", "text": "leukaemic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "536461_1_Ent0", "text": "leukaemic patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "536470_2", "wnd_id": "536470_2_1", "text": "While sulindac failed to affect significantly warfarin - induced hypoprothrombinemia in normal male volunteers , it markedly prolonged prothrombin time in a patient with a renal tubular defect who had been anticoagulated with warfarin .", "tokens": ["While", "sulindac", "failed", "to", "affect", "significantly", "warfarin", "-", "induced", "hypoprothrombinemia", "in", "normal", "male", "volunteers", ",", "it", "markedly", "prolonged", "prothrombin", "time", "in", "a", "patient", "with", "a", "renal", "tubular", "defect", "who", "had", "been", "anticoagulated", "with", "warfarin", "."], "event_mentions": [{"id": "536470_2_Evt2", "event_type": "Adverse_event", "trigger": {"text": "affect", "start": 4, "end": 5}, "arguments": [{"entity_id": "536470_2_Ent15", "role": "Treatment", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent16", "role": "Treatment_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent14", "role": "Effect", "text": "affect significantly warfarin - induced hypoprothrombinemia", "start": 4, "end": 10}, {"entity_id": "536470_2_Ent12", "role": "Subject", "text": "normal male volunteers", "start": 11, "end": 14}, {"entity_id": "536470_2_Ent13", "role": "Subject_Gender", "text": "male", "start": 12, "end": 13}]}, {"id": "536470_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "536470_2_Ent10", "role": "Treatment", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "536470_2_Ent11", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "536470_2_Ent9", "role": "Effect", "text": "hypoprothrombinemia", "start": 9, "end": 10}]}, {"id": "536470_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 20, "end": 21}, "arguments": [{"entity_id": "536470_2_Ent3", "role": "Treatment", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent5", "role": "Treatment_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent8", "role": "Combination_Drug", "text": "sulindac", "start": 1, "end": 2}, {"entity_id": "536470_2_Ent2", "role": "Effect", "text": "markedly prolonged prothrombin time", "start": 16, "end": 20}, {"entity_id": "536470_2_Ent0", "role": "Subject", "text": "a patient with a renal tubular defect", "start": 21, "end": 28}, {"entity_id": "536470_2_Ent1", "role": "Subject_Disorder", "text": "renal tubular defect", "start": 25, "end": 28}, {"entity_id": "536470_2_Ent4", "role": "Treatment", "text": "had been anticoagulated with warfarin", "start": 29, "end": 34}, {"entity_id": "536470_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "536470_2_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "536470_2_Ent3", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent5", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent8", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent15", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent16", "text": "sulindac", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "536470_2_Ent14", "text": "affect significantly warfarin - induced hypoprothrombinemia", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "536470_2_Ent10", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "536470_2_Ent11", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "536470_2_Ent9", "text": "hypoprothrombinemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "536470_2_Ent12", "text": "normal male volunteers", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "536470_2_Ent13", "text": "male", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "536470_2_Ent2", "text": "markedly prolonged prothrombin time", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "536470_2_Ent0", "text": "a patient with a renal tubular defect", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "536470_2_Ent1", "text": "renal tubular defect", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "536470_2_Ent4", "text": "had been anticoagulated with warfarin", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "536470_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "536470_2_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "566977_3", "wnd_id": "566977_3_1", "text": "Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated metabolic acidosis due to absorbed formic acid .", "tokens": ["Intravenous", "sodium", "bicarbonate", "appears", "to", "be", "indicated", "prophylactically", "in", "combating", "the", "associated", "metabolic", "acidosis", "due", "to", "absorbed", "formic", "acid", "."], "event_mentions": [{"id": "566977_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "combating", "start": 9, "end": 10}, "arguments": [{"entity_id": "566977_3_Ent5", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "566977_3_Ent3", "role": "Treatment", "text": "Intravenous sodium bicarbonate", "start": 0, "end": 3}, {"entity_id": "566977_3_Ent6", "role": "Treatment_Drug", "text": "sodium bicarbonate", "start": 1, "end": 3}, {"entity_id": "566977_3_Ent4", "role": "Treatment_Disorder", "text": "metabolic acidosis due to absorbed formic acid", "start": 12, "end": 19}]}, {"id": "566977_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 14, "end": 15}, "arguments": [{"entity_id": "566977_3_Ent0", "role": "Effect", "text": "metabolic acidosis", "start": 12, "end": 14}, {"entity_id": "566977_3_Ent1", "role": "Treatment", "text": "absorbed formic acid", "start": 16, "end": 19}, {"entity_id": "566977_3_Ent2", "role": "Treatment_Drug", "text": "formic acid", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "566977_3_Ent5", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "566977_3_Ent3", "text": "Intravenous sodium bicarbonate", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "566977_3_Ent6", "text": "sodium bicarbonate", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "566977_3_Ent0", "text": "metabolic acidosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "566977_3_Ent4", "text": "metabolic acidosis due to absorbed formic acid", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "566977_3_Ent1", "text": "absorbed formic acid", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "566977_3_Ent2", "text": "formic acid", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "576675_1", "wnd_id": "576675_1_1", "text": "A 15 - kg weight gain developed in a patient during the third week of ibuprofen therapy .", "tokens": ["A", "15", "-", "kg", "weight", "gain", "developed", "in", "a", "patient", "during", "the", "third", "week", "of", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "576675_1_Ent1", "role": "Effect", "text": "A 15 - kg weight gain", "start": 0, "end": 6}, {"entity_id": "576675_1_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "576675_1_Ent4", "role": "Treatment_Time_elapsed", "text": "the third week", "start": 11, "end": 14}, {"entity_id": "576675_1_Ent2", "role": "Treatment", "text": "ibuprofen", "start": 15, "end": 16}, {"entity_id": "576675_1_Ent3", "role": "Treatment_Drug", "text": "ibuprofen", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "576675_1_Ent1", "text": "A 15 - kg weight gain", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "576675_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "576675_1_Ent4", "text": "the third week", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "576675_1_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "576675_1_Ent3", "text": "ibuprofen", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "578255_1", "wnd_id": "578255_1_1", "text": "Allopurinol - associated hand and foot deformities in chronic tophaceous gout .", "tokens": ["Allopurinol", "-", "associated", "hand", "and", "foot", "deformities", "in", "chronic", "tophaceous", "gout", "."], "event_mentions": [{"id": "578255_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "578255_1_Ent1", "role": "Treatment", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent2", "role": "Treatment_Drug", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent0", "role": "Effect", "text": "hand and foot deformities", "start": 3, "end": 7}, {"entity_id": "578255_1_Ent3", "role": "Treatment_Disorder", "text": "chronic tophaceous gout", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "578255_1_Ent1", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent2", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent0", "text": "hand and foot deformities", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "578255_1_Ent3", "text": "chronic tophaceous gout", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "582099_1", "wnd_id": "582099_1_1", "text": "A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B , and an acute toxic delirium with EEG abnormalities developed .", "tokens": ["A", "patient", "with", "coccidioidal", "meningitis", "was", "treated", "with", "intrathecally", "administered", "amphotericin", "B", ",", "and", "an", "acute", "toxic", "delirium", "with", "EEG", "abnormalities", "developed", "."], "event_mentions": [{"id": "582099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "582099_1_Ent0", "role": "Subject", "text": "A patient with coccidioidal meningitis", "start": 0, "end": 5}, {"entity_id": "582099_1_Ent3", "role": "Treatment_Disorder", "text": "coccidioidal meningitis", "start": 3, "end": 5}, {"entity_id": "582099_1_Ent5", "role": "Treatment_Route", "text": "intrathecally", "start": 8, "end": 9}, {"entity_id": "582099_1_Ent2", "role": "Treatment", "text": "intrathecally administered amphotericin B", "start": 8, "end": 12}, {"entity_id": "582099_1_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "582099_1_Ent1", "role": "Effect", "text": "an acute toxic delirium with EEG abnormalities", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "582099_1_Ent0", "text": "A patient with coccidioidal meningitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "582099_1_Ent3", "text": "coccidioidal meningitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "582099_1_Ent5", "text": "intrathecally", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "582099_1_Ent2", "text": "intrathecally administered amphotericin B", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "582099_1_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "582099_1_Ent1", "text": "an acute toxic delirium with EEG abnormalities", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "6142995_1", "wnd_id": "6142995_1_1", "text": "Chlorambucil - induced chromosome damage to human lymphocytes is dose - dependent and cumulative .", "tokens": ["Chlorambucil", "-", "induced", "chromosome", "damage", "to", "human", "lymphocytes", "is", "dose", "-", "dependent", "and", "cumulative", "."], "event_mentions": [{"id": "6142995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6142995_1_Ent1", "role": "Treatment", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "6142995_1_Ent2", "role": "Treatment_Drug", "text": "Chlorambucil", "start": 0, "end": 1}, {"entity_id": "6142995_1_Ent0", "role": "Effect", "text": "chromosome damage", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "6142995_1_Ent1", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6142995_1_Ent2", "text": "Chlorambucil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6142995_1_Ent0", "text": "chromosome damage", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6142995_2", "wnd_id": "6142995_2_1", "text": "Sister chromatid exchanges ( SCEs ) , a sensitive measure of chromosome damage , were counted in peripheral - blood lymphocytes from 10 patients with Behcet 's syndrome receiving chlorambucil .", "tokens": ["Sister", "chromatid", "exchanges", "(", "SCEs", ")", ",", "a", "sensitive", "measure", "of", "chromosome", "damage", ",", "were", "counted", "in", "peripheral", "-", "blood", "lymphocytes", "from", "10", "patients", "with", "Behcet", "'s", "syndrome", "receiving", "chlorambucil", "."], "event_mentions": [{"id": "6142995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 28, "end": 29}, "arguments": [{"entity_id": "6142995_2_Ent2", "role": "Effect", "text": "chromosome damage", "start": 11, "end": 13}, {"entity_id": "6142995_2_Ent1", "role": "Subject_Population", "text": "10", "start": 22, "end": 23}, {"entity_id": "6142995_2_Ent0", "role": "Subject", "text": "10 patients with Behcet 's syndrome", "start": 22, "end": 28}, {"entity_id": "6142995_2_Ent4", "role": "Treatment_Disorder", "text": "Behcet 's syndrome", "start": 25, "end": 28}, {"entity_id": "6142995_2_Ent3", "role": "Treatment", "text": "chlorambucil", "start": 29, "end": 30}, {"entity_id": "6142995_2_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6142995_2_Ent2", "text": "chromosome damage", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6142995_2_Ent1", "text": "10", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6142995_2_Ent0", "text": "10 patients with Behcet 's syndrome", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "6142995_2_Ent4", "text": "Behcet 's syndrome", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6142995_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6142995_2_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6149250_4", "wnd_id": "6149250_4_1", "text": "The second patient suffered from high blood pressure , which was controlled with beta - blocker drugs .", "tokens": ["The", "second", "patient", "suffered", "from", "high", "blood", "pressure", ",", "which", "was", "controlled", "with", "beta", "-", "blocker", "drugs", "."], "event_mentions": [{"id": "6149250_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "controlled", "start": 11, "end": 12}, "arguments": [{"entity_id": "6149250_4_Ent0", "role": "Subject", "text": "The second patient suffered from high blood pressure", "start": 0, "end": 8}, {"entity_id": "6149250_4_Ent2", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 5, "end": 8}, {"entity_id": "6149250_4_Ent1", "role": "Treatment", "text": "beta - blocker drugs", "start": 13, "end": 17}, {"entity_id": "6149250_4_Ent3", "role": "Treatment_Drug", "text": "beta - blocker drugs", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "6149250_4_Ent0", "text": "The second patient suffered from high blood pressure", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6149250_4_Ent2", "text": "high blood pressure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6149250_4_Ent1", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6149250_4_Ent3", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "6159523_2", "wnd_id": "6159523_2_1", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50 % solution of dextrose .", "tokens": ["Two", "patients", "with", "extrinsic", "asthma", "and", "coexistent", "insulin", "-", "dependent", "diabetes", "mellitus", "sustained", "an", "anaphylactoid", "reaction", "after", "the", "intravenous", "administration", "of", "50", "%", "solution", "of", "dextrose", "."], "event_mentions": [{"id": "6159523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "6159523_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6159523_2_Ent0", "role": "Subject", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "start": 0, "end": 12}, {"entity_id": "6159523_2_Ent2", "role": "Subject_Disorder", "text": "extrinsic asthma", "start": 3, "end": 5}, {"entity_id": "6159523_2_Ent3", "role": "Subject_Disorder", "text": "insulin - dependent diabetes mellitus", "start": 7, "end": 12}, {"entity_id": "6159523_2_Ent4", "role": "Effect", "text": "anaphylactoid reaction", "start": 14, "end": 16}, {"entity_id": "6159523_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 18, "end": 19}, {"entity_id": "6159523_2_Ent5", "role": "Treatment", "text": "intravenous administration of 50 % solution of dextrose", "start": 18, "end": 26}, {"entity_id": "6159523_2_Ent7", "role": "Treatment_Drug", "text": "dextrose", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "6159523_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6159523_2_Ent0", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6159523_2_Ent2", "text": "extrinsic asthma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6159523_2_Ent3", "text": "insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6159523_2_Ent4", "text": "anaphylactoid reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6159523_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6159523_2_Ent5", "text": "intravenous administration of 50 % solution of dextrose", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "6159523_2_Ent7", "text": "dextrose", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "6221046_2", "wnd_id": "6221046_2_1", "text": "Multiple complications of propylthiouracil treatment : granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization .", "tokens": ["Multiple", "complications", "of", "propylthiouracil", "treatment", ":", "granulocytopenia", ",", "eosinophilia", ",", "skin", "reaction", "and", "hepatitis", "with", "lymphocyte", "sensitization", "."], "event_mentions": [{"id": "6221046_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 1, "end": 2}, "arguments": [{"entity_id": "6221046_2_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "6221046_2_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "6221046_2_Ent0", "role": "Effect", "text": "granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization", "start": 6, "end": 17}]}], "entity_mentions": [{"id": "6221046_2_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6221046_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6221046_2_Ent0", "text": "granulocytopenia , eosinophilia , skin reaction and hepatitis with lymphocyte sensitization", "entity_type": "Entity", "start": 6, "end": 17}], "lang": "en"}
{"doc_id": "623061_1", "wnd_id": "623061_1_1", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia developed in seven children , 5 years of age and younger , following administration of an antiemetic combination of pentobarbital and pyrilamine maleate .", "tokens": ["A", "toxic", "encephalopathy", "characterized", "by", "depressed", "level", "of", "consciousness", ",", "marked", "irritability", ",", "and", "ataxia", "developed", "in", "seven", "children", ",", "5", "years", "of", "age", "and", "younger", ",", "following", "administration", "of", "an", "antiemetic", "combination", "of", "pentobarbital", "and", "pyrilamine", "maleate", "."], "event_mentions": [{"id": "623061_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "623061_1_Ent3", "role": "Effect", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia", "start": 0, "end": 15}, {"entity_id": "623061_1_Ent1", "role": "Subject_Population", "text": "seven", "start": 17, "end": 18}, {"entity_id": "623061_1_Ent0", "role": "Subject", "text": "seven children , 5 years of age and younger", "start": 17, "end": 26}, {"entity_id": "623061_1_Ent2", "role": "Subject_Age", "text": "children , 5 years of age and younger", "start": 18, "end": 26}, {"entity_id": "623061_1_Ent4", "role": "Treatment", "text": "administration of an antiemetic combination of pentobarbital and pyrilamine maleate", "start": 28, "end": 38}, {"entity_id": "623061_1_Ent5", "role": "Treatment_Drug", "text": "pentobarbital", "start": 34, "end": 35}, {"entity_id": "623061_1_Ent7", "role": "Combination_Drug", "text": "pentobarbital", "start": 34, "end": 35}, {"entity_id": "623061_1_Ent6", "role": "Treatment_Drug", "text": "pyrilamine maleate", "start": 36, "end": 38}, {"entity_id": "623061_1_Ent8", "role": "Combination_Drug", "text": "pyrilamine maleate", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "623061_1_Ent3", "text": "A toxic encephalopathy characterized by depressed level of consciousness , marked irritability , and ataxia", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "623061_1_Ent1", "text": "seven", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "623061_1_Ent0", "text": "seven children , 5 years of age and younger", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "623061_1_Ent2", "text": "children , 5 years of age and younger", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "623061_1_Ent4", "text": "administration of an antiemetic combination of pentobarbital and pyrilamine maleate", "entity_type": "Entity", "start": 28, "end": 38}, {"id": "623061_1_Ent5", "text": "pentobarbital", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "623061_1_Ent7", "text": "pentobarbital", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "623061_1_Ent6", "text": "pyrilamine maleate", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "623061_1_Ent8", "text": "pyrilamine maleate", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "6233326_2", "wnd_id": "6233326_2_1", "text": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D - penicillamine for about 1 year .", "tokens": ["Optic", "neuropathy", "developed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "who", "had", "been", "receiving", "D", "-", "penicillamine", "for", "about", "1", "year", "."], "event_mentions": [{"id": "6233326_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6233326_2_Ent1", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "6233326_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 4, "end": 9}, {"entity_id": "6233326_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "6233326_2_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "6233326_2_Ent2", "role": "Treatment", "text": "D - penicillamine for about 1 year", "start": 13, "end": 20}, {"entity_id": "6233326_2_Ent5", "role": "Treatment_Duration", "text": "1 year", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "6233326_2_Ent1", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6233326_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "6233326_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6233326_2_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "6233326_2_Ent2", "text": "D - penicillamine for about 1 year", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "6233326_2_Ent5", "text": "1 year", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "6245286_2", "wnd_id": "6245286_2_1", "text": "In three of these patients the infection was clinically unsuspected ; in the fourth , cutaneous herpes zoster developed after administration of 300 mg of cytarabine daily for the preceding five days .", "tokens": ["In", "three", "of", "these", "patients", "the", "infection", "was", "clinically", "unsuspected", ";", "in", "the", "fourth", ",", "cutaneous", "herpes", "zoster", "developed", "after", "administration", "of", "300", "mg", "of", "cytarabine", "daily", "for", "the", "preceding", "five", "days", "."], "event_mentions": [{"id": "6245286_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "6245286_2_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "6245286_2_Ent0", "role": "Subject", "text": "three of these patients", "start": 1, "end": 5}, {"entity_id": "6245286_2_Ent2", "role": "Effect", "text": "cutaneous herpes zoster", "start": 15, "end": 18}, {"entity_id": "6245286_2_Ent4", "role": "Treatment_Dosage", "text": "300 mg", "start": 22, "end": 24}, {"entity_id": "6245286_2_Ent3", "role": "Treatment", "text": "300 mg of cytarabine daily for the preceding five days", "start": 22, "end": 32}, {"entity_id": "6245286_2_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 25, "end": 26}, {"entity_id": "6245286_2_Ent6", "role": "Treatment_Freq", "text": "daily", "start": 26, "end": 27}, {"entity_id": "6245286_2_Ent7", "role": "Treatment_Duration", "text": "preceding five days", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "6245286_2_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6245286_2_Ent0", "text": "three of these patients", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6245286_2_Ent2", "text": "cutaneous herpes zoster", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "6245286_2_Ent4", "text": "300 mg", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "6245286_2_Ent3", "text": "300 mg of cytarabine daily for the preceding five days", "entity_type": "Entity", "start": 22, "end": 32}, {"id": "6245286_2_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6245286_2_Ent6", "text": "daily", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6245286_2_Ent7", "text": "preceding five days", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "6405633_2", "wnd_id": "6405633_2_1", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced tremor during lithium carbonate therapy .", "tokens": ["Two", "patients", "with", "bipolar", "affective", "disorder", "and", "a", "history", "of", "bronchospastic", "phenomena", "experienced", "tremor", "during", "lithium", "carbonate", "therapy", "."], "event_mentions": [{"id": "6405633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 12, "end": 13}, "arguments": [{"entity_id": "6405633_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6405633_2_Ent0", "role": "Subject", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "start": 0, "end": 12}, {"entity_id": "6405633_2_Ent6", "role": "Treatment_Disorder", "text": "bipolar affective disorder", "start": 3, "end": 6}, {"entity_id": "6405633_2_Ent2", "role": "Subject_Disorder", "text": "a history of bronchospastic phenomena", "start": 7, "end": 12}, {"entity_id": "6405633_2_Ent3", "role": "Effect", "text": "tremor", "start": 13, "end": 14}, {"entity_id": "6405633_2_Ent5", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 15, "end": 17}, {"entity_id": "6405633_2_Ent4", "role": "Treatment", "text": "lithium carbonate therapy", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "6405633_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6405633_2_Ent0", "text": "Two patients with bipolar affective disorder and a history of bronchospastic phenomena", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6405633_2_Ent6", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6405633_2_Ent2", "text": "a history of bronchospastic phenomena", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6405633_2_Ent3", "text": "tremor", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6405633_2_Ent5", "text": "lithium carbonate", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6405633_2_Ent4", "text": "lithium carbonate therapy", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "6414095_1", "wnd_id": "6414095_1_1", "text": "Transient hemiparesis caused by phenytoin toxicity .", "tokens": ["Transient", "hemiparesis", "caused", "by", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "6414095_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "6414095_1_Ent0", "role": "Effect", "text": "Transient hemiparesis", "start": 0, "end": 2}, {"entity_id": "6414095_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "6414095_1_Ent1", "role": "Treatment", "text": "phenytoin toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "6414095_1_Ent0", "text": "Transient hemiparesis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6414095_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6414095_1_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "6414095_3", "wnd_id": "6414095_3_1", "text": "A 52 - year - old Black woman on phenytoin therapy for post - traumatic epilepsy developed transient hemiparesis contralateral to the injury .", "tokens": ["A", "52", "-", "year", "-", "old", "Black", "woman", "on", "phenytoin", "therapy", "for", "post", "-", "traumatic", "epilepsy", "developed", "transient", "hemiparesis", "contralateral", "to", "the", "injury", "."], "event_mentions": [{"id": "6414095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "6414095_3_Ent0", "role": "Subject", "text": "A 52 - year - old Black woman", "start": 0, "end": 8}, {"entity_id": "6414095_3_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6414095_3_Ent2", "role": "Subject_Race", "text": "Black", "start": 6, "end": 7}, {"entity_id": "6414095_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "6414095_3_Ent5", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent6", "role": "Treatment_Disorder", "text": "post - traumatic epilepsy", "start": 12, "end": 16}, {"entity_id": "6414095_3_Ent4", "role": "Effect", "text": "transient hemiparesis contralateral to the injury", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "6414095_3_Ent0", "text": "A 52 - year - old Black woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6414095_3_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6414095_3_Ent2", "text": "Black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6414095_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6414095_3_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent6", "text": "post - traumatic epilepsy", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6414095_3_Ent4", "text": "transient hemiparesis contralateral to the injury", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "6440806_1", "wnd_id": "6440806_1_1", "text": "A 52 - year - old , white female developed low - grade fever , cough , and dyspnea after 8 weeks treatment with sodium aurothiomalate for rheumatoid arthritis .", "tokens": ["A", "52", "-", "year", "-", "old", ",", "white", "female", "developed", "low", "-", "grade", "fever", ",", "cough", ",", "and", "dyspnea", "after", "8", "weeks", "treatment", "with", "sodium", "aurothiomalate", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6440806_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6440806_1_Ent0", "role": "Subject", "text": "A 52 - year - old", "start": 0, "end": 6}, {"entity_id": "6440806_1_Ent2", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6440806_1_Ent3", "role": "Subject_Race", "text": "white", "start": 7, "end": 8}, {"entity_id": "6440806_1_Ent1", "role": "Subject", "text": "white female", "start": 7, "end": 9}, {"entity_id": "6440806_1_Ent4", "role": "Subject_Gender", "text": "female", "start": 8, "end": 9}, {"entity_id": "6440806_1_Ent5", "role": "Effect", "text": "low - grade fever , cough , and dyspnea", "start": 10, "end": 19}, {"entity_id": "6440806_1_Ent7", "role": "Treatment_Time_elapsed", "text": "8 weeks", "start": 20, "end": 22}, {"entity_id": "6440806_1_Ent6", "role": "Treatment", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent8", "role": "Treatment_Drug", "text": "sodium aurothiomalate", "start": 24, "end": 26}, {"entity_id": "6440806_1_Ent9", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "6440806_1_Ent0", "text": "A 52 - year - old", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6440806_1_Ent2", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6440806_1_Ent3", "text": "white", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6440806_1_Ent1", "text": "white female", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6440806_1_Ent4", "text": "female", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6440806_1_Ent5", "text": "low - grade fever , cough , and dyspnea", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "6440806_1_Ent7", "text": "8 weeks", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "6440806_1_Ent6", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent8", "text": "sodium aurothiomalate", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "6440806_1_Ent9", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "644545_1", "wnd_id": "644545_1_1", "text": "Cyclophosphamide can rarely cause interstitial pneumonitis and fibrosis .", "tokens": ["Cyclophosphamide", "can", "rarely", "cause", "interstitial", "pneumonitis", "and", "fibrosis", "."], "event_mentions": [{"id": "644545_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "644545_1_Ent1", "role": "Treatment", "text": "Cyclophosphamide", "start": 0, "end": 1}, {"entity_id": "644545_1_Ent2", "role": "Treatment_Drug", "text": "Cyclophosphamide", "start": 0, "end": 1}, {"entity_id": "644545_1_Ent0", "role": "Effect", "text": "interstitial pneumonitis and fibrosis", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "644545_1_Ent1", "text": "Cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "644545_1_Ent2", "text": "Cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "644545_1_Ent0", "text": "interstitial pneumonitis and fibrosis", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "6453500_2", "wnd_id": "6453500_2_1", "text": "Toxic hepatitis induced by disulfiram in a non - alcoholic .", "tokens": ["Toxic", "hepatitis", "induced", "by", "disulfiram", "in", "a", "non", "-", "alcoholic", "."], "event_mentions": [{"id": "6453500_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6453500_2_Ent1", "role": "Effect", "text": "Toxic hepatitis", "start": 0, "end": 2}, {"entity_id": "6453500_2_Ent2", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6453500_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6453500_2_Ent0", "role": "Subject", "text": "a non - alcoholic", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "6453500_2_Ent1", "text": "Toxic hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6453500_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6453500_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6453500_2_Ent0", "text": "a non - alcoholic", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "6507240_3", "wnd_id": "6507240_3_1", "text": "It is concluded that SIADH is an important side effect of lorcainide therapy .", "tokens": ["It", "is", "concluded", "that", "SIADH", "is", "an", "important", "side", "effect", "of", "lorcainide", "therapy", "."], "event_mentions": [{"id": "6507240_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 8, "end": 10}, "arguments": [{"entity_id": "6507240_3_Ent0", "role": "Effect", "text": "SIADH", "start": 4, "end": 5}, {"entity_id": "6507240_3_Ent2", "role": "Treatment_Drug", "text": "lorcainide", "start": 11, "end": 12}, {"entity_id": "6507240_3_Ent1", "role": "Treatment", "text": "lorcainide therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "6507240_3_Ent0", "text": "SIADH", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6507240_3_Ent2", "text": "lorcainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6507240_3_Ent1", "text": "lorcainide therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "6578007_1", "wnd_id": "6578007_1_1", "text": "Additive pulmonary toxicity with melphalan and busulfan therapy .", "tokens": ["Additive", "pulmonary", "toxicity", "with", "melphalan", "and", "busulfan", "therapy", "."], "event_mentions": [{"id": "6578007_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6578007_1_Ent0", "role": "Effect", "text": "Additive pulmonary toxicity", "start": 0, "end": 3}, {"entity_id": "6578007_1_Ent2", "role": "Treatment_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent4", "role": "Combination_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent1", "role": "Treatment", "text": "melphalan and busulfan therapy", "start": 4, "end": 8}, {"entity_id": "6578007_1_Ent3", "role": "Treatment_Drug", "text": "busulfan", "start": 6, "end": 7}, {"entity_id": "6578007_1_Ent5", "role": "Combination_Drug", "text": "busulfan", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6578007_1_Ent0", "text": "Additive pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6578007_1_Ent2", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent4", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent1", "text": "melphalan and busulfan therapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6578007_1_Ent3", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6578007_1_Ent5", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6608139_1", "wnd_id": "6608139_1_1", "text": "Although myelosuppression is mild , immunosuppression and superinfection are potential hazards of treatment with DCF .", "tokens": ["Although", "myelosuppression", "is", "mild", ",", "immunosuppression", "and", "superinfection", "are", "potential", "hazards", "of", "treatment", "with", "DCF", "."], "event_mentions": [{"id": "6608139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "hazards", "start": 10, "end": 11}, "arguments": [{"entity_id": "6608139_1_Ent0", "role": "Effect", "text": "myelosuppression", "start": 1, "end": 2}, {"entity_id": "6608139_1_Ent1", "role": "Effect", "text": "immunosuppression and superinfection", "start": 5, "end": 8}, {"entity_id": "6608139_1_Ent2", "role": "Treatment", "text": "DCF", "start": 14, "end": 15}, {"entity_id": "6608139_1_Ent3", "role": "Treatment_Drug", "text": "DCF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6608139_1_Ent0", "text": "myelosuppression", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6608139_1_Ent1", "text": "immunosuppression and superinfection", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6608139_1_Ent2", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6608139_1_Ent3", "text": "DCF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6614033_2", "wnd_id": "6614033_2_1", "text": "Amphotericin B nephrotoxicity in humans decreased by salt repletion .", "tokens": ["Amphotericin", "B", "nephrotoxicity", "in", "humans", "decreased", "by", "salt", "repletion", "."], "event_mentions": [{"id": "6614033_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "decreased", "start": 5, "end": 6}, "arguments": [{"entity_id": "6614033_2_Ent1", "role": "Effect", "text": "Amphotericin B nephrotoxicity in humans decreased", "start": 0, "end": 6}, {"entity_id": "6614033_2_Ent0", "role": "Subject", "text": "humans", "start": 4, "end": 5}, {"entity_id": "6614033_2_Ent3", "role": "Treatment_Drug", "text": "salt", "start": 7, "end": 8}, {"entity_id": "6614033_2_Ent2", "role": "Treatment", "text": "salt repletion", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6614033_2_Ent1", "text": "Amphotericin B nephrotoxicity in humans decreased", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6614033_2_Ent0", "text": "humans", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6614033_2_Ent3", "text": "salt", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6614033_2_Ent2", "text": "salt repletion", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6618859_1", "wnd_id": "6618859_1_1", "text": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered .", "tokens": ["Gynecomastia", "developed", "in", "two", "epileptic", "patients", "some", "months", "after", "the", "addition", "of", "oral", "fluoresone", "750", "mg", "daily", "to", "the", "phenobarbital", "and", "phenytoin", "already", "being", "administered", "."], "event_mentions": [{"id": "6618859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "6618859_1_Ent2", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6618859_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "6618859_1_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 3, "end": 6}, {"entity_id": "6618859_1_Ent10", "role": "Treatment_Disorder", "text": "epileptic", "start": 4, "end": 5}, {"entity_id": "6618859_1_Ent11", "role": "Treatment_Time_elapsed", "text": "some months after", "start": 6, "end": 9}, {"entity_id": "6618859_1_Ent3", "role": "Treatment", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "start": 6, "end": 25}, {"entity_id": "6618859_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "6618859_1_Ent5", "role": "Treatment_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent12", "role": "Combination_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent8", "role": "Treatment_Dosage", "text": "750 mg", "start": 14, "end": 16}, {"entity_id": "6618859_1_Ent9", "role": "Treatment_Freq", "text": "daily", "start": 16, "end": 17}, {"entity_id": "6618859_1_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent13", "role": "Combination_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "6618859_1_Ent14", "role": "Combination_Drug", "text": "phenytoin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6618859_1_Ent2", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6618859_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6618859_1_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6618859_1_Ent10", "text": "epileptic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6618859_1_Ent11", "text": "some months after", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "6618859_1_Ent3", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "entity_type": "Entity", "start": 6, "end": 25}, {"id": "6618859_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6618859_1_Ent5", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent12", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent8", "text": "750 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6618859_1_Ent9", "text": "daily", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6618859_1_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent13", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6618859_1_Ent14", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6618859_2", "wnd_id": "6618859_2_1", "text": "Gynecomastia in epileptics treated with phenobarbital , phenytoin and fluoresone : two case reports .", "tokens": ["Gynecomastia", "in", "epileptics", "treated", "with", "phenobarbital", ",", "phenytoin", "and", "fluoresone", ":", "two", "case", "reports", "."], "event_mentions": [{"id": "6618859_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "6618859_2_Ent0", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6618859_2_Ent2", "role": "Treatment_Disorder", "text": "epileptics", "start": 2, "end": 3}, {"entity_id": "6618859_2_Ent3", "role": "Treatment_Drug", "text": "phenobarbital", "start": 5, "end": 6}, {"entity_id": "6618859_2_Ent6", "role": "Combination_Drug", "text": "phenobarbital", "start": 5, "end": 6}, {"entity_id": "6618859_2_Ent1", "role": "Treatment", "text": "phenobarbital , phenytoin and fluoresone", "start": 5, "end": 10}, {"entity_id": "6618859_2_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 7, "end": 8}, {"entity_id": "6618859_2_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 7, "end": 8}, {"entity_id": "6618859_2_Ent5", "role": "Treatment_Drug", "text": "fluoresone", "start": 9, "end": 10}, {"entity_id": "6618859_2_Ent8", "role": "Combination_Drug", "text": "fluoresone", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6618859_2_Ent0", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6618859_2_Ent2", "text": "epileptics", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6618859_2_Ent3", "text": "phenobarbital", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6618859_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6618859_2_Ent1", "text": "phenobarbital , phenytoin and fluoresone", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "6618859_2_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6618859_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6618859_2_Ent5", "text": "fluoresone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6618859_2_Ent8", "text": "fluoresone", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6683487_2", "wnd_id": "6683487_2_1", "text": "Thrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1/2 months of treatment with penicillamine .", "tokens": ["Thrombotic", "thrombocytopenic", "purpura", "(", "TTP", ")", "developed", "in", "a", "patient", "with", "seropositive", "rheumatoid", "arthritis", "(", "RA", ")", "after", "2", "1/2", "months", "of", "treatment", "with", "penicillamine", "."], "event_mentions": [{"id": "6683487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "6683487_2_Ent1", "role": "Effect", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "start": 0, "end": 6}, {"entity_id": "6683487_2_Ent0", "role": "Subject", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "start": 8, "end": 17}, {"entity_id": "6683487_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "6683487_2_Ent5", "role": "Treatment_Duration", "text": "2 1/2 months", "start": 18, "end": 21}, {"entity_id": "6683487_2_Ent2", "role": "Treatment", "text": "2 1/2 months of treatment with penicillamine", "start": 18, "end": 25}, {"entity_id": "6683487_2_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "6683487_2_Ent1", "text": "Thrombotic thrombocytopenic purpura ( TTP )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6683487_2_Ent0", "text": "a patient with seropositive rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "6683487_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6683487_2_Ent5", "text": "2 1/2 months", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "6683487_2_Ent2", "text": "2 1/2 months of treatment with penicillamine", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "6683487_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "6683487_4", "wnd_id": "6683487_4_1", "text": "To our knowledge , no prior cases of penicillamine - induced TTP in RA have been reported .", "tokens": ["To", "our", "knowledge", ",", "no", "prior", "cases", "of", "penicillamine", "-", "induced", "TTP", "in", "RA", "have", "been", "reported", "."], "event_mentions": [{"id": "6683487_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "6683487_4_Ent1", "role": "Treatment", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 8, "end": 9}, {"entity_id": "6683487_4_Ent0", "role": "Effect", "text": "TTP", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6683487_4_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6683487_4_Ent0", "text": "TTP", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6692713_2", "wnd_id": "6692713_2_1", "text": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy .", "tokens": ["Possible", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "following", "corticosteroid", "therapy", "."], "event_mentions": [{"id": "6692713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "6692713_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "6692713_2_Ent0", "role": "Effect", "text": "amiodarone pulmonary toxicity", "start": 3, "end": 6}, {"entity_id": "6692713_2_Ent1", "role": "Treatment", "text": "corticosteroid", "start": 7, "end": 8}, {"entity_id": "6692713_2_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6692713_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6692713_2_Ent0", "text": "amiodarone pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6692713_2_Ent1", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_2_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6692713_3", "wnd_id": "6692713_3_1", "text": "To our knowledge , this recurrence of amiodarone pulmonary toxicity has not been reported previously .", "tokens": ["To", "our", "knowledge", ",", "this", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "has", "not", "been", "reported", "previously", "."], "event_mentions": [{"id": "6692713_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 9, "end": 10}, "arguments": [{"entity_id": "6692713_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "6692713_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 7, "end": 8}, {"entity_id": "6692713_3_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "6692713_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_3_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "6693840_1", "wnd_id": "6693840_1_1", "text": "A 61 year - old male patient developed gynecomastia after starting theophylline .", "tokens": ["A", "61", "year", "-", "old", "male", "patient", "developed", "gynecomastia", "after", "starting", "theophylline", "."], "event_mentions": [{"id": "6693840_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_1_Ent0", "role": "Subject", "text": "A 61 year - old male patient", "start": 0, "end": 7}, {"entity_id": "6693840_1_Ent1", "role": "Subject_Age", "text": "61 year - old", "start": 1, "end": 5}, {"entity_id": "6693840_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "6693840_1_Ent3", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_1_Ent4", "role": "Treatment", "text": "theophylline", "start": 11, "end": 12}, {"entity_id": "6693840_1_Ent5", "role": "Treatment_Drug", "text": "theophylline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6693840_1_Ent0", "text": "A 61 year - old male patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6693840_1_Ent1", "text": "61 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6693840_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_1_Ent3", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_1_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6693840_1_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6702890_1", "wnd_id": "6702890_1_1", "text": "A 69 - year - old man developed pure red cell aplasia after taking fenoprofen for ten months .", "tokens": ["A", "69", "-", "year", "-", "old", "man", "developed", "pure", "red", "cell", "aplasia", "after", "taking", "fenoprofen", "for", "ten", "months", "."], "event_mentions": [{"id": "6702890_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6702890_1_Ent0", "role": "Subject", "text": "A 69 - year - old man", "start": 0, "end": 7}, {"entity_id": "6702890_1_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 1, "end": 6}, {"entity_id": "6702890_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6702890_1_Ent3", "role": "Effect", "text": "pure red cell aplasia", "start": 8, "end": 12}, {"entity_id": "6702890_1_Ent4", "role": "Treatment", "text": "taking fenoprofen for ten months", "start": 13, "end": 18}, {"entity_id": "6702890_1_Ent5", "role": "Treatment_Drug", "text": "fenoprofen", "start": 14, "end": 15}, {"entity_id": "6702890_1_Ent6", "role": "Treatment_Time_elapsed", "text": "ten months", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "6702890_1_Ent0", "text": "A 69 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6702890_1_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6702890_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6702890_1_Ent3", "text": "pure red cell aplasia", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "6702890_1_Ent4", "text": "taking fenoprofen for ten months", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "6702890_1_Ent5", "text": "fenoprofen", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6702890_1_Ent6", "text": "ten months", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "6731466_1", "wnd_id": "6731466_1_1", "text": "Focal renal cortical necrosis associated with zomepirac .", "tokens": ["Focal", "renal", "cortical", "necrosis", "associated", "with", "zomepirac", "."], "event_mentions": [{"id": "6731466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6731466_1_Ent0", "role": "Effect", "text": "Focal renal cortical necrosis", "start": 0, "end": 4}, {"entity_id": "6731466_1_Ent1", "role": "Treatment", "text": "zomepirac", "start": 6, "end": 7}, {"entity_id": "6731466_1_Ent2", "role": "Treatment_Drug", "text": "zomepirac", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6731466_1_Ent0", "text": "Focal renal cortical necrosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6731466_1_Ent1", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6731466_1_Ent2", "text": "zomepirac", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6733633_2", "wnd_id": "6733633_2_1", "text": "Cimetidine is a rare cause of drug - induced fever .", "tokens": ["Cimetidine", "is", "a", "rare", "cause", "of", "drug", "-", "induced", "fever", "."], "event_mentions": [{"id": "6733633_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "6733633_2_Ent1", "role": "Treatment", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent2", "role": "Treatment_Drug", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_2_Ent0", "role": "Effect", "text": "fever", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "6733633_2_Ent1", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent2", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "6833205_2", "wnd_id": "6833205_2_1", "text": "Desipramine - associated SIADH in an elderly woman : case report .", "tokens": ["Desipramine", "-", "associated", "SIADH", "in", "an", "elderly", "woman", ":", "case", "report", "."], "event_mentions": [{"id": "6833205_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6833205_2_Ent4", "role": "Treatment", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent5", "role": "Treatment_Drug", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_2_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "6833205_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "6833205_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6833205_2_Ent4", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent5", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_2_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6833205_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6860059_1", "wnd_id": "6860059_1_1", "text": "Fulminant hepatitis associated with disulfiram .", "tokens": ["Fulminant", "hepatitis", "associated", "with", "disulfiram", "."], "event_mentions": [{"id": "6860059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6860059_1_Ent0", "role": "Effect", "text": "Fulminant hepatitis", "start": 0, "end": 2}, {"entity_id": "6860059_1_Ent1", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6860059_1_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6860059_1_Ent0", "text": "Fulminant hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6860059_1_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6860059_1_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6928097_1", "wnd_id": "6928097_1_1", "text": "She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy , but 6 months later died of Adriamycin toxicity .", "tokens": ["She", "was", "placed", "on", "adjuvant", "Adriamycin", "(", "doxorubicin", ")", "chemotherapy", ",", "but", "6", "months", "later", "died", "of", "Adriamycin", "toxicity", "."], "event_mentions": [{"id": "6928097_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 18, "end": 19}, "arguments": [{"entity_id": "6928097_1_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "6928097_1_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "6928097_1_Ent3", "role": "Treatment", "text": "adjuvant Adriamycin ( doxorubicin ) chemotherapy", "start": 4, "end": 10}, {"entity_id": "6928097_1_Ent4", "role": "Treatment_Drug", "text": "Adriamycin", "start": 5, "end": 6}, {"entity_id": "6928097_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 9, "end": 10}, {"entity_id": "6928097_1_Ent5", "role": "Treatment_Time_elapsed", "text": "6 months", "start": 12, "end": 14}, {"entity_id": "6928097_1_Ent2", "role": "Effect", "text": "died of Adriamycin toxicity", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "6928097_1_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6928097_1_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6928097_1_Ent3", "text": "adjuvant Adriamycin ( doxorubicin ) chemotherapy", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "6928097_1_Ent4", "text": "Adriamycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6928097_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6928097_1_Ent5", "text": "6 months", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "6928097_1_Ent2", "text": "died of Adriamycin toxicity", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "7035691_2", "wnd_id": "7035691_2_1", "text": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril .", "tokens": ["We", "report", "on", "a", "patient", "with", "renal", "artery", "stenosis", "who", "had", "only", "1", "kidney", "and", "in", "whom", "acute", "renal", "impairment", "developed", "with", "transient", "anuria", "after", "the", "administration", "of", "captopril", "."], "event_mentions": [{"id": "7035691_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "7035691_2_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis who had only 1 kidney", "start": 3, "end": 14}, {"entity_id": "7035691_2_Ent1", "role": "Subject_Disorder", "text": "renal artery stenosis who had only 1 kidney", "start": 6, "end": 14}, {"entity_id": "7035691_2_Ent2", "role": "Effect", "text": "acute renal impairment developed with transient anuria", "start": 17, "end": 24}, {"entity_id": "7035691_2_Ent3", "role": "Treatment", "text": "the administration of captopril", "start": 25, "end": 29}, {"entity_id": "7035691_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7035691_2_Ent0", "text": "a patient with renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "7035691_2_Ent1", "text": "renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7035691_2_Ent2", "text": "acute renal impairment developed with transient anuria", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "7035691_2_Ent3", "text": "the administration of captopril", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7035691_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7056119_1", "wnd_id": "7056119_1_1", "text": "Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : arrhythmia previously induced by quinidine and disopyramide .", "tokens": ["Atypical", "ventricular", "tachycardia", "(", "torsade", "de", "pointes", ")", "induced", "by", "amiodarone", ":", "arrhythmia", "previously", "induced", "by", "quinidine", "and", "disopyramide", "."], "event_mentions": [{"id": "7056119_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "7056119_1_Ent0", "role": "Effect", "text": "Atypical ventricular tachycardia ( torsade de pointes )", "start": 0, "end": 8}, {"entity_id": "7056119_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 10, "end": 11}, {"entity_id": "7056119_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "7056119_1_Ent0", "text": "Atypical ventricular tachycardia ( torsade de pointes )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "7056119_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7056119_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "7056119_6", "wnd_id": "7056119_6_1", "text": "Amiodarone was the third drug to induce AVT in this patient ; she received 200 mg / day six days per week for six months .", "tokens": ["Amiodarone", "was", "the", "third", "drug", "to", "induce", "AVT", "in", "this", "patient", ";", "she", "received", "200", "mg", "/", "day", "six", "days", "per", "week", "for", "six", "months", "."], "event_mentions": [{"id": "7056119_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 6, "end": 7}, "arguments": [{"entity_id": "7056119_6_Ent4", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent6", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "7056119_6_Ent3", "role": "Effect", "text": "AVT", "start": 7, "end": 8}, {"entity_id": "7056119_6_Ent0", "role": "Subject", "text": "patient", "start": 10, "end": 11}, {"entity_id": "7056119_6_Ent1", "role": "Subject", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent2", "role": "Subject_Gender", "text": "she", "start": 12, "end": 13}, {"entity_id": "7056119_6_Ent7", "role": "Treatment_Dosage", "text": "200 mg / day", "start": 14, "end": 18}, {"entity_id": "7056119_6_Ent5", "role": "Treatment", "text": "200 mg / day six days per week for six months", "start": 14, "end": 25}, {"entity_id": "7056119_6_Ent8", "role": "Treatment_Freq", "text": "six days per week", "start": 18, "end": 22}, {"entity_id": "7056119_6_Ent9", "role": "Treatment_Freq", "text": "six months", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "7056119_6_Ent4", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent6", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7056119_6_Ent3", "text": "AVT", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7056119_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7056119_6_Ent1", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent2", "text": "she", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7056119_6_Ent7", "text": "200 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7056119_6_Ent5", "text": "200 mg / day six days per week for six months", "entity_type": "Entity", "start": 14, "end": 25}, {"id": "7056119_6_Ent8", "text": "six days per week", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "7056119_6_Ent9", "text": "six months", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "7081289_2", "wnd_id": "7081289_2_1", "text": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed .", "tokens": ["The", "case", "of", "an", "adult", "who", "developed", "both", "hepatic", "dysfunction", "and", "an", "impaired", "macrophage", "migration", "after", "exposure", "to", "cimetidine", "is", "discussed", "."], "event_mentions": [{"id": "7081289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "7081289_2_Ent0", "role": "Subject", "text": "an adult", "start": 3, "end": 5}, {"entity_id": "7081289_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 4, "end": 5}, {"entity_id": "7081289_2_Ent2", "role": "Effect", "text": "hepatic dysfunction and an impaired macrophage migration", "start": 8, "end": 15}, {"entity_id": "7081289_2_Ent4", "role": "Treatment_Drug", "text": "cimetidine", "start": 18, "end": 19}, {"entity_id": "7081289_2_Ent3", "role": "Treatment", "text": "cimetidine is discussed", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "7081289_2_Ent0", "text": "an adult", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7081289_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7081289_2_Ent2", "text": "hepatic dysfunction and an impaired macrophage migration", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "7081289_2_Ent4", "text": "cimetidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7081289_2_Ent3", "text": "cimetidine is discussed", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "7117795_2", "wnd_id": "7117795_2_1", "text": "This report describes a case of flucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing , ulceration , and marked separation of loops of bowel .", "tokens": ["This", "report", "describes", "a", "case", "of", "flucytosine", "-", "associated", "ulcerating", "enteritis", "in", "which", "the", "small", "bowel", "x", "-", "ray", "demonstrated", "severe", "luminal", "narrowing", ",", "ulceration", ",", "and", "marked", "separation", "of", "loops", "of", "bowel", "."], "event_mentions": [{"id": "7117795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "7117795_2_Ent1", "role": "Treatment", "text": "flucytosine", "start": 6, "end": 7}, {"entity_id": "7117795_2_Ent2", "role": "Treatment_Drug", "text": "flucytosine", "start": 6, "end": 7}, {"entity_id": "7117795_2_Ent0", "role": "Effect", "text": "ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing , ulceration , and marked separation of loops of bowel", "start": 9, "end": 33}]}], "entity_mentions": [{"id": "7117795_2_Ent1", "text": "flucytosine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7117795_2_Ent2", "text": "flucytosine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7117795_2_Ent0", "text": "ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing , ulceration , and marked separation of loops of bowel", "entity_type": "Entity", "start": 9, "end": 33}], "lang": "en"}
{"doc_id": "7117795_3", "wnd_id": "7117795_3_1", "text": "Ulcerating enteritis associated with flucytosine therapy .", "tokens": ["Ulcerating", "enteritis", "associated", "with", "flucytosine", "therapy", "."], "event_mentions": [{"id": "7117795_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "7117795_3_Ent0", "role": "Effect", "text": "Ulcerating enteritis", "start": 0, "end": 2}, {"entity_id": "7117795_3_Ent2", "role": "Treatment_Drug", "text": "flucytosine", "start": 4, "end": 5}, {"entity_id": "7117795_3_Ent1", "role": "Treatment", "text": "flucytosine therapy", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7117795_3_Ent0", "text": "Ulcerating enteritis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7117795_3_Ent2", "text": "flucytosine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7117795_3_Ent1", "text": "flucytosine therapy", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7151655_1", "wnd_id": "7151655_1_1", "text": "In one patient , treatment with DCA was associated with a decrease in blood lactate levels from 11.2 mM before treatment to 0.8 mM 16 h later .", "tokens": ["In", "one", "patient", ",", "treatment", "with", "DCA", "was", "associated", "with", "a", "decrease", "in", "blood", "lactate", "levels", "from", "11.2", "mM", "before", "treatment", "to", "0.8", "mM", "16", "h", "later", "."], "event_mentions": [{"id": "7151655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "7151655_1_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "7151655_1_Ent0", "role": "Subject", "text": "one patient", "start": 1, "end": 3}, {"entity_id": "7151655_1_Ent3", "role": "Treatment", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent4", "role": "Treatment_Drug", "text": "DCA", "start": 6, "end": 7}, {"entity_id": "7151655_1_Ent2", "role": "Effect", "text": "decrease in blood lactate levels", "start": 11, "end": 16}, {"entity_id": "7151655_1_Ent5", "role": "Treatment_Time_elapsed", "text": "16 h later", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "7151655_1_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7151655_1_Ent0", "text": "one patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "7151655_1_Ent3", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent4", "text": "DCA", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7151655_1_Ent2", "text": "decrease in blood lactate levels", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7151655_1_Ent5", "text": "16 h later", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "717931_2", "wnd_id": "717931_2_1", "text": "Marked hyperkalemia was observed during and immediately after an infusion of arginine monohydrochloride in two patients with severe hepatic disease and moderate renal insufficiency .", "tokens": ["Marked", "hyperkalemia", "was", "observed", "during", "and", "immediately", "after", "an", "infusion", "of", "arginine", "monohydrochloride", "in", "two", "patients", "with", "severe", "hepatic", "disease", "and", "moderate", "renal", "insufficiency", "."], "event_mentions": [{"id": "717931_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "717931_2_Ent3", "role": "Effect", "text": "Marked hyperkalemia", "start": 0, "end": 2}, {"entity_id": "717931_2_Ent4", "role": "Treatment", "text": "during and immediately after an infusion of arginine monohydrochloride", "start": 4, "end": 13}, {"entity_id": "717931_2_Ent7", "role": "Treatment_Time_elapsed", "text": "immediately", "start": 6, "end": 7}, {"entity_id": "717931_2_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 9, "end": 10}, {"entity_id": "717931_2_Ent5", "role": "Treatment_Drug", "text": "arginine monohydrochloride", "start": 11, "end": 13}, {"entity_id": "717931_2_Ent1", "role": "Subject_Population", "text": "two", "start": 14, "end": 15}, {"entity_id": "717931_2_Ent0", "role": "Subject", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "start": 14, "end": 24}, {"entity_id": "717931_2_Ent8", "role": "Treatment_Disorder", "text": "hepatic disease", "start": 18, "end": 20}, {"entity_id": "717931_2_Ent2", "role": "Subject_Disorder", "text": "moderate renal insufficiency", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "717931_2_Ent3", "text": "Marked hyperkalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "717931_2_Ent4", "text": "during and immediately after an infusion of arginine monohydrochloride", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "717931_2_Ent7", "text": "immediately", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "717931_2_Ent6", "text": "infusion", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "717931_2_Ent5", "text": "arginine monohydrochloride", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "717931_2_Ent1", "text": "two", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "717931_2_Ent0", "text": "two patients with severe hepatic disease and moderate renal insufficiency", "entity_type": "Entity", "start": 14, "end": 24}, {"id": "717931_2_Ent8", "text": "hepatic disease", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "717931_2_Ent2", "text": "moderate renal insufficiency", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "71813_4", "wnd_id": "71813_4_1", "text": "The case history confirms that gold treatment , even in the same patient , can give rise to a wide range of skin disturbances , which in many cases do not break out until long after the drug has been withdrawn .", "tokens": ["The", "case", "history", "confirms", "that", "gold", "treatment", ",", "even", "in", "the", "same", "patient", ",", "can", "give", "rise", "to", "a", "wide", "range", "of", "skin", "disturbances", ",", "which", "in", "many", "cases", "do", "not", "break", "out", "until", "long", "after", "the", "drug", "has", "been", "withdrawn", "."], "event_mentions": [{"id": "71813_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "give rise", "start": 15, "end": 17}, "arguments": [{"entity_id": "71813_4_Ent2", "role": "Treatment", "text": "gold", "start": 5, "end": 6}, {"entity_id": "71813_4_Ent3", "role": "Treatment_Drug", "text": "gold", "start": 5, "end": 6}, {"entity_id": "71813_4_Ent0", "role": "Subject", "text": "in the same patient ,", "start": 9, "end": 14}, {"entity_id": "71813_4_Ent1", "role": "Effect", "text": "wide range of skin disturbances , which in many cases do not break out until long after the drug has been withdrawn", "start": 19, "end": 41}]}], "entity_mentions": [{"id": "71813_4_Ent2", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "71813_4_Ent3", "text": "gold", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "71813_4_Ent0", "text": "in the same patient ,", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "71813_4_Ent1", "text": "wide range of skin disturbances , which in many cases do not break out until long after the drug has been withdrawn", "entity_type": "Entity", "start": 19, "end": 41}], "lang": "en"}
{"doc_id": "7212107_2", "wnd_id": "7212107_2_1", "text": "These results indicate that lithium may cause biochemical hyperparathyroidism .", "tokens": ["These", "results", "indicate", "that", "lithium", "may", "cause", "biochemical", "hyperparathyroidism", "."], "event_mentions": [{"id": "7212107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "may", "start": 5, "end": 6}, "arguments": [{"entity_id": "7212107_2_Ent1", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent0", "role": "Effect", "text": "biochemical hyperparathyroidism", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7212107_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent0", "text": "biochemical hyperparathyroidism", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7235792_4", "wnd_id": "7235792_4_1", "text": "Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy .", "tokens": ["Paradoxical", "ventricular", "tachycardia", "and", "fibrillation", "after", "intravenous", "bretylium", "therapy", "."], "event_mentions": [{"id": "7235792_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "7235792_4_Ent0", "role": "Effect", "text": "Paradoxical ventricular tachycardia and fibrillation", "start": 0, "end": 5}, {"entity_id": "7235792_4_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "7235792_4_Ent1", "role": "Treatment", "text": "intravenous bretylium", "start": 6, "end": 8}, {"entity_id": "7235792_4_Ent3", "role": "Treatment_Drug", "text": "bretylium", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7235792_4_Ent0", "text": "Paradoxical ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7235792_4_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7235792_4_Ent1", "text": "intravenous bretylium", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7235792_4_Ent3", "text": "bretylium", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7249424_3", "wnd_id": "7249424_3_1", "text": "Two patients on long - term lithium therapy developed the nephrotic syndrome .", "tokens": ["Two", "patients", "on", "long", "-", "term", "lithium", "therapy", "developed", "the", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "7249424_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "7249424_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7249424_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7249424_3_Ent3", "role": "Treatment", "text": "long - term lithium therapy", "start": 3, "end": 8}, {"entity_id": "7249424_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7249424_3_Ent2", "role": "Effect", "text": "nephrotic syndrome", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7249424_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7249424_3_Ent3", "text": "long - term lithium therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7249424_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7249424_3_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7351000_1", "wnd_id": "7351000_1_1", "text": "Acute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan (= dihydroxybusulfan ) .", "tokens": ["Acute", "non", "-", "lymphocytic", "leukemia", "in", "patients", "with", "ovarian", "carcinoma", "following", "long", "-", "term", "treatment", "with", "Treosulfan", "(=", "dihydroxybusulfan", ")", "."], "event_mentions": [{"id": "7351000_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "7351000_1_Ent1", "role": "Effect", "text": "Acute non - lymphocytic leukemia", "start": 0, "end": 5}, {"entity_id": "7351000_1_Ent0", "role": "Subject", "text": "patients with ovarian carcinoma", "start": 6, "end": 10}, {"entity_id": "7351000_1_Ent4", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 8, "end": 10}, {"entity_id": "7351000_1_Ent2", "role": "Treatment", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "start": 11, "end": 20}, {"entity_id": "7351000_1_Ent3", "role": "Treatment_Drug", "text": "Treosulfan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7351000_1_Ent1", "text": "Acute non - lymphocytic leukemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_1_Ent0", "text": "patients with ovarian carcinoma", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7351000_1_Ent4", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7351000_1_Ent2", "text": "long - term treatment with Treosulfan (= dihydroxybusulfan )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "7351000_1_Ent3", "text": "Treosulfan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7355327_2", "wnd_id": "7355327_2_1", "text": "Regardless of a negative history of asthma , therefore , life - threatening bronchospasm must be considered a possible complication of propranolol therapy .", "tokens": ["Regardless", "of", "a", "negative", "history", "of", "asthma", ",", "therefore", ",", "life", "-", "threatening", "bronchospasm", "must", "be", "considered", "a", "possible", "complication", "of", "propranolol", "therapy", "."], "event_mentions": [{"id": "7355327_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 19, "end": 20}, "arguments": [{"entity_id": "7355327_2_Ent0", "role": "Effect", "text": "life - threatening bronchospasm", "start": 10, "end": 14}, {"entity_id": "7355327_2_Ent1", "role": "Treatment", "text": "propranolol", "start": 21, "end": 22}, {"entity_id": "7355327_2_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "7355327_2_Ent0", "text": "life - threatening bronchospasm", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7355327_2_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7355327_2_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "7362333_1", "wnd_id": "7362333_1_1", "text": "Propranolol : an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass .", "tokens": ["Propranolol", ":", "an", "unrecognized", "cause", "of", "central", "nervous", "system", "dysfunction", "in", "patients", "undergoing", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "7362333_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7362333_1_Ent3", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent4", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent2", "role": "Effect", "text": "central nervous system dysfunction", "start": 6, "end": 10}, {"entity_id": "7362333_1_Ent0", "role": "Subject", "text": "patients undergoing cardiopulmonary bypass", "start": 11, "end": 15}, {"entity_id": "7362333_1_Ent1", "role": "Subject_Disorder", "text": "cardiopulmonary bypass", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7362333_1_Ent3", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent4", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent2", "text": "central nervous system dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7362333_1_Ent0", "text": "patients undergoing cardiopulmonary bypass", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7362333_1_Ent1", "text": "cardiopulmonary bypass", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7379406_1", "wnd_id": "7379406_1_1", "text": "Niflumic acid - induced skeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis ?", "tokens": ["Niflumic", "acid", "-", "induced", "skeletal", "fluorosis", ":", "iatrogenic", "disease", "or", "therapeutic", "perspective", "for", "osteoporosis", "?"], "event_mentions": [{"id": "7379406_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7379406_1_Ent1", "role": "Treatment", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent2", "role": "Treatment_Drug", "text": "Niflumic acid", "start": 0, "end": 2}, {"entity_id": "7379406_1_Ent0", "role": "Effect", "text": "skeletal fluorosis", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7379406_1_Ent1", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent2", "text": "Niflumic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7379406_1_Ent0", "text": "skeletal fluorosis", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7387219_1", "wnd_id": "7387219_1_1", "text": "Hepatotoxicity associated with use of D - penicillamine in rheumatoid arthritis .", "tokens": ["Hepatotoxicity", "associated", "with", "use", "of", "D", "-", "penicillamine", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "7387219_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "7387219_1_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "7387219_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7387219_1_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7387219_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7393795_2", "wnd_id": "7393795_2_1", "text": "Para - aminosalicylic acid - induced hypoglycaemia in a patient with diabetic nephropathy .", "tokens": ["Para", "-", "aminosalicylic", "acid", "-", "induced", "hypoglycaemia", "in", "a", "patient", "with", "diabetic", "nephropathy", "."], "event_mentions": [{"id": "7393795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7393795_2_Ent3", "role": "Treatment", "text": "Para - aminosalicylic acid", "start": 0, "end": 4}, {"entity_id": "7393795_2_Ent4", "role": "Treatment_Drug", "text": "Para - aminosalicylic acid", "start": 0, "end": 4}, {"entity_id": "7393795_2_Ent2", "role": "Effect", "text": "hypoglycaemia", "start": 6, "end": 7}, {"entity_id": "7393795_2_Ent0", "role": "Subject", "text": "a patient with diabetic nephropathy", "start": 8, "end": 13}, {"entity_id": "7393795_2_Ent1", "role": "Subject_Disorder", "text": "diabetic nephropathy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7393795_2_Ent3", "text": "Para - aminosalicylic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7393795_2_Ent4", "text": "Para - aminosalicylic acid", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7393795_2_Ent2", "text": "hypoglycaemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7393795_2_Ent0", "text": "a patient with diabetic nephropathy", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "7393795_2_Ent1", "text": "diabetic nephropathy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7393795_4", "wnd_id": "7393795_4_1", "text": "The introduction of para - aminosalicylic acid ( PAS ) led to hypoglycaemic coma .", "tokens": ["The", "introduction", "of", "para", "-", "aminosalicylic", "acid", "(", "PAS", ")", "led", "to", "hypoglycaemic", "coma", "."], "event_mentions": [{"id": "7393795_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led to", "start": 10, "end": 12}, "arguments": [{"entity_id": "7393795_4_Ent1", "role": "Treatment", "text": "The introduction of para - aminosalicylic acid ( PAS )", "start": 0, "end": 10}, {"entity_id": "7393795_4_Ent2", "role": "Treatment_Drug", "text": "para - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "7393795_4_Ent0", "role": "Effect", "text": "hypoglycaemic coma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "7393795_4_Ent1", "text": "The introduction of para - aminosalicylic acid ( PAS )", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "7393795_4_Ent2", "text": "para - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7393795_4_Ent0", "text": "hypoglycaemic coma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "7416268_2", "wnd_id": "7416268_2_1", "text": "The authors describe a case of the catatonia syndrome associated with disulfiram therapy .", "tokens": ["The", "authors", "describe", "a", "case", "of", "the", "catatonia", "syndrome", "associated", "with", "disulfiram", "therapy", "."], "event_mentions": [{"id": "7416268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "7416268_2_Ent0", "role": "Effect", "text": "catatonia syndrome", "start": 7, "end": 9}, {"entity_id": "7416268_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 11, "end": 12}, {"entity_id": "7416268_2_Ent1", "role": "Treatment", "text": "disulfiram therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7416268_2_Ent0", "text": "catatonia syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7416268_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7416268_2_Ent1", "text": "disulfiram therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7420580_1", "wnd_id": "7420580_1_1", "text": "Inappropriate antidiuretic hormone secretion after high dose vinblastine .", "tokens": ["Inappropriate", "antidiuretic", "hormone", "secretion", "after", "high", "dose", "vinblastine", "."], "event_mentions": [{"id": "7420580_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "7420580_1_Ent0", "role": "Effect", "text": "Inappropriate antidiuretic hormone secretion", "start": 0, "end": 4}, {"entity_id": "7420580_1_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 5, "end": 7}, {"entity_id": "7420580_1_Ent1", "role": "Treatment", "text": "high dose vinblastine", "start": 5, "end": 8}, {"entity_id": "7420580_1_Ent2", "role": "Treatment_Drug", "text": "vinblastine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7420580_1_Ent0", "text": "Inappropriate antidiuretic hormone secretion", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7420580_1_Ent3", "text": "high dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7420580_1_Ent1", "text": "high dose vinblastine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7420580_1_Ent2", "text": "vinblastine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7468565_1", "wnd_id": "7468565_1_1", "text": "Barbiturate - induced submassive hepatic necrosis .", "tokens": ["Barbiturate", "-", "induced", "submassive", "hepatic", "necrosis", "."], "event_mentions": [{"id": "7468565_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7468565_1_Ent1", "role": "Treatment", "text": "Barbiturate", "start": 0, "end": 1}, {"entity_id": "7468565_1_Ent2", "role": "Treatment_Drug", "text": "Barbiturate", "start": 0, "end": 1}, {"entity_id": "7468565_1_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "7468565_1_Ent1", "text": "Barbiturate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7468565_1_Ent2", "text": "Barbiturate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7468565_1_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7468565_3", "wnd_id": "7468565_3_1", "text": "A case of barbiturate - induced submassive hepatic necrosis is presented and the literature is reviewed .", "tokens": ["A", "case", "of", "barbiturate", "-", "induced", "submassive", "hepatic", "necrosis", "is", "presented", "and", "the", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "7468565_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7468565_3_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "7468565_3_Ent2", "role": "Treatment", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent3", "role": "Treatment_Drug", "text": "barbiturate", "start": 3, "end": 4}, {"entity_id": "7468565_3_Ent1", "role": "Effect", "text": "submassive hepatic necrosis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7468565_3_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7468565_3_Ent2", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent3", "text": "barbiturate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7468565_3_Ent1", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7468565_4", "wnd_id": "7468565_4_1", "text": "The patient 's clinical presentation , histologic features on liver biopsy and favorable course after stopping the drug suggest that barbiturates can be added to the list of agents which can cause submassive hepatic necrosis .", "tokens": ["The", "patient", "'s", "clinical", "presentation", ",", "histologic", "features", "on", "liver", "biopsy", "and", "favorable", "course", "after", "stopping", "the", "drug", "suggest", "that", "barbiturates", "can", "be", "added", "to", "the", "list", "of", "agents", "which", "can", "cause", "submassive", "hepatic", "necrosis", "."], "event_mentions": [{"id": "7468565_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 31, "end": 32}, "arguments": [{"entity_id": "7468565_4_Ent1", "role": "Treatment", "text": "barbiturates", "start": 20, "end": 21}, {"entity_id": "7468565_4_Ent2", "role": "Treatment_Drug", "text": "barbiturates", "start": 20, "end": 21}, {"entity_id": "7468565_4_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "7468565_4_Ent1", "text": "barbiturates", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7468565_4_Ent2", "text": "barbiturates", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7468565_4_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "7474364_1", "wnd_id": "7474364_1_1", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained - release procainamide ( 750 mg / day ) .", "tokens": ["A", "71", "-", "year", "-", "old", "man", "with", "paroxysmal", "atrial", "fibrillation", "who", "had", "a", "previous", "anterior", "myocardial", "infarction", "exhibited", "granulocytopenia", "8", "days", "following", "the", "administration", "of", "oral", "sustained", "-", "release", "procainamide", "(", "750", "mg", "/", "day", ")", "."], "event_mentions": [{"id": "7474364_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 18, "end": 19}, "arguments": [{"entity_id": "7474364_1_Ent0", "role": "Subject", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "start": 0, "end": 18}, {"entity_id": "7474364_1_Ent1", "role": "Subject_Age", "text": "71 - year - old", "start": 1, "end": 6}, {"entity_id": "7474364_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "7474364_1_Ent10", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 8, "end": 11}, {"entity_id": "7474364_1_Ent3", "role": "Subject_Disorder", "text": "anterior myocardial infarction", "start": 15, "end": 18}, {"entity_id": "7474364_1_Ent4", "role": "Effect", "text": "granulocytopenia", "start": 19, "end": 20}, {"entity_id": "7474364_1_Ent6", "role": "Treatment_Time_elapsed", "text": "8 days", "start": 20, "end": 22}, {"entity_id": "7474364_1_Ent8", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "7474364_1_Ent5", "role": "Treatment", "text": "oral sustained - release procainamide ( 750 mg / day )", "start": 26, "end": 37}, {"entity_id": "7474364_1_Ent7", "role": "Treatment_Drug", "text": "sustained - release procainamide", "start": 27, "end": 31}, {"entity_id": "7474364_1_Ent9", "role": "Treatment_Dosage", "text": "750 mg / day", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "7474364_1_Ent0", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "7474364_1_Ent1", "text": "71 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7474364_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7474364_1_Ent10", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7474364_1_Ent3", "text": "anterior myocardial infarction", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "7474364_1_Ent4", "text": "granulocytopenia", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7474364_1_Ent6", "text": "8 days", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "7474364_1_Ent8", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7474364_1_Ent5", "text": "oral sustained - release procainamide ( 750 mg / day )", "entity_type": "Entity", "start": 26, "end": 37}, {"id": "7474364_1_Ent7", "text": "sustained - release procainamide", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "7474364_1_Ent9", "text": "750 mg / day", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "7474364_2", "wnd_id": "7474364_2_1", "text": "Sustained - release procainamide - induced reversible granulocytopenia after myocardial infarction .", "tokens": ["Sustained", "-", "release", "procainamide", "-", "induced", "reversible", "granulocytopenia", "after", "myocardial", "infarction", "."], "event_mentions": [{"id": "7474364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7474364_2_Ent1", "role": "Treatment", "text": "Sustained - release procainamide", "start": 0, "end": 4}, {"entity_id": "7474364_2_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 3, "end": 4}, {"entity_id": "7474364_2_Ent0", "role": "Effect", "text": "reversible granulocytopenia", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "7474364_2_Ent1", "text": "Sustained - release procainamide", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7474364_2_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7474364_2_Ent0", "text": "reversible granulocytopenia", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "7485371_2", "wnd_id": "7485371_2_1", "text": "PURPOSE : We studied a case of vortex keratopathy that was associated with the use of atovaquone .", "tokens": ["PURPOSE", ":", "We", "studied", "a", "case", "of", "vortex", "keratopathy", "that", "was", "associated", "with", "the", "use", "of", "atovaquone", "."], "event_mentions": [{"id": "7485371_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "7485371_2_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "7485371_2_Ent1", "role": "Effect", "text": "vortex keratopathy", "start": 7, "end": 9}, {"entity_id": "7485371_2_Ent2", "role": "Treatment", "text": "atovaquone", "start": 16, "end": 17}, {"entity_id": "7485371_2_Ent3", "role": "Treatment_Drug", "text": "atovaquone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7485371_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7485371_2_Ent1", "text": "vortex keratopathy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7485371_2_Ent2", "text": "atovaquone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7485371_2_Ent3", "text": "atovaquone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7519913_1", "wnd_id": "7519913_1_1", "text": "However , there remain questions concerning whether these drugs , especially methimazole ( MMI ) , may be associated with aplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use .", "tokens": ["However", ",", "there", "remain", "questions", "concerning", "whether", "these", "drugs", ",", "especially", "methimazole", "(", "MMI", ")", ",", "may", "be", "associated", "with", "aplasia", "cutis", "congenita", "(", "ACC", ")", "and", "how", "best", "to", "avoid", "impairment", "of", "fetal", "thyroid", "function", "during", "their", "use", "."], "event_mentions": [{"id": "7519913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "7519913_1_Ent1", "role": "Treatment", "text": "methimazole", "start": 11, "end": 12}, {"entity_id": "7519913_1_Ent2", "role": "Treatment_Drug", "text": "methimazole ( MMI )", "start": 11, "end": 15}, {"entity_id": "7519913_1_Ent0", "role": "Effect", "text": "aplasia cutis congenita", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "7519913_1_Ent1", "text": "methimazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7519913_1_Ent2", "text": "methimazole ( MMI )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7519913_1_Ent0", "text": "aplasia cutis congenita", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "7545251_1", "wnd_id": "7545251_1_1", "text": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer .", "tokens": ["Chlormadinone", "acetate", "withdrawal", "syndrome", "under", "combined", "androgen", "blockade", "for", "advanced", "prostate", "cancer", "."], "event_mentions": [{"id": "7545251_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "under", "start": 4, "end": 5}, "arguments": [{"entity_id": "7545251_1_Ent0", "role": "Treatment", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent3", "role": "Treatment_Drug", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent6", "role": "Combination_Drug", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent1", "role": "Treatment", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent4", "role": "Treatment_Drug", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent5", "role": "Combination_Drug", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent2", "role": "Treatment_Disorder", "text": "advanced prostate cancer", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "7545251_1_Ent0", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent3", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent6", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent1", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent4", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent5", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent2", "text": "advanced prostate cancer", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7606071_3", "wnd_id": "7606071_3_1", "text": "CONCLUSIONS : We conclude that a high dose combined with a short infusion time increases the risk of anaphylactoid reactions with the administration of intraperitoneal cisplatin .", "tokens": ["CONCLUSIONS", ":", "We", "conclude", "that", "a", "high", "dose", "combined", "with", "a", "short", "infusion", "time", "increases", "the", "risk", "of", "anaphylactoid", "reactions", "with", "the", "administration", "of", "intraperitoneal", "cisplatin", "."], "event_mentions": [{"id": "7606071_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 20, "end": 21}, "arguments": [{"entity_id": "7606071_3_Ent1", "role": "Treatment", "text": "a high dose combined with a short infusion time", "start": 5, "end": 14}, {"entity_id": "7606071_3_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 6, "end": 8}, {"entity_id": "7606071_3_Ent0", "role": "Effect", "text": "anaphylactoid reactions", "start": 18, "end": 20}, {"entity_id": "7606071_3_Ent2", "role": "Treatment", "text": "administration of intraperitoneal cisplatin", "start": 22, "end": 26}, {"entity_id": "7606071_3_Ent5", "role": "Treatment_Route", "text": "intraperitoneal", "start": 24, "end": 25}, {"entity_id": "7606071_3_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "7606071_3_Ent1", "text": "a high dose combined with a short infusion time", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "7606071_3_Ent3", "text": "high dose", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7606071_3_Ent0", "text": "anaphylactoid reactions", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "7606071_3_Ent2", "text": "administration of intraperitoneal cisplatin", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "7606071_3_Ent5", "text": "intraperitoneal", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "7606071_3_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "7655130_1", "wnd_id": "7655130_1_1", "text": "CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .", "tokens": ["CASE", "SUMMARIES", ":", "Two", "patients", "with", "stable", "hypothyroidism", "experienced", "symptoms", "of", "hypothyroidism", "with", "increased", "serum", "thyroid", "-", "stimulating", "hormone", "(", "TSH", ")", "concentrations", "after", "switching", "from", "1", "levothyroxine", "product", "to", "another", "."], "event_mentions": [{"id": "7655130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "7655130_1_Ent1", "role": "Subject_Population", "text": "Two", "start": 3, "end": 4}, {"entity_id": "7655130_1_Ent0", "role": "Subject", "text": "Two patients with stable hypothyroidism", "start": 3, "end": 8}, {"entity_id": "7655130_1_Ent4", "role": "Treatment_Disorder", "text": "stable hypothyroidism", "start": 6, "end": 8}, {"entity_id": "7655130_1_Ent2", "role": "Effect", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "start": 11, "end": 19}, {"entity_id": "7655130_1_Ent3", "role": "Treatment", "text": "switching from 1 levothyroxine product to another", "start": 24, "end": 31}, {"entity_id": "7655130_1_Ent5", "role": "Treatment_Drug", "text": "levothyroxine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7655130_1_Ent1", "text": "Two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7655130_1_Ent0", "text": "Two patients with stable hypothyroidism", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7655130_1_Ent4", "text": "stable hypothyroidism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7655130_1_Ent2", "text": "hypothyroidism with increased serum thyroid - stimulating hormone", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "7655130_1_Ent3", "text": "switching from 1 levothyroxine product to another", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "7655130_1_Ent5", "text": "levothyroxine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7668127_3", "wnd_id": "7668127_3_1", "text": "To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published .", "tokens": ["To", "the", "best", "of", "our", "knowledge", "no", "comparable", "case", "and", "no", "discussion", "of", "possible", "complications", "of", "aspirin", "prophylaxis", "in", "patients", "with", "brain", "tumours", "have", "been", "published", "."], "event_mentions": [{"id": "7668127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 14, "end": 15}, "arguments": [{"entity_id": "7668127_3_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 16, "end": 17}, {"entity_id": "7668127_3_Ent2", "role": "Treatment", "text": "aspirin prophylaxis", "start": 16, "end": 18}, {"entity_id": "7668127_3_Ent0", "role": "Subject", "text": "patients with brain tumours", "start": 19, "end": 23}, {"entity_id": "7668127_3_Ent1", "role": "Subject_Disorder", "text": "brain tumours", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "7668127_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7668127_3_Ent2", "text": "aspirin prophylaxis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7668127_3_Ent0", "text": "patients with brain tumours", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "7668127_3_Ent1", "text": "brain tumours", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "7673653_2", "wnd_id": "7673653_2_1", "text": "Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .", "tokens": ["Extrapyramidal", "side", "effects", "induced", "by", "some", "selective", "serotonin", "reuptake", "inhibitors", "(", "SSRIs", ")", ",", "i.e.", "fluoxetine", "and", "sertraline", ",", "have", "been", "previously", "reported", "in", "patients", "with", "depression", "and", "obsessive", "-", "compulsive", "disorder", "(", "OCD", ")", "."], "event_mentions": [{"id": "7673653_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "7673653_2_Ent1", "role": "Effect", "text": "Extrapyramidal side effects", "start": 0, "end": 3}, {"entity_id": "7673653_2_Ent2", "role": "Treatment", "text": "some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline", "start": 5, "end": 18}, {"entity_id": "7673653_2_Ent7", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 7, "end": 10}, {"entity_id": "7673653_2_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 15, "end": 16}, {"entity_id": "7673653_2_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 17, "end": 18}, {"entity_id": "7673653_2_Ent0", "role": "Subject", "text": "patients with depression and obsessive - compulsive disorder ( OCD )", "start": 24, "end": 35}, {"entity_id": "7673653_2_Ent3", "role": "Treatment_Disorder", "text": "depression", "start": 26, "end": 27}, {"entity_id": "7673653_2_Ent4", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder ( OCD )", "start": 28, "end": 35}]}], "entity_mentions": [{"id": "7673653_2_Ent1", "text": "Extrapyramidal side effects", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7673653_2_Ent2", "text": "some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "7673653_2_Ent7", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7673653_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7673653_2_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7673653_2_Ent0", "text": "patients with depression and obsessive - compulsive disorder ( OCD )", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "7673653_2_Ent3", "text": "depression", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7673653_2_Ent4", "text": "obsessive - compulsive disorder ( OCD )", "entity_type": "Entity", "start": 28, "end": 35}], "lang": "en"}
{"doc_id": "7679525_2", "wnd_id": "7679525_2_1", "text": "A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .", "tokens": ["A", "42", "year", "old", "man", ",", "treated", "for", "testicular", "carcinoma", "with", "combination", "chemotherapy", "that", "included", "bleomycin", ",", "developed", "life", "threatening", "interstitial", "pneumonitis", "."], "event_mentions": [{"id": "7679525_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7679525_2_Ent1", "role": "Subject_Age", "text": "42 year old", "start": 1, "end": 4}, {"entity_id": "7679525_2_Ent0", "role": "Subject", "text": "42 year old man", "start": 1, "end": 5}, {"entity_id": "7679525_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "7679525_2_Ent5", "role": "Treatment_Disorder", "text": "testicular carcinoma", "start": 8, "end": 10}, {"entity_id": "7679525_2_Ent4", "role": "Treatment", "text": "combination chemotherapy that included bleomycin ,", "start": 11, "end": 17}, {"entity_id": "7679525_2_Ent6", "role": "Treatment_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "7679525_2_Ent3", "role": "Effect", "text": "interstitial pneumonitis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "7679525_2_Ent1", "text": "42 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7679525_2_Ent0", "text": "42 year old man", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "7679525_2_Ent2", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7679525_2_Ent5", "text": "testicular carcinoma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7679525_2_Ent4", "text": "combination chemotherapy that included bleomycin ,", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "7679525_2_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7679525_2_Ent3", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "7685228_1", "wnd_id": "7685228_1_1", "text": "Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .", "tokens": ["Reversal", "of", "gold", "-", "induced", "neutropenia", "with", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "7685228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7685228_1_Ent2", "role": "Treatment", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent1", "role": "Effect", "text": "neutropenia", "start": 5, "end": 6}, {"entity_id": "7685228_1_Ent0", "role": "Subject", "text": "granulocyte colony - stimulating factor", "start": 7, "end": 12}, {"entity_id": "7685228_1_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "7685228_1_Ent2", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent4", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7685228_1_Ent0", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7685228_1_Ent3", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "7696938_1", "wnd_id": "7696938_1_1", "text": "Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .", "tokens": ["Arrhythmias", "and", "cardiac", "arrest", "have", "been", "reported", "during", "amphotericin", "B", "administration", "but", "no", "effective", "technique", "has", "been", "described", "to", "prevent", "them", "."], "event_mentions": [{"id": "7696938_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "7696938_1_Ent0", "role": "Effect", "text": "Arrhythmias and cardiac arrest", "start": 0, "end": 4}, {"entity_id": "7696938_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 8, "end": 10}, {"entity_id": "7696938_1_Ent1", "role": "Treatment", "text": "amphotericin B administration", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "7696938_1_Ent0", "text": "Arrhythmias and cardiac arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7696938_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7696938_1_Ent1", "text": "amphotericin B administration", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "7696938_3", "wnd_id": "7696938_3_1", "text": "I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .", "tokens": ["I", "saw", "two", "patients", "with", "kala", "-", "azar", "resistant", "to", "sodium", "stibogluconate", "who", "developed", "cardiac", "arrest", "after", "amphotericin", "infusion", "(", "in", "spite", "of", "tolerating", "a", "test", "dose", ")", "."], "event_mentions": [{"id": "7696938_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "7696938_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "7696938_3_Ent0", "role": "Subject", "text": "two patients with kala - azar resistant to sodium stibogluconate", "start": 2, "end": 12}, {"entity_id": "7696938_3_Ent5", "role": "Treatment_Disorder", "text": "kala - azar", "start": 5, "end": 8}, {"entity_id": "7696938_3_Ent2", "role": "Subject_Disorder", "text": "resistant to sodium stibogluconate", "start": 8, "end": 12}, {"entity_id": "7696938_3_Ent3", "role": "Effect", "text": "cardiac arrest", "start": 14, "end": 16}, {"entity_id": "7696938_3_Ent6", "role": "Treatment_Drug", "text": "amphotericin", "start": 17, "end": 18}, {"entity_id": "7696938_3_Ent4", "role": "Treatment", "text": "amphotericin infusion", "start": 17, "end": 19}, {"entity_id": "7696938_3_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7696938_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7696938_3_Ent0", "text": "two patients with kala - azar resistant to sodium stibogluconate", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "7696938_3_Ent5", "text": "kala - azar", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7696938_3_Ent2", "text": "resistant to sodium stibogluconate", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7696938_3_Ent3", "text": "cardiac arrest", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "7696938_3_Ent6", "text": "amphotericin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7696938_3_Ent4", "text": "amphotericin infusion", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7696938_3_Ent7", "text": "infusion", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7718983_1", "wnd_id": "7718983_1_1", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "tokens": ["Graves", "'", "hyperthyroidism", "following", "transient", "thyrotoxicosis", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "type", "C."], "event_mentions": [{"id": "7718983_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "7718983_1_Ent0", "role": "Effect", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "start": 0, "end": 6}, {"entity_id": "7718983_1_Ent1", "role": "Treatment", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis type C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "7718983_1_Ent0", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7718983_1_Ent1", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent2", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent3", "text": "chronic hepatitis type C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "7724306_4", "wnd_id": "7724306_4_1", "text": "In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .", "tokens": ["In", "patients", "with", "a", "known", "access", "to", "INH", ",", "seizures", "should", "be", "considered", "to", "be", "caused", "by", "INH", "toxicity", "unless", "proved", "otherwise", "."], "event_mentions": [{"id": "7724306_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "7724306_4_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_4_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}, {"entity_id": "7724306_4_Ent0", "role": "Effect", "text": "seizures", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7724306_4_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_4_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_4_Ent0", "text": "seizures", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7761316_1", "wnd_id": "7761316_1_1", "text": "Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .", "tokens": ["Musculoskeletal", "complaints", "were", "the", "presenting", "symptoms", "in", "four", "of", "44", "children", "(", "9", "%", ")", "treated", "for", "relapsed", "Wilms", "'", "tumors", "with", "ifosfamide", ",", "a", "derivative", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "7761316_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 21, "end": 22}, "arguments": [{"entity_id": "7761316_1_Ent3", "role": "Effect", "text": "Musculoskeletal complaints", "start": 0, "end": 2}, {"entity_id": "7761316_1_Ent1", "role": "Subject_Population", "text": "four of 44", "start": 7, "end": 10}, {"entity_id": "7761316_1_Ent0", "role": "Subject", "text": "four of 44 children ( 9 % )", "start": 7, "end": 15}, {"entity_id": "7761316_1_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "7761316_1_Ent5", "role": "Treatment_Disorder", "text": "relapsed Wilms ' tumors", "start": 17, "end": 21}, {"entity_id": "7761316_1_Ent4", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "7761316_1_Ent6", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7761316_1_Ent3", "text": "Musculoskeletal complaints", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7761316_1_Ent1", "text": "four of 44", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7761316_1_Ent0", "text": "four of 44 children ( 9 % )", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "7761316_1_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7761316_1_Ent5", "text": "relapsed Wilms ' tumors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7761316_1_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7761316_1_Ent6", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7761316_2", "wnd_id": "7761316_2_1", "text": "Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .", "tokens": ["Recognition", "of", "a", "potential", "drug", "-", "induced", "Fanconi", "syndrome", "is", "important", "when", "managing", "pediatric", "oncology", "patients", "previously", "treated", "with", "ifosfamide", "."], "event_mentions": [{"id": "7761316_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "7761316_2_Ent2", "role": "Effect", "text": "drug - induced Fanconi syndrome", "start": 4, "end": 9}, {"entity_id": "7761316_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 13, "end": 14}, {"entity_id": "7761316_2_Ent0", "role": "Subject", "text": "pediatric oncology patients", "start": 13, "end": 16}, {"entity_id": "7761316_2_Ent4", "role": "Treatment_Disorder", "text": "oncology", "start": 14, "end": 15}, {"entity_id": "7761316_2_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 19, "end": 20}, {"entity_id": "7761316_2_Ent5", "role": "Treatment_Drug", "text": "ifosfamide", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7761316_2_Ent2", "text": "drug - induced Fanconi syndrome", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "7761316_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7761316_2_Ent0", "text": "pediatric oncology patients", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "7761316_2_Ent4", "text": "oncology", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7761316_2_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7761316_2_Ent5", "text": "ifosfamide", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7781845_2", "wnd_id": "7781845_2_1", "text": "Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .", "tokens": ["Quinine", "and", "its", "isomer", "quinidine", "are", "well", "-", "known", "causes", "of", "iatrogenic", "hypoglycaemia", ",", "due", "to", "excessive", "insulin", "secretion", "."], "event_mentions": [{"id": "7781845_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 9, "end": 10}, "arguments": [{"entity_id": "7781845_2_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "7781845_2_Ent1", "role": "Treatment", "text": "Quinine and its isomer quinidine", "start": 0, "end": 5}, {"entity_id": "7781845_2_Ent0", "role": "Effect", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "start": 11, "end": 19}]}], "entity_mentions": [{"id": "7781845_2_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_2_Ent1", "text": "Quinine and its isomer quinidine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7781845_2_Ent0", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "entity_type": "Entity", "start": 11, "end": 19}], "lang": "en"}
{"doc_id": "7783891_1", "wnd_id": "7783891_1_1", "text": "Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .", "tokens": ["Because", "sumatriptan", "can", "cause", "coronary", "artery", "vasospasm", ",", "patients", "with", "significant", "risk", "factors", "for", "coronary", "artery", "disease", "should", "be", "carefully", "evaluated", "for", "cardiovascular", "disease", "prior", "to", "the", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "7783891_1_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 1, "end": 2}, {"entity_id": "7783891_1_Ent0", "role": "Effect", "text": "coronary artery vasospasm", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7783891_1_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7783891_1_Ent0", "text": "coronary artery vasospasm", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7787496_1", "wnd_id": "7787496_1_1", "text": "Sotalol - induced bradycardia reversed by glucagon .", "tokens": ["Sotalol", "-", "induced", "bradycardia", "reversed", "by", "glucagon", "."], "event_mentions": [{"id": "7787496_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7787496_1_Ent4", "role": "Treatment", "text": "Sotalol", "start": 0, "end": 1}, {"entity_id": "7787496_1_Ent5", "role": "Treatment_Drug", "text": "Sotalol", "start": 0, "end": 1}, {"entity_id": "7787496_1_Ent3", "role": "Effect", "text": "bradycardia", "start": 3, "end": 4}]}, {"id": "7787496_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 4, "end": 5}, "arguments": [{"entity_id": "7787496_1_Ent1", "role": "Treatment_Disorder", "text": "Sotalol - induced bradycardia", "start": 0, "end": 4}, {"entity_id": "7787496_1_Ent0", "role": "Treatment", "text": "glucagon", "start": 6, "end": 7}, {"entity_id": "7787496_1_Ent2", "role": "Treatment_Drug", "text": "glucagon", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7787496_1_Ent4", "text": "Sotalol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7787496_1_Ent5", "text": "Sotalol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7787496_1_Ent1", "text": "Sotalol - induced bradycardia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7787496_1_Ent3", "text": "bradycardia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7787496_1_Ent0", "text": "glucagon", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7787496_1_Ent2", "text": "glucagon", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7789881_3", "wnd_id": "7789881_3_1", "text": "We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .", "tokens": ["We", "believe", "that", "this", "is", "the", "first", "report", "of", "secretory", "carcinoma", "of", "the", "endometrium", "associated", "with", "tamoxifen", "use", "."], "event_mentions": [{"id": "7789881_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "7789881_3_Ent0", "role": "Effect", "text": "secretory carcinoma of the endometrium", "start": 9, "end": 14}, {"entity_id": "7789881_3_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 16, "end": 17}, {"entity_id": "7789881_3_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7789881_3_Ent0", "text": "secretory carcinoma of the endometrium", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "7789881_3_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7789881_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7835785_1", "wnd_id": "7835785_1_1", "text": "Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .", "tokens": ["Ovarian", "endometrioid", "carcinoma", "and", "endometriosis", "developing", "in", "a", "postmenopausal", "breast", "cancer", "patient", "during", "tamoxifen", "therapy", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "7835785_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "7835785_1_Ent2", "role": "Effect", "text": "Ovarian endometrioid carcinoma and endometriosis", "start": 0, "end": 5}, {"entity_id": "7835785_1_Ent0", "role": "Subject", "text": "a postmenopausal breast cancer patient", "start": 7, "end": 12}, {"entity_id": "7835785_1_Ent1", "role": "Subject_Disorder", "text": "postmenopausal", "start": 8, "end": 9}, {"entity_id": "7835785_1_Ent5", "role": "Treatment_Disorder", "text": "breast cancer", "start": 9, "end": 11}, {"entity_id": "7835785_1_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 13, "end": 14}, {"entity_id": "7835785_1_Ent3", "role": "Treatment", "text": "tamoxifen therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7835785_1_Ent2", "text": "Ovarian endometrioid carcinoma and endometriosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7835785_1_Ent0", "text": "a postmenopausal breast cancer patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7835785_1_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7835785_1_Ent5", "text": "breast cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7835785_1_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7835785_1_Ent3", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7854541_1", "wnd_id": "7854541_1_1", "text": "Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .", "tokens": ["Cerebral", "demyelinating", "disease", "developed", "in", "a", "patient", "during", "adjuvant", "therapy", "with", "levamisole", "for", "malignant", "melanoma", "."], "event_mentions": [{"id": "7854541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "7854541_1_Ent1", "role": "Effect", "text": "Cerebral demyelinating disease", "start": 0, "end": 3}, {"entity_id": "7854541_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "7854541_1_Ent2", "role": "Treatment", "text": "adjuvant therapy with levamisole", "start": 8, "end": 12}, {"entity_id": "7854541_1_Ent3", "role": "Treatment_Drug", "text": "levamisole", "start": 11, "end": 12}, {"entity_id": "7854541_1_Ent4", "role": "Treatment_Disorder", "text": "malignant melanoma", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7854541_1_Ent1", "text": "Cerebral demyelinating disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7854541_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7854541_1_Ent2", "text": "adjuvant therapy with levamisole", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7854541_1_Ent3", "text": "levamisole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7854541_1_Ent4", "text": "malignant melanoma", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7900744_1", "wnd_id": "7900744_1_1", "text": "Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .", "tokens": ["Case", "report", ":", "mannitol", "nephrotoxicity", "syndrome", ":", "role", "of", "hemodialysis", "and", "postulate", "of", "mechanisms", "."], "event_mentions": [{"id": "7900744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "syndrome", "start": 5, "end": 6}, "arguments": [{"entity_id": "7900744_1_Ent1", "role": "Treatment", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent2", "role": "Treatment_Drug", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7900744_1_Ent1", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent2", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7949255_2", "wnd_id": "7949255_2_1", "text": "This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .", "tokens": ["This", "patient", "developed", "sequential", "symptoms", "including", "alternative", "hemiparesis", ",", "dysarthria", "and", "altered", "consciousness", "5", "days", "after", "the", "second", "course", "of", "HD", "-", "MTX", "(", "8", "gm", "/", "m2", "by", "6", "h", "continuous", "infusion", ")", "with", "leucovorin", "rescue", "."], "event_mentions": [{"id": "7949255_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "7949255_2_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "7949255_2_Ent1", "role": "Effect", "text": "sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness", "start": 3, "end": 13}, {"entity_id": "7949255_2_Ent3", "role": "Treatment_Time_elapsed", "text": "5 days after the second course", "start": 13, "end": 19}, {"entity_id": "7949255_2_Ent2", "role": "Treatment", "text": "the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue", "start": 16, "end": 37}, {"entity_id": "7949255_2_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 22, "end": 23}, {"entity_id": "7949255_2_Ent9", "role": "Combination_Drug", "text": "MTX", "start": 22, "end": 23}, {"entity_id": "7949255_2_Ent6", "role": "Treatment_Dosage", "text": "8 gm / m2 by 6 h continuous", "start": 24, "end": 32}, {"entity_id": "7949255_2_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 32, "end": 33}, {"entity_id": "7949255_2_Ent5", "role": "Treatment_Drug", "text": "leucovorin rescue", "start": 35, "end": 37}, {"entity_id": "7949255_2_Ent8", "role": "Combination_Drug", "text": "leucovorin rescue", "start": 35, "end": 37}]}], "entity_mentions": [{"id": "7949255_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7949255_2_Ent1", "text": "sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "7949255_2_Ent3", "text": "5 days after the second course", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "7949255_2_Ent2", "text": "the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue", "entity_type": "Entity", "start": 16, "end": 37}, {"id": "7949255_2_Ent4", "text": "MTX", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7949255_2_Ent9", "text": "MTX", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7949255_2_Ent6", "text": "8 gm / m2 by 6 h continuous", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "7949255_2_Ent7", "text": "infusion", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "7949255_2_Ent5", "text": "leucovorin rescue", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "7949255_2_Ent8", "text": "leucovorin rescue", "entity_type": "Entity", "start": 35, "end": 37}], "lang": "en"}
{"doc_id": "7962394_1", "wnd_id": "7962394_1_1", "text": "Acute pancreatitis associated with danazol treatment for endometriosis .", "tokens": ["Acute", "pancreatitis", "associated", "with", "danazol", "treatment", "for", "endometriosis", "."], "event_mentions": [{"id": "7962394_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7962394_1_Ent0", "role": "Effect", "text": "Acute pancreatitis", "start": 0, "end": 2}, {"entity_id": "7962394_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 4, "end": 5}, {"entity_id": "7962394_1_Ent1", "role": "Treatment", "text": "danazol treatment", "start": 4, "end": 6}, {"entity_id": "7962394_1_Ent3", "role": "Treatment_Disorder", "text": "endometriosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "7962394_1_Ent0", "text": "Acute pancreatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7962394_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7962394_1_Ent1", "text": "danazol treatment", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_1_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "7962394_3", "wnd_id": "7962394_3_1", "text": "Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .", "tokens": ["Hypo", "-", "oestrogenic", "and", "anabolic", "/", "androgenic", "side", "-", "effects", "of", "danazol", "are", "well", "known", "by", "the", "gynaecologist", "and", "some", "of", "them", "are", "present", "in", ">", "50", "%", "of", "patients", "being", "treated", "for", "endometriosis", "."], "event_mentions": [{"id": "7962394_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effects", "start": 7, "end": 10}, "arguments": [{"entity_id": "7962394_3_Ent0", "role": "Effect", "text": "Hypo - oestrogenic and anabolic / androgenic", "start": 0, "end": 7}, {"entity_id": "7962394_3_Ent1", "role": "Treatment", "text": "danazol", "start": 11, "end": 12}, {"entity_id": "7962394_3_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 11, "end": 12}, {"entity_id": "7962394_3_Ent3", "role": "Treatment_Disorder", "text": "endometriosis", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "7962394_3_Ent0", "text": "Hypo - oestrogenic and anabolic / androgenic", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "7962394_3_Ent1", "text": "danazol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7962394_3_Ent2", "text": "danazol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7962394_3_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "7995001_1", "wnd_id": "7995001_1_1", "text": "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole .", "tokens": ["Oral", "triazolam", "is", "potentially", "hazardous", "to", "patients", "receiving", "systemic", "antimycotics", "ketoconazole", "or", "itraconazole", "."], "event_mentions": [{"id": "7995001_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "7995001_1_Ent6", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "7995001_1_Ent2", "role": "Treatment", "text": "triazolam", "start": 1, "end": 2}, {"entity_id": "7995001_1_Ent3", "role": "Treatment_Drug", "text": "triazolam", "start": 1, "end": 2}, {"entity_id": "7995001_1_Ent1", "role": "Effect", "text": "hazardous", "start": 4, "end": 5}, {"entity_id": "7995001_1_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "7995001_1_Ent4", "role": "Treatment_Drug", "text": "ketoconazole", "start": 10, "end": 11}, {"entity_id": "7995001_1_Ent5", "role": "Treatment_Drug", "text": "itraconazole", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7995001_1_Ent6", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7995001_1_Ent2", "text": "triazolam", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7995001_1_Ent3", "text": "triazolam", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7995001_1_Ent1", "text": "hazardous", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7995001_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7995001_1_Ent4", "text": "ketoconazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7995001_1_Ent5", "text": "itraconazole", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8002140_3", "wnd_id": "8002140_3_1", "text": "METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .", "tokens": ["METHODS", ":", "Five", "cases", "of", "contact", "dermatitis", "due", "to", "budesonide", ",", "a", "nonhalogenated", "steroid", ",", "are", "described", "."], "event_mentions": [{"id": "8002140_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 7, "end": 9}, "arguments": [{"entity_id": "8002140_3_Ent1", "role": "Subject_Population", "text": "Five", "start": 2, "end": 3}, {"entity_id": "8002140_3_Ent0", "role": "Subject", "text": "Five cases", "start": 2, "end": 4}, {"entity_id": "8002140_3_Ent2", "role": "Effect", "text": "contact dermatitis", "start": 5, "end": 7}, {"entity_id": "8002140_3_Ent3", "role": "Treatment", "text": "budesonide", "start": 9, "end": 10}, {"entity_id": "8002140_3_Ent4", "role": "Treatment_Drug", "text": "budesonide", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8002140_3_Ent1", "text": "Five", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8002140_3_Ent0", "text": "Five cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8002140_3_Ent2", "text": "contact dermatitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8002140_3_Ent3", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8002140_3_Ent4", "text": "budesonide", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8034807_1", "wnd_id": "8034807_1_1", "text": "The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .", "tokens": ["The", "use", "of", "methotrexate", "(", "MTX", ")", "has", "been", "contraindicated", "for", "treatment", "of", "severe", "psoriasis", "in", "HIV", "infection", "on", "the", "basis", "of", "six", "previously", "reported", "cases", "in", "which", "MTX", "appeared", "to", "potentiate", "opportunistic", "infections", "and", "accelerate", "HIV", "disease", "."], "event_mentions": [{"id": "8034807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 35, "end": 36}, "arguments": [{"entity_id": "8034807_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate ( MTX )", "start": 3, "end": 7}, {"entity_id": "8034807_1_Ent1", "role": "Treatment", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 28, "end": 29}, {"entity_id": "8034807_1_Ent0", "role": "Effect", "text": "HIV disease", "start": 36, "end": 38}]}], "entity_mentions": [{"id": "8034807_1_Ent2", "text": "methotrexate ( MTX )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8034807_1_Ent1", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent3", "text": "MTX", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8034807_1_Ent0", "text": "HIV disease", "entity_type": "Entity", "start": 36, "end": 38}], "lang": "en"}
{"doc_id": "8053440_4", "wnd_id": "8053440_4_1", "text": "This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .", "tokens": ["This", "is", "the", "first", "description", ",", "to", "our", "knowledge", ",", "of", "ductopenia", "apparently", "caused", "by", "clindamycin", "."], "event_mentions": [{"id": "8053440_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "8053440_4_Ent0", "role": "Effect", "text": "ductopenia", "start": 11, "end": 12}, {"entity_id": "8053440_4_Ent1", "role": "Treatment", "text": "clindamycin", "start": 15, "end": 16}, {"entity_id": "8053440_4_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8053440_4_Ent0", "text": "ductopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8053440_4_Ent1", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8053440_4_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8120934_2", "wnd_id": "8120934_2_1", "text": "Bromocriptine - induced schizophrenia .", "tokens": ["Bromocriptine", "-", "induced", "schizophrenia", "."], "event_mentions": [{"id": "8120934_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8120934_2_Ent1", "role": "Treatment", "text": "Bromocriptine", "start": 0, "end": 1}, {"entity_id": "8120934_2_Ent2", "role": "Treatment_Drug", "text": "Bromocriptine", "start": 0, "end": 1}, {"entity_id": "8120934_2_Ent0", "role": "Effect", "text": "schizophrenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8120934_2_Ent1", "text": "Bromocriptine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8120934_2_Ent2", "text": "Bromocriptine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8120934_2_Ent0", "text": "schizophrenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8140860_5", "wnd_id": "8140860_5_1", "text": "In this case , the increase in the INR value with associated bruising after the addition of amoxycillin suggests a drug interaction between acenocoumarol and amoxycillin , other possible causes having been eliminated .", "tokens": ["In", "this", "case", ",", "the", "increase", "in", "the", "INR", "value", "with", "associated", "bruising", "after", "the", "addition", "of", "amoxycillin", "suggests", "a", "drug", "interaction", "between", "acenocoumarol", "and", "amoxycillin", ",", "other", "possible", "causes", "having", "been", "eliminated", "."], "event_mentions": [{"id": "8140860_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "8140860_5_Ent0", "role": "Effect", "text": "the increase in the INR value with associated bruising", "start": 4, "end": 13}, {"entity_id": "8140860_5_Ent1", "role": "Treatment", "text": "amoxycillin", "start": 17, "end": 18}, {"entity_id": "8140860_5_Ent2", "role": "Treatment_Drug", "text": "amoxycillin", "start": 17, "end": 18}, {"entity_id": "8140860_5_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 23, "end": 24}, {"entity_id": "8140860_5_Ent5", "role": "Combination_Drug", "text": "acenocoumarol", "start": 23, "end": 24}, {"entity_id": "8140860_5_Ent4", "role": "Treatment_Drug", "text": "amoxycillin", "start": 25, "end": 26}, {"entity_id": "8140860_5_Ent6", "role": "Combination_Drug", "text": "amoxycillin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "8140860_5_Ent0", "text": "the increase in the INR value with associated bruising", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "8140860_5_Ent1", "text": "amoxycillin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8140860_5_Ent2", "text": "amoxycillin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8140860_5_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8140860_5_Ent5", "text": "acenocoumarol", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8140860_5_Ent4", "text": "amoxycillin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "8140860_5_Ent6", "text": "amoxycillin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "8149366_1", "wnd_id": "8149366_1_1", "text": "In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .", "tokens": ["In", "two", "patients", ",", "apomorphine", "remained", "effective", "in", "the", "morning", ",", "but", "increased", "the", "intensity", "of", "the", "dyskinesias", "in", "the", "afternoon", "."], "event_mentions": [{"id": "8149366_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 12, "end": 13}, "arguments": [{"entity_id": "8149366_1_Ent0", "role": "Subject", "text": "In two patients", "start": 0, "end": 3}, {"entity_id": "8149366_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "8149366_1_Ent3", "role": "Treatment", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent4", "role": "Treatment_Drug", "text": "apomorphine", "start": 4, "end": 5}, {"entity_id": "8149366_1_Ent2", "role": "Effect", "text": "intensity of the dyskinesias in the afternoon", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "8149366_1_Ent0", "text": "In two patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8149366_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8149366_1_Ent3", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent4", "text": "apomorphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8149366_1_Ent2", "text": "intensity of the dyskinesias in the afternoon", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "8162401_1", "wnd_id": "8162401_1_1", "text": "A case of fluoxetine induced seizures , in a person with Down syndrome , is described .", "tokens": ["A", "case", "of", "fluoxetine", "induced", "seizures", ",", "in", "a", "person", "with", "Down", "syndrome", ",", "is", "described", "."], "event_mentions": [{"id": "8162401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "8162401_1_Ent3", "role": "Treatment", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_1_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_1_Ent2", "role": "Effect", "text": "seizures", "start": 5, "end": 6}, {"entity_id": "8162401_1_Ent0", "role": "Subject", "text": "a person with Down syndrome", "start": 8, "end": 13}, {"entity_id": "8162401_1_Ent1", "role": "Subject_Disorder", "text": "Down syndrome", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "8162401_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_1_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_1_Ent2", "text": "seizures", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8162401_1_Ent0", "text": "a person with Down syndrome", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8162401_1_Ent1", "text": "Down syndrome", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "8162401_3", "wnd_id": "8162401_3_1", "text": "Seizures associated with fluoxetine therapy .", "tokens": ["Seizures", "associated", "with", "fluoxetine", "therapy", "."], "event_mentions": [{"id": "8162401_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 1, "end": 3}, "arguments": [{"entity_id": "8162401_3_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8162401_3_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_3_Ent1", "role": "Treatment", "text": "fluoxetine therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8162401_3_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8162401_3_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_3_Ent1", "text": "fluoxetine therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8175330_2", "wnd_id": "8175330_2_1", "text": "We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .", "tokens": ["We", "present", "findings", "from", "three", "patients", "who", "experienced", "a", "psoriasiform", "eruption", "apparently", "due", "to", "the", "antiepileptic", "agents", "sodium", "valproate", "and", "carbamazepine", "."], "event_mentions": [{"id": "8175330_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "8175330_2_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8175330_2_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8175330_2_Ent2", "role": "Effect", "text": "psoriasiform eruption", "start": 9, "end": 11}, {"entity_id": "8175330_2_Ent3", "role": "Treatment", "text": "antiepileptic agents sodium valproate and carbamazepine", "start": 15, "end": 21}, {"entity_id": "8175330_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent6", "role": "Combination_Drug", "text": "sodium valproate", "start": 17, "end": 19}, {"entity_id": "8175330_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 20, "end": 21}, {"entity_id": "8175330_2_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8175330_2_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8175330_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8175330_2_Ent2", "text": "psoriasiform eruption", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8175330_2_Ent3", "text": "antiepileptic agents sodium valproate and carbamazepine", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8175330_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent6", "text": "sodium valproate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8175330_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8175330_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8192712_1", "wnd_id": "8192712_1_1", "text": "Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .", "tokens": ["Based", "on", "our", "experience", "and", "on", "previously", "published", "data", ",", "serum", "ammonia", "levels", "appear", "to", "be", "indicated", "in", "all", "ED", "patients", "on", "valproic", "acid", "therapy", "who", "present", "with", "altered", "mental", "status", "."], "event_mentions": [{"id": "8192712_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 26, "end": 27}, "arguments": [{"entity_id": "8192712_1_Ent0", "role": "Subject", "text": "all ED patients", "start": 18, "end": 21}, {"entity_id": "8192712_1_Ent3", "role": "Treatment_Disorder", "text": "ED", "start": 19, "end": 20}, {"entity_id": "8192712_1_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 22, "end": 24}, {"entity_id": "8192712_1_Ent2", "role": "Treatment", "text": "valproic acid therapy", "start": 22, "end": 25}, {"entity_id": "8192712_1_Ent1", "role": "Effect", "text": "altered mental status", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "8192712_1_Ent0", "text": "all ED patients", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8192712_1_Ent3", "text": "ED", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8192712_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "8192712_1_Ent2", "text": "valproic acid therapy", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8192712_1_Ent1", "text": "altered mental status", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "8192712_3", "wnd_id": "8192712_3_1", "text": "Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .", "tokens": ["Hyperammonemia", "secondary", "to", "valproic", "acid", "as", "a", "cause", "of", "lethargy", "in", "a", "postictal", "patient", "."], "event_mentions": [{"id": "8192712_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "8192712_3_Ent1", "role": "Effect", "text": "Hyperammonemia", "start": 0, "end": 1}, {"entity_id": "8192712_3_Ent2", "role": "Treatment", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 3, "end": 5}, {"entity_id": "8192712_3_Ent0", "role": "Subject", "text": "a postictal patient", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "8192712_3_Ent1", "text": "Hyperammonemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8192712_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8192712_3_Ent0", "text": "a postictal patient", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "8222875_3", "wnd_id": "8222875_3_1", "text": "Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .", "tokens": ["Pulmonary", "hemorrhage", "is", "an", "uncommon", "feature", "in", "the", "HUS", ",", "and", "seems", "to", "appear", "especially", "in", "the", "HUS", "associated", "with", "MMC", "therapy", "."], "event_mentions": [{"id": "8222875_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_3_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_3_Ent1", "role": "Treatment", "text": "MMC", "start": 20, "end": 21}, {"entity_id": "8222875_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8222875_3_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8222875_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8222875_4", "wnd_id": "8222875_4_1", "text": "We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .", "tokens": ["We", "describe", "two", "women", "who", "developed", "HUS", "after", "MMC", "therapy", "and", "presented", "massive", "pulmonary", "bleeding", "."], "event_mentions": [{"id": "8222875_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8222875_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8222875_4_Ent0", "role": "Subject", "text": "two women", "start": 2, "end": 4}, {"entity_id": "8222875_4_Ent2", "role": "Subject_Gender", "text": "women", "start": 3, "end": 4}, {"entity_id": "8222875_4_Ent3", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "8222875_4_Ent5", "role": "Treatment", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent6", "role": "Treatment_Drug", "text": "MMC", "start": 8, "end": 9}, {"entity_id": "8222875_4_Ent4", "role": "Effect", "text": "massive pulmonary bleeding", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8222875_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8222875_4_Ent0", "text": "two women", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8222875_4_Ent2", "text": "women", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8222875_4_Ent3", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8222875_4_Ent5", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent6", "text": "MMC", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8222875_4_Ent4", "text": "massive pulmonary bleeding", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8239963_1", "wnd_id": "8239963_1_1", "text": "Clonidine - induced bradycardia in patients with spinal cord injury .", "tokens": ["Clonidine", "-", "induced", "bradycardia", "in", "patients", "with", "spinal", "cord", "injury", "."], "event_mentions": [{"id": "8239963_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8239963_1_Ent2", "role": "Treatment", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent4", "role": "Treatment_Drug", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent1", "role": "Effect", "text": "bradycardia", "start": 3, "end": 4}, {"entity_id": "8239963_1_Ent0", "role": "Subject", "text": "patients with spinal cord injury", "start": 5, "end": 10}, {"entity_id": "8239963_1_Ent3", "role": "Treatment_Disorder", "text": "spinal cord injury", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "8239963_1_Ent2", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent4", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent1", "text": "bradycardia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8239963_1_Ent0", "text": "patients with spinal cord injury", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8239963_1_Ent3", "text": "spinal cord injury", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "8239963_2", "wnd_id": "8239963_2_1", "text": "Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .", "tokens": ["Possible", "mechanisms", "by", "which", "clonidine", "decreases", "spasticity", "are", "described", ",", "probable", "mechanisms", "of", "induced", "bradycardia", "are", "reviewed", ",", "and", "specific", "treatment", "recommendations", "for", "the", "use", "of", "clonidine", "in", "spinal", "cord", "injured", "patients", "are", "presented", "."], "event_mentions": [{"id": "8239963_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "8239963_2_Ent1", "role": "Treatment", "text": "clonidine", "start": 4, "end": 5}, {"entity_id": "8239963_2_Ent2", "role": "Treatment_Drug", "text": "clonidine", "start": 4, "end": 5}, {"entity_id": "8239963_2_Ent0", "role": "Effect", "text": "bradycardia", "start": 14, "end": 15}, {"entity_id": "8239963_2_Ent3", "role": "Treatment_Disorder", "text": "spinal cord injured", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "8239963_2_Ent1", "text": "clonidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8239963_2_Ent2", "text": "clonidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8239963_2_Ent0", "text": "bradycardia", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8239963_2_Ent3", "text": "spinal cord injured", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "8244201_2", "wnd_id": "8244201_2_1", "text": "Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .", "tokens": ["Hyperkalaemia", "with", "renal", "tubular", "dysfunction", "by", "oral", "therapy", "of", "sulfamethoxazole", "-", "trimethoprim", "(", "co", "-", "trimoxazole", ")", "is", "described", "in", "2", "elderly", "Japanese", "patients", "with", "lymphoid", "malignancy", ",", "who", "developed", "Pneumocystis", "carinii", "pneumonia", "and", "improved", "."], "event_mentions": [{"id": "8244201_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 18, "end": 19}, "arguments": [{"entity_id": "8244201_2_Ent5", "role": "Effect", "text": "Hyperkalaemia with renal tubular dysfunction", "start": 0, "end": 5}, {"entity_id": "8244201_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 6, "end": 7}, {"entity_id": "8244201_2_Ent6", "role": "Treatment", "text": "oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole )", "start": 6, "end": 17}, {"entity_id": "8244201_2_Ent8", "role": "Treatment_Drug", "text": "sulfamethoxazole - trimethoprim", "start": 9, "end": 12}, {"entity_id": "8244201_2_Ent1", "role": "Subject_Population", "text": "2", "start": 20, "end": 21}, {"entity_id": "8244201_2_Ent0", "role": "Subject", "text": "2 elderly Japanese patients with lymphoid malignancy", "start": 20, "end": 27}, {"entity_id": "8244201_2_Ent2", "role": "Subject_Age", "text": "elderly", "start": 21, "end": 22}, {"entity_id": "8244201_2_Ent3", "role": "Subject_Race", "text": "Japanese", "start": 22, "end": 23}, {"entity_id": "8244201_2_Ent4", "role": "Subject_Disorder", "text": "lymphoid malignancy", "start": 25, "end": 27}, {"entity_id": "8244201_2_Ent9", "role": "Treatment_Disorder", "text": "Pneumocystis carinii pneumonia", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "8244201_2_Ent5", "text": "Hyperkalaemia with renal tubular dysfunction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8244201_2_Ent6", "text": "oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole )", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "8244201_2_Ent8", "text": "sulfamethoxazole - trimethoprim", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8244201_2_Ent1", "text": "2", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8244201_2_Ent0", "text": "2 elderly Japanese patients with lymphoid malignancy", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "8244201_2_Ent2", "text": "elderly", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8244201_2_Ent3", "text": "Japanese", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8244201_2_Ent4", "text": "lymphoid malignancy", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_2_Ent9", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "8244201_3", "wnd_id": "8244201_3_1", "text": "Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .", "tokens": ["Hyperkalaemia", "with", "renal", "tubular", "dysfunction", "by", "sulfamethoxazole", "-", "trimethoprim", "for", "Pneumocystis", "carinii", "pneumonia", "in", "patients", "with", "lymphoid", "malignancy", "."], "event_mentions": [{"id": "8244201_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 5, "end": 6}, "arguments": [{"entity_id": "8244201_3_Ent2", "role": "Effect", "text": "Hyperkalaemia with renal tubular dysfunction", "start": 0, "end": 5}, {"entity_id": "8244201_3_Ent5", "role": "Treatment_Drug", "text": "sulfamethoxazole - trimethoprim", "start": 6, "end": 9}, {"entity_id": "8244201_3_Ent3", "role": "Treatment", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "start": 6, "end": 13}, {"entity_id": "8244201_3_Ent4", "role": "Treatment_Disorder", "text": "Pneumocystis carinii pneumonia", "start": 10, "end": 13}, {"entity_id": "8244201_3_Ent0", "role": "Subject", "text": "patients with lymphoid malignancy", "start": 14, "end": 18}, {"entity_id": "8244201_3_Ent1", "role": "Subject_Disorder", "text": "lymphoid malignancy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8244201_3_Ent2", "text": "Hyperkalaemia with renal tubular dysfunction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_3_Ent5", "text": "sulfamethoxazole - trimethoprim", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8244201_3_Ent3", "text": "sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "8244201_3_Ent4", "text": "Pneumocystis carinii pneumonia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8244201_3_Ent0", "text": "patients with lymphoid malignancy", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8244201_3_Ent1", "text": "lymphoid malignancy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8260059_2", "wnd_id": "8260059_2_1", "text": "No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .", "tokens": ["No", "explanation", "for", "this", "delay", "was", "found", ",", "other", "than", "the", "possibility", "that", "magnesium", "sulfate", "treatment", "impeded", "lactogenesis", "."], "event_mentions": [{"id": "8260059_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "impeded", "start": 16, "end": 17}, "arguments": [{"entity_id": "8260059_2_Ent1", "role": "Treatment", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent2", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8260059_2_Ent0", "role": "Effect", "text": "lactogenesis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8260059_2_Ent1", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8260059_2_Ent0", "text": "lactogenesis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8301877_2", "wnd_id": "8301877_2_1", "text": "Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .", "tokens": ["Myoclonus", "and", "seizures", "in", "a", "patient", "with", "parkinsonism", ":", "induction", "by", "levodopa", "and", "its", "confirmation", "on", "SEPs", "."], "event_mentions": [{"id": "8301877_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induction", "start": 9, "end": 10}, "arguments": [{"entity_id": "8301877_2_Ent1", "role": "Effect", "text": "Myoclonus and seizures", "start": 0, "end": 3}, {"entity_id": "8301877_2_Ent0", "role": "Subject", "text": "a patient with parkinsonism", "start": 4, "end": 8}, {"entity_id": "8301877_2_Ent3", "role": "Treatment_Disorder", "text": "parkinsonism", "start": 7, "end": 8}, {"entity_id": "8301877_2_Ent2", "role": "Treatment", "text": "levodopa", "start": 11, "end": 12}, {"entity_id": "8301877_2_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8301877_2_Ent1", "text": "Myoclonus and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8301877_2_Ent0", "text": "a patient with parkinsonism", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8301877_2_Ent3", "text": "parkinsonism", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8301877_2_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8301877_2_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8301877_3", "wnd_id": "8301877_3_1", "text": "Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .", "tokens": ["Myoclonus", "was", "induced", "and", "enhanced", "by", "L", "-", "dopa", ",", "developing", "into", "generalized", "seizures", "."], "event_mentions": [{"id": "8301877_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced and enhanced", "start": 2, "end": 5}, "arguments": [{"entity_id": "8301877_3_Ent1", "role": "Effect", "text": "Myoclonus", "start": 0, "end": 1}, {"entity_id": "8301877_3_Ent2", "role": "Treatment", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "8301877_3_Ent0", "role": "Effect", "text": "developing into generalized seizures", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "8301877_3_Ent1", "text": "Myoclonus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8301877_3_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8301877_3_Ent0", "text": "developing into generalized seizures", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "8305778_3", "wnd_id": "8305778_3_1", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "history", "of", "congestive", "heart", "failure", "and", "coronary", "artery", "disease", "began", "taking", "amiodarone", "to", "suppress", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "8305778_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "suppress", "start": 22, "end": 23}, "arguments": [{"entity_id": "8305778_3_Ent0", "role": "Subject", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "start": 0, "end": 18}, {"entity_id": "8305778_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8305778_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8305778_3_Ent3", "role": "Subject_Disorder", "text": "congestive heart failure", "start": 11, "end": 14}, {"entity_id": "8305778_3_Ent4", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 15, "end": 18}, {"entity_id": "8305778_3_Ent5", "role": "Treatment", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent7", "role": "Treatment_Disorder", "text": "sustained ventricular tachycardia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "8305778_3_Ent0", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "8305778_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8305778_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8305778_3_Ent3", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8305778_3_Ent4", "text": "coronary artery disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8305778_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent7", "text": "sustained ventricular tachycardia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "8316494_2", "wnd_id": "8316494_2_1", "text": "We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .", "tokens": ["We", "describe", "a", "41", "yr", "old", "leprosy", "patient", "treated", "for", "10", "yrs", "with", "clofazimine", "who", "underwent", "laparotomy", "for", "severe", "abdominal", "pain", "."], "event_mentions": [{"id": "8316494_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 17, "end": 18}, "arguments": [{"entity_id": "8316494_2_Ent0", "role": "Subject", "text": "a 41 yr old leprosy patient", "start": 2, "end": 8}, {"entity_id": "8316494_2_Ent1", "role": "Subject_Age", "text": "41 yr old", "start": 3, "end": 6}, {"entity_id": "8316494_2_Ent4", "role": "Treatment_Disorder", "text": "leprosy", "start": 6, "end": 7}, {"entity_id": "8316494_2_Ent5", "role": "Treatment_Duration", "text": "10 yrs", "start": 10, "end": 12}, {"entity_id": "8316494_2_Ent3", "role": "Treatment", "text": "10 yrs with clofazimine", "start": 10, "end": 14}, {"entity_id": "8316494_2_Ent6", "role": "Treatment_Drug", "text": "clofazimine", "start": 13, "end": 14}, {"entity_id": "8316494_2_Ent2", "role": "Effect", "text": "severe abdominal pain", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8316494_2_Ent0", "text": "a 41 yr old leprosy patient", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "8316494_2_Ent1", "text": "41 yr old", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8316494_2_Ent4", "text": "leprosy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8316494_2_Ent5", "text": "10 yrs", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8316494_2_Ent3", "text": "10 yrs with clofazimine", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8316494_2_Ent6", "text": "clofazimine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8316494_2_Ent2", "text": "severe abdominal pain", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8329789_9", "wnd_id": "8329789_9_1", "text": "CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .", "tokens": ["CONCLUSIONS", ":", "Amphotericin", "B", "overdose", "can", "be", "fatal", "in", "children", "and", "infants", "."], "event_mentions": [{"id": "8329789_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 6, "end": 7}, "arguments": [{"entity_id": "8329789_9_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 2, "end": 4}, {"entity_id": "8329789_9_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 2, "end": 5}, {"entity_id": "8329789_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8329789_9_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "8329789_9_Ent0", "role": "Subject", "text": "children and infants", "start": 9, "end": 12}, {"entity_id": "8329789_9_Ent2", "role": "Subject_Age", "text": "infants", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8329789_9_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8329789_9_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8329789_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_9_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8329789_9_Ent0", "text": "children and infants", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_9_Ent2", "text": "infants", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8345435_1", "wnd_id": "8345435_1_1", "text": "Hepatotoxic effects in a child receiving valproate and carnitine .", "tokens": ["Hepatotoxic", "effects", "in", "a", "child", "receiving", "valproate", "and", "carnitine", "."], "event_mentions": [{"id": "8345435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 5, "end": 6}, "arguments": [{"entity_id": "8345435_1_Ent2", "role": "Effect", "text": "Hepatotoxic effects", "start": 0, "end": 2}, {"entity_id": "8345435_1_Ent0", "role": "Subject", "text": "a child", "start": 3, "end": 5}, {"entity_id": "8345435_1_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "8345435_1_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 6, "end": 7}, {"entity_id": "8345435_1_Ent6", "role": "Combination_Drug", "text": "valproate", "start": 6, "end": 7}, {"entity_id": "8345435_1_Ent3", "role": "Treatment", "text": "valproate and carnitine", "start": 6, "end": 9}, {"entity_id": "8345435_1_Ent5", "role": "Treatment_Drug", "text": "carnitine", "start": 8, "end": 9}, {"entity_id": "8345435_1_Ent7", "role": "Combination_Drug", "text": "carnitine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8345435_1_Ent2", "text": "Hepatotoxic effects", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8345435_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8345435_1_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8345435_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8345435_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8345435_1_Ent3", "text": "valproate and carnitine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8345435_1_Ent5", "text": "carnitine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8345435_1_Ent7", "text": "carnitine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8360712_2", "wnd_id": "8360712_2_1", "text": "Delayed neurotoxicity of intraventricular interleukin - 2 : a case report .", "tokens": ["Delayed", "neurotoxicity", "of", "intraventricular", "interleukin", "-", "2", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8360712_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "8360712_2_Ent1", "role": "Effect", "text": "Delayed neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8360712_2_Ent4", "role": "Treatment_Route", "text": "intraventricular", "start": 3, "end": 4}, {"entity_id": "8360712_2_Ent2", "role": "Treatment", "text": "intraventricular interleukin - 2", "start": 3, "end": 7}, {"entity_id": "8360712_2_Ent3", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 4, "end": 7}, {"entity_id": "8360712_2_Ent0", "role": "Subject", "text": "a case report", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8360712_2_Ent1", "text": "Delayed neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8360712_2_Ent4", "text": "intraventricular", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8360712_2_Ent2", "text": "intraventricular interleukin - 2", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8360712_2_Ent3", "text": "interleukin - 2", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8360712_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8363533_3", "wnd_id": "8363533_3_1", "text": "Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .", "tokens": ["Lithium", "-", "associated", "transient", "thyrotoxicosis", "in", "4", "Chinese", "women", "with", "autoimmune", "thyroiditis", "."], "event_mentions": [{"id": "8363533_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8363533_3_Ent6", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8363533_3_Ent7", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "8363533_3_Ent5", "role": "Effect", "text": "transient thyrotoxicosis", "start": 3, "end": 5}, {"entity_id": "8363533_3_Ent1", "role": "Subject_Population", "text": "4", "start": 6, "end": 7}, {"entity_id": "8363533_3_Ent0", "role": "Subject", "text": "4 Chinese women with autoimmune thyroiditis", "start": 6, "end": 12}, {"entity_id": "8363533_3_Ent2", "role": "Subject_Race", "text": "Chinese", "start": 7, "end": 8}, {"entity_id": "8363533_3_Ent3", "role": "Subject_Gender", "text": "women", "start": 8, "end": 9}, {"entity_id": "8363533_3_Ent4", "role": "Subject_Disorder", "text": "autoimmune thyroiditis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "8363533_3_Ent6", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8363533_3_Ent7", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8363533_3_Ent5", "text": "transient thyrotoxicosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8363533_3_Ent1", "text": "4", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8363533_3_Ent0", "text": "4 Chinese women with autoimmune thyroiditis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "8363533_3_Ent2", "text": "Chinese", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8363533_3_Ent3", "text": "women", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8363533_3_Ent4", "text": "autoimmune thyroiditis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "8384030_2", "wnd_id": "8384030_2_1", "text": "DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .", "tokens": ["DISCUSSION", ":", "Electrolyte", "disorders", "associated", "with", "foscarnet", "are", "reviewed", "."], "event_mentions": [{"id": "8384030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "8384030_2_Ent0", "role": "Effect", "text": "Electrolyte disorders", "start": 2, "end": 4}, {"entity_id": "8384030_2_Ent1", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8384030_2_Ent0", "text": "Electrolyte disorders", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8384030_2_Ent1", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8384030_3", "wnd_id": "8384030_3_1", "text": "Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .", "tokens": ["Foscarnet", "-", "induced", "severe", "hypomagnesemia", "and", "other", "electrolyte", "disorders", "."], "event_mentions": [{"id": "8384030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8384030_3_Ent1", "role": "Treatment", "text": "Foscarnet", "start": 0, "end": 1}, {"entity_id": "8384030_3_Ent2", "role": "Treatment_Drug", "text": "Foscarnet", "start": 0, "end": 1}, {"entity_id": "8384030_3_Ent0", "role": "Effect", "text": "hypomagnesemia and other electrolyte disorders", "start": 4, "end": 9}]}], "entity_mentions": [{"id": "8384030_3_Ent1", "text": "Foscarnet", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8384030_3_Ent2", "text": "Foscarnet", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8384030_3_Ent0", "text": "hypomagnesemia and other electrolyte disorders", "entity_type": "Entity", "start": 4, "end": 9}], "lang": "en"}
{"doc_id": "8391300_2", "wnd_id": "8391300_2_1", "text": "Vasospasm associated with ergotamine is a well - known phenomenon .", "tokens": ["Vasospasm", "associated", "with", "ergotamine", "is", "a", "well", "-", "known", "phenomenon", "."], "event_mentions": [{"id": "8391300_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8391300_2_Ent0", "role": "Effect", "text": "Vasospasm", "start": 0, "end": 1}, {"entity_id": "8391300_2_Ent1", "role": "Treatment", "text": "ergotamine", "start": 3, "end": 4}, {"entity_id": "8391300_2_Ent2", "role": "Treatment_Drug", "text": "ergotamine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8391300_2_Ent0", "text": "Vasospasm", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8391300_2_Ent1", "text": "ergotamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8391300_2_Ent2", "text": "ergotamine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8396491_2", "wnd_id": "8396491_2_1", "text": "The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .", "tokens": ["The", "results", "clearly", "demonstrate", "that", "CPH82", "was", "associated", "with", "suppression", "of", "the", "endogeneous", "production", "of", "ACTH", "and", "cortisol", "with", "a", "concomitant", "paradoxical", "picture", "of", "clinical", "hypercortisolism", "."], "event_mentions": [{"id": "8396491_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "8396491_2_Ent1", "role": "Treatment", "text": "CPH82", "start": 5, "end": 6}, {"entity_id": "8396491_2_Ent2", "role": "Treatment_Drug", "text": "CPH82", "start": 5, "end": 6}, {"entity_id": "8396491_2_Ent0", "role": "Effect", "text": "suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism", "start": 9, "end": 26}]}], "entity_mentions": [{"id": "8396491_2_Ent1", "text": "CPH82", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8396491_2_Ent2", "text": "CPH82", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8396491_2_Ent0", "text": "suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism", "entity_type": "Entity", "start": 9, "end": 26}], "lang": "en"}
{"doc_id": "8404753_3", "wnd_id": "8404753_3_1", "text": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .", "tokens": ["We", "report", "3", "children", "with", "epilepsy", "who", "developed", "facial", "motor", "tics", "after", "initiation", "of", "CBZ", "for", "complex", "partial", "seizures", "."], "event_mentions": [{"id": "8404753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8404753_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "8404753_3_Ent0", "role": "Subject", "text": "3 children with epilepsy", "start": 2, "end": 6}, {"entity_id": "8404753_3_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "8404753_3_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 5, "end": 6}, {"entity_id": "8404753_3_Ent3", "role": "Effect", "text": "facial motor tics", "start": 8, "end": 11}, {"entity_id": "8404753_3_Ent4", "role": "Treatment", "text": "CBZ", "start": 14, "end": 15}, {"entity_id": "8404753_3_Ent6", "role": "Treatment_Drug", "text": "CBZ", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8404753_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8404753_3_Ent0", "text": "3 children with epilepsy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8404753_3_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8404753_3_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8404753_3_Ent3", "text": "facial motor tics", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8404753_3_Ent4", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8404753_3_Ent6", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8404753_7", "wnd_id": "8404753_7_1", "text": "After development of the tics in 2 , CBZ was continued at the same or higher dose , and the tics abated and then ceased spontaneously < or = 6 months .", "tokens": ["After", "development", "of", "the", "tics", "in", "2", ",", "CBZ", "was", "continued", "at", "the", "same", "or", "higher", "dose", ",", "and", "the", "tics", "abated", "and", "then", "ceased", "spontaneously", "<", "or", "=", "6", "months", "."], "event_mentions": [{"id": "8404753_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "8404753_7_Ent0", "role": "Effect", "text": "tics", "start": 4, "end": 5}, {"entity_id": "8404753_7_Ent1", "role": "Treatment", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "8404753_7_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 8, "end": 9}, {"entity_id": "8404753_7_Ent3", "role": "Treatment_Dosage", "text": "the same or higher dose", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "8404753_7_Ent0", "text": "tics", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8404753_7_Ent1", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8404753_7_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8404753_7_Ent3", "text": "the same or higher dose", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "8430717_4", "wnd_id": "8430717_4_1", "text": "PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .", "tokens": ["PURPOSE", ":", "To", "investigate", "the", "concentration", "-", "side", "effect", "relationship", "in", "a", "patient", "with", "severe", "acyclovir", "-", "induced", "neurotoxicity", "and", "to", "summarize", "the", "information", "available", "in", "the", "literature", "about", "central", "nervous", "system", "side", "effects", "due", "to", "acyclovir", "."], "event_mentions": [{"id": "8430717_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "8430717_4_Ent2", "role": "Treatment", "text": "acyclovir", "start": 15, "end": 16}, {"entity_id": "8430717_4_Ent3", "role": "Treatment_Drug", "text": "acyclovir", "start": 15, "end": 16}, {"entity_id": "8430717_4_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 18, "end": 19}, {"entity_id": "8430717_4_Ent1", "role": "Effect", "text": "central nervous system side effects", "start": 29, "end": 34}]}], "entity_mentions": [{"id": "8430717_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8430717_4_Ent3", "text": "acyclovir", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8430717_4_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8430717_4_Ent1", "text": "central nervous system side effects", "entity_type": "Entity", "start": 29, "end": 34}], "lang": "en"}
{"doc_id": "8442800_2", "wnd_id": "8442800_2_1", "text": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse .", "tokens": ["Disulfiram", "has", "been", "used", "effectively", "to", "deter", "alcohol", "consumption", "in", "patients", "with", "a", "history", "of", "alcohol", "abuse", "."], "event_mentions": [{"id": "8442800_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "8442800_2_Ent1", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent2", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent0", "role": "Subject", "text": "patients with a history of alcohol abuse", "start": 10, "end": 17}, {"entity_id": "8442800_2_Ent3", "role": "Treatment_Disorder", "text": "history of alcohol abuse", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "8442800_2_Ent1", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent0", "text": "patients with a history of alcohol abuse", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "8442800_2_Ent3", "text": "history of alcohol abuse", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "8445549_1", "wnd_id": "8445549_1_1", "text": "Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .", "tokens": ["Although", "the", "essential", "cause", "of", "PV", "is", "unclear", ",", "its", "onset", "has", "occasionally", "been", "associated", "with", "drug", "therapy", ",", "in", "particular", "penicillamine", "."], "event_mentions": [{"id": "8445549_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "8445549_1_Ent0", "role": "Effect", "text": "PV", "start": 5, "end": 6}, {"entity_id": "8445549_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 21, "end": 22}, {"entity_id": "8445549_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "8445549_1_Ent0", "text": "PV", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8445549_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8445549_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "8461228_1", "wnd_id": "8461228_1_1", "text": "A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .", "tokens": ["A", "12", "year", "old", "patient", "with", "atrial", "flutter", "is", "presented", ",", "in", "whom", "intravenous", "adenosine", "was", "followed", "by", "acceleration", "of", "the", "heart", "rate", "to", "a", "potentially", "dangerous", "arrhythmia", "."], "event_mentions": [{"id": "8461228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed by", "start": 16, "end": 18}, "arguments": [{"entity_id": "8461228_1_Ent1", "role": "Subject_Age", "text": "12 year old", "start": 1, "end": 4}, {"entity_id": "8461228_1_Ent0", "role": "Subject", "text": "12 year old patient with atrial flutter", "start": 1, "end": 8}, {"entity_id": "8461228_1_Ent6", "role": "Treatment_Disorder", "text": "atrial flutter", "start": 6, "end": 8}, {"entity_id": "8461228_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 13, "end": 14}, {"entity_id": "8461228_1_Ent3", "role": "Treatment", "text": "intravenous adenosine", "start": 13, "end": 15}, {"entity_id": "8461228_1_Ent4", "role": "Treatment_Drug", "text": "adenosine", "start": 14, "end": 15}, {"entity_id": "8461228_1_Ent2", "role": "Effect", "text": "acceleration of the heart rate to a potentially dangerous arrhythmia", "start": 18, "end": 28}]}], "entity_mentions": [{"id": "8461228_1_Ent1", "text": "12 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "8461228_1_Ent0", "text": "12 year old patient with atrial flutter", "entity_type": "Entity", "start": 1, "end": 8}, {"id": "8461228_1_Ent6", "text": "atrial flutter", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8461228_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8461228_1_Ent3", "text": "intravenous adenosine", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8461228_1_Ent4", "text": "adenosine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8461228_1_Ent2", "text": "acceleration of the heart rate to a potentially dangerous arrhythmia", "entity_type": "Entity", "start": 18, "end": 28}], "lang": "en"}
{"doc_id": "8485005_3", "wnd_id": "8485005_3_1", "text": "We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "Kaposi", "'s", "sarcoma", "(", "KS", ")", "on", "the", "sole", "of", "the", "right", "foot", "in", "a", "71", "-", "year", "-", "old", "man", ",", "treated", "for", "6", "months", "with", "corticosteroid", "therapy", "(", "prednisolone", "25", "mg", "/", "day", ")", "for", "pericardial", "effusion", "."], "event_mentions": [{"id": "8485005_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8485005_3_Ent0", "role": "Subject", "text": "a case of", "start": 2, "end": 5}, {"entity_id": "8485005_3_Ent5", "role": "Effect", "text": "Kaposi 's sarcoma ( KS )", "start": 8, "end": 14}, {"entity_id": "8485005_3_Ent1", "role": "Subject", "text": "a 71 - year - old man", "start": 22, "end": 29}, {"entity_id": "8485005_3_Ent3", "role": "Subject_Age", "text": "71 - year - old", "start": 23, "end": 28}, {"entity_id": "8485005_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 28, "end": 29}, {"entity_id": "8485005_3_Ent7", "role": "Treatment_Duration", "text": "6 months", "start": 32, "end": 34}, {"entity_id": "8485005_3_Ent6", "role": "Treatment", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "start": 32, "end": 44}, {"entity_id": "8485005_3_Ent9", "role": "Treatment_Drug", "text": "prednisolone", "start": 38, "end": 39}, {"entity_id": "8485005_3_Ent8", "role": "Treatment_Dosage", "text": "25 mg / day", "start": 39, "end": 43}, {"entity_id": "8485005_3_Ent2", "role": "Subject", "text": "for pericardial effusion", "start": 44, "end": 47}, {"entity_id": "8485005_3_Ent10", "role": "Treatment_Disorder", "text": "pericardial effusion", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "8485005_3_Ent0", "text": "a case of", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8485005_3_Ent5", "text": "Kaposi 's sarcoma ( KS )", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8485005_3_Ent1", "text": "a 71 - year - old man", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "8485005_3_Ent3", "text": "71 - year - old", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "8485005_3_Ent4", "text": "man", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8485005_3_Ent7", "text": "6 months", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8485005_3_Ent6", "text": "6 months with corticosteroid therapy ( prednisolone 25 mg / day )", "entity_type": "Entity", "start": 32, "end": 44}, {"id": "8485005_3_Ent9", "text": "prednisolone", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "8485005_3_Ent8", "text": "25 mg / day", "entity_type": "Entity", "start": 39, "end": 43}, {"id": "8485005_3_Ent2", "text": "for pericardial effusion", "entity_type": "Entity", "start": 44, "end": 47}, {"id": "8485005_3_Ent10", "text": "pericardial effusion", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "8503421_2", "wnd_id": "8503421_2_1", "text": "Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .", "tokens": ["Cholesterol", "crystal", "embolization", "-", "associated", "renal", "failure", "after", "therapy", "with", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "."], "event_mentions": [{"id": "8503421_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "8503421_2_Ent0", "role": "Effect", "text": "Cholesterol crystal embolization - associated renal failure", "start": 0, "end": 7}, {"entity_id": "8503421_2_Ent1", "role": "Treatment", "text": "therapy with recombinant tissue - type plasminogen activator", "start": 8, "end": 16}, {"entity_id": "8503421_2_Ent2", "role": "Treatment_Drug", "text": "plasminogen activator", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8503421_2_Ent0", "text": "Cholesterol crystal embolization - associated renal failure", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8503421_2_Ent1", "text": "therapy with recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "8503421_2_Ent2", "text": "plasminogen activator", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8520081_1", "wnd_id": "8520081_1_1", "text": "Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .", "tokens": ["Intravenous", "haloperidol", "is", "generally", "well", "tolerated", ",", "but", "multiform", "ventricular", "tachycardia", "has", "been", "reported", "."], "event_mentions": [{"id": "8520081_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 13, "end": 14}, "arguments": [{"entity_id": "8520081_1_Ent1", "role": "Treatment", "text": "Intravenous haloperidol", "start": 0, "end": 2}, {"entity_id": "8520081_1_Ent0", "role": "Effect", "text": "multiform ventricular tachycardia", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8520081_1_Ent1", "text": "Intravenous haloperidol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8520081_1_Ent0", "text": "multiform ventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8530331_1", "wnd_id": "8530331_1_1", "text": "Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson 's disease and other akinetic - rigid syndromes .", "tokens": ["Risperidone", "versus", "clozapine", "in", "the", "treatment", "of", "psychosis", "in", "six", "patients", "with", "Parkinson", "'s", "disease", "and", "other", "akinetic", "-", "rigid", "syndromes", "."], "event_mentions": [{"id": "8530331_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 5, "end": 6}, "arguments": [{"entity_id": "8530331_1_Ent5", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "8530331_1_Ent4", "role": "Treatment", "text": "Risperidone versus clozapine", "start": 0, "end": 3}, {"entity_id": "8530331_1_Ent6", "role": "Treatment_Drug", "text": "clozapine", "start": 2, "end": 3}, {"entity_id": "8530331_1_Ent7", "role": "Treatment_Disorder", "text": "psychosis", "start": 7, "end": 8}, {"entity_id": "8530331_1_Ent1", "role": "Subject_Population", "text": "six", "start": 9, "end": 10}, {"entity_id": "8530331_1_Ent0", "role": "Subject", "text": "six patients with Parkinson 's disease and other akinetic - rigid syndromes", "start": 9, "end": 21}, {"entity_id": "8530331_1_Ent2", "role": "Subject_Disorder", "text": "Parkinson 's disease", "start": 12, "end": 15}, {"entity_id": "8530331_1_Ent3", "role": "Subject_Disorder", "text": "akinetic - rigid syndromes", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "8530331_1_Ent5", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8530331_1_Ent4", "text": "Risperidone versus clozapine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8530331_1_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8530331_1_Ent7", "text": "psychosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8530331_1_Ent1", "text": "six", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8530331_1_Ent0", "text": "six patients with Parkinson 's disease and other akinetic - rigid syndromes", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "8530331_1_Ent2", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8530331_1_Ent3", "text": "akinetic - rigid syndromes", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "8530331_6", "wnd_id": "8530331_6_1", "text": "Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .", "tokens": ["Two", "of", "the", "five", "patients", "who", "worsened", "motorically", "also", "developed", "encephalopathy", "during", "risperidone", "treatment", ";", "the", "encephalopathy", "resolved", "when", "the", "patients", "were", "switched", "to", "clozapine", "treatment", "."], "event_mentions": [{"id": "8530331_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "8530331_6_Ent1", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent0", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent2", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent3", "role": "Effect", "text": "encephalopathy", "start": 10, "end": 11}, {"entity_id": "8530331_6_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 12, "end": 13}, {"entity_id": "8530331_6_Ent4", "role": "Treatment", "text": "risperidone treatment", "start": 12, "end": 14}]}, {"id": "8530331_6_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 17, "end": 18}, "arguments": [{"entity_id": "8530331_6_Ent7", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent6", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent8", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent10", "role": "Treatment_Disorder", "text": "encephalopathy", "start": 16, "end": 17}, {"entity_id": "8530331_6_Ent9", "role": "Treatment", "text": "switched to clozapine treatment", "start": 22, "end": 26}, {"entity_id": "8530331_6_Ent11", "role": "Treatment_Drug", "text": "clozapine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "8530331_6_Ent1", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent7", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent0", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent6", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent2", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent8", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8530331_6_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8530331_6_Ent4", "text": "risperidone treatment", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8530331_6_Ent10", "text": "encephalopathy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_6_Ent9", "text": "switched to clozapine treatment", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "8530331_6_Ent11", "text": "clozapine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "8551001_4", "wnd_id": "8551001_4_1", "text": "Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .", "tokens": ["Thiopurine", "methyltransferase", "deficiency", "occurs", "at", "a", "frequency", "of", "one", "in", "300", "and", "is", "associated", "with", "profound", "myelosuppression", "after", "a", "short", "course", "of", "azathioprine", "."], "event_mentions": [{"id": "8551001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 17, "end": 18}, "arguments": [{"entity_id": "8551001_4_Ent0", "role": "Effect", "text": "profound myelosuppression", "start": 15, "end": 17}, {"entity_id": "8551001_4_Ent3", "role": "Treatment_Time_elapsed", "text": "a short course", "start": 18, "end": 21}, {"entity_id": "8551001_4_Ent1", "role": "Treatment", "text": "a short course of azathioprine", "start": 18, "end": 23}, {"entity_id": "8551001_4_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8551001_4_Ent0", "text": "profound myelosuppression", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8551001_4_Ent3", "text": "a short course", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8551001_4_Ent1", "text": "a short course of azathioprine", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "8551001_4_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8579054_3", "wnd_id": "8579054_3_1", "text": "Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .", "tokens": ["Prolonged", "used", "of", "hydroxyurea", "in", "patients", "with", "ET", "may", "lead", "to", "therapy", "-", "associated", "acute", "leukemia", "."], "event_mentions": [{"id": "8579054_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8579054_3_Ent5", "role": "Treatment_Freq", "text": "Prolonged used", "start": 0, "end": 2}, {"entity_id": "8579054_3_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 3, "end": 4}, {"entity_id": "8579054_3_Ent0", "role": "Subject", "text": "patients with ET", "start": 5, "end": 8}, {"entity_id": "8579054_3_Ent4", "role": "Treatment_Disorder", "text": "ET", "start": 7, "end": 8}, {"entity_id": "8579054_3_Ent1", "role": "Effect", "text": "therapy - associated acute leukemia", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "8579054_3_Ent5", "text": "Prolonged used", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8579054_3_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8579054_3_Ent0", "text": "patients with ET", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8579054_3_Ent4", "text": "ET", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8579054_3_Ent1", "text": "therapy - associated acute leukemia", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "8586895_4", "wnd_id": "8586895_4_1", "text": "The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .", "tokens": ["The", "pharmaceutical", "company", "producing", "Halfan", "has", "reported", "8", "cardiac", "arrests", ",", "leading", "to", "6", "deaths", ",", "when", "a", "higher", "dose", "than", "recommended", "was", "used", ",", "there", "was", "recent", "or", "concomitant", "treatment", "with", "mefloquine", ",", "there", "was", "pre", "-", "existing", "prolongation", "of", "the", "QT", "interval", "or", "the", "patient", "had", "a", "thiamine", "deficiency", "."], "event_mentions": [{"id": "8586895_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "8586895_4_Ent2", "role": "Treatment", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent4", "role": "Treatment_Drug", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent0", "role": "Effect", "text": "8 cardiac arrests", "start": 7, "end": 10}, {"entity_id": "8586895_4_Ent1", "role": "Effect", "text": "6 deaths", "start": 13, "end": 15}, {"entity_id": "8586895_4_Ent3", "role": "Treatment", "text": "when a higher dose than recommended was used", "start": 16, "end": 24}, {"entity_id": "8586895_4_Ent6", "role": "Treatment_Dosage", "text": "a higher dose than recommended", "start": 17, "end": 22}, {"entity_id": "8586895_4_Ent5", "role": "Treatment_Drug", "text": "mefloquine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8586895_4_Ent2", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent4", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent0", "text": "8 cardiac arrests", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8586895_4_Ent1", "text": "6 deaths", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8586895_4_Ent3", "text": "when a higher dose than recommended was used", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "8586895_4_Ent6", "text": "a higher dose than recommended", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "8586895_4_Ent5", "text": "mefloquine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8597009_3", "wnd_id": "8597009_3_1", "text": "Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .", "tokens": ["Slow", "acetylators", ",", "who", "comprise", "roughly", "50", "%", "of", "the", "South", "African", "population", ",", "are", "likely", "to", "develop", "clinical", "and", "biochemical", "features", "of", "phenytoin", "toxicity", "when", "this", "drug", "is", "given", "together", "with", "antituberculosis", "therapy", "."], "event_mentions": [{"id": "8597009_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 17, "end": 18}, "arguments": [{"entity_id": "8597009_3_Ent0", "role": "Subject", "text": "Slow acetylators", "start": 0, "end": 2}, {"entity_id": "8597009_3_Ent1", "role": "Subject_Disorder", "text": "Slow acetylators", "start": 0, "end": 2}, {"entity_id": "8597009_3_Ent2", "role": "Effect", "text": "clinical and biochemical features of phenytoin toxicity", "start": 18, "end": 25}, {"entity_id": "8597009_3_Ent3", "role": "Treatment", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent6", "role": "Treatment_Drug", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 23, "end": 24}, {"entity_id": "8597009_3_Ent4", "role": "Treatment", "text": "together with antituberculosis", "start": 30, "end": 33}, {"entity_id": "8597009_3_Ent5", "role": "Treatment_Drug", "text": "antituberculosis", "start": 32, "end": 33}, {"entity_id": "8597009_3_Ent8", "role": "Combination_Drug", "text": "antituberculosis", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8597009_3_Ent0", "text": "Slow acetylators", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_3_Ent1", "text": "Slow acetylators", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8597009_3_Ent2", "text": "clinical and biochemical features of phenytoin toxicity", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "8597009_3_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent6", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8597009_3_Ent4", "text": "together with antituberculosis", "entity_type": "Entity", "start": 30, "end": 33}, {"id": "8597009_3_Ent5", "text": "antituberculosis", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "8597009_3_Ent8", "text": "antituberculosis", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8604715_1", "wnd_id": "8604715_1_1", "text": "Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .", "tokens": ["Nephrogenic", "diabetes", "insipidus", "and", "renal", "tubular", "acidosis", "secondary", "to", "foscarnet", "therapy", "."], "event_mentions": [{"id": "8604715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "8604715_1_Ent0", "role": "Effect", "text": "Nephrogenic diabetes insipidus and renal tubular acidosis", "start": 0, "end": 7}, {"entity_id": "8604715_1_Ent1", "role": "Treatment", "text": "foscarnet", "start": 9, "end": 10}, {"entity_id": "8604715_1_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8604715_1_Ent0", "text": "Nephrogenic diabetes insipidus and renal tubular acidosis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8604715_1_Ent1", "text": "foscarnet", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8604715_1_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8604715_2", "wnd_id": "8604715_2_1", "text": "No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .", "tokens": ["No", "cases", "of", "renal", "acidosis", ",", "and", "only", "one", "case", "of", "nephrogenic", "diabetes", "insipidus", ",", "has", "been", "previously", "reported", "as", "a", "complication", "of", "foscarnet", "treatment", "."], "event_mentions": [{"id": "8604715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 18, "end": 19}, "arguments": [{"entity_id": "8604715_2_Ent0", "role": "Effect", "text": "nephrogenic diabetes insipidus", "start": 11, "end": 14}, {"entity_id": "8604715_2_Ent2", "role": "Treatment_Drug", "text": "foscarnet", "start": 23, "end": 24}, {"entity_id": "8604715_2_Ent1", "role": "Treatment", "text": "foscarnet treatment", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8604715_2_Ent0", "text": "nephrogenic diabetes insipidus", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8604715_2_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8604715_2_Ent1", "text": "foscarnet treatment", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8604715_4", "wnd_id": "8604715_4_1", "text": "We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .", "tokens": ["We", "present", "a", "patient", "with", "human", "immunodeficiency", "virus", "infection", "under", "treatment", "with", "foscarnet", "for", "CMV", "retinitis", "who", "complained", "of", "thirst", "and", "polyuria", "."], "event_mentions": [{"id": "8604715_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 17, "end": 18}, "arguments": [{"entity_id": "8604715_4_Ent0", "role": "Subject", "text": "a patient with human immunodeficiency virus infection", "start": 2, "end": 9}, {"entity_id": "8604715_4_Ent1", "role": "Subject_Disorder", "text": "human immunodeficiency virus infection", "start": 5, "end": 9}, {"entity_id": "8604715_4_Ent3", "role": "Treatment", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent5", "role": "Treatment_Drug", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent4", "role": "Treatment_Disorder", "text": "CMV retinitis", "start": 14, "end": 16}, {"entity_id": "8604715_4_Ent2", "role": "Effect", "text": "thirst and polyuria", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "8604715_4_Ent0", "text": "a patient with human immunodeficiency virus infection", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "8604715_4_Ent1", "text": "human immunodeficiency virus infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8604715_4_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent5", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent4", "text": "CMV retinitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8604715_4_Ent2", "text": "thirst and polyuria", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "8627446_2", "wnd_id": "8627446_2_1", "text": "We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .", "tokens": ["We", "describe", "two", "patients", "with", "rheumatoid", "factor", "-", "positive", ",", "polyarticular", "-", "onset", "juvenile", "rheumatoid", "arthritis", "in", "whom", "accelerated", "nodulosis", "developed", "during", "methotrexate", "therapy", "."], "event_mentions": [{"id": "8627446_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8627446_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8627446_2_Ent0", "role": "Subject", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 2, "end": 16}, {"entity_id": "8627446_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 5, "end": 16}, {"entity_id": "8627446_2_Ent2", "role": "Effect", "text": "accelerated nodulosis", "start": 18, "end": 20}, {"entity_id": "8627446_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8627446_2_Ent3", "role": "Treatment", "text": "methotrexate therapy", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "8627446_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8627446_2_Ent0", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 16}, {"id": "8627446_2_Ent5", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "8627446_2_Ent2", "text": "accelerated nodulosis", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8627446_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8627446_2_Ent3", "text": "methotrexate therapy", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "8645078_3", "wnd_id": "8645078_3_1", "text": "Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .", "tokens": ["Captopril", "is", "known", "to", "be", "associated", "with", "dermatologic", ",", "hematologic", ",", "and", "pulmonary", "adverse", "effects", "."], "event_mentions": [{"id": "8645078_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "8645078_3_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_3_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_3_Ent0", "role": "Effect", "text": "dermatologic , hematologic , and pulmonary adverse effects", "start": 7, "end": 15}]}], "entity_mentions": [{"id": "8645078_3_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_3_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_3_Ent0", "text": "dermatologic , hematologic , and pulmonary adverse effects", "entity_type": "Entity", "start": 7, "end": 15}], "lang": "en"}
{"doc_id": "8667442_1", "wnd_id": "8667442_1_1", "text": "Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .", "tokens": ["Milk", "-", "alkali", "syndrome", "induced", "by", "1,25(OH)2D", "in", "a", "patient", "with", "hypoparathyroidism", "."], "event_mentions": [{"id": "8667442_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "8667442_1_Ent1", "role": "Effect", "text": "Milk - alkali syndrome", "start": 0, "end": 4}, {"entity_id": "8667442_1_Ent2", "role": "Treatment", "text": "1,25(OH)2D", "start": 6, "end": 7}, {"entity_id": "8667442_1_Ent3", "role": "Treatment_Drug", "text": "1,25(OH)2D", "start": 6, "end": 7}, {"entity_id": "8667442_1_Ent0", "role": "Subject", "text": "a patient with hypoparathyroidism .", "start": 8, "end": 13}, {"entity_id": "8667442_1_Ent4", "role": "Treatment_Disorder", "text": "hypoparathyroidism", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8667442_1_Ent1", "text": "Milk - alkali syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8667442_1_Ent2", "text": "1,25(OH)2D", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8667442_1_Ent3", "text": "1,25(OH)2D", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8667442_1_Ent0", "text": "a patient with hypoparathyroidism .", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8667442_1_Ent4", "text": "hypoparathyroidism", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8678015_2", "wnd_id": "8678015_2_1", "text": "Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .", "tokens": ["Although", "a", "few", "case", "reports", "link", "metronidazole", "with", "the", "development", "of", "pseudomembranous", "colitis", ",", "albendazole", "has", "not", "been", "associated", "with", "the", "development", "of", "this", "condition", "."], "event_mentions": [{"id": "8678015_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "8678015_2_Ent1", "role": "Treatment", "text": "metronidazole", "start": 6, "end": 7}, {"entity_id": "8678015_2_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 6, "end": 7}, {"entity_id": "8678015_2_Ent0", "role": "Effect", "text": "pseudomembranous colitis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "8678015_2_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_2_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8678015_2_Ent0", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "8684546_1", "wnd_id": "8684546_1_1", "text": "Aluminum intoxication , along with other factors , was considered to be the cause of TC development .", "tokens": ["Aluminum", "intoxication", ",", "along", "with", "other", "factors", ",", "was", "considered", "to", "be", "the", "cause", "of", "TC", "development", "."], "event_mentions": [{"id": "8684546_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "8684546_1_Ent2", "role": "Treatment_Drug", "text": "Aluminum", "start": 0, "end": 1}, {"entity_id": "8684546_1_Ent1", "role": "Treatment", "text": "Aluminum intoxication", "start": 0, "end": 2}, {"entity_id": "8684546_1_Ent0", "role": "Effect", "text": "TC development", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8684546_1_Ent2", "text": "Aluminum", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8684546_1_Ent1", "text": "Aluminum intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8684546_1_Ent0", "text": "TC development", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8691927_4", "wnd_id": "8691927_4_1", "text": "INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .", "tokens": ["INTERPRETATION", ":", "When", "high", "doses", "of", "fluticasone", "propionate", "are", "used", ",", "growth", "may", "be", "retarded", "and", "adrenal", "suppression", "may", "occur", "."], "event_mentions": [{"id": "8691927_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 19, "end": 20}, "arguments": [{"entity_id": "8691927_4_Ent2", "role": "Treatment_Dosage", "text": "high doses", "start": 3, "end": 5}, {"entity_id": "8691927_4_Ent1", "role": "Treatment", "text": "high doses of fluticasone propionate", "start": 3, "end": 8}, {"entity_id": "8691927_4_Ent3", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 6, "end": 8}, {"entity_id": "8691927_4_Ent0", "role": "Effect", "text": "growth may be retarded and adrenal suppression", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "8691927_4_Ent2", "text": "high doses", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8691927_4_Ent1", "text": "high doses of fluticasone propionate", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "8691927_4_Ent3", "text": "fluticasone propionate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8691927_4_Ent0", "text": "growth may be retarded and adrenal suppression", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "8691927_5", "wnd_id": "8691927_5_1", "text": "METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .", "tokens": ["METHODS", ":", "Growth", "retardation", "was", "observed", "in", "six", "severely", "asthmatic", "children", "after", "introduction", "of", "high", "-", "dose", "fluticasone", "propionate", "treatment", "(", "dry", "powder", ")", "."], "event_mentions": [{"id": "8691927_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8691927_5_Ent3", "role": "Effect", "text": "Growth retardation", "start": 2, "end": 4}, {"entity_id": "8691927_5_Ent1", "role": "Subject_Population", "text": "six", "start": 7, "end": 8}, {"entity_id": "8691927_5_Ent0", "role": "Subject", "text": "six severely asthmatic children", "start": 7, "end": 11}, {"entity_id": "8691927_5_Ent5", "role": "Treatment_Disorder", "text": "severely asthmatic", "start": 8, "end": 10}, {"entity_id": "8691927_5_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "8691927_5_Ent4", "role": "Treatment", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "start": 12, "end": 24}, {"entity_id": "8691927_5_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 14, "end": 17}, {"entity_id": "8691927_5_Ent7", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 17, "end": 19}, {"entity_id": "8691927_5_Ent8", "role": "Treatment_Route", "text": "dry powder", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8691927_5_Ent3", "text": "Growth retardation", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8691927_5_Ent1", "text": "six", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8691927_5_Ent0", "text": "six severely asthmatic children", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8691927_5_Ent5", "text": "severely asthmatic", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8691927_5_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8691927_5_Ent4", "text": "introduction of high - dose fluticasone propionate treatment ( dry powder )", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "8691927_5_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "8691927_5_Ent7", "text": "fluticasone propionate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8691927_5_Ent8", "text": "dry powder", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "8700794_1", "wnd_id": "8700794_1_1", "text": "A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .", "tokens": ["A", "review", "of", "the", "literature", "found", "11", "children", "and", "2", "adults", "in", "whom", "intranasal", "desmopressin", "was", "associated", "with", "hyponatremia", ",", "all", "of", "whom", "experienced", "seizures", "or", "altered", "mental", "status", "."], "event_mentions": [{"id": "8700794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "8700794_1_Ent1", "role": "Subject_Population", "text": "11", "start": 6, "end": 7}, {"entity_id": "8700794_1_Ent0", "role": "Subject", "text": "11 children and 2 adults", "start": 6, "end": 11}, {"entity_id": "8700794_1_Ent3", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "8700794_1_Ent2", "role": "Subject_Population", "text": "2", "start": 9, "end": 10}, {"entity_id": "8700794_1_Ent4", "role": "Subject_Age", "text": "adults", "start": 10, "end": 11}, {"entity_id": "8700794_1_Ent9", "role": "Treatment_Route", "text": "intranasal", "start": 13, "end": 14}, {"entity_id": "8700794_1_Ent7", "role": "Treatment", "text": "intranasal desmopressin", "start": 13, "end": 15}, {"entity_id": "8700794_1_Ent8", "role": "Treatment_Drug", "text": "desmopressin", "start": 14, "end": 15}, {"entity_id": "8700794_1_Ent5", "role": "Effect", "text": "hyponatremia", "start": 18, "end": 19}, {"entity_id": "8700794_1_Ent6", "role": "Effect", "text": "seizures or altered mental status", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "8700794_1_Ent1", "text": "11", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8700794_1_Ent0", "text": "11 children and 2 adults", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8700794_1_Ent3", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8700794_1_Ent2", "text": "2", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8700794_1_Ent4", "text": "adults", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8700794_1_Ent9", "text": "intranasal", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8700794_1_Ent7", "text": "intranasal desmopressin", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8700794_1_Ent8", "text": "desmopressin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8700794_1_Ent5", "text": "hyponatremia", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8700794_1_Ent6", "text": "seizures or altered mental status", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "8726608_3", "wnd_id": "8726608_3_1", "text": "This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .", "tokens": ["This", "case", "suggests", "that", "acyclovir", "when", "given", "intravenously", "in", "doses", "of", "10", "mg", "/", "kg", "may", "result", "in", "increased", "serum", "lithium", "concentrations", "."], "event_mentions": [{"id": "8726608_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 16, "end": 17}, "arguments": [{"entity_id": "8726608_3_Ent1", "role": "Treatment", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 4, "end": 5}, {"entity_id": "8726608_3_Ent3", "role": "Treatment_Dosage", "text": "10 mg / kg", "start": 11, "end": 15}, {"entity_id": "8726608_3_Ent0", "role": "Effect", "text": "increased serum lithium concentrations", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "8726608_3_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8726608_3_Ent3", "text": "10 mg / kg", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "8726608_3_Ent0", "text": "increased serum lithium concentrations", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "8726608_4", "wnd_id": "8726608_4_1", "text": "Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .", "tokens": ["Until", "additional", "data", "are", "available", ",", "if", "intravenous", "acyclovir", "is", "administered", "concurrently", "with", "lithium", ",", "we", "recommend", "closely", "monitoring", "patients", "for", "signs", "of", "lithium", "toxicity", "and", "measuring", "serum", "lithium", "levels", "every", "second", "or", "third", "day", "."], "event_mentions": [{"id": "8726608_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 21, "end": 22}, "arguments": [{"entity_id": "8726608_4_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "8726608_4_Ent1", "role": "Treatment", "text": "intravenous acyclovir is administered concurrently with lithium", "start": 7, "end": 14}, {"entity_id": "8726608_4_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent6", "role": "Combination_Drug", "text": "acyclovir", "start": 8, "end": 9}, {"entity_id": "8726608_4_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8726608_4_Ent0", "role": "Effect", "text": "lithium toxicity", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8726608_4_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8726608_4_Ent1", "text": "intravenous acyclovir is administered concurrently with lithium", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "8726608_4_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent6", "text": "acyclovir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8726608_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_4_Ent0", "text": "lithium toxicity", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8726608_5", "wnd_id": "8726608_5_1", "text": "When measured , the serum lithium level had increased 4 - fold during acyclovir therapy .", "tokens": ["When", "measured", ",", "the", "serum", "lithium", "level", "had", "increased", "4", "-", "fold", "during", "acyclovir", "therapy", "."], "event_mentions": [{"id": "8726608_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "8726608_5_Ent0", "role": "Effect", "text": "serum lithium level had increased 4 - fold", "start": 4, "end": 12}, {"entity_id": "8726608_5_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent4", "role": "Combination_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8726608_5_Ent1", "role": "Treatment", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent2", "role": "Treatment_Drug", "text": "acyclovir", "start": 13, "end": 14}, {"entity_id": "8726608_5_Ent5", "role": "Combination_Drug", "text": "acyclovir", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8726608_5_Ent0", "text": "serum lithium level had increased 4 - fold", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8726608_5_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8726608_5_Ent1", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent2", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8726608_5_Ent5", "text": "acyclovir", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8739289_2", "wnd_id": "8739289_2_1", "text": "Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .", "tokens": ["Nephrogenic", "diabetes", "insipidus", "(", "NDI", ")", "is", "a", "well", "-", "documented", "complication", "of", "lithium", "use", "."], "event_mentions": [{"id": "8739289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "8739289_2_Ent0", "role": "Effect", "text": "Nephrogenic diabetes insipidus ( NDI )", "start": 0, "end": 6}, {"entity_id": "8739289_2_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "8739289_2_Ent0", "text": "Nephrogenic diabetes insipidus ( NDI )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8739289_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8739289_5", "wnd_id": "8739289_5_1", "text": "To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "lithium", "-", "associated", "CDI", "and", "NDI", "presenting", "concurrently", "."], "event_mentions": [{"id": "8739289_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "8739289_5_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent0", "role": "Effect", "text": "CDI and NDI", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "8739289_5_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent0", "text": "CDI and NDI", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "8739289_6", "wnd_id": "8739289_6_1", "text": "Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .", "tokens": ["Potential", "mechanisms", "regarding", "the", "pathophysiology", "of", "lithium", "-", "associated", "CDI", "are", "discussed", "."], "event_mentions": [{"id": "8739289_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8739289_6_Ent1", "role": "Treatment", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_6_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_6_Ent0", "role": "Effect", "text": "CDI", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8739289_6_Ent1", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_6_Ent2", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_6_Ent0", "text": "CDI", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8742573_3", "wnd_id": "8742573_3_1", "text": "Human insulin - induced lipoatrophy .", "tokens": ["Human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "8742573_3_Ent1", "role": "Treatment", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent2", "role": "Treatment_Drug", "text": "Human insulin", "start": 0, "end": 2}, {"entity_id": "8742573_3_Ent0", "role": "Effect", "text": "lipoatrophy", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8742573_3_Ent1", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent2", "text": "Human insulin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8742573_3_Ent0", "text": "lipoatrophy", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8742573_4", "wnd_id": "8742573_4_1", "text": "OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .", "tokens": ["OBJECTIVE", ":", "To", "evaluate", "the", "efficacy", "of", "the", "administration", "of", "insulin", "by", "a", "jet", "-", "injector", "device", "in", "stopping", "and", "reversing", "severe", "human", "insulin", "-", "induced", "lipoatrophy", "."], "event_mentions": [{"id": "8742573_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 25, "end": 26}, "arguments": [{"entity_id": "8742573_4_Ent0", "role": "Effect", "text": "severe human", "start": 21, "end": 23}, {"entity_id": "8742573_4_Ent2", "role": "Treatment", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 23, "end": 24}, {"entity_id": "8742573_4_Ent1", "role": "Effect", "text": "lipoatrophy", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "8742573_4_Ent0", "text": "severe human", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8742573_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent3", "text": "insulin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "8742573_4_Ent1", "text": "lipoatrophy", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "879939_2", "wnd_id": "879939_2_1", "text": "Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .", "tokens": ["Severe", "osteomalacia", "was", "present", "in", "two", "epileptic", "patients", "who", "were", "under", "long", "-", "term", "treatment", "with", "congeners", "of", "phenytoin", ",", "phenobarbital", ",", "and", "acetazolamide", "."], "event_mentions": [{"id": "879939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_2_Ent2", "role": "Effect", "text": "osteomalacia", "start": 1, "end": 2}, {"entity_id": "879939_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "879939_2_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 5, "end": 8}, {"entity_id": "879939_2_Ent4", "role": "Treatment_Disorder", "text": "epileptic", "start": 6, "end": 7}, {"entity_id": "879939_2_Ent3", "role": "Treatment", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "start": 11, "end": 24}, {"entity_id": "879939_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent9", "role": "Combination_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent7", "role": "Treatment_Drug", "text": "acetazolamide", "start": 23, "end": 24}, {"entity_id": "879939_2_Ent10", "role": "Combination_Drug", "text": "acetazolamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "879939_2_Ent2", "text": "osteomalacia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "879939_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "879939_2_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "879939_2_Ent4", "text": "epileptic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "879939_2_Ent3", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "879939_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent9", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent7", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "879939_2_Ent10", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "8835752_1", "wnd_id": "8835752_1_1", "text": "Hepatobiliary disorders associated with orally administered terbinafine have rarely been reported .", "tokens": ["Hepatobiliary", "disorders", "associated", "with", "orally", "administered", "terbinafine", "have", "rarely", "been", "reported", "."], "event_mentions": [{"id": "8835752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8835752_1_Ent0", "role": "Effect", "text": "Hepatobiliary disorders", "start": 0, "end": 2}, {"entity_id": "8835752_1_Ent3", "role": "Treatment_Route", "text": "orally", "start": 4, "end": 5}, {"entity_id": "8835752_1_Ent1", "role": "Treatment", "text": "orally administered terbinafine", "start": 4, "end": 7}, {"entity_id": "8835752_1_Ent2", "role": "Treatment_Drug", "text": "terbinafine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8835752_1_Ent0", "text": "Hepatobiliary disorders", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8835752_1_Ent3", "text": "orally", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8835752_1_Ent1", "text": "orally administered terbinafine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8835752_1_Ent2", "text": "terbinafine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8850251_2", "wnd_id": "8850251_2_1", "text": "In addition , an immediate erythematous macule was observed on the photopatch test site of mequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy .", "tokens": ["In", "addition", ",", "an", "immediate", "erythematous", "macule", "was", "observed", "on", "the", "photopatch", "test", "site", "of", "mequitazine", "directly", "after", "UV", "exposure", "which", "was", "similar", "to", "the", "immediate", "erythema", "noted", "in", "chlorpromazine", "photoallergy", "."], "event_mentions": [{"id": "8850251_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 8, "end": 9}, "arguments": [{"entity_id": "8850251_2_Ent0", "role": "Effect", "text": "an immediate erythematous macule", "start": 3, "end": 7}, {"entity_id": "8850251_2_Ent2", "role": "Treatment_Drug", "text": "mequitazine", "start": 15, "end": 16}, {"entity_id": "8850251_2_Ent1", "role": "Treatment", "text": "mequitazine directly after UV exposure", "start": 15, "end": 20}, {"entity_id": "8850251_2_Ent3", "role": "Treatment_Route", "text": "UV exposure", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "8850251_2_Ent0", "text": "an immediate erythematous macule", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8850251_2_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8850251_2_Ent1", "text": "mequitazine directly after UV exposure", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "8850251_2_Ent3", "text": "UV exposure", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "8850251_6", "wnd_id": "8850251_6_1", "text": "We experienced 2 cases of mequitazine - induced photosensitivity reaction in patients who took mequitazine for their dermatologic problems .", "tokens": ["We", "experienced", "2", "cases", "of", "mequitazine", "-", "induced", "photosensitivity", "reaction", "in", "patients", "who", "took", "mequitazine", "for", "their", "dermatologic", "problems", "."], "event_mentions": [{"id": "8850251_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8850251_6_Ent2", "role": "Treatment", "text": "mequitazine", "start": 5, "end": 6}, {"entity_id": "8850251_6_Ent4", "role": "Treatment_Drug", "text": "mequitazine", "start": 5, "end": 6}, {"entity_id": "8850251_6_Ent1", "role": "Effect", "text": "photosensitivity reaction", "start": 8, "end": 10}, {"entity_id": "8850251_6_Ent0", "role": "Subject", "text": "patients", "start": 11, "end": 12}, {"entity_id": "8850251_6_Ent3", "role": "Treatment_Disorder", "text": "dermatologic problems", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "8850251_6_Ent2", "text": "mequitazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8850251_6_Ent4", "text": "mequitazine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8850251_6_Ent1", "text": "photosensitivity reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8850251_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8850251_6_Ent3", "text": "dermatologic problems", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "8862924_2", "wnd_id": "8862924_2_1", "text": "Methamphetamine 's extensive physiologic effects , inconsistent street purity , and multiple routes of administration offer many possibilities for injury to the cornea .", "tokens": ["Methamphetamine", "'s", "extensive", "physiologic", "effects", ",", "inconsistent", "street", "purity", ",", "and", "multiple", "routes", "of", "administration", "offer", "many", "possibilities", "for", "injury", "to", "the", "cornea", "."], "event_mentions": [{"id": "8862924_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "offer", "start": 15, "end": 16}, "arguments": [{"entity_id": "8862924_2_Ent0", "role": "Treatment", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent2", "role": "Treatment_Drug", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent1", "role": "Treatment_Disorder", "text": "injury to the cornea", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "8862924_2_Ent0", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent2", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent1", "text": "injury to the cornea", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "8876616_2", "wnd_id": "8876616_2_1", "text": "We report the case of a 74 - year - old female patient who received the antide - pressant amitriptyline because of a major depression .", "tokens": ["We", "report", "the", "case", "of", "a", "74", "-", "year", "-", "old", "female", "patient", "who", "received", "the", "antide", "-", "pressant", "amitriptyline", "because", "of", "a", "major", "depression", "."], "event_mentions": [{"id": "8876616_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 14, "end": 15}, "arguments": [{"entity_id": "8876616_2_Ent0", "role": "Subject", "text": "a 74 - year - old female patient", "start": 5, "end": 13}, {"entity_id": "8876616_2_Ent2", "role": "Subject_Age", "text": "74 - year - old", "start": 6, "end": 11}, {"entity_id": "8876616_2_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "8876616_2_Ent4", "role": "Treatment", "text": "antide - pressant amitriptyline", "start": 16, "end": 20}, {"entity_id": "8876616_2_Ent6", "role": "Treatment_Drug", "text": "amitriptyline", "start": 19, "end": 20}, {"entity_id": "8876616_2_Ent1", "role": "Subject", "text": "a major depression", "start": 22, "end": 25}, {"entity_id": "8876616_2_Ent5", "role": "Treatment_Disorder", "text": "major depression", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8876616_2_Ent0", "text": "a 74 - year - old female patient", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "8876616_2_Ent2", "text": "74 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8876616_2_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8876616_2_Ent4", "text": "antide - pressant amitriptyline", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "8876616_2_Ent6", "text": "amitriptyline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8876616_2_Ent1", "text": "a major depression", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8876616_2_Ent5", "text": "major depression", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8891729_1", "wnd_id": "8891729_1_1", "text": "Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia .", "tokens": ["Fatal", "intravascular", "autoimmune", "hemolytic", "anemia", "after", "fludarabine", "treatment", "for", "chronic", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "8891729_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "8891729_1_Ent0", "role": "Effect", "text": "Fatal intravascular autoimmune hemolytic anemia", "start": 0, "end": 5}, {"entity_id": "8891729_1_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 6, "end": 7}, {"entity_id": "8891729_1_Ent1", "role": "Treatment", "text": "fludarabine treatment", "start": 6, "end": 8}, {"entity_id": "8891729_1_Ent3", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "8891729_1_Ent0", "text": "Fatal intravascular autoimmune hemolytic anemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8891729_1_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8891729_1_Ent1", "text": "fludarabine treatment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8891729_1_Ent3", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "8903300_3", "wnd_id": "8903300_3_1", "text": "This pattern is suggestive of renal toxicity due to tobramycin .", "tokens": ["This", "pattern", "is", "suggestive", "of", "renal", "toxicity", "due", "to", "tobramycin", "."], "event_mentions": [{"id": "8903300_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 7, "end": 9}, "arguments": [{"entity_id": "8903300_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 5, "end": 7}, {"entity_id": "8903300_3_Ent1", "role": "Treatment", "text": "tobramycin", "start": 9, "end": 10}, {"entity_id": "8903300_3_Ent2", "role": "Treatment_Drug", "text": "tobramycin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8903300_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8903300_3_Ent1", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8903300_3_Ent2", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8908396_2", "wnd_id": "8908396_2_1", "text": "Insulin - induced lipoatrophy in type I diabetes .", "tokens": ["Insulin", "-", "induced", "lipoatrophy", "in", "type", "I", "diabetes", "."], "event_mentions": [{"id": "8908396_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8908396_2_Ent1", "role": "Treatment", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "8908396_2_Ent3", "role": "Treatment_Drug", "text": "Insulin", "start": 0, "end": 1}, {"entity_id": "8908396_2_Ent0", "role": "Effect", "text": "lipoatrophy", "start": 3, "end": 4}, {"entity_id": "8908396_2_Ent2", "role": "Treatment_Disorder", "text": "type I diabetes", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "8908396_2_Ent1", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8908396_2_Ent3", "text": "Insulin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8908396_2_Ent0", "text": "lipoatrophy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8908396_2_Ent2", "text": "type I diabetes", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "8912599_6", "wnd_id": "8912599_6_1", "text": "Erosion of psoriatic plaques : an early sign of methotrexate toxicity .", "tokens": ["Erosion", "of", "psoriatic", "plaques", ":", "an", "early", "sign", "of", "methotrexate", "toxicity", "."], "event_mentions": [{"id": "8912599_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "8912599_6_Ent0", "role": "Effect", "text": "Erosion of psoriatic plaques", "start": 0, "end": 4}, {"entity_id": "8912599_6_Ent1", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8912599_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8912599_6_Ent0", "text": "Erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8912599_6_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8912599_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8936932_1", "wnd_id": "8936932_1_1", "text": "Acute esmolol toxicity may be self - limiting because of its extremely short half - life .", "tokens": ["Acute", "esmolol", "toxicity", "may", "be", "self", "-", "limiting", "because", "of", "its", "extremely", "short", "half", "-", "life", "."], "event_mentions": [{"id": "8936932_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 4, "end": 5}, "arguments": [{"entity_id": "8936932_1_Ent1", "role": "Treatment", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent2", "role": "Treatment_Drug", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "8936932_1_Ent1", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent2", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "8961730_1", "wnd_id": "8961730_1_1", "text": "Psychotic disorder associated with isoniazid .", "tokens": ["Psychotic", "disorder", "associated", "with", "isoniazid", "."], "event_mentions": [{"id": "8961730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8961730_1_Ent0", "role": "Effect", "text": "Psychotic disorder", "start": 0, "end": 2}, {"entity_id": "8961730_1_Ent1", "role": "Treatment", "text": "isoniazid", "start": 4, "end": 5}, {"entity_id": "8961730_1_Ent2", "role": "Treatment_Drug", "text": "isoniazid", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8961730_1_Ent0", "text": "Psychotic disorder", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8961730_1_Ent1", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8961730_1_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8969033_2", "wnd_id": "8969033_2_1", "text": "Ketanserin in the treatment of protamine - induced pulmonary hypertension .", "tokens": ["Ketanserin", "in", "the", "treatment", "of", "protamine", "-", "induced", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "8969033_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "8969033_2_Ent1", "role": "Treatment", "text": "protamine", "start": 5, "end": 6}, {"entity_id": "8969033_2_Ent2", "role": "Treatment_Drug", "text": "protamine", "start": 5, "end": 6}, {"entity_id": "8969033_2_Ent0", "role": "Effect", "text": "pulmonary hypertension .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8969033_2_Ent1", "text": "protamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8969033_2_Ent2", "text": "protamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8969033_2_Ent0", "text": "pulmonary hypertension .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "897744_1", "wnd_id": "897744_1_1", "text": "Focal glomerulonephritis and interstitial nephritis in methicillin - treated , heroin - related infective endocarditis .", "tokens": ["Focal", "glomerulonephritis", "and", "interstitial", "nephritis", "in", "methicillin", "-", "treated", ",", "heroin", "-", "related", "infective", "endocarditis", "."], "event_mentions": [{"id": "897744_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "897744_1_Ent3", "role": "Effect", "text": "Focal glomerulonephritis and interstitial nephritis", "start": 0, "end": 5}, {"entity_id": "897744_1_Ent4", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent6", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent5", "role": "Treatment_Disorder", "text": "heroin - related infective endocarditis", "start": 10, "end": 15}]}, {"id": "897744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "897744_1_Ent1", "role": "Treatment", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent0", "role": "Effect", "text": "infective endocarditis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "897744_1_Ent3", "text": "Focal glomerulonephritis and interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "897744_1_Ent4", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent6", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent1", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent2", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent5", "text": "heroin - related infective endocarditis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "897744_1_Ent0", "text": "infective endocarditis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "8979664_2", "wnd_id": "8979664_2_1", "text": "over the past 3 years there have been several reports of uveitis associated with rifabutin therapy .", "tokens": ["over", "the", "past", "3", "years", "there", "have", "been", "several", "reports", "of", "uveitis", "associated", "with", "rifabutin", "therapy", "."], "event_mentions": [{"id": "8979664_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "8979664_2_Ent0", "role": "Effect", "text": "uveitis", "start": 11, "end": 12}, {"entity_id": "8979664_2_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 14, "end": 15}, {"entity_id": "8979664_2_Ent1", "role": "Treatment", "text": "rifabutin therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8979664_2_Ent0", "text": "uveitis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_2_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8979664_2_Ent1", "text": "rifabutin therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8996514_2", "wnd_id": "8996514_2_1", "text": "Large cerebral infarction during praziquantel therapy in neurocysticercosis .", "tokens": ["Large", "cerebral", "infarction", "during", "praziquantel", "therapy", "in", "neurocysticercosis", "."], "event_mentions": [{"id": "8996514_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "8996514_2_Ent0", "role": "Effect", "text": "Large cerebral infarction", "start": 0, "end": 3}, {"entity_id": "8996514_2_Ent1", "role": "Treatment", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent2", "role": "Treatment_Drug", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent3", "role": "Treatment_Disorder", "text": "neurocysticercosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "8996514_2_Ent0", "text": "Large cerebral infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8996514_2_Ent1", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent2", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent3", "text": "neurocysticercosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9022114_2", "wnd_id": "9022114_2_1", "text": "CONCLUSION : The findings in these two patients suggest that colchicine may delay corneal wound healing .", "tokens": ["CONCLUSION", ":", "The", "findings", "in", "these", "two", "patients", "suggest", "that", "colchicine", "may", "delay", "corneal", "wound", "healing", "."], "event_mentions": [{"id": "9022114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "delay", "start": 12, "end": 13}, "arguments": [{"entity_id": "9022114_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "9022114_2_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "9022114_2_Ent3", "role": "Treatment", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "9022114_2_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "9022114_2_Ent2", "role": "Effect", "text": "delay corneal wound healing", "start": 12, "end": 16}, {"entity_id": "9022114_2_Ent5", "role": "Treatment_Disorder", "text": "corneal wound", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9022114_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9022114_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9022114_2_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9022114_2_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9022114_2_Ent2", "text": "delay corneal wound healing", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "9022114_2_Ent5", "text": "corneal wound", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9022114_3", "wnd_id": "9022114_3_1", "text": "Delay of corneal wound healing in patients treated with colchicine .", "tokens": ["Delay", "of", "corneal", "wound", "healing", "in", "patients", "treated", "with", "colchicine", "."], "event_mentions": [{"id": "9022114_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9022114_3_Ent1", "role": "Effect", "text": "Delay of corneal wound healing", "start": 0, "end": 5}, {"entity_id": "9022114_3_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "9022114_3_Ent2", "role": "Treatment", "text": "colchicine", "start": 9, "end": 10}, {"entity_id": "9022114_3_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9022114_3_Ent1", "text": "Delay of corneal wound healing", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9022114_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9022114_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9022114_3_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9022114_4", "wnd_id": "9022114_4_1", "text": "The authors report on two patients with corneal ulcers refractory to conventional treatment while the patients were undergoing oral colchicine therapy .", "tokens": ["The", "authors", "report", "on", "two", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "while", "the", "patients", "were", "undergoing", "oral", "colchicine", "therapy", "."], "event_mentions": [{"id": "9022114_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 17, "end": 18}, "arguments": [{"entity_id": "9022114_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "9022114_4_Ent0", "role": "Subject", "text": "two patients", "start": 4, "end": 6}, {"entity_id": "9022114_4_Ent2", "role": "Effect", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_4_Ent5", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "9022114_4_Ent3", "role": "Treatment", "text": "oral colchicine therapy", "start": 18, "end": 21}, {"entity_id": "9022114_4_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9022114_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9022114_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9022114_4_Ent2", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_4_Ent5", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9022114_4_Ent3", "text": "oral colchicine therapy", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9022114_4_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9022114_5", "wnd_id": "9022114_5_1", "text": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine , cessation of colchicine therapy should be considered .", "tokens": ["The", "authors", "suggest", "that", "in", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "who", "are", "receiving", "colchicine", ",", "cessation", "of", "colchicine", "therapy", "should", "be", "considered", "."], "event_mentions": [{"id": "9022114_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 15, "end": 16}, "arguments": [{"entity_id": "9022114_5_Ent0", "role": "Subject", "text": "patients with corneal ulcers", "start": 5, "end": 9}, {"entity_id": "9022114_5_Ent3", "role": "Treatment_Disorder", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "9022114_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9022114_5_Ent0", "text": "patients with corneal ulcers", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9022114_5_Ent3", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9022114_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9052919_2", "wnd_id": "9052919_2_1", "text": "One patient had MRI T2 abnormalities compatible with cyclosporin neurotoxicity .", "tokens": ["One", "patient", "had", "MRI", "T2", "abnormalities", "compatible", "with", "cyclosporin", "neurotoxicity", "."], "event_mentions": [{"id": "9052919_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 2, "end": 3}, "arguments": [{"entity_id": "9052919_2_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "9052919_2_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "9052919_2_Ent3", "role": "Effect", "text": "MRI T2 abnormalities", "start": 3, "end": 6}, {"entity_id": "9052919_2_Ent4", "role": "Treatment", "text": "cyclosporin", "start": 8, "end": 9}, {"entity_id": "9052919_2_Ent5", "role": "Treatment_Drug", "text": "cyclosporin", "start": 8, "end": 9}, {"entity_id": "9052919_2_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9052919_2_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9052919_2_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9052919_2_Ent3", "text": "MRI T2 abnormalities", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9052919_2_Ent4", "text": "cyclosporin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_2_Ent5", "text": "cyclosporin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9052919_2_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9094821_1", "wnd_id": "9094821_1_1", "text": "The possible effects of tamoxifen upon the uterus are discussed in this article , in view of reports of tamoxifen associated with endometrial carcinoma and endometriosis .", "tokens": ["The", "possible", "effects", "of", "tamoxifen", "upon", "the", "uterus", "are", "discussed", "in", "this", "article", ",", "in", "view", "of", "reports", "of", "tamoxifen", "associated", "with", "endometrial", "carcinoma", "and", "endometriosis", "."], "event_mentions": [{"id": "9094821_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "9094821_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 19, "end": 20}, {"entity_id": "9094821_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 19, "end": 20}, {"entity_id": "9094821_1_Ent0", "role": "Effect", "text": "endometrial carcinoma and endometriosis", "start": 22, "end": 26}]}], "entity_mentions": [{"id": "9094821_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9094821_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9094821_1_Ent0", "text": "endometrial carcinoma and endometriosis", "entity_type": "Entity", "start": 22, "end": 26}], "lang": "en"}
{"doc_id": "9161656_14", "wnd_id": "9161656_14_1", "text": "Although dyspnea associated with verapamil administration has been reported , this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained - release verapamil administration .", "tokens": ["Although", "dyspnea", "associated", "with", "verapamil", "administration", "has", "been", "reported", ",", "this", "is", "the", "first", "report", "of", "an", "elderly", "asymptomatic", "asthmatic", "patient", "with", "hypertension", "who", "developed", "an", "acute", "asthma", "attack", "following", "sustained", "-", "release", "verapamil", "administration", "."], "event_mentions": [{"id": "9161656_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "9161656_14_Ent0", "role": "Subject", "text": "an elderly asymptomatic asthmatic patient with hypertension", "start": 16, "end": 23}, {"entity_id": "9161656_14_Ent1", "role": "Subject_Age", "text": "elderly", "start": 17, "end": 18}, {"entity_id": "9161656_14_Ent2", "role": "Subject_Disorder", "text": "asymptomatic asthmatic", "start": 18, "end": 20}, {"entity_id": "9161656_14_Ent6", "role": "Treatment_Disorder", "text": "hypertension", "start": 22, "end": 23}, {"entity_id": "9161656_14_Ent3", "role": "Effect", "text": "an acute asthma attack", "start": 25, "end": 29}, {"entity_id": "9161656_14_Ent5", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 30, "end": 34}, {"entity_id": "9161656_14_Ent4", "role": "Treatment", "text": "sustained - release verapamil administration", "start": 30, "end": 35}]}], "entity_mentions": [{"id": "9161656_14_Ent0", "text": "an elderly asymptomatic asthmatic patient with hypertension", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "9161656_14_Ent1", "text": "elderly", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9161656_14_Ent2", "text": "asymptomatic asthmatic", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9161656_14_Ent6", "text": "hypertension", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9161656_14_Ent3", "text": "an acute asthma attack", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "9161656_14_Ent5", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "9161656_14_Ent4", "text": "sustained - release verapamil administration", "entity_type": "Entity", "start": 30, "end": 35}], "lang": "en"}
{"doc_id": "9161656_16", "wnd_id": "9161656_16_1", "text": "She continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil , and her asthma symptoms disappeared .", "tokens": ["She", "continued", "taking", "verapamil", "for", "6", "months", ",", "then", ",", "on", "her", "own", ",", "stopped", "all", "medications", "including", "the", "sustained", "-", "release", "verapamil", ",", "and", "her", "asthma", "symptoms", "disappeared", "."], "event_mentions": [{"id": "9161656_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 28, "end": 29}, "arguments": [{"entity_id": "9161656_16_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent2", "role": "Treatment", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "start": 1, "end": 23}, {"entity_id": "9161656_16_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "9161656_16_Ent5", "role": "Treatment_Duration", "text": "for 6 months", "start": 4, "end": 7}, {"entity_id": "9161656_16_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9161656_16_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent2", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "entity_type": "Entity", "start": 1, "end": 23}, {"id": "9161656_16_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9161656_16_Ent5", "text": "for 6 months", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9161656_16_Ent3", "text": "asthma", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9169264_1", "wnd_id": "9169264_1_1", "text": "Cephalexin rash in infectious mononucleosis .", "tokens": ["Cephalexin", "rash", "in", "infectious", "mononucleosis", "."], "event_mentions": [{"id": "9169264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "9169264_1_Ent1", "role": "Treatment", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent2", "role": "Treatment_Drug", "text": "Cephalexin", "start": 0, "end": 1}, {"entity_id": "9169264_1_Ent0", "role": "Effect", "text": "Cephalexin rash", "start": 0, "end": 2}, {"entity_id": "9169264_1_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9169264_1_Ent1", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent2", "text": "Cephalexin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9169264_1_Ent0", "text": "Cephalexin rash", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9169264_1_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9169264_2", "wnd_id": "9169264_2_1", "text": "The ampicillin rash occurring in cases of infectious mononucleosis is well documented .", "tokens": ["The", "ampicillin", "rash", "occurring", "in", "cases", "of", "infectious", "mononucleosis", "is", "well", "documented", "."], "event_mentions": [{"id": "9169264_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 3, "end": 4}, "arguments": [{"entity_id": "9169264_2_Ent0", "role": "Effect", "text": "The ampicillin rash", "start": 0, "end": 3}, {"entity_id": "9169264_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 1, "end": 2}, {"entity_id": "9169264_2_Ent3", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9169264_2_Ent0", "text": "The ampicillin rash", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9169264_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9169264_2_Ent3", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9230324_1", "wnd_id": "9230324_1_1", "text": "We report the specifics of 12 cases of severe hypertension after the intraoperative use of topical phenylephrine , submucosal epinephrine , or both .", "tokens": ["We", "report", "the", "specifics", "of", "12", "cases", "of", "severe", "hypertension", "after", "the", "intraoperative", "use", "of", "topical", "phenylephrine", ",", "submucosal", "epinephrine", ",", "or", "both", "."], "event_mentions": [{"id": "9230324_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "9230324_1_Ent1", "role": "Subject_Population", "text": "12", "start": 5, "end": 6}, {"entity_id": "9230324_1_Ent0", "role": "Subject", "text": "12 cases", "start": 5, "end": 7}, {"entity_id": "9230324_1_Ent2", "role": "Effect", "text": "hypertension", "start": 9, "end": 10}, {"entity_id": "9230324_1_Ent3", "role": "Treatment", "text": "intraoperative use of topical phenylephrine , submucosal epinephrine , or both", "start": 12, "end": 23}, {"entity_id": "9230324_1_Ent6", "role": "Treatment_Route", "text": "topical", "start": 15, "end": 16}, {"entity_id": "9230324_1_Ent4", "role": "Treatment_Drug", "text": "phenylephrine", "start": 16, "end": 17}, {"entity_id": "9230324_1_Ent9", "role": "Combination_Drug", "text": "phenylephrine", "start": 16, "end": 17}, {"entity_id": "9230324_1_Ent7", "role": "Treatment_Route", "text": "submucosal", "start": 18, "end": 19}, {"entity_id": "9230324_1_Ent5", "role": "Treatment_Drug", "text": "epinephrine", "start": 19, "end": 20}, {"entity_id": "9230324_1_Ent8", "role": "Combination_Drug", "text": "epinephrine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9230324_1_Ent1", "text": "12", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9230324_1_Ent0", "text": "12 cases", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9230324_1_Ent2", "text": "hypertension", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9230324_1_Ent3", "text": "intraoperative use of topical phenylephrine , submucosal epinephrine , or both", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "9230324_1_Ent6", "text": "topical", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9230324_1_Ent4", "text": "phenylephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9230324_1_Ent9", "text": "phenylephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9230324_1_Ent7", "text": "submucosal", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9230324_1_Ent5", "text": "epinephrine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9230324_1_Ent8", "text": "epinephrine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9279731_1", "wnd_id": "9279731_1_1", "text": "When the disease recurred conventional amphotericin B was used again , but had to be stopped because of severe side effects .", "tokens": ["When", "the", "disease", "recurred", "conventional", "amphotericin", "B", "was", "used", "again", ",", "but", "had", "to", "be", "stopped", "because", "of", "severe", "side", "effects", "."], "event_mentions": [{"id": "9279731_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 17, "end": 18}, "arguments": [{"entity_id": "9279731_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 5, "end": 7}, {"entity_id": "9279731_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 5, "end": 7}, {"entity_id": "9279731_1_Ent0", "role": "Effect", "text": "side effects", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "9279731_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9279731_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9279731_1_Ent0", "text": "side effects", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "9337441_14", "wnd_id": "9337441_14_1", "text": "To our knowledge , this case report represents only the third description of laxative - induced TEN .", "tokens": ["To", "our", "knowledge", ",", "this", "case", "report", "represents", "only", "the", "third", "description", "of", "laxative", "-", "induced", "TEN", "."], "event_mentions": [{"id": "9337441_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "9337441_14_Ent1", "role": "Treatment", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent2", "role": "Treatment_Drug", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent0", "role": "Effect", "text": "TEN", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9337441_14_Ent1", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent2", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent0", "text": "TEN", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9337441_18", "wnd_id": "9337441_18_1", "text": "Clinicians should include phenolphthalein in their list of possible causes of drug - induced TEN .", "tokens": ["Clinicians", "should", "include", "phenolphthalein", "in", "their", "list", "of", "possible", "causes", "of", "drug", "-", "induced", "TEN", "."], "event_mentions": [{"id": "9337441_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9337441_18_Ent1", "role": "Treatment", "text": "phenolphthalein", "start": 3, "end": 4}, {"entity_id": "9337441_18_Ent2", "role": "Treatment_Drug", "text": "phenolphthalein", "start": 3, "end": 4}, {"entity_id": "9337441_18_Ent0", "role": "Effect", "text": "TEN", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9337441_18_Ent1", "text": "phenolphthalein", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9337441_18_Ent2", "text": "phenolphthalein", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9337441_18_Ent0", "text": "TEN", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9352164_4", "wnd_id": "9352164_4_1", "text": "We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["We", "experienced", "a", "case", "of", "chronic", "renal", "failure", "in", "a", "patient", "suffering", "from", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "9352164_4_Ent0", "role": "Subject", "text": "a case of chronic renal failure in a patient", "start": 2, "end": 11}, {"entity_id": "9352164_4_Ent1", "role": "Subject_Disorder", "text": "chronic renal failure", "start": 5, "end": 8}, {"entity_id": "9352164_4_Ent2", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_4_Ent3", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_4_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9352164_4_Ent0", "text": "a case of chronic renal failure in a patient", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "9352164_4_Ent1", "text": "chronic renal failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9352164_4_Ent2", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_4_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_4_Ent4", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9352164_5", "wnd_id": "9352164_5_1", "text": "We thus concluded that an excessive dose of AZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis .", "tokens": ["We", "thus", "concluded", "that", "an", "excessive", "dose", "of", "AZ", "had", "probably", "destroyed", "the", "gastric", "mucosal", "barrier", "or", "thrombocytopenia", "due", "to", "bone", "marrow", "disorder", "and", "thus", "eventually", "led", "to", "the", "development", "of", "hemorrhagic", "gastritis", "."], "event_mentions": [{"id": "9352164_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 9, "end": 10}, "arguments": [{"entity_id": "9352164_5_Ent3", "role": "Treatment_Dosage", "text": "excessive dose", "start": 5, "end": 7}, {"entity_id": "9352164_5_Ent2", "role": "Treatment", "text": "excessive dose of AZ", "start": 5, "end": 9}, {"entity_id": "9352164_5_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 8, "end": 9}, {"entity_id": "9352164_5_Ent0", "role": "Effect", "text": "destroyed the gastric mucosal barrier or thrombocytopenia", "start": 11, "end": 18}, {"entity_id": "9352164_5_Ent1", "role": "Effect", "text": "hemorrhagic gastritis", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "9352164_5_Ent3", "text": "excessive dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9352164_5_Ent2", "text": "excessive dose of AZ", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9352164_5_Ent4", "text": "AZ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9352164_5_Ent0", "text": "destroyed the gastric mucosal barrier or thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "9352164_5_Ent1", "text": "hemorrhagic gastritis", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "9362107_2", "wnd_id": "9362107_2_1", "text": "On the next day , after a total dose of only 600 mg of danazol , gingival bleeding and purpura occurred .", "tokens": ["On", "the", "next", "day", ",", "after", "a", "total", "dose", "of", "only", "600", "mg", "of", "danazol", ",", "gingival", "bleeding", "and", "purpura", "occurred", "."], "event_mentions": [{"id": "9362107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 20, "end": 21}, "arguments": [{"entity_id": "9362107_2_Ent1", "role": "Treatment", "text": "On the next day , after a total dose of only 600 mg of danazol", "start": 0, "end": 15}, {"entity_id": "9362107_2_Ent3", "role": "Treatment_Dosage", "text": "a total dose of only 600 mg", "start": 6, "end": 13}, {"entity_id": "9362107_2_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 14, "end": 15}, {"entity_id": "9362107_2_Ent0", "role": "Effect", "text": "gingival bleeding and purpura", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "9362107_2_Ent1", "text": "On the next day , after a total dose of only 600 mg of danazol", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "9362107_2_Ent3", "text": "a total dose of only 600 mg", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9362107_2_Ent2", "text": "danazol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9362107_2_Ent0", "text": "gingival bleeding and purpura", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "9375469_3", "wnd_id": "9375469_3_1", "text": "We report a case of contact dermatitis due to sodium bisulfite in Tathion eye drops .", "tokens": ["We", "report", "a", "case", "of", "contact", "dermatitis", "due", "to", "sodium", "bisulfite", "in", "Tathion", "eye", "drops", "."], "event_mentions": [{"id": "9375469_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "9375469_3_Ent0", "role": "Effect", "text": "contact dermatitis", "start": 5, "end": 7}, {"entity_id": "9375469_3_Ent1", "role": "Treatment", "text": "sodium bisulfite", "start": 9, "end": 11}, {"entity_id": "9375469_3_Ent2", "role": "Treatment_Drug", "text": "sodium bisulfite", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9375469_3_Ent0", "text": "contact dermatitis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9375469_3_Ent1", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9375469_3_Ent2", "text": "sodium bisulfite", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9399776_3", "wnd_id": "9399776_3_1", "text": "A rechallenge , performed in both patients , confirmed the diagnosis of mesalamine - induced pancreatitis .", "tokens": ["A", "rechallenge", ",", "performed", "in", "both", "patients", ",", "confirmed", "the", "diagnosis", "of", "mesalamine", "-", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9399776_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9399776_3_Ent0", "role": "Subject", "text": "both patients", "start": 5, "end": 7}, {"entity_id": "9399776_3_Ent2", "role": "Treatment", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent3", "role": "Treatment_Drug", "text": "mesalamine", "start": 12, "end": 13}, {"entity_id": "9399776_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9399776_3_Ent0", "text": "both patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9399776_3_Ent2", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent3", "text": "mesalamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9399776_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9407188_1", "wnd_id": "9407188_1_1", "text": "Early ritonavir - induced maculopapular eruption .", "tokens": ["Early", "ritonavir", "-", "induced", "maculopapular", "eruption", "."], "event_mentions": [{"id": "9407188_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "9407188_1_Ent1", "role": "Treatment", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent2", "role": "Treatment_Drug", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent0", "role": "Effect", "text": "maculopapular eruption", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "9407188_1_Ent1", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent0", "text": "maculopapular eruption", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "9413296_2", "wnd_id": "9413296_2_1", "text": "Methysergide - induced retroperitoneal fibrosis : successful outcome and two new laboratory features .", "tokens": ["Methysergide", "-", "induced", "retroperitoneal", "fibrosis", ":", "successful", "outcome", "and", "two", "new", "laboratory", "features", "."], "event_mentions": [{"id": "9413296_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9413296_2_Ent1", "role": "Treatment", "text": "Methysergide", "start": 0, "end": 1}, {"entity_id": "9413296_2_Ent2", "role": "Treatment_Drug", "text": "Methysergide", "start": 0, "end": 1}, {"entity_id": "9413296_2_Ent0", "role": "Effect", "text": "retroperitoneal fibrosis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9413296_2_Ent1", "text": "Methysergide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9413296_2_Ent2", "text": "Methysergide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9413296_2_Ent0", "text": "retroperitoneal fibrosis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9466030_2", "wnd_id": "9466030_2_1", "text": "Approximately 15 min after the first administration of nebulised morphine the patient became markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command .", "tokens": ["Approximately", "15", "min", "after", "the", "first", "administration", "of", "nebulised", "morphine", "the", "patient", "became", "markedly", "bradypneic", "(", "respiratory", "rate", ":", "4", "-", "5", "bpm", ")", ",", "hypotensive", "(", "BP", "70/40", "mmHg", ")", ",", "and", "responded", "only", "partially", "to", "command", "."], "event_mentions": [{"id": "9466030_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 12, "end": 13}, "arguments": [{"entity_id": "9466030_2_Ent5", "role": "Treatment_Time_elapsed", "text": "15 min", "start": 1, "end": 3}, {"entity_id": "9466030_2_Ent4", "role": "Treatment_Route", "text": "nebulised", "start": 8, "end": 9}, {"entity_id": "9466030_2_Ent2", "role": "Treatment", "text": "nebulised morphine", "start": 8, "end": 10}, {"entity_id": "9466030_2_Ent3", "role": "Treatment_Drug", "text": "morphine", "start": 9, "end": 10}, {"entity_id": "9466030_2_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "9466030_2_Ent1", "role": "Effect", "text": "markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command", "start": 13, "end": 38}]}], "entity_mentions": [{"id": "9466030_2_Ent5", "text": "15 min", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9466030_2_Ent4", "text": "nebulised", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9466030_2_Ent2", "text": "nebulised morphine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9466030_2_Ent3", "text": "morphine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9466030_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9466030_2_Ent1", "text": "markedly bradypneic ( respiratory rate : 4 - 5 bpm ) , hypotensive ( BP 70/40 mmHg ) , and responded only partially to command", "entity_type": "Entity", "start": 13, "end": 38}], "lang": "en"}
{"doc_id": "9466030_3", "wnd_id": "9466030_3_1", "text": "PURPOSE : To present a case of respiratory depression following the administration of nebulised morphine .", "tokens": ["PURPOSE", ":", "To", "present", "a", "case", "of", "respiratory", "depression", "following", "the", "administration", "of", "nebulised", "morphine", "."], "event_mentions": [{"id": "9466030_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "9466030_3_Ent0", "role": "Effect", "text": "respiratory depression", "start": 7, "end": 9}, {"entity_id": "9466030_3_Ent3", "role": "Treatment_Route", "text": "nebulised", "start": 13, "end": 14}, {"entity_id": "9466030_3_Ent1", "role": "Treatment", "text": "nebulised morphine", "start": 13, "end": 15}, {"entity_id": "9466030_3_Ent2", "role": "Treatment_Drug", "text": "morphine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9466030_3_Ent0", "text": "respiratory depression", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9466030_3_Ent3", "text": "nebulised", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9466030_3_Ent1", "text": "nebulised morphine", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9466030_3_Ent2", "text": "morphine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9476721_3", "wnd_id": "9476721_3_1", "text": "We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d - penicillamine 125 - 500 mg daily .", "tokens": ["We", "reported", "3", "patients", "who", "developed", "acute", "generalized", "dystonia", "and", "akinetic", "rigid", "syndrome", "following", "an", "initial", "therapy", "with", "d", "-", "penicillamine", "125", "-", "500", "mg", "daily", "."], "event_mentions": [{"id": "9476721_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "9476721_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9476721_3_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "9476721_3_Ent2", "role": "Effect", "text": "acute generalized dystonia and akinetic rigid syndrome", "start": 6, "end": 13}, {"entity_id": "9476721_3_Ent4", "role": "Treatment_Drug", "text": "d - penicillamine", "start": 18, "end": 21}, {"entity_id": "9476721_3_Ent3", "role": "Treatment", "text": "d - penicillamine 125 - 500 mg daily", "start": 18, "end": 26}, {"entity_id": "9476721_3_Ent5", "role": "Treatment_Dosage", "text": "125 - 500 mg daily", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "9476721_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9476721_3_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9476721_3_Ent2", "text": "acute generalized dystonia and akinetic rigid syndrome", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9476721_3_Ent4", "text": "d - penicillamine", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "9476721_3_Ent3", "text": "d - penicillamine 125 - 500 mg daily", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "9476721_3_Ent5", "text": "125 - 500 mg daily", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "9494448_1", "wnd_id": "9494448_1_1", "text": "A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine .", "tokens": ["A", "MEDLINE", "search", "identified", "all", "the", "reported", "cases", "of", "hypersensitivity", "reactions", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 10, "end": 11}, "arguments": [{"entity_id": "9494448_1_Ent0", "role": "Effect", "text": "hypersensitivity reactions", "start": 9, "end": 11}, {"entity_id": "9494448_1_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "9494448_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9494448_1_Ent0", "text": "hypersensitivity reactions", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_1_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9494448_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9494448_5", "wnd_id": "9494448_5_1", "text": "Fortunately , a hypersensitivity reaction to one formulation of cyclosporine does not preclude use of a different formulation .", "tokens": ["Fortunately", ",", "a", "hypersensitivity", "reaction", "to", "one", "formulation", "of", "cyclosporine", "does", "not", "preclude", "use", "of", "a", "different", "formulation", "."], "event_mentions": [{"id": "9494448_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 5, "end": 6}, "arguments": [{"entity_id": "9494448_5_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 3, "end": 5}, {"entity_id": "9494448_5_Ent1", "role": "Treatment", "text": "one formulation of cyclosporine", "start": 6, "end": 10}, {"entity_id": "9494448_5_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9494448_5_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9494448_5_Ent1", "text": "one formulation of cyclosporine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9494448_5_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9494448_6", "wnd_id": "9494448_6_1", "text": "METHODS : We report a patient who had an anaphylactic reaction during the intravenous infusion of cyclosporine .", "tokens": ["METHODS", ":", "We", "report", "a", "patient", "who", "had", "an", "anaphylactic", "reaction", "during", "the", "intravenous", "infusion", "of", "cyclosporine", "."], "event_mentions": [{"id": "9494448_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "9494448_6_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "9494448_6_Ent1", "role": "Effect", "text": "anaphylactic reaction", "start": 9, "end": 11}, {"entity_id": "9494448_6_Ent4", "role": "Treatment_Route", "text": "intravenous infusion", "start": 13, "end": 15}, {"entity_id": "9494448_6_Ent2", "role": "Treatment", "text": "intravenous infusion of cyclosporine", "start": 13, "end": 17}, {"entity_id": "9494448_6_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9494448_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_6_Ent1", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_6_Ent4", "text": "intravenous infusion", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9494448_6_Ent2", "text": "intravenous infusion of cyclosporine", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "9494448_6_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9509511_1", "wnd_id": "9509511_1_1", "text": "The chemotherapeutics , including vincristine , actinomycin D , and epirubicin in case 1 and vincristine and actinomycin D in case 2 , were given before the hepatotoxicity developed .", "tokens": ["The", "chemotherapeutics", ",", "including", "vincristine", ",", "actinomycin", "D", ",", "and", "epirubicin", "in", "case", "1", "and", "vincristine", "and", "actinomycin", "D", "in", "case", "2", ",", "were", "given", "before", "the", "hepatotoxicity", "developed", "."], "event_mentions": [{"id": "9509511_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 24, "end": 25}, "arguments": [{"entity_id": "9509511_1_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 15, "end": 16}, {"entity_id": "9509511_1_Ent4", "role": "Combination_Drug", "text": "vincristine", "start": 15, "end": 16}, {"entity_id": "9509511_1_Ent1", "role": "Treatment", "text": "vincristine and actinomycin D", "start": 15, "end": 19}, {"entity_id": "9509511_1_Ent3", "role": "Treatment_Drug", "text": "actinomycin D", "start": 17, "end": 19}, {"entity_id": "9509511_1_Ent5", "role": "Combination_Drug", "text": "actinomycin D", "start": 17, "end": 19}, {"entity_id": "9509511_1_Ent0", "role": "Effect", "text": "hepatotoxicity developed", "start": 27, "end": 29}]}, {"id": "9509511_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 24, "end": 25}, "arguments": [{"entity_id": "9509511_1_Ent7", "role": "Treatment", "text": "chemotherapeutics , including vincristine , actinomycin D , and epirubicin", "start": 1, "end": 11}, {"entity_id": "9509511_1_Ent8", "role": "Treatment_Drug", "text": "vincristine", "start": 4, "end": 5}, {"entity_id": "9509511_1_Ent13", "role": "Combination_Drug", "text": "vincristine", "start": 4, "end": 5}, {"entity_id": "9509511_1_Ent9", "role": "Treatment_Drug", "text": "actinomycin D", "start": 6, "end": 8}, {"entity_id": "9509511_1_Ent12", "role": "Combination_Drug", "text": "actinomycin D", "start": 6, "end": 8}, {"entity_id": "9509511_1_Ent10", "role": "Treatment_Drug", "text": "epirubicin", "start": 10, "end": 11}, {"entity_id": "9509511_1_Ent11", "role": "Combination_Drug", "text": "epirubicin", "start": 10, "end": 11}, {"entity_id": "9509511_1_Ent6", "role": "Effect", "text": "hepatotoxicity developed", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "9509511_1_Ent7", "text": "chemotherapeutics , including vincristine , actinomycin D , and epirubicin", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "9509511_1_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9509511_1_Ent13", "text": "vincristine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9509511_1_Ent9", "text": "actinomycin D", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9509511_1_Ent12", "text": "actinomycin D", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9509511_1_Ent10", "text": "epirubicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9509511_1_Ent11", "text": "epirubicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9509511_1_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9509511_1_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9509511_1_Ent1", "text": "vincristine and actinomycin D", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "9509511_1_Ent3", "text": "actinomycin D", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9509511_1_Ent5", "text": "actinomycin D", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9509511_1_Ent0", "text": "hepatotoxicity developed", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "9509511_1_Ent6", "text": "hepatotoxicity developed", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "9512187_1", "wnd_id": "9512187_1_1", "text": "Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi 's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud 's phenomenon under chemotherapy .", "tokens": ["Because", "the", "combination", "of", "bleomycin", "and", "vinca", "alkaloids", "is", "commonly", "used", "for", "the", "treatment", "of", "AIDS", "-", "related", "Kaposi", "'s", "sarcoma", ",", "clinicians", "should", "be", "aware", "of", "the", "risk", "of", "provoking", "acral", "necrosis", "in", "patients", "who", "develop", "Raynaud", "'s", "phenomenon", "under", "chemotherapy", "."], "event_mentions": [{"id": "9512187_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoking", "start": 30, "end": 31}, "arguments": [{"entity_id": "9512187_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent6", "role": "Combination_Drug", "text": "bleomycin", "start": 4, "end": 5}, {"entity_id": "9512187_1_Ent3", "role": "Treatment", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent5", "role": "Treatment_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent7", "role": "Combination_Drug", "text": "vinca alkaloids", "start": 6, "end": 8}, {"entity_id": "9512187_1_Ent0", "role": "Effect", "text": "acral necrosis", "start": 31, "end": 33}, {"entity_id": "9512187_1_Ent1", "role": "Effect", "text": "Raynaud 's phenomenon", "start": 37, "end": 40}]}], "entity_mentions": [{"id": "9512187_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent6", "text": "bleomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9512187_1_Ent3", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent5", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent7", "text": "vinca alkaloids", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9512187_1_Ent0", "text": "acral necrosis", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "9512187_1_Ent1", "text": "Raynaud 's phenomenon", "entity_type": "Entity", "start": 37, "end": 40}], "lang": "en"}
{"doc_id": "9545161_5", "wnd_id": "9545161_5_1", "text": "To date , eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature .", "tokens": ["To", "date", ",", "eight", "cases", "of", "TEN", "and", "one", "of", "SJS", "related", "to", "lamotrigine", "administration", "have", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "9545161_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "9545161_5_Ent0", "role": "Effect", "text": "TEN", "start": 6, "end": 7}, {"entity_id": "9545161_5_Ent1", "role": "Effect", "text": "SJS", "start": 10, "end": 11}, {"entity_id": "9545161_5_Ent2", "role": "Treatment", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "9545161_5_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9545161_5_Ent0", "text": "TEN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9545161_5_Ent1", "text": "SJS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9545161_5_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9545161_5_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9550246_4", "wnd_id": "9550246_4_1", "text": "The authors suggest that risperidone may increase affect in patients with schizophrenia and that some patients , especially those with anxiety , may have difficulty managing the increase .", "tokens": ["The", "authors", "suggest", "that", "risperidone", "may", "increase", "affect", "in", "patients", "with", "schizophrenia", "and", "that", "some", "patients", ",", "especially", "those", "with", "anxiety", ",", "may", "have", "difficulty", "managing", "the", "increase", "."], "event_mentions": [{"id": "9550246_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 6, "end": 7}, "arguments": [{"entity_id": "9550246_4_Ent2", "role": "Treatment", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 4, "end": 5}, {"entity_id": "9550246_4_Ent1", "role": "Effect", "text": "increase affect", "start": 6, "end": 8}, {"entity_id": "9550246_4_Ent0", "role": "Subject", "text": "patients with schizophrenia", "start": 9, "end": 12}, {"entity_id": "9550246_4_Ent4", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9550246_4_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9550246_4_Ent1", "text": "increase affect", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9550246_4_Ent0", "text": "patients with schizophrenia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9550246_4_Ent4", "text": "schizophrenia", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9554064_4", "wnd_id": "9554064_4_1", "text": "We present a fatal case of subacute methanol toxicity with associated diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression .", "tokens": ["We", "present", "a", "fatal", "case", "of", "subacute", "methanol", "toxicity", "with", "associated", "diffuse", "brain", "involvement", ",", "including", "bilateral", "putaminal", "necrosis", "and", "cerebral", "edema", "with", "ventricular", "compression", "."], "event_mentions": [{"id": "9554064_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "9554064_4_Ent1", "role": "Treatment", "text": "methanol", "start": 7, "end": 8}, {"entity_id": "9554064_4_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 7, "end": 8}, {"entity_id": "9554064_4_Ent0", "role": "Effect", "text": "diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression", "start": 11, "end": 25}]}], "entity_mentions": [{"id": "9554064_4_Ent1", "text": "methanol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9554064_4_Ent2", "text": "methanol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9554064_4_Ent0", "text": "diffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression", "entity_type": "Entity", "start": 11, "end": 25}], "lang": "en"}
{"doc_id": "9562211_2", "wnd_id": "9562211_2_1", "text": "Risperidone - induced tardive dyskinesia .", "tokens": ["Risperidone", "-", "induced", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "9562211_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9562211_2_Ent1", "role": "Treatment", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "9562211_2_Ent2", "role": "Treatment_Drug", "text": "Risperidone", "start": 0, "end": 1}, {"entity_id": "9562211_2_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9562211_2_Ent1", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9562211_2_Ent2", "text": "Risperidone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9562211_2_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9562211_3", "wnd_id": "9562211_3_1", "text": "This report presents a potential case of risperidone - induced tardive dyskinesia .", "tokens": ["This", "report", "presents", "a", "potential", "case", "of", "risperidone", "-", "induced", "tardive", "dyskinesia", "."], "event_mentions": [{"id": "9562211_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9562211_3_Ent0", "role": "Subject", "text": "a potential case", "start": 3, "end": 6}, {"entity_id": "9562211_3_Ent2", "role": "Treatment", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "9562211_3_Ent1", "role": "Effect", "text": "tardive dyskinesia", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "9562211_3_Ent0", "text": "a potential case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9562211_3_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9562211_3_Ent1", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "9619226_2", "wnd_id": "9619226_2_1", "text": "We postulate that the bolus of sulprostone resulted in possible coronary spasm that resulted in cardiac arrest .", "tokens": ["We", "postulate", "that", "the", "bolus", "of", "sulprostone", "resulted", "in", "possible", "coronary", "spasm", "that", "resulted", "in", "cardiac", "arrest", "."], "event_mentions": [{"id": "9619226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 7, "end": 8}, "arguments": [{"entity_id": "9619226_2_Ent1", "role": "Treatment", "text": "sulprostone", "start": 6, "end": 7}, {"entity_id": "9619226_2_Ent2", "role": "Treatment_Drug", "text": "sulprostone", "start": 6, "end": 7}, {"entity_id": "9619226_2_Ent0", "role": "Effect", "text": "coronary spasm that resulted in cardiac arrest", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "9619226_2_Ent1", "text": "sulprostone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9619226_2_Ent2", "text": "sulprostone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9619226_2_Ent0", "text": "coronary spasm that resulted in cardiac arrest", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "9634122_2", "wnd_id": "9634122_2_1", "text": "Prolonged prostate - specific antigen response in flutamide withdrawal syndrome despite disease progression .", "tokens": ["Prolonged", "prostate", "-", "specific", "antigen", "response", "in", "flutamide", "withdrawal", "syndrome", "despite", "disease", "progression", "."], "event_mentions": [{"id": "9634122_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "9634122_2_Ent0", "role": "Effect", "text": "Prolonged prostate - specific antigen response", "start": 0, "end": 6}, {"entity_id": "9634122_2_Ent1", "role": "Treatment", "text": "flutamide", "start": 7, "end": 8}, {"entity_id": "9634122_2_Ent2", "role": "Treatment_Drug", "text": "flutamide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9634122_2_Ent0", "text": "Prolonged prostate - specific antigen response", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9634122_2_Ent1", "text": "flutamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9634122_2_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9642842_2", "wnd_id": "9642842_2_1", "text": "We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic anaphylactic reaction to oral prednisone .", "tokens": ["We", "describe", "the", "case", "of", "a", "nonatopic", "17", "-", "year", "-", "old", "girl", "with", "bronchial", "asthma", "and", "aspirin", "intolerance", "who", "developed", "a", "dramatic", "anaphylactic", "reaction", "to", "oral", "prednisone", "."], "event_mentions": [{"id": "9642842_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "9642842_2_Ent0", "role": "Subject", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "start": 5, "end": 19}, {"entity_id": "9642842_2_Ent1", "role": "Subject_Disorder", "text": "nonatopic", "start": 6, "end": 7}, {"entity_id": "9642842_2_Ent3", "role": "Subject_Age", "text": "17 - year - old", "start": 7, "end": 12}, {"entity_id": "9642842_2_Ent4", "role": "Subject_Gender", "text": "girl", "start": 12, "end": 13}, {"entity_id": "9642842_2_Ent9", "role": "Treatment_Disorder", "text": "bronchial asthma", "start": 14, "end": 16}, {"entity_id": "9642842_2_Ent2", "role": "Subject_Disorder", "text": "aspirin intolerance", "start": 17, "end": 19}, {"entity_id": "9642842_2_Ent5", "role": "Effect", "text": "a dramatic anaphylactic reaction", "start": 21, "end": 25}, {"entity_id": "9642842_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "9642842_2_Ent6", "role": "Treatment", "text": "oral prednisone", "start": 26, "end": 28}, {"entity_id": "9642842_2_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "9642842_2_Ent0", "text": "a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "9642842_2_Ent1", "text": "nonatopic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9642842_2_Ent3", "text": "17 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "9642842_2_Ent4", "text": "girl", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9642842_2_Ent9", "text": "bronchial asthma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9642842_2_Ent2", "text": "aspirin intolerance", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9642842_2_Ent5", "text": "a dramatic anaphylactic reaction", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "9642842_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9642842_2_Ent6", "text": "oral prednisone", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "9642842_2_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "9651465_1", "wnd_id": "9651465_1_1", "text": "METHODS : Double - blind , placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite vomiting within 1 to 1.5 hours after challenges with Viokase and Pancrease MT 16 , but not with placebo .", "tokens": ["METHODS", ":", "Double", "-", "blind", ",", "placebo", "-", "controlled", "titrated", "oral", "challenges", "with", "pancreatic", "enzymes", "resulted", "in", "definite", "vomiting", "within", "1", "to", "1.5", "hours", "after", "challenges", "with", "Viokase", "and", "Pancrease", "MT", "16", ",", "but", "not", "with", "placebo", "."], "event_mentions": [{"id": "9651465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 15, "end": 17}, "arguments": [{"entity_id": "9651465_1_Ent0", "role": "Effect", "text": "vomiting", "start": 18, "end": 19}, {"entity_id": "9651465_1_Ent2", "role": "Treatment_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent4", "role": "Combination_Drug", "text": "Viokase", "start": 27, "end": 28}, {"entity_id": "9651465_1_Ent1", "role": "Treatment", "text": "Viokase and Pancrease MT 16", "start": 27, "end": 32}, {"entity_id": "9651465_1_Ent3", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}, {"entity_id": "9651465_1_Ent5", "role": "Combination_Drug", "text": "Pancrease MT 16", "start": 29, "end": 32}]}], "entity_mentions": [{"id": "9651465_1_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9651465_1_Ent2", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent4", "text": "Viokase", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "9651465_1_Ent1", "text": "Viokase and Pancrease MT 16", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "9651465_1_Ent3", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "9651465_1_Ent5", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 29, "end": 32}], "lang": "en"}
{"doc_id": "9660541_1", "wnd_id": "9660541_1_1", "text": "In rare cases mitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome , which is characterized by hemolytic anemia , thrombocytopenia and progressive renal failure .", "tokens": ["In", "rare", "cases", "mitomycin", "C", "(", "MMC", ")", "may", "induce", "cancer", "-", "associated", "hemolytic", "uremic", "syndrome", ",", "which", "is", "characterized", "by", "hemolytic", "anemia", ",", "thrombocytopenia", "and", "progressive", "renal", "failure", "."], "event_mentions": [{"id": "9660541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 9, "end": 10}, "arguments": [{"entity_id": "9660541_1_Ent0", "role": "Subject", "text": "In rare cases", "start": 0, "end": 3}, {"entity_id": "9660541_1_Ent4", "role": "Treatment_Drug", "text": "mitomycin C", "start": 3, "end": 5}, {"entity_id": "9660541_1_Ent3", "role": "Treatment", "text": "mitomycin C ( MMC )", "start": 3, "end": 8}, {"entity_id": "9660541_1_Ent1", "role": "Effect", "text": "cancer - associated hemolytic uremic syndrome", "start": 10, "end": 16}, {"entity_id": "9660541_1_Ent2", "role": "Effect", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "start": 21, "end": 29}]}], "entity_mentions": [{"id": "9660541_1_Ent0", "text": "In rare cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9660541_1_Ent4", "text": "mitomycin C", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9660541_1_Ent3", "text": "mitomycin C ( MMC )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9660541_1_Ent1", "text": "cancer - associated hemolytic uremic syndrome", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9660541_1_Ent2", "text": "hemolytic anemia , thrombocytopenia and progressive renal failure", "entity_type": "Entity", "start": 21, "end": 29}], "lang": "en"}
{"doc_id": "9660541_2", "wnd_id": "9660541_2_1", "text": "Mitomycin C - related hemolytic uremic syndrome in cancer patients .", "tokens": ["Mitomycin", "C", "-", "related", "hemolytic", "uremic", "syndrome", "in", "cancer", "patients", "."], "event_mentions": [{"id": "9660541_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "9660541_2_Ent2", "role": "Treatment", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "9660541_2_Ent1", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 4, "end": 7}, {"entity_id": "9660541_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 8, "end": 9}, {"entity_id": "9660541_2_Ent0", "role": "Subject", "text": "cancer patients", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9660541_2_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent3", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9660541_2_Ent1", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9660541_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9660541_2_Ent0", "text": "cancer patients", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9660541_3", "wnd_id": "9660541_3_1", "text": "We report a case of MMC - related hemolytic uremic syndrome , and discuss the etiologic parameters , clinical aspects , prognosis and treatment modalities of this severe syndrome .", "tokens": ["We", "report", "a", "case", "of", "MMC", "-", "related", "hemolytic", "uremic", "syndrome", ",", "and", "discuss", "the", "etiologic", "parameters", ",", "clinical", "aspects", ",", "prognosis", "and", "treatment", "modalities", "of", "this", "severe", "syndrome", "."], "event_mentions": [{"id": "9660541_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "9660541_3_Ent1", "role": "Treatment", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 5, "end": 6}, {"entity_id": "9660541_3_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "9660541_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9660541_3_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "9681092_10", "wnd_id": "9681092_10_1", "text": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration .", "tokens": ["The", "combination", "of", "cyclobenzaprine", "and", "fluoxetine", "resulted", "in", "significant", "QT", "prolongation", "in", "our", "patient", "that", "progressed", "to", "torsade", "de", "pointes", "after", "preoperative", "droperidol", "administration", "."], "event_mentions": [{"id": "9681092_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_10_Ent3", "role": "Treatment", "text": "The combination of cyclobenzaprine and fluoxetine", "start": 0, "end": 6}, {"entity_id": "9681092_10_Ent5", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent9", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent6", "role": "Treatment_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent10", "role": "Combination_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent1", "role": "Effect", "text": "significant QT prolongation", "start": 8, "end": 11}, {"entity_id": "9681092_10_Ent0", "role": "Subject", "text": "our patient", "start": 12, "end": 14}, {"entity_id": "9681092_10_Ent2", "role": "Effect", "text": "progressed to torsade de pointes", "start": 15, "end": 20}, {"entity_id": "9681092_10_Ent8", "role": "Treatment_Time_elapsed", "text": "preoperative", "start": 21, "end": 22}, {"entity_id": "9681092_10_Ent4", "role": "Treatment", "text": "preoperative droperidol administration", "start": 21, "end": 24}, {"entity_id": "9681092_10_Ent7", "role": "Treatment_Drug", "text": "droperidol", "start": 22, "end": 23}, {"entity_id": "9681092_10_Ent11", "role": "Combination_Drug", "text": "droperidol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9681092_10_Ent3", "text": "The combination of cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9681092_10_Ent5", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent9", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent10", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent1", "text": "significant QT prolongation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9681092_10_Ent0", "text": "our patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_10_Ent2", "text": "progressed to torsade de pointes", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "9681092_10_Ent8", "text": "preoperative", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9681092_10_Ent4", "text": "preoperative droperidol administration", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "9681092_10_Ent7", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9681092_10_Ent11", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9681092_13", "wnd_id": "9681092_13_1", "text": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine , monitor for other cytochrome P450 inhibitors , and avoid concomitant drugs known to prolong the QT interval .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "dysrhythmic", "potential", "of", "cyclobenzaprine", "and", "fluoxetine", ",", "monitor", "for", "other", "cytochrome", "P450", "inhibitors", ",", "and", "avoid", "concomitant", "drugs", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 7, "end": 8}, "arguments": [{"entity_id": "9681092_13_Ent0", "role": "Effect", "text": "dysrhythmic", "start": 6, "end": 7}, {"entity_id": "9681092_13_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent4", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent1", "role": "Treatment", "text": "cyclobenzaprine and fluoxetine", "start": 9, "end": 12}, {"entity_id": "9681092_13_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "9681092_13_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9681092_13_Ent0", "text": "dysrhythmic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9681092_13_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent4", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent1", "text": "cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9681092_13_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9681092_13_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "968449_2", "wnd_id": "968449_2_1", "text": "Bone marrow chromosomes were studied in 2 patients with polycythaemia vera ( PV ) at the time of diagnosis and several times subsequently during therapy with chlorambucil .", "tokens": ["Bone", "marrow", "chromosomes", "were", "studied", "in", "2", "patients", "with", "polycythaemia", "vera", "(", "PV", ")", "at", "the", "time", "of", "diagnosis", "and", "several", "times", "subsequently", "during", "therapy", "with", "chlorambucil", "."], "event_mentions": [{"id": "968449_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 24, "end": 25}, "arguments": [{"entity_id": "968449_2_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "968449_2_Ent0", "role": "Subject", "text": "2 patients with polycythaemia vera ( PV )", "start": 6, "end": 14}, {"entity_id": "968449_2_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera ( PV )", "start": 9, "end": 14}, {"entity_id": "968449_2_Ent2", "role": "Treatment", "text": "chlorambucil", "start": 26, "end": 27}, {"entity_id": "968449_2_Ent4", "role": "Treatment_Drug", "text": "chlorambucil", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "968449_2_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "968449_2_Ent0", "text": "2 patients with polycythaemia vera ( PV )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "968449_2_Ent3", "text": "polycythaemia vera ( PV )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "968449_2_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "968449_2_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9695308_2", "wnd_id": "9695308_2_1", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis associated with propylthiouracil therapy .", "tokens": ["Antineutrophil", "cytoplasmic", "antibody", "-", "positive", "crescentic", "glomerulonephritis", "associated", "with", "propylthiouracil", "therapy", "."], "event_mentions": [{"id": "9695308_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9695308_2_Ent0", "role": "Effect", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis", "start": 0, "end": 7}, {"entity_id": "9695308_2_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 9, "end": 10}, {"entity_id": "9695308_2_Ent1", "role": "Treatment", "text": "propylthiouracil therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9695308_2_Ent0", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9695308_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9695308_2_Ent1", "text": "propylthiouracil therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9709726_1", "wnd_id": "9709726_1_1", "text": "We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug - seeking behavior or anticholinergic symptoms with the use of diphenhydramine .", "tokens": ["We", "describe", "children", "and", "adolescents", "with", "chronic", "hematologic", "and", "oncologic", "diseases", "who", "exhibited", "drug", "-", "seeking", "behavior", "or", "anticholinergic", "symptoms", "with", "the", "use", "of", "diphenhydramine", "."], "event_mentions": [{"id": "9709726_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 12, "end": 13}, "arguments": [{"entity_id": "9709726_1_Ent1", "role": "Subject_Age", "text": "children", "start": 2, "end": 3}, {"entity_id": "9709726_1_Ent0", "role": "Subject", "text": "children and adolescents with chronic hematologic and oncologic diseases", "start": 2, "end": 11}, {"entity_id": "9709726_1_Ent2", "role": "Subject_Age", "text": "adolescents", "start": 4, "end": 5}, {"entity_id": "9709726_1_Ent6", "role": "Treatment_Disorder", "text": "chronic hematologic and oncologic diseases", "start": 6, "end": 11}, {"entity_id": "9709726_1_Ent3", "role": "Effect", "text": "drug - seeking behavior or anticholinergic symptoms", "start": 13, "end": 20}, {"entity_id": "9709726_1_Ent4", "role": "Treatment", "text": "diphenhydramine", "start": 24, "end": 25}, {"entity_id": "9709726_1_Ent5", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "9709726_1_Ent1", "text": "children", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9709726_1_Ent0", "text": "children and adolescents with chronic hematologic and oncologic diseases", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "9709726_1_Ent2", "text": "adolescents", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9709726_1_Ent6", "text": "chronic hematologic and oncologic diseases", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9709726_1_Ent3", "text": "drug - seeking behavior or anticholinergic symptoms", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "9709726_1_Ent4", "text": "diphenhydramine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9709726_1_Ent5", "text": "diphenhydramine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "9725786_1", "wnd_id": "9725786_1_1", "text": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess .", "tokens": ["We", "describe", "a", "renal", "transplant", "recipient", "maintained", "on", "cyclosporine", "and", "prednisone", "developing", "Nocardia", "Asteroides", "brain", "abscess", "."], "event_mentions": [{"id": "9725786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 11, "end": 12}, "arguments": [{"entity_id": "9725786_1_Ent0", "role": "Subject", "text": "a renal transplant recipient", "start": 2, "end": 6}, {"entity_id": "9725786_1_Ent5", "role": "Treatment_Disorder", "text": "renal transplant recipient", "start": 3, "end": 6}, {"entity_id": "9725786_1_Ent2", "role": "Treatment", "text": "maintained on cyclosporine and prednisone", "start": 6, "end": 11}, {"entity_id": "9725786_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent7", "role": "Combination_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent1", "role": "Effect", "text": "Nocardia Asteroides brain abscess", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "9725786_1_Ent0", "text": "a renal transplant recipient", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9725786_1_Ent5", "text": "renal transplant recipient", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9725786_1_Ent2", "text": "maintained on cyclosporine and prednisone", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9725786_1_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent1", "text": "Nocardia Asteroides brain abscess", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "9726762_2", "wnd_id": "9726762_2_1", "text": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil .", "tokens": ["The", "following", "describes", "a", "patient", "on", "a", "stable", "regimen", "of", "warfarin", "who", "developed", "severe", "hypoprothrombinemia", "and", "bleeding", "4", "weeks", "after", "starting", "gemfibrozil", "."], "event_mentions": [{"id": "9726762_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "9726762_2_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "9726762_2_Ent2", "role": "Treatment", "text": "on a stable regimen of warfarin", "start": 5, "end": 11}, {"entity_id": "9726762_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 10, "end": 11}, {"entity_id": "9726762_2_Ent1", "role": "Effect", "text": "hypoprothrombinemia and bleeding", "start": 14, "end": 17}, {"entity_id": "9726762_2_Ent6", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 17, "end": 19}, {"entity_id": "9726762_2_Ent3", "role": "Treatment", "text": "4 weeks after starting gemfibrozil", "start": 17, "end": 22}, {"entity_id": "9726762_2_Ent5", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9726762_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9726762_2_Ent2", "text": "on a stable regimen of warfarin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "9726762_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9726762_2_Ent1", "text": "hypoprothrombinemia and bleeding", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "9726762_2_Ent6", "text": "4 weeks", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9726762_2_Ent3", "text": "4 weeks after starting gemfibrozil", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9726762_2_Ent5", "text": "gemfibrozil", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9726762_4", "wnd_id": "9726762_4_1", "text": "This interaction may be overlooked by clinicians , which may result in a serious bleeding risk for patients on warfarin .", "tokens": ["This", "interaction", "may", "be", "overlooked", "by", "clinicians", ",", "which", "may", "result", "in", "a", "serious", "bleeding", "risk", "for", "patients", "on", "warfarin", "."], "event_mentions": [{"id": "9726762_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result in", "start": 10, "end": 12}, "arguments": [{"entity_id": "9726762_4_Ent1", "role": "Effect", "text": "serious bleeding risk", "start": 13, "end": 16}, {"entity_id": "9726762_4_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "9726762_4_Ent2", "role": "Treatment", "text": "warfarin", "start": 19, "end": 20}, {"entity_id": "9726762_4_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9726762_4_Ent1", "text": "serious bleeding risk", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9726762_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9726762_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9726762_4_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9777751_1", "wnd_id": "9777751_1_1", "text": "Methimazole - induced aplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor .", "tokens": ["Methimazole", "-", "induced", "aplastic", "anemia", "in", "third", "exposure", ":", "successful", "treatment", "with", "recombinant", "human", "granulocyte", "colony", "-", "stimulating", "factor", "."], "event_mentions": [{"id": "9777751_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9777751_1_Ent1", "role": "Treatment", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent2", "role": "Treatment_Drug", "text": "Methimazole", "start": 0, "end": 1}, {"entity_id": "9777751_1_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}, {"entity_id": "9777751_1_Ent3", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "9777751_1_Ent1", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent2", "text": "Methimazole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9777751_1_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9777751_1_Ent3", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "9788533_1", "wnd_id": "9788533_1_1", "text": "Fatal multiple drug intoxication following acute sertraline use .", "tokens": ["Fatal", "multiple", "drug", "intoxication", "following", "acute", "sertraline", "use", "."], "event_mentions": [{"id": "9788533_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "9788533_1_Ent0", "role": "Effect", "text": "multiple drug intoxication", "start": 1, "end": 4}, {"entity_id": "9788533_1_Ent1", "role": "Treatment", "text": "acute sertraline use", "start": 5, "end": 8}, {"entity_id": "9788533_1_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9788533_1_Ent0", "text": "multiple drug intoxication", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9788533_1_Ent1", "text": "acute sertraline use", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9788533_1_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9788533_8", "wnd_id": "9788533_8_1", "text": "The cause of death was multiple drug intoxication following acute use of sertraline , the manner of death was suicide , and the mechanism of death is an unexplained drug interaction and/or toxicity .", "tokens": ["The", "cause", "of", "death", "was", "multiple", "drug", "intoxication", "following", "acute", "use", "of", "sertraline", ",", "the", "manner", "of", "death", "was", "suicide", ",", "and", "the", "mechanism", "of", "death", "is", "an", "unexplained", "drug", "interaction", "and/or", "toxicity", "."], "event_mentions": [{"id": "9788533_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "9788533_8_Ent0", "role": "Effect", "text": "multiple drug intoxication", "start": 5, "end": 8}, {"entity_id": "9788533_8_Ent1", "role": "Treatment", "text": "sertraline", "start": 12, "end": 13}, {"entity_id": "9788533_8_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9788533_8_Ent0", "text": "multiple drug intoxication", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9788533_8_Ent1", "text": "sertraline", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9788533_8_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9792602_3", "wnd_id": "9792602_3_1", "text": "Within 6 months of pranlukast withdrawal , anemia resolved and urinary sediment and renal function normalized .", "tokens": ["Within", "6", "months", "of", "pranlukast", "withdrawal", ",", "anemia", "resolved", "and", "urinary", "sediment", "and", "renal", "function", "normalized", "."], "event_mentions": [{"id": "9792602_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "withdrawal", "start": 5, "end": 6}, "arguments": [{"entity_id": "9792602_3_Ent3", "role": "Treatment_Time_elapsed", "text": "6 months", "start": 1, "end": 3}, {"entity_id": "9792602_3_Ent1", "role": "Treatment", "text": "pranlukast", "start": 4, "end": 5}, {"entity_id": "9792602_3_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 4, "end": 5}, {"entity_id": "9792602_3_Ent4", "role": "Treatment_Disorder", "text": "anemia", "start": 7, "end": 8}, {"entity_id": "9792602_3_Ent0", "role": "Effect", "text": "anemia resolved and urinary sediment and renal function normalized", "start": 7, "end": 16}, {"entity_id": "9792602_3_Ent5", "role": "Treatment_Disorder", "text": "urinary sediment", "start": 10, "end": 12}, {"entity_id": "9792602_3_Ent6", "role": "Treatment_Disorder", "text": "renal function", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9792602_3_Ent3", "text": "6 months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9792602_3_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9792602_3_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9792602_3_Ent4", "text": "anemia", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9792602_3_Ent0", "text": "anemia resolved and urinary sediment and renal function normalized", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "9792602_3_Ent5", "text": "urinary sediment", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9792602_3_Ent6", "text": "renal function", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9796135_4", "wnd_id": "9796135_4_1", "text": "Syncope in a 65 - year - old woman after nitrate ingestion .", "tokens": ["Syncope", "in", "a", "65", "-", "year", "-", "old", "woman", "after", "nitrate", "ingestion", "."], "event_mentions": [{"id": "9796135_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "9796135_4_Ent3", "role": "Effect", "text": "Syncope", "start": 0, "end": 1}, {"entity_id": "9796135_4_Ent0", "role": "Subject", "text": "a 65 - year - old woman", "start": 2, "end": 9}, {"entity_id": "9796135_4_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 3, "end": 8}, {"entity_id": "9796135_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "9796135_4_Ent5", "role": "Treatment_Drug", "text": "nitrate", "start": 10, "end": 11}, {"entity_id": "9796135_4_Ent4", "role": "Treatment", "text": "nitrate ingestion", "start": 10, "end": 12}, {"entity_id": "9796135_4_Ent6", "role": "Treatment_Route", "text": "ingestion", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9796135_4_Ent3", "text": "Syncope", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9796135_4_Ent0", "text": "a 65 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "9796135_4_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9796135_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9796135_4_Ent5", "text": "nitrate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9796135_4_Ent4", "text": "nitrate ingestion", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9796135_4_Ent6", "text": "ingestion", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9804082_1", "wnd_id": "9804082_1_1", "text": "Three diabetic cases of acute dizziness due to initial administration of voglibose .", "tokens": ["Three", "diabetic", "cases", "of", "acute", "dizziness", "due", "to", "initial", "administration", "of", "voglibose", "."], "event_mentions": [{"id": "9804082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "9804082_1_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "9804082_1_Ent0", "role": "Subject", "text": "Three diabetic cases", "start": 0, "end": 3}, {"entity_id": "9804082_1_Ent5", "role": "Treatment_Disorder", "text": "diabetic", "start": 1, "end": 2}, {"entity_id": "9804082_1_Ent2", "role": "Effect", "text": "acute dizziness", "start": 4, "end": 6}, {"entity_id": "9804082_1_Ent3", "role": "Treatment", "text": "initial administration of voglibose", "start": 8, "end": 12}, {"entity_id": "9804082_1_Ent4", "role": "Treatment_Drug", "text": "voglibose", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9804082_1_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9804082_1_Ent0", "text": "Three diabetic cases", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9804082_1_Ent5", "text": "diabetic", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9804082_1_Ent2", "text": "acute dizziness", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9804082_1_Ent3", "text": "initial administration of voglibose", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9804082_1_Ent4", "text": "voglibose", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9819544_2", "wnd_id": "9819544_2_1", "text": "Naproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include tinnitus and transient hearing loss .", "tokens": ["Naproxen", "is", "a", "commonly", "used", "nonsteroidal", "anti", "-", "inflammatory", "drug", "(", "NSAID", ")", "whose", "side", "effects", "include", "tinnitus", "and", "transient", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "include", "start": 16, "end": 17}, "arguments": [{"entity_id": "9819544_2_Ent1", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_2_Ent2", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_2_Ent0", "role": "Effect", "text": "tinnitus and transient hearing loss", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "9819544_2_Ent1", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_2_Ent2", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_2_Ent0", "text": "tinnitus and transient hearing loss", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "9824032_1", "wnd_id": "9824032_1_1", "text": "Dental and gingival pain as side effects of niacin therapy .", "tokens": ["Dental", "and", "gingival", "pain", "as", "side", "effects", "of", "niacin", "therapy", "."], "event_mentions": [{"id": "9824032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "9824032_1_Ent0", "role": "Effect", "text": "Dental and gingival pain", "start": 0, "end": 4}, {"entity_id": "9824032_1_Ent1", "role": "Treatment", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "9824032_1_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9824032_1_Ent0", "text": "Dental and gingival pain", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9824032_1_Ent1", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9824032_1_Ent2", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9824032_2", "wnd_id": "9824032_2_1", "text": "The cause of these previously unreported side effects of niacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth .", "tokens": ["The", "cause", "of", "these", "previously", "unreported", "side", "effects", "of", "niacin", "therapy", "is", "uncertain", "but", "may", "be", "related", "to", "prostaglandin", "-", "mediated", "vasodilatation", ",", "hyperalgesia", "of", "sensory", "nerve", "receptors", ",", "and", "potentiation", "of", "inflammation", "in", "the", "gingiva", "with", "referral", "of", "pain", "to", "the", "teeth", "."], "event_mentions": [{"id": "9824032_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 16, "end": 17}, "arguments": [{"entity_id": "9824032_2_Ent1", "role": "Treatment", "text": "niacin", "start": 9, "end": 10}, {"entity_id": "9824032_2_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 9, "end": 10}, {"entity_id": "9824032_2_Ent0", "role": "Effect", "text": "prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth", "start": 18, "end": 43}]}], "entity_mentions": [{"id": "9824032_2_Ent1", "text": "niacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9824032_2_Ent2", "text": "niacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9824032_2_Ent0", "text": "prostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth", "entity_type": "Entity", "start": 18, "end": 43}], "lang": "en"}
{"doc_id": "9831311_1", "wnd_id": "9831311_1_1", "text": "Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication , potassium loss also should be kept in mind .", "tokens": ["Although", "major", "hazards", "of", "treatment", "of", "hypophosphatemic", "osteomalacia", "with", "phosphate", "and", "calcitriol", "are", "secondary", "hyperparathyroidism", "and", "vitamin", "D", "intoxication", ",", "potassium", "loss", "also", "should", "be", "kept", "in", "mind", "."], "event_mentions": [{"id": "9831311_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "major hazards", "start": 1, "end": 3}, "arguments": [{"entity_id": "9831311_1_Ent4", "role": "Treatment_Disorder", "text": "hypophosphatemic osteomalacia", "start": 6, "end": 8}, {"entity_id": "9831311_1_Ent1", "role": "Treatment", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "start": 6, "end": 12}, {"entity_id": "9831311_1_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent5", "role": "Combination_Drug", "text": "phosphate", "start": 9, "end": 10}, {"entity_id": "9831311_1_Ent3", "role": "Treatment_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent6", "role": "Combination_Drug", "text": "calcitriol", "start": 11, "end": 12}, {"entity_id": "9831311_1_Ent0", "role": "Effect", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "9831311_1_Ent4", "text": "hypophosphatemic osteomalacia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9831311_1_Ent1", "text": "hypophosphatemic osteomalacia with phosphate and calcitriol", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "9831311_1_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent5", "text": "phosphate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9831311_1_Ent3", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent6", "text": "calcitriol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9831311_1_Ent0", "text": "secondary hyperparathyroidism and vitamin D intoxication , potassium loss", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "9831311_4", "wnd_id": "9831311_4_1", "text": "Progressive hypokalemia developed during phosphate treatment .", "tokens": ["Progressive", "hypokalemia", "developed", "during", "phosphate", "treatment", "."], "event_mentions": [{"id": "9831311_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "9831311_4_Ent0", "role": "Effect", "text": "Progressive hypokalemia", "start": 0, "end": 2}, {"entity_id": "9831311_4_Ent1", "role": "Treatment", "text": "phosphate", "start": 4, "end": 5}, {"entity_id": "9831311_4_Ent2", "role": "Treatment_Drug", "text": "phosphate", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "9831311_4_Ent0", "text": "Progressive hypokalemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9831311_4_Ent1", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9831311_4_Ent2", "text": "phosphate", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "9846036_4", "wnd_id": "9846036_4_1", "text": "Clozapine , an atypical antipsychotic , can be toxic at doses 4 times a moderate dose .", "tokens": ["Clozapine", ",", "an", "atypical", "antipsychotic", ",", "can", "be", "toxic", "at", "doses", "4", "times", "a", "moderate", "dose", "."], "event_mentions": [{"id": "9846036_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 7, "end": 8}, "arguments": [{"entity_id": "9846036_4_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent0", "role": "Effect", "text": "toxic", "start": 8, "end": 9}, {"entity_id": "9846036_4_Ent1", "role": "Treatment", "text": "doses 4 times a moderate dose", "start": 10, "end": 16}, {"entity_id": "9846036_4_Ent3", "role": "Treatment_Dosage", "text": "4 times a moderate dose", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "9846036_4_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent0", "text": "toxic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9846036_4_Ent1", "text": "doses 4 times a moderate dose", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9846036_4_Ent3", "text": "4 times a moderate dose", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "9865241_2", "wnd_id": "9865241_2_1", "text": "Pamidronate therapy should be considered in patients with hypercalcemia secondary to acute vitamin D poisoning .", "tokens": ["Pamidronate", "therapy", "should", "be", "considered", "in", "patients", "with", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 1, "end": 2}, "arguments": [{"entity_id": "9865241_2_Ent3", "role": "Treatment", "text": "Pamidronate", "start": 0, "end": 1}, {"entity_id": "9865241_2_Ent5", "role": "Treatment_Drug", "text": "Pamidronate", "start": 0, "end": 1}, {"entity_id": "9865241_2_Ent4", "role": "Treatment_Disorder", "text": "hypercalcemia", "start": 8, "end": 9}]}, {"id": "9865241_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 9, "end": 10}, "arguments": [{"entity_id": "9865241_2_Ent0", "role": "Effect", "text": "hypercalcemia", "start": 8, "end": 9}, {"entity_id": "9865241_2_Ent1", "role": "Treatment", "text": "vitamin D", "start": 12, "end": 14}, {"entity_id": "9865241_2_Ent2", "role": "Treatment_Drug", "text": "vitamin D", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9865241_2_Ent3", "text": "Pamidronate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9865241_2_Ent5", "text": "Pamidronate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9865241_2_Ent0", "text": "hypercalcemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_2_Ent4", "text": "hypercalcemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9865241_2_Ent1", "text": "vitamin D", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9865241_2_Ent2", "text": "vitamin D", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9865241_4", "wnd_id": "9865241_4_1", "text": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication .", "tokens": ["The", "use", "of", "pamidronate", "for", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "intoxication", "."], "event_mentions": [{"id": "9865241_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "9865241_4_Ent0", "role": "Treatment", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent1", "role": "Treatment_Disorder", "text": "hypercalcemia secondary to acute vitamin D intoxication", "start": 5, "end": 12}]}, {"id": "9865241_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_4_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 5, "end": 6}, {"entity_id": "9865241_4_Ent4", "role": "Treatment", "text": "vitamin D", "start": 9, "end": 11}, {"entity_id": "9865241_4_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9865241_4_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_4_Ent1", "text": "hypercalcemia secondary to acute vitamin D intoxication", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9865241_4_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9865241_4_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9865241_5", "wnd_id": "9865241_5_1", "text": "We report the use of pamidronate for acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning .", "tokens": ["We", "report", "the", "use", "of", "pamidronate", "for", "acute", ",", "severe", "hypercalcemia", "secondary", "to", "iatrogenic", "vitamin", "D", "poisoning", "."], "event_mentions": [{"id": "9865241_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_5_Ent0", "role": "Treatment", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 5, "end": 6}, {"entity_id": "9865241_5_Ent1", "role": "Treatment_Disorder", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "start": 7, "end": 17}]}, {"id": "9865241_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 11, "end": 12}, "arguments": [{"entity_id": "9865241_5_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 10, "end": 11}, {"entity_id": "9865241_5_Ent4", "role": "Treatment", "text": "vitamin D", "start": 14, "end": 16}, {"entity_id": "9865241_5_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "9865241_5_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_5_Ent1", "text": "acute , severe hypercalcemia secondary to iatrogenic vitamin D poisoning", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "9865241_5_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9865241_5_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9865241_5_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "9876809_2", "wnd_id": "9876809_2_1", "text": "To report a probable case of ticlopidine - induced phenytoin toxicity .", "tokens": ["To", "report", "a", "probable", "case", "of", "ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9876809_2_Ent0", "role": "Subject", "text": "a probable case", "start": 2, "end": 5}, {"entity_id": "9876809_2_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent6", "role": "Combination_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent2", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9876809_2_Ent0", "text": "a probable case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9876809_2_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9876812_1", "wnd_id": "9876812_1_1", "text": "Clinicians should be aware of the possibility that vinorelbine may cause SIADH and possibly hypokalemia .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "possibility", "that", "vinorelbine", "may", "cause", "SIADH", "and", "possibly", "hypokalemia", "."], "event_mentions": [{"id": "9876812_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "9876812_1_Ent1", "role": "Treatment", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent2", "role": "Treatment_Drug", "text": "vinorelbine", "start": 8, "end": 9}, {"entity_id": "9876812_1_Ent0", "role": "Effect", "text": "SIADH and possibly hypokalemia", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "9876812_1_Ent1", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent2", "text": "vinorelbine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9876812_1_Ent0", "text": "SIADH and possibly hypokalemia", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "9886213_1", "wnd_id": "9886213_1_1", "text": "Disseminated muscular cysticercosis with myositis induced by praziquantel therapy .", "tokens": ["Disseminated", "muscular", "cysticercosis", "with", "myositis", "induced", "by", "praziquantel", "therapy", "."], "event_mentions": [{"id": "9886213_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "9886213_1_Ent0", "role": "Effect", "text": "Disseminated muscular cysticercosis with myositis", "start": 0, "end": 5}, {"entity_id": "9886213_1_Ent2", "role": "Treatment_Drug", "text": "praziquantel", "start": 7, "end": 8}, {"entity_id": "9886213_1_Ent1", "role": "Treatment", "text": "praziquantel therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9886213_1_Ent0", "text": "Disseminated muscular cysticercosis with myositis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9886213_1_Ent2", "text": "praziquantel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9886213_1_Ent1", "text": "praziquantel therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9886213_4", "wnd_id": "9886213_4_1", "text": "We describe a case of disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by praziquantel therapy , an event not described previously .", "tokens": ["We", "describe", "a", "case", "of", "disseminated", "muscular", "cysticercosis", "followed", "by", "myositis", "(", "fever", ",", "diffuse", "myalgia", ",", "weakness", "of", "the", "lower", "limbs", ",", "and", "inflammatory", "reaction", "around", "dying", "cysticerci", ")", "induced", "by", "praziquantel", "therapy", ",", "an", "event", "not", "described", "previously", "."], "event_mentions": [{"id": "9886213_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 30, "end": 31}, "arguments": [{"entity_id": "9886213_4_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "9886213_4_Ent1", "role": "Effect", "text": "disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci )", "start": 5, "end": 30}, {"entity_id": "9886213_4_Ent3", "role": "Treatment_Drug", "text": "praziquantel", "start": 32, "end": 33}, {"entity_id": "9886213_4_Ent2", "role": "Treatment", "text": "praziquantel therapy", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "9886213_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9886213_4_Ent1", "text": "disseminated muscular cysticercosis followed by myositis ( fever , diffuse myalgia , weakness of the lower limbs , and inflammatory reaction around dying cysticerci )", "entity_type": "Entity", "start": 5, "end": 30}, {"id": "9886213_4_Ent3", "text": "praziquantel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "9886213_4_Ent2", "text": "praziquantel therapy", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "9925865_2", "wnd_id": "9925865_2_1", "text": "In patients with swallowing dysfunction and pneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred .", "tokens": ["In", "patients", "with", "swallowing", "dysfunction", "and", "pneumonia", ",", "a", "history", "of", "mineral", "oil", "use", "should", "be", "obtained", "and", "a", "diagnosis", "of", "ELP", "should", "be", "considered", "in", "the", "differential", "diagnoses", "if", "mineral", "oil", "use", "has", "occurred", "."], "event_mentions": [{"id": "9925865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 24, "end": 25}, "arguments": [{"entity_id": "9925865_2_Ent0", "role": "Subject", "text": "In patients with swallowing dysfunction and pneumonia", "start": 0, "end": 7}, {"entity_id": "9925865_2_Ent2", "role": "Treatment", "text": "a history of mineral oil use", "start": 8, "end": 14}, {"entity_id": "9925865_2_Ent3", "role": "Treatment_Drug", "text": "mineral oil", "start": 11, "end": 13}, {"entity_id": "9925865_2_Ent1", "role": "Effect", "text": "ELP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9925865_2_Ent0", "text": "In patients with swallowing dysfunction and pneumonia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9925865_2_Ent2", "text": "a history of mineral oil use", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9925865_2_Ent3", "text": "mineral oil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9925865_2_Ent1", "text": "ELP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9972383_1", "wnd_id": "9972383_1_1", "text": "CONCLUSIONS : Metoclopramide may cause reversible nonthrombocytopenic vascular - type palpable purpura .", "tokens": ["CONCLUSIONS", ":", "Metoclopramide", "may", "cause", "reversible", "nonthrombocytopenic", "vascular", "-", "type", "palpable", "purpura", "."], "event_mentions": [{"id": "9972383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9972383_1_Ent1", "role": "Treatment", "text": "Metoclopramide", "start": 2, "end": 3}, {"entity_id": "9972383_1_Ent2", "role": "Treatment_Drug", "text": "Metoclopramide", "start": 2, "end": 3}, {"entity_id": "9972383_1_Ent0", "role": "Effect", "text": "reversible nonthrombocytopenic vascular - type palpable purpura", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "9972383_1_Ent1", "text": "Metoclopramide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9972383_1_Ent2", "text": "Metoclopramide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9972383_1_Ent0", "text": "reversible nonthrombocytopenic vascular - type palpable purpura", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "9972383_3", "wnd_id": "9972383_3_1", "text": "Reversible nonthrombocytopenic palpable purpura associated with metoclopramide .", "tokens": ["Reversible", "nonthrombocytopenic", "palpable", "purpura", "associated", "with", "metoclopramide", "."], "event_mentions": [{"id": "9972383_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "9972383_3_Ent0", "role": "Effect", "text": "Reversible nonthrombocytopenic palpable purpura", "start": 0, "end": 4}, {"entity_id": "9972383_3_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 6, "end": 7}, {"entity_id": "9972383_3_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9972383_3_Ent0", "text": "Reversible nonthrombocytopenic palpable purpura", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9972383_3_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9972383_3_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
